FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Jordan, MR Bennett, DE Wainberg, MA Havlir, D Hammer, S Yang, C Morris, L Peeters, M Wensing, AM Parkin, N Nachega, JB Phillips, A De Luca, A Geng, E Calmy, A Raizes, E Sandstrom, P Archibald, CP Perriens, J McClure, CM Hong, SY McMahon, JH Dedes, N Sutherland, D Bertagnolio, S AF Jordan, M. R. Bennett, D. E. Wainberg, M. A. Havlir, D. Hammer, S. Yang, C. Morris, L. Peeters, M. Wensing, A. M. Parkin, N. Nachega, J. B. Phillips, A. De Luca, A. Geng, E. Calmy, A. Raizes, E. Sandstrom, P. Archibald, C. P. Perriens, J. McClure, C. M. Hong, S. Y. McMahon, J. H. Dedes, N. Sutherland, D. Bertagnolio, S. TI Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; RESOURCE-LIMITED SETTINGS; VIROLOGICAL FAILURE; SURVEILLANCE; ADHERENCE; INDIVIDUALS; PREDICTORS; MUTATIONS; REGIMENS; SITES AB The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission. C1 [Jordan, M. R.] World Hlth Org, Dept HIV, CH-1211 Geneva 27, Switzerland. [Jordan, M. R.; Hong, S. Y.; McMahon, J. H.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Bennett, D. E.; Yang, C.; Raizes, E.] US Ctr Dis Control & Prevent, Atlanta, GA USA. McGill Univ, Jewish Gen Hosp, AIDS Ctr, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada. [Havlir, D.; Geng, E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hammer, S.] Columbia Univ, Med Ctr, New York, NY USA. [Morris, L.] Natl Inst Communicable Dis, AIDS Virus Res Unit, Johannesburg, South Africa. [Peeters, M.] Inst Rech Dev, UMI 233 TransVIHMI, Montpellier, France. [Peeters, M.] Univ Montpellier I, F-34006 Montpellier, France. [Wensing, A. M.] Univ Med Ctr Utrecht, Utrecht, Netherlands. [Parkin, N.] Data First Consulting, Belmont, CA USA. [Nachega, J. B.] Univ Stellenbosch, Cape Town, South Africa. [Nachega, J. B.] Johns Hopkins Bloomberg, Sch Publ Hlth, Baltimore, MD USA. [Phillips, A.] UCL, London WC1E 6BT, England. [De Luca, A.] Univ Cattolica Sacro Cuore, Inst Clin Infect Dis, Rome, Italy. [De Luca, A.] Siena Univ Hosp, Div Infect Dis, Siena, Italy. [Calmy, A.] Univ Hosp Geneva, Geneva, Switzerland. [Sandstrom, P.; Archibald, C. P.; Sutherland, D.] Publ Hlth Agcy Canada, Ottawa, ON, Canada. [McMahon, J. H.] Alfred Hosp, Melbourne, Vic, Australia. [Dedes, N.] Int Treatment Preparedness Coalit, Bangkok, Thailand. [Calmy, A.] Med Sans Frontiere Access Campaign, Geneva, Switzerland. RP Jordan, MR (reprint author), World Hlth Org, Dept HIV, Ave Appia 20, CH-1211 Geneva 27, Switzerland. EM jordanm@who.int RI Yang, Chunfu/G-6890-2013; Phillips, Andrew/B-4427-2008 OI Phillips, Andrew/0000-0003-2384-4807 FU Bill & Melinda Gates Foundation [38180]; government of Canada; government of Italy; government of Spain; National Institutes of Health [K23 AI074423-05, 5T32AI007438-19]; Lifespan/Tufts/Brown Center for AIDS Research [P30AI4853]; European Community [223131] FX The authors sincerely acknowledge The Bill & Melinda Gates Foundation, which has generously funded the WHO Global HIVDR Strategy since 2007. The authors acknowledge the governments of Canada, Italy, and Spain, which have provided significant financial contributions leading to the success of WHO's HIVDR prevention and assessment strategy. The authors acknowledge the contributions of the US CDC, PEPFAR, PharmAccess, Treat Asia, and the Agence National de Recherche sur le SIDA et les Hepatites for their strong support as implementing partners. The authors acknowledge the valuable contribution of Mark Myatt, Brixton Health, UK, to the development of the epidemiological and statistical methods used in the strategy. The authors acknowledge the contribution of Jesper Kjaer, Copenhagen HIV Program.; This work was supported by grants from the National Institutes of Health (K23 AI074423-05 to M. R. J. and 5T32AI007438-19 to S. Y. H.) and the Lifespan/Tufts/Brown Center for AIDS Research (P30AI4853 to J. H. M.). The research leading to these results has received partial funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under the project "Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)" (grant agreement No. 223131).; This article was published as part of a supplement entitled "The World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: Global, Regional, and Country Progress," sponsored by The Bill & Melinda Gates Foundation (38180). NR 47 TC 29 Z9 30 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 15 PY 2012 VL 54 SU 4 BP S245 EP S249 DI 10.1093/cid/cis206 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 933EA UT WOS:000303341300001 PM 22544182 ER PT J AU Ugbena, R Aberle-Grasse, J Diallo, K Bassey, O Jelpe, T Rottinghaus, E Azeez, A Akpan, R Muhammad, M Shanmugam, V Singh, S Yang, C AF Ugbena, Richard Aberle-Grasse, John Diallo, Karidia Bassey, Orji Jelpe, Tapdiyel Rottinghaus, Erin Azeez, Aderemi Akpan, Raphael Muhammad, Mukhtar Shanmugam, Vedapuri Singh, Satvinder Yang, Chunfu TI Virological Response and HIV Drug Resistance 12 Months After Antiretroviral Therapy Initiation at 2 Clinics in Nigeria SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID REVERSE-TRANSCRIPTASE; K65R MUTATION; PREVENTION AB This report describes a pilot study, conducted in Nigeria, of the World Health Organization protocol for monitoring human immunodeficiency virus (HIV) drug resistance (HIVDR) and associated program factors among patients receiving first-line antiretroviral therapy (ART). In 2008, 283 HIV-infected patients starting ART were consecutively enrolled at 2 ART clinics in Abuja. Twelve months after ART initiation, 62% were alive and on first-line ART, 3% had died, 1% had transferred out of the program, and 34% were lost to follow-up. Among patients on first-line ART at 12 months, 90% had viral suppression. However, in view of the high loss to follow-up rate (34%), strategies for patient retention and tracking are critical to minimize possible HIVDR and optimize treatment outcomes. C1 [Diallo, Karidia; Rottinghaus, Erin; Shanmugam, Vedapuri; Yang, Chunfu] Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, CGH, Atlanta, GA 30333 USA. [Aberle-Grasse, John] Ctr Dis Control & Prevent, Strateg Informat & Epidemiol Branch, Div Global HIV AIDS, CGH, Atlanta, GA 30333 USA. [Ugbena, Richard; Bassey, Orji; Jelpe, Tapdiyel; Akpan, Raphael; Muhammad, Mukhtar; Singh, Satvinder] Ctr Dis Control & Prevent, CDC Nigeria, Abuja, Nigeria. [Azeez, Aderemi] Minist Fed Hlth Nigeria, Abuja, Nigeria. RP Yang, C (reprint author), Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, CGH, Mail Stop A-11,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM cyang1@cdc.gov RI Yang, Chunfu/G-6890-2013 FU American Public Health Laboratory; CDC; US President's Emergency Plan for AIDS Relief; Bill & Melinda Gates Foundation [38180] FX The authors acknowledge the patients who participated in this survey, the staff of Wuse General Hospital and Abuja University Teaching Hospital, Institute of Human Virology Nigeria/University of Maryland, Family Health International/Global HIV/AIDS Initiative in Nigeria, HIV/AIDS Division, Federal Ministry of Health, Nigeria for their leadership role, WHO Nigeria, International Laboratory Branch and HIVDR monitoring Team, Division of Global HIV/AIDS, Center for Global Health, US Centers for Disease Control and Prevention (CDC Atlanta), CDC Nigeria, and Drs Diane Bennett (CDC Atlanta) and Don Sutherland (Public Health Agency of Canada) for their guidance. We also thank Dr Michael R. Jordan (WHO Geneva) for his support in data analysis and writing the manuscript. Dr Erin Rottinghaus was a recipient of 2009-2011 Emerging Infectious Disease (EID) Fellowship Programs sponsored by American Public Health Laboratory and the CDC.; This work was supported by the US President's Emergency Plan for AIDS Relief.; This article was published as part of a supplement entitled "The World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: Global, Regional, and Country Progress," sponsored by The Bill & Melinda Gates Foundation (38180). NR 22 TC 13 Z9 13 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 15 PY 2012 VL 54 SU 4 BP S375 EP S380 DI 10.1093/cid/cir1064 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 933EA UT WOS:000303341300025 PM 22544206 ER PT J AU Wadonda-Kabondo, N Bennett, D van Oosterhout, JJ Moyo, K Hosseinipour, M DeVos, J Zhou, ZY Aberle-Grasse, J Warne, TR Mtika, C Chilima, B Banda, R Pasulani, O Porter, C Phiri, S Jahn, A Kamwendo, D Jordan, MR Kabuluzi, S Chimbwandira, F Kagoli, M Matatiyo, B Demby, A Yang, CF AF Wadonda-Kabondo, Nellie Bennett, Diane van Oosterhout, Joep J. Moyo, Kundai Hosseinipour, Mina DeVos, Josh Zhou, Zhiyong Aberle-Grasse, John Warne, Thomas R. Mtika, Clement Chilima, Ben Banda, Richard Pasulani, Olesi Porter, Carol Phiri, Sam Jahn, Andreas Kamwendo, Debbie Jordan, Michael R. Kabuluzi, Storn Chimbwandira, Frank Kagoli, Mathew Matatiyo, Blackson Demby, Austin Yang, Chunfu TI Prevalence of HIV Drug Resistance Before and 1 Year After Treatment Initiation in 4 Sites in the Malawi Antiretroviral Treatment Program SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID FIXED-DOSE COMBINATION; WORLD-HEALTH-ORGANIZATION; REVERSE-TRANSCRIPTASE; SOUTH-AFRICA; TREATMENT FAILURE; THERAPY; MUTATIONS; ADULTS; CHILDREN; REGIMEN AB Since 2004, the Malawi antiretroviral treatment (ART) program has provided a public health-focused system based on World Health Organization clinical staging, standardized first-line ART regimens, limited laboratory monitoring, and no patient-level monitoring of human immunodeficiency virus drug resistance (HIVDR). The Malawi Ministry of Health conducts periodic evaluations of HIVDR development in prospective cohorts at sentinel clinics. We evaluated viral load suppression, HIVDR, and factors associated with HIVDR in 4 ART sites at 12-15 months after ART initiation. More than 70% of patients initiating ART had viral suppression at 12 months. HIVDR prevalence (6.1%) after 12 months of ART was low and largely associated with baseline HIVDR. Better follow-up, removal of barriers to on-time drug pickups, and adherence education for patients 16-24 years of age may further prevent HIVDR. C1 [Wadonda-Kabondo, Nellie] Minist Hlth, Community Hlth Serv Unit, Dept Prevent Hlth, Lilongwe, Malawi. [Bennett, Diane; Aberle-Grasse, John] Ctr Dis Control & Prevent, Strateg Informat & Epidemiol Branch, Div Global HIV AIDS, Atlanta, GA USA. [van Oosterhout, Joep J.] Univ Malawi, Coll Med, Blantyre, Malawi. [Hosseinipour, Mina; Kamwendo, Debbie] UNC Project, Lilongwe, Malawi. [DeVos, Josh; Zhou, Zhiyong; Yang, Chunfu] Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Atlanta, GA USA. [Warne, Thomas R.; Demby, Austin] Ctr Dis Control, Lilongwe, Malawi. [Warne, Thomas R.; Demby, Austin] Prevent Global AIDS Program, Lilongwe, Malawi. [Mtika, Clement] Mzuzu Cent Hosp, Minist Hlth, Lilongwe, Malawi. [Banda, Richard] World Hlth Org, Dept Inter Country Support, Harare, Zimbabwe. [Jahn, Andreas] Minist Hlth, HIV AIDS Dept, Lilongwe, Malawi. [Jordan, Michael R.] World Hlth Org, Dept HIV, Geneva, Switzerland. [Jordan, Michael R.] Tufts Univ, Sch Med, Dept Geog Med & Infect Dis, Boston, MA 02111 USA. RP Wadonda-Kabondo, N (reprint author), Minist Hlth, Community Hlth Serv Unit, Dept Prevent Hlth, Lilongwe, Malawi. EM nelliewadonda@hotmail.com RI Yang, Chunfu/G-6890-2013 FU World Health Organization; US President's Emergency Plan for AIDS Relief through International Laboratory Branch, Division of Global HIV/AIDS, Center for Global Health, CDC; National Institutes of Health [K23 AI074423-05]; Bill & Melinda Gates Foundation [38180] FX This work was supported by the World Health Organization and the US President's Emergency Plan for AIDS Relief through the support of the International Laboratory Branch, Division of Global HIV/AIDS, Center for Global Health, CDC; and the National Institutes of Health (K23 AI074423-05 to M. R. J.).; This article was published as part of a supplement entitled "The World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: Global, Regional, and Country Progress," sponsored by The Bill & Melinda Gates Foundation (38180). NR 28 TC 9 Z9 9 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 15 PY 2012 VL 54 SU 4 BP S362 EP S368 DI 10.1093/cid/cir987 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 933EA UT WOS:000303341300023 PM 22544204 ER PT J AU Wadonda-Kabondo, N Hedt, BL van Oosterhout, JJ Moyo, K Limbambala, E Bello, G Chilima, B Schouten, E Harries, A Massaquoi, M Porter, C Weigel, R Hosseinipour, M Aberle-Grasse, J Jordan, MR Kabuluzi, S Bennett, DE AF Wadonda-Kabondo, Nellie Hedt, Bethany L. van Oosterhout, Joep J. Moyo, Kundai Limbambala, Eddie Bello, George Chilima, Ben Schouten, Erik Harries, Anthony Massaquoi, Moses Porter, Carol Weigel, Ralf Hosseinipour, Mina Aberle-Grasse, John Jordan, Michael R. Kabuluzi, Storn Bennett, Diane E. TI A Retrospective Survey of HIV Drug Resistance Among Patients 1 Year After Initiation of Antiretroviral Therapy at 4 Clinics in Malawi SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID WORLD-HEALTH-ORGANIZATION; FIXED-DOSE COMBINATION; SOUTH-AFRICA; FAILURE; SURVEILLANCE; REGIMEN; ADULTS; INDIVIDUALS; PREVALENCE; PREVENTION AB In 2004, Malawi began scaling up its national antiretroviral therapy (ART) program. Because of limited treatment options, population-level surveillance of acquired human immunodeficiency virus drug resistance (HIVDR) is critical to ensuring long-term treatment success. The World Health Organization target for clinic-level HIVDR prevention at 12 months after ART initiation is >= 70%. In 2007, viral load and HIVDR genotyping was performed in a retrospective cohort of 596 patients at 4 ART clinics. Overall, HIVDR prevention (using viral load < 400 copies/mL) was 72% (95% confidence interval [CI], 67%-77%; range by site, 60%-83%) and detected HIVDR was 3.4% (95% CI, 1.8%-5.8%; range by site, 2.5%-4.7%). Results demonstrate virological suppression and HIVDR consistent with previous reports from sub-Saharan Africa. High rates of attrition because of loss to follow-up were noted and merit attention. C1 [Wadonda-Kabondo, Nellie] Minist Hlth, Community Hlth Serv Unit, Lilongwe, Malawi. [Hedt, Bethany L.] Harvard Univ, Sch Med, Community Hlth Sci Unit, Boston, MA USA. [van Oosterhout, Joep J.] Univ Malawi, Coll Med, Queen Elizabeth Cent Hosp, Blantyre, Malawi. [Limbambala, Eddie] World Hlth Org, Lilongwe, Malawi. [Harries, Anthony] Int Union TB & Lung Dis, Paris, France. [Harries, Anthony] London Sch Hyg & Trop Med, London, England. [Massaquoi, Moses] Thyolo Dist Hosp, Lilongwe, Malawi. [Porter, Carol] Howard Univ, Tech Support Project, Lilongwe, Malawi. [Weigel, Ralf] Lighthouse Trust, Lilongwe, Malawi. [Weigel, Ralf] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England. [Hosseinipour, Mina] Univ N Carolina Project, Lilongwe, Malawi. [Aberle-Grasse, John; Bennett, Diane E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jordan, Michael R.] World Hlth Org, Geneva, Switzerland. [Jordan, Michael R.] Tufts Univ, Sch Med, Boston, MA 02111 USA. RP Wadonda-Kabondo, N (reprint author), Minist Hlth, Community Hlth Serv Unit, Lilongwe, Malawi. EM nelliewadonda@hotmail.com OI Weigel, Ralf/0000-0001-9034-2634 FU WHO; National Institutes of Health [NIH K23 AI074423-05, T32 AI007358]; Bill & Melinda Gates Foundation [38180] FX This survey was supported by the WHO and the National Institutes of Health (grant NIH K23 AI074423-05 to M. R. J.). B. L. H. received funding from the National Institutes of Health (grant T32 AI007358) and was an American Schools of Public Health fellow during the implementation of the survey.; This article was published as part of a supplement entitled "The World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: Global, Regional, and Country Progress," sponsored by The Bill & Melinda Gates Foundation (38180). NR 25 TC 8 Z9 8 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 15 PY 2012 VL 54 SU 4 BP S355 EP S361 DI 10.1093/cid/cis004 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 933EA UT WOS:000303341300022 PM 22544203 ER PT J AU Wroe, PC Finkelstein, JA Ray, GT Linder, JA Johnson, KM Rifas-Shiman, S Moore, MR Huang, SS AF Wroe, Peter C. Finkelstein, Jonathan A. Ray, G. Thomas Linder, Jeffrey A. Johnson, Kristen M. Rifas-Shiman, Sheryl Moore, Matthew R. Huang, Susan S. TI Aging Population and Future Burden of Pneumococcal Pneumonia in the United States SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID HEALTH; DISEASE; IMPACT; COSTS AB Pneumococcal pneumonia is concentrated among the elderly. Using a decision analytic model, we projected the future incidence of pneumococcal pneumonia and associated healthcare utilization and costs accounting for an aging US population. Between 2004 and 2040, as the population increases by 38%, pneumococcal pneumonia hospitalizations will increase by 96% (from 401 000 to 790 000), because population growth is fastest in older age groups experiencing the highest rates of pneumococcal disease. Absent intervention, the total cost of pneumococcal pneumonia will increase by $2.5 billion annually, and the demand for healthcare services for pneumococcal pneumonia, especially inpatient capacity, will double in coming decades. C1 [Wroe, Peter C.; Finkelstein, Jonathan A.; Johnson, Kristen M.; Rifas-Shiman, Sheryl] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Wroe, Peter C.; Finkelstein, Jonathan A.; Johnson, Kristen M.; Rifas-Shiman, Sheryl] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Finkelstein, Jonathan A.] Childrens Hosp Boston, Div Gen Pediat, Boston, MA USA. [Ray, G. Thomas] Kaiser Permanente, Div Res, Oakland, CA USA. [Linder, Jeffrey A.] Brigham & Womens Hosp, Dept Med, Div Gen Med & Primary Care, Boston, MA 02115 USA. [Moore, Matthew R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Huang, Susan S.] Univ Calif Irvine, Irvine Sch Med, Div Infect Dis, Orange, CA 92868 USA. [Huang, Susan S.] Univ Calif Irvine, Irvine Sch Med, Hlth Policy Res Inst, Orange, CA 92868 USA. RP Huang, SS (reprint author), Univ Calif Irvine, Irvine Sch Med, Div Infect Dis, 101 City Dr S,City Tower,Suite 400,ZC 4081, Orange, CA 92868 USA. EM sshuang@uci.edu FU CDC [TS-1363]; Pfizer FX This work was supported by the CDC (grant number TS-1363 to J. A. F.).; J. A. L. has received research grants from Pfizer to study electronic adverse drug event reporting and Roche to study use of anti-influenza medications. G. T. R. has received research support from Pfizer, GlaxoSmithKline, and Merck. All other authors report no potential conflicts. NR 13 TC 43 Z9 44 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 15 PY 2012 VL 205 IS 10 BP 1589 EP 1592 DI 10.1093/infdis/jis240 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 932ZO UT WOS:000303329200016 PM 22448012 ER PT J AU Cuevas, LE Browning, R Bossuyt, P Casenghi, M Cotton, MF Cruz, AT Dodd, LE Drobniewski, F Gale, M Graham, SM Grzemska, M Heinrich, N Hesseling, AC Huebner, R Jean-Philippe, P Kabra, SK Kampmann, B Lewinsohn, D Li, MJ Lienhardt, C Mandalakas, AM Marais, BJ Menzies, HJ Montepiedra, G Mwansambo, C Oberhelman, R Palumbo, P Russek-Cohen, E Shapiro, DE Smith, B Soto-Castellares, G Starke, JR Swaminathan, S Wingfield, C Worrell, C AF Cuevas, Luis E. Browning, Renee Bossuyt, Patrick Casenghi, Martina Cotton, Mark F. Cruz, Andrea T. Dodd, Lori E. Drobniewski, Francis Gale, Marianne Graham, Stephen M. Grzemska, Malgosia Heinrich, Norbert Hesseling, Anneke C. Huebner, Robin Jean-Philippe, Patrick Kabra, Sushil Kumar Kampmann, Beate Lewinsohn, Deborah Li, Meijuan Lienhardt, Christian Mandalakas, Anna M. Marais, Ben J. Menzies, Heather J. Montepiedra, Grace Mwansambo, Charles Oberhelman, Richard Palumbo, Paul Russek-Cohen, Estelle Shapiro, David E. Smith, Betsy Soto-Castellares, Giselle Starke, Jeffrey R. Swaminathan, Soumya Wingfield, Claire Worrell, Carol TI Evaluation of Tuberculosis Diagnostics in Children: 2. Methodological Issues for Conducting and Reporting Research Evaluations of Tuberculosis Diagnostics for Intrathoracic Tuberculosis in Children. Consensus From an Expert Panel(a) SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID DRUG-SUSCEPTIBILITY ASSAY; POLYMERASE-CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; MICROSCOPIC-OBSERVATION; PULMONARY TUBERCULOSIS; ACCURACY; SPUTUM; TESTS AB Confirming the diagnosis of childhood tuberculosis is a major challenge. However, research on childhood tuberculosis as it relates to better diagnostics is often neglected because of technical difficulties, such as the slow growth in culture, the difficulty of obtaining specimens, and the diverse and relatively nonspecific clinical presentation of tuberculosis in this age group. Researchers often use individually designed criteria for enrollment, diagnostic classifications, and reference standards, thereby hindering the interpretation and comparability of their findings. The development of standardized research approaches and definitions is therefore needed to strengthen the evaluation of new diagnostics for detection and confirmation of tuberculosis in children. In this article we present consensus statements on methodological issues for conducting research of Tuberculosis diagnostics among children, with a focus on intrathoracic tuberculosis. The statements are complementary to a clinical research case definition presented in an accompanying publication and suggest a phased approach to diagnostics evaluation; entry criteria for enrollment; methods for classification of disease certainty, including the rational use of culture within the case definition; age categories and comorbidities for reporting results; and the need to use standard operating procedures. Special consideration is given to the performance of microbiological culture in children and we also recommend for alternative methodological approaches to report findings in a standardized manner to overcome these limitations are made. This consensus statement is an important step toward ensuring greater rigor and comparability of pediatric tuberculosis diagnostic research, with the aim of realizing the full potential of better tests for children. C1 [Cuevas, Luis E.] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England. [Browning, Renee; Jean-Philippe, Patrick] NIAID, Henry Jackson Fdn, HIV AIDS Sci & Operat Support HJF DAIDS, Bethesda, MD 20892 USA. [Bossuyt, Patrick] Univ Amsterdam, NL-1012 WX Amsterdam, Netherlands. [Casenghi, Martina] Med Sans Frontieres, Geneva, Switzerland. [Cotton, Mark F.] Univ Stellenbosch, Tygerberg Childrens Hosp, Childrens Infect Dis Clin Res Unit, Cape Town, South Africa. [Cruz, Andrea T.; Starke, Jeffrey R.] Baylor Sch Med, Houston, TX USA. [Dodd, Lori E.] NIAID, Biostat Res Branch, NIH, Bethesda, MD 20892 USA. [Drobniewski, Francis] Barts & London Queen Marys Sch Med & Dent, Hlth Protect Agcy, Natl Mycobacterium Reference Lab, London, England. [Drobniewski, Francis] Barts & London Queen Marys Sch Med & Dent, Clin TB & HIV Grp, London, England. [Gale, Marianne] Med Sans Frontieres, Sydney, NSW, Australia. [Graham, Stephen M.] Univ Melbourne, Dept Paediat, Ctr Int Child Hlth, Melbourne, Vic 3010, Australia. [Graham, Stephen M.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Murdoch, WA, Australia. [Grzemska, Malgosia; Lienhardt, Christian] WHO, STOP TB Dept, CH-1211 Geneva, Switzerland. [Heinrich, Norbert] Univ Munich, Med Ctr, Div Infect Dis & Trop Med, D-80539 Munich, Germany. [Hesseling, Anneke C.] Univ Stellenbosch, Desmond Tutu TB Ctr, Cape Town, South Africa. [Huebner, Robin] NIAID, Epidemiol Branch, Div Aids, NIH, Bethesda, MD 20892 USA. [Kabra, Sushil Kumar] All India Inst Med Sci, New Delhi, India. [Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London SW7 2AZ, England. [Kampmann, Beate] MRC, Banjul, Gambia. [Lewinsohn, Deborah] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA. [Li, Meijuan] US FDA, Div Biostat, Ctr Devices & Radiol Hlth, Silver Spring, MD USA. [Mandalakas, Anna M.] Texas Childrens Hosp, Baylor Coll Med, Ctr Global Hlth, Sect Retrovirol & Global Hlth, Houston, TX 77030 USA. [Marais, Ben J.] Univ Sydney, Childrens Hosp Westmead, Sydney, NSW 2006, Australia. [Menzies, Heather J.] Ctr Dis Control & Prevent, Int Res & Programs Branch, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Montepiedra, Grace; Shapiro, David E.] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA. [Mwansambo, Charles] Minist Hlth, Lilongwe, Malawi. [Oberhelman, Richard] Tulane Sch Publ Hlth & Trop Med, Dept Trop Med, New Orleans, LA USA. [Oberhelman, Richard] Tulane Sch Publ Hlth & Trop Med, Dept Pediat, New Orleans, LA USA. [Palumbo, Paul] Dartmouth Med Sch, Lebanon, NH USA. [Russek-Cohen, Estelle] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA. [Smith, Betsy] NIAID, Maternal Adolescent Pediat Res Branch, Div Aids, NIH, Bethesda, MD 20892 USA. [Soto-Castellares, Giselle] USN, Dept Emerging Infect Dis, Med Res Unit 6, Bellavista, Callao, Peru. [Swaminathan, Soumya] Natl Inst Res TB, Madras, Tamil Nadu, India. [Wingfield, Claire] Treatment Act Grp, New York, NY USA. [Worrell, Carol] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, NIH, Rockville, MD USA. RP Cuevas, LE (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Pembroke Pl, Liverpool L3 5QA, Merseyside, England. EM lcuevas@liv.ac.uk RI Bossuyt, Patrick/B-4557-2016; Heinrich, Norbert/B-3750-2014; OI Bossuyt, Patrick/0000-0003-4427-0128; Cuevas, Luis E./0000-0002-6581-0587 FU National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Institute of Child Health and Human Development; Centers for Disease Control and Prevention; Office of Global AIDS Coordinator; US Department of Department of Health and Human Services [HHSN272200800014C]; International Maternal Pediatric Adolescent AIDS Clinical Trials Group Statistical and Data Management Center [UM01 AI068616]; Thrasher Research Fund [02824-6] FX This work was supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, National Institute of Child Health and Human Development, Centers for Disease Control and Prevention, and Office of Global AIDS Coordinator. Funding from these institutions was not associated with a research grant but supported directly the scientific workshop from which this work was generated. The project was also supported in part with US federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and US Department of Department of Health and Human Services (contract HHSN272200800014C). D. S. and G. M. were supported by the International Maternal Pediatric Adolescent AIDS Clinical Trials Group Statistical and Data Management Center grant (grant No UM01 AI068616). L. E. C. was supported by a Thrasher Research Fund grant (contract 02824-6). NR 26 TC 37 Z9 37 U1 1 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 15 PY 2012 VL 205 SU 2 BP S209 EP S215 DI 10.1093/infdis/jir879 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 932ZT UT WOS:000303329700008 PM 22476719 ER PT J AU Graham, SM Ahmed, T Amanullah, F Browning, R Cardenas, V Casenghi, M Cuevas, LE Gale, M Gie, RP Grzemska, M Handelsman, E Hatherill, M Hesseling, AC Jean-Philippe, P Kampmann, B Kabra, SK Lienhardt, C Lighter-Fisher, J Madhi, S Makhene, M Marais, BJ McNeeley, DF Menzies, H Mitchell, C Modi, S Mofenson, L Musoke, P Nachman, S Powell, C Rigaud, M Rouzier, V Starke, JR Swaminathan, S Wingfield, C AF Graham, Stephen M. Ahmed, Tahmeed Amanullah, Farhana Browning, Renee Cardenas, Vicky Casenghi, Martina Cuevas, Luis E. Gale, Marianne Gie, Robert P. Grzemska, Malgosia Handelsman, Ed Hatherill, Mark Hesseling, Anneke C. Jean-Philippe, Patrick Kampmann, Beate Kabra, Sushil Kumar Lienhardt, Christian Lighter-Fisher, Jennifer Madhi, Shabir Makhene, Mamodikoe Marais, Ben J. McNeeley, David F. Menzies, Heather Mitchell, Charles Modi, Surbhi Mofenson, Lynne Musoke, Philippa Nachman, Sharon Powell, Clydette Rigaud, Mona Rouzier, Vanessa Starke, Jeffrey R. Swaminathan, Soumya Wingfield, Claire TI Evaluation of Tuberculosis Diagnostics in Children: 1. Proposed Clinical Case Definitions for Classification of Intrathoracic Tuberculosis Disease. Consensus From an Expert Panel SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID HIV-INFECTED ADULTS; XPERT MTB/RIF TEST; CHILDHOOD TUBERCULOSIS; PULMONARY TUBERCULOSIS; SOUTH-AFRICA; PEDIATRIC TUBERCULOSIS; RESISTANT TUBERCULOSIS; ACCURACY AB There is a critical need for improved diagnosis of tuberculosis in children, particularly in young children with intrathoracic disease as this represents the most common type of tuberculosis in children and the greatest diagnostic challenge. There is also a need for standardized clinical case definitions for the evaluation of diagnostics in prospective clinical research studies that include children in whom tuberculosis is suspected but not confirmed by culture of Mycobacterium tuberculosis. A panel representing a wide range of expertise and child tuberculosis research experience aimed to develop standardized clinical research case definitions for intrathoracic tuberculosis in children to enable harmonized evaluation of new tuberculosis diagnostic technologies in pediatric populations. Draft definitions and statements were proposed and circulated widely for feedback. An expert panel then considered each of the proposed definitions and statements relating to clinical definitions. Formal group consensus rules were established and consensus was reached for each statement. The definitions presented in this article are intended for use in clinical research to evaluate diagnostic assays and not for individual patient diagnosis or treatment decisions. A complementary article addresses methodological issues to consider for research of diagnostics in children with suspected tuberculosis. C1 [Graham, Stephen M.] Univ Melbourne, Royal Childrens Hosp, Ctr Int Child Hlth, Dept Paediat & Murdoch Childrens,Res Inst, Parkville, Vic 3052, Australia. [Graham, Stephen M.] Int Union TB & Lung Dis, Paris, France. [Ahmed, Tahmeed] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Amanullah, Farhana] Indus Hosp, Karachi, Pakistan. [Browning, Renee; Jean-Philippe, Patrick] NIAID, Henry Jackson Fdn, Maternal Adolescent Pediat Res Branch, Div Aids,NIH, Bethesda, MD 20892 USA. [Cardenas, Vicky] Aeras, Rockville, MD USA. [Casenghi, Martina] Med Sans Frontieres, Geneva, Switzerland. [Cuevas, Luis E.] Univ Liverpool, Sch Trop Med, Liverpool L69 3BX, Merseyside, England. [Gale, Marianne] Med Sans Frontieres, Sydney, NSW, Australia. [Gie, Robert P.] Univ Stellenbosch, Dept Paediat & Child Hlth, Cape Town, South Africa. [Grzemska, Malgosia; Lienhardt, Christian] WHO, Stop TB Partnership, CH-1211 Geneva, Switzerland. [Handelsman, Ed] NIAID, Maternal Adolescent Pediat Res Branch, Div Aids, NIH, Bethesda, MD 20892 USA. [Hatherill, Mark] Univ Cape Town, Sch Child & Adolescent Hlth, S African TB Vaccine Initiat, ZA-7925 Cape Town, South Africa. [Hesseling, Anneke C.] Univ Stellenbosch, Desmond Tutu TB Ctr, Dept Paediat & Child Hlth, Cape Town, South Africa. [Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London, England. [Kampmann, Beate] MRC Labs, Banjul, Gambia. [Kabra, Sushil Kumar] All India Inst Med Sci, New Delhi, India. [Lighter-Fisher, Jennifer; Rigaud, Mona] NYU, Sch Med, New York, NY USA. [Madhi, Shabir] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Johannesburg, South Africa. [Makhene, Mamodikoe] NIAID, Div Microbiol & Infect Dis, NIH, Bethesda, MD 20892 USA. [Marais, Ben J.] Univ Sydney, Childrens Hosp Westmead, Sydney, NSW 2006, Australia. [McNeeley, David F.] Med Serv Corp Int, Arlington, VA USA. [Menzies, Heather] Ctr Dis Control & Prevent, Int Res & Programs Branch, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Mitchell, Charles] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Modi, Surbhi] Ctr Dis Control & Prevent, Maternal & Child Hlth Branch, Div Global HIV AIDS, Atlanta, GA USA. [Mofenson, Lynne] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, NIH, Rockville, MD USA. [Musoke, Philippa] Makerere Univ Johns Hopkins Univ Res Collaborat, Kampala, Uganda. [Nachman, Sharon] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA. [Powell, Clydette] US Agcy Int Dev, Div Infect Dis, Off Hlth Infect Dis & Nutr, Bur Global Hlth, Washington, DC 20523 USA. [Rouzier, Vanessa] GHESKIO Ctr, Port Au Prince, Haiti. [Starke, Jeffrey R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Swaminathan, Soumya] Natl Inst Res TB, Chennai, Tamil Nadu, India. [Wingfield, Claire] Treatment Act Grp, New York, NY USA. RP Graham, SM (reprint author), Univ Melbourne, Royal Childrens Hosp, Ctr Int Child Hlth, Dept Paediat, Flemington Rd, Parkville, Vic 3052, Australia. EM steve.graham@rch.org.au; jeanphilippep@niaid.nih.gov OI Mofenson, Lynne/0000-0002-2818-9808; Lighter, Jennifer/0000-0002-9313-2103; Cuevas, Luis E./0000-0002-6581-0587; Kampmann, Beate/0000-0002-6546-4709 FU NIAID/NIH; Eunice Kennedy Shriver NICHD; CDC; OGAC; NIAID/NIH, US DHHS [HHSN272200800014C] FX This work was supported by NIAID/NIH, Eunice Kennedy Shriver NICHD, CDC, and OGAC. This project has also been supported in part with federal funds from the NIAID/NIH, US DHHS, under contract no. HHSN272200800014C. NR 32 TC 124 Z9 124 U1 0 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 15 PY 2012 VL 205 SU 2 BP S199 EP S208 DI 10.1093/infdis/jis008 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 932ZT UT WOS:000303329700007 PM 22448023 ER PT J AU Nahid, P Kim, PS Evans, CA Alland, D Barer, M Diefenbach, J Ellner, J Hafner, R Hamilton, CD Iademarco, MF Ireton, G Kimerling, ME Lienhardt, C MacKenzie, WR Murray, M Perkins, MD Posey, JE Roberts, T Sizemore, C Stevens, WS Via, L Williams, SD Yew, WW Swindells, S AF Nahid, Payam Kim, Peter S. Evans, Carlton A. Alland, David Barer, Michael Diefenbach, Jane Ellner, Jerrold Hafner, Richard Hamilton, Carol Dukes Iademarco, Michael F. Ireton, Gregory Kimerling, Michael E. Lienhardt, Christian MacKenzie, William R. Murray, Megan Perkins, Mark D. Posey, Jamie E. Roberts, Teri Sizemore, Christine Stevens, Wendy S. Via, Laura Williams, Sharon D. Yew, Wing W. Swindells, Susan TI Clinical Research and Development of Tuberculosis Diagnostics: Moving From Silos to Synergy SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID MEDIATED ISOTHERMAL AMPLIFICATION; MULTIDRUG-RESISTANT TUBERCULOSIS; DRUG-SUSCEPTIBILITY ASSAY; SPUTUM SMEAR MICROSCOPY; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; MOLECULAR-DETECTION; MASS-SPECTROMETRY; META-REGRESSION; LIQUID CULTURE AB The development, evaluation, and implementation of new and improved diagnostics have been identified as critical needs by human immunodeficiency virus (HIV) and tuberculosis researchers and clinicians alike. These needs exist in international and domestic settings and in adult and pediatric populations. Experts in tuberculosis and HIV care, researchers, healthcare providers, public health experts, and industry representatives, as well as representatives of pertinent US federal agencies (Centers for Disease Control and Prevention, Food and Drug Administration, National Institutes of Health, United States Agency for International Development) assembled at a workshop proposed by the Diagnostics Working Group of the Federal Tuberculosis Taskforce to review the state of tuberculosis diagnostics development in adult and pediatric populations. C1 [Nahid, Payam] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA 94110 USA. [Nahid, Payam] Univ Calif San Francisco, Curry Int TB Ctr, San Francisco, CA 94110 USA. [Kim, Peter S.; Hafner, Richard; Williams, Sharon D.] NIAID, Div Aids, Bethesda, MD 20892 USA. [Evans, Carlton A.] Univ Peruana Cayetano Heredia, IFHAD, Lima, Peru. [Evans, Carlton A.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis & Immun, London SW7 2AZ, England. [Alland, David] Univ Med & Dent New Jersey, Dept Med, Ctr Emerging & Reemerging Pathogens, Newark, NJ 07103 USA. [Barer, Michael] Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England. [Diefenbach, Jane] PharmaStat LLC, Newark, CA USA. [Ellner, Jerrold] Boston Univ Sch Med & Med Ctr, Dept Med, Infect Dis Sect, Boston, MA USA. [Hamilton, Carol Dukes] Family Hlth Int, Durham, NC USA. [Ireton, Gregory] Bill & Melinda Gates Fdn, Infect Dis Res Inst, Seattle, WA USA. [Kimerling, Michael E.] Bill & Melinda Gates Fdn, Global Hlth Program, Seattle, WA USA. [Lienhardt, Christian] WHO, Stop TB Partnership, CH-1211 Geneva, Switzerland. [Iademarco, Michael F.; MacKenzie, William R.; Posey, Jamie E.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Murray, Megan] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Perkins, Mark D.] Fdn Innovat New Diagnost, Geneva, Switzerland. [Roberts, Teri] Med San Frontieres, Campaign Access Essential Med, Geneva, Switzerland. [Sizemore, Christine] NIAID, Div Microbiol & Infect Dis, Bethesda, MD 20892 USA. [Stevens, Wendy S.] Univ Witwatersrand, Johannesburg, South Africa. [Stevens, Wendy S.] Natl Hlth Lab Serv, Johannesburg, South Africa. [Via, Laura] NIAID, Lab Clin Infect Dis, TB Res Sect, Bethesda, MD 20892 USA. [Yew, Wing W.] Hong Kong TB Chest & Heart Dis Assoc, Hong Kong, Hong Kong, Peoples R China. [Swindells, Susan] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA. RP Nahid, P (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Pulm & Crit Care Med, 1001 Potrero Ave,5K1, San Francisco, CA 94110 USA. EM pnahid@ucsf.edu; kimp2@niaid.nih.gov; rhafner@niaid.nih.gov RI Mac Kenzie, William /F-1528-2013; OI Mac Kenzie, William /0000-0001-7723-0339; Evans, Carlton/0000-0002-6873-5447; Via, Laura/0000-0001-6074-9521 FU CDC; NIAID; Office of the Global AIDS Coordinator; National Institute of Child Health and Human Development; National Heart, Lung, and Blood Institute of the NIH [K23HL092629]; Wellcome Trust; Bill and Melinda Gates Foundation [28766.01]; FIND; Innovation For Health and Development FX We thank the meeting organizing committee (Ms Bonnie Plikaytis [CDC], and Drs Gail Jacobs [NIAID], Mamodikoe Makhene [NIAID], and Christine Sizemore [NIAID]), and the sponsors (CDC, NIAID, Office of the Global AIDS Coordinator, and the National Institute of Child Health and Human Development) for organizing and supporting this workshop.; This work was supported by the National Heart, Lung, and Blood Institute of the NIH (K23HL092629 to P. N.) and the Wellcome Trust, FIND, and Innovation For Health and Development (to C.A. E.).; M. P. has no commercial associations or other conflicts of interest relevant to the work presented. He was supported by a grant from the Bill and Melinda Gates Foundation (grant number 28766.01). A. D. reports that he and his laboratory receive licensing income for the use of molecular beacons in the GeneXpert MTB/RIF assay. His personal income has been voluntarily and irrevocably capped at $5,000 per year and income to his laboratory has been voluntarily capped at $50,000 per year. All other authors: no reported conflicts. NR 61 TC 14 Z9 15 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 15 PY 2012 VL 205 SU 2 BP S159 EP S168 DI 10.1093/infdis/jis194 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 932ZT UT WOS:000303329700003 PM 22476718 ER PT J AU Schito, M Peter, TF Cavanaugh, S Piatek, AS Young, GJ Alexander, H Coggin, W Domingo, GJ Ellenberger, D Ermantraut, E Jani, IV Katamba, A Palamountain, KM Essajee, S Dowdy, DW AF Schito, Marco Peter, Trevor F. Cavanaugh, Sean Piatek, Amy S. Young, Gloria J. Alexander, Heather Coggin, William Domingo, Gonzalo J. Ellenberger, Dennis Ermantraut, Eugen Jani, Ilesh V. Katamba, Achilles Palamountain, Kara M. Essajee, Shaffiq Dowdy, David W. TI Opportunities and Challenges for Cost-Efficient Implementation of New Point-of-Care Diagnostics for HIV and Tuberculosis SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID RESOURCE-LIMITED SETTINGS; ANTIRETROVIRAL THERAPY; INFECTED ADULTS; SCALING-UP; HEALTH; TESTS; PREVENTION; TRANSMISSION; TECHNOLOGIES; METAANALYSIS AB Stakeholders agree that supporting high-quality diagnostics is essential if we are to continue to make strides in the fight against human immunodeficiency virus (HIV) and tuberculosis. Despite the need to strengthen existing laboratory infrastructure, which includes expanding and developing new laboratories, there are clear diagnostic needs where conventional laboratory support is insufficient. Regarding HIV, rapid point-of-care (POC) testing for initial HIV diagnosis has been successful, but several needs remain. For tuberculosis, several new diagnostic tests have recently been endorsed by the World Health Organization, but a POC test remains elusive. Human immunodeficiency virus and tuberculosis are coendemic in many high prevalence locations, making parallel diagnosis of these conditions an important consideration. Despite its clear advantages, POC testing has important limitations, and laboratory-based testing will continue to be an important component of future diagnostic networks. Ideally, a strategic deployment plan should be used to define where and how POC technologies can be most efficiently and cost effectively integrated into diagnostic algorithms and existing test networks prior to widespread scale-up. In this fashion, the global community can best harness the tremendous capacity of novel diagnostics in fighting these 2 scourges. C1 [Schito, Marco] NIAID, Henry M Jackson Fdn Adv Mil Med, Vaccine Clin Res Branch, Div Aids,NIH, Bethesda, MD 20892 USA. [Peter, Trevor F.] Clinton Hlth Access Initiat, Boston, MA USA. [Cavanaugh, Sean] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Piatek, Amy S.] US Agcy Int Dev, Washington, DC 20523 USA. [Young, Gloria J.] Becton Dickinson Biosci, San Jose, CA USA. [Alexander, Heather; Ellenberger, Dennis] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Coggin, William] US Dept State, Off US Global AIDS, Washington, DC 20520 USA. [Domingo, Gonzalo J.] PATH, Seattle, WA USA. [Ermantraut, Eugen] Alere Technol GmbH, Jena, Germany. [Jani, Ilesh V.] Inst Nacl Saude, Maputo, Mozambique. [Katamba, Achilles] Makerere Univ, Kampala, Uganda. [Palamountain, Kara M.] Northwestern Univ, Kellogg Sch Management, Evanston, IL USA. [Essajee, Shaffiq] WHO, HIV Dept, CH-1211 Geneva, Switzerland. [Dowdy, David W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Schito, M (reprint author), NIAID, Henry M Jackson Fdn Adv Mil Med, Vaccine Clin Res Branch, Div Aids,NIH, 6700-B Rockledge Dr,Rm 5255, Bethesda, MD 20892 USA. EM schitom@niaid.nih.gov FU Office of the US Global AIDS Coordinator, US Department of State; US Centers for Disease Control and Prevention; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200800014C] FX This project has been funded in part with federal funds from the Office of the US Global AIDS Coordinator, US Department of State, US Centers for Disease Control and Prevention, and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services (contract HHSN272200800014C). NR 67 TC 34 Z9 34 U1 0 U2 18 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 15 PY 2012 VL 205 SU 2 BP S169 EP S180 DI 10.1093/infdis/jis044 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 932ZT UT WOS:000303329700004 PM 22457286 ER PT J AU Byrd, KK Lu, PJ Murphy, TV AF Byrd, Kathy K. Lu, Peng-jun Murphy, Trudy V. TI Baseline hepatitis B vaccination coverage among persons with diabetes before implementing a US recommendation for vaccination SO VACCINE LA English DT Article DE Hepatitis B vaccination; Diabetes; Vaccination ID UNITED-STATES; LIVER-DISEASE; ADULTS; VIRUS AB Background: Recent data suggest that adults with diabetes are at increased risk of incident hepatitis B infection and may suffer increased morbidity or mortality from chronic hepatitis B infection. In October 2011, the Advisory Committee on Immunization Practices (ACIP) recommended hepatitis B vaccination (HepB) for persons with diabetes aged 19-59 years and stated that persons with diabetes aged 60 years and older should be considered for vaccination. Objective: To determine HepB coverage among persons with diabetes aged >= 19 years prior to implementation of the new ACIP recommendation and to determine predictors for vaccination. Methods: We used the 2009 National Health Interview Survey to determine weighted proportions of self-reported HepB coverage (>= 1 and >= 3 doses) among persons with diabetes aged >= 19 years. A multivariable logistic regression analysis was performed to determine factors independently associated with vaccination. Results: Overall, 19.5% (95% CI: 17.4-21.6%) and 16.6% (14.7-18.6%) of persons with diabetes, aged >= 19 years, reported receiving >= 1 and >= 3 doses of HepB, respectively, compared with 30.3% (29.4-31.3%) and 26.5% (25.5-27.4%) among persons without diabetes. While unadjusted HepB coverage was higher among persons without diabetes, diabetes status was not associated with >= 1 or >= 3 dose vaccination. Among persons with diabetes, being a healthcare provider (OR 4.2, 2.5-7.0), ever tested for HIV (OR 2.6, 1.8-3.6), high-risk behaviors (OR 1.8, 1.0-3.4, P-value = 0.053) and having some college education (OR 1.7, 1.2-2.4) were all independently associated with vaccination. Conclusion: HepB coverage among persons with diabetes is low. These data can be used to provide a baseline for measuring future progress toward vaccination of persons with diabetes. Published by Elsevier Ltd. C1 [Byrd, Kathy K.; Murphy, Trudy V.] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Byrd, KK (reprint author), Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd,NE,Mail Stop G-37, Atlanta, GA 30333 USA. EM gdn8@cdc.gov NR 16 TC 4 Z9 4 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 14 PY 2012 VL 30 IS 23 BP 3376 EP 3382 DI 10.1016/j.vaccine.2012.03.055 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 937WW UT WOS:000303695500005 PM 22472793 ER PT J AU Gidengil, C Lieu, TA Payne, K Rusinak, D Messonnier, M Prosser, LA AF Gidengil, Courtney Lieu, Tracy A. Payne, Katherine Rusinak, Donna Messonnier, Mark Prosser, Lisa A. TI Parental and societal values for the risks and benefits of childhood combination vaccines SO VACCINE LA English DT Article DE Vaccines; Combination vaccines; Childhood vaccines; Economic analysis; Discrete choice experiment ID WILLINGNESS-TO-PAY; HEALTH-CARE; VACCINATION; PREFERENCES AB Background: New combination vaccines reduce the number of injections needed for immunization. However, possible drawbacks include higher prices, extra doses of vaccine antigens and increased minor adverse events. Our objective was to measure parental and societal values for attributes of childhood combination vaccines. Methods: We conducted a discrete choice experiment using an online survey of adults administered by Knowledge Networks. Values were measured for attributes of combination vaccines for a hypothetical child aged 6 months: (1) number of injections, (2) extra dose of hepatitis B vaccine, (3) 20% higher chance of fever, (4) community-level immunization coverage of 2-year-olds of 90% or 80%, and (5) cost per visit. Logistic regression with generalized estimating equations was used to analyze the value of different attributes and generate a marginal willingness-to-pay for a change in attribute level. Results: The response rate was 64% (N = 558). Most respondents were parents (63%) and most respondents agreed that combination vaccines were safe (77%). Respondents were willing to pay $7.68 to avoid an injection (compared to $9.94 when looking at parents only). However, respondents were willing to pay $41.57 to avoid higher risk of fever after one set of immunizations (10% versus 30%) and $65.42 for higher immunization coverage rates. These results were very similar for parents only. There was no significant preference to avoid an extra dose of hepatitis B vaccine. Conclusions: Respondents were willing to pay larger amounts to avoid increased risk of minor adverse events and to increase community-level immunization coverage than to avoid injections. These values should be taken into account when determining the risks and benefits of combination vaccines. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Gidengil, Courtney] RAND Corp, Boston, MA 02116 USA. [Gidengil, Courtney] Harvard Pediat Hlth Serv Res Fellowship, Boston, MA USA. [Gidengil, Courtney] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Infect Dis, Boston, MA USA. [Lieu, Tracy A.; Rusinak, Donna; Prosser, Lisa A.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Ctr Child Hlth Care Studies, Boston, MA USA. [Lieu, Tracy A.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Gen Pediat, Boston, MA USA. [Payne, Katherine] Univ Manchester, Sch Community Based Med, Manchester M13 9PL, Lancs, England. [Messonnier, Mark] Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, Atlanta, GA USA. [Prosser, Lisa A.] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Child Hlth Evaluat & Res Unit, Ann Arbor, MI USA. RP Gidengil, C (reprint author), RAND Corp, 20 Pk Plaza,Suite 920, Boston, MA 02116 USA. EM gidengil@rand.org OI Payne, Katherine/0000-0002-3938-4350 FU Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases [U01 IP000143-01]; Agency for Healthcare Research and Quality (AHRQ) through the Harvard Pediatric Health Services FX The authors have no financial disclosures or conflict of interest to report. This study was funded by cooperative agreement U01 IP000143-01 from the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases. The views in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention, US Department of Health and Human Services. Dr. Gidengil was supported by Grant T32 HS000063-13 from the Agency for Healthcare Research and Quality (AHRQ) through the Harvard Pediatric Health Services Research Fellowship Program. The funders had no role in the design and conduct of the study; or collection, management, analysis, and interpretation of the data. The CDC reviewed the manuscript. All authors made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted. All authors have approved the final article. NR 29 TC 15 Z9 16 U1 0 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 14 PY 2012 VL 30 IS 23 BP 3445 EP 3452 DI 10.1016/j.vaccine.2012.03.022 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 937WW UT WOS:000303695500014 PM 22449423 ER PT J AU Kourtis, AP Bulterys, M Hu, DJ Jamieson, DJ AF Kourtis, Athena P. Bulterys, Marc Hu, Dale J. Jamieson, Denise J. TI HIV-HBV Coinfection - A Global Challenge SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID HEPATITIS-B; TRANSMISSION C1 [Kourtis, Athena P.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Hu, Dale J.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Bulterys, Marc] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Bulterys, Marc] CDC Global AIDS Program, Beijing, Peoples R China. RP Kourtis, AP (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. FU Intramural CDC HHS [CC999999] NR 5 TC 57 Z9 60 U1 0 U2 10 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 10 PY 2012 VL 366 IS 19 BP 1749 EP 1752 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 939NB UT WOS:000303817000001 PM 22571198 ER PT J AU Zheng, Q Ruone, S Switzer, WM Heneine, W Garcia-Lerma, JG AF Zheng, Qi Ruone, Susan Switzer, William M. Heneine, Walid Garcia-Lerma, J. Gerardo TI Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis SO RETROVIROLOGY LA English DT Article DE Single genome amplification; Pre-exposure prophylaxis; Emtricitabine; Truvada ID IMMUNODEFICIENCY-VIRUS-INFECTION; RHESUS MACAQUES; HIV-1 INFECTION; TRANSMISSION; REPLICATION; EVOLUTION; VARIANTS; ENVELOPE AB Background: Pre-exposure prophylaxis (PrEP) with daily Truvada [a combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF)] is a novel HIV prevention strategy recently found to prevent HIV transmission among men who have sex with men and heterosexual couples. Acute infection in adherent persons who fail PrEP will inevitably occur under concurrent antiretroviral therapy, thus raising questions regarding the potential impact of PrEP on early viral dynamics. We investigated viral evolution dynamics in a macaque model of PrEP consisting of repeated rectal exposures to SHIV162P3 in the presence of PrEP. Results: Four macaques were infected during daily or intermittent PrEP with FTC or FTC/TDF, and five were untreated controls. SHIV env sequence evolution was monitored by single genome amplification with phylogenetic and sequence analysis. Mean nucleotide divergence from transmitted founder viruses calculated 17 weeks (range = 12 20) post peak viremia was significantly lower in PrEP failures than in control animals (7.2 x 10(-3) compared to 1.6 x 10(-2) nucleotide substitutions per site per year, respectively, p < 0.0001). Mean virus diversity was also lower in PrEP failures after 17 weeks (0.13% vs. 0.53% in controls, p < 0.0001). Conclusions: Our results in a macaque model of acute HIV infection suggest that infection during PrEP limits early virus evolution likely because of a direct antiviral effect of PrEP and/or reduced target cell availability. Reduced virus diversification during early infection might enhance immune control by slowing the selection of escape mutants. C1 [Garcia-Lerma, J. Gerardo] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Garcia-Lerma, JG (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM GGarcia-Lerma@cdc.gov FU CDC [Y1-AI-0681-02]; NIH [Y1-AI-0681-02] FX This work was partially supported by Interagency Agreement Y1-AI-0681-02 between CDC and NIH. NR 28 TC 8 Z9 8 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4690 J9 RETROVIROLOGY JI Retrovirology PD MAY 9 PY 2012 VL 9 AR 40 DI 10.1186/1742-4690-9-40 PG 11 WC Virology SC Virology GA 985XN UT WOS:000307303900001 PM 22571771 ER PT J AU Lu, PJ Dorell, C Yankey, D Santibanez, TA Singleton, JA AF Lu, Peng-jun Dorell, Christina Yankey, David Santibanez, Tammy A. Singleton, James A. TI A comparison of parent and provider reported influenza vaccination status of adolescents SO VACCINE LA English DT Article DE Influenza vaccination; Vaccination coverage; Parent report; Adolescent; Validity ID IMMUNIZATION SURVEY-TEEN; MOTHERS REPORTS; CHILDREN; ACCURACY; EMERGENCY; VALIDITY; RECALL; CARE; HISTORIES; VACCINES AB Objective: To compare parent and provider reported influenza vaccination status among adolescents. Methods: Data from the 2009 National Immunization Survey-Teen (NIS-Teen) were analyzed. The NIS-Teen is a nationally representative random-digit-dialed telephone survey of households with adolescents 13-17 years at the time of interview, followed by a mail survey to the adolescent's vaccination providers to obtain provider-reported vaccination histories. During the interview a parent or guardian was asked if the adolescent had received an influenza vaccination and whether their response was based upon recall only or from consulting a parent-held vaccination record (i.e., shot card) with recall of additional vaccinations not recorded on the shot card. Parent-reported influenza vaccination status was compared with provider-reported vaccination status by calculating various validity measures (sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV], and kappa), overall and stratified by several demographic characteristics. In the main analysis, provider-reported vaccinations were considered the gold standard. To evaluate the completeness of provider-reporting, we conducted additional analysis that also considered vaccinations reported by parents from the shot card or reported received in a non-medical setting as "true" vaccinations. Results: During the 2008-2009 season, influenza vaccination coverage among adolescents based on provider report was 11.3%. Based on parent report, influenza vaccination coverage was 21.7%. Twenty-two percent of parents retrieved and referred to a shot card during the interview. In the shot card group, provider versus parent reported coverage was 12.5% versus 18.2% while among the recall only group coverage was 10.9% versus 22.7%, respectively. Overall, compared to provider report as the gold standard, parental report of influenza vaccination had a sensitivity of 86.7%, a specificity of 86.2%, a positive predictive value (PPV) of 43.1%, and a negative predictive value (NPV) of 98.0%. Among the shot card group, of vaccinations reported either by provider or by parent reading vaccination off shot card, only 66% were reported by providers. In the shot card group, the "true" vaccination level (16-17%) was closer to the parent reported coverage when it was assumed that vaccinations read by the parent from a shot card but not reported by a provider were considered true vaccinations. Overall, assuming that providers reported 64% of "true" vaccinations, sensitivity increased to 91%, specificity to 93%, and PPV to 71%. Conclusions: Overall estimated influenza vaccination coverage was more than ten percentage points higher based on parental report than on provider report, with the difference between provider and parent report greater among the recall only group. The two estimates are closer for those with shot cards, but few parents utilized shot cards in our study and most national surveys do not ask parents to consult shot cards when responding about their adolescent's vaccination. The actual vaccination coverage of adolescents studied is likely between coverage estimates obtained from parent report and provider report. Published by Elsevier Ltd. C1 [Lu, Peng-jun; Dorell, Christina; Yankey, David; Santibanez, Tammy A.; Singleton, James A.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Lu, PJ (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop A-19, Atlanta, GA 30333 USA. EM lhp8@cdc.gov NR 33 TC 7 Z9 8 U1 2 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 9 PY 2012 VL 30 IS 22 BP 3278 EP 3285 DI 10.1016/j.vaccine.2012.03.015 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 940PH UT WOS:000303905000005 PM 22445809 ER PT J AU Herrick, H Pleasants, R Wheaton, AG Liu, Y Ford, ES Presley-Cantrell, LR Croft, JB AF Herrick, Harry Pleasants, Roy Wheaton, Anne G. Liu, Yong Ford, Earl S. Presley-Cantrell, Letitia R. Croft, Janet B. TI Chronic Obstructive Pulmonary Disease and Associated Health-Care Resource Use-North Carolina, 2007 and 2009 (Reprinted from MMWR, vol 61, pg 143-146, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID SMOKING C1 [Wheaton, Anne G.; Liu, Yong; Ford, Earl S.; Presley-Cantrell, Letitia R.; Croft, Janet B.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Pleasants, Roy] Duke Univ, Sch Med, Durham, NC USA. RP Wheaton, AG (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM awheaton@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 9 PY 2012 VL 307 IS 18 BP 1905 EP 1908 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 938OD UT WOS:000303741900009 ER PT J AU Forshey, TM Byrum, BA Machesky, KD Roney, CS Gomez, TM Mitchell, JR Behravesh, CB Hausman, LB O'Connor, KA AF Forshey, Tony M. Byrum, Beverly A. Machesky, Kimberly D. Roney, C. Stephen Gomez, Thomas M. Mitchell, Jennifer R. Behravesh, Casey Barton Hausman, Leslie B. O'Connor, Katherine A. TI Notes From the Field: Multistate Outbreak of Salmonella Altona and Johannesburg Infections Linked to Chicks and Ducklings From a Mail-Order Hatchery-United States, February-October 2011 (Reprinted from MMWR vol 61, pg 195, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Mitchell, Jennifer R.; Behravesh, Casey Barton; Hausman, Leslie B.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Forshey, Tony M.; Byrum, Beverly A.] Ohio Dept Agr, Reynoldsburg, OH USA. [Machesky, Kimberly D.] Ohio Dept Hlth, Columbus, OH 43266 USA. [Roney, C. Stephen; Gomez, Thomas M.] USDA, Washington, DC USA. [O'Connor, Katherine A.] CDC, EIS, Atlanta, GA 30333 USA. RP Mitchell, JR (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM itz4@cdc.gov NR 4 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 9 PY 2012 VL 307 IS 18 BP 1908 EP 1908 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 938OD UT WOS:000303741900010 ER PT J AU Moore, S Shrestha, S Tomlinson, KW Vuong, H AF Moore, Sean Shrestha, Sourya Tomlinson, Kyle W. Vuong, Holly TI Predicting the effect of climate change on African trypanosomiasis: integrating epidemiology with parasite and vector biology SO JOURNAL OF THE ROYAL SOCIETY INTERFACE LA English DT Article DE sleeping sickness; trypanosomiasis; disease ecology; vector; climate; global warming ID MORSITANS MORSITANS DIPTERA; SENSED VEGETATION DATA; SOUTH-EASTERN UGANDA; COMMON FLY BELT; SLEEPING SICKNESS; INFECTIOUS-DISEASES; GLOSSINA-MORSITANS; BRUCEI-RHODESIENSE; TSETSE-FLIES; POPULATION-DYNAMICS AB Climate warming over the next century is expected to have a large impact on the interactions between pathogens and their animal and human hosts. Vector-borne diseases are particularly sensitive to warming because temperature changes can alter vector development rates, shift their geographical distribution and alter transmission dynamics. For this reason, African trypanosomiasis ( sleeping sickness), a vector-borne disease of humans and animals, was recently identified as one of the 12 infectious diseases likely to spread owing to climate change. We combine a variety of direct effects of temperature on vector ecology, vector biology and vector-parasite interactions via a disease transmission model and extrapolate the potential compounding effects of projected warming on the epidemiology of African trypanosomiasis. The model predicts that epidemics can occur when mean temperatures are between 20.7 degrees C and 26.1 degrees C. Our model does not predict a large-range expansion, but rather a large shift of up to 60 per cent in the geographical extent of the range. The model also predicts that 46-77 million additional people may be at risk of exposure by 2090. Future research could expand our analysis to include other environmental factors that influence tsetse populations and disease transmission such as humidity, as well as changes to human, livestock and wildlife distributions. The modelling approach presented here provides a framework for using the climate-sensitive aspects of vector and pathogen biology to predict changes in disease prevalence and risk owing to climate change. C1 [Moore, Sean] Natl Ctr Atmospher Res, Boulder, CO 80307 USA. [Moore, Sean] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO 80521 USA. [Shrestha, Sourya] Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA. [Shrestha, Sourya] Univ Michigan, Ctr Study Complex Syst, Ann Arbor, MI 48109 USA. [Tomlinson, Kyle W.] Wageningen Univ, Resource Ecol Grp, NL-6708 PB Wageningen, Netherlands. [Vuong, Holly] Rutgers State Univ, Ecol & Evolut Grad Program, New Brunswick, NJ 08901 USA. [Vuong, Holly] Cary Inst Ecosyst Studies, Millbrook, NY 12545 USA. RP Moore, S (reprint author), Natl Ctr Atmospher Res, POB 3000, Boulder, CO 80307 USA. EM smoore@ucar.edu RI Barley, Kamal/F-9579-2011; OI Barley, Kamal/0000-0003-1874-9813; Shrestha, Sourya/0000-0002-6106-6834 FU NSF; DIMACS; African Institute for Mathematics; SACEMA; NSF IGERT [NSF 0333257] FX We thank E. Borer, J. Hargrove, J. Dushoff, J. Pulliam, E. Lungo, W. Getz, T. Porco, J. Lloyd-Smith and two anonymous reviewers for comments and suggestions; and NSF, DIMACS, the African Institute for Mathematics and SACEMA for support. Funding for S.M. provided by an NSF IGERT Fellowship in Ecosystem Informatics (NSF 0333257). NR 86 TC 25 Z9 27 U1 4 U2 78 PU ROYAL SOC PI LONDON PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND SN 1742-5689 EI 1742-5662 J9 J R SOC INTERFACE JI J. R. Soc. Interface PD MAY 7 PY 2012 VL 9 IS 70 BP 817 EP 830 DI 10.1098/rsif.2011.0654 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 916WQ UT WOS:000302134300002 PM 22072451 ER PT J AU Cherutich, P Kaiser, R Galbraith, J Williamson, J Shiraishi, RW Ngare, C Mermin, J Marum, E Bunnell, R AF Cherutich, Peter Kaiser, Reinhard Galbraith, Jennifer Williamson, John Shiraishi, Ray W. Ngare, Carol Mermin, Jonathan Marum, Elizabeth Bunnell, Rebecca CA KAIS Study Grp TI Lack of Knowledge of HIV Status a Major Barrier to HIV Prevention, Care and Treatment Efforts in Kenya: Results from a Nationally Representative Study SO PLOS ONE LA English DT Article ID RISK-REDUCTION; AFRICA; UGANDA; TRANSMISSION AB Background: We analyzed HIV testing rates, prevalence of undiagnosed HIV, and predictors of testing in the Kenya AIDS Indicator Survey (KAIS) 2007. Methods: KAIS was a nationally representative sero-survey that included demographic and behavioral indicators and testing for HIV, HSV-2, syphilis, and CD4 cell counts in the population aged 15-64 years. We used gender-specific multivariable regression models to identify factors independently associated with HIV testing in sexually active persons. Results: Of 19,840 eligible persons, 80% consented to interviews and blood specimen collection. National HIV prevalence was 7.1% (95% CI 6.5-7.7). Among ever sexually active persons, 27.4% (95% CI 25.6-29.2) of men and 44.2% (95% CI 42.5-46.0) of women reported previous HIV testing. Among HIV-infected persons, 83.6% (95% CI 76.2-91.0) were unaware of their HIV infection. Among sexually active women aged 15-49 years, 48.7% (95% CI 46.8-50.6) had their last HIV test during antenatal care (ANC). In multivariable analyses, the adjusted odds ratio (AOR) for ever HIV testing in women >= 35 versus 15-19 years was 0.2 (95% CI: 0.1-0.3; p<0.0001). Other independent associations with ever HIV testing included urban residence (AOR 1.6, 95% CI: 1.2-2.0; p = 0.0005, women only), highest wealth index versus the four lower quintiles combined (AOR 1.8, 95% CI: 1.3-2.5; p = 0.0006, men only), and an increasing testing trend with higher levels of education. Missed opportunities for testing were identified during general or pregnancy-specific contacts with health facilities; 89% of adults said they would participate in home-based HIV testing. Conclusions: The vast majority of HIV-infected persons in Kenya are unaware of their HIV status, posing a major barrier to HIV prevention, care and treatment efforts. New approaches to HIV testing provision and education, including home-based testing, may increase coverage. Targeted interventions should involve sexually active men, sexually active women without access to ANC, and rural and disadvantaged populations. C1 [Cherutich, Peter; Ngare, Carol] Natl AIDS STI Control Programme NASCOP, Nairobi, Kenya. [Kaiser, Reinhard; Galbraith, Jennifer; Williamson, John; Mermin, Jonathan; Bunnell, Rebecca] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Nairobi, Kenya. [Shiraishi, Ray W.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Mermin, Jonathan] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Marum, Elizabeth] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Lusaka, Zambia. [Bunnell, Rebecca] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Cherutich, P (reprint author), Natl AIDS STI Control Programme NASCOP, Nairobi, Kenya. EM r_kaiser@gmx.de RI Mermin, Jonathan/J-9847-2012 FU United States President's Emergency Plan for AIDS Relief; Department of Health and Human Services; Centers for Disease Control and Prevention (CDC) FX This study was funded through the United States President's Emergency Plan for AIDS Relief and the Department of Health and Human Services. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was also funded through the Centers for Disease Control and Prevention (CDC). Several authors are employees of CDC and contributed to study design, data collection and analysis, decision to publish, and preparation of the manuscript. NR 30 TC 30 Z9 30 U1 2 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 4 PY 2012 VL 7 IS 5 AR e36797 DI 10.1371/journal.pone.0036797 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 959WV UT WOS:000305349800123 PM 22574226 ER PT J AU Morris, DS Tynan, MA AF Morris, Daniel S. Tynan, Michael A. TI Fiscal and Policy Implications of Selling Pipe Tobacco for Roll-Your-Own Cigarettes in the United States SO PLOS ONE LA English DT Article AB Background: The Federal excise tax was increased for tobacco products on April 1, 2009. While excise tax rates prior to the increase were the same for roll-your-own (RYO) and pipe tobacco, the tax on pipe tobacco was $21.95 per pound less than the tax on RYO tobacco after the increase. Subsequently, tobacco manufacturers began labeling loose tobacco as pipe tobacco and marketing these products to RYO consumers at a lower price. Retailers refer to these products as "dual purpose'' or "dual use'' pipe tobacco. Methods: Data on tobacco tax collections comes from the Alcohol and Tobacco Tax and Trade Bureau. Joinpoint software was used to identify changes in sales trends. Estimates were generated for the amount of pipe tobacco sold for RYO use and for Federal and state tax revenue lost through August 2011. Results: Approximately 45 million pounds of pipe tobacco has been sold for RYO use from April 2009 to August 2011, lowering state and Federal revenue by over $1.3 billion. Conclusions: Marketing pipe tobacco as "dual purpose'' and selling it for RYO use provides an opportunity to avoid paying higher cigarette prices. This blunts the public health impact excise tax increases would otherwise have on reducing tobacco use through higher prices. Selling pipe tobacco for RYO use decreases state and Federal revenue and also avoids regulations on flavored tobacco, banned descriptors, prohibitions on shipping, and reporting requirements. C1 [Morris, Daniel S.] Oregon Hlth Author, Tobacco Prevent & Educ Program, Portland, OR USA. [Tynan, Michael A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Morris, DS (reprint author), Oregon Hlth Author, Tobacco Prevent & Educ Program, Portland, OR USA. EM daniel.s.morris@state.or.us NR 24 TC 11 Z9 12 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 2 PY 2012 VL 7 IS 5 AR e36487 DI 10.1371/journal.pone.0036487 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 959US UT WOS:000305341500078 PM 22567159 ER PT J AU Miramontes, R Pratt, R Price, SF Jeffries, C Navin, TR Oramasionwu, GE AF Miramontes, Roque Pratt, Robert Price, Sandy F. Jeffries, Carla Navin, Thomas R. Oramasionwu, Gloria E. TI Trends in Tuberculosis-United States, 2011 (Reprinted from MMWR, vol 61, pg 181-185, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID RIFAPENTINE; INFECTION C1 [Oramasionwu, Gloria E.] CDC, EIS, Atlanta, GA 30333 USA. RP Oramasionwu, GE (reprint author), CDC, EIS, Atlanta, GA 30333 USA. EM iyo8@cdc.gov NR 11 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 2 PY 2012 VL 307 IS 17 BP 1791 EP 1793 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 933TV UT WOS:000303386800008 ER PT J AU Kusin, S Tesar, J Hatten, B Horowitz, BZ Hendrickson, R Leman, R Buser, G AF Kusin, Shana Tesar, Jeremy Hatten, Ben Horowitz, B. Zane Hendrickson, Robert Leman, Richard Buser, Genevieve TI Severe Methemoglobinemia and Hemolytic Anemia From Aniline Purchased as 2C-E (4-ethyl-2, 5-dimethoxyphenethylamine), a Recreational Drug, on the Internet-Oregon, 2011 (Reprinted from MMWR, vol 61, pg 85-88, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Leman, Richard] CDC, Oregon Publ Hlth Div, Atlanta, GA 30333 USA. [Buser, Genevieve] CDC, EIS, Atlanta, GA 30333 USA. EM horowiza@ohsu.edu NR 1 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 2 PY 2012 VL 307 IS 17 BP 1793 EP 1795 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 933TV UT WOS:000303386800009 ER PT J AU Williams, RE Sena, AC Moorman, AC Moore, ZS Sharapov, UM Drobenuic, J Hu, DJ Wood, HW Xing, J Spradling, PR AF Williams, Roxanne E. Sena, Arlene C. Moorman, Anne C. Moore, Zack S. Sharapov, Umid M. Drobenuic, Jan Hu, Dale J. Wood, Hattie W. Xing, Jian Spradling, Philip R. TI Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak SO VACCINE LA English DT Article DE Hepatitis B; HBV; Vaccination; Elderly; Diabetic ID ANTIBODY-RESPONSE; VIRUS INFECTION; UNITED-STATES; IMMUNOGENICITY; VACCINES; ADULTS; RISK AB Protection of older persons, particularly those with diabetes, against hepatitis B virus (HBV) infection is of growing concern because of increased reports of outbreaks among long-term care facility residents receiving assisted blood glucose monitoring. We evaluated hepatitis B vaccine immunogenicity among residents immunized in response to two such outbreaks in skilled nursing facilities during June 2009-July 2010. One hundred forty-eight (71%) of 209 residents were found to be susceptible to HBV infection. Of 105 patients who began a vaccination series with Twinrix (R) (0-, 1-, 6-month dosing), 86(82%) completed the series and postvaccination testing. Of these, most were elderly (median age 79.5 years; range 45-101), female (56%), and African-American (51%). Twenty-nine (34%) vaccinated residents had post-vaccination hepatitis B surface antibody levels >= 10 mIU/ml. There were no significant differences in vaccine response by age, gender, race, diabetes status, body mass index, or current smoking status. Our findings indicate that a low proportion of skilled nursing facility residents achieved a seroprotective response after hepatitis B vaccination. Published by Elsevier Ltd. C1 [Williams, Roxanne E.; Moorman, Anne C.; Sharapov, Umid M.; Drobenuic, Jan; Hu, Dale J.; Xing, Jian; Spradling, Philip R.] Ctr Dis Control, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Sena, Arlene C.; Wood, Hattie W.] Durham Cty Hlth Dept, Durham, NC USA. [Sena, Arlene C.] Univ N Carolina, Chapel Hill, NC USA. RP Moorman, AC (reprint author), Ctr Dis Control, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM acm4@cdc.gov NR 23 TC 16 Z9 16 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD MAY 2 PY 2012 VL 30 IS 21 BP 3147 EP 3150 DI 10.1016/j.vaccine.2012.02.078 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 932PL UT WOS:000303302900001 PM 22421557 ER PT J AU Cassell, CH Mendez, DD Strauss, RP AF Cassell, Cynthia H. Mendez, Dara D. Strauss, Ronald P. TI Maternal Perspectives: Qualitative Responses About Perceived Barriers to Care Among Children With Orofacial Clefts in North Carolina SO CLEFT PALATE-CRANIOFACIAL JOURNAL LA English DT Article DE barriers to care; cleft lip/palate; maternal perceptions ID HEALTH-CARE; NATIONAL-SURVEY; MEDICAL HOME; MANAGED CARE; PARENTS PERSPECTIVES; CRANIOFACIAL TEAMS; BIRTH-DEFECTS; PRENATAL-CARE; DOWN-SYNDROME; UNMET NEED AB Objective: To examine maternal perceptions of barriers to care of children with orofacial clefts (OFC) in a population-based survey that solicited open-ended qualitative responses. Design and Setting: In 2006, a combination mail/phone survey was sent to all mothers of children with OFC. The questionnaire included 76 items. A final open-ended question was included for additional information about cleft-related care. The analysis included responses to the open-ended question and sociodemographic characteristics of the respondents. Qualitative responses were transcribed and entered into a qualitative software package for analysis, and common themes were elucidated. Participants/Patients: The North Carolina Birth Defects Monitoring Program was used to identify all resident infants born with OFC from 2001 to 2004. Of 478 eligible mothers, 52.9% (n = 248) responded to the survey, and 39.5% (n = 98) responded to the final open-ended question. Main Outcome Measures: Percentage reporting problems accessing care, frequency of positive and negative comments, and indicators of financial, personal, and structural barriers to care. Results: Of the 98 respondents, the majority (n = 95, 96.99%) were the biological mother. Almost 40% of mothers indicated that accessing primary craniofacial care was a problem. Of those citing perceived barriers to care, the major issues cited were financial, structural, and personal barriers. Conclusions: Collaborative efforts between craniofacial centers and teams, health care systems, and birth defects registries are warranted to reduce perceived barriers to care among families of children with OFC. Further exploration of the themes and factors associated with barriers to care and services is needed. C1 [Cassell, Cynthia H.] Univ N Carolina, Dept Publ Hlth Sci, Charlotte, NC 28223 USA. [Mendez, Dara D.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Strauss, Ronald P.] Univ N Carolina, Dept Dent Ecol, Chapel Hill, NC USA. [Strauss, Ronald P.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Strauss, Ronald P.] Univ N Carolina, Dept Social Med, Chapel Hill, NC USA. RP Cassell, CH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mail Stop E86, Atlanta, GA 30333 USA. EM chcassell@cdc.gov OI Mendez, Dara/0000-0003-3999-1991 FU National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention [U50/CCU422096]; National Foundation for Facial Reconstruction FX U50/CCU422096, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (funding supported by National Foundation for Facial Reconstruction). NR 65 TC 10 Z9 10 U1 2 U2 4 PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS PI LAWRENCE PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA SN 1545-1569 J9 CLEFT PALATE-CRAN J JI Cleft Palate-Craniofac. J. PD MAY PY 2012 VL 49 IS 3 BP 262 EP 269 DI 10.1597/09-235 PG 8 WC Dentistry, Oral Surgery & Medicine; Surgery SC Dentistry, Oral Surgery & Medicine; Surgery GA 083ZU UT WOS:000314506400005 PM 21740175 ER PT J AU Kimmons, J Jones, S McPeak, HH Bowden, B AF Kimmons, Joel Jones, Sonya McPeak, Holly H. Bowden, Brian TI Developing and Implementing Health and Sustainability Guidelines for Institutional Food Service SO ADVANCES IN NUTRITION LA English DT Article ID PHYSICAL-ACTIVITY; ENVIRONMENTAL INTERVENTIONS; INCREASE FRUIT; NUTRITION; PROMOTION; CONSUMPTION; RESOURCES; PURCHASES; SUPPORT; OBESITY AB Health and sustainability guidelines for institutional food service are directed at improving dietary intake and increasing the ecological benefits of the food system. The development and implementation of institutional food service guidelines, such as the Health and Human Services (HHS) and General Services Administration (GSA) Health and Sustainability Guidelines for Federal Concessions and Vending Operations (HHS/GSA Guidelines), have the potential to improve the health and sustainability of the food system. Institutional guidelines assist staff, managers, and vendors in aligning the food environment at food service venues with healthier and more sustainable choices and practices. Guideline specifics and their effective implementation depend on the size, culture, nature, and management structure of an institution and the individuals affected. They may be applied anywhere food is sold, served, or consumed. Changing institutional food service practice requires comprehensive analysis, engagement, and education. of all relevant stakeholders including institutional management, members of the food supply chain, and customers. Current examples of food service guidelines presented here are the HHS and GSA Health and Sustainability Guidelines for Federal Concessions and Vending Operations, which translate evidence-based recommendations on health and sustainability into institutional food service practices and are currently being implemented at the federal level. Developing and implementing guidelines has the potential to improve long-term population health outcomes while simultaneously benefitting the food system. Nutritionists, public health practitioners, and researchers should consider working with institutions to develop, implement, and evaluate food service guidelines for health and sustainability. Adv. Nutr. 3: 337-342, 2012. C1 [Kimmons, Joel] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Jones, Sonya] Univ S Carolina, Ctr Res Nutr & Hlth Dispar, Columbia, SC 29208 USA. [Jones, Sonya] Univ S Carolina, Dept Hlth Promot Educ & Behav, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. [McPeak, Holly H.] US Dept HHS, Off Dis Prevent & Hlth Promot, Off Assistant Secretary Hlth, Rockville, MD USA. [Bowden, Brian] Ctr Dis Control & Prevent, Off Associate Director Policy, Atlanta, GA USA. RP Kimmons, J (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM jkimmons@cdc.gov NR 56 TC 9 Z9 9 U1 1 U2 17 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 2161-8313 J9 ADV NUTR JI Adv. Nutr. PD MAY PY 2012 VL 3 IS 3 BP 337 EP 342 DI 10.3945/an.111.001354 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 066KP UT WOS:000313220000010 PM 22585909 ER PT J AU Harris, D Lott, M Lakins, V Bowden, B Kimmons, J AF Harris, Diane Lott, Megan Lakins, Velma Bowden, Brian Kimmons, Joel TI Farm to Institution: Creating Access to Healthy Local and Regional Foods SO ADVANCES IN NUTRITION LA English DT Article ID GROWN PRODUCE AB Farm to Institution (FTI) programs are one approach to align food service operations with health and sustainability guidelines, such as those recently developed by the U.S. Department of Health and Human Services and General Services Administration. Programs and policies that support sourcing local and regional foods for schools, hospitals, faith-based organizations, and worksites may benefit institutional customers and their families, farmers, the local community, and the economy. Different models of FTI programs exist. On-site farmer's markets at institutions have been promoted on federal government property, healthcare facilities, and private institutions nationwide. Farm to School programs focus on connecting schools with local agricultural production with the goal of improving school meals and increasing intake of fruits and vegetables in children. Sourcing food from local farms presents a number of challenges including cost and availability of local products, food safety, and liability considerations and lack of skilled labor for food preparation. Institutions utilize multiple strategies to address these barriers, and local, state, and federal polices can help facilitate FTI approaches. FTI enables the purchasing power of institutions to contribute to regional and local food systems, thus potentially affecting social, economic, and ecological systems. Local and state food policy councils can assist in bringing stakeholders together to inform this process. Rigorous research and evaluation is needed to determine and document best practices and substantiate links between FTI and multiple outcomes. Nutritionists, public health practitioners, and researchers can help communities work with institutions to develop, implement, and evaluate programs and policies supporting FTI. Adv. Nutr. 3: 343-349, 2012. C1 [Harris, Diane; Kimmons, Joel] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Lott, Megan] Community Food Secur Coalit, Natl Farm Sch Network, Washington, DC USA. [Lakins, Velma] Agr Mkt Serv, USDA, Washington, DC USA. [Bowden, Brian] Ctr Dis Control & Prevent, Off Associate Director Policy, Atlanta, GA USA. RP Harris, D (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM dmharris@cdc.gov NR 47 TC 6 Z9 6 U1 3 U2 63 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 2161-8313 J9 ADV NUTR JI Adv. Nutr. PD MAY PY 2012 VL 3 IS 3 BP 343 EP 349 DI 10.3945/an.111.001677 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 066KP UT WOS:000313220000011 PM 22585910 ER PT J AU Hootman, J Brown, D AF Hootman, Jennifer Brown, David TI Physical Activity Level and Poor Disability Profile Among Adults with Arthritis SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Hootman, Jennifer; Brown, David] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 92 EP 92 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363300027 ER PT J AU Harris, CD Carroll, DD Fulton, JE AF Harris, Carmen D. Carroll, Dianna D. Fulton, Janet E. TI Access To And Use Of School Facilities For Physical Activity Among Adults SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Harris, Carmen D.; Carroll, Dianna D.; Fulton, Janet E.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 104 EP 104 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363300067 ER PT J AU Carroll, DD Dorn, JM Fulton, JE AF Carroll, Dianna D. Dorn, Joan M. Fulton, Janet E. TI Facilitators And Barriers To Active Transportation In US Adults, Healthstyles 2009 SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Carroll, Dianna D.; Dorn, Joan M.; Fulton, Janet E.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 106 EP 106 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363300072 ER PT J AU Cardona, AM Torres, A Donado, C Stauber, C Sarmiento, OL AF Cardona, Ana M. Torres, Andrea Donado, Carolina Stauber, Christine Sarmiento, Olga Lucia TI Contribution Of The CiclovIA And Cicloruta Programs In BogotA-colombia To Meeting The Physical Activity Recommendations SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Cardona, Ana M.; Donado, Carolina; Sarmiento, Olga Lucia] Univ Los Andes, Bogota, Colombia. [Torres, Andrea] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Stauber, Christine] Georgia State Univ, Atlanta, GA 30303 USA. NR 0 TC 0 Z9 0 U1 3 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 107 EP 107 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363300074 ER PT J AU Paul, P Carroll, DD Fulton, JE AF Paul, Prabasaj Carroll, Dianna D. Fulton, Janet E. TI Walking For Transportation And Leisure: National Health Interview Survey, 2010 SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Paul, Prabasaj; Carroll, Dianna D.; Fulton, Janet E.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 232 EP 232 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363301287 ER PT J AU Kim, JH Roberge, RJ Benson, SM AF Kim, Jung-Hyun Roberge, Raymond J. Benson, Stacey M. TI Physiological and Thermoregulatory Responses to Wearing N95 Filtering Facepiece Respirators SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Kim, Jung-Hyun; Roberge, Raymond J.; Benson, Stacey M.] NIOSH, CDC, NPPTL, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 319 EP 319 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363302185 ER PT J AU Soares, J Owens, C Epping, J Brown, DR Lankford, T AF Soares, Jesus Owens, Chantelle Epping, Jacqueline Brown, David R. Lankford, Tina TI Likelihood of Meeting Physical Activity Guidelines Comparing those Who Walk Dogs and Those That Don't SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Soares, Jesus; Owens, Chantelle; Epping, Jacqueline; Brown, David R.; Lankford, Tina] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 562 EP 562 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363303218 ER PT J AU Brown, DR Soares, J Epping, J Lankford, T AF Brown, David R. Soares, Jesus Epping, Jacqueline Lankford, Tina TI Mass Media Campaigns: Outcomes Vary by Degree to Which Self-Reported Measures Assess Weekly Physical Activity SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Brown, David R.; Soares, Jesus; Epping, Jacqueline; Lankford, Tina] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 648 EP 648 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363303522 ER PT J AU Song, MK Carroll, DD Lee, SM Fulton, JE AF Song, MinKyoung Carroll, Dianna D. Lee, Sarah M. Fulton, Janet E. TI Types of Physical Activities Among High School Students - United States, 2010 SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Song, MinKyoung; Carroll, Dianna D.; Lee, Sarah M.; Fulton, Janet E.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 658 EP 658 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363303556 ER PT J AU Epping, JN AF Epping, Jacqueline N. TI Dogs and Docs - Getting Patients More Active SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Epping, Jacqueline N.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 702 EP 702 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363303708 ER PT J AU Glynn, NW Santanasto, AJ Newman, MA Taylor, CA Newman, AB Goodpaster, BH AF Glynn, Nancy W. Santanasto, Adam J. Newman, Mark A. Taylor, Christopher A. Newman, Anne B. Goodpaster, Bret H. TI Over-ground Vs. Treadmill Walking In Older Adults: Comparison Of Accelerometry Counts And Metabolic Demands SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Glynn, Nancy W.; Santanasto, Adam J.; Newman, Mark A.; Newman, Anne B.; Goodpaster, Bret H.] Univ Pittsburgh, Pittsburgh, PA USA. [Taylor, Christopher A.] Ctr Dis Control, Atlanta, GA 30333 USA. RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 818 EP 818 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363304303 ER PT J AU Santos, R Pratt, M Okely, AD Mota, J Moreira, C Coelho-e-Silva, MJ Vale, S Sardinha, LB AF Santos, Rute Pratt, Micheal Okely, Anthony D. Mota, Jorge Moreira, Carla Coelho-e-Silva, Manuel J. Vale, Susana Sardinha, Luis B. TI The Combined Influence Of Sedentary Behavior And Physical Activity On Cardiorespiratory Fitness SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Santos, Rute; Mota, Jorge; Moreira, Carla; Vale, Susana] Univ Porto, Res Ctr Phys Act, Hlth & Leisure Fac Sport, P-4100 Oporto, Portugal. [Pratt, Micheal] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Okely, Anthony D.] Univ Wollongong, Interdisciplinary Educ Res Inst, Wollongong, NSW 2522, Australia. [Coelho-e-Silva, Manuel J.] Univ Coimbra, Fac Sport Sci & Phys Educ, Res Ctr Anthropol & Health, Coimbra, Portugal. [Sardinha, Luis B.] Univ Tecn Lisboa, Fac Human Movement, Exercise & Hlth Lab, Lisbon, Portugal. RI mota, jorge/B-2980-2013; Sardinha, Luis/F-2641-2013; Vale, Susana/L-8367-2013; Santos, Rute/A-6401-2012 OI mota, jorge/0000-0001-7571-9181; Sardinha, Luis/0000-0002-6230-6027; Santos, Rute/0000-0002-7604-5753 NR 0 TC 0 Z9 0 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 920 EP 920 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363304653 ER PT J AU Powell, JB Coca, A Jung-Hyun, K Williams, WJ Roberge, RJ AF Powell, Jeffrey B. Coca, Aitor Jung-Hyun, Kim Williams, W. Jon Roberge, Raymon J. TI Physiological Measurement Comparison From A Portable Sensor System And Standard Laboratory Equipment During Graded Exercise SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Meeting Abstract C1 [Powell, Jeffrey B.; Coca, Aitor; Jung-Hyun, Kim; Williams, W. Jon; Roberge, Raymon J.] NIOSH, CDC, NPPTL, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD MAY PY 2012 VL 44 SU 2 BP 925 EP 925 PG 1 WC Sport Sciences SC Sport Sciences GA 027OT UT WOS:000310363304669 ER PT J AU Crim, MT Yoon, SS Ortiz, E Wall, HK Schober, S Gillespie, C Sorlie, P Keenan, N Labarthe, D Hong, YL AF Crim, Matthew T. Yoon, Sung Sug (Sarah) Ortiz, Eduardo Wall, Hilary K. Schober, Susan Gillespie, Cathleen Sorlie, Paul Keenan, Nora Labarthe, Darwin Hong, Yuling TI National Surveillance Definitions for Hypertension Prevalence and Control Among Adults SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE hypertension; epidemiology; surveillance; health policy; prevention ID NUTRITION EXAMINATION SURVEY; BLOOD-PRESSURE CONTROL; UNITED-STATES ADULTS; CHRONIC KIDNEY-DISEASE; US ADULTS; RISK-FACTORS; HEALTH; AWARENESS; TRENDS; SUBCOMMITTEE AB Background-Clear and consistent definitions of hypertension and hypertension control are crucial to guide diagnosis, treatment, and surveillance. A variety of surveillance definitions are in frequent use, resulting in variation of reported hypertension prevalence and control, even when based on the same data set. Methods and Results-To assess the variety of published surveillance definitions and rates, we performed a literature search for studies and reports that used National Health and Nutrition Examination Surveys (NHANES) data from at least as recent as the 2003 to 2004 survey cycle. We identified 19 studies that used various criteria for defining hypertension and hypertension control, as well as different parameters for age adjustment and inclusion of subpopulations. This resulted in variation of reported age-standardized hypertension prevalence from 28.9% to 32.1% and hypertension control from 35.1% to 64%. We then assessed the effects of varying the definitions of hypertension and hypertension control, parameters for age adjustment, and inclusion of subpopulations on NHANES data from both 2007 to 2008 (n=5645) and 2005 to 2008 (n=10 365). We propose standard surveillance definitions and age-adjustment parameters for hypertension and hypertension control. By using our recommended approach with NHANES 2007 to 2008 data, the age-standardized prevalence of hypertension in the United States was 29.8% (SE, 0.62%) and the rate of hypertension control was 45.8% (SE, 4.03%). Conclusions-Surveillance definitions of hypertension and hypertension control vary in the literature. We present standard definitions of hypertension prevalence and control among adults and standard parameters for age-adjustment and population composition that will enable meaningful population comparisons and monitoring of trends. (Circ Cardiovasc Qual Outcomes. 2012; 5:343-351.) C1 [Crim, Matthew T.; Wall, Hilary K.; Gillespie, Cathleen; Keenan, Nora; Labarthe, Darwin; Hong, Yuling] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Chamblee, GA 30341 USA. [Yoon, Sung Sug (Sarah); Schober, Susan] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Ortiz, Eduardo; Sorlie, Paul] NHLBI, NIH, Bethesda, MD 20892 USA. RP Hong, YL (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS F-72, Chamblee, GA 30341 USA. EM ico2@cdc.gov FU Intramural NIH HHS [Z99 HL999999] NR 42 TC 20 Z9 22 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD MAY PY 2012 VL 5 IS 3 BP 343 EP 351 DI 10.1161/CIRCOUTCOMES.111.963439 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 002NO UT WOS:000308539100018 PM 22550130 ER PT J AU Ngundi, MM Meade, BD Little, SF Quinn, CP Corbett, CR Brady, RA Burns, DL AF Ngundi, Miriam M. Meade, Bruce D. Little, Stephen F. Quinn, Conrad P. Corbett, Cindi R. Brady, Rebecca A. Burns, Drusilla L. TI Analysis of Defined Combinations of Monoclonal Antibodies in Anthrax Toxin Neutralization Assays and Their Synergistic Action SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID PROTECTIVE ANTIGEN; BACILLUS-ANTHRACIS; LETHAL TOXIN; IN-VITRO; INHALATIONAL ANTHRAX; RHESUS MACAQUES; FC-RECEPTORS; GUINEA-PIGS; VACCINE; IMMUNITY AB Antibodies against the protective antigen (PA) component of anthrax toxin play an important role in protection against disease caused by Bacillus anthracis. In this study, we examined defined combinations of PA-specific monoclonal antibodies for their ability to neutralize anthrax toxin in cell culture assays. We observed additive, synergistic, and antagonistic effects of the antibodies depending on the specific antibody combination examined and the specific assay used. Synergistic toxin-neutralizing antibody interactions were examined in more detail. We found that one mechanism that can lead to antibody synergy is the bridging of PA monomers by one antibody, with resultant bivalent binding of the second antibody. These results may aid in optimal design of new vaccines and antibody therapies against anthrax. C1 [Ngundi, Miriam M.; Brady, Rebecca A.; Burns, Drusilla L.] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA. [Little, Stephen F.] USA, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA. [Meade, Bruce D.] Meade Biol, Hillsborough, NC USA. [Quinn, Conrad P.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Corbett, Cindi R.] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada. RP Burns, DL (reprint author), US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA. EM drusilla.burns@fda.hhs.gov FU National Institute of Allergy and Infectious Diseases, NIH; Food and Drug Administration FX This work was supported in part by an interagency agreement between the National Institute of Allergy and Infectious Diseases, NIH, and the Food and Drug Administration. NR 42 TC 9 Z9 9 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD MAY PY 2012 VL 19 IS 5 BP 731 EP 739 DI 10.1128/CVI.05714-11 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 983GU UT WOS:000307108600014 PM 22441391 ER PT J AU Anderson, TC Crawford, PC Katz, JM Dubovi, EJ Landolt, G Gibbs, EPJ AF Anderson, Tara C. Crawford, P. Cynda Katz, Jacqueline M. Dubovi, Edward J. Landolt, Gabriele Gibbs, E. Paul J. TI Diagnostic performance of the canine Influenza A Virus subtype H3N8 hemagglutination inhibition assay SO JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION LA English DT Article DE Canine influenza virus; diagnosis; H3N8; hemagglutination inhibition; serology; sensitivity; specificity ID SIALIC-ACID; RECEPTOR SPECIFICITY; SEROLOGICAL SURVEY; CELL GLYCOLIPIDS; DOGS; SEROPREVALENCE; ANTIBODIES; ERYTHROCYTES; TRANSMISSION; INFECTION AB Canine Influenza A virus subtype H3N8 (H3N8 CIV) was recognized in 2004 as a novel respiratory pathogen for dogs. To date, infections have been diagnosed in thousands of dogs in 38 U. S. states. Diagnostic techniques such as reverse transcription polymerase chain reaction (RT-PCR) and virus isolation may yield false-negative results if samples are collected after virus shedding has ceased. Therefore, serology is often necessary to confirm diagnosis. The hemagglutination inhibition (HI) assay is the test of choice for serological diagnosis of influenza infections in animals. However, discrepancies exist between diagnostic laboratories and research groups in some of the test parameters for the H3N8 CIV HI assay and the cutoff antibody titer for seropositivity. The objectives of the current study were 1) to assess the diagnostic performance of a H3N8 CIV HI assay using field sera from canine infectious respiratory disease outbreaks and 2) to evaluate the effect of test parameter variations on test performance, including the use of different red blood cell (RBC) species, serum treatment methods, and virus isolates. Based on a receiver operating characteristic analysis using serum microneutralization assay titers as the gold standard, the H3N8 CIV HI assay described in the present study is highly sensitive (99.6%) and specific (94.6%) when the cutoff antibody titer for seropositivity is 32. Evaluation of parameter variations determined that the sensitivity and specificity of the H3N8 CIV HI assay depend on serum pretreatment with a receptor-destroying enzyme or periodate, use of 0.5% turkey or chicken RBCs, and use of antigenically well-matched H3N8 virus strains. C1 [Anderson, Tara C.; Crawford, P. Cynda; Gibbs, E. Paul J.] Univ Florida, Coll Vet Med, Gainesville, FL 32610 USA. [Katz, Jacqueline M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Dubovi, Edward J.] Cornell Univ, Coll Vet Med, Anim Hlth Diagnost Ctr, Ithaca, NY 14853 USA. [Landolt, Gabriele] Colorado State Univ, Coll Vet Med & Biomed Sci, Ft Collins, CO 80523 USA. RP Crawford, PC (reprint author), Univ Florida, Coll Vet Med, POB 100126, Gainesville, FL 32610 USA. EM crawfordc@ufl.edu FU Morris Animal Foundation [D06CA-071] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded in part by the Morris Animal Foundation (grant no. D06CA-071). NR 36 TC 5 Z9 6 U1 0 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1040-6387 J9 J VET DIAGN INVEST JI J. Vet. Diagn. Invest. PD MAY PY 2012 VL 24 IS 3 BP 499 EP 508 DI 10.1177/1040638712440992 PG 10 WC Veterinary Sciences SC Veterinary Sciences GA 983JT UT WOS:000307116300005 PM 22529116 ER PT J AU Luncheon, C Zack, M AF Luncheon, Cecily Zack, Matthew TI Health-Related Quality of Life Among US Veterans and Civilians by Race and Ethnicity SO PREVENTING CHRONIC DISEASE LA English DT Article ID FACTOR SURVEILLANCE SYSTEM; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; MILITARY PERSONNEL; POPULATION; SERVICE; ADULTS; IRAQ; AFGHANISTAN; PREVALENCE AB Introduction Among veterans, having been selected into the military and having easy access to medical care during and after military service may reduce premature mortality but not morbidity from mental distress and may not improve health-related quality of life. The objective of this study was to determine whether veterans in different racial/ethnic groups differ in their health-related quality of life from each other and from their civilian counterparts. Methods Among 800,000 respondents to the 2007-2009 Behavioral Risk Factor Surveillance System surveys, approximately 110,000 identified themselves as veterans and answered questions about their sociodemographic characteristics, self-rated health, and recent health-related quality of life. Nonoverlapping 95% confidence intervals of means distinguished veterans and civilians of different racial/ethnic groups. Results Veteran and civilian American Indians/Alaska Natives reported more physically unhealthy days, mentally unhealthy days, and recent activity limitation days than their veteran and civilian counterparts in other racial/ethnic groups. Non -Hispanic white veterans and Hispanic veterans reported more physically unhealthy days, mentally unhealthy days, and recent activity limitation days than their civilian counterparts. Conclusion Unlike findings in other studies, our findings show that veterans' health-related quality of life differs from that of civilians both within the same racial/ethnic group and among different racial/ethnic groups. Because once-healthy soldiers may not be as healthy when they return to civilian life, assessing their health-related quality of life over time may identify those who need help to regain their health. C1 [Luncheon, Cecily; Zack, Matthew] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Zack, M (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,MS K-51, Atlanta, GA 30341 USA. EM Matthew.Zack@cdc.hhs.gov FU appointment to the Research Participation Program for CDC FX This project was supported in part by appointment to the Research Participation Program for CDC administered by the Oak Ridge Institute for Science and Education through an agreement between the Department of Energy and CDC. This research received no specific grant from any funding agency in the public, commercial, or nonprofit sectors. NR 30 TC 2 Z9 2 U1 2 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAY PY 2012 VL 9 AR 110138 DI 10.5888/pcd9.110138 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 977HU UT WOS:000306648100015 ER PT J AU Mendiola, J Meeker, JD Jorgensen, N Andersson, AM Liu, F Calafat, AM Redmon, JB Drobnis, EZ Sparks, AE Wang, C Hauser, R Swan, SH AF Mendiola, Jaime Meeker, John D. Jorgensen, Niels Andersson, Anna-Maria Liu, Fan Calafat, Antonia M. Redmon, J. Bruce Drobnis, Erma Z. Sparks, Amy E. Wang, Christina Hauser, Russ Swan, Shanna H. TI Urinary Concentrations of Di(2-ethylhexyl) Phthalate Metabolites and Serum Reproductive Hormones: Pooled Analysis of Fertile and Infertile Men SO JOURNAL OF ANDROLOGY LA English DT Article DE Anti-androgens; DEHP metabolites; endocrine disruptor; male hormones ID FOLLICLE-STIMULATING-HORMONE; RAT GRANULOSA-CELLS; MONO-(2-ETHYLHEXYL) PHTHALATE; NEONATAL-RATS; SEMEN QUALITY; YOUNG MEN; DIETHYLHEXYL PHTHALATE; SEXUAL-DIFFERENTIATION; TEMPORAL VARIABILITY; ESTRADIOL PRODUCTION AB Urinary concentrations of metabolites of the anti-androgenic xenobiotic di-(2-ethylhexyl) phthalate (DEHP) were previously shown to be weakly associated with serum levels of several hormones in 2 disparate US populations: partners of pregnant women participating in the Study for Future Families and partners in infertile couples from Massachusetts General Hospital infertility clinic. The observed associations between phthalate metabolites and reproductive hormones were robust and insensitive to the characteristics of the subpopulation or the laboratory in which the hormones were measured, despite the fact that these 2 populations span a range of fertility, urinary phthalate metabolites, and reproductive hormone levels. We therefore examined associations between urinary metabolites of DEHP and reproductive hormones follicle-stimulating hormone, luteinizing hormone, testosterone (T), inhibin B, and estradiol (E-2) and sex hormone binding globulin (SHBG) in the pooled population. The magnitude of the associations seen were similar to those reported for each population separately, but effect estimates were more precise because of the increased sample size and the greater range of phthalate metabolite concentrations and hormone levels. Urinary concentrations of 3 metabolites of DEHP [mono(2-ethylhexyl) phthalate (MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono(2-ethyl-5-oxohexyl) phthalate (MEOHP)] were inversely associated with the free androgen index (FAI = T/SHBG) and calculated free testosterone. Urinary concentrations of MEHHP and MEOHP were positively associated with SHBG, and MEHP was inversely associated with E2. No other phthalate metabolites were associated with serum hormones, consistent with results in each population. Our results in this diverse population suggest that DEHP exposure is robustly associated with some male sex steroid hormones. C1 [Mendiola, Jaime; Liu, Fan; Hauser, Russ; Swan, Shanna H.] Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, Rochester, NY 14642 USA. [Meeker, John D.] Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Jorgensen, Niels; Andersson, Anna-Maria] Univ Copenhagen, Rigshosp, Univ Dept Growth & Reprod, DK-2100 Copenhagen, Denmark. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Redmon, J. Bruce] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. [Redmon, J. Bruce] Univ Minnesota, Sch Med, Dept Urol Surg, Minneapolis, MN 55455 USA. [Drobnis, Erma Z.] Univ Missouri, Sch Med, Dept Obstet Gynecol & Womens Hlth, Columbia, MO USA. [Sparks, Amy E.] Univ Iowa, Dept Obstet & Gynecol, Iowa City, IA 52242 USA. [Wang, Christina] Harbor UCLA Med Ctr, Dept Med, Div Endocrinol, Torrance, CA 90509 USA. [Wang, Christina] Los Angeles Biomed Res Inst, Torrance, CA USA. [Hauser, Russ] Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Androl Lab, Vitro Fertilizat Unit, Boston, MA 02114 USA. [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Swan, Shanna H.] Mt Sinai Sch Med, Dept Prevent Med, New York, NY USA. RP Swan, SH (reprint author), Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, 601 Elmwood Ave,Box 668, Rochester, NY 14642 USA. EM shanna_swan@urmc.rochester.edu RI Jorgensen, Niels/A-8148-2012; Andersson, Anna-Maria/F-5842-2013; OI Jorgensen, Niels/0000-0003-4827-0838; Andersson, Anna-Maria/0000-0002-7300-1659; Redmon, J. Bruce/0000-0002-1883-9467; Drobnis, Erma Z./0000-0001-5495-3489; Meeker, John/0000-0001-8357-5085 FU Danish Agency for Science, Technology, and Innovation [271070678]; University of Iowa Center for Health Effects of Environmental Contamination cooperative project grant; General Clinical Research Center at Harbor UCLA Medical Center [MO1 RR00425]; NIEHS [ES009718] FX This study is supported by The Danish Agency for Science, Technology, and Innovation, grant 271070678 to N.J.; a University of Iowa Center for Health Effects of Environmental Contamination cooperative project grant to A.E.S.; the General Clinical Research Center at Harbor UCLA Medical Center (MO1 RR00425); and NIEHS grant ES009718 to R.H. NR 52 TC 33 Z9 33 U1 2 U2 14 PU AMER SOC ANDROLOGY, INC PI LAWRENCE PA C/O ALLEN PRESS, INC PO BOX 368, LAWRENCE, KS 66044 USA SN 0196-3635 J9 J ANDROL JI J. Androl. PD MAY-JUN PY 2012 VL 33 IS 3 BP 488 EP 498 DI 10.2164/jandrol.111.013557 PG 11 WC Andrology SC Endocrinology & Metabolism GA 959JM UT WOS:000305308700025 PM 21597090 ER PT J AU Rein, DB Wittenborn, JS Zhang, XZ Song, M Saaddine, JB AF Rein, David B. Wittenborn, John S. Zhang, Xinzhi Song, Michael Saaddine, Jinan B. CA Vision Cost-Effectiveness Study TI The Potential Cost-Effectiveness of Amblyopia Screening Programs SO JOURNAL OF PEDIATRIC OPHTHALMOLOGY & STRABISMUS LA English DT Article ID RANDOMIZED-TRIAL; MODERATE AMBLYOPIA; VISUAL-ACUITY; ECONOMIC-EVALUATION; UNITED-STATES; PRESCHOOL-CHILDREN; MARKOV MODEL; LEA SYMBOLS; FOLLOW-UP; VISION AB Purpose: To estimate the incremental cost-effectiveness of amblyopia screening at preschool and kindergarten, the costs and benefits of three amblyopia screening scenarios were compared to no screening and to each other: (1) acuity/stereopsis (A/S) screening at kindergarten, (2) A/S screening at preschool and kindergarten, and (3) photoscreening at preschool and A/S screening at kindergarten. Methods: A probabilistic microsimulation model of amblyopia natural history and response to treatment with screening costs and outcomes estimated from two state programs was programmed. The probability was calculated that no screening and each of the three interventions were most cost-effective per incremental quality-adjusted life year (QALY) gained and case avoided. Results: Assuming a minimal 0.01 utility loss from monocular vision loss, no screening was most cost-effective with a willingness to pay (WTP) of less than $16,000 per QALY gained. A/S screening at kindergarten alone was most cost-effective at a WTP between $17,000 and $21,000. A/S screening at preschool and kindergarten was most cost-effective at a WTP between $22,000 and $75,000, and photoscreening at preschool and A/S screening at kindergarten was most cost-effective at a WTP greater than $75,000. Cost-effectiveness substantially improved when assuming a greater utility loss. All scenarios were cost-effective when assuming a WTP of $10,500 per case of amblyopia cured. Conclusion: All three screening interventions evaluated are likely to be considered cost-effective relative to many other potential public health programs. The choice of screening option depends on budgetary resources and the value placed on monocular vision loss prevention by funding agencies. C1 [Rein, David B.] Univ Chicago, NORC, Chicago, IL 60637 USA. [Zhang, Xinzhi; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Rein, DB (reprint author), 55 E Monroe St,Suite 3000, Chicago, IL 60603 USA. EM rein-david@norc.org FU Centers for Disease Control and Prevention, Atlanta, Georgia [200-2008-F-26421]; National Eye Institute, Bethesda, Maryland [REY019173A] FX Supported by the Centers for Disease Control and Prevention, Atlanta, Georgia (contract no. 200-2008-F-26421), and the National Eye Institute, Bethesda, Maryland (contract no. REY019173A). NR 58 TC 6 Z9 6 U1 2 U2 6 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0191-3913 J9 J PEDIAT OPHTH STRAB JI J. Pediatr. Ophthalmol. Strabismus. PD MAY-JUN PY 2012 VL 49 IS 3 BP 146 EP 155 DI 10.3928/01913913-20110823-02 PG 10 WC Ophthalmology; Pediatrics SC Ophthalmology; Pediatrics GA 958AX UT WOS:000305209400004 PM 21877675 ER PT J AU Erickson, JD AF Erickson, J. D. TI An Epidemiologic Enterprise: From Fluoride to Folate SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Erickson, J. D.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2012 VL 94 IS 5 SI SI BP 292 EP 292 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 956FF UT WOS:000305074800002 ER PT J AU Yang, W Carmichael, SL Tinker, S Shaw, GM AF Yang, W. Carmichael, S. L. Tinker, S. Shaw, G. M. TI The Association between Weight Gain during Pregnancy and Neural Tube Defects and Gastroschisis in Offspring SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Yang, W.; Carmichael, S. L.; Shaw, G. M.] Stanford Univ, Stanford, CA 94305 USA. [Tinker, S.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2012 VL 94 IS 5 SI SI BP 336 EP 336 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 956FF UT WOS:000305074800083 ER PT J AU Cragan, J Riordan, S AF Cragan, J. Riordan, S. TI Interpreting Data from Pregnancy Registries: Who, When, and How? SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Cragan, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Riordan, S.] Org Teratol Specialists, Foster City, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2012 VL 94 IS 5 SI SI BP 366 EP 366 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 956FF UT WOS:000305074800140 ER PT J AU Caldwell, KL Mortensen, ME Pan, Y Merrill, LS Moye, JH AF Caldwell, K. L. Mortensen, M. E. Pan, Y. Merrill, L. S. Moye, J. H. TI Urine Iodine in Pregnant Women Enrolled in the National Children's Study SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Caldwell, K. L.; Mortensen, M. E.; Pan, Y.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Merrill, L. S.] Westat Corp, Rockville, MD USA. [Moye, J. H.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NCS Program Off, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2012 VL 94 IS 5 SI SI BP 385 EP 385 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 956FF UT WOS:000305074800173 ER PT J AU Mortensen, ME Calafat, AM Wong, LY Ye, X Pirkle, JL Merrill, LS Moye, JH AF Mortensen, M. E. Calafat, A. M. Wong, L. Y. Ye, X. Pirkle, J. L. Merrill, L. S. Moye, J. H. TI Exposure to Environmental Phenols in Pregnant Women Enrolled in the National Children's Study SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Mortensen, M. E.; Calafat, A. M.; Wong, L. Y.; Ye, X.; Pirkle, J. L.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Merrill, L. S.] Westat Corp, Rockville, MD USA. [Moye, J. H.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NCS Program Off, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2012 VL 94 IS 5 SI SI BP 385 EP 385 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 956FF UT WOS:000305074800174 ER PT J AU Lavigne, S Nichols, G Cragan, J AF Lavigne, S. Nichols, G. Cragan, J. TI Connecticut Pregnancy Exposure Information Service (CPEIS) Experience with a Collaborative Project to Evaluate the Quality of Interview Data Collected by Teratology Information Services (TIS) About Medication Use during Pregnancy and Lactation, Pregnancy Outcomes, and Maternal and Infant Health SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Lavigne, S.; Nichols, G.] Univ Connecticut, Ctr Hlth, Div Human Genet, Farmington, CT USA. [Lavigne, S.; Nichols, G.] Univ Connecticut, Ctr Hlth, Connecticut Pregnancy Exposure Informat Serv, Farmington, CT USA. [Cragan, J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2012 VL 94 IS 5 SI SI BP 411 EP 411 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 956FF UT WOS:000305074800197 ER PT J AU Klein, NP Lewis, E Baxter, R Weintraub, E Glanz, J Naleway, A Jackson, LA Nordin, J Lieu, T Belongia, EA Fireman, B AF Klein, Nicola P. Lewis, Edwin Baxter, Roger Weintraub, Eric Glanz, Jason Naleway, Allison Jackson, Lisa A. Nordin, James Lieu, Tracy Belongia, Edward A. Fireman, Bruce TI Measles-Containing Vaccines and Febrile Seizures in Children Age 4 to 6 Years SO PEDIATRICS LA English DT Article DE measles; varicella; seizures; vaccine; fever ID IMMUNIZATION PRACTICES ACIP; RUBELLA-VARICELLA VACCINE; ADVERSE EVENTS; COMBINATION MEASLES; ADVISORY-COMMITTEE; SAFETY DATALINK; MMRV VACCINE; MUMPS; IMMUNOGENICITY; SURVEILLANCE AB BACKGROUND: In the United States, children receive 2 doses of measles-mumps-rubella vaccine (MMR) and varicella vaccine (V), the first between ages 1 to 2 years and the second between ages 4 to 6 years. Among 1- to 2-year-olds, the risk of febrile seizures 7 to 10 days after MMRV is double that after separate MMR + V. Whether MMRV or MMR + V affects risk for febrile seizure risk among 4- to 6-year-olds has not been reported. METHODS: Among 4- to 6-year-old Vaccine Safety Datalink members, we identified seizures in the emergency department and hospital from 2000 to 2008 and outpatient visits for fever from 2006 to 2008 during days 7 to 10 and 0 to 42 after MMRV and MMR + V. Incorporating medical record reviews, we assessed seizure risk after MMRV and MMR + V. RESULTS: From 2006 through 2008, 86 750 children received MMRV; from 2000 through 2008, 67 438 received same-day MMR + V. Seizures were rare throughout days 0 to 42 without peaking during days 7 to 10. There was 1 febrile seizure 7 to 10 days after MMRV and 0 after MMR + V. Febrile seizure risk was 1 per 86 750 MMRV doses (95% confidence interval, 1 per 3 426 441, 1 per 15 570) and 0 per 67 438 MMR + V doses (1 per 18 282). CONCLUSIONS: This study provides reassurance that MMRV and MMR + V were not associated with increased risk of febrile seizures among 4- to 6-year-olds. We can rule out with 95% confidence a risk greater than 1 febrile seizure per 15 500 MMRV doses and 1 per 18 000 MMR + V doses. Pediatrics 2012;129:809-814 C1 [Klein, Nicola P.; Lewis, Edwin; Baxter, Roger; Fireman, Bruce] Kaiser Permanente Vaccine Study Ctr, Oakland, CA 94612 USA. [Weintraub, Eric] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. [Glanz, Jason] Kaiser Permanente Colorado, Denver, CO USA. [Glanz, Jason] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Naleway, Allison] Kaiser Permanente NW, Portland, OR USA. [Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA. [Nordin, James] HealthPartners Res Fdn, Minneapolis, MN USA. [Lieu, Tracy] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Ctr Child Hlth Care Studies, Boston, MA USA. [Lieu, Tracy] Harvard Univ, Sch Med, Boston, MA USA. [Lieu, Tracy] Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA. [Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA. RP Klein, NP (reprint author), Kaiser Permanente Vaccine Study Ctr, 1 Kaiser Plaza,16th Floor, Oakland, CA 94612 USA. EM Nicola.Klein@kp.org OI Naleway, Allison/0000-0001-5747-4643 FU Merck Co; Novartis; GlaxoSmithKline; Pfizer; Sanofi-Pasteur; Novartis Vaccines; MedImmune; Centers for Disease Control and Prevention (CDC) [200-2002-00732] FX Drs Klein and Baxter reports research support from Merck & Co, Novartis, GlaxoSmithKline, Pfizer, and Sanofi-Pasteur; Dr Jackson reports research support from Novartis Vaccines, Sanofi-Pasteur, and Pfizer; Dr Belongia receives reports research support from MedImmune; the other authors have indicated they have no financial relationships relevant to this article to disclose.; This work was supported by a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732 from the Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC. NR 15 TC 19 Z9 19 U1 0 U2 6 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAY PY 2012 VL 129 IS 5 BP 809 EP 814 DI 10.1542/peds.2011-3198 PG 6 WC Pediatrics SC Pediatrics GA 951GT UT WOS:000304709600027 PM 22473362 ER PT J AU Wen, XZ Gillman, MW Rifas-Shiman, SL Sherry, B Kleinman, K Taveras, EM AF Wen, Xiaozhong Gillman, Matthew W. Rifas-Shiman, Sheryl L. Sherry, Bettylou Kleinman, Ken Taveras, Elsie M. TI Decreasing Prevalence of Obesity Among Young Children in Massachusetts From 2004 to 2008 SO PEDIATRICS LA English DT Article DE obesity; BMI; child; infant; prevalence; trends; epidemiology ID BODY-MASS INDEX; PRESCHOOL-AGED CHILDREN; UNITED-STATES; CHILDHOOD OBESITY; US CHILDREN; LOW-INCOME; OVERWEIGHT PREVALENCE; PEDIATRIC OBESITY; TRENDS; ADOLESCENTS AB OBJECTIVE: To examine whether the obesity prevalence is increasing, level, or decreasing among young US children (aged <6 years) in the past decade; and to compare regional data to those of 2 national databases. METHODS: We analyzed data from 108 762 well-child visits (36 827 children) at a multisite pediatric practice in eastern Massachusetts during 1999-2008. By using the Centers for Disease Control and Prevention 2000 gender-specific growth charts, we defined obesity as weight-for-length >= 95th percentile for children aged <24 months and BMI >= 95th percentile for children aged 24 to <72 months. By using multivariable logistic regression, we estimated gender-specific obesity trends in 2 separate periods, 1999-2003 and 2004-2008, adjusting for age group, race/ethnicity, health insurance, and practice site. RESULTS: From 1999 to 2003, the obesity prevalence was fairly stable among both boys and girls. From 2004 to 2008, the obesity prevalence substantially decreased among both boys and girls. The decline in obesity prevalence during 2004-2008 was more pronounced among children insured by non-Medicaid health plans than among those insured by Medicaid. CONCLUSIONS: Among children aged <6 years at this multisite pediatric practice, obesity prevalence decreased during 2004-2008, which is in line with national data showing no increase in prevalence during this time period. The smaller decrease among Medicaid-insured children may portend widening of socioeconomic disparities in childhood obesity. Pediatrics 2012;129:823-831 C1 [Wen, Xiaozhong; Gillman, Matthew W.; Rifas-Shiman, Sheryl L.; Kleinman, Ken; Taveras, Elsie M.] Harvard Univ, Sch Med, Dept Populat Med, Obes Prevent Program, Boston, MA 02215 USA. [Wen, Xiaozhong; Gillman, Matthew W.; Rifas-Shiman, Sheryl L.; Kleinman, Ken; Taveras, Elsie M.] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA. [Sherry, Bettylou] Ctr Dis Control & Prevent, Obes Prevent & Control Branch, Div Nutr Phys Act & Obes, Atlanta, GA USA. RP Wen, XZ (reprint author), Harvard Univ, Sch Med, Dept Populat Med, Obes Prevent Program, 133 Brookline Ave,3rd Floor, Boston, MA 02215 USA. EM xiaozhongwen@hotmail.com FU Centers for Disease Control and Prevention; National Center for Chronic Disease Prevention and Health Promotion [200-2008-M-26882]; National Center on Minority Health and Health Disparities [MD 003963]; National institutes of Health (NIH) FX This work was supported in part by the Centers for Disease Control and Prevention, the National Center for Chronic Disease Prevention and Health Promotion (contract 200-2008-M-26882). This study was also supported by the National Center on Minority Health and Health Disparities (grant MD 003963). Funded by the National institutes of Health (NIH). NR 39 TC 36 Z9 36 U1 1 U2 8 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAY PY 2012 VL 129 IS 5 BP 823 EP 831 DI 10.1542/peds.2011-1833 PG 9 WC Pediatrics SC Pediatrics GA 951GT UT WOS:000304709600029 PM 22529276 ER PT J AU Ramowski, SK Nystrom, RJ Rosenberg, KD Gilchrist, J Chaumeton, NR AF Ramowski, Sarah K. Nystrom, Robert J. Rosenberg, Kenneth D. Gilchrist, Julie Chaumeton, Nigel R. TI Health Risks of Oregon Eighth-Grade Participants in the "Choking Game": Results From a Population-Based Survey SO PEDIATRICS LA English DT Article DE adolescent medicine; adolescents; injury prevention and control; preventive health care visits; risk assessment ID UNINTENTIONAL-STRANGULATION; ASPHYXIAL GAMES; BEHAVIOR AB OBJECTIVE: To examine the risk behaviors associated with participation in the "choking game" by eighth-graders in Oregon. METHODS: We obtained data from the 2009 Oregon Healthy Teens survey, a cross-sectional weighted survey of 5348 eighth-graders that questioned lifetime prevalence and frequency of choking game participation. The survey also included questions about physical and mental health, gambling, sexual activity, nutrition, physical activity/body image, exposure to violence, and substance use. RESULTS: Lifetime prevalence of choking game participation was 6.1% for Oregon eighth-graders, with no differences between males and females. Of the eighth-grade choking game participants, 64% had engaged in the activity more than once and 26.6% >5 times. Among males, black youth were more likely to participate than white youth. Among both females and males, Pacific Islander youth were much more likely to participate than white youth. Multivariate logistic regression revealed that sexual activity and substance use were significantly associated with choking game participation for both males and females. CONCLUSIONS: At >6%, the prevalence of choking game participation among Oregon youth is consistent with previous findings. However, we found that most of those who participate will put themselves at risk more than once. Participants also have other associated health risk behaviors. The comprehensive adolescent well visit, as recommended by the American Academy of Pediatrics, is a good opportunity for providers to conduct a health behavior risk assessment and, if appropriate, discuss the dangers of engaging in this activity. Pediatrics 2012;129:846-851 C1 [Ramowski, Sarah K.; Nystrom, Robert J.; Rosenberg, Kenneth D.; Chaumeton, Nigel R.] Publ Hlth Div, Oregon Hlth Author, Portland, OR USA. [Gilchrist, Julie] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Nystrom, RJ (reprint author), Oregon Publ Hlth Div, 800 NE Oregon St,Suite 805, Portland, OR 97232 USA. EM robert.j.nystrom@state.or.us OI Knipper, Sarah/0000-0002-9953-2749 NR 18 TC 6 Z9 6 U1 0 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAY PY 2012 VL 129 IS 5 BP 846 EP 851 DI 10.1542/peds.2011-2482 PG 6 WC Pediatrics SC Pediatrics GA 951GT UT WOS:000304709600032 PM 22508913 ER PT J AU Bulkow, LR Singleton, RJ DeByle, C Miernyk, K Redding, G Hummel, KB Chikoyak, L Hennessy, TW AF Bulkow, Lisa R. Singleton, Rosalyn J. DeByle, Carolynn Miernyk, Karen Redding, Gregory Hummel, Kimberlee Boyd Chikoyak, Lori Hennessy, Thomas W. TI Risk Factors for Hospitalization With Lower Respiratory Tract Infections in Children in Rural Alaska SO PEDIATRICS LA English DT Article DE pneumonia; respiratory infectious diseases; case-control study; risk factors; Alaska Native ID SYNCYTIAL VIRUS-INFECTION; CANADIAN INUIT CHILDREN; NATIVE CHILDREN; HUMAN METAPNEUMOVIRUS; HEALTHY INFANTS; EARLY-CHILDHOOD; YOUNG-CHILDREN; US CHILDREN; DISEASE; POPULATION AB WHAT'S KNOWN ON THIS SUBJECT: Rural Alaska children have high rates of hospitalization with lower respiratory tract infections from a variety of pathogens. Past studies of risk factors for respiratory syncytial virus infection associated medically high-risk status, household crowding, and infant feeding practices with hospitalization. WHAT THIS STUDY ADDS: This study reveals the importance of medically high-risk status and infant feeding practices as important factors in respiratory hospitalization. In addition, we identified woodstove use and the absence of 2 or more sinks in household as risk factors for hospitalization. C1 [Bulkow, Lisa R.; DeByle, Carolynn; Miernyk, Karen; Hummel, Kimberlee Boyd; Hennessy, Thomas W.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK 99508 USA. [Singleton, Rosalyn J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Redding, Gregory] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA. [Chikoyak, Lori] Yukon Kuskokwim Hlth Corp, Bethel, AK USA. RP Bulkow, LR (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM lrb2@cdc.gov FU Pfizer; Medimmune FX Dr Singleton received grant funding from Pfizer; the other authors have indicated they have no financial relationships relevant to this article to disclose.; This study was supported in part by a grant from Medimmune to Dr Singleton. NR 38 TC 19 Z9 20 U1 0 U2 1 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD MAY PY 2012 VL 129 IS 5 BP E1220 EP E1227 DI 10.1542/peds.2011-1943 PG 8 WC Pediatrics SC Pediatrics GA 951GT UT WOS:000304709600003 PM 22508919 ER PT J AU Coyle, CM Mahanty, S Zunt, JR Wallin, MT Cantey, PT White, AC O'Neal, SE Serpa, JA Southern, PM Wilkins, P McCarthy, AE Higgs, ES Nash, TE AF Coyle, Christina M. Mahanty, Siddhartha Zunt, Joseph R. Wallin, Mitchell T. Cantey, Paul T. White, A. Clinton, Jr. O'Neal, Seth E. Serpa, Jose A. Southern, Paul M. Wilkins, Patricia McCarthy, Anne E. Higgs, Elizabeth S. Nash, Theodore E. TI Neurocysticercosis: Neglected but Not Forgotten SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID HUMAN CYSTICERCOSIS; DISEASE BURDEN; EPILEPSY; AFRICA; SEROPREVALENCE; EPIDEMIOLOGY; PREVALENCE; DIAGNOSIS; SEROLOGY; CAMEROON C1 [Coyle, Christina M.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Mahanty, Siddhartha] NIAID, NIH, Helminth Immunol Sect, Parasit Dis Lab, Bethesda, MD 20892 USA. [Zunt, Joseph R.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Zunt, Joseph R.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Wallin, Mitchell T.] Georgetown Univ, Dept Neurol, Washington, DC USA. [Wallin, Mitchell T.] Univ Maryland, Baltimore, MD 21201 USA. [Cantey, Paul T.; Wilkins, Patricia] Ctr Dis Control, Div Parasit Dis, Atlanta, GA 30333 USA. [White, A. Clinton, Jr.] Univ Texas Galveston, Dept Internal Med, Div Infect Dis, Galveston, TX USA. [O'Neal, Seth E.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Serpa, Jose A.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA. [Southern, Paul M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [McCarthy, Anne E.] Ottawa Gen Hosp, Dept Med, Ottawa, ON K1H 8L6, Canada. [Higgs, Elizabeth S.] NIAID, NIH, Collaborat Clin Res Branch, Div Clin Res, Bethesda, MD 20892 USA. [Nash, Theodore E.] NIAID, NIH, Gastrointestinal Parasites Sect, Parasit Dis Lab, Bethesda, MD 20892 USA. RP Coyle, CM (reprint author), Albert Einstein Coll Med, Bronx, NY 10467 USA. EM christina.coyle@einstein.yu.edu; tnash@niaid.nih.gov OI White, A Clinton/0000-0002-9668-4632; McCarthy, Anne/0000-0001-7195-6366; Mahanty, Siddhartha/0000-0003-1068-0524 FU Division of Intramural Research, National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health; Office of Rare Diseases, National Center for Advancing Translational Sciences, NIH FX Funding for this work was provided in part by the Division of Intramural Research, National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health and by and the Office of Rare Diseases, National Center for Advancing Translational Sciences, NIH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders financially supported the formation of the consortium (e. g., paid for initial meeting), and communication between the members. NR 31 TC 41 Z9 41 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAY PY 2012 VL 6 IS 5 AR e1500 DI 10.1371/journal.pntd.0001500 PG 3 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 951ZG UT WOS:000304758900002 PM 22666505 ER PT J AU Crabtree, MB Crockett, RJK Bird, BH Nichol, ST Erickson, BR Biggerstaff, BJ Horiuchi, K Miller, BR AF Crabtree, Mary B. Crockett, Rebekah J. Kent Bird, Brian H. Nichol, Stuart T. Erickson, Bobbie Rae Biggerstaff, Brad J. Horiuchi, Kalanthe Miller, Barry R. TI Infection and Transmission of Rift Valley Fever Viruses Lacking the NSs and/or NSm Genes in Mosquitoes: Potential Role for NSm in Mosquito Infection SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID WEST-NILE-VIRUS; NORTH-AMERICAN MOSQUITOS; CULEX-PIPIENS COMPLEX; SAUDI-ARABIA; LOGISTIC-REGRESSION; VACCINATED ANIMALS; DIPTERA-CULICIDAE; VECTOR COMPETENCE; REPLICATION; PROTEIN AB Background: Rift Valley fever virus is an arthropod-borne human and animal pathogen responsible for large outbreaks of acute and febrile illness throughout Africa and the Arabian Peninsula. Reverse genetics technology has been used to develop deletion mutants of the virus that lack the NSs and/or NSm virulence genes and have been shown to be stable, immunogenic and protective against Rift Valley fever virus infection in animals. We assessed the potential for these deletion mutant viruses to infect and be transmitted by Aedes mosquitoes, which are the principal vectors for maintenance of the virus in nature and emergence of virus initiating disease outbreaks, and by Culex mosquitoes which are important amplification vectors. Methodology and Principal Findings: Aedes aegypti and Culex quinquefasciatus mosquitoes were fed bloodmeals containing the deletion mutant viruses. Two weeks post-exposure mosquitoes were assayed for infection, dissemination, and transmission. In Ae. aegypti, infection and transmission rates of the NSs deletion virus were similar to wild type virus while dissemination rates were significantly reduced. Infection and dissemination rates for the NSm deletion virus were lower compared to wild type. Virus lacking both NSs and NSm failed to infect Ae. aegypti. In Cx. quinquefasciatus, infection rates for viruses lacking NSm or both NSs and NSm were lower than for wild type virus. Conclusions/Significance: In both species, deletion of NSm or both NSs and NSm reduced the infection and transmission potential of the virus. Deletion of both NSs and NSm resulted in the highest level of attenuation of virus replication. Deletion of NSm alone was sufficient to nearly abolish infection in Aedes aegypti mosquitoes, indicating an important role for this protein. The double deleted viruses represent an ideal vaccine profile in terms of environmental containment due to lack of ability to efficiently infect and be transmitted by mosquitoes. C1 [Crabtree, Mary B.; Crockett, Rebekah J. Kent; Biggerstaff, Brad J.; Horiuchi, Kalanthe; Miller, Barry R.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Bird, Brian H.; Nichol, Stuart T.; Erickson, Bobbie Rae] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Crabtree, MB (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. EM mcrabtree@cdc.gov RI Kading, Rebekah/E-5633-2017 OI Kading, Rebekah/0000-0002-4996-915X NR 48 TC 33 Z9 33 U1 1 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAY PY 2012 VL 6 IS 5 AR e1639 DI 10.1371/journal.pntd.0001639 PG 8 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 951ZG UT WOS:000304758900022 PM 22563517 ER PT J AU Li, PC Liao, MY Cheng, PC Liang, JJ Liu, IJ Chiu, CY Lin, YL Chang, GJJ Wu, HC AF Li, Pi-Chun Liao, Mei-Ying Cheng, Ping-Chang Liang, Jian-Jong Liu, I-Ju Chiu, Chien-Yu Lin, Yi-Ling Chang, Gwong-Jen J. Wu, Han-Chung TI Development of a Humanized Antibody with High Therapeutic Potential against Dengue Virus Type 2 SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID WEST-NILE-VIRUS; JAPANESE ENCEPHALITIS-VIRUS; POLYMERASE-CHAIN-REACTION; B-CELL EPITOPES; MONOCLONAL-ANTIBODIES; ENVELOPE GLYCOPROTEIN; FUSION LOOP; DEPENDENT ENHANCEMENT; FLAVIVIRUS INFECTION; PEPTIDE ANTIGENS AB Background: Dengue virus (DENV) is a significant public health threat in tropical and subtropical regions of the world. A therapeutic antibody against the viral envelope (E) protein represents a promising immunotherapy for disease control. Methodology/Principal Findings: We generated seventeen novel mouse monoclonal antibodies (mAbs) with high reactivity against E protein of dengue virus type 2 (DENV-2). The mAbs were further dissected using recombinant E protein domain I-II (E-DI-II) and III (E-DIII) of DENV-2. Using plaque reduction neutralization test (PRNT) and mouse protection assay with lethal doses of DENV-2, we identified four serotype-specific mAbs that had high neutralizing activity against DENV-2 infection. Of the four, E-DIII targeting mAb DB32-6 was the strongest neutralizing mAb against diverse DENV-2 strains. Using phage display and virus-like particles (VLPs) we found that residue K310 in the E-DIII A-strand was key to mAb DB32-6 binding E-DIII. We successfully converted DB32-6 to a humanized version that retained potency for the neutralization of DENV-2 and did not enhance the viral infection. The DB32-6 showed therapeutic efficacy against mortality induced by different strains of DENV-2 in two mouse models even in post-exposure trials. Conclusions/Significance: We used novel epitope mapping strategies, by combining phage display with VLPs, to identify the important A-strand epitopes with strong neutralizing activity. This study introduced potential therapeutic antibodies that might be capable of providing broad protection against diverse DENV-2 infections without enhancing activity in humans. C1 [Li, Pi-Chun; Wu, Han-Chung] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan. [Li, Pi-Chun; Liao, Mei-Ying; Cheng, Ping-Chang; Liu, I-Ju; Chiu, Chien-Yu; Wu, Han-Chung] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan. [Liang, Jian-Jong; Lin, Yi-Ling] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan. [Chang, Gwong-Jen J.] Ctr Dis Control & Prevent, Arbovirus Dis Branch, Div Vector Borne Infect Dis, Publ Hlth Serv,US Dept Hlth & Human Serv, Ft Collins, CO USA. RP Li, PC (reprint author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan. EM hcw0928@gate.sinica.edu.tw RI Wu, Han-Chung/B-1209-2011 OI Wu, Han-Chung/0000-0002-5185-1169 FU Academia Sinica; National Science Council, Taiwan [NSC-99-3111-B-001-007, NSC-99-2323-B-001-002] FX This work was supported by Academia Sinica (to HCW) and National Science Council, Taiwan, grants NSC-99-3111-B-001-007 and NSC-99-2323-B-001-002 (to HCW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 58 TC 22 Z9 23 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAY PY 2012 VL 6 IS 5 AR e1636 DI 10.1371/journal.pntd.0001636 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 951ZG UT WOS:000304758900019 PM 22563515 ER PT J AU Mourya, DT Yadav, PD Shete, AM Gurav, YK Raut, CG Jadi, RS Pawar, SD Nichol, ST Mishra, AC AF Mourya, Devendra T. Yadav, Pragya D. Shete, Anita M. Gurav, Yogesh K. Raut, Chandrashekhar G. Jadi, Ramesh S. Pawar, Shailesh D. Nichol, Stuart T. Mishra, Akhilesh C. TI Detection, Isolation and Confirmation of Crimean-Congo Hemorrhagic Fever Virus in Human, Ticks and Animals in Ahmadabad, India, 2010-2011 SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID BORNE VIRUSES; OUTBREAK; PAKISTAN AB Background: In January 2011, human cases with hemorrhagic manifestations in the hospital staff were reported from a tertiary care hospital in Ahmadabad, India. This paper reports a detailed epidemiological investigation of nosocomial outbreak from the affected area of Ahmadabad, Gujarat, India. Principal Findings: Samples from 3 suspected cases, 83 contacts, Hyalomma ticks and livestock were screened for Crimean-Congo hemorrhagic fever (CCHF) virus by qRT-PCR of which samples of two medical professionals (case C and E) and the husband of the index case (case D) were positive for CCHFV. The sensitivity and specificity of indigenous developed IgM ELISA to screen CCHFV specific antibodies in human serum was 75.0% and 97.5% respectively as compared to commercial kit. About 17.0% domestic animals from Kolat, Ahmadabad were positive for IgG antibodies while only two cattle and a goat showed positivity by qRT-PCR. Surprisingly, 43.0% domestic animals (Buffalo, cattle, sheep and goat) showed IgG antibodies in the adjoining village Jivanpara but only one of the buffalo was positive for CCHFV. The Hyalomma anatolicum anatolicum ticks were positive in PCR and virus isolation. CCHFV was isolated from the blood sample of case C, E in Vero E-6 cells and Swiss albino mice. In partial nucleocapsid gene phylogeny from CCHFV positive human samples of the years 2010 and 2011, livestock and ticks showed this virus was similar to Tajikistan (strain TAJ/H08966), which belongs in the Asian/middle east genetic lineage IV. Conclusions: The likely source of CCHFV was identified as virus infected Hyalomma ticks and livestock at the rural village residence of the primary case (case A). In addition, retrospective sample analysis revealed the existence of CCHFV in Gujarat and Rajasthan states before this outbreak. An indigenous developed IgM ELISA kit will be of great use for screening this virus in India. C1 [Mourya, Devendra T.; Yadav, Pragya D.; Shete, Anita M.; Gurav, Yogesh K.; Raut, Chandrashekhar G.; Jadi, Ramesh S.; Pawar, Shailesh D.; Mishra, Akhilesh C.] Natl Inst Virol, Pune, Maharashtra, India. [Nichol, Stuart T.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Mourya, DT (reprint author), Natl Inst Virol, Pune, Maharashtra, India. EM mourya.dt@niv.co.in FU National Institute of Virology FX The grant for this study was obtained from the National Institute of Virology from the Outbreak Investigation Fund. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 20 TC 23 Z9 25 U1 1 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAY PY 2012 VL 6 IS 5 AR e1653 DI 10.1371/journal.pntd.0001653 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 951ZG UT WOS:000304758900033 PM 22616022 ER PT J AU Gaydos, CA Farshy, C Barnes, M Quinn, N Agreda, P Rivers, CA Schwebke, J Papp, J AF Gaydos, Charlotte A. Farshy, Carol Barnes, Mathilda Quinn, Nicole Agreda, Patricia Rivers, Charles A. Schwebke, Jane Papp, John TI Can mailed swab samples be dry-shipped for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by nucleic acid amplification tests? SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Dry-shipped simulated swabs; Chlamydia; Gonorrhea; Trichomonas; NAAT testing ID SEXUALLY-TRANSMITTED INFECTIONS; MULTICENTER EVALUATION; URINE SPECIMENS; INTERNET; WOMEN; PREVALENCE AB Dry-shipped and mailed vaginal swabs collected at home have been used in research studies for the detection of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV) by nucleic acid amplification tests (NAATs) in screening programs. A verification study was performed to compare the limit of detection of CT, GC, and TV on swabs that were dry-shipped to paired swabs that were wet-shipped in transport media through the US mail. The Centers for Disease Control and Prevention prepared inocula in sterile water to mock simulated urogenital swabs with high to low concentrations of CT and GC. Replicate swabs were inoculated with 100 mu L of dilutions and were dry transported or placed into commercial transport media ("wet") for mailing for NAAT testing. The University of Alabama prepared replicate concentrations of TV, which were similarly shipped and tested by NAAT. All paired dry and wet swabs were detectable for CT. For GC, all paired dry and wet swabs were detectable for GC at concentrations >= 10(3). At 10(2) and 10 CFU/mL, the 10 replicate GC results were variably positive. For TV, wet and dry shipped concentrations >10(2) TV/mL tested positive, while results at 10 TV/mL were negative for dry swabs. Holding replicate dry swabs at 55 degrees C 5 days before testing did not affect results. NAATs were able to detect CT, GC, and TV on dry transported swabs. Using NAATs for testing home-collected, urogenital swabs mailed in a dry state to a laboratory may be useful for outreach screening programs. D (C) 2012 Elsevier Inc. All rights reserved. C1 [Gaydos, Charlotte A.; Barnes, Mathilda; Quinn, Nicole; Agreda, Patricia] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA. [Farshy, Carol; Papp, John] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rivers, Charles A.; Schwebke, Jane] Univ Alabama Birmingham, Birmingham, AL USA. RP Gaydos, CA (reprint author), Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA. EM cgaydos@jhmi.edu FU NIBIB, NIH [U54EB007958]; NIAID, NIH HPTN [U01 AI068613] FX NIBIB, NIH U54EB007958: NIAID, NIH HPTN U01 AI068613. NR 33 TC 12 Z9 12 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD MAY PY 2012 VL 73 IS 1 BP 16 EP 20 DI 10.1016/j.diagmicrobio.2012.02.008 PG 5 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 948ME UT WOS:000304506500003 PM 22578934 ER PT J AU Piesman, J Gray, J AF Piesman, Joseph Gray, Jeremy TI Letter in response to the Hynote article SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Letter ID BORRELIA-BURGDORFERI; LYME-DISEASE; TICK ATTACHMENT; IXODES-RICINUS; DURATION; TRANSMISSION; AREA; RISK; BITE C1 [Piesman, Joseph] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA. [Gray, Jeremy] Univ Coll Dublin, Sch Biol & Environm Sci, Dublin 4, Ireland. RP Piesman, J (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA. EM jfp2@cdc.gov NR 12 TC 0 Z9 0 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD MAY PY 2012 VL 73 IS 1 BP 103 EP 104 DI 10.1016/j.diagmicrobio.2012.01.007 PG 2 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 948ME UT WOS:000304506500025 PM 22424899 ER PT J AU Person, B Loo, JD Owuor, M Ogange, L Jefferds, MED Cohen, AL AF Person, Bobbie Loo, Jennifer D. Owuor, Mercy Ogange, Lorraine Jefferds, Maria Elena D. Cohen, Adam L. TI "It Is Good for My Family's Health and Cooks Food in a Way That My Heart Loves": Qualitative Findings and Implications for Scaling Up an Improved Cookstove Project in Rural Kenya SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE improved cookstoves; developing countries; indoor air pollution; formative research ID INDOOR AIR-POLLUTION; INTERVENTION; WOMEN; PNEUMONIA; IMPACT; TRIAL AB The use of indoor, three-stone fire pits in resource-poor countries is a substantial burden on human health and the environment. We conducted a pilot intervention promoting the purchase and use of an improved cookstove in rural Kenya. The goals of this qualitative inquiry were to understand the motivation to purchase and use; perceived benefits and challenges of cookstove use; and the most influential promotion activities for scaling up future cookstove promotion. Purposive sampling was used to recruit 10 cookstove promoters and 30 cookstove purchasers in the Luo community. Qualitative semi-structured interviews were transcribed and a thematic analysis conducted. Women reported the need for less firewood, fuel cost savings, reduced smoke, improved cooking efficiency, reduced eye irritation, lung congestion and coughing as major benefits of the cookstove. Cost appeared to be a barrier to wider adoption. The most persuasive promotion strategies were interpersonal communication through social networks and cooking demonstrations. Despite this cost barrier, many women still considered the improved cookstove to be a great asset within their household. This inquiry provided important guidance for future cookstove implementation projects. C1 [Person, Bobbie] Ctr Dis Control & Prevent, Natl Ctr Zoonot & Emerging Infect Dis, Off Director, Atlanta, GA 30333 USA. [Loo, Jennifer D.; Cohen, Adam L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Resp Dis Branch, Atlanta, GA 30333 USA. [Owuor, Mercy; Ogange, Lorraine] Kenya Govt Med Res Ctr, Kisumu, Kenya. [Jefferds, Maria Elena D.] Ctr Dis Control & Prevent, Div Nutr, Int Micronutr Malnutr Prevent & Control Program, Atlanta, GA 30333 USA. [Jefferds, Maria Elena D.] Ctr Dis Control & Prevent, Div Phys Activ & Obes, Atlanta, GA 30333 USA. RP Person, B (reprint author), Ctr Dis Control & Prevent, Natl Ctr Zoonot & Emerging Infect Dis, Off Director, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM BPerson@cdc.gov; ihi4@cdc.gov; owuormercy@gmail.com; archielaogange@yahoo.com; mnj5@cdc.gov; cohena@sa.cdc.gov NR 34 TC 9 Z9 9 U1 3 U2 17 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD MAY PY 2012 VL 9 IS 5 BP 1566 EP 1580 DI 10.3390/ijerph9051566 PG 15 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 948ZJ UT WOS:000304543200003 PM 22754457 ER PT J AU Fairman, J Carroll, T Liu, F Hancock, K Katz, J Lu, XH Matzinger, S Miller, C AF Fairman, Jeffery Carroll, Tim Liu, Feng Hancock, Kathy Katz, Jacqueline Lu, Xiuhua Matzinger, Shannon Miller, Chris TI Adjuvanting influenza vaccines for enhanced immunity to seasonal or pandemic influenza virus SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT 99th Annual Meeting of the American-Association-of-Immunologists CY MAY 04-08, 2012 CL Boston, MA SP Amer Assoc Immunol C1 [Fairman, Jeffery] Colby Pharmaceut Co, San Jose, CA USA. [Carroll, Tim; Matzinger, Shannon; Miller, Chris] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA USA. [Liu, Feng; Hancock, Kathy; Katz, Jacqueline; Lu, Xiuhua] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2012 VL 188 PG 1 WC Immunology SC Immunology GA 950OX UT WOS:000304659700580 ER PT J AU Cannon, MJ Westbrook, K Levis, D Schleiss, MR Thackeray, R Pass, RF AF Cannon, Michael J. Westbrook, Kyresa Levis, Denise Schleiss, Mark R. Thackeray, Rosemary Pass, Robert F. TI Awareness of and behaviors related to child-to-mother transmission of cytomegalovirus SO PREVENTIVE MEDICINE LA English DT Article DE Cytomegalovirus; Congenital; Awareness; Behavior; Pregnancy ID CONGENITAL-CYTOMEGALOVIRUS; UNITED-STATES; PREGNANT-WOMEN; RISK-FACTORS; INFECTION; SEROPREVALENCE; PREVENTION; SEROCONVERSION; EPIDEMIOLOGY; KNOWLEDGE AB Objective. Congenital cytomegalovirus (CMV) infection is a common cause of hearing loss and intellectual disability. We assessed CMV knowledge and the frequency of women's behaviors that may enable CMV transmission to inform strategies for communicating prevention messages to women. Methods. We analyzed survey responses from 4184 participants (2181 women, 2003 men) in the 2010 HealthStyles survey, a national mail survey designed to be similar to the United States population. Results. Only 7% of men and 13% of women had heard of congenital CMV. Women with children under age 19 (n = 918) practiced the following risk behaviors at least once per week while their youngest child was still in diapers: kissing on the lips (69%), sharing utensils (42%), sharing cups (37%), and sharing food (62%). Women practiced protective, hand cleansing behaviors most of the time or always after: changing a dirty diaper (95%), changing a wet diaper (85%), or wiping the child's nose (65%), but less commonly after handling the child's toys (26%). Conclusions. Few women are aware of CMV and most regularly practice behaviors that may place them at risk when interacting with young children. Women should be informed of practices that can reduce their risk of CMV infection during pregnancy. Published by Elsevier Inc. C1 [Cannon, Michael J.; Westbrook, Kyresa; Levis, Denise] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Schleiss, Mark R.] Univ Minnesota, Sch Med, Div Pediat Infect Dis, Ctr Infect Dis & Microbiol Translat Res, Minneapolis, MN 55455 USA. [Schleiss, Mark R.] Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA. [Thackeray, Rosemary] Brigham Young Univ, Dept Hlth Sci, Provo, UT 84602 USA. [Pass, Robert F.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA. RP Cannon, MJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mailstop E-86, Atlanta, GA 30333 USA. EM mcannon@cdc.gov RI Cannon, Michael/E-5894-2011 OI Cannon, Michael/0000-0001-5776-5010 FU Intramural CDC HHS [CC999999] NR 36 TC 31 Z9 33 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD MAY 1 PY 2012 VL 54 IS 5 BP 351 EP 357 DI 10.1016/j.ypmed.2012.03.009 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 948IW UT WOS:000304497800013 PM 22465669 ER PT J AU Zhao, GX Ford, ES Tsai, J Li, CY Croft, JB AF Zhao, Guixiang Ford, Earl S. Tsai, James Li, Chaoyang Croft, Janet B. TI Low concentrations of serum 25-hydroxyvitamin D associated with increased risk for chronic bronchitis among US adults SO BRITISH JOURNAL OF NUTRITION LA English DT Article DE Vitamin D; 25-Hydroxyvitamin D; Chronic bronchitis; National Health and Nutrition Examination Survey ID OBSTRUCTIVE PULMONARY-DISEASE; VITAMIN-D DEFICIENCY; NUTRITION EXAMINATION SURVEY; REDUCED LUNG-FUNCTION; 3RD NATIONAL-HEALTH; IMMUNE-SYSTEM; ASTHMA; COPD; INHIBITION; MORTALITY AB Increasing evidence suggests that vitamin D benefits both innate and adaptive immunity, thereby eliciting an anti-inflammatory effect and reducing the risk of infectious disease. The present study examined the association between serum 25-hydroxyvitamin D (25(OH)D) levels and the risk of chronic bronchitis among US adults. We analysed data from 6872 US adults aged >= 20 years who participated in the 2003-6 National Health and Nutrition Examination Survey. Prevalence and OR with 95% CI of having self-reported chronic bronchitis were estimated by quintiles of 25(OH)D or vitamin D-deficiency status after adjustment for potential confounders. The results showed that the adjusted prevalence of chronic bronchitis ranged from 2.4 (95% CI 1.4, 3.3)% among adults in the highest quintile of 25(OH)D (>= 30 ng/ml) to 4.1 (95% CI 2.5, 5.6)% among adults in the lowest quintile (<15 ng/ml; P for trend<0.01). The adjusted OR for chronic bronchitis was 1.85 (95% CI 1.06, 3.24) in adults with <15 ng/ml 25(OH)D and 1.77 (95% CI 1.19, 2.65) in those with 15 to <20 ng/ml 25(OH)D compared with adults with >= 30 ng/ml 25(OH)D. Additionally, the adjusted OR for chronic bronchitis was 1.52 (95% CI 1.03, 2.26) among adults with vitamin D deficiency (<20 ng/ml 25(OH)D) compared with those with >= 20 ng/ml 25(OH)D. For every 1 ng/ml increase in 25(OH)D, the likelihood of having chronic bronchitis fell by 2.6% (P=0.016). In conclusion, low serum 25(OH)D levels are associated with the increased risk of chronic bronchitis among US adults. The present results provide support for continuing research on the role of vitamin D in lung diseases. C1 [Zhao, Guixiang; Ford, Earl S.; Tsai, James; Croft, Janet B.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Li, Chaoyang] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30341 USA. RP Zhao, GX (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,Mailstop K67, Atlanta, GA 30341 USA. EM fwj4@cdc.gov NR 42 TC 4 Z9 5 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0007-1145 EI 1475-2662 J9 BRIT J NUTR JI Br. J. Nutr. PD MAY PY 2012 VL 107 IS 9 BP 1386 EP 1392 DI 10.1017/S0007114511004417 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 944ZT UT WOS:000304243000015 PM 21899806 ER PT J AU Jones, RT Bernhardt, SA Martin, AP Gage, KL AF Jones, Ryan T. Bernhardt, Scott A. Martin, Andrew P. Gage, Kenneth L. TI Interactions Among Symbionts of Oropsylla spp. (Siphonoptera: Ceratophyllidae) SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE microbial biogeography; community assembly; symbiosis; pyrosequencing; Buchnera ID TAILED PRAIRIE DOGS; BACTERIAL COMMUNITIES; CYNOMYS-LUDOVICIANUS; DIVERSITY; PLAGUE; INFECTION; WOLBACHIA; BUCHNERA; PATTERNS; VECTORS AB We used high-throughput DNA sequencing to explore bacterial communities of three species of Oropyslla fleas [Oropsylla hirsuta (Baker), Oropsylla montana (Baker), and Oropsylla tuberculata cynomuris (Jellison)] and detected seven bacterial lineages related to known insect symbionts. No significant co-occurrence patterns were detected among bacterial lineages, but relative abundance data suggest that the two most common lineages (Bartonella and Rickettsiales) interact negatively. Furthermore, presence of these two lineages significantly reduced bacterial diversity within fleas. C1 [Jones, Ryan T.; Bernhardt, Scott A.; Gage, Kenneth L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Martin, Andrew P.] Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA. RP Jones, RT (reprint author), Univ Sydney, Fac Agr & Environm, Suite 401,Biomed Bldg,Australian Technol Pk, Eveleigh, NSW 2015, Australia. EM drryanjones@gmail.com NR 24 TC 6 Z9 6 U1 1 U2 14 PU ENTOMOLOGICAL SOC AMER PI LANHAM PA 10001 DEREKWOOD LANE, STE 100, LANHAM, MD 20706-4876 USA SN 0022-2585 J9 J MED ENTOMOL JI J. Med. Entomol. PD MAY PY 2012 VL 49 IS 3 BP 492 EP 496 DI 10.1603/ME11244 PG 5 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 941TU UT WOS:000303989900008 PM 22679855 ER PT J AU Mutebi, JP Swope, BN Doyle, MS Biggerstaff, BJ AF Mutebi, J. -P. Swope, B. N. Doyle, M. S. Biggerstaff, B. J. TI Vector Competence of Culex restuans (Diptera: Culicidae) From Two Regions of Chicago With Low and High Prevalence of West Nile Virus Human Infections SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE Culex restuans; vector competence; WNV; Chicago ID UNITED-STATES; GEOGRAPHIC-VARIATION; AEDES-AEGYPTI; PIPIENS DIPTERA; CATCH BASINS; MOSQUITOS; SUSCEPTIBILITY; SURVEILLANCE; CONNECTICUT; FIELD AB Vector competence studies for West Nile virus (WNV) were conducted for two Culex (Culex) restuans Theobald populations Edison Park (EP) and Illinois Medical District (IMD), in Chicago, IL. The aim was to determine if there were differences between mosquito populations that contributed to the observed differences in the prevalence of WNV. Percentages of orally infected, disseminated, and transmitting mosquitoes were estimated using a generalized linear mixed effects model including a random effect for family to account for anticipated within-family correlation. Analysis indicated that percentages of infected, disseminated, and transmitting mosquitoes were not significantly different between EP and IMD. The within-family correlation was 0.46 (95% CI 0.28, 0.67), indicating reasonably strong tendency for WNV titers of bodies, saliva, and legs within families to be similar. Overall, our results show that vector competence of Cx. restuans for WNV is not a contributing factor to the observed differences in WNV human cases between the EP and IMD areas of Chicago. C1 [Mutebi, J. -P.; Swope, B. N.; Doyle, M. S.; Biggerstaff, B. J.] Ctr Dis Control & Prevent CDC, Div Vector Borne Dis DVBD, Ft Collins, CO 80521 USA. RP Mutebi, JP (reprint author), Ctr Dis Control & Prevent CDC, Div Vector Borne Dis DVBD, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM jmutebi@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX We thank Court and Claudia Blanco of the Chicago Department of Public Health (CDPH) for use of laboratory facilities. We thank Dan Markowski and Cristina Flores of VDCI and the Chicago WNV program interns for field assistance during this project. We thank Erin Borland and Andrea Peterson for help with larval rearing, and Marv Godsey and Harry Savage for laboratory assistance. This project was supported by funds from the Centers for Disease Control and Prevention (CDC). NR 43 TC 1 Z9 1 U1 1 U2 12 PU ENTOMOLOGICAL SOC AMER PI LANHAM PA 10001 DEREKWOOD LANE, STE 100, LANHAM, MD 20706-4876 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD MAY PY 2012 VL 49 IS 3 BP 678 EP 686 DI 10.1603/ME11193 PG 9 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 941TU UT WOS:000303989900030 PM 22679877 ER PT J AU Zemtsova, GE Gleim, E Yabsley, MJ Conner, LM Mann, T Brown, MD Wendland, L Levin, ML AF Zemtsova, Galina E. Gleim, Elizabeth Yabsley, Michael J. Conner, L. Mike Mann, Tom Brown, Mary D. Wendland, Lori Levin, Michael L. TI Detection of a Novel Spotted Fever Group Rickettsia in the Gophertortoise Tick SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE Amblyomma tuberculatum; SFG Rickettsia; phylogenetic analysis ID FRAGMENT-LENGTH-POLYMORPHISM; PCR-AMPLIFIED DNA; PHYLOGENETIC ANALYSIS; GENE; PROTEIN; ACARI; DIFFERENTIATION; SEQUENCES; IXODIDAE AB The gophertortoise tick, Amblyomma tuberculatum (Marx), is distributed throughout the southeastern United States, and its immature life stages have been reported to occasionally bite humans. Here we report detection of a novel spotted fever group (SFG) Rickettsia in A. tuberculatum ticks collected in the southern United States. Among questing ticks collected in Georgia, 10 pools of larvae were identified as gophertortoise ticks, A. tuberculatum. Each of these samples was positive for SFG Rickettsiae. The restriction fragment-length polymorphism profiles were identical to each other, but distinct from those of other rickettsiae previously found in Amblyomma spp. ticks. Partial genetic characterization of the novel agent was achieved by sequencing the 17 kDa, gltA, ompB, ompA, rpoB, and sca4 genes. Analysis of a concatenated tree of four genes (gltA, ompB, ompA, and sca4) demonstrates close relatedness of the detected Rickettsia to several SFG Rickettsia spp. The identical rickettsial DNA was detected in 50 and 70% of adult A. tuberculatum ticks from Mississippi and Florida, respectively. The results indicate wide distribution of a novel Rickettsia, capability for transovarial transmission, and high prevalence in tested tick populations. C1 [Zemtsova, Galina E.; Levin, Michael L.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA 30029 USA. [Gleim, Elizabeth; Yabsley, Michael J.] Univ Georgia, Warnell Sch Forestry & Nat Resources, Athens, GA 30609 USA. [Gleim, Elizabeth; Yabsley, Michael J.] Univ Georgia, SE Cooperat Wildlife Dis Study, Coll Vet Med, Dept Populat Hlth, Athens, GA 30609 USA. [Conner, L. Mike] Joseph W Jones Ecol Res Ctr Ichauway, Newton, GA 39870 USA. [Mann, Tom] Mississippi Museum Nat Sci, Mississippi Nat Heritage Program, Jackson, MS 39202 USA. [Brown, Mary D.; Wendland, Lori] Univ Florida, Coll Vet Med, Dept Infect Dis & Pathol, Gainesville, FL 32611 USA. RP Zemtsova, GE (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA 30029 USA. EM gzemtsova@cdc.gov FU Centers for Disease Control and Prevention/University of Georgia [8212]; Warnell School of Forestry and Natural Resources; National Science Foundation, Ecology of Infectious Diseases [DEB-0224953]; National Institutes of Health [5K08AI57722] FX This work was funded in part by Centers for Disease Control and Prevention/University of Georgia collaborative grant (8212, Ecosystem Health and Human Health: Understanding the Ecological Effects of Prescribed Fire Regimes on the Distribution and Population Dynamics of Tick-Borne Zoonoses). Partial support of E. L. G. was provided by the Warnell School of Forestry and Natural Resources. Collection of ticks from Florida was supported by grants from the National Science Foundation, Ecology of Infectious Diseases program (DEB-0224953; to M. B. B.) and the National Institutes of Health (5K08AI57722; to L. D. W.). The R17K probe and primers were designed and PCR protocol was developed by A. Loftis and used in this study with her permission. NR 16 TC 5 Z9 5 U1 0 U2 3 PU ENTOMOLOGICAL SOC AMER PI LANHAM PA 10001 DEREKWOOD LANE, STE 100, LANHAM, MD 20706-4876 USA SN 0022-2585 J9 J MED ENTOMOL JI J. Med. Entomol. PD MAY PY 2012 VL 49 IS 3 BP 783 EP 786 DI 10.1603/ME11264 PG 4 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 941TU UT WOS:000303989900043 PM 22679890 ER PT J AU Whitmore, SK Taylor, AW Espinoza, L Shouse, RL Lampe, MA Nesheim, S AF Whitmore, Suzanne K. Taylor, Allan W. Espinoza, Lorena Shouse, R. Luke Lampe, Margaret A. Nesheim, Steven TI Correlates of Mother-to-Child Transmission of Human Immunodeficiency Virus in the United States and Puerto Rico EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Whitmore, Suzanne K.; Taylor, Allan W.; Espinoza, Lorena; Shouse, R. Luke; Lampe, Margaret A.; Nesheim, Steven] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Whitmore, SK (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD MAY PY 2012 VL 67 IS 5 BP 277 EP 279 DI 10.1097/OGX.0b013e3182562ce5 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 946NA UT WOS:000304357400008 ER PT J AU Pappas, RS AF Pappas, R. Steven TI Atomic Perspectives Sample Preparation Problem Solving for Inductively Coupled Plasma-Mass Spectrometry with Liquid Introduction Systems: Solubility, Chelation, and Memory Effects. SO SPECTROSCOPY LA English DT Article ID ICP-MS; MERCURY; URINE; BLOOD AB In inductively coupled plasma mass spectrometry (ICP-MS), problems persist in the determination of analytes that are commonly investigated as well as in specialty applications for those seldom considered by most analysts. Understanding the chemistry that is common to different groups of analytes permits the development of successful approaches to rinse-out and elimination of memory effects. It also equips analysts for development of successful elemental analytical approaches with a broad spectrum of matrices and other analytical challenges, whether the sample is solid or liquid. C1 US Ctr Dis Control & Prevent, Volatile Organ & Tobacco Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Pappas, RS (reprint author), US Ctr Dis Control & Prevent, Volatile Organ & Tobacco Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM RPappas@cdc.gov FU Intramural CDC HHS [CC999999] NR 14 TC 0 Z9 0 U1 0 U2 14 PU ADVANSTAR COMMUNICATIONS INC PI DULUTH PA 131 W 1ST STREET, DULUTH, MN 55802 USA SN 0887-6703 J9 SPECTROSCOPY-US JI Spectroscopy PD MAY PY 2012 VL 27 IS 5 BP 20 EP + PG 11 WC Spectroscopy SC Spectroscopy GA 946UR UT WOS:000304383500002 PM 26321788 ER PT J AU Rein, DB Wittenborn, JS Zhang, XZ Hoerger, TJ Zhang, P Klein, BEK Lee, KE Klein, R Saaddine, JB AF Rein, David B. Wittenborn, John S. Zhang, Xinzhi Hoerger, Thomas J. Zhang, Ping Klein, Barbara Eden Kobrin Lee, Kris E. Klein, Ronald Saaddine, Jinan B. TI The Cost-effectiveness of Welcome to Medicare Visual Acuity Screening and a Possible Alternative Welcome to Medicare Eye Evaluation Among Persons Without Diagnosed Diabetes Mellitus SO ARCHIVES OF OPHTHALMOLOGY LA English DT Article ID RANDOMIZED CLINICAL-TRIALS; BEAVER DAM EYE; MACULAR DEGENERATION; REFRACTIVE ERRORS; LENS OPACITIES; RETINOPATHY; MACULOPATHY; POPULATION; IMPAIRMENT; INTERVALS AB Objective: To estimate the cost-effectiveness of visual acuity screening performed in primary care settings and of dilated eye evaluations performed by an eye care professional among new Medicare enrollees with no diagnosed eye disorders. Medicare currently reimburses visual acuity screening for new enrollees during their initial preventive primary care health check, but dilated eye evaluations may be a more cost-effective policy. Design: Monte Carlo cost-effectiveness simulation model with a total of 50 000 simulated patients with demographic characteristics matched to persons 65 years of age in the US population. Results: Compared with no screening policy, dilated eye evaluations increased quality-adjusted life-years (QALYs) by 0.008 (95% credible interval [CrI], 0.005-0.011) and increased costs by $94 (95% CrI, -$35 to $222). A visual acuity screening increased QALYs in less than 95% of the simulations (0.001 (95% CrI, -0.002 to 0.004) and increased total costs by $32 (95% CrI, -$97 to $159) per person. The incremental cost-effectiveness ratio of a visual acuity screening and an eye examination compared with no screening were $29 000 and $12 000 per QALY gained, respectively. At a willingness-to-pay value of $15 000 or more per QALY gained, a dilated eye evaluation was the policy option most likely to be cost-effective. Conclusions: The currently recommended visual acuity screening showed limited efficacy and cost-effectiveness compared with no screening. In contrast, a new policy of reimbursement for Welcome to Medicare dilated eye evaluations was highly cost-effective. C1 [Rein, David B.] Univ Chicago, NORC, Atlanta, GA 30305 USA. [Zhang, Xinzhi; Zhang, Ping; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA USA. [Wittenborn, John S.; Hoerger, Thomas J.] RTI Int, Res Triangle Pk, NC USA. [Klein, Barbara Eden Kobrin; Lee, Kris E.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA. RP Rein, DB (reprint author), Univ Chicago, NORC, 3520 Piedmont Rd NE,Ste 225, Atlanta, GA 30305 USA. EM rein-david@norc.org OI Klein, Ronald/0000-0002-4428-6237 FU Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia [200-2008-27958]; National Eye Institute [R21 EY019173, U10 EY006594-21A1]; Research to Prevent Blindness FX This study was funded by the Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia (contract 200-2008-27958), by the National Eye Institute (awards R21 EY019173 and U10 EY006594-21A1 to Drs B. E. K. Klein and R. Klein), and through a Senior Scientific Investigator Award from Research to Prevent Blindness (to Drs B. E. K. Klein and R. Klein). NR 46 TC 6 Z9 6 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD MAY PY 2012 VL 130 IS 5 BP 607 EP 614 DI 10.1001/archopthalmol.2011.1921 PG 8 WC Ophthalmology SC Ophthalmology GA 941YJ UT WOS:000304005200009 PM 22232367 ER PT J AU Schober, DJ Fawcett, SB Thigpen, S Curtis, A Wright, R AF Schober, Daniel J. Fawcett, Stephen B. Thigpen, Sally Curtis, Anna Wright, Renee TI An empirical case study of a child sexual abuse prevention initiative in Georgia SO HEALTH EDUCATION JOURNAL LA English DT Article DE child sexual abuse; community; primary prevention; training ID PROGRAM AB Objective: This empirical case study describes Prevent Child Abuse Georgia's effort to prevent child sexual abuse (CSA) by educating communities throughout the state on supporting preventive behaviour. The initiative consisted of three major components: (1) dissemination of CSA prevention messages and materials; (2) a statewide helpline that helped callers respond to the warning signs of CSA and engage in protective behaviours; and (3) a statewide education and training programme. Design: An empirical case study design was used. Setting: This prevention initiative took place across the state of Georgia. Method: Archival records kept by Prevent Child Abuse Georgia were reviewed to determine the outputs of this statewide effort. Additionally, the annual incidence of child sexual abuse substantiated by the Georgia Department of Human Resources (cases per 100,000 children < 18 years of age) was calculated to examine changes in the broader context of Prevent Child Abuse Georgia's statewide CSA prevention effort (from 1997-2007). Results: Results show that Prevent Child Abuse Georgia provided 232,822 informational materials to Georgia residents, assisted 1,271 helpline callers to support responses to the warning signs of CSA, and trained 7,700 individuals. According to records from the Georgia Department of Human Services, from 2002-7, the incidence of child sexual abuse decreased four of the five years of the implementation period. Conclusion: This empirical case study describes the steps a statewide effort can take to promote the primary prevention of CSA. Prevent Child Abuse Georgia engaged in a variety of activities to educate the public, increase CSA prevention knowledge, and promote preventive behaviour. C1 [Schober, Daniel J.] Univ Kansas, Work Grp Community Hlth & Dev, Dole Ctr, Lawrence, KS 66045 USA. [Thigpen, Sally; Wright, Renee] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Curtis, Anna] Prevent Child Abuse Georgia, Atlanta, GA USA. RP Schober, DJ (reprint author), Univ Kansas, Work Grp Community Hlth & Dev, Dole Ctr, 1000 Sunnyside Ave,Room 4082, Lawrence, KS 66045 USA. EM schoberd@gmail.com NR 18 TC 1 Z9 1 U1 1 U2 8 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0017-8969 J9 HEALTH EDUC J JI Health Educ. J. PD MAY PY 2012 VL 71 IS 3 BP 291 EP 298 DI 10.1177/0017896911430546 PG 8 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA 942XL UT WOS:000304084800005 ER PT J AU Ferguson, PL Pickelsimer, EE Corrigan, JD Bogner, JA Wald, M AF Ferguson, Pamela L. Pickelsimer, Emily Elisabeth Corrigan, John D. Bogner, Jennifer A. Wald, Marlena TI Prevalence of Traumatic Brain Injury Among Prisoners in South Carolina SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE brain injuries; craniocerebral trauma; epidemiology; postconcussion syndrome; prevalence; prisoners ID VIOLENT CRIMINAL BEHAVIOR; TBI IDENTIFICATION METHOD; HEAD-INJURY; SUBSTANCE-ABUSE; PSYCHIATRIC-DISORDERS; SEXUAL OFFENSES; BIRTH COHORT; FOLLOW-UP; POPULATION; VALIDITY AB Objective: To determine lifetime prevalence of traumatic brain injury (TBI) in a statewide sample of prisoners. Design: Retrospective and cross-sectional cohort study. Participants: Stratified random sample of prisoners scheduled to be released by release type for each gender (275 men and 267 women with completed sentences and 19 men and 15 women granted parole) and a random sample of prisoners by gender with lifetime or death sentences (26 men and 34 women). Primary Measure: Weighted prevalence of TBI. In-person interviews ascertained history of TBI using a customized version of the Ohio State University TBI Identification Method. Results: Sixty-five percent of male releases and nonreleases, and 72% and 73% of female releases and nonreleases, reported at least 1 TBI with an alteration of consciousness. Forty-two percent of male releases and 50% of nonreleases, and 50% of female releases and 33% of nonreleases, reported at least 1 TBI with loss of consciousness. Thirty-five percent of male releases and 42% of nonreleases, and 55% of female releases and 58% of nonreleases, reported ongoing symptoms from TBI. Conclusions: A substantial proportion of prisoners reported having experienced a TBI during their lifetime. The ongoing TBI symptoms reported by prisoners may impact their success on release. C1 [Ferguson, Pamela L.; Pickelsimer, Emily Elisabeth] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Corrigan, John D.; Bogner, Jennifer A.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA. [Wald, Marlena] Ctr Dis Control & Prevent, Natl Ctr Injury Control & Prevent, Atlanta, GA USA. RP Ferguson, PL (reprint author), Med Univ S Carolina, Dept Med, 135 Cannon St,Ste 303,MSC 835, Charleston, SC 29425 USA. EM ferguspl@musc.edu RI Corrigan, John/E-2921-2011; Bogner, Jennifer/E-2773-2011 FU NCIPC CDC HHS [U49CE001318] NR 74 TC 20 Z9 20 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAY-JUN PY 2012 VL 27 IS 3 BP E11 EP E20 DI 10.1097/HTR.0b013e31824e5f47 PG 10 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 941CV UT WOS:000303941500002 PM 22573044 ER PT J AU Lamaro-Cardoso, J de Lemos, APS Carvalho, MD Pimenta, FC Roundtree, A Motta, L Vieira, MA Sgambatti, S Thorn, LK Pessoa, V Minamisava, R Harrison, LH Beall, BW Brandileone, MCD Andrade, AL AF Lamaro-Cardoso, Juliana de Lemos, Ana Paula S. Carvalho, Maria da Gloria Pimenta, Fabiana Cristina Roundtree, Alexis Motta, Lorena Vieira, Maria Aparecida Sgambatti, Sabrina Thoern, Licia Kamila Pessoa-Junior, Vicente Minamisava, Ruth Harrison, Lee H. Beall, Bernard W. de Cunto Brandileone, Maria Cristina Andrade, Ana Lucia TI Molecular epidemiological investigation to determine the source of a fatal case of serotype 22F pneumococcal meningitis SO JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Article ID SEQUENTIAL MULTIPLEX PCR; RESISTANT STREPTOCOCCUS-PNEUMONIAE; DETERMINING CAPSULAR SEROTYPES; NASOPHARYNGEAL SECRETIONS; BRAZILIAN CHILDREN; YOUNG-CHILDREN; CARRIAGE; DISEASE; CARE; VACCINES AB A child's death due to pneumococcal meningitis after contracting the disease in an after-school programme prompted an investigation to assess nasopharyngeal (NP) carriage among her contacts. The serotype of the meningitis case isolate was determined, together with the serotypes of the NP specimens of contacts, comprising the case patient's brother, the case patient's after-school programme contacts and the brother's day-care centre (DCC) contacts. NP swabs from 155 children and 69 adults were obtained. Real-time PCR and conventional multiplex PCR (CM-PCR) assays were used to detect pneumococcal carriage and determine serotypes. Broth-enriched culture of NP specimens followed by pneumococcal isolation and Quellung-based serotyping were also performed. DNA extracts prepared from cerebrospinal fluid of the index case and from the NP strain isolated from the brother and from one attendee of the brother's DCC were subjected to genotyping. Pneumococcal carriage assessed by real-time PCR and culture was 49.6 and 36.6%, respectively (P<0.05). Twenty-three serotypes were detected using CM-PCR, with serotypes 6A/6B, 14, 19F, 6C/6D, 22F/22A, 23F and 11A/11D being the most frequent. All eight serotype 22F/22A NP specimens recovered were from children attending the brother's DCC. The meningitis case isolate and the NP carriage isolate from the patient's brother were both serotype 22F and shared the same new multilocus sequence type (ST6403) with the attendee of the brother's DCC. CM-PCR proved to be useful for assessing carriage serotype distribution in a setting of high-risk pneumococcal transmission. The causal serotype appeared to be linked to the brother of the case patient and attendees of his DCC. C1 [Motta, Lorena; Thoern, Licia Kamila; Pessoa-Junior, Vicente; Andrade, Ana Lucia] Univ Fed Goias, Dept Community Hlth, Goiania, Go, Brazil. [Lamaro-Cardoso, Juliana] Univ Fed Goias, Dept Microbiol Immunol Parasitol & Pathol, Goiania, Go, Brazil. [de Lemos, Ana Paula S.; de Cunto Brandileone, Maria Cristina] Adolfo Lutz Inst, Sao Paulo, Brazil. [Carvalho, Maria da Gloria; Pimenta, Fabiana Cristina; Roundtree, Alexis; Beall, Bernard W.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. [Vieira, Maria Aparecida; Sgambatti, Sabrina] Pontifical Catholic Univ Goias, Goiania, Go, Brazil. [Minamisava, Ruth] Univ Fed Goias, Sch Nursing, Goiania, Go, Brazil. [Harrison, Lee H.] Univ Pittsburgh, Grad Sch Publ Hlth, Infect Dis Epidemiol Res Unit, Pittsburgh, PA USA. [Harrison, Lee H.] Sch 26 Med, Pittsburgh, PA USA. RP Andrade, AL (reprint author), Univ Fed Goias, Dept Community Hlth, Goiania, Go, Brazil. EM alssandrade@gmail.com RI Iats, Inct/K-2300-2013; Andrade, Ana Lucia/L-5751-2013; OI Minamisava, Ruth/0000-0001-9352-5567 FU Fogarty International Center, National Institutes of Health [5D43TW006592]; Brazilian National Council for Scientific and Technological 317 Development/CNPq [306096/2010-2, 302175/2010-5] FX This study was partially supported by a Fogarty International Center Global Infectious Diseases Research Training Program grant, National Institutes of Health to the University of Pittsburgh (5D43TW006592) and by the Secretary of Health of Municipality of Goiania, Goias, Brazil. A. L.A. and M. C. C. B. are research fellows of The Brazilian National Council for Scientific and Technological 317 Development/CNPq. (research grant nos 306096/2010-2 and 302175/2010-5, respectively) We thank Robert Gertz and Zhongya Li for MLST results. NR 23 TC 0 Z9 0 U1 0 U2 1 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-2615 J9 J MED MICROBIOL JI J. Med. Microbiol. PD MAY PY 2012 VL 61 IS 5 BP 686 EP 692 DI 10.1099/jmm.0.040790-0 PG 7 WC Microbiology SC Microbiology GA 944QA UT WOS:000304217700011 PM 22286925 ER PT J AU Ta, ML VanEenwyk, J Bensley, L AF Ta, Myduc L. VanEenwyk, Juliet Bensley, Lillian TI Limited Percentages of Adults in Washington State Meet the Dietary Guidelines for Americans Recommended Intakes of Fruits and Vegetables SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Dietary guidelines; Nutritional surveys; Fruits; Vegetables ID NONRESPONSE RATES; UNITED-STATES; CONSUMPTION; BIAS; IMPACT AB Nutritious diets that include sufficient intake of fruits and vegetables promote health and reduce risk for chronic diseases. The 2005 Dietary Guidelines for Americans recommend four to 13 servings of fruits and vegetables daily for energy intake levels of 1,000 to 3,200 kcal, including seven to 13 servings for 1,600 to 3,000 kcal/day as recommended for adults aged >= 25 years. The 2006-2007 Washington Adult Health Survey, a cross-sectional study designed to measure risk factors for cardiovascular disease among a representative sample of Washington State residents aged >= 25 years, included a food frequency questionnaire (FFQ). The FFQ included approximately 120 food items and summary questions for fruits and vegetables that were used to compute energy intake and two measures of fruit and vegetable intake. Measure 1 was computed as the sum of intake of individual FFQ fruit and vegetable items; Measure 2 combined the summary questions with selected individual FFQ fruit and vegetable items. Depending on the measure used, approximately 14% to 22% of 519 participants with complete information met the guidelines for fruits, 11% to 15% for vegetables, and 5% to 6% for both fruits and vegetables. Participants aged >= 65 years and women were more likely to meet recommendations, compared with younger participants and men. Despite decades of public health attention, the vast majority of Washington State residents do not consume the recommended amount of fruits or vegetables daily. These findings underscore the need for developing and evaluating new approaches to promote fruit and vegetable consumption. J Acad Nutr Diet. 2012;112:699-704. C1 [VanEenwyk, Juliet] Washington State Dept Hlth, Noninfect Condit Epidemiol Unit, Olympia, WA 98504 USA. [Ta, Myduc L.] Publ Hlth Seattle & King Cty, Assessment Policy Dev & Evaluat Unit, Seattle, WA USA. [Ta, Myduc L.] Ctr Dis Control & Prevent, Washington State Dept Hlth, Atlanta, GA USA. RP VanEenwyk, J (reprint author), Washington State Dept Hlth, Noninfect Condit Epidemiol Unit, POB 47812, Olympia, WA 98504 USA. EM juliet.vaneenwyk@doh.wa.gov FU Centers for Disease Control and Prevention [U50/CCU021339-05]; Washington State Department of Health FX This study was funded by the Centers for Disease Control and Prevention Contract No. U50/CCU021339-05 and the Washington State Department of Health. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 21 TC 0 Z9 1 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD MAY PY 2012 VL 112 IS 5 BP 699 EP 704 DI 10.1016/j.jand.2011.12.005 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 943NO UT WOS:000304131200017 PM 22709774 ER PT J AU Cleveland, JL Junger, ML Saraiya, M Markowitz, LE Dunne, EF Epstein, JB AF Cleveland, Jennifer L. Junger, Michele L. Saraiya, Mona Markowitz, Lauri E. Dunne, Eileen F. Epstein, Joel B. TI HPV AND ORAL HEALTH Response SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Letter ID INFECTION C1 [Dunne, Eileen F.] Ctr Dis Control & Prevent, Natl Ctr Hepatitis HIV AIDS Sexually Transmitted, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. [Epstein, Joel B.] City Hope Natl Med Ctr, Div Head & Neck Surg, Duarte, CA 91010 USA. [Epstein, Joel B.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 7 TC 0 Z9 0 U1 0 U2 1 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD MAY PY 2012 VL 143 IS 5 BP 440 EP 442 PG 3 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 944FS UT WOS:000304185300005 ER PT J AU Yen, IH Anderson, LA AF Yen, Irene H. Anderson, Lynda A. TI Built Environment and Mobility of Older Adults: Important Policy and Practice Efforts SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE healthy aging; mobility; neighborhood; public policy ID MULTILEVEL ANALYSIS; PHYSICAL-ACTIVITY; HEALTH; WALKING; POPULATION; EXERCISE AB As people age, they prefer to age in place. The concept of aging in place refers to the ability to live in one's own home, wherever that might be, for as long as one can feel confident and comfortable. Where people live and whether these environments can support them are critical questions for public health and public policy, especially since the baby boomers began to turn 65 on January 1, 2011. Equally important for public policy, those aged 85 and older are the fastest growing population group in the United States. The Health and Aging Policy Fellows Program, with the Centers for Disease Control and Prevention Healthy Aging Program, has supported a project to determine how design features of the built environment can support the mobility of older adults. Mobility refers to physical activity, usually walking, but also encompasses the ability to stay connected to nearby community resources and services. The project's purpose is to investigate features that support mobility in built environments. This policy brief introduces the realist synthesis method used in the project and selected national initiatives and activities to place this work in a broader context. Given the importance of mobility concerns to older adults, it must be determined without delay which design features support mobility and how local areas can better prepare to support the health of their aging populations. J Am Geriatr Soc 60:951-956, 2012. C1 [Yen, Irene H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94118 USA. [Anderson, Lynda A.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Anderson, Lynda A.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Yen, IH (reprint author), Univ Calif San Francisco, Dept Med, 3333 Calif St,Suite 335, San Francisco, CA 94118 USA. EM irene.yen@ucsf.edu FU Health and Aging Policy Fellowship; Atlantic Philanthropies; CDC FX This work is supported by the Health and Aging Policy Fellowship, funded by Atlantic Philanthropies and the CDC Healthy Aging Program. We thank Johnna Fandel for editorial assistance, Jessica Gill for her work on the conceptual framework, and Chris Kochtitzky, MSP, for background information on city planning policies. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the CDC. NR 48 TC 19 Z9 19 U1 1 U2 19 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2012 VL 60 IS 5 BP 951 EP 956 DI 10.1111/j.1532-5415.2012.03949.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 942HE UT WOS:000304033900020 PM 22568533 ER PT J AU Kroelinger, CD AF Kroelinger, Charlan D. TI Collaboration at the Federal, State, and Local Levels to Build Capacity in Maternal and Child Health: The Impact of the Maternal and Child Health Epidemiology Program SO JOURNAL OF WOMENS HEALTH LA English DT Editorial Material AB This article provides a description of the Maternal and Child Health Epidemiology Program housed in the Division of Reproductive Health at the Centers for Disease Control and Prevention. The article highlights programmatic efforts to build capacity and increase infrastructure within states, localities, and among tribes in the field of maternal and child health by leveraging partnerships with other federal, nonprofit, private, and academic agencies. C1 Ctr Dis Control & Prevent, Maternal & Child Hlth Epidemiol Program, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Kroelinger, CD (reprint author), Ctr Dis Control & Prevent, Maternal & Child Hlth Epidemiol Program, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K-22, Atlanta, GA 30341 USA. EM ckroelinger@cdc.gov FU Intramural CDC HHS [CC999999] NR 10 TC 2 Z9 2 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAY PY 2012 VL 21 IS 5 BP 471 EP 475 DI 10.1089/jwh.2012.3488 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 942OO UT WOS:000304054900001 PM 22587622 ER PT J AU Tepper, NK Farr, SL Cohen, BB Nannini, A Zhang, Z Anderson, JE Jamieson, DJ Macaluso, M AF Tepper, Naomi K. Farr, Sherry L. Cohen, Bruce B. Nannini, Angela Zhang, Zi Anderson, John E. Jamieson, Denise J. Macaluso, Maurizio TI Singleton Preterm Birth: Risk Factors and Association with Assisted Reproductive Technology SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Assisted reproductive technology; Early preterm birth; Late preterm birth; Risk factors ID IN-VITRO FERTILIZATION; UNITED-STATES; UNINTENDED PREGNANCY; PERINATAL OUTCOMES; MASSACHUSETTS; POPULATION; INTENTION; WEIGHT; IMPACT; RATES AB The objectives of this study were to determine risk factors for early (less than 34 weeks gestation) and late (34-36 weeks gestation) preterm singleton birth, by assisted reproductive technology (ART) status. We linked data from Massachusetts birth records and ART records representing singleton live births from 1997 through 2004. Using multinomial regression models, we assessed risk factors for early and late preterm birth by ART status. From 1997 to 2004 in Massachusetts, among non-ART births, risk factors for early and late preterm birth were similar and included women < 15 and a parts per thousand yen35 years of age, those of non-white race or Hispanic ethnicity, those with a parts per thousand currency sign12 years of education, those with chronic diabetes, those with gestational diabetes, those with gestational hypertension, those who smoked during pregnancy, those who used fertility medications, and those who had not had a previous live birth. Among ART births, risk factors for early and late preterm birth differed and odds of early preterm birth were increased among women with a parts per thousand currency sign12 years of education while odds of late preterm birth were increased among women with gestational diabetes. Odds of both early and late preterm birth were increased among women of non-white race or Hispanic ethnicity and among women with gestational hypertension. Among non-ART births, increased risk for preterm birth was more strongly related to socioeconomic factors than among ART births. Medical conditions were associated with an increased risk for preterm birth regardless of women's ART status. Efforts to prevent preterm births should focus on reducing modifiable risk factors. C1 [Tepper, Naomi K.; Farr, Sherry L.; Anderson, John E.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Cohen, Bruce B.] Massachusetts Dept Publ Hlth, Bur Hlth Informat Stat Res & Evaluat, Boston, MA 02108 USA. [Nannini, Angela] Univ Massachusetts, Dept Nursing, Coll Hlth & Environm, Lowell, MA 01854 USA. [Zhang, Zi] Univ Massachusetts, Sch Med, Ctr Hlth Policy & Res, Shrewsbury, MA 01545 USA. [Macaluso, Maurizio] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA. RP Tepper, NK (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,Mailstop K-34, Atlanta, GA 30341 USA. EM ntepper@cdc.gov RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 NR 25 TC 14 Z9 14 U1 1 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD MAY PY 2012 VL 16 IS 4 BP 807 EP 813 DI 10.1007/s10995-011-0787-8 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 934GY UT WOS:000303433400010 PM 21516300 ER PT J AU Armstrong, GL AF Armstrong, Gregory L. TI Respiratory Syncytial Virus in Indonesian Children SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Letter ID INFECTION; AGE C1 Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Armstrong, GL (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAY PY 2012 VL 31 IS 5 BP 539 EP 539 DI 10.1097/INF.0b013e31824e290c PG 1 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 938JS UT WOS:000303730400029 PM 22510994 ER PT J AU Knust, B MacNeil, A Rollin, PE AF Knust, Barbara MacNeil, Adam Rollin, Pierre E. TI Hantavirus Pulmonary Syndrome Clinical Findings: Evaluating a Surveillance Case Definition SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Hantavirus pulmonary syndrome; Public health surveillance; Sin Nombre virus; Statistical analysis ID CARDIOPULMONARY SYNDROME; LIKELIHOOD RATIOS; UNITED-STATES; DIAGNOSIS; DISEASE AB Clinical cases of hantavirus pulmonary syndrome (HPS) can be challenging to differentiate from other acute respiratory diseases, which can lead to delays in diagnosis, treatment, and disease reporting. Rapid onset of severe disease occurs, at times before diagnostic test results are available. This study's objective was to examine the clinical characteristics of patients that would indicate HPS to aid in detection and reporting. Test results of blood samples from U. S. patients suspected of having HPS submitted to the Centers for Disease Control and Prevention from 1998-2010 were reviewed. Patient information collected by case report forms was compared between HPS-confirmed and test-negative patients. Diagnostic sensitivity, specificity, predictive values, and likelihood ratios were calculated for individual clinical findings and combinations of variables. Of 567 patients included, 36% were HPS-confirmed. Thrombocytopenia, chest x-rays with suggestive signs, and receiving supplemental oxygenation were highly sensitive (>95%), while elevated hematocrit was highly specific (83%) in detecting HPS. Combinations that maximized sensitivity required the presence of thrombocytopenia. Using a national sample of suspect patients, we found that thrombocytopenia was a highly sensitive indicator of HPS and should be included in surveillance definitions for suspected HPS. Using a sensitive suspect case definition to identify potential HPS patients that are confirmed by highly specific diagnostic testing will ensure accurate reporting of this disease. C1 [Knust, Barbara; MacNeil, Adam; Rollin, Pierre E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Knust, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,NE Mailstop G-14, Atlanta, GA 30333 USA. EM bknust@cdc.gov FU Centers for Disease Control and Prevention FX The authors would like to thank Thomas G. Ksiazek, Stuart T. Nichol, James A. Comer, and Kent D. Wagoner, for their assistance in the creation and maintenance of the national HPS surveillance system. Additional thanks are due to personnel at state and local departments of health. This study was funded by the Centers for Disease Control and Prevention. The findings and conclusions detailed in this manuscript are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 26 TC 5 Z9 5 U1 1 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD MAY PY 2012 VL 12 IS 5 BP 393 EP 399 DI 10.1089/vbz.2011.0764 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 941BX UT WOS:000303938500008 PM 22214273 ER PT J AU Wejnert, C Pham, H Krishna, N Le, B DiNenno, E AF Wejnert, Cyprian Huong Pham Krishna, Nevin Le, Binh DiNenno, Elizabeth TI Estimating Design Effect and Calculating Sample Size for Respondent-Driven Sampling Studies of Injection Drug Users in the United States SO AIDS AND BEHAVIOR LA English DT Article DE Respondent-driven sampling; Design effect; Sample size; Injecting drug users; HIV; Hidden populations ID BEHAVIORAL SURVEILLANCE SYSTEM; HIDDEN POPULATIONS; HIV; PREVALENCE; VARIANCE; CITIES AB Respondent-driven sampling (RDS) has become increasingly popular for sampling hidden populations, including injecting drug users (IDU). However, RDS data are unique and require specialized analysis techniques, many of which remain underdeveloped. RDS sample size estimation requires knowing design effect (DE), which can only be calculated post hoc. Few studies have analyzed RDS DE using real world empirical data. We analyze estimated DE from 43 samples of IDU collected using a standardized protocol. We find the previous recommendation that sample size be at least doubled, consistent with DE = 2, underestimates true DE and recommend researchers use DE = 4 as an alternate estimate when calculating sample size. A formula for calculating sample size for RDS studies among IDU is presented. Researchers faced with limited resources may wish to accept slightly higher standard errors to keep sample size requirements low. Our results highlight dangers of ignoring sampling design in analysis. C1 [Wejnert, Cyprian; Krishna, Nevin; Le, Binh; DiNenno, Elizabeth] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Huong Pham] ICF Int, Atlanta, GA USA. RP Wejnert, C (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mailstop E-46, Atlanta, GA 30333 USA. EM cwejnert@cdc.gov NR 27 TC 32 Z9 32 U1 1 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD MAY PY 2012 VL 16 IS 4 BP 797 EP 806 DI 10.1007/s10461-012-0147-8 PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 935GV UT WOS:000303508000002 PM 22350828 ER PT J AU Li, RW Magadia, J Fein, SB Grummer-Strawn, LM AF Li, Ruowei Magadia, Joselito Fein, Sara B. Grummer-Strawn, Laurence M. TI Risk of Bottle-feeding for Rapid Weight Gain During the First Year of Life SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID BODY-MASS INDEX; US CHILDREN; OVERWEIGHT; OBESITY; ADOLESCENTS; PREVALENCE; MILK; CONSEQUENCES; METAANALYSIS; DURATION AB Objective: To better understand the mechanisms behind breastfeeding and childhood obesity, we assessed the association of weight gain with the mode of milk delivery aside from the type of milk given to infants. Design: A longitudinal study of infants followed up from birth to age 1 year. Multilevel analyses were conducted to estimate infant weight gain by type of milk and feeding mode. Setting: Pregnant women were recruited from a consumer mail panel throughout the United States between May 2005 and June 2007. Participants: One thousand eight hundred ninety nine infants with at least 3 weight measurements reported during the first year. Main Exposures: Six mutually exclusive feeding categories and proportions of milk feedings given as breastmilk or by bottle. Main Outcome Measures: Weight measurements reported on 3-, 5-, 7-, and 12-month surveys. Results: Compared with infants fed at the breast, infants fed only by bottle gained 71 or 89 g more per month when fed nonhuman milk only (P < .001) or human milk only (P =. 02), respectively. Weight gain was negatively associated with proportion of breastmilk feedings, but it was positively associated with proportion of bottle-feedings among those who received mostly breastmilk. Among infants fed only breastmilk, monthly weight gain increased from 729 g when few feedings were by bottle to 780 g when most feedings were by bottle. Conclusions: Infant weight gain might be associated not only with type of milk consumed but also with mode of milk delivery. Regardless of milk type in the bottle, bottle-feeding might be distinct from feeding at the breast in its effect on infants' weight gain. Arch Pediatr Adolesc Med. 2012; 166(5): 431-436 C1 [Li, Ruowei; Grummer-Strawn, Laurence M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Magadia, Joselito] Univ Philippines Diliman, Sch Stat, Quezon City, Philippines. [Fein, Sara B.] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA. RP Li, RW (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, 4770 Buford Highway,MS K25, Atlanta, GA 30341 USA. EM ril6@cdc.gov FU Food and Drug Administration, Centers for Disease Control and Prevention, Office of Women's Health, National Institutes of Health; Maternal and Child Health Bureau in the US Department of Health and Human Services FX The Infant Feeding Practices Study II was funded by the Food and Drug Administration, Centers for Disease Control and Prevention, Office of Women's Health, National Institutes of Health, and Maternal and Child Health Bureau in the US Department of Health and Human Services. NR 34 TC 53 Z9 55 U1 2 U2 21 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD MAY PY 2012 VL 166 IS 5 SI SI BP 431 EP 436 PG 6 WC Pediatrics SC Pediatrics GA 937PB UT WOS:000303669300006 PM 22566543 ER PT J AU Lipscomb, J Gillespie, TW Goodman, M Richardson, LC Pollack, LA Ryerson, AB Ward, KC AF Lipscomb, Joseph Gillespie, Theresa W. Goodman, Michael Richardson, Lisa C. Pollack, Lori A. Ryerson, A. Blythe Ward, Kevin C. TI Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Cancer health disparities; Adjuvant chemotherapy; Racial differences in cancer care; Cancer care in rural regions ID OLDER WOMEN; RACIAL DISPARITIES; INSURANCE STATUS; OUTCOMES; SURVIVAL; THERAPY; CARE; RACE/ETHNICITY; ASSOCIATION; POPULATION AB Recent breast cancer treatment studies conducted in large urban settings have reported racial disparities in the appropriate use of adjuvant chemotherapy. This article presents the first focused evaluation of black-white differences in receipt and completion of chemotherapy for breast cancer in a primarily rural region of the United States. We performed chart abstraction on initial therapy received by 868 women diagnosed with Stages I, IIA, IIB, or IIIA breast cancer in 2001-2003 in southwest Georgia (SWGA). For chemotherapy, information collected included treatment plan, dates of delivery, concordance between therapy planned and received, and date and reasons for end of treatment. The patient's age at diagnosis, race, marital status, insurance coverage, hormone receptor status, comorbidities, socioeconomic status, urban/rural status, treatment site, and distance to the site were also collected. Following univariate analyses, we used multivariable logistic regression modeling to examine the impact of race on the likelihood of (1) receiving chemotherapy and (2) completing planned chemotherapy. For patients terminating chemotherapy prematurely, the reasons were documented. The results showed that the unadjusted black-white difference in receipt of chemotherapy (48.3 vs. 36.0%) was significant, but in the multivariable analysis the black-white odds ratio (OR = 1.18) was not. While the unadjusted black-white difference (92.0 vs. 87.8%) in completing chemotherapy was not significant, in multivariable models black race was positively associated with completing care (p ranging from 0.032 to 0.087 and OR, correspondingly, from 2.16 to 2.64). The impact of race on completing chemotherapy was influenced by marital status, with a significant black-white difference for patients not married (OR = 4.67), but no difference for those married (OR = 1.06). We find compelling racial differences in this largely rural region-with black breast cancer patients receiving or completing chemotherapy at rates that equal or exceed white patients. Further investigation is warranted, both in SWGA and in other rural regions. C1 [Lipscomb, Joseph] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. [Lipscomb, Joseph; Gillespie, Theresa W.; Goodman, Michael; Ward, Kevin C.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Lipscomb, Joseph; Gillespie, Theresa W.] Atlanta VA Med Ctr, Decatur, GA USA. [Gillespie, Theresa W.] Emory Univ, Dept Surg, Robert W Woodruff Hlth Sci Ctr, Atlanta, GA 30322 USA. [Goodman, Michael; Ryerson, A. Blythe; Ward, Kevin C.] Emory Univ, Rollins Sch Publ Hlth, Georgia Ctr Canc Stat, Dept Epidemiol, Atlanta, GA 30322 USA. [Richardson, Lisa C.; Pollack, Lori A.; Ryerson, A. Blythe] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Lipscomb, J (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. EM jlipsco@sph.emory.edu FU Emory Prevention Research Center [U48 DP000043]; Centers for Disease Control and Prevention; National Cancer Institute through cancer center [5P30CA138292] FX Funding was made possible by cooperative agreement #U48 DP000043 for the Emory Prevention Research Center, from the Centers for Disease Control and Prevention. Additional support was provided by the National Cancer Institute through cancer center support grant 5P30CA138292 to Winship Cancer Institute of Emory University. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute. NR 27 TC 18 Z9 18 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD MAY PY 2012 VL 133 IS 1 BP 285 EP 296 DI 10.1007/s10549-011-1916-1 PG 12 WC Oncology SC Oncology GA 935HH UT WOS:000303509200027 PM 22278190 ER PT J AU Dorman, JS Valdez, R Liu, TB Wang, C Rubinstein, WS O'Neill, SM Acheson, LS Ruffin, MT Khoury, MJ AF Dorman, Janice S. Valdez, Rodolfo Liu, Tiebin Wang, Catharine Rubinstein, Wendy S. O'Neill, Suzanne M. Acheson, Louise S. Ruffin, Mack T. Khoury, Muin J. TI Health beliefs among individuals at increased familial risk for type 2 diabetes: Implications for prevention SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Family history; Health beliefs; Diabetes; Coronary heart disease; Stroke ID LIFE-STYLE INTERVENTION; CORONARY-HEART-DISEASE; SCREENING TOOL; CAROTID-ARTERY; IMPACT TRIAL; HISTORY; MELLITUS; PERCEPTIONS; POPULATION; STROKE AB Aim: To evaluate perceived risk, control, worry, and severity about diabetes, coronary heart disease (CHD) and stroke among individuals at increased familial risk of diabetes. Methods: Data analyses were based on the Family Healthware (TM) Impact Trial. Baseline health beliefs were compared across three groups: (1) no family history of diabetes, CHD or stroke (n = 836), (2) family history of diabetes alone (n = 267), and (3) family history of diabetes and CHD and/or stroke (n = 978). Results: After adjusting for age, gender, race, education and BMI, scores for perceived risk for diabetes (p < 0.0001), CHD (p < 0.0001) and stroke (p < 0.0001) were lowest in Group 1 and highest in Group 3. Similar results were observed about worry for diabetes (p < 0.0001), CHD (p < 0.0001) and stroke (p < 0.0001). Perceptions of control or severity for diabetes, CHD or stroke did not vary across the three groups. Conclusions: Among individuals at increased familial risk for diabetes, having family members affected with CHD and/or stroke significantly influenced perceived risk and worry. Tailored lifestyle interventions for this group that assess health beliefs and emphasize approaches for preventing diabetes, as well as its vascular complications, may be an effective strategy for reducing the global burden of these serious but related chronic disorders. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [Dorman, Janice S.] Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15261 USA. [Valdez, Rodolfo; Liu, Tiebin; Khoury, Muin J.] Ctr Dis Control, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Wang, Catharine] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA USA. [Rubinstein, Wendy S.] NorthShore Univ HealthSyst, Dept Med, Div Genet, Evanston, IL USA. [Rubinstein, Wendy S.] Univ Chicago, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA. [Rubinstein, Wendy S.] NIH, Natl Ctr Biotechnol Informat, Bethesda, MD 20892 USA. [O'Neill, Suzanne M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Acheson, Louise S.] Case Western Reserve Univ, Dept Family Med, Div Res, Cleveland, OH 44106 USA. [Acheson, Louise S.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Acheson, Louise S.] Case Comprehens Canc Ctr, Cleveland, OH USA. [Ruffin, Mack T.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. RP Dorman, JS (reprint author), Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15261 USA. EM jsd@pitt.edu OI Ruffin, Mack/0000-0001-8336-478X; Wang, Catharine/0000-0001-8584-2781 FU Centers for Disease Control; Association for Prevention Teaching and Research [ENH-U50/CCU300860 TS-1216]; American Association of Medical Colleges [UM-U36/CCU319276 MM-0789, CWR-U36/CCU319276 MM0630]; National Cancer Institute [K07 CA086958, NCT00164658] FX Sources of support: The Family Healthware (TM) Impact Trial (FHITr) was supported through cooperative agreements between the Centers for Disease Control and the Association for Prevention Teaching and Research (ENH-U50/CCU300860 TS-1216) and the American Association of Medical Colleges (Grants UM-U36/CCU319276 MM-0789 and CWR-U36/CCU319276 MM0630). Drs. Acheson (K07 CA086958) and Wang (K07 CA131103) also received salary support from the National Cancer Institute. Trial Registration: NCT00164658 'Evaluating Tools for Health Promotion and Disease Prevention'. NR 49 TC 10 Z9 11 U1 1 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD MAY PY 2012 VL 96 IS 2 BP 156 EP 162 DI 10.1016/j.diabres.2011.12.017 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 937OO UT WOS:000303668000020 PM 22257420 ER PT J AU Lindstrom, S Garten, R Balish, A Shu, B Emery, S Berman, L Barnes, N Sleeman, K Gubareva, L Villanueva, J Klimov, A AF Lindstrom, Stephen Garten, Rebecca Balish, Amanda Shu, Bo Emery, Shannon Berman, LaShondra Barnes, Nathelia Sleeman, Katrina Gubareva, Larisa Villanueva, Julie Klimov, Alexander TI Human Infections with Novel Reassortant Influenza A(H3N2)v Viruses, United States, 2011 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID A H3N2 VIRUS; SWINE INFLUENZA AB During July December 2011, a variant virus, influenza A(H3N2)v, caused 12 human cases of influenza. The virus contained genes originating from swine, avian, and human viruses, including the M gene from influenza A(H1N1)pdm09 virus. Influenza A(H3N2)v viruses were antigenically distinct from seasonal influenza viruses and similar to proposed vaccine virus A/Minnesota/11/2010. C1 [Lindstrom, Stephen; Klimov, Alexander] Ctr Dis Control & Prevent, Influenza Div, Virus Surveillance & Diag Branch, Diagnost Dev Team, Atlanta, GA 30333 USA. [Barnes, Nathelia] Battelle Mem Inst, Atlanta, GA USA. RP Klimov, A (reprint author), Ctr Dis Control & Prevent, Influenza Div, Virus Surveillance & Diag Branch, Diagnost Dev Team, Mailstop G16,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM axk0@cdc.gov NR 15 TC 75 Z9 77 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2012 VL 18 IS 5 BP 834 EP 837 DI 10.3201/eid1805.111922 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 935XZ UT WOS:000303556800018 PM 22516540 ER PT J AU Self, WH Grijalva, CG Zhu, YW Talbot, HK Jules, A Widmer, KE Edwards, KM Williams, JV Shay, DK Griffin, MR AF Self, Wesley H. Grijalva, Carlos G. Zhu, Yuwei Talbot, H. Keipp Jules, Astride Widmer, Kyle E. Edwards, Kathryn M. Williams, John V. Shay, David K. Griffin, Marie R. TI Emergency Department Visits for Influenza A(H1N1)pdm09, Davidson County, Tennessee, USA SO EMERGING INFECTIOUS DISEASES LA English DT Article ID H1N1 INFLUENZA; OLDER-ADULTS AB To determine the number of emergency department visits attributable to influenza A(H1N1)pdm09 in Davidson County, Tennessee, USA, we used active, population-based surveillance and laboratory-confirmed influenza data. We estimated approximate to 10 visits per 1,000 residents during the pandemic period. This estimate should help emergency departments prepare for future pandemics. C1 [Griffin, Marie R.] Vanderbilt Univ, Med Ctr Village Vanderbilt, Dept Prevent Med, Nashville, TN 37212 USA. [Self, Wesley H.; Griffin, Marie R.] Vet Affairs Tennessee Valley Hlth Care Syst, Nashville, TN USA. [Shay, David K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Self, Wesley H.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. RP Griffin, MR (reprint author), Vanderbilt Univ, Med Ctr Village Vanderbilt, Dept Prevent Med, Suite 2600,1500 21st Ave S, Nashville, TN 37212 USA. EM marie.griffin@vanderbilt.edu RI Williams, John/F-6962-2010; OI Williams, John/0000-0001-8377-5175; Shay, David/0000-0001-9619-4820 FU Centers for Disease Control and Prevention [U01 IP000184]; National Institute of Allergy and Infectious Diseases [IK23AI074863]; Office of Academic Affiliations, Department of Veterans Affairs FX Financial support for this study was provided by Centers for Disease Control and Prevention Cooperative Agreement U01 IP000184; National Institute of Allergy and Infectious Diseases grant IK23AI074863 (to H.K.T.); and the Office of Academic Affiliations, Department of Veterans Affairs, VA National Quality Scholars Program (to W.H.S.). NR 14 TC 6 Z9 6 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2012 VL 18 IS 5 BP 863 EP 865 DI 10.3201/eid1805.111233 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 935XZ UT WOS:000303556800026 PM 22516043 ER PT J AU Lee, LE Cebelinski, EA Fuller, C Keene, WE Smith, K Vinje, J Besser, JM AF Lee, Lore E. Cebelinski, Elizabeth A. Fuller, Candace Keene, William E. Smith, Kirk Vinje, Jan Besser, John M. TI Sapovirus Outbreaks in Long-Term Care Facilities, Oregon and Minnesota, USA, 2002-2009 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID GASTROENTERITIS OUTBREAKS; GENOTYPE ANALYSIS; EPIDEMIOLOGY; CALICIVIRUS AB We tested fecal samples from 93 norovirus-negative gastroenteritis outbreaks; 21 outbreaks were caused by sapovirus. Of these, 71% were caused by sapovirus genogroup IV and 66% occurred in long-term care facilities. Future investigation of gastroenteritis outbreaks should include multi-organism testing. C1 [Lee, Lore E.; Keene, William E.] Oregon Publ Hlth Div, Portland, OR 97232 USA. [Cebelinski, Elizabeth A.; Fuller, Candace; Smith, Kirk] Minnesota Dept Hlth, St Paul, MN USA. [Vinje, Jan; Besser, John M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Lee, LE (reprint author), Oregon Publ Hlth Div, 800 NE Oregon St,Suite 772, Portland, OR 97232 USA. EM lore.e.lee@state.or.us OI Vinje, Jan/0000-0002-1530-3675 NR 15 TC 25 Z9 25 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2012 VL 18 IS 5 BP 873 EP 876 DI 10.3201/eid1805.111843 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 935XZ UT WOS:000303556800029 PM 22516204 ER PT J AU Sharp, TM Bracero, J Rivera, A Shieh, WJ Bhatnagar, J Rivera-Diez, I Hunsperger, E Munoz-Jordan, J Zaki, SR Tomashek, KM AF Sharp, Tyler M. Bracero, Julio Rivera, Aidsa Shieh, Wun-Ju Bhatnagar, Julu Rivera-Diez, Irma Hunsperger, Elizabeth Munoz-Jordan, Jorge Zaki, Sherif R. Tomashek, Kay M. TI Fatal Human Co-infection with Leptospira spp. and Dengue Virus, Puerto Rico, 2010 SO EMERGING INFECTIOUS DISEASES LA English DT Letter C1 [Sharp, Tyler M.; Rivera, Aidsa; Hunsperger, Elizabeth; Munoz-Jordan, Jorge; Tomashek, Kay M.] Ctr Dis Control & Prevent, San Juan, PR 00920 USA. [Sharp, Tyler M.; Shieh, Wun-Ju; Bhatnagar, Julu; Zaki, Sherif R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bracero, Julio] Hosp Episcopal San Lucas, Ponce, PR USA. [Rivera-Diez, Irma] Inst Ciencias Forenses, Dept Patol, San Juan, PR USA. RP Tomashek, KM (reprint author), Ctr Dis Control & Prevent, 1324 Calle Canada, San Juan, PR 00920 USA. EM kct9@cdc.gov NR 11 TC 6 Z9 6 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2012 VL 18 IS 5 BP 878 EP 880 DI 10.3201/eid1805.111555 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 935XZ UT WOS:000303556800031 PM 22516301 ER PT J AU Potter, P AF Potter, Polyxeni TI Health and the Myrmidons SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAY PY 2012 VL 18 IS 5 BP 893 EP 894 DI 10.3201/eid1412.080470 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 935XZ UT WOS:000303556800042 ER PT J AU Rivera-Nunez, Z Wright, JM Blount, BC Silva, LK Jones, E Chan, RL Pegram, RA Singer, PC Savitz, DA AF Rivera-Nunez, Zorimar Wright, J. Michael Blount, Benjamin C. Silva, Lalith K. Jones, Elizabeth Chan, Ronna L. Pegram, Rex A. Singer, Philip C. Savitz, David A. TI Comparison of Trihalomethanes in Tap Water and Blood: A Case Study in the United States SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE blood THM; blood-water correlations; brominated THMs; noningestion water activities; trihalomethanes ID DISINFECTION BY-PRODUCTS; PUBLIC DRINKING-WATER; INDOOR SWIMMING POOLS; EXPOSURE ASSESSMENT; BLADDER-CANCER; FETAL-GROWTH; BIRTH OUTCOMES; BUTYL ETHER; BROMODICHLOROMETHANE; CHLOROFORM AB BACKGROUND: Epidemiological studies have used various measures to characterize trihalomethane (THM) exposures, but the relationship of these indicators to exposure biomarkers remains unclear. OBJECTIVES: We examined temporal and spatial variability in baseline blood THM concentrations and assessed the relationship between these concentrations and several exposure indicators (tap water concentration, water-use activities, multiroute exposure metrics). METHODS: We measured water-use activity and THM concentrations in blood and residential tap water from 150 postpartum women from three U.S. locations. RESULTS: Blood Sigma THM [sum of chloroform (TCM), bromodichloromethane (BDCM), dibromochloromethane (DBCM), and bromoform (TBM)] concentrations varied by site and season. As expected based on variable tap water concentrations and toxicokinetic properties, the proportion of brominated species (BDCM, DBCM, and TBM) in blood varied by site (site 1, 24%; site 2, 29%; site 3, 57%) but varied less markedly than in tap water (site 1, 35%; site 2, 75%; site 3, 68%). The blood-water Sigma THM Spearman rank correlation coefficient was 0.36, with correlations higher for individual brominated species (BDCM, 0.62; DBCM, 0.53; TBM, 0.54) than for TCM (0.37). Noningestion water activities contributed more to the total exposure metric than did ingestion, but tap water THM concentrations were more predictive of blood THM levels than were metrics that incorporated water use. CONCLUSIONS: Spatial and temporal variability in THM concentrations was greater in water than in blood. We found consistent blood-water correlations across season and site for BDCM and DBCM, and multivariate regression results suggest that water THM concentrations may be an adequate surro gate for baseline blood levels. C1 [Wright, J. Michael] US EPA, Natl Ctr Environm Assessment, Cincinnati, OH 45268 USA. [Rivera-Nunez, Zorimar] CNR, Washington, DC 20418 USA. [Blount, Benjamin C.; Silva, Lalith K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jones, Elizabeth] Assoc Sch Publ Hlth, Washington, DC USA. [Chan, Ronna L.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Pegram, Rex A.] US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA. [Singer, Philip C.] Univ N Carolina, Dept Environm Sci & Engn, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Savitz, David A.] Brown Univ, Dept Community Hlth, Providence, RI 02912 USA. [Savitz, David A.] Brown Univ, Dept Obstet & Gynecol, Providence, RI 02912 USA. RP Wright, JM (reprint author), US EPA, Natl Ctr Environm Assessment, 26 W Martin King Dr,MS A-110, Cincinnati, OH 45268 USA. EM wright.michael@epa.gov FU American Water Works Association Research Foundation [2579]; U.S. Environmental Protection Agency [CR825625-01, CR827268-01, CR828216-01]; Center for Environmental Health and Susceptibility at the University of North Carolina-Chapel Hill [P30E510126] FX This work was supported jointly by the American Water Works Association Research Foundation (project 2579) and the U.S. Environmental Protection Agency under cooperative agreements CR825625-01, CR827268-01, and CR828216-01 with the Center for Environmental Health and Susceptibility at the University of North Carolina-Chapel Hill (P30E510126). NR 59 TC 20 Z9 20 U1 1 U2 21 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAY PY 2012 VL 120 IS 5 BP 661 EP 667 DI 10.1289/ehp.1104347 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 935UF UT WOS:000303546000028 PM 22281753 ER PT J AU Silverstone, AE Rosenbaum, PF Weinstock, RS Bartell, SM Foushee, HR Shelton, C Pavuk, M AF Silverstone, Allen E. Rosenbaum, Paula F. Weinstock, Ruth S. Bartell, Scott M. Foushee, Herman R. Shelton, Christie Pavuk, Marian CA Anniston Environm Hlth Res Consort TI Polychlorinated Biphenyl (PCB) Exposure and Diabetes: Results from the Anniston Community Health Survey SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE diabetes; epidemiology; polychlorinated biphenyls (PCBs); POPs ID PERSISTENT ORGANIC POLLUTANTS; POLYBROMINATED BIPHENYLS; SERUM CONCENTRATIONS; DIOXINS; ASSOCIATIONS; PREVALENCE; PESTICIDES; ADJUSTMENT; CONGENERS; MELLITUS AB BACKGROUND: Polychlorinated biphenyls (PCBs) manufactured in Anniston, Alabama, from 1929 to 1971 caused significant environmental contamination. The Anniston population remains one of the most highly exposed in the world. OBJECTIVES: Reports of increased diabetes in PCB-exposed populations led us to examine possible associations in Anniston residents. METHODS: Volunteers (n = 774) from a cross-sectional study of randomly selected households and adults who completed the Anniston Community Health Survey also underwent measurements of height, weight, fasting glucose, lipid, and PCB congener levels and verification of medications. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the relationships between PCBs and diabetes, adjusting for diabetes risk factors. Participants with prediabetes were excluded from the logistic regression analyses. RESULTS: Participants were 47% African American, 70% female, with a mean age of 54.8 years. The prevalence of diabetes was 27% in the study population, corresponding to an estimated prevalence of 16% for Anniston overall; the PCB body burden of 35 major congeners ranged from 0.11 to 170.42 ppb, wet weight. The adjusted OR comparing the prevalence of diabetes in the fifth versus first quintile of serum PCB was 2.78 (95% CI: 1.00, 7.73), with similar associations estimated for second through fourth quintiles. In participants < 55 years of age, the adjusted OR for diabetes for the highest versus lowest quintile was 4.78 (95% CI: 1.11, 20.6), whereas in those >= 55 years of age, we observed no significant associations with PCBs. Elevated diabetes prevalence was observed with a 1 SD increase in log PCB levels in women (OR = 1.52; 95% CI: 1.01, 2.28); a decreased prevalence was observed in men (OR = 0.68; 95% CI: 0.33, 1.41). CONCLUSIONS: We observed significant associations between elevated PCB levels and diabetes mostly due to associations in women and in individuals < 55 years of age. C1 [Silverstone, Allen E.; Rosenbaum, Paula F.; Weinstock, Ruth S.] SUNY Upstate Med Univ, Dept Microbiol & Immunol, Syracuse, NY 13210 USA. [Weinstock, Ruth S.] Vet Adm Med Ctr, Dept Vet Affairs, Syracuse, NY 13210 USA. [Bartell, Scott M.] Univ Calif Irvine, Irvine, CA USA. [Foushee, Herman R.] Univ Alabama Birmingham, Birmingham, AL USA. [Shelton, Christie] Jacksonville State Univ, Coll Nursing & Hlth Sci, Jacksonville, AL 36265 USA. [Pavuk, Marian] Agcy Tox Subst & Dis Registry, Atlanta, GA USA. RP Silverstone, AE (reprint author), SUNY Upstate Med Univ, Dept Microbiol & Immunol, 750 E Adams St, Syracuse, NY 13210 USA. EM silversa@upstate.edu RI Bartell, Scott/M-8919-2013 OI Bartell, Scott/0000-0001-7797-2906 FU Agency for Toxic Substances and Disease Registry [U50/ATU473215]; Anniston Environmental Health Consortium, Polychlorinated Biphenyls Exposure and Adverse Health Effects in Anniston, AL FX This work was funded by grant U50/ATU473215 from the Agency for Toxic Substances and Disease Registry (C. Shelton, principal investigator) and the Anniston Environmental Health Consortium, Polychlorinated Biphenyls Exposure and Adverse Health Effects in Anniston, AL. NR 39 TC 43 Z9 46 U1 4 U2 32 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAY PY 2012 VL 120 IS 5 BP 727 EP 732 DI 10.1289/ehp.1104247 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 935UF UT WOS:000303546000038 PM 22334129 ER PT J AU Herbstman, JB Tang, DL Zhu, DG Qu, LR Sjodin, A Li, Z Camann, D Perera, FP AF Herbstman, Julie B. Tang, Deliang Zhu, Deguang Qu, Lirong Sjoedin, Andreas Li, Zheng Camann, David Perera, Frederica P. TI Prenatal Exposure to Polycyclic Aromatic Hydrocarbons, Benzo[a]pyrene-DNA Adducts, and Genomic DNA Methylation in Cord Blood SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE adducts; epigenetics; methylation; polycyclic aromatic hydrocarbons; prenatal; umbilical cord blood ID NEW-YORK-CITY; DIOL-EPOXIDE; CYTOSINE METHYLATION; MASS-SPECTROMETRY; CANCER-RISK; HOT-SPOTS; P53 GENE; CPG; DAMAGE; CARCINOGENS AB BACKGROUND: Polycyclic aromatic hydrocarbons (PAHs) are carcinogenic environmental pollutants generated during incomplete combustion. After exposure and during metabolism, PAHs can form reactive epoxides that can covalently bind to DNA. These PAH-DNA adducts are established markers of cancer risk. PAH exposure has been associated with epigenetic alterations, including genomic cytosine methylation. Both global hypomethylation and hypermethylation of specific genes have been associated with cancer and other diseases in humans. Experimental evidence suggests that PAH-DNA adduct formation may preferentially target methylated genomic regions. Early embryonic development may be a particularly susceptible period for PAH exposure, resulting in both increased PAH-DNA adducts and altered DNA methylation. OBJECTIVE: We explored whether prenatal exposure to PAHs is associated with genomic DNA methylation in cord blood and whether methylation levels are associated with the presence of detectable PAH-DNA adducts. METHODS: In a longitudinal cohort study of non smoking women in New York City, we measured PAH exposure during pregnancy using personal air monitors, assessed PAH internal dose using prenatal urinary metabolites (in a subset), and quantified benzo[a]pyrene-DNA adducts and genomic DNA methylation in cord blood DNA among 164 participants. RESULTS: Prenatal PAH exposure was associated with lower global methylation in umbilical cord white blood cells (p = 0.05), but global methylation levels were positively associated with the presence of detectable adducts in cord blood (p = 0.01). CONCLUSIONS: These observations suggest that PAH exposure was adequate to alter global methylation in our study population. Additional epidemiologic studies that can measure site-specific cytosine methylation and adduct formation will improve our ability to understand this complex molecular pathway in vivo. C1 [Herbstman, Julie B.; Tang, Deliang; Zhu, Deguang; Qu, Lirong; Perera, Frederica P.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA. [Sjoedin, Andreas; Li, Zheng] Ctr Dis Control & Prevent, Atlanta, GA USA. [Camann, David] SW Res Inst, San Antonio, TX USA. RP Herbstman, JB (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 722 W 168th St,Room 1217, New York, NY 10032 USA. EM jh2678@columbia.edu RI Sjodin, Andreas/F-2464-2010 FU National Institute of Environmental Health Sciences [1K99ES017051-01, 2P01ES009600-11, 5P50ES015905-03, P30ES009089, 1R01ES015282-01A2]; U.S. Environmental Protection Agency [RD-83450901]; National Cancer Institute [5R25CA094061-08]; John and Wendy Neu Family Foundation; New York Community Trust; Blanchette Hooker Rockefeller Fund FX This work was supported by National Institute of Environmental Health Sciences grants 1K99ES017051-01, 2P01ES009600-11, 5P50ES015905-03, P30ES009089, and 1R01ES015282-01A2, U.S. Environmental Protection Agency grant RD-83450901, National Cancer Institute grant 5R25CA094061-08, the John and Wendy Neu Family Foundation, the New York Community Trust, and the Trustees of the Blanchette Hooker Rockefeller Fund. NR 37 TC 67 Z9 73 U1 5 U2 60 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAY PY 2012 VL 120 IS 5 BP 733 EP 738 DI 10.1289/ehp.1104056 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 935UF UT WOS:000303546000039 PM 22256332 ER PT J AU Braun, JM Smith, KW Williams, PL Calafat, AM Berry, K Ehrlich, S Hauser, R AF Braun, Joe M. Smith, Kristen W. Williams, Paige L. Calafat, Antonia M. Berry, Katharine Ehrlich, Shelley Hauser, Russ TI Variability of Urinary Phthalate Metabolite and Bisphenol A Concentrations before and during Pregnancy SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE bisphenol A; endocrine disruptors; epidemiology; phthalates; pregnancy; variability ID CARE PRODUCT USE; TEMPORAL VARIABILITY; US POPULATION; EXPOSURE; WOMEN; MEN; PREDICTORS; TOXICITY; PHENOLS; SAMPLES AB BACKGROUND: Gestational phthalate and bisphenol A (BPA) exposure may increase the risk of adverse maternal/child health outcomes, but there are few data on the variability of urinary biomarkers before and during pregnancy. OBJECTIVE: We characterized the variability of urinary phthalate metabolite and BPA concentrations before and during pregnancy and the ability of a single spot urine sample to classify average gestational exposure. METHODS: We collected 1,001 urine samples before and during pregnancy from 137 women who were partners in couples attending a Boston fertility clinic and who had a live birth. Women provided spot urine samples before (n >= 2) and during (n >= 2) pregnancy. We measured urinary concentrations of monoethyl phthalate (MEP), mono-n-butyl phthalate (MBP), mono-iso-butyl phthalate, monobenzyl phthalate (MBzP), four metabolites of di-(2-ethylhexyl) phthalate (DEHP), and BPA. After adjusting for specific gravity, we characterized biomarker variability using intraclass correlation coefficients (ICCs) and conducted several surrogate category analyses to determine whether a single spot urine sample could adequately classify average gestational exposure. RESULTS: Absolute concentrations of phthalate metabolites and BPA were similar before and during pregnancy. Variability was higher during pregnancy than before pregnancy for BPA and MBzP, but similar during and before pregnancy for MBP, MEP, and Sigma DEHP. During pregnancy, MEP (ICC = 0.50) and MBP (ICC = 0.45) were less variable than BPA (ICC = 0.12), MBzP (ICC = 0.25), and Sigma DEHP metabolites (ICC = 0.08). Surrogate analyses suggested that a single spot urine sample may reasonably classify MEP and MBP concentrations during pregnancy, but more than one sample may be necessary for MBzP, DEHP, and BPA. CONCLUSIONS: Urinary phthalate metabolites and BPA concentrations were variable before and during pregnancy, but the magnitude of variability was biomarker specific. A single spot urine sample adequately classified MBP and MEP concentrations during pregnancy. The present results may be related to unique features of the women studied, and replication in other pregnancy cohorts is recommended. C1 [Braun, Joe M.; Smith, Kristen W.; Berry, Katharine; Ehrlich, Shelley; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Berry, Katharine] Brigham & Womens Hosp, Div Reprod Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. RP Hauser, R (reprint author), 665 Huntington Ave,Bldg 1,14th Floor, Boston, MA 02115 USA. EM rhauser@hohp.harvard.edu RI Braun, Joseph/H-8649-2014; Ehrlich , Shelley/L-6991-2015 FU National Institute of Environmental Health Sciences [T32 ES007069, R01 ES009718, P30 ES000002]; Leaves of Grass Fund FX This work was supported by grants T32 ES007069, R01 ES009718, and P30 ES000002 from the National Institute of Environmental Health Sciences, and by the Leaves of Grass Fund. NR 37 TC 124 Z9 125 U1 4 U2 44 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAY PY 2012 VL 120 IS 5 BP 739 EP 745 DI 10.1289/ehp.1104139 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 935UF UT WOS:000303546000040 PM 22262702 ER PT J AU Hsiao, CJ Decker, SL Hing, E Sisk, JE AF Hsiao, Chun-Ju Decker, Sandra L. Hing, Esther Sisk, Jane E. TI Most Physicians Were Eligible For Federal Incentives In 2011, But Few Had EHR Systems That Met Meaningful-Use Criteria SO HEALTH AFFAIRS LA English DT Article AB As more physicians adopt electronic health record systems in their practices, policy interest is focusing on whether physicians are ready to meet the federal "meaningful use" criteria-a vital threshold to qualify for financial incentives. In our analysis of a 2011 nationally representative survey of office-based physicians, we found that 91 percent of physicians were eligible for Medicare or Medicaid meaningful-use incentives. About half of all physicians intended to apply. However, only 11 percent both intended to apply for the incentives and had electronic health record systems with the capabilities to support even two-thirds of the stage 1 core objectives required for meaningful use. Although the federal Medicare incentives will be available through 2016, and Medicaid incentives through 2021, widespread gaps in readiness throughout the states illustrate the challenges physicians face in meeting the federal schedule for the incentive programs. C1 [Hsiao, Chun-Ju] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Sisk, Jane E.] Natl Acad Sci, Inst Med, Washington, DC 20418 USA. RP Hsiao, CJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM hwd3@cdc.gov FU Office of the National Coordinator for Health Information Technology FX The authors thank the Office of the National Coordinator for Health Information Technology for funding the Electronic Medical Records Supplement to the National Ambulatory Medical Care Survey. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention, the Institute of Medicine, or the Office of the National Coordinator for Health Information Technology. [Published online April 24, 2012.] NR 10 TC 20 Z9 20 U1 1 U2 4 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD MAY PY 2012 VL 31 IS 5 BP 1100 EP 1107 DI 10.1377/hlthaff.2011.1315 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 940EP UT WOS:000303873100027 PM 22535501 ER PT J AU Decker, SL Jamoom, EW Sisk, JE AF Decker, Sandra L. Jamoom, Eric W. Sisk, Jane E. TI Physicians In Nonprimary Care And Small Practices And Those Age 55 And Older Lag In Adopting Electronic Health Record Systems SO HEALTH AFFAIRS LA English DT Article AB By 2011 more than half of all office-based physicians were using electronic health record systems, but only about one-third of those physicians had systems with basic features such as the abilities to record information on patient demographics, view laboratory and imaging results, maintain problem lists, compile clinical notes, or manage computerized prescription ordering. Basic features are considered important to realize the potential of these systems to improve health care. We found that although trends in adoption of electronic health record systems across geographic regions converged from 2002 through 2011, adoption continued to lag for non-primary care specialists, physicians age fifty-five and older, and physicians in small (1-2 providers) and physician-owned practices. Federal policies are specifically aimed at encouraging primary care providers and small practices to achieve widespread use of electronic health records. To achieve their nationwide adoption, federal policies may also have to focus on encouraging adoption among non-primary care specialists, as well as addressing persistent gaps in the use of electronic record systems by practice size, physician age, and ownership status. C1 [Decker, Sandra L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Sisk, Jane E.] Natl Acad Sci, Inst Med, Washington, DC 20418 USA. RP Decker, SL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM sdecker@cdc.gov FU Office of the National Coordinator for Health Information Technology FX The authors thank the Office of the National Coordinator for Health Information Technology for funding the National Ambulatory Medical Care Electronic Medical Records supplement. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention, the Institute of Medicine, or the Office of the National Coordinator. [Published online April 24, 2012.] NR 15 TC 46 Z9 46 U1 0 U2 8 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD MAY PY 2012 VL 31 IS 5 BP 1108 EP 1114 DI 10.1377/hlthaff.2011.1121 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 940EP UT WOS:000303873100028 PM 22535502 ER PT J AU Marston, BJ De Cock, KM AF Marston, Barbara J. De Cock, Kevin M. TI How can this be? Preventing death in patients with HIV-associated tuberculosis SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Editorial Material ID ANTIRETROVIRAL THERAPY; INITIATION C1 [Marston, Barbara J.; De Cock, Kevin M.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Marston, BJ (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30333 USA. EM kmd2@cdc.gov FU Intramural CDC HHS [CC999999] NR 11 TC 0 Z9 0 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAY PY 2012 VL 16 IS 5 BP 569 EP 570 DI 10.5588/ijtld.12.0016 PG 2 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 937YR UT WOS:000303700600001 PM 22507928 ER PT J AU Click, ES Feleke, B Pevzner, E Fantu, R Gadisa, T Assefa, D Melaku, Z Cain, K Menzies, H AF Click, E. S. Feleke, B. Pevzner, E. Fantu, R. Gadisa, T. Assefa, D. Melaku, Z. Cain, K. Menzies, H. TI Evaluation of integrated registers for tuberculosis and HIV surveillance in children, Ethiopia, 2007-2009 SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE pediatric; tuberculosis; TB; HIV ID CHILDHOOD TUBERCULOSIS AB In 2008, Ethiopia implemented tuberculosis (TB) treatment registers that included columns for recording human immunodeficiency virus (HIV) test results (integrated registers) to replace the previous system of separate TB and HIV registers (pre-integration registers). We compared the proportion of children with documented HIV rapid test results at eight hospitals before and after adopting the integrated registers. HIV status was more consistently documented in the integrated registers; however, HIV status for infants aged <18 months could not be assessed, as the registers did not capture results from polymerase chain reaction-based testing. Recording procedures should be revised to document age-appropriate HIV diagnostic results and ensure referral for appropriate care. C1 [Click, E. S.; Pevzner, E.; Cain, K.; Menzies, H.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Click, E. S.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Feleke, B.; Fantu, R.] Ctr Dis Control & Prevent, Global AIDS Program Ethiopia, Addis Ababa, Ethiopia. [Gadisa, T.; Assefa, D.; Melaku, Z.] Int Ctr AIDS Care & Treatment Programs, Addis Ababa, Ethiopia. RP Click, ES (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd,MS E-10, Atlanta, GA 30333 USA. EM eoc9@cdc.gov FU President's Emergency Plan for AIDS Relief, Global AIDS Program of Ethiopia FX The authors thank K Gutama and B Kiflu for data collection and C Heilig for figure preparation. Funding for this study was provided by the President's Emergency Plan for AIDS Relief, Global AIDS Program of Ethiopia. NR 6 TC 2 Z9 2 U1 0 U2 4 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAY PY 2012 VL 16 IS 5 BP 625 EP 627 DI 10.5588/ijtld.11.0655 PG 3 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 937YR UT WOS:000303700600013 PM 22417732 ER PT J AU Datema, TAM Oskam, L Engelberts, MFM van Beers, SM Shinnick, TM Baker, M Ridderhof, JC Scholten, J van Deun, A Gilpin, C Klatser, PR AF Datema, Tjeerd A. M. Oskam, Linda Engelberts, Mirjam F. M. van Beers, Stella M. Shinnick, Thomas M. Baker, Martin Ridderhof, John C. Scholten, Jerod van Deun, Armand Gilpin, Christopher Klatser, Paul R. TI Global laboratory initiative tool for a stepwise process towards tuberculosis laboratory accreditation SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Letter ID SYSTEMS; QUALITY C1 [Datema, Tjeerd A. M.; Oskam, Linda; Engelberts, Mirjam F. M.; van Beers, Stella M.; Klatser, Paul R.] KIT Biomed Res, Royal Trop Inst, Amsterdam, Netherlands. [Shinnick, Thomas M.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. [Baker, Martin] Univ Massachusetts, UMASS Med Sch, Worcester, MA 01605 USA. [Ridderhof, John C.] Ctr Dis Control & Prevent, Div Lab Syst, Publ Hlth Practice Program Off, Atlanta, GA USA. [Scholten, Jerod] KNCV TB Fdn, The Hague, Netherlands. [van Deun, Armand] Int Union TB & Lung Dis, Paris, France. [Gilpin, Christopher] WHO, Stop TB Dept, CH-1211 Geneva, Switzerland. RP Datema, TAM (reprint author), KIT Biomed Res, Royal Trop Inst, Amsterdam, Netherlands. EM p.klatser@kit.nl OI Klatser, Paul/0000-0003-2127-9138 NR 6 TC 4 Z9 5 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAY PY 2012 VL 16 IS 5 BP 704 EP 705 DI 10.5588/ijtld.11.0701 PG 2 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 937YR UT WOS:000303700600031 PM 22507938 ER PT J AU Huhman, M Lowry, R Lee, SM Fulton, JE Carlson, SA Patnode, CD AF Huhman, Marian Lowry, Richard Lee, Sarah M. Fulton, Janet E. Carlson, Susan A. Patnode, Carrie D. TI Physical Activity and Screen Time: Trends in U.S. Children Aged 9 to 13 Years, 2002-2006 SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE youth; tweens ID SEDENTARY BEHAVIOR; ADOLESCENTS; TELEVISION; YOUTH; MEDIA; RISK; DETERMINANTS; CAMPAIGN; HEALTH AB Background: We examined trends of physical activity and screen time among nationally representative samples of children aged 9-13 years to explore whether children overall are becoming less physically active and less likely to be in compliance with screen time recommendations. Methods: We analyzed Youth Media Campaign Longitudinal Survey data for trends and demographic patterns of free time and organized physical activity, and hours and minutes of watching television and playing video or computer games. Child-parent dyads for 2002 (N = 3114), 2004 (N = 5177), and 2006 (N = 1200) were analyzed. Results: On the day before the interview, and for free time physical activity in the past week, children reported a significant increase in physical activity from 2002-2006. Screen time levels were stable overall; 76.4% of children met the recommendations of 2 hours or less of daily screen time. Conclusion: Levels of physical activity among U.S. children aged 9-13 years were stable, or levels slightly improved from 2002-2006. Except for some subgroup differences, trends for compliance with screen time recommendations were also stable from 2002-2006 for U.S. children aged 9-13 years. C1 [Huhman, Marian] Univ Illinois, Dept Commun, Urbana, IL 61801 USA. [Lowry, Richard; Lee, Sarah M.; Fulton, Janet E.; Carlson, Susan A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Patnode, Carrie D.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA. RP Huhman, M (reprint author), Univ Illinois, Dept Commun, Urbana, IL 61801 USA. NR 33 TC 8 Z9 8 U1 2 U2 9 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD MAY PY 2012 VL 9 IS 4 BP 508 EP 515 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 941DU UT WOS:000303944700006 PM 21946472 ER PT J AU Olsen, GL Deitz, KL Flaherty, HA Lockhart, SR Hurst, SF Haynes, JS AF Olsen, Gavin L. Deitz, Krysta L. Flaherty, Heather A. Lockhart, Shawn R. Hurst, Steven F. Haynes, Joseph S. TI Use of Terbinafine in the Treatment Protocol of Intestinal Cryptococcus neoformans in a Dog SO JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION LA English DT Article ID GASTROINTESTINAL PYTHIOSIS; FLUCONAZOLE; DIAGNOSIS; THERAPY AB A 2.5 yr old sexually intact male vizsla was admitted to the Iowa State University Veterinary Teaching Hospital for persistent diarrhea, weight loss, and panhypoproteinemia. Examination revealed an emaciated condition and melena. Two masses were palpated in the cranial abdomen. Hematology and serum biochemistry exhibited a regenerative anemia and confirmed the presence of panhypoproteinemia, suggestive of a protein-losing eneteropathy. Distinct areas of thickened intestinal wall and enlarged mesenteric lymph nodes were found on abdominal ultrasound. Cytology from those nodes showed the presence of suspected Cryptococcus spp., and infection was confirmed utilizing a cryptococcal antigen titer. Medical therapy with lipid-complexed amphotericin B and fluconazole was unsuccessful. Two surgical procedures were performed to remove the affected areas of intestine and lymph nodes, but the disease persisted as evidenced by a persistently elevated cryptococcal antigen titer. Terbinafine was prescribed, which resulted in complete resolution of clinical signs and a steadily decreasing cryptococcal antigen titer. Very few cases of intestinal cryptococcosis have been reported. In this case, infection resulted in a protein-losing enteropathy. In addition, this article describes the use of terbinafine in the treatment of intestinal cryptococcal infection in the dog, which has not been previously reported. (J Am Anim Hosp Assoc 2012; 48:216-220. DOI 10.5326/JAAHA-MS-5813) C1 [Olsen, Gavin L.; Deitz, Krysta L.; Flaherty, Heather A.; Haynes, Joseph S.] Iowa State Univ, Vet Teaching Hosp, Internal Med Serv, Dept Vet Clin Sci, Ames, IA USA. [Lockhart, Shawn R.; Hurst, Steven F.] Ctr Dis Control & Prevent, Antifungal Drug Unit, Fungal Reference Unit, Mycot Dis Branch, Atlanta, GA USA. RP Olsen, GL (reprint author), Iowa Vet Specialties, Des Moines, IA 50321 USA. EM golsendvm@gmail.com NR 20 TC 3 Z9 3 U1 1 U2 6 PU AMER ANIMAL HOSPITAL ASSOC PI LAKEWOOD PA PO BOX 150899, LAKEWOOD, CO 80215-0899 USA SN 0587-2871 J9 J AM ANIM HOSP ASSOC JI J. Am. Anim. Hosp. Assoc. PD MAY-JUN PY 2012 VL 48 IS 3 BP 216 EP 220 DI 10.5326/JAAHA-MS-5813 PG 5 WC Veterinary Sciences SC Veterinary Sciences GA 940XO UT WOS:000303926600011 PM 22474053 ER PT J AU Goodwin, KD Taylor, MM Brown, ECF Winscott, M Scanlon, M Hodge, JG Mickey, T England, B AF Goodwin, Kimberly D. Taylor, Melanie M. Brown, Erin C. Fuse Winscott, Michelle Scanlon, Megan Hodge, James G., Jr. Mickey, Tom England, Bob TI Protecting Adolescents' Right to Seek Treatment for Sexually Transmitted Diseases without Parental Consent: The Arizona Experience with Senate Bill 1309 SO PUBLIC HEALTH REPORTS LA English DT Editorial Material ID UNITED-STATES; HEALTH; INFECTION; WOMEN AB In 2010, Senate Bill 1309 included language to repeal an existing Arizona law that enables minors younger than 18 years of age to seek diagnosis and treatment of sexually transmitted diseases (STDs) without parental consent. Numerous implications were identified that would have stemmed from parental consent provisions originally proffered in Senate Bill 1309. These implications included diminished access to essential health services among minors, exacerbated existing health disparities, increased health-care spending costs, and thwarted efforts to curb the spread of STDs. Lastly, minors would have been deprived of existing privacy protections concerning their STD-related medical information. This case study describes how collaborative advocacy efforts resulted in the successful amendment of Senate Bill 1309 to avert the negative sexual and reproductive health outcomes among adolescents stemming from the potential repeal of their existing legal right to seek STD treatment without parental consent. C1 [Goodwin, Kimberly D.; Mickey, Tom; England, Bob] Maricopa Cty Dept Publ Hlth, Phoenix, AZ 85012 USA. [Goodwin, Kimberly D.; Taylor, Melanie M.] Ctr Dis Control & Prevent, Div Publ Hlth Capac Dev, Atlanta, GA USA. [Taylor, Melanie M.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Brown, Erin C. Fuse; Scanlon, Megan; Hodge, James G., Jr.] Arizona State Univ, Sandra Day OConnor Coll Law, Publ Hlth Law & Policy Program, Tempe, AZ USA. [Winscott, Michelle] Mayo Clin, Scottsdale, AZ USA. RP Goodwin, KD (reprint author), Maricopa Cty Dept Publ Hlth, 4041 N Cent Ave,Ste 600, Phoenix, AZ 85012 USA. EM kimberlygoodwin@mail.maricopa.gov NR 16 TC 2 Z9 2 U1 0 U2 0 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2012 VL 127 IS 3 BP 253 EP 258 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 937ZK UT WOS:000303702500004 PM 22547855 ER PT J AU Papagiotas, SS Frank, M Bruce, S Posid, JM AF Papagiotas, Stephen S. Frank, Mark Bruce, Sherrie Posid, Joseph M. TI From SARS to 2009 H1N1 Influenza: The Evolution of a Public Health Incident Management System at CDC SO PUBLIC HEALTH REPORTS LA English DT Article AB The organization of the response to infectious disease outbreaks by public health agencies at the federal, state, and local levels has historically been based on traditional public health functions (e.g., epidemiology, surveillance, laboratory, infection control, and health communications). Federal guidance has established a framework for the management of domestic incidents, including public health emergencies. Therefore, public health agencies have had to find a way to incorporate traditional public health functions into the common response framework of the National Incident Management System. One solution is the development of a Science Section, containing public health functions, that is equivalent to the traditional incident command system sections. Public health agencies experiencing difficulties in developing incident management systems should consider the feasibility and suitability of creating a Science Section to allow a more seamless and effective coordination of a public health response, while remaining consistent with current federal guidance. C1 [Papagiotas, Stephen S.; Bruce, Sherrie; Posid, Joseph M.] Ctr Dis Control & Prevent, Off Infect Dis, Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, Atlanta, GA 30333 USA. [Frank, Mark] Ctr Dis Control & Prevent, Off Infect Dis, Influenza Coordinat Unit, Atlanta, GA 30333 USA. RP Papagiotas, SS (reprint author), Ctr Dis Control & Prevent, Off Infect Dis, Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, 1600 Clifton Rd NE,MS C-18, Atlanta, GA 30333 USA. EM spapagiotas@cdc.gov NR 3 TC 7 Z9 8 U1 0 U2 9 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2012 VL 127 IS 3 BP 267 EP 274 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 937ZK UT WOS:000303702500006 PM 22547857 ER PT J AU Newman, LM Dowell, D Bernstein, K Donnelly, J Martins, S Stenger, M Stover, J Weinstock, H AF Newman, Lori Marie Dowell, Deborah Bernstein, Kyle Donnelly, Jennifer Martins, Summer Stenger, Mark Stover, Jeffrey Weinstock, Hillard TI A Tale of Two Gonorrhea Epidemics: Results from the STD Surveillance Network SO PUBLIC HEALTH REPORTS LA English DT Article ID INFECTION AB Objective. An increasing proportion of gonorrhea in the United States is diagnosed in the private sector, posing a challenge to existing national surveillance systems. We described gonorrhea epidemiology outside sexually transmitted disease (STD) clinic settings. Methods. Through the STD Surveillance Network (SSuN), health departments in the San Francisco, Seattle, Denver, Minneapolis, and Richmond, Virginia, metropolitan areas interviewed systematic samples of men and women reported with gonorrhea by non-STD clinic providers from 2006 through 2008. Results. Of 2,138 interviews, 10.0% were from San Francisco, 26.4% were from Seattle, 25.2% were from Denver, 22.9% were from Minneapolis, and 15.5% were from Richmond. A total of 1,165 women were interviewed; 70.1% (815/1,163) were <= 24 years of age, 51.3% (598/1,165) were non-Hispanic black, and 19.0% (213/1,121) reported recent incarceration of self or sex partner. Among 610 men who have sex with only women, 50.9% were <= 24 years of age, 65.1% were non-Hispanic black, 14.1% reported incarceration of self or sex partner, and 16.7% reported anonymous sex. Among 363 men who have sex with men (MSM), 20.9% were <= 24 years of age, 61.6% were non-Hispanic white, 39.8% reported anonymous sex, 35.7% reported using the Internet to meet sex partners, and 12.1% reported methamphetamine use. Conclusions. These data identified two concurrent gonorrhea epidemics in minority populations: a young, black, heterosexual epidemic with frequently reported recent incarceration, and an older, mostly white MSM epidemic with more frequently reported anonymous sex, Internet use to meet sex partners, and methamphetamine use. C1 [Newman, Lori Marie; Dowell, Deborah; Weinstock, Hillard] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Bernstein, Kyle; Stenger, Mark; Stover, Jeffrey] STD Prevent & Control Serv, San Francisco Dept Publ Hlth, San Francisco, CA USA. [Donnelly, Jennifer] Colorado Dept Publ Hlth & Environm Dis Control &, Denver, CO USA. Washington State Dept Hlth, Infect Dis & Reprod Hlth Assessment Unit, Olympia, WA USA. Virginia Commonwealth Univ, Div Dis Prevent, Richmond, VA USA. Virginia Dept Hlth, Richmond, VA USA. RP Newman, LM (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd NE,MS E-02, Atlanta, GA 30333 USA. EM len4@cdc.gov FU Centers for Disease Control and Prevention (CDC) [AA-055]; San Francisco Department of Public Health; Colorado Department of Public Health and Environment; Minnesota Department of Health; Washington State Department of Health; Virginia Department of Health FX The STD Surveillance Network (SSuN) was established through funds by the Centers for Disease Control and Prevention (CDC) grant #AA-055. These activities were also supported in part by SSuN-participating state and city health departments: San Francisco Department of Public Health, Colorado Department of Public Health and Environment, Minnesota Department of Health, Washington State Department of Health, and Virginia Department of Health. NR 16 TC 11 Z9 11 U1 2 U2 7 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2012 VL 127 IS 3 BP 282 EP 292 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 937ZK UT WOS:000303702500008 PM 22547859 ER PT J AU Samoff, E Waller, A Fleischauer, A Ising, A Davis, MK Park, M Haas, SW DiBiase, L MacDonald, PDM AF Samoff, Erika Waller, Anna Fleischauer, Aaron Ising, Amy Davis, Meredith K. Park, Mike Haas, Stephanie W. DiBiase, Lauren MacDonald, Pia D. M. TI Integration of Syndromic Surveillance Data into Public Health Practice at State and Local Levels in North Carolina SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; SYSTEMS; DEPARTMENTS; CAPACITY AB Objectives. We sought to describe the integration of syndromic surveillance data into daily surveillance practice at local health departments (LHDs) and make recommendations for the effective integration of syndromic and reportable disease data for public health use. Methods. Structured interviews were conducted with local health directors and communicable disease nursing staff from a stratified random sample of LHDs from May through September 2009. Interviews captured information on direct access to the North Carolina syndromic surveillance system and on the use of syndromic surveillance information for outbreak management, program management, and the creation of reports. We analyzed syndromic surveillance system data to assess the number of signals resulting in a public health response. Results. Syndromic surveillance data were used for outbreak investigation (19% of respondents) and program management and report writing (43% of respondents); a minority reported use of both syndromic and reportable disease data for these purposes (15% and 23%, respectively). Receiving data from frequent system users was associated with using data for these purposes (p=0.016 and p=0.033, respectively, for syndromic and reportable disease data). A small proportion of signals (<25%) resulted in a public health response. Conclusions. Use of syndromic surveillance data by North Carolina local public health authorities resulted in meaningful public health action, including both case investigation and program management. While useful, the syndromic surveillance data system was oriented toward sensitivity rather than efficiency. Successful incorporation of new surveillance data is likely to require systems that are oriented toward efficiency. C1 [Samoff, Erika; Davis, Meredith K.; Park, Mike; DiBiase, Lauren; MacDonald, Pia D. M.] Univ N Carolina, Gillings Sch Global Publ Hlth, Inst Publ Hlth, Chapel Hill, NC USA. [Waller, Anna; Ising, Amy] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA. [Fleischauer, Aaron] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Fleischauer, Aaron] N Carolina Div Publ Hlth, Raleigh, NC USA. [Haas, Stephanie W.] Univ N Carolina, Sch Informat & Lib Sci, Chapel Hill, NC USA. [MacDonald, Pia D. M.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. RP Samoff, E (reprint author), NC DETECT, 100 Market St, Chapel Hill, NC 27516 USA. EM erika.samoff@unc.edu RI Haas, Stephanie/O-7765-2015 FU Centers for Disease Control and Prevention (CDC) [PO1 TP 000296-02] FX This research was carried out by the North Carolina Preparedness and Emergency Response Research Center, which is part of The University of North Carolina (UNC) Center for Public Health Preparedness at The UNC at Chapel Hill's Gillings School of Global Public Health, and was supported by Grant/Cooperative Agreement #PO1 TP 000296-02 from the Centers for Disease Control and Prevention (CDC). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of CDC. The survey was exempted from review by the Institutional Review Board of The UNC at Chapel Hill. NR 21 TC 6 Z9 6 U1 0 U2 3 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2012 VL 127 IS 3 BP 310 EP 317 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 937ZK UT WOS:000303702500011 PM 22547862 ER PT J AU Clark, TA Messonnier, NE Nadler, SC AF Clark, Thomas A. Messonnier, Nancy E. Nadler, Stephen C. TI Pertussis control: time for something new? SO TRENDS IN MICROBIOLOGY LA English DT Editorial Material DE pertussis; vaccines; epidemiology ID VACCINE EFFECTIVENESS; BORDETELLA-PERTUSSIS; ADULT TETANUS; UNITED-STATES; ADOLESCENT; DIPHTHERIA; IMMUNIZATION; AUSTRALIA; IMMUNITY; IMPACT AB Childhood acellular pertussis vaccines were licensed and implemented in the US in the 1990s following an effort to improve on the safety profile of whole-cell vaccines. However, waning of immunity from acellular vaccines may be driving the recent resurgence of pertussis, raising the need to consider new prevention strategies. C1 [Clark, Thomas A.; Messonnier, Nancy E.; Nadler, Stephen C.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA 30333 USA. RP Clark, TA (reprint author), Ctr Dis Control & Prevent, Div Bacterial Dis, 1600 Clifton Rd,Mailstop C-25, Atlanta, GA 30333 USA. EM tnc4@cdc.gov NR 15 TC 46 Z9 49 U1 0 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0966-842X J9 TRENDS MICROBIOL JI Trends Microbiol. PD MAY PY 2012 VL 20 IS 5 BP 211 EP 213 DI 10.1016/j.tim.2012.03.003 PG 3 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA 941LF UT WOS:000303964000002 PM 22494804 ER PT J AU Bay, B Stovring, H Wimberley, T Denny, CH Mortensen, EL Eriksen, HLF Kesmodel, US AF Bay, Bjorn Stovring, Henrik Wimberley, Theresa Denny, Clark H. Mortensen, Erik L. Eriksen, Hanne-Lise F. Kesmodel, Ulrik S. TI Low to Moderate Alcohol Intake During Pregnancy and Risk of Psychomotor Deficits SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Pregnancy; Prenatal Alcohol Exposure; Fetal Development; Motor Function ID MOVEMENT ASSESSMENT BATTERY; DEVELOPMENTAL COORDINATION DISORDERS; PRENATAL ALCOHOL; FETAL ALCOHOL; FOLLOW-UP; MOTOR-PERFORMANCE; MATCHED CONTROLS; BINGE DRINKING; CHILDREN; EXPOSURE AB Background: To examine the effects of low to moderate alcohol consumption during pregnancy on child motor function at age 5. Methods: A prospective follow-up study of 685 women and their children sampled from the Danish National Birth Cohort based on maternal alcohol consumption during pregnancy. At 5 years of age, the children were tested with the Movement Assessment Battery for Children (MABC). Parental education, maternal IQ, prenatal maternal smoking, the childs age at testing, and gender of child were considered core confounders, while the full model also controlled for prenatal maternal binge drinking episodes, age, maternal prepregnancy body mass index, parity, home environment, postnatal parental smoking, health status, and indicators for hearing and vision impairment. Results: There were no systematic or significant differences in motor function between children of mothers reporting low to moderate levels of average alcohol consumption during pregnancy and children of mothers who abstained. Conclusions: In this study, we found no systematic association between low to moderate maternal alcohol intake during pregnancy and child motor function at age 5. C1 [Bay, Bjorn; Eriksen, Hanne-Lise F.; Kesmodel, Ulrik S.] Aarhus Univ, Sch Publ Hlth, Dept Epidemiol, DK-8000 Aarhus C, Denmark. [Stovring, Henrik; Wimberley, Theresa] Aarhus Univ, Sch Publ Hlth, Dept Biostat, DK-8000 Aarhus C, Denmark. [Denny, Clark H.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Mortensen, Erik L.] Univ Copenhagen, Inst Publ Hlth, Copenhagen, Denmark. RP Bay, B (reprint author), Aarhus Univ, Sch Publ Hlth, Dept Epidemiol, Bartholins Alle 2, DK-8000 Aarhus C, Denmark. EM bjornbay@me.com RI Stovring, Henrik/I-4683-2012; OI Stovring, Henrik/0000-0002-5821-2351; Mortensen, Erik Lykke/0000-0002-6985-451X FU Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA FX This study was primarily supported by the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. Additional support was obtained from the Danish Research Council. The Danish National Research Foundation has established the Danish Epidemiology Science Centre that initiated and created the Danish National Birth Cohort. The cohort was furthermore a result of a major grant from this Foundation. Additional support for the Danish National Birth Cohort was obtained from the Pharmacy Foundation, the Egmont Foundation, the March of Dimes Birth Defects Foundation, the Augustinus Foundation, and the Health Foundation. The authors would like to thank all the participants for their time. NR 39 TC 10 Z9 10 U1 1 U2 14 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2012 VL 36 IS 5 BP 807 EP 814 DI 10.1111/j.1530-0277.2011.01657.x PG 8 WC Substance Abuse SC Substance Abuse GA 933UJ UT WOS:000303388500008 PM 21995343 ER PT J AU Lee, GM Hartmann, CW Graham, D Kassler, W Linn, MD Krein, S Saint, S Goldmann, DA Fridkin, S Horan, T Jernigan, J Jha, A AF Lee, Grace M. Hartmann, Christine W. Graham, Denise Kassler, William Linn, Maya Dutta Krein, Sarah Saint, Sanjay Goldmann, Donald A. Fridkin, Scott Horan, Teresa Jernigan, John Jha, Ashish TI Perceived impact of the Medicare policy to adjust payment for health care-associated infections SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Non-payment for preventable complications; Unintended consequences; Organizational culture; Organizational resources ID URINARY-TRACT-INFECTION; QUALITY IMPROVEMENT; UNITED-STATES; PERFORMANCE; PAY; REIMBURSEMENT; NONPAYMENT; PREVENTION; OUTCOMES; CONTEXT AB Background: In 2008, the Centers for Medicare and Medicaid Services (CMS) ceased additional payment for hospitalizations resulting in complications deemed preventable, including several health care-associated infections. We sought to understand the impact of the CMS payment policy on infection prevention efforts. Methods: A national survey of infection preventionists from a random sample of US hospitals was conducted in December 2010. Results: Eighty-one percent reported increased attention to HAIs targeted by the CMS policy, whereas one-third reported spending less time on nontargeted HAIs. Only 15% reported increased funding for infection control as a result of the CMS policy, whereas most reported stable (77%) funding. Respondents reported faster removal of urinary (71%) and central venous (50%) catheters as a result of the CMS policy, whereas routine urine and blood cultures on admission occurred infrequently (27% and 13%, respectively). Resource shifting (ie, less time spent on nontargeted HAIs) occurred more commonly in large hospitals (odds ratio, 2.3; 95% confidence interval: 1.0-5.1; P = .038) but less often in hospitals where front-line staff were receptive to changes in clinical processes (odds ratio, 0.5; 95% confidence interval: 0.3-0.8; P = .005). Conclusion: Infection preventionists reported greater hospital attention to preventing targeted HAIs as a result of the CMS nonpayment policy. Whether the increased focus and greater engagement in HAI prevention practices has led to better patient outcomes is unclear. Copyright (C) 2012 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Lee, Grace M.; Linn, Maya Dutta] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. [Lee, Grace M.; Linn, Maya Dutta] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Lee, Grace M.] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA. [Lee, Grace M.] Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Hartmann, Christine W.] Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Hartmann, Christine W.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Graham, Denise] Assoc Profess Infect Control & Epidemiol, Washington, DC USA. [Kassler, William] Ctr Medicare Serv, Boston, MA USA. [Kassler, William] Ctr Medicaid Serv, Boston, MA USA. [Krein, Sarah; Saint, Sanjay] Ann Arbor VA Med Ctr, Ann Arbor, MI USA. [Krein, Sarah; Saint, Sanjay] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Goldmann, Donald A.] Inst Healthcare Improvement, Cambridge, MA USA. [Fridkin, Scott; Horan, Teresa; Jernigan, John] Ctr Dis Control & Prevent, Div Healthcare Qual & Promot, Atlanta, GA USA. [Jha, Ashish] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. RP Lee, GM (reprint author), Harvard Pilgrim Hlth Care, Dept Populat Med, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA. EM grace.lee@childrens.harvard.edu RI Krein, Sarah/E-2742-2014 OI Krein, Sarah/0000-0003-2111-8131 FU National Institute of Allergy and Infectious Diseases [R21AI083888] FX The project was funded by award number R21AI083888 (to G.M.L.) from the National Institute of Allergy and Infectious Diseases, which did not play a role in the design, conduct of the study, collection, management, analysis, data interpretation, preparation, review, or approval of the manuscript. NR 37 TC 16 Z9 16 U1 1 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAY PY 2012 VL 40 IS 4 BP 314 EP 319 DI 10.1016/j.ajic.2011.11.003 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 934CJ UT WOS:000303418400008 PM 22541855 ER PT J AU Perry, J Jagger, J Parker, G Phillips, EK Gomaa, A AF Perry, Jane Jagger, Janine Parker, Ginger Phillips, Elayne Kornblatt Gomaa, Ahmed TI Disposal of sharps medical waste in the United States: Impact of recommendations and regulations, 1987-2007 SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Needlestick; Bloodborne pathogen exposure; Health care worker safety; Percutaneous injury ID PREVENTION AB Background: To gauge the impact of regulatory-driven improvements in sharps disposal practices in the United States over the last 2 decades, we analyzed percutaneous injury (PI) data from a national surveillance network from 2 periods, 1993-1994 and 2006-2007, to see whether changes in disposal-related injury patterns could be detected. Methods: Data were derived from the EPINet Sharps Injury Surveillance Research Group, established in 1993 and coordinated by the International Healthcare Worker Safety Center at the University of Virginia. For the period 1993-1994, 69 hospitals contributed data; the combined average daily census for the 2 years was 24,495, and the total number of PIs reported was 7,854. For the period 2006-2007, 33 hospitals contributed data; the combined average daily census was 6,800, and the total number of PIs reported was 1901. Results: In 1992-1993, 36.8% of PIs reported were related to disposal of sharp devices. In 2006-2007, this proportion was 19.3%, a 53% decline. Conclusions: This comparison provides evidence that implementation of point-of-use, puncture-resistant sharps disposal containers, combined with large-scale use of safety-engineered sharp devices, has resulted in a marked decline in sharps disposal-related injury rates in the United States. The protocol for removing and replacing full sharps disposal containers remains a critical part of disposal safety. Copyright (C) 2012 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Perry, Jane; Jagger, Janine; Parker, Ginger; Phillips, Elayne Kornblatt] Univ Virginia Hlth Syst, Dept Med, Div Infect Dis, Int Healthcare Worker Safety Ctr, Charlottesville, VA USA. [Gomaa, Ahmed] NIOSH, Surveillance Branch, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Perry, J (reprint author), Univ Virginia, IHWSC, POB 800764, Charlottesville, VA 22908 USA. EM janeperry@virginia.edu FU National Institute for Occupational Safety and Health [211-2009-M-29912] FX This article was written as part of a larger research project on sharps disposal and sharps disposal containers in the United States and other countries, produced under contract to the National Institute for Occupational Safety and Health (Requisition 211-2009-M-29912). NR 16 TC 9 Z9 10 U1 1 U2 11 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAY PY 2012 VL 40 IS 4 BP 354 EP 358 DI 10.1016/j.ajic.2011.04.328 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 934CJ UT WOS:000303418400017 PM 21824683 ER PT J AU Bergman, MS Viscusi, DJ Zhuang, ZQ Palmiero, AJ Powell, JB Shaffer, RE AF Bergman, Michael S. Viscusi, Dennis J. Zhuang, Ziqing Palmiero, Andrew J. Powell, Jeffrey B. Shaffer, Ronald E. TI Impact of multiple consecutive donnings on filtering facepiece respirator fit SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Respiratory protection; Fit test; Health care worker; N95 respirator fit; Multiple donnings; Respirator reuse ID PERFORMANCE; ERRORS AB Background: A concern with reuse of National Institute for Occupational Safety and Health-certified N95 filtering facepiece respirators (FFRs) is that multiple donnings could stress FFR components, impairing fit. This study investigated the impact of multiple donnings on the facepiece fit of 6 N95 FFR models using a group of 10 experienced test subjects per model. Methods: The TSI PORTACOUNT Plus and N95 Companion accessory were used for all tests. After qualifying by passing a standard Occupational Safety and Health Administration fit test, subjects performed up to 20 consecutive tests on an individual FFR sample using a modified protocol. Regression analyses were performed for the percentage of donnings resulting in fit factors (FFs) > 100 for all 6 FFR models combined. Results: Regression analyses showed statistical significance for donning groups 1-10, 1-15, and 1-20. The mean percentage of donnings with an FF >= 100 was 81%-93% for donning group 1-5, but dropped to 53%-75% for donning group 16-20. Conclusions: Our results show that multiple donnings had a model-dependent impact on fit for the 6 N95 models evaluated. The data suggest that 5 consecutive donnings can be performed before FFs consistently drop below 100. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Shaffer, Ronald E.] NIOSH, Technol Res Branch, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, Pittsburgh, PA 15236 USA. [Bergman, Michael S.; Palmiero, Andrew J.] URS Corp, Pittsburgh, PA USA. RP Shaffer, RE (reprint author), NIOSH, Technol Res Branch, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, 626 Cochrans Mill Rd,Bldg 29,POB 18070, Pittsburgh, PA 15236 USA. EM RShaffer@cdc.gov RI Shaffer, Ronald/I-2134-2012; Zhuang, Ziqing/K-5462-2012 NR 22 TC 6 Z9 6 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAY PY 2012 VL 40 IS 4 BP 375 EP 380 DI 10.1016/j.ajic.2011.05.003 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 934CJ UT WOS:000303418400021 PM 21864945 ER PT J AU Russo, ET Sheth, A Menon, M Wannemuehler, K Weinger, M Kudzala, AC Tauzie, B Masuku, HD Msowoya, TE Quick, R AF Russo, Elizabeth T. Sheth, Anandi Menon, Manoj Wannemuehler, Kathleen Weinger, Merri Kudzala, Amose C. Tauzie, Blessius Masuku, Humphreys D. Msowoya, Tapona E. Quick, Robert TI Water Treatment and Handwashing Behaviors among Non-Pregnant Friends and Relatives of Participants in an Antenatal Hygiene Promotion Program in Malawi SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID WESTERN KENYA; INTERVENTIONS; DIFFUSION; COUNTRIES; DIARRHEA; CHILDREN AB Access to safe drinking water and improved hygiene are essential for preventing diarrhea! diseases. To integrate hygiene improvement with antenatal care, free hygiene kits (water storage containers, water treatment solution, soap) and educational messages were distributed to pregnant women at antenatal clinics in Malawi. We assessed water treatment and hygiene practices of 275 non-pregnant friends and relatives of the hygiene kit recipients at baseline and follow-up nine months later to measure program impact on non-participants in the same communities. At follow-up, friends and relatives who did not receive kits or education were more likely than at baseline to purchase and use water treatment solution (25% versus 1%; P < 0.0001) and demonstrate correct handwashing practices (60% versus 18%; P < 0.0001). This antenatal clinic based program resulted in improved water treatment and hygiene behaviors among non-pregnant friends and relatives living in the same communities as hygiene kit recipients, suggesting that program benefits extended beyond direct beneficiaries. C1 [Quick, Robert] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Russo, Elizabeth T.; Sheth, Anandi; Menon, Manoj] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Weinger, Merri] US Agcy Int Dev, Arlington, VA USA. [Kudzala, Amose C.; Tauzie, Blessius; Msowoya, Tapona E.] United Nations Childrens Fund, New York, NY USA. [Masuku, Humphreys D.] Govt Malawi Minist Hlth, Blantyre, Malawi. RP Quick, R (reprint author), Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30333 USA. EM elizabeth.russo@gmail.com; asheth@cdc.gov; mmenon@gmail.com; kpw9@cdc.gov; mweinger@usaid.gov; akudzala@unicef.org; btauzie@unicef.org; dzanjom@yahoo.co.uk; tmsowoya@unicef.org; rquick@cdc.gov FU United States Agency for International Development FX This study was supported by the United States Agency for International Development. NR 19 TC 6 Z9 6 U1 2 U2 6 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2012 VL 86 IS 5 BP 860 EP 865 DI 10.4269/ajtmh.2012.11-0259 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 935WY UT WOS:000303554100023 PM 22556088 ER PT J AU Gibney, KB Colborn, J Baty, S Patterson, AMB Sylvester, T Briggs, G Stewart, T Levy, C Komatsu, K MacMillan, K Delorey, MJ Mutebi, JP Fischer, M Staples, JE AF Gibney, Katherine B. Colborn, James Baty, Steven Patterson, Andrean M. Bunko Sylvester, Tammy Briggs, Graham Stewart, Tasha Levy, Craig Komatsu, Ken MacMillan, Katherine Delorey, Mark J. Mutebi, John-Paul Fischer, Marc Staples, J. Erin TI Modifiable Risk Factors for West Nile Virus Infection during an Outbreak - Arizona, 2010 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ST-LOUIS ENCEPHALITIS; CULEX MOSQUITOS DIPTERA; DENGUE-FEVER; NEW-YORK; EPIDEMIC; CALIFORNIA; DISEASE; COUNTY; CULICIDAE; AREA AB West Nile virus (WNV) is the leading cause of mosquito-borne disease in the United States; however, risk factors for infection are poorly defined. We performed a case-control study to identify modifiable risk factors for WNV infection. Case-patients (N = 49) had laboratory evidence of recent WNV infection, whereas control-subjects (N = 74) had negative WNV serology. We interviewed participants, surveyed households, and assessed environmental data. WNV infection was associated with living in or near Water District X within Gilbert Township (adjusted odds ratio [aOR] 5.2; 95% confidence interval [95% CI] = 1.5-18.1), having water-holding containers in their yard (aOR 5.0; 95% Cl = 1.5-17.3), and not working or attending school outside the home (aOR 2.4; 95% CT = 1.1-5.5). During this outbreak, WNV infection was likely primarily acquired pen-domestically with increased risk associated with potential mosquito larval habitats around the home and neighborhood. C1 Ctr Dis Control & Prevent CDC, Div Vector Borne Dis, Ft Collins, CO USA. CDC, Epidem Intelligence Serv Program, Atlanta, GA 30333 USA. Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA. Pinal Cty Div Publ Hlth, Florence, AZ USA. RP Staples, JE (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM AUV1@cdc.gov OI Gibney, Katherine/0000-0001-5851-5339 NR 32 TC 10 Z9 11 U1 1 U2 13 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD MAY PY 2012 VL 86 IS 5 BP 895 EP 901 DI 10.4269/ajtmh.2012.11-0502 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 935WY UT WOS:000303554100028 PM 22556093 ER PT J AU Higgins, J Stuber, T Quance, C Edwards, WH Tiller, RV Linfield, T Rhyan, J Berte, A Harris, B AF Higgins, James Stuber, Tod Quance, Christine Edwards, William H. Tiller, Rebekah V. Linfield, Tom Rhyan, Jack Berte, Angela Harris, Beth TI Molecular Epidemiology of Brucella abortus Isolates from Cattle, Elk, and Bison in the United States, 1998 to 2011 SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID GREATER YELLOWSTONE ECOSYSTEM; TANDEM-REPEAT MARKERS; FREE-RANGING ELK; VACCINE STRAINS; NATIONAL-PARK; NUMBER; IDENTIFICATION; ASSAY; INFECTION; PCR AB A variable-number tandem repeat (VNTR) protocol targeting 10 loci in the Brucella abortus genome was used to assess genetic diversity among 366 field isolates recovered from cattle, bison, and elk in the Greater Yellowstone Area (GYA) and Texas during 1998 to 2011. Minimum spanning tree (MST) and unweighted-pair group method with arithmetic mean (UPGMA) analyses of VNTR data identified 237 different VNTR types, among which 14 prominent clusters of isolates could be identified. Cattle isolates from Texas segregated into three clusters: one comprised of field isolates from 1998 to 2005, one comprised of vaccination-associated infections, and one associated with an outbreak in Starr County in January 2011. An isolate obtained from a feral sow trapped on property adjacent to the Starr County herd in May 2011 clustered with the cattle isolates, suggesting a role for feral swine as B. abortus reservoirs in Starr County. Isolates from a 2005 cattle outbreak in Wyoming displayed VNTR-10 profiles matching those of strains recovered from Wyoming and Idaho elk. Additionally, isolates associated with cattle outbreaks in Idaho in 2002, Montana in 2008 and 2011, and Wyoming in 2010 primarily clustered with isolates recovered from GYA elk. This study indicates that elk play a predominant role in the transmission of B. abortus to cattle located in the GYA. C1 [Higgins, James; Stuber, Tod; Quance, Christine; Berte, Angela; Harris, Beth] USDA APHIS, Natl Vet Serv Labs, Mycobacteria & Brucella Sect, Ames, IA USA. [Edwards, William H.] Wyoming Game & Fish Dept, Laramie, WY USA. [Tiller, Rebekah V.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Linfield, Tom] USDA APHIS Vet Serv, Helena, MT USA. [Rhyan, Jack] USDA APHIS Vet Serv, Ft Collins, CO USA. RP Higgins, J (reprint author), USDA APHIS, Natl Vet Serv Labs, Mycobacteria & Brucella Sect, Ames, IA USA. EM James.A.Higgins@aphis.usda.gov NR 29 TC 14 Z9 14 U1 0 U2 13 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD MAY PY 2012 VL 78 IS 10 BP 3674 EP 3684 DI 10.1128/AEM.00045-12 PG 11 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 935WW UT WOS:000303553900019 PM 22427502 ER PT J AU Reveille, JD Hirsch, R Dillon, CF Carroll, MD Weisman, MH AF Reveille, John D. Hirsch, Rosemarie Dillon, Charles F. Carroll, Margaret D. Weisman, Michael H. TI The prevalence of HLA-B27 in the US: Data from the US National Health and Nutrition Examination Survey, 2009 SO ARTHRITIS AND RHEUMATISM LA English DT Article ID ANKYLOSING-SPONDYLITIS; SUBTYPES AB Objective To carry out the first large-scale population study of the prevalence of HLAB27 in the US, which is needed for public health planning purposes because of recent improvements in medical therapy and diagnostic testing for ankylosing spondylitis (AS). Methods The national prevalence of HLAB27 was determined as part of the 2009 US National Health and Nutrition Examination Survey (NHANES), a cross-sectional survey monitoring the health and nutritional status of the US civilian, noninstitutionalized population. DNA polymerase chain reaction analysis was conducted in samples from 2,320 adults ages 2069 years from this nationally representative sample. Results The age-adjusted US prevalence of B27 was 6.1% (95% confidence interval [95% CI] 4.68.2). By race/ethnicity, the prevalence of B27 was 7.5% (95% CI 5.310.4) among non-Hispanic whites and 3.5% (95% CI 2.54.8) among all other US races/ethnicities combined. In Mexican Americans, the prevalence was 4.6% (95% CI 3.46.1). The prevalence of B27 could not be reliably estimated for other US racial/ethnic groups because of the low number of B27-positive individuals in those groups. For adults 5069 years of age, the prevalence of B27 was 3.6% (95% CI 2.25.8), which suggested a decrease in B27 with age. These prevalence estimates took into account the NHANES survey design and are reviewed with respect to data from the medical literature. Conclusion Our findings provide the first US national prevalence estimates for HLAB27. A decline in the prevalence of HLAB27 with age is suggested by these data but must be confirmed by additional studies. C1 [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Div Rheumatol, Houston, TX 77030 USA. [Hirsch, Rosemarie; Dillon, Charles F.; Carroll, Margaret D.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Weisman, Michael H.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RP Reveille, JD (reprint author), Univ Texas Hlth Sci Ctr Houston, Div Rheumatol, 6431 Fannin St,MSB 5-270, Houston, TX 77030 USA. EM John.D.Reveille@uth.tmc.edu FU CDC; CDC Foundation through Spondyloarthritis Association of America; Spondyloarthritis Research and Treatment Network; Spondylitis Association of America (SAA); Spondyloarthritis Research and Treatment Network (SPARTAN) FX Supported by the CDC, the CDC Foundation (through an unrestricted grant from the Spondyloarthritis Association of America), and the Spondyloarthritis Research and Treatment Network.; The efforts of the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN) to help support and field the 2009 NHANES study are gratefully acknowledged. Also especially acknowledged is the generous voluntary participation of the US residents who have given their personal time to make the NHANES surveys possible. NR 10 TC 27 Z9 29 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD MAY PY 2012 VL 64 IS 5 BP 1407 EP 1411 DI 10.1002/art.33503 PG 5 WC Rheumatology SC Rheumatology GA 931SG UT WOS:000303239000015 PM 22139851 ER PT J AU Rogowski, WH Grosse, SD Meyer, E John, J Palmer, S AF Rogowski, W. H. Grosse, S. D. Meyer, E. John, J. Palmer, S. TI Using value of information analysis in decision making about applied research SO BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ LA German DT Article DE Value of information; Cost-effectiveness; Hereditary hemochromatosis; Translational research; Adherence ID ADJUSTED LIFE-YEAR; HEREDITARY HEMOCHROMATOSIS; COST-EFFECTIVENESS; HEALTH-CARE; ECONOMIC-EVALUATION; PROGRAM; INTERVENTION; POPULATION; MEDICINE; SCIENCE AB Public decision makers face demands to invest in applied research in order to accelerate the adoption of new genetic tests. However, such an investment is profitable only if the results gained from further investigations have a significant impact on health care practice. An upper limit for the value of additional information aimed at improving the basis for reimbursement decisions is given by the expected value of perfect information (EVPI). This study illustrates the significance of the concept of EVPI on the basis of a probabilistic cost-effectiveness model of screening for hereditary hemochromatosis among German men. In the present example, population-based screening can barely be recommended at threshold values of 50,000 or 100,000 Euro per life year gained and also the value of additional research which might cause this decision to be overturned is small: At the mentioned threshold values, the EVPI in the German public health care system was ca. 500,000 and 2,200,000 Euro, respectively. An analysis of EVPI by individual parameters or groups of parameters shows that additional research about adherence to preventive phlebotomy could potentially provide the highest benefit. The potential value of further research also depends on methodological assumptions regarding the decision maker's time horizon as well as on scenarios with an impact on the number of affected patients and the cost-effectiveness of screening. C1 [Rogowski, W. H.; Meyer, E.; John, J.] Deutsch Forschungszentrum Gesundheit & Umwelt Gmb, Inst Gesundheitsokon & Management Gesundheitswese, Helmholtz Zentrum Munchen, D-85758 Neuherberg, Germany. [Rogowski, W. H.] Klinikum Ludwig Maximilians Univ, Inst & Poliklin Arbeits Sozial & Umweltmed, Munich, Germany. [Palmer, S.] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England. [Grosse, S. D.] CDC Ctr Dis Control & Prevent, Atlanta, GA USA. RP Rogowski, WH (reprint author), Deutsch Forschungszentrum Gesundheit & Umwelt Gmb, Inst Gesundheitsokon & Management Gesundheitswese, Helmholtz Zentrum Munchen, Postfach 1129, D-85758 Neuherberg, Germany. EM rogowski@helmholtz-muenchen.de RI Rogowski, Wolf/D-9334-2013 NR 38 TC 3 Z9 3 U1 0 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1436-9990 J9 BUNDESGESUNDHEITSBLA JI Bundesgesundheitsblatt-Gesund. PD MAY PY 2012 VL 55 IS 5 BP 700 EP 709 DI 10.1007/s00103-012-1474-7 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 933GG UT WOS:000303348000013 PM 22526859 ER PT J AU Reding, KW Chen, C Lowe, K Doody, DR Carlson, CS Chen, CT Houck, J Weiss, LK Marchbanks, PA Bernstein, L Spirtas, R McDonald, JA Strom, BL Burkman, RT Simon, MS Liff, JM Daling, JR Malone, KE AF Reding, Kerryn W. Chen, Chu Lowe, Kimberly Doody, David R. Carlson, Christopher S. Chen, Christina T. Houck, John Weiss, Linda K. Marchbanks, Polly A. Bernstein, Leslie Spirtas, Robert McDonald, Jill A. Strom, Brian L. Burkman, Ronald T. Simon, Michael S. Liff, Jonathan M. Daling, Janet R. Malone, Kathleen E. TI Estrogen-related genes and their contribution to racial differences in breast cancer risk SO CANCER CAUSES & CONTROL LA English DT Article DE Breast cancer; Genetic variation; Racial disparities; Gene-environment interactions; Hormone therapy ID HORMONE-REPLACEMENT THERAPY; AFRICAN-AMERICAN WOMEN; MULTILOCUS GENOTYPE DATA; POPULATION-STRUCTURE; RECEPTOR STATUS; REPRODUCTIVE EXPERIENCES; TUMOR CHARACTERISTICS; METABOLISM GENOTYPES; ENDOGENOUS HORMONES; MULTIETHNIC COHORT AB Racial differences in breast cancer risk, including the risks of hormone receptor subtypes of breast cancer, have been previously reported. We evaluated whether variation in genes related to estrogen metabolism (COMT, CYP1A1, CYP1B1, CYP17A1, CYP19A1, ESR1, GSTM1, GSTP1, GSTT1, HSD17B1, SULT1A1, and UGT1A1) contributes to breast cancer risk and/or racial differences in risk within the CARE study, a multi-centered, population-based case-control study of breast cancer. Genetic variation was assessed as single nucleotide polymorphisms (SNPs), haplotypes, and SNP-hormone therapy (HT) interactions within a subset of 1,644 cases and 1,451 controls, including 949 Black women (493 cases and 456 controls), sampled from the CARE study population. No appreciable associations with breast cancer risk were detected for single SNPs or haplotypes in women overall. We detected SNP-HT interactions in women overall within CYP1B1 (rs1800440; p (het) = 0.003) and within CYP17A1 (rs743572; p (het) = 0.009) in which never users of HT were at a decreased risk of breast cancer, while ever users were at a non-significant increased risk. When investigated among racial groups, we detected evidence of an SNP-HT interaction with CYP1B1 in White women (p value = 0.02) and with CYP17A1 in Black women (p value = 0.04). This analysis suggests that HT use may modify the effect of variation in estrogen-related genes on breast cancer risk, which may affect Black and White women to a different extent. C1 [Reding, Kerryn W.; Chen, Chu; Doody, David R.; Carlson, Christopher S.; Chen, Christina T.; Houck, John; Daling, Janet R.; Malone, Kathleen E.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Reding, Kerryn W.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Chen, Chu; Carlson, Christopher S.; Malone, Kathleen E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Lowe, Kimberly] Exponent, Seattle, WA USA. [Weiss, Linda K.] NCI, Canc Ctr Program, Rockville, MD USA. [Marchbanks, Polly A.; McDonald, Jill A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA. [Spirtas, Robert] George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC USA. [Strom, Brian L.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Strom, Brian L.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Burkman, Ronald T.] Baystate Hlth, Dept Obstet & Gynecol, Springfield, MA USA. [Simon, Michael S.] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA. [Liff, Jonathan M.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Reding, KW (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,Mail Stop M4-B874, Seattle, WA 98109 USA. EM kreding@u.washington.edu FU National Institute of Child Health and Human Development; National Cancer Institute, through Emory University [N01 HD 3-3168]; Fred Hutchinson Cancer Research Center [N01 HD 2-3166]; Karmanos Cancer Institute at Wayne State University [N01 HD 3-3174]; University of Pennsylvania [N01 HD-3-3176]; University of Southern California [N01 HD 3-3175]; Centers for Disease Control and Prevention [Y01 HD 7022]; National Cancer Institute [R03 CA 123584]; Cancer Epidemiology and Biostatistics Training Grant [2 T32 CA 09168]; NINR [K99NR012232] FX The authors would like to thank the study participants for their contribution to this research. The CARE study was supported by the National Institute of Child Health and Human Development, with additional support from the National Cancer Institute, through contracts with Emory University (N01 HD 3-3168), the Fred Hutchinson Cancer Research Center (N01 HD 2-3166), Karmanos Cancer Institute at Wayne State University (N01 HD 3-3174), the University of Pennsylvania (N01 HD-3-3176), and the University of Southern California (N01 HD 3-3175) and through an intraagency agreement with the Centers for Disease Control and Prevention (Y01 HD 7022). The research generating the AIMs data was supported by the National Cancer Institute (R03 CA 123584). KWR was supported by the Cancer Epidemiology and Biostatistics Training Grant (2 T32 CA 09168) and NINR grant K99NR012232. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the National Institutes of Health or the Centers for Disease Control and Prevention. This research was supported by funding from the National Institute of Child Health and Human Development with additional support from the Centers for Disease Control and Prevention and the National Cancer Institute. NR 72 TC 18 Z9 19 U1 0 U2 9 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2012 VL 23 IS 5 BP 671 EP 681 DI 10.1007/s10552-012-9925-x PG 11 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 934CI UT WOS:000303418200002 PM 22418777 ER PT J AU Hoffman, HJ Dobie, RA Ko, CW Themann, CL Murphy, WJ AF Hoffman, Howard J. Dobie, Robert A. Ko, Chia-Wen Themann, Christa L. Murphy, William J. TI Hearing Threshold Levels at Age 70 Years (65-74 Years) in the Unscreened Older Adult Population of the United States, 1959-1962 and 1999-2006 SO EAR AND HEARING LA English DT Article AB Objectives: To provide hearing threshold percentiles from unscreened older adults for creating new Annex B reference standards. Design: Percentiles are calculated, and 95% confidence intervals for medians from two U. S. surveys are compared graphically. Results: Median thresholds are lower (better) in the 1999-2006 National Health and Nutrition Examination Survey for men across all frequencies except 1 kHz. Results for women are similar; however, there is more overlap in confidence intervals across frequencies. Conclusions: The prevalence of hearing impairment in older adults, age 70 years (65-74 years), is lower in 1999-2006 compared with 19591962, consistent with our earlier findings for younger adults. C1 [Hoffman, Howard J.] Natl Inst Deafness & Other Commun Disorders, Epidemiol & Stat Program, NIH, Bethesda, MD 20892 USA. [Dobie, Robert A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Otolaryngol Head & Neck Surg, San Antonio, TX 78229 USA. [Ko, Chia-Wen] US FDA, Off Translat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Themann, Christa L.; Murphy, William J.] NIOSH, Hearing Loss Prevent Team, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Hoffman, HJ (reprint author), Natl Inst Deafness & Other Commun Disorders, Epidemiol & Stat Program, NIH, Suite 400A,Execut Plaza S Bldg,6120 Execut Blvd, Bethesda, MD 20892 USA. EM hoffmanh@nidcd.nih.gov FU National Institute on Deafness and Other Communication Disorders; National Institute for Occupational Safety and Health FX The National Health and Nutrition Examination Survey 1999-2006 audiometric data collection was funded with National Institute on Deafness and Other Communication Disorders research contract funds via an Interagency Agreement between the National Institute on Deafness and Other Communication Disorders and the National Center for Health Statistics. The National Institute for Occupational Safety and Health provided funding for the audiometric testing equipment, training and monitoring of technicians, and editing of preliminary data files. The National Institute for Occupational Safety and Healt collaboration was funded and managed via Interagency Agreements with the National Institute on Deafness and Other Communication Disorders and the National Center for Health Statistics. Audiometric testing was conducted in the field by health technicians employed by Westat, Inc., under contract with the National Center for Health Statistics. NR 15 TC 15 Z9 15 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 J9 EAR HEARING JI Ear Hear. PD MAY-JUN PY 2012 VL 33 IS 3 BP 437 EP 440 DI 10.1097/AUD.0b013e3182362790 PG 4 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 934OT UT WOS:000303454400013 PM 22080933 ER PT J AU Pichel, M Brengi, SP Cooper, KLF Ribot, EM Al-Busaidy, S Araya, P Fernandez, J Vaz, TI Kam, KM Morcos, M Nielsen, EM Nadon, C Pimentel, G Perez-Gutierrez, E Gerner-Smidt, P Binsztein, N AF Pichel, Mariana Brengi, Silvina P. Cooper, Kara L. F. Ribot, Efrain M. Al-Busaidy, Suleiman Araya, Pamela Fernandez, Jorge Vaz, Tania Ibelli Kam, Kai Man Morcos, Myriam Nielsen, Eva M. Nadon, Celine Pimentel, Guillermo Perez-Gutierrez, Enrique Gerner-Smidt, Peter Binsztein, Norma CA Shigella Flexneri PulseNet PFGE Pr TI Standardization and International Multicenter Validation of a PulseNet Pulsed-Field Gel Electrophoresis Protocol for Subtyping Shigella flexneri Isolates SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID SONNEI-GASTROENTERITIS; OUTBREAK; CONSUMPTION; MANAGEMENT; INFECTION AB Shigella flexneri is one of the agents most frequently linked to diarrheal illness in developing countries and often causes outbreaks in settings with poor hygiene or sanitary conditions. Travel is one of the means by which S. flexneri can be imported into developed countries, where this pathogen is not commonly seen. A robust and discriminatory subtyping method is needed for the surveillance of S. flexneri locally and regionally, and to aid in the detection and investigation of outbreaks. The PulseNet International network utilizes standardized pulsed-field gel electrophoresis (PFGE) protocols to carry out laboratory-based surveillance of foodborne pathogens in combination with epidemiologic data. A multicenter validation was carried out in nine PulseNet laboratories located in North and South America, Europe, and Asia, and it demonstrated that a new protocol is highly robust and reproducible for subtyping of S. flexneri. This protocol, already approved for PulseNet laboratories, applies NotI and XbaI as primary and secondary restriction enzymes, respectively, under electrophoresis conditions of initial switch time of 5 s to final switch time of 35 s, at 6 volts/cm. C1 [Pichel, Mariana; Brengi, Silvina P.; Binsztein, Norma] ANLIS Carlos G Malbran, Inst Nacl Enfermedades Infecciosas, Buenos Aires, DF, Argentina. [Cooper, Kara L. F.; Ribot, Efrain M.; Gerner-Smidt, Peter] Ctr Dis Control & Prevent, Atlanta, GA USA. [Al-Busaidy, Suleiman] Cent Publ Hlth Lab, Muscat, Oman. [Araya, Pamela; Fernandez, Jorge] Inst Salud Publ Chile, Santiago, Chile. [Vaz, Tania Ibelli] Inst Adolfo Lutz Registro, Sao Paulo, Brazil. [Kam, Kai Man] Publ Hlth Lab Ctr, Kowloon, Hong Kong, Peoples R China. [Morcos, Myriam; Pimentel, Guillermo] US Naval Med Res Unit 3 NAMRU 3, Global Dis Detect GDD Reg Ctr, Cairo, Egypt. [Nielsen, Eva M.] Statens Serum Inst, DK-2300 Copenhagen, Denmark. [Nadon, Celine] Natl Microbiol Lab, Winnipeg, MB, Canada. [Perez-Gutierrez, Enrique] PAHO WHO, VPH PANAFTOSA, Panama City, Panama. RP Pichel, M (reprint author), ANLIS Carlos G Malbran, Inst Nacl Enfermedades Infecciosas, Av Velez Sarsfield 563, Buenos Aires, DF, Argentina. EM mpichel@anlis.gov.ar RI Nielsen, Eva Moller/B-9157-2011; Kam, Kai Man/K-4546-2012; OI Nielsen, Eva Moller/0000-0002-5349-7802; Kam, Kai Man/0000-0003-0579-0307; Pimentel, Guillermo/0000-0003-2464-1526 NR 21 TC 8 Z9 8 U1 0 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD MAY PY 2012 VL 9 IS 5 BP 418 EP 424 DI 10.1089/fpd.2011.1067 PG 7 WC Food Science & Technology SC Food Science & Technology GA 936MZ UT WOS:000303595800006 PM 22506731 ER PT J AU Song, EY Leichliter, JS Bloom, FR Vissman, AT O'Brien, MC Rhodes, SD AF Song, Eun-Young Leichliter, Jami S. Bloom, Frederick R. Vissman, Aaron T. O'Brien, Mary Claire Rhodes, Scott D. TI The Use of Prescription Medications Obtained from Non-medical Sources among Immigrant Latinos in the Rural Southeastern U.S. SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Prescription medications; non-medical sources; Latino immigrants; ethnic minority groups ID SOUTH-EASTERN USA; NEW-YORK-CITY; PARTICIPATORY RESEARCH; HEALTH-CARE; HIDDEN POPULATIONS; AFRICAN-AMERICAN; RISK BEHAVIORS; NORTH-CAROLINA; UNITED-STATES; SEXUAL RISK AB We explored the relationships between behavioral, socio-cultural, and psychological characteristics and the use of prescription medications obtained from non-medical sources among predominantly Spanish-speaking Latinos in the rural southeastern U.S. Respondent-driven sampling (RDS) was used to identify, recruit, and enroll immigrant Latinos to participate in an interviewer-administered assessment. A total of 164 respondents were interviewed in 2009. Average age was 34 years old, 64% of respondents were female, and nearly 85% reported being from Mexico. Unweighted and RDS-weighted prevalence estimates of any non-medical source of prescription medications were 22.6% and 15.1%, respectively. In multivariable modeling, respondents who perceived their documentation status as a barrier to health care and those with higher educational attainment were significantly more likely to report use of non-medical sources. Interventions are needed to increase knowledge of eligibility to sources of medical care and treatment and ensure culturally congruent services for immigrant communities in the U.S. C1 [Song, Eun-Young] Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC 27157 USA. [Leichliter, Jami S.; Bloom, Frederick R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Vissman, Aaron T.] Emory Univ, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. RP Song, EY (reprint author), Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM esong@wakehealth.edu NR 50 TC 6 Z9 6 U1 1 U2 5 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD MAY PY 2012 VL 23 IS 2 BP 678 EP 693 PG 16 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 934EY UT WOS:000303427600017 PM 22643616 ER PT J AU Desai, M Dellicour, S AF Desai, Meghna Dellicour, Stephanie TI Effects of malaria and its treatment in early pregnancy SO LANCET INFECTIOUS DISEASES LA English DT Editorial Material C1 [Desai, Meghna; Dellicour, Stephanie] Kenya Govt Med Res Ctr, Res & Publ Hlth Collaborat, Ctr Dis Control & Prevent KEMRI CDC, Kisumu, Kenya. [Desai, Meghna] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA USA. [Dellicour, Stephanie] Liverpool Sch Trop Med & Hyg, Child & Reprod Hlth Grp, Liverpool, Merseyside, England. RP Desai, M (reprint author), Kenya Govt Med Res Ctr, Res & Publ Hlth Collaborat, Ctr Dis Control & Prevent KEMRI CDC, Kisumu, Kenya. NR 7 TC 4 Z9 4 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAY PY 2012 VL 12 IS 5 BP 359 EP 360 DI 10.1016/S1473-3099(11)70345-0 PG 2 WC Infectious Diseases SC Infectious Diseases GA 934DF UT WOS:000303422700004 PM 22169410 ER PT J AU Zachariah, R Ford, N Maher, D Bissell, K Van den Bergh, R van den Boogaard, W Reid, T Castro, KG Draguez, B von Schreeb, J Chakaya, J Atun, R Lienhardt, C Enarson, DA Harries, AD AF Zachariah, Rony Ford, Nathan Maher, Dermot Bissell, Karen Van den Bergh, Rafael van den Boogaard, Wilma Reid, Tony Castro, Kenneth G. Draguez, Bertrand von Schreeb, Johan Chakaya, Jeremiah Atun, Rifat Lienhardt, Christian Enarson, Don A. Harries, Anthony D. TI Is operational research delivering the goods? The journey to success in low-income countries SO LANCET INFECTIOUS DISEASES LA English DT Article ID RAPID SCALE-UP; TUBERCULOSIS-CONTROL; ANTIRETROVIRAL THERAPY; PUBLIC-HEALTH; KNOWLEDGE TRANSLATION; MALAWI; CAPACITY; POLICY; ACCESS; HIV AB Operational research in low-income countries has a key role in filling the gap between what we know from research and what we do with that knowledge- the so-called know-do gap, or implementation gap. Planned research that does not tangibly affect policies and practices is ineffective and wasteful, especially in settings where resources are scarce and disease burden is high. Clear parameters are urgently needed to measure and judge the success of operational research. We define operational research and its relation with policy and practice, identify why operational research might fail to affect policy and practice, and offer possible solutions to address these shortcomings. We also propose measures of success for operational research. Adoption and use of these measures could help to ensure that operational research better changes policy and practice and improves health-care delivery and disease programmes. C1 [Zachariah, Rony] Med Sans Frontieres, Operat Res Unit, Brussels Operat Ctr, Dept Med, L-1617 Luxembourg, Luxembourg. [Ford, Nathan] Med Sans Frontieres, Access Med Unit, Geneva, Switzerland. [Maher, Dermot; Harries, Anthony D.] London Sch Hyg & Trop Med, London WC1, England. [Bissell, Karen; Enarson, Don A.; Harries, Anthony D.] Int Union TB & Lung Dis, Ctr Operat Res, Paris, France. [Van den Bergh, Rafael] Vlaams Inst Biotechnol, Dept Mol & Cellular Interact, Brussels, Belgium. [Van den Bergh, Rafael] Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium. [Castro, Kenneth G.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIVAIDS Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [von Schreeb, Johan] Karolinska Inst, Dept Publ Hlth, Div Global Hlth IHCAR, Stockholm, Sweden. [Chakaya, Jeremiah] Minist Hlth, Kenya Med Res Inst, Nairobi, Kenya. [Atun, Rifat] Global Fund Fight HIV TB & Malaria, Geneva, Switzerland. [Atun, Rifat] Univ London Imperial Coll Sci Technol & Med, London, England. [Lienhardt, Christian] WHO, Stop TB Partnership, CH-1211 Geneva, Switzerland. RP Zachariah, R (reprint author), Med Sans Frontieres, Operat Res Unit, Brussels Operat Ctr, Dept Med, 68 Rue Gasperich, L-1617 Luxembourg, Luxembourg. EM zachariah@internet.lu NR 63 TC 28 Z9 28 U1 1 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAY PY 2012 VL 12 IS 5 BP 415 EP 421 DI 10.1016/S1473-3099(11)20309-7 PG 7 WC Infectious Diseases SC Infectious Diseases GA 934DF UT WOS:000303422700022 PM 22326018 ER PT J AU Hartzell, JD Gleeson, T Scoville, S Massung, RF Wortmann, G Martin, GJ AF Hartzell, Joshua D. Gleeson, Todd Scoville, Stephanie Massung, Robert F. Wortmann, Glenn Martin, Gregory J. TI Practice Guidelines for the Diagnosis and Management of Patients With Q Fever by the Armed Forces Infectious Diseases Society SO MILITARY MEDICINE LA English DT Article ID COXIELLA-BURNETII; FOLLOW-UP; US MILITARY; DOPPLER-ECHOCARDIOGRAPHY; BACTERICIDAL ACTIVITIES; VASCULAR COMPLICATIONS; CHAMBER QUANTIFICATION; STANDARDS COMMITTEE; OF-ECHOCARDIOGRAPHY; ENDOCARDITIS AB This issue in the series Current Topics in Military Tropical Medicine focuses on Q Fever. Q fever is a zoonotic infection caused by the bacterium Caxiella burnetii. Over 150 confirmed cases have occurred among U.S. military personnel deployed to Iraq since 2007. Acute Q fever is underdiagnosed because of a myriad of possible clinical presentations but typically presents as a flu-like illness. The most common chronic manifestation is endocarditis. Most providers are not familiar with the diagnosis, treatment, or appropriate follow-up of this disease. In order to facilitate the care of patients infected with C. burnetii, the Armed Forces Infectious Diseases Society convened a panel of experts in the field to develop practical guidelines for those caring for infected patients. The recommendations and rationale are reviewed in this article. C1 [Hartzell, Joshua D.; Wortmann, Glenn; Martin, Gregory J.] Walter Reed Natl Mil Med Ctr, Infect Dis Serv, Bethesda, MD 20889 USA. [Gleeson, Todd] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA. [Scoville, Stephanie] USA, Publ Hlth Command, Army Inst Publ Hlth, Aberdeen Proving Ground, MD 21010 USA. [Massung, Robert F.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Hartzell, JD (reprint author), Walter Reed Natl Mil Med Ctr, Infect Dis Serv, Bldg 7,1st Floor,8901 Rockville Pike, Bethesda, MD 20889 USA. FU Navy Medicine Professional Development Center FX The series Current Topics in Military Tropical Medicine is an educational outreach program developed by the faculty of the U.S. Military Tropical Medicine program (MTM) and Military Medicine. MTM is a joint program which educates and trains military medical personnel in the practice of medicine in developing areas under the auspices of the Navy Medicine Professional Development Center. Questions and comments on this series should be directed to the series subeditor and Program Director, U.S. Military Tropical Medicine, Director.MTM@med.navy.mil. NR 70 TC 7 Z9 7 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD MAY PY 2012 VL 177 IS 5 BP 484 EP 494 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 936XK UT WOS:000303623100004 PM 22645872 ER PT J AU Documet, PI Trauth, JM Key, M Flatt, J Jernigan, J AF Documet, Patricia I. Trauth, Jeanette M. Key, Meghan Flatt, Jason Jernigan, Jan TI Breast Cancer Survivors' Perception of Survivorship SO ONCOLOGY NURSING FORUM LA English DT Article ID QUALITY-OF-LIFE; BEHAVIORAL STRESS-MANAGEMENT; POSTTRAUMATIC GROWTH; BENEFIT; WOMEN; DIAGNOSIS; IDENTITY; YOUNGER; TRIAL; NEEDS AB Purpose/Objectives: To explore (a) how women who were diagnosed with breast cancer (BC) defined themselves as survivors and when this occurred, and (b) the types of benefits they derived from their experiences. Research Approach: An exploratory, qualitative approach. Participants: 112 women who had BC (response rate = 70%). Setting: Participants were recruited from two cancer survivor organizations in a northeastern U.S. city. Methodologic Approach: Responses to open-ended questions in telephone interviews were examined by age at diagnosis using thematic analysis. Chi squares were used to conduct analyses by age (younger than 51 years; aged 51 years or older). Main Research Variables: Meaning of survivorship, defining moment, benefits derived from surviving from breast cancer. Findings: Participants' perceptions of survivorship included two main components, a defining moment and the meaning attached to being a survivor. Becoming a survivor is an active process, except in the case of those participants who realized they were survivors when informed by a third party. Meanings differed by age at diagnosis. Most participants listed at least one benefit from surviving cancer. Conclusions: The definitions of survivorship and benefits outlined here suggest that many positive aspects of the survivorship experience exist that may inform future interventions' designs. Implications for Practice: Providers should acknowledge the strength survivors show in the process of meaning-making and finding benefits in their adverse experiences. The use of expressive and supportive interventions may hold promise for women facing difficulties in coping with their diagnosis. C1 [Documet, Patricia I.; Trauth, Jeanette M.; Flatt, Jason] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15260 USA. [Key, Meghan] Kids Count Family Psychol, Kittanning, PA USA. [Jernigan, Jan] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. RP Documet, PI (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15260 USA. EM pdocumet@pitt.edu OI Trauth, Jeanette/0000-0002-7635-1734 FU National Cancer Institutes [P30CA047904] FX Patricia I. Documet, MD, DrPH, is an assistant professor and Jeanette M. Trauth, PhD, is an associate professor, both in the Department of Behavioral and Community Health Sciences in the Graduate School of Public Health at the University of Pittsburgh in Pennsylvania; Meghan Key, MPH, is a permanency caseworker at Kids Count Family Psychological in Kittanning, PA; Jason Flatt, MPH, MCHES, is a graduate student researcher in the Fall Free PA research study in the Department of Behavioral and Community Health Sciences in the Graduate School of Public Health at the University of Pittsburgh; and Jan Jernigan, PhD, is a senior evaluator in the Division of Nutrition, Physical Activity, and Obesity at the Centers for Disease Control and Prevention in Atlanta, GA. This study was supported in part by a Supplement to a National Cancer Institutes award (P30CA047904). Documet can be reached at pdocumet@pitt.edu, with copy to editor at ONFEditor@ons.org. (Submitted May 2011. Accepted for publication September 12, 2011.) NR 25 TC 4 Z9 4 U1 1 U2 7 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X EI 1538-0688 J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAY PY 2012 VL 39 IS 3 BP 309 EP 315 DI 10.1188/12.ONF.309-315 PG 7 WC Oncology; Nursing SC Oncology; Nursing GA 937EO UT WOS:000303642000013 PM 22543389 ER PT J AU Robson, LS Stephenson, CM Schulte, PA Amick, BC Irvin, EL Eggerth, DE Chan, S Bielecky, AR Wang, AM Heidotting, TL Peters, RH Clarke, JA Cullen, K Rotunda, CJ Grubb, PL AF Robson, Lynda S. Stephenson, Carol M. Schulte, Paul A. Amick, Benjamin C., III Irvin, Emma L. Eggerth, Donald E. Chan, Stella Bielecky, Amber R. Wang, Anna M. Heidotting, Terri L. Peters, Robert H. Clarke, Judith A. Cullen, Kimberley Rotunda, Cathy J. Grubb, Paula L. TI A systematic review of the effectiveness of occupational health and safety training SO SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH LA English DT Review DE education; evaluation; intervention; OHS; OHS training; prevention; primary prevention ID FACTORY-WORKERS USE; LOW-BACK-PAIN; HEARING PROTECTION; WORKING ENVIRONMENT; WORKPLACE DATA; INTERVENTION; PREVENTION; INJURIES; PROGRAM; DISORDERS AB Objectives Training is regarded as an important component of occupational health and safety (OHS) programs. This paper primarily addresses whether OHS training has a beneficial effect on workers. The paper also examines whether higher engagement OHS training has a greater effect than lower engagement training. Methods Ten bibliographic databases were searched for pre-post randomized trial studies published in journals between 1996 and November 2007. Training interventions were included if they were delivered to workers and were concerned with primary prevention of occupational illness or injury. The methodological quality of each relevant study was assessed and data was extracted. The impacts of OHS training in each study were summarized by calculating the standardized mean differences. The strength of the evidence on training's effectiveness was assessed for (i) knowledge, (ii) attitudes and beliefs, (ili) behaviors, and (iv) health using the US Centers for Disease Control and Prevention's Guide to Community Preventive Services, a qualitative evidence synthesis method. Results Twenty-two studies met the relevance criteria of the review. They involved a variety of study populations, occupational hazards, and types of training. Strong evidence was found for the effectiveness of training on worker OHS behaviors, but insufficient evidence was found of its effectiveness on health (ie, symptoms, injuries, illnesses). Conclusions The review team recommends that workplaces continue to deliver OHS training to employees because training positively affects worker practices. However, large impacts of training on health cannot be expected based on research evidence. C1 [Robson, Lynda S.; Amick, Benjamin C., III; Irvin, Emma L.; Bielecky, Amber R.; Wang, Anna M.; Clarke, Judith A.; Cullen, Kimberley] Inst Work & Hlth, Toronto, ON MSG 2E9, Canada. [Stephenson, Carol M.; Schulte, Paul A.; Eggerth, Donald E.] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA. [Amick, Benjamin C., III] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [Chan, Stella] Canc Care Ontario, Toronto, ON, Canada. [Heidotting, Terri L.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA. [Peters, Robert H.] NIOSH, Off Mine Safety & Hlth Res, Pittsburgh, PA USA. [Rotunda, Cathy J.] NIOSH, Educ & Informat Div, Morgantown, WV USA. [Grubb, Paula L.] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Robson, LS (reprint author), Inst Work & Hlth, 481 Univ Ave,Suite 800, Toronto, ON MSG 2E9, Canada. EM lrobson@iwh.on.ca FU Prevention Reviews pilot initiative; WSIB FX The project was supported in part through a Prevention Reviews pilot initiative funded by the WSIB and directed to the Institute for Work & Health, Toronto, Ontario. Apart from giving feedback as one of many stakeholder lay organizations (see above), the funding agency was not involved in the research or the reporting of it. The findings and conclusions are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 65 TC 33 Z9 34 U1 6 U2 54 PU SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH PI HELSINKI PA TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND SN 0355-3140 EI 1795-990X J9 SCAND J WORK ENV HEA JI Scand. J. Work Environ. Health PD MAY PY 2012 VL 38 IS 3 BP 193 EP 208 DI 10.5271/sjweh.3259 PG 16 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 937CM UT WOS:000303636600002 PM 22045515 ER PT J AU Virji, MA Park, JY Stefaniak, AB Stanton, ML Day, GA Kent, MS Kreiss, K Schuler, CR AF Virji, M. Abbas Park, Ji Young Stefaniak, Aleksandr B. Stanton, Marcia L. Day, Gregory A. Kent, Michael S. Kreiss, Kathleen Schuler, Christine R. TI Sensitization and chronic beryllium disease at a primary manufacturing facility, part 1: historical exposure reconstruction SO SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH LA English DT Article DE average exposure; cumulative exposure; peak exposure; respirable exposure; submicron exposure; total exposure ID OCCUPATIONAL-EXPOSURE; LONG-TERM; INHALATION EXPOSURE; TRENDS; PLANT; EPIDEMIOLOGY; PARTICULATE; INDUSTRY; WORKERS; TIME AB Objectives Previous epidemiologic studies of beryllium sensitization (BeS) and chronic beryllium disease (CBD) have reported inconsistent exposure-response relationships, likely due to exposure misclassification. The objective of this study was to develop historical estimates of size-selective personal exposure to beryllium for an epidemiologic study. Methods In 1999, a cross-sectional survey of workers hired after I January 1994 was conducted at a beryllium production facility. Personal exposure data from two air sampling surveys conducted in 1999 were used to obtain total, respirable, and submicron particle baseline exposure estimates (BEE) for a job-exposure matrix (JEM). General area air samples collected from 1994-1999 were used to estimate annual changes in exposures (temporal factors) for 24 different process areas. Historical exposure estimates (HEE) were calculated by applying the temporal factors to the BEE. Workers were assigned HEE based on their work history, and their historical exposure profile was summarized as cumulative, average, or highest-ever job exposure. Results Changes in exposure over a 6-year period were observed in 10 of the 24 process areas with an overall mean decline of 18% per year. The overall total exposure for study participants over their work tenure ranged from: 0.001-34.44 mu g/m(3)-year, 0.01-16.26 mu g/m(3), and 0.01-17.54 mu g/m(3) for cumulative, average, and highest-ever job, respectively. For respirable exposures, the ranges were: 0.001-15.54 mu g/m(3)-year, 0.01-3.56 mu g/m(3), 0.01-5.54 mu g/m(3) for cumulative, average, and highest-ever job, respectively. Conclusions Using this JEM, exposure-response relationships for BeS and CBD can be explored over a range of exposure metrics such as total, respirable, and submicron beryllium mass concentrations, including summary measures such as cumulative, average, or highest exposures, with the ultimate objective of elucidating a quantitative exposure-response relationship. C1 [Virji, M. Abbas] NIOSH, Ctr Dis Control & Prevent, Div Resp Dis Studies, Morgantown, WV 26505 USA. [Kent, Michael S.] Mater Brush Inc, Elmore, OH USA. RP Virji, MA (reprint author), NIOSH, Ctr Dis Control & Prevent, Div Resp Dis Studies, Mailstop H-2800, Morgantown, WV 26505 USA. EM MVirji@cdc.gov RI Stefaniak, Aleksandr/I-3616-2012 NR 35 TC 6 Z9 7 U1 0 U2 1 PU SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH PI HELSINKI PA TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND SN 0355-3140 J9 SCAND J WORK ENV HEA JI Scand. J. Work Environ. Health PD MAY PY 2012 VL 38 IS 3 BP 247 EP 258 DI 10.5271/sjweh.3188 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 937CM UT WOS:000303636600007 PM 21850365 ER PT J AU Park, JY Virji, MA Stefaniak, AB Stanton, ML Day, GA Kent, MS Schuler, CR Kreiss, K AF Park, Ji Young Virji, M. Abbas Stefaniak, Aleksandr B. Stanton, Marcia L. Day, Gregory A. Kent, Michael S. Schuler, Christine R. Kreiss, Kathleen TI Sensitization and chronic beryllium disease at a primary manufacturing facility, part 2: validation of historical exposures SO SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH LA English DT Article DE agreement; exposure reconstruction; job exposure matrix; total exposure; validation ID CONCORDANCE CORRELATION-COEFFICIENT; RETROSPECTIVE EXPOSURE; ASSESSING AGREEMENT; WORKERS; PLANT; MORTALITY; BENZENE; MODELS; ISSUES; OXIDE AB Objective The aim of this study was to evaluate the validity of a job exposure matrix (JEM) constructed for the period 1994-1999. Historical exposure estimates (HEE) for the JEM were constructed for all job and year combinations by applying temporal factors reflecting annual change in area air measurements (1994-1998) to the personal baseline exposure estimates (BEE) collected in 1999. The JEM was generated for an epidemiologic study to examine quantitative exposure response relationships with sensitization and chronic beryllium disease. Methods The validity of the BEE and HEE was evaluated by comparing them with a validation dataset of independently collected personal beryllium exposure measurements from 1999 and 1994-1998, respectively. Agreement between the JEM and validation data was assessed using relative bias and concordance correlation coefficients (CCC). Results The BEE and HEE overestimated the measured exposures in their respective validation datasets by 8% and 6%, respectively. The CCC reflecting the deviation of the fitted line from the concordance line, showed good agreement for both BEE (CCC=0.80) and HEE (CCC=0.72). Proportional difference did not change with exposure levels or by process area and year. Overall, the agreement between the JEM and validation estimates (from combined HEE and BEE) was high (CCC=0.77). Conclusions This study demonstrated that the reconstructed beryllium exposures at a manufacturing facility were reliable and can be used in epidemiologic studies. C1 [Virji, M. Abbas] NIOSH, Ctr Dis Control & Prevent, Div Resp Dis Studies, Morgantown, WV 26505 USA. [Kent, Michael S.] Mater Brush Inc, Elmore, OH USA. RP Virji, MA (reprint author), NIOSH, Ctr Dis Control & Prevent, Div Resp Dis Studies, Mailstop H-2800, Morgantown, WV 26505 USA. EM MVirji@cdc.gov RI Stefaniak, Aleksandr/I-3616-2012 NR 39 TC 2 Z9 2 U1 0 U2 1 PU SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH PI HELSINKI PA TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND SN 0355-3140 J9 SCAND J WORK ENV HEA JI Scand. J. Work Environ. Health PD MAY PY 2012 VL 38 IS 3 BP 259 EP 269 DI 10.5271/sjweh.3187 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 937CM UT WOS:000303636600008 PM 21847507 ER PT J AU Schuler, CR Virji, MA Deubner, DC Stanton, ML Stefaniak, AB Day, GA Park, JY Kent, MS Sparks, R Kreiss, K AF Schuler, Christine R. Virji, M. Abbas Deubner, David C. Stanton, Marcia L. Stefaniak, Aleksandr B. Day, Gregory A. Park, Ji Young Kent, Michael S. Sparks, Rachel Kreiss, Kathleen TI Sensitization and chronic beryllium disease at a primary manufacturing facility, part 3: exposure-response among short-term workers SO SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH LA English DT Article DE average exposure; beryllium disease; cumulative exposure; occupational respiratory disease; peak exposure ID MACHINING PLANT; LONG-TERM; ALLOY; RISK; EPIDEMIOLOGY; SURVEILLANCE; OXIDE; METAL AB Objectives Exposure-response relations for beryllium sensitization (BeS) and chronic beryllium disease (CBD) using aerosol mass concentration have been inconsistent, although process-related risks found in most studies suggest that exposure-dependent risks exist. We examined exposure-response relations using personal exposure estimates in a beryllium worker cohort with limited work tenure to minimize exposure misclassification. Methods The population comprised workers employed in 1999 with six years or less tenure. Each completed a work history questionnaire and was evaluated for immunological sensitization and CBD. A job-exposure matrix was combined with work histories to create individual estimates of average, cumulative, and highest-job-worked exposure for total, respirable, and submicron beryllium mass concentrations. We obtained odds ratios from logistic regression models for exposure-response relations, and evaluated process-related risks. Results Participation was 90.7% (264/291 eligible). Sensitization prevalence was 9.8% (26/264), with 6 sensitized also diagnosed with CBD (2.3%, 6/264). A general pattern of increasing sensitization prevalence was observed as exposure quartile increased. Both total and respirable beryllium mass concentration estimates were positively associated with sensitization (average and highest job), and CBD (cumulative). Increased sensitization prevalence was identified in metal/oxide production, alloy melting and casting, and maintenance, and for CBD in melting and casting. Lower sensitization prevalence was observed in plant-area administrative work. Conclusions Sensitization was associated with average and highest job exposures, and CBD was associated with cumulative exposure. Both total and respirable mass concentrations were relevant predictors of risk. New process-related risks were identified in melting and casting and maintenance. C1 [Schuler, Christine R.] NIOSH, Div Resp Dis Studies, Field Studies Branch, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Deubner, David C.; Kent, Michael S.] Mater Brush Inc, Elmore, OH USA. RP Schuler, CR (reprint author), NIOSH, Div Resp Dis Studies, Field Studies Branch, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS H2800, Morgantown, WV 26505 USA. EM cschuler@cdc.gov RI Stefaniak, Aleksandr/I-3616-2012 NR 30 TC 16 Z9 17 U1 0 U2 4 PU SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH PI HELSINKI PA TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND SN 0355-3140 J9 SCAND J WORK ENV HEA JI Scand. J. Work Environ. Health PD MAY PY 2012 VL 38 IS 3 BP 270 EP 281 DI 10.5271/sjweh.3192 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 937CM UT WOS:000303636600009 PM 21877099 ER PT J AU Boulet, SL Amendah, D Grosse, SD Hooper, WC AF Boulet, Sheree L. Amendah, Djesika Grosse, Scott D. Hooper, W. Craig TI Health care expenditures associated with venous thromboembolism among children SO THROMBOSIS RESEARCH LA English DT Article DE Venous thromboembolism; Deep vein thrombosis; Pulmonary embolism; Health expenditures; Pediatrics ID DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; UNITED-STATES; RISK-FACTORS; REGISTRY; POPULATION; CHILDHOOD; OUTCOMES; DISEASE; MODELS AB Introduction: We used health insurance claims data from large samples of Medicaid-enrolled and privately insured children to identify children with venous thromboembolism (VTE) and to assess their use of health services and associated expenditures during 2009. Materials and Methods: Data from the 2009 Thomson Reuters MarketScan (R) Commercial Database and Multi-State Medicaid database were used to estimate annual expenditures for children 1-17 years of age with VTE. Generalized linear models were used to calculate adjusted annual expenditures for Medicaid-enrolled and privately insured children with VTE, controlling for age, sex, type of health plan, VTE classification (deep vein thrombosis and/or pulmonary embolism), and type of VTE event (idiopathic or secondary) and race (Medicaid only) or region (Commercial only). Results: During 2009, Medicaid-enrolled and privately insured children with VTE had an average of 1-2 inpatient admissions and 8-10 non-emergency department visits. Unadjusted mean total expenditures were similar for Medicaid-enrolled and privately insured children with VTE, $105,359 and $87,767, respectively. Adjusted mean expenditures for children with secondary VTE were five times higher than for children with idiopathic VTE. Conclusions: Given the high frequency of secondary VTE in children, most of the associated expenditures may be due to other health conditions. However, children who develop a VTE incur substantial costs of care, even in the absence of related conditions. Additional research is needed to evaluate the long term outcomes for children with VTE including rates of readmission, complications, and the impact of co-morbid conditions. Published by Elsevier Ltd. C1 [Boulet, Sheree L.; Amendah, Djesika; Grosse, Scott D.; Hooper, W. Craig] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Boulet, SL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS D02, Atlanta, GA 30333 USA. EM sbu1@cdc.gov NR 27 TC 8 Z9 8 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0049-3848 J9 THROMB RES JI Thromb. Res. PD MAY PY 2012 VL 129 IS 5 BP 583 EP 587 DI 10.1016/j.thromres.2011.08.006 PG 5 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 934GZ UT WOS:000303433500027 PM 21872297 ER PT J AU Rider, CV Dourson, ML Hertzberg, RC Mumtaz, MM Price, PS Simmons, JE AF Rider, Cynthia V. Dourson, Michael L. Hertzberg, Richard C. Mumtaz, Moiz M. Price, Paul S. Simmons, Jane Ellen TI Incorporating Nonchemical Stressors Into Cumulative Risk Assessments SO TOXICOLOGICAL SCIENCES LA English DT Editorial Material DE joint action; exposure; dose response; modeling ID HEALTH; PESTICIDE; FRAMEWORK; EXPOSURES; AGGREGATE AB The role of nonchemical stressors in modulating the human health risk associated with chemical exposures is an area of increasing attention. On 9 March 2011, a workshop titled "Approaches for Incorporating Nonchemical Stressors into Cumulative Risk Assessment" took place during the 50th Anniversary Annual Society of Toxicology Meeting in Washington D.C. Objectives of the workshop included describing the current state of the science from various perspectives (i.e., regulatory, exposure, modeling, and risk assessment) and presenting expert opinions on currently available methods for incorporating nonchemical stressors into cumulative risk assessments. Herein, distinct frameworks for characterizing exposure to, joint effects of, and risk associated with chemical and nonchemical stressors are discussed. C1 [Rider, Cynthia V.] NIEHS, Natl Toxicol Program, Res Triangle Pk, NC 27709 USA. [Dourson, Michael L.] Toxicol Excellence Risk Assessment TERA, Cincinnati, OH 45211 USA. [Hertzberg, Richard C.] Biomath Consulting, Atlanta, GA 30322 USA. [Mumtaz, Moiz M.] Agcy Tox Subst & Dis Registry, Atlanta, GA 30333 USA. [Price, Paul S.] Dow Chem Co USA, Midland, MI 48674 USA. [Simmons, Jane Ellen] US EPA, Natl Hlth & Environm Effects Res Lab, Off Res & Dev, Res Triangle Pk, NC 27711 USA. RP Rider, CV (reprint author), NIEHS, Natl Toxicol Program, 111 TW Alexander Dr,POB 12233,MD K2-12, Res Triangle Pk, NC 27709 USA. EM ridercv@niehs.nih.gov NR 20 TC 4 Z9 4 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1096-6080 J9 TOXICOL SCI JI Toxicol. Sci. PD MAY PY 2012 VL 127 IS 1 BP 10 EP 17 DI 10.1093/toxsci/kfs088 PG 8 WC Toxicology SC Toxicology GA 935AT UT WOS:000303490100002 PM 22345310 ER PT J AU Kristiansen, PA Ouedraogo, AS Sanou, I Ba, AK Ouedraogo, CD Sangare, L Ouedraogo, R Kandolo, D Diomande, F Kabore, P Hassan-King, M Thomas, JD Hatcher, CP Andreasson, I Clark, TA Preziosi, MP LaForce, M Caugant, DA AF Kristiansen, Paul A. Ouedraogo, Abdoul-Salam Sanou, Idrissa Ba, Absatou Ky Ouedraogo, Charles D. Sangare, Lassana Ouedraogo, Rasmata Kandolo, Denis Diomande, Fabien Kabore, Pascal Hassan-King, Musa Thomas, Jennifer Dolan Hatcher, Cynthia P. Andreasson, Ida Clark, Thomas A. Preziosi, Marie-Pierre LaForce, Marc Caugant, Dominique A. TI Laboratory quality control in a multicentre meningococcal carriage study in Burkina Faso SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE LA English DT Article DE Neisseria meningitidis; Carriage; Quality control; Africa; Burkina Faso; Meningitis belt ID AFRICAN MENINGITIS BELT; NEISSERIA-MENINGITIDIS; IDENTIFICATION AB To investigate the potential herd immunity effect of MenAfriVac, a new conjugate vaccine against serogroup A Neisseria meningitidis, a multiple cross-sectional carriage study was conducted in three districts in Burkina Faso in 2009, yielding a total of 20326 oropharyngeal samples. A major challenge was the harmonisation of operational procedures and ensuring the reliability of results. Here we describe the laboratory quality control (QC) system that was implemented. Laboratory analysis performed by three local laboratories included colony morphology assessment,. oxidase test, Gram stain,beta-galactosidase activity using o-nitrophenyl-beta-galactopyranoside (ONPG), gamma-glutamyl transferase (GGT) activity and slide agglutination serogrouping. Internal QC was performed on media, reagents, laboratory equipment and field conditions. Confirmation of results and molecular characterisation was performed at the Norwegian Institute of Public Health (Oslo, Norway). External QC was performed on 3% of specimens where no colonies morphologically resembling N. meningitidis had been identified and on 10% of non-ONPG-/GGT+ isolates. The QC system was a critical element: it identified logistical and operational problems in real time and ensured accuracy of the final data. The overall N. meningitidis carriage prevalence (3.98%) was probably slightly underestimated and the calculated true prevalence was 4.48%. The components of the presented QC system can easily be implemented in any other laboratory study. (C) 2012 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved. C1 [Caugant, Dominique A.] Norwegian Inst Publ Hlth, Collaborating Ctr Reference & Res Meningococci, WHO, N-0403 Oslo, Norway. [Ouedraogo, Abdoul-Salam] CHU Souro Sanou, Bobo Dioulasso, Burkina Faso. [Sanou, Idrissa; Sangare, Lassana] CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso. [Ba, Absatou Ky] Lab Natl Sante Publ, Ouagadougou, Burkina Faso. [Ouedraogo, Charles D.] CHR Kaya, Kayo, Burkina Faso. [Ouedraogo, Rasmata] CHUP Charles de Gaulle, Ouagadougou, Burkina Faso. [Kandolo, Denis; Diomande, Fabien] WHO, Inter Country Support Team, Ouagadougou, Burkina Faso. [Diomande, Fabien; Thomas, Jennifer Dolan; Hatcher, Cynthia P.; Clark, Thomas A.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Hassan-King, Musa; LaForce, Marc] Meningitis Vaccine Project, Ferney, France. [Preziosi, Marie-Pierre] WHO, Initiat Vaccine Res, CH-1211 Geneva, Switzerland. [Caugant, Dominique A.] Univ Oslo, Fac Med, Oslo, Norway. RP Caugant, DA (reprint author), Norwegian Inst Publ Hlth, Collaborating Ctr Reference & Res Meningococci, WHO, POB 4404, N-0403 Oslo, Norway. EM dominique.caugant@fhi.no FU Norwegian Research Council [185784] FX This project was supported by the Norwegian Research Council (grant no. 185784 to DAC). NR 17 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0035-9203 J9 T ROY SOC TROP MED H JI Trans. Roy. Soc. Trop. Med. Hyg. PD MAY PY 2012 VL 106 IS 5 BP 289 EP 297 DI 10.1016/j.trstmh.2011.12.009 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 937WA UT WOS:000303692500003 PM 22341686 ER PT J AU Ogden, CL Freedman, DS AF Ogden, Cynthia L. Freedman, David S. TI Secular trends in pediatric BMI SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Editorial Material ID BODY-MASS INDEX; CHILDREN; OVERWEIGHT; ADIPOSITY; OBESITY C1 [Ogden, Cynthia L.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Freedman, David S.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Ogden, CL (reprint author), CDC, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4415, Hyattsville, MD 20782 USA. EM cogden@cdc.gov NR 11 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD MAY PY 2012 VL 95 IS 5 BP 999 EP 1000 DI 10.3945/ajcn.112.035667 PG 2 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 930LK UT WOS:000303140700002 PM 22492376 ER PT J AU Suchdev, PS Ruth, LJ Woodruff, BA Mbakaya, C Mandava, U Flores-Ayala, R Jefferds, MED Quick, R AF Suchdev, Parminder S. Ruth, Laird J. Woodruff, Bradley A. Mbakaya, Charles Mandava, Usha Flores-Ayala, Rafael Jefferds, Maria Elena D. Quick, Robert TI Selling Sprinkles micronutrient powder reduces anemia, iron deficiency, and vitamin A deficiency in young children in Western Kenya: a cluster-randomized controlled trial SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID SOLUBLE TRANSFERRIN RECEPTOR; PLACEBO-CONTROLLED TRIAL; PRESCHOOL-CHILDREN; HOME FORTIFICATION; DOUBLE-BLIND; FOLIC-ACID; SUPPLEMENTATION; METAANALYSIS; HEMOGLOBIN; PREVALENCE AB Background: Although the efficacy of micronutrient powders [MNPs; eg, Sprinkles MNP (Sprinkles Global Health Initiative)] in the reduction of anemia has been established, the effectiveness of these powders in real-world programs has seldom been assessed. Objective: In this study, we evaluated the effect of community-based marketing and distribution of Sprinkles MNP on childhood rates of anemia and iron and vitamin A deficiency. Design: In a cluster-randomized trial in children aged 6-35 mo in Western Kenya, 60 villages were randomly assigned to either intervention or control groups. Community vendors marketed and sold sachets of Sprinkles MNP in intervention villages. Biweekly household visits monitored the use of Sprinkles MNP. Hemoglobin, ferritin, retinol binding protein, malaria, and anthropometric measures were assessed at baseline (n = 1063) and 12 mo of follow-up (n = 862). Data were analyzed by using an intention-to-treat analysis and generalized linear mixed models. Results: On average, 33% of households in intervention villages purchased Sprinkles MNP; the average weekly intake per child was 0.9 sachets (similar to 11.3 mg Fe and similar to 328 mu g vitamin A). Compared with control subjects, intervention children had greater improvements in hemoglobin concentrations (increase of 0.9 compared with 0.6 g/dL, respectively; P = 0.02), iron deficiency (decrease of 19.3% compared with 5.3%, respectively; P = 0.001), and vitamin A deficiency (decrease of 7.5% compared with an increase of 2.5%, respectively; P = 0.01). Results adjusted for age, sex, socioeconomic status, and maternal education showed a significant association between the hemoglobin, iron, and vitamin A concentrations of children and the number of Sprinkles MNP sachets the children consumed. The prevalence of malaria, wasting, and stunting did not change significantly in either group. Conclusion: Even with relatively low and infrequent use, Sprinkles MNP sales through community vendors were associated with decreased rates of anemia and iron and vitamin A deficiency in children in a resource-poor setting. This trial was registered at clinicaltrials. gov as NCT01088958. Am J Clin Nutr 2012;95:1223-30. C1 [Suchdev, Parminder S.; Ruth, Laird J.; Woodruff, Bradley A.; Mandava, Usha; Flores-Ayala, Rafael; Jefferds, Maria Elena D.] CDC, Nutr Branch, Atlanta, GA 30341 USA. [Suchdev, Parminder S.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Mbakaya, Charles] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Quick, Robert] CDC, Waterborne Dis Prevent Branch, Atlanta, GA 30341 USA. RP Suchdev, PS (reprint author), CDC, Nutr Branch, 4770 Buford Highway NE,MS K25, Atlanta, GA 30341 USA. EM psuchdev@cdc.gov RI Suchdev, Parmi/K-4851-2012; OI Suchdev, Parmi/0000-0002-0350-3469 FU CDC through Kenya Medical Research Institute FX Supported by the CDC through a cooperative agreement between the CDC and Kenya Medical Research Institute. Global Alliance for Improved Nutrition contributed funds for the follow-up evaluation. Sprinkles Global Health Initiative provided Sprinkles sachets. NR 36 TC 24 Z9 27 U1 0 U2 16 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD MAY PY 2012 VL 95 IS 5 BP 1223 EP 1230 DI 10.3945/ajcn.111.030072 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 930LK UT WOS:000303140700029 PM 22492366 ER PT J AU Grant, FKE Martorell, R Flores-Ayala, R Cole, CR Ruth, LJ Ramakrishnan, U Suchdev, PS AF Grant, Frederick K. E. Martorell, Reynaldo Flores-Ayala, Rafael Cole, Conrad R. Ruth, Laird J. Ramakrishnan, Usha Suchdev, Parminder S. TI Comparison of indicators of iron deficiency in Kenyan children SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID SERUM TRANSFERRIN RECEPTOR; FERRITIN CONCENTRATIONS; PRESCHOOL-CHILDREN; CAPILLARY BLOOD; ANEMIA; WOMEN; AGE; INFLAMMATION; POPULATION; HEMOGLOBIN AB Background: In the absence of a feasible, noninvasive gold standard, iron deficiency (ID) is best measured by the use of multiple indicators. However, the choice of an appropriate single iron biomarker to replace the multiple-criteria model for screening for ID at the population level continues to be debated. Objective: We compared ID defined as >= 2 of 3 abnormal ferritin (<12 mu g/L), soluble transferrin receptor (TfR; >8.3 mg/L), or zinc protoporphyrin (ZP; >80 mu mol/mol) concentrations (ie, multiplecriteria model) with ID defined by abnormal concentrations of any of the independent candidate iron biomarkers (ferritin alone, TfR alone, or ZP alone) and TfR/ferritin index (ID, >500). Values either were adjusted for inflammation [as measured by C-reactive protein (>5 mg/L) and alpha(1)-acid glycoprotein (>1 g/L) before applying cutoffs for ID] or were unadjusted. Design: In this community-based cluster survey, capillary blood was obtained from 680 children (aged 6-35 mo) for measurement of iron status by using ferritin, TfR, and ZP. Results: On the basis of the multiple-criteria model, the mean (+/- SE) prevalence of ID was 61.9 +/- 2.2%, whereas the prevalences based on abnormal ferritin, TfR, or ZP concentrations or an abnormal TfR/ferritin index were 26.9 +/- 1.7%, 60.9 +/- 2.2%, 82.8 +/- 1.6%, and 43.1 +/- 2.3%, respectively, for unadjusted values. The prevalences of ID were higher for adjusted values only for low ferritin and an elevated TfR/ferritin index compared with the unadjusted values. The kappa statistics for agreement between the multiple-criteria model and the other iron indicators ranged from 0.35 to 0.88; TfR had the best agreement (kappa = 0.88) with the multiplecriteria model. Positive predictive values of ID based on the other iron indicators in predicting ID based on the multiple-criteria model were highest for ferritin and TfR. Receiver operating characteristic curve analysis indicated that TfR (AUC = 0.94) was superior to the other indicators in diagnosing ID based on the multiple-criteria model (P < 0.001). The inflammation effect did not appear to alter these observations appreciably. Conclusion: TfR better estimates the prevalence of ID in preschoolers than do ferritin. ZP, and the TfR/ferritin index on the basis of multiple indexes in a high inflammation, resource-poor setting. This trial was registered at clinicaltrials.gov as NCT101088958. Am J Clin Nutr 2012;95:1231-7. C1 [Grant, Frederick K. E.; Martorell, Reynaldo; Ramakrishnan, Usha; Suchdev, Parminder S.] Emory Univ, Nutr & Hlth Sci Program, Grad Div Biol & Biomed Sci, Atlanta, GA 30322 USA. [Suchdev, Parminder S.] Emory Univ, Dept Pediat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Grant, Frederick K. E.; Flores-Ayala, Rafael; Ramakrishnan, Usha; Suchdev, Parminder S.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Cole, Conrad R.] Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH USA. [Flores-Ayala, Rafael; Ruth, Laird J.; Suchdev, Parminder S.] CDC, Atlanta, GA 30333 USA. RP Grant, FKE (reprint author), Emory Univ, Nutr & Hlth Sci Program, Grad Div Biol & Biomed Sci, 1599 Clifton Rd NE,Room 6-434, Atlanta, GA 30322 USA. EM ebogrant5@yahoo.com RI Martorell, Reynaldo /I-2539-2012; Suchdev, Parmi/K-4851-2012; Ramakrishnan, Usha/L-8921-2016; OI Suchdev, Parmi/0000-0002-0350-3469 FU Medical Foundation/Nevin Scrimshaw International Nutrition Foundation; CDC FX Supported in part by an Ellison Medical Foundation/Nevin Scrimshaw International Nutrition Foundation fellowship (FKEG) and the CDC (PSS). NR 41 TC 16 Z9 17 U1 0 U2 5 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD MAY PY 2012 VL 95 IS 5 BP 1231 EP 1237 DI 10.3945/ajcn.111.029900 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 930LK UT WOS:000303140700030 PM 22456661 ER PT J AU Yang, QH Bailey, L Clarke, R Flanders, WD Liu, TB Yesupriya, A Khoury, MJ Friedman, JM AF Yang, Quanhe Bailey, Lynn Clarke, Robert Flanders, W. Dana Liu, Tiebin Yesupriya, Ajay Khoury, Muin J. Friedman, Jan M. TI Prospective study of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of all-cause and cardiovascular disease mortality among 6000 US adults SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID CORONARY-HEART-DISEASE; TOTAL HOMOCYSTEINE CONCENTRATIONS; RANDOMIZED CONTROLLED-TRIAL; 3RD NATIONAL-HEALTH; FOLIC-ACID; MENDELIAN RANDOMIZATION; B-VITAMINS; MYOCARDIAL-INFARCTION; UNITED-STATES; SERUM FOLATE AB Background: The association between blood homocysteine concentration and the risk of cardiovascular disease (CVD) remains controversial, but few studies have examined the association between MTHFR C677T (a proxy for high homocysteine concentration) and death from CVD. Objective: The objective was to examine associations of MTHFR C677T, a proxy for high homocysteine concentrations, with CVD mortality and with all-cause mortality in a national representative prospective cohort of the US adult population before the introduction of mandatory folic acid fortification of flour. Design: We used Mendelian randomization to examine the association of MTHFR C677T with cause-specific mortality in 5925 participants by accessing the NHANES III (1991-1994) Linked Mortality File (through 2006). Results: A comparison of homozygotes at baseline showed that individuals with a TT genotype had a 2.2-mu mol/L higher homocysteine and a 1.4-ng/mL lower folate concentration, respectively, than did those with a CC genotype. The TT genotype frequency varied from 1.2% (95% CI: 0.7. 2.0) in non-Hispanic blacks and 11.6% (95% CI: 9.6, 14.0) in non-Hispanic whites to 19.4% (95% CI: 16.7, 22.3) in Mexican Americans. After adjustment for ethnic group and other CVD risk factors, the MTHFR C677T TT genotype was associated with significantly lower CVD mortality (HR: 0.69; 95% CI: 0.50, 0. 95) but had no significant effect on all-cause mortality (HR: 0.79; 95% CI: 0.59, 1.05). After stratification by period of followup, the inverse association of MTHFR with CVD mortality was significant only in the period after introduction of mandatory folic acid fortification. Conclusion: The inverse association of MTHFR with CVD mortality was unexpected and highlights the need for caution in interpretation of Mendelian randomization studies, which, like other observational studies, can be influenced by chance, bias, or confounding. Am J Clin Nutr 2012;95:1245-53. C1 [Yang, Quanhe] CDC, Div Heart Dis & Stroke Prevent, Off Publ Hlth Genom, Atlanta, GA 30341 USA. [Bailey, Lynn] Univ Georgia, Dept Foods & Nutr, Athens, GA 30602 USA. [Clarke, Robert] Univ Oxford, Clin Trial Serv Unit, Oxford, England. [Clarke, Robert] Univ Oxford, Epidemiol Studies Unit, Oxford, England. [Flanders, W. Dana] Emory Univ, Dept Epidemiol, Rolling Sch Publ Hlth, Atlanta, GA 30322 USA. [Friedman, Jan M.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. RP Yang, QH (reprint author), CDC, Div Heart Dis & Stroke Prevent, Off Publ Hlth Genom, 4770 Buford Highway NE,Mail Stop F-72, Atlanta, GA 30341 USA. EM qay0@cdc.gov FU Medical Research Council [MC_U137686857] NR 48 TC 26 Z9 26 U1 0 U2 12 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD MAY PY 2012 VL 95 IS 5 BP 1245 EP 1253 DI 10.3945/ajcn.111.022384 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 930LK UT WOS:000303140700032 PM 22492374 ER PT J AU Gupta, S Siddiqi, AEA Soucie, JM Manco-Johnson, MJ Kulkarni, R Lane, H Ingram-Rich, R Gill, JC AF Gupta, Sweta Siddiqi, Azfar-E-Alam Soucie, J. Michael Manco-Johnson, Marilyn J. Kulkarni, Roshni Lane, Heidi Ingram-Rich, Robina Gill, Joan C. TI Effect of Secondary Prophylaxis Versus Episodic Treatment on Range of Motion of a Target Joint in Hemophilia Patients SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Meeting Abstract C1 [Gupta, Sweta] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA. [Siddiqi, Azfar-E-Alam; Soucie, J. Michael] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. [Manco-Johnson, Marilyn J.] Univ Colorado, Denver, CO 80202 USA. [Kulkarni, Roshni] Michigan State Univ, E Lansing, MI 48824 USA. [Lane, Heidi] Intermt Hemophilia & Thrombosis Ctr, Salt Lake City, UT USA. [Ingram-Rich, Robina] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Gill, Joan C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD MAY PY 2012 VL 87 SU 1 BP S161 EP S162 PG 2 WC Hematology SC Hematology GA 928RB UT WOS:000302999500068 ER PT J AU McCann, ME Tencza, CB McDermott, L Wirth, D Peltier, S McCool, K Varga, E Damiano, ML Riske, B Critchley, S Hassell, K Brownstein, AP AF McCann, Mary Ellen Tencza, Catherine B. McDermott, Laura Wirth, Diane Peltier, Skye McCool, Kathleen Varga, Elizabeth Damiano, Mary Lou Riske, Brenda Critchley, Sara Hassell, Kathryn Brownstein, Alan P. TI Tactics to Promote Thrombosis and Thrombophilia Awareness in Healthcare Professionals SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Meeting Abstract C1 [McCann, Mary Ellen; Brownstein, Alan P.] Natl Blood Clot Alliance, Tarrytown, NY USA. [Tencza, Catherine B.] Tencza Designs, Alpharetta, GA USA. [McDermott, Laura] Univ New Mexico Hosp, Albuquerque, NM USA. [Wirth, Diane] Grady Hlth Syst, Atlanta, GA USA. [Peltier, Skye] Childrens Hosp, Minneapolis, MN USA. [Peltier, Skye] Clin Minnesota, Minneapolis, MN USA. [McCool, Kathleen] Kaiser Permanente, Aurora, CO USA. [Varga, Elizabeth] Nationwide Childrens Hosp, Columbus, OH USA. [Damiano, Mary Lou] Arizona Hlth Sci Ctr, Tucson, AZ 85724 USA. [Riske, Brenda] Mt States Reg Hemophilia & Thrombosis Ctr, Aurora, CO USA. [Critchley, Sara] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hassell, Kathryn] Univ Colorado, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD MAY PY 2012 VL 87 SU 1 BP S190 EP S191 PG 2 WC Hematology SC Hematology GA 928RB UT WOS:000302999500141 ER PT J AU Bateman, BT Callaghan, WM Kuklina, EV AF Bateman, Brian T. Callaghan, William M. Kuklina, Elena V. TI Safety and efficiency of multiple square sutures to avoid peripartum hysterectomy REPLY SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Letter C1 [Bateman, Brian T.] Harvard Univ, Massachusetts Gen Hosp, Div Obstet Anesthesia, Dept Anesthesia Crit Care & Pain Med,Med Sch, Boston, MA 02114 USA. [Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Kuklina, Elena V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Bateman, BT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Div Obstet Anesthesia, Dept Anesthesia Crit Care & Pain Med,Med Sch, 55 Fruit St, Boston, MA 02114 USA. EM BBateman@partners.org FU Intramural CDC HHS [CC999999] NR 3 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD MAY PY 2012 VL 206 IS 5 BP E5 EP E6 DI 10.1016/j.ajog.2012.02.039 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 931JB UT WOS:000303211100007 PM 22459344 ER PT J AU Harshbarger, CL O'Donnell, LN Warner, L Margolis, AD Richardson, DB Novey, SR Glover, LC Klausner, JD Malotte, CK Rietmeijer, CA AF Harshbarger, Camilla L. O'Donnell, Lydia N. Warner, Lee Margolis, Andrew D. Richardson, Doug B. Novey, Sharon R. Glover, LaShon C. Klausner, Jeffrey D. Malotte, C. Kevin Rietmeijer, Cornelis A. TI Safe in the City Effective Prevention Interventions for Human Immunodeficiency Virus and Sexually Transmitted Infections SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID NATIONAL HIV/AIDS STRATEGY; UNITED-STATES; EFFICACY; TRIALS AB Background: The public health literature documents the efficacy-effectiveness gap between research and practice resulting from the research priority of demonstrating efficacy at the expense of testing for effectiveness. Purpose: The Safe in the City video-based HIV/sexually transmitted infection (STI) prevention intervention designed for sexually transmitted disease (STD) clinic waiting rooms is presented as a case study to demonstrate the application of a new framework to bridge efficacy and effectiveness. The goal of the study is to determine the extent to which clinics are implementing the intervention. Methods: As part of the case study, data were collected from a convenience sample of 81 publicly funded STD clinics during program implementation to determine whether clinics were showing the video. A baseline telephone survey was administered to clinic directors from November to December 2008, and a follow-up was conducted from March to May 2009. Data analysis was completed in 2009. Results: At baseline, 41% of STD clinics were showing Safe in the City, which increased to 58% at follow-up. None reported previous implementation of behavioral interventions delivered in waiting rooms. Almost one fourth of clinics adapted the intervention by showing the video on laptop computers in examination rooms or in other venues with different audiences. Conclusions: The Safe in the City intervention was implemented by the majority of STD clinics and adapted for implementation. The framework for HIV/STI prevention intervention illustrates how measures of effectiveness were increased in the development, evaluation, dissemination, implementation and sustainability phases of research and program. (Am J Prev Med 2012;42(5):468-472) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Harshbarger, Camilla L.; Warner, Lee; Margolis, Andrew D.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Warner, Lee] CDC, Div Reprod Hlth, Natl Ctr Chron Dis & Hlth Promot, Atlanta, GA 30333 USA. [O'Donnell, Lydia N.] Educ Dev Ctr, Newton, MA USA. [Richardson, Doug B.] Denver Hlth & Hosp Author, Dept Community Hlth Serv, Denver, CO USA. [Rietmeijer, Cornelis A.] Denver Publ Hlth Dept, Denver, CO USA. [Novey, Sharon R.; Glover, LaShon C.] Acad Educ Dev, Washington, DC USA. [Klausner, Jeffrey D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Malotte, C. Kevin] Calif State Univ Long Beach, Long Beach, CA 90840 USA. RP Harshbarger, CL (reprint author), 1600 Clifton Rd NE,Mailstop E-37, Atlanta, GA 30333 USA. EM uzz9@cdc.gov FU CDC [200-2003-01924]; Academy for Educational Development; Denver Health and Hospital authority; San Francisco Department of Public Health, San Francisco, California; Denver Department of Public Health, Denver, Colorado; California State University, Long Beach, California; Education Development Center, Inc., Newton, Massachusetts FX The authors gratefully acknowledge support for the assessment of the implementation of Safe in the City from the CDC Contract No. 200-2003-01924 conducted in collaboration with the Academy for Educational Development and Denver Health and Hospital authority. The authors thank Teri Sapp-Jones, Benton Westergaard, and Jun Zhang for data collection and management. The development and evaluation of the intervention was funded by the CDC, and conducted in collaboration with the San Francisco Department of Public Health, San Francisco, California; Denver Department of Public Health, Denver, Colorado; California State University, Long Beach, California; and the Education Development Center, Inc., Newton, Massachusetts, in collaboration with the Safe City Study Group. We thank Jeffrey Herbst and Patricia Coury-Doniger for comments on an earlier draft of the manuscript. NR 23 TC 2 Z9 2 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2012 VL 42 IS 5 BP 468 EP 472 DI 10.1016/j.amepre.2012.01.029 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 928ED UT WOS:000302963300011 PM 22516486 ER PT J CA Community Preventive Serv Task Force TI Recommendation from the Community Preventive Services Task Force for Use of Collaborative Care for the Management of Depressive Disorders SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; CHRONIC ILLNESS; PILOT; INTERVENTION; DISEASE; CANCER; NURSE AB The Community Preventive Services Task Force recommends collaborative care for management of depressive disorders, based on strong evidence of effectiveness in improving depression symptoms, adherence to treatment, response to treatment, and remission and recovery from depression. (Am J Prev Med 2012;42(5):521-524) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 Care of Thota A, CDC, Community Guide Branch, Atlanta, GA 30333 USA. RP Care of Thota A, CDC, Community Guide Branch, 1600 Clifton Rd,Mailstop E69, Atlanta, GA 30333 USA. NR 25 TC 0 Z9 1 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2012 VL 42 IS 5 BP 521 EP 524 DI 10.1016/j.amepre.2012.01.010 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 928ED UT WOS:000302963300019 ER PT J AU Thota, AB Sipe, TA Byard, GJ Zometa, CS Hahn, RA McKnight-Eily, LR Chapman, DP Abraido-Lanza, AF Pearson, JL Anderson, CW Gelenberg, AJ Hennessy, KD Duffy, FF Vernon-Smiley, ME Nease, DE Williams, SP AF Thota, Anilkrishna B. Sipe, Theresa Ann Byard, Guthrie J. Zometa, Carlos S. Hahn, Robert A. McKnight-Eily, Lela R. Chapman, Daniel P. Abraido-Lanza, Ana F. Pearson, Jane L. Anderson, Clinton W. Gelenberg, Alan J. Hennessy, Kevin D. Duffy, Farifteh F. Vernon-Smiley, Mary E. Nease, Donald E., Jr. Williams, Samantha P. CA Community Preventive Serv Task TI Collaborative Care to Improve the Management of Depressive Disorders A Community Guide Systematic Review and Meta-Analysis SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; OLDER MEDICAL INPATIENTS; UK PRIMARY-CARE; PREVENTIVE-SERVICES; UNITED-STATES; QUALITY IMPROVEMENT; CHRONIC ILLNESS; HEALTH-CARE; TASK-FORCE; INTERVENTION AB Context: To improve the quality of depression management, collaborative care models have been developed from the Chronic Care Model over the past 20 years. Collaborative care is a multicomponent, healthcare system-level intervention that uses case managers to link primary care providers, patients, and mental health specialists. In addition to case management support, primary care providers receive consultation and decision support from mental health specialists (i.e., psychiatrists and psychologists). This collaboration is designed to (1) improve routine screening and diagnosis of depressive disorders; (2) increase provider use of evidence-based protocols for the proactive management of diagnosed depressive disorders; and (3) improve clinical and community support for active client/patient engagement in treatment goal-setting and self-management. Evidence acquisition: A team of subject matter experts in mental health, representing various agencies and institutions, conceptualized and conducted a systematic review and meta-analysis on collaborative care for improving the management of depressive disorders. This team worked under the guidance of the Community Preventive Services Task Force, a nonfederal, independent, volunteer body of public health and prevention experts. Community Guide systematic review methods were used to identify, evaluate, and analyze available evidence. Evidence synthesis: An earlier systematic review with 37 RCTs of collaborative care studies published through 2004 found evidence of effectiveness of these models in improving depression outcomes. An additional 32 studies of collaborative care models conducted between 2004 and 2009 were found for this current review and analyzed. The results from the meta-analyses suggest robust evidence of effectiveness of collaborative care in improving depression symptoms (standardized mean difference [SMD] = 0.34); adherence to treatment (OR = 2.22); response to treatment (OR = 1.78); remission of symptoms (OR = 1.74); recovery from symptoms (OR = 1.75); quality of life/functional status (SMD = 0.12); and satisfaction with care (SMD = 0.39) for patients diagnosed with depression (all effect estimates were significant). Conclusions: Collaborative care models are effective in achieving clinically meaningful improvements in depression outcomes and public health benefits in a wide range of populations, settings, and organizations. Collaborative care interventions provide a supportive network of professionals and peers for patients with depression, especially at the primary care level. (Am J Prev Med 2012;42(5):525-538) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Thota, Anilkrishna B.; Sipe, Theresa Ann; Byard, Guthrie J.; Zometa, Carlos S.; Hahn, Robert A.] CDC, Community Guide Branch, Epidemiol & Anal Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [McKnight-Eily, Lela R.; Chapman, Daniel P.] CDC, Div Populat Hlth, Atlanta, GA 30333 USA. [Vernon-Smiley, Mary E.] CDC, Div Adolescent & Sch Hlth, Atlanta, GA 30333 USA. [Williams, Samantha P.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Williams, Samantha P.] CDC, Behav Intervent & Res Branch, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Abraido-Lanza, Ana F.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Pearson, Jane L.] NIMH, Bethesda, MD 20892 USA. [Hennessy, Kevin D.] Subst Abuse & Mental Hlth Serv Adm, Rockville, MD USA. [Anderson, Clinton W.] Amer Psychol Assoc, Washington, DC 20036 USA. [Gelenberg, Alan J.] Penn State Hershey Med Ctr, Dept Psychiat, Hershey, PA USA. [Duffy, Farifteh F.] Amer Psychiat Assoc, Arlington, VA USA. [Nease, Donald E., Jr.] Amer Acad Family Phys, Denver, CO USA. RP Thota, AB (reprint author), CDC, Community Guide Branch, Epidemiol & Anal Program Off, Off Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd,Mailstop E69, Atlanta, GA 30333 USA. EM athota@cdc.gov RI Thota, Anilkrishna/J-1743-2012; Nease, Donald/B-6206-2013 OI Nease, Donald/0000-0001-8323-3720 FU Pfizer Pharmaceuticals FX AJG is a major stock owner of Healthcare Technology Stystems, Inc.; he consults to Dey Pharma, PGxHealth, Myriad Genetics, and Zynx Health; and is the principal investigator on an investigator-initiated grant from Pfizer Pharmaceuticals to Penn State. No other financial disclosures were reported by the authors of this paper. NR 76 TC 148 Z9 149 U1 8 U2 41 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2012 VL 42 IS 5 BP 525 EP 538 DI 10.1016/j.amepre.2012.01.019 PG 14 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 928ED UT WOS:000302963300020 PM 22516495 ER PT J AU Jacob, V Chattopadhyay, SK Sipe, TA Thota, AB Byard, GJ Chapman, DP AF Jacob, Verughese Chattopadhyay, Sajal K. Sipe, Theresa Ann Thota, Anilkrishna B. Byard, Guthrie J. Chapman, Daniel P. CA Community Preventive Serv Task TI Economics of Collaborative Care for Management of Depressive Disorders A Community Guide Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; COST-EFFECTIVENESS; UNITED-STATES; PREVENTIVE-SERVICES; MAJOR DEPRESSION; INTERVENTION; BURDEN; IMPACT; COMORBIDITY; PREVALENCE AB Context: Major depressive disorders are frequently underdiagnosed and undertreated. Collaborative Care models developed from the Chronic Care Model during the past 20 years have improved the quality of depression management in the community, raising intervention cost incrementally above usual care. This paper assesses the economic efficiency of collaborative care for management of depressive disorders by comparing its economic costs and economic benefits to usual care, as informed by a systematic review of the literature. Evidence acquisition: The economic review of collaborative care for management of depressive disorders was conducted in tandem with a review of effectiveness, under the guidance of the Community Preventive Services Task Force, a nonfederal, independent group of public health leaders and experts. Economic review methods developed by the Guide to Community Preventive Services were used by two economists to screen, abstract, adjust, and summarize the economic evidence of collaborative care from societal and other perspectives. An earlier economic review that included eight RCTs was included as part of the evidence. The present economic review expanded the evidence with results from studies published from 1980 to 2009 and included both RCTs and other study designs. Evidence synthesis: In addition to the eight RCTs included in the earlier review, 22 more studies of collaborative care that provided estimates for economic outcomes were identified, 20 of which were evaluations of actual interventions and two of which were based on models. Of seven studies that measured only economic benefits of collaborative care in terms of averted healthcare or productivity loss, four found positive economic benefits due to intervention and three found minimal or no incremental benefit. Of five studies that measured both benefits and costs, three found lower collaborative care cost because of reduced healthcare utilization or enhanced productivity, and one found the same for a subpopulation of the intervention group. One study found that willingness to pay for collaborative care exceeded program costs. Among six cost-utility studies, five found collaborative care was cost effective. In two modeled studies, one showed cost effectiveness based on comparison of $/disability-adjusted life-year to annual per capita income; the other demonstrated cost effectiveness based on the standard threshold of $50,000/quality-adjusted life year, unadjusted for inflation. Finally, six of eight studies in the earlier review reported that interventions were cost effective on the basis of the standard threshold. Conclusions: The evidence indicates that collaborative care for management of depressive disorders provides good economic value. (Am J Prev Med 2012; 42(5): 539-549) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Jacob, Verughese; Chattopadhyay, Sajal K.; Sipe, Theresa Ann; Thota, Anilkrishna B.; Byard, Guthrie J.] CDC, Community Guide Branch, Epidemiol & Anal Program Off, Atlanta, GA 30333 USA. [Chapman, Daniel P.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Chattopadhyay, SK (reprint author), CDC, Community Guide Branch, Epidemiol & Anal Program Off, 1600 Clifton Rd,Mailstop E69, Atlanta, GA 30333 USA. EM skc9@cdc.gov RI Thota, Anilkrishna/J-1743-2012; OI Jacob, Verughese/0000-0001-6833-6588 NR 47 TC 44 Z9 45 U1 1 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2012 VL 42 IS 5 BP 539 EP 549 DI 10.1016/j.amepre.2012.01.011 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 928ED UT WOS:000302963300021 PM 22516496 ER PT J AU Dietz, WH AF Dietz, William H. TI Implications of the Energy Gap for the Prevention and Treatment of Childhood Obesity SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID BODY-MASS INDEX; CHILDREN; US; MANAGEMENT C1 CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Dietz, WH (reprint author), CDC, Div Nutr Phys Act & Obes, 3440 Buford Hwy NE,MS-K24, Atlanta, GA 30341 USA. EM wcd4@cdc.gov NR 13 TC 2 Z9 2 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2012 VL 42 IS 5 BP 560 EP 561 DI 10.1016/j.amepre.2012.02.001 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 928ED UT WOS:000302963300026 PM 22516501 ER PT J AU McCarthy, KD Cain, KP Winthrop, KL Udomsantisuk, N Lan, NTN Sar, B Kimerling, ME Kanara, N Lynen, L Monkongdee, P Tasaneeyapan, T Varma, JK AF McCarthy, Kimberly D. Cain, Kevin P. Winthrop, Kevin L. Udomsantisuk, Nibondh Lan, Nguyen T. N. Sar, Borann Kimerling, Michael E. Kanara, Nong Lynen, Lut Monkongdee, Patama Tasaneeyapan, Theerawit Varma, Jay K. TI Nontuberculous Mycobacterial Disease in Patients with HIV in Southeast Asia SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE Mycobacterium species; pathogenic; immunocompromised; diagnosis ID ACQUIRED IMMUNODEFICIENCY SYNDROME; ACTIVE ANTIRETROVIRAL THERAPY; AVIUM COMPLEX INFECTION; PULMONARY-DISEASE; TUBERCULOSIS; EPIDEMIOLOGY; DIAGNOSIS; AIDS; IDENTIFICATION; PERFORMANCE AB Rationale: Although nontuberculous mycobacteria (NTM) are widely documented as a cause of illness among HIV-infected people in the developed world, studies describing the prevalence of NTM disease among HIV-infected people in most resource-limited settings are rare. Objectives: To evaluate the prevalence of mycobacterial disease in HIV-infected patients in Southeast Asia. Methods: We enrolled people with HIV from three countries in Southeast Asia and collected pulmonary and extrapulmonary specimens to evaluate the prevalence of mycobacterial disease. We adapted American Thoracic Society/Infectious Disease Society of America guidelines to classify patients into NTM pulmonary disease, NTM pulmonary disease suspects, NTM disseminated disease, and no NTM categories. Measurements and Main Results: Ill Cambodia, where solid media alone was used, NTM was rare. 0 1,060 patients enrolled in Thailand and Vietnam, where liquid culture was performed, 124(12%) had tuberculosis and 218 (21%) had NTM. Of 218 patients with NTM, 66(30%) were classified as NTM pulmonary disease suspects, 9(4%) with NTM pulmonary disease, and 10(5%) with NTM disseminated disease. The prevalence of NTM disease was 2% (19 of 1,060). Of 51 patients receiving antiretroviral therapy (ART), none had NTM disease compared with 19(2%) of 1,009 not receiving ART. Conclusions: Although people with HIV frequently have sputum cultures positive for NTM, few meet a strict case definition for NTM disease. Consistent with previous studies, ART was associated with lower odds of having NTM disease. Further studies of NTM in HIV-infected individuals in tuberculosis-endemic countries are needed to develop and validate case definitions. C1 [McCarthy, Kimberly D.; Cain, Kevin P.; Varma, Jay K.] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Udomsantisuk, Nibondh] Chulalongkorn Univ, Fac Med, Dept Microbiol, Bangkok 10330, Thailand. [Lan, Nguyen T. N.] Pham Ngoc Thach Hosp TB & Lung Dis, Ho Chi Minh City, Vietnam. [Sar, Borann] Inst Pasteur Cambodia, Phnom Penh, Cambodia. [Kimerling, Michael E.] Univ Alabama Birmingham, Birmingham, AL USA. [Kimerling, Michael E.] Bill & Melinda Gates Fdn, Seattle, WA USA. [Kanara, Nong] US Ctr Dis Control & Prevent, Global AIDS Program, Phnom Penh, Cambodia. [Lynen, Lut] Inst Trop Med, B-2000 Antwerp, Belgium. [Monkongdee, Patama; Tasaneeyapan, Theerawit; Varma, Jay K.] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. RP McCarthy, KD (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS-F-08, Atlanta, GA 30333 USA. EM kmccarthy3@cdc.gov RI Lynen, Lutgarde/A-1212-2014 OI Lynen, Lutgarde/0000-0001-7183-4895 NR 39 TC 21 Z9 23 U1 0 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAY 1 PY 2012 VL 185 IS 9 BP 981 EP 988 DI 10.1164/rccm.201107.1327OC PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 930ZE UT WOS:000303182700013 PM 22345581 ER PT J AU Chin-Hong, PV Bosserman, E Montgomery, SP Moore, A Herwaldt, B Schwartz, BS Bern, C AF Chin-Hong, P. V. Bosserman, E. Montgomery, S. P. Moore, A. Herwaldt, B. Schwartz, B. S. Bern, C. TI Reactivation of Chagas Disease in US Transplant Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY MAY, 2012 CL Boston, MA C1 [Chin-Hong, P. V.; Schwartz, B. S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Bosserman, E.; Montgomery, S. P.; Moore, A.; Herwaldt, B.; Bern, C.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2012 VL 12 SU 3 SI SI MA 309 BP 118 EP 118 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 931QX UT WOS:000303235500310 ER PT J AU Metzger, RA Angelis, M Johnson, W Chen, JG Martin, M Visvesvara, GS Beach, MJ Yoder, JS Roy, SL AF Metzger, R. A. Angelis, M. Johnson, W. Chen, J. G. Martin, M. Visvesvara, G. S. Beach, M. J. Yoder, J. S. Roy, S. L. TI Outcomes of Solid Organ Transplant Recipients from Donors with Primary Amebic Meningoencephalitis (PAM) Due to Naegleria fowleri SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY MAY, 2012 CL Boston, MA C1 [Metzger, R. A.; Angelis, M.; Johnson, W.] TransLife Organ Procurement Org, Winter Pk, FL USA. [Metzger, R. A.; Angelis, M.] Florida Hosp Transplant Ctr, Dept Transplantat, Orlando, FL USA. [Chen, J. G.; Martin, M.] Arnold Palmer Hosp Children, Orlando, FL USA. [Visvesvara, G. S.; Beach, M. J.; Yoder, J. S.; Roy, S. L.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2012 VL 12 SU 3 SI SI MA 313 BP 119 EP 119 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 931QX UT WOS:000303235500314 ER PT J AU Vikram, HR Weber, IB Winston, DJ Honng, JC Mulligan, DC Dhillon, GS Nowicki, MJ Mone, TD Civen, RH Tecle, SA Trivedi, KK Hocevar, SN AF Vikram, H. R. Weber, I. B. Winston, D. J. Honng, J. C. Mulligan, D. C. Dhillon, G. S. Nowicki, M. J. Mone, T. D. Civen, R. H. Tecle, S. A. Trivedi, K. K. Hocevar, S. N. TI Investigation of Donor-Derived West Nile Virus (WNV) Infection in Four Recipients. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY MAY, 2012 CL Boston, MA C1 [Vikram, H. R.; Mulligan, D. C.] Mayo Clin, Phoenix, AZ USA. [Weber, I. B.; Hocevar, S. N.] CDC, Atlanta, GA 30333 USA. [Winston, D. J.; Honng, J. C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Dhillon, G. S.] Stanford, Palo Alto, CA USA. [Nowicki, M. J.] MNIT, Los Angeles, CA USA. [Mone, T. D.] OneLegacy, Los Angeles, CA USA. [Civen, R. H.] LA Cty Dept Publ Hlth, Los Angeles, CA USA. [Tecle, S. A.] AZ Dept Hlth Serv, Phoenix, AZ USA. [Trivedi, K. K.] CA Dept Publ Hlth, Richmond, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2012 VL 12 SU 3 SI SI MA LB14 BP 360 EP 360 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 931QX UT WOS:000303235503029 ER PT J AU Mahajan, R Hocevar, S Kuehnert, MJ Holmberg, SD Thoroughman, D Marvin, MR AF Mahajan, R. Hocevar, S. Kuehnert, M. J. Holmberg, S. D. Thoroughman, D. Marvin, M. R. TI Transmission of Hepatitis C Virus through Transplanted Organs and Tissues-Kentucky and Massachusetts, 2011 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY MAY, 2012 CL Boston, MA C1 [Mahajan, R.; Hocevar, S.; Kuehnert, M. J.; Holmberg, S. D.] CDC, Atlanta, GA 30333 USA. [Marvin, M. R.] Univ Louisville, Jewish Hosp, Louisville, KY 40292 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2012 VL 12 SU 3 SI SI MA LB37 BP 453 EP 453 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 931QX UT WOS:000303235504028 ER PT J AU Greenland, S AF Greenland, Sander TI Underestimating effects: Why causation probabilities need to be replaced in regulation, policy, and the law SO BULLETIN OF THE ATOMIC SCIENTISTS LA English DT Article DE attributable fraction; causation; compensation; epidemiology; exposure; probability of causation; radiation; risk ID RELATIVE RISK; ESTIMABILITY; FRACTIONS; CANCER; MODEL AB Causation probabilities are often a component of decisions on awarding compensation for radiation exposure and descriptions of the number of cancers caused by radiation releases. In many instances, the use of epidemiologic data to calculate such probabilities may seriously underestimate the number of people harmed and the percentage of cancers induced or accelerated by the radiation exposure. Epidemiologic studies can more reliably underpin systems that award compensation using years of healthy life lost due to the exposure. Such a system has its own imprecisions but is more scientifically supportable than using causation probabilities to award compensation. C1 [Greenland, Sander] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Greenland, Sander] US FDA, Rockville, MD 20857 USA. [Greenland, Sander] Ctr Dis Control, Atlanta, GA 30333 USA. RP Greenland, S (reprint author), Univ Calif Los Angeles, Los Angeles, CA 90024 USA. NR 11 TC 3 Z9 3 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0096-3402 J9 B ATOM SCI JI Bull. Atom. Scient. PD MAY-JUN PY 2012 VL 68 IS 3 BP 76 EP 83 DI 10.1177/0096340212444873 PG 8 WC International Relations; Social Issues SC International Relations; Social Issues GA 933WL UT WOS:000303395900010 ER PT J AU Eheman, C Henley, SJ Ballard-Barbash, R Jacobs, EJ Schymura, MJ Noone, AM Pan, LP Anderson, RN Fulton, JE Kohler, BA Jemal, A Ward, E Plescia, M Ries, LAG Edwards, BK AF Eheman, Christie Henley, S. Jane Ballard-Barbash, Rachel Jacobs, Eric J. Schymura, Maria J. Noone, Anne-Michelle Pan, Liping Anderson, Robert N. Fulton, Janet E. Kohler, Betsy A. Jemal, Ahmedin Ward, Elizabeth Plescia, Marcus Ries, Lynn A. G. Edwards, Brenda K. TI Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity SO CANCER LA English DT Editorial Material DE cancer; incidence; mortality; Surveillance; Epidemiology; and End Results; the North American Association of Central Cancer Registries; National Program of Cancer Registries; United States; obesity; physical inactivity ID BODY-MASS INDEX; UNITED-STATES; COLORECTAL-CANCER; BREAST-CANCER; CHILDHOOD OBESITY; INCIDENCE RATES; COLON-CANCER; RISK-FACTORS; LUNG-CANCER; EPIDEMIOLOGIC EVIDENCE AB BACKGROUND: Annual updates on cancer occurrence and trends in the United States are provided through collaboration between the American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR). This year's report highlights the increased cancer risk associated with excess weight (overweight or obesity) and lack of sufficient physical activity (<150 minutes of physical activity per week). METHODS: Data on cancer incidence were obtained from the CDC, NCI, and NAACCR; data on cancer deaths were obtained from the CDC's National Center for Health Statistics. Annual percent changes in incidence and death rates (age-standardized to the 2000 US population) for all cancers combined and for the leading cancers among men and among women were estimated by joinpoint analysis of long-term trends (incidence for 1992-2008 and mortality for 1975-2008) and short-term trends (1999-2008). Information was obtained from national surveys about the proportion of US children, adolescents, and adults who are overweight, obese, insufficiently physically active, or physically inactive. RESULTS: Death rates from all cancers combined decreased from 1999 to 2008, continuing a decline that began in the early 1990s, among men and among women in most racial and ethnic groups. Death rates decreased from 1999 to 2008 for most cancer sites, including the 4 most common cancers (lung, colorectum, breast, and prostate). The incidence of prostate and colorectal cancers also decreased from 1999 to 2008. Lung cancer incidence declined from 1999 to 2008 among men and from 2004 to 2008 among women. Breast cancer incidence decreased from 1999 to 2004 but was stable from 2004 to 2008. Incidence increased for several cancers, including pancreas, kidney, and adenocarcinoma of the esophagus, which are associated with excess weight. CONCLUSIONS: Although improvements are reported in the US cancer burden, excess weight and lack of sufficient physical activity contribute to the increased incidence of many cancers, adversely affect quality of life for cancer survivors, and may worsen prognosis for several cancers. The current report highlights the importance of efforts to promote healthy weight and sufficient physical activity in reducing the cancer burden in the United States.* Cancer 2012; 118: 2338-66. (C) 2012 American Cancer Society. C1 [Eheman, Christie; Henley, S. Jane; Plescia, Marcus] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Ballard-Barbash, Rachel; Noone, Anne-Michelle; Ries, Lynn A. G.; Edwards, Brenda K.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Jacobs, Eric J.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA. [Schymura, Maria J.; Kohler, Betsy A.] N Amer Assoc Cent Canc Registries, Springfield, IL USA. [Schymura, Maria J.] New York State Canc Registry, Albany, NY USA. [Pan, Liping; Fulton, Janet E.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Anderson, Robert N.] Ctr Dis Control & Prevent, Div Vital Stat, Natl Ctr Hlth Stat, Atlanta, GA 30341 USA. [Jemal, Ahmedin; Ward, Elizabeth] Amer Canc Soc, Surveillance & Hlth Policy Res Dept, Atlanta, GA 30329 USA. RP Eheman, C (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F-69, Atlanta, GA 30341 USA. EM cre1@cdc.gov OI Henley, S Jane/0000-0002-2420-306X FU Intramural CDC HHS [CC999999] NR 134 TC 212 Z9 223 U1 11 U2 57 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD MAY 1 PY 2012 VL 118 IS 9 BP 2338 EP 2366 DI 10.1002/cncr.27514 PG 29 WC Oncology SC Oncology GA 929ES UT WOS:000303044600003 PM 22460733 ER PT J AU Wheeler, SB Wu, Y Meyer, AM Carpenter, WR Richardson, LC Smith, JL Lewis, MA Weiner, BJ AF Wheeler, Stephanie B. Wu, Yang Meyer, Anne-Marie Carpenter, William R. Richardson, Lisa C. Smith, Judith Lee Lewis, Megan A. Weiner, Bryan J. TI Use and Timeliness of Radiation Therapy After Breast-Conserving Surgery in Low-Income Women With Early-Stage Breast Cancer SO CANCER INVESTIGATION LA English DT Article DE Breast cancer; Quality; Medicaid; Radiation therapy; Breast-conserving surgery ID SOCIOECONOMIC-STATUS; UNITED-STATES; CONSERVATION SURGERY; RACIAL DISPARITIES; LOCAL RECURRENCE; SURVIVAL; CARCINOMA; RADIOTHERAPY; MASTECTOMY; QUALITY AB Purpose: To characterize overall receipt and timeliness of radiation therapy (RT) following breast-conserving surgery among Medicaid-insured patients. Method: State cancer registry data linked with Medicaid claims from2003 to 2009 were analyzed. Multivariate logistic and Cox proportional hazards regressions were employed. Results: Overall, 81% of patients received guideline-recommended RT. Significant variation in timing of RT initiation was documented. Having fewer comorbitidies and receiving chemotherapy were correlated with higher odds of RT initiation within 1 year. Conclusion: Although RT use in Medicaid-insured women appears to have improved since earlier studies, documented delays in RT are troublesome and warrant further investigation. C1 [Wheeler, Stephanie B.; Carpenter, William R.; Weiner, Bryan J.] Univ N Carolina, Dept Hlth Policy & Management, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. [Wu, Yang; Meyer, Anne-Marie] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Richardson, Lisa C.; Smith, Judith Lee] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Lewis, Megan A.] RTI Int, Res Triangle Pk, NC USA. RP Wheeler, SB (reprint author), Univ N Carolina, Dept Hlth Policy & Management, Gillings Sch Global Publ Hlth, 1103C McGavran Greenberg Hall,135 Dauer Dr,CB 741, Chapel Hill, NC 27599 USA. EM Stephanie_wheeler@unc.edu RI Carpenter, William/E-5125-2013 FU Centers for Disease Control and Prevention, Division of Cancer Prevention and Control [S3665-25/26]; Dr. Wheeler's Agency for Healthcare Research and Quality (AHRQ) [K-12 HS019468-01]; Integrated Cancer Information and Surveillance System (ICISS); UNC Lineberger Comprehensive Cancer Center; University Cancer Research Fund (UCRF) via the State of North Carolina FX Financial support for this study was provided by the Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, contract no. S3665-25/26, and by Dr. Wheeler's Agency for Healthcare Research and Quality (AHRQ) Mentored Clinical Scientists Comparative Effectiveness Development Award (K12), grant no. K-12 HS019468-01 (PI: Weinberger). Analytic support for this study was provided by the Integrated Cancer Information and Surveillance System (ICISS), UNC Lineberger Comprehensive Cancer Center, with funding provided by the University Cancer Research Fund (UCRF) via the State of North Carolina. NR 48 TC 7 Z9 8 U1 0 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0735-7907 J9 CANCER INVEST JI Cancer Invest. PD MAY PY 2012 VL 30 IS 4 BP 258 EP 267 DI 10.3109/07357907.2012.658937 PG 10 WC Oncology SC Oncology GA 931WE UT WOS:000303249200002 PM 22489864 ER PT J AU Dooley, KE Bliven-Sizemore, EE Weiner, M Lu, Y Nuermberger, EL Hubbard, WC Fuchs, EJ Melia, MT Burman, WJ Dorman, SE AF Dooley, K. E. Bliven-Sizemore, E. E. Weiner, M. Lu, Y. Nuermberger, E. L. Hubbard, W. C. Fuchs, E. J. Melia, M. T. Burman, W. J. Dorman, S. E. TI Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Article ID ACQUIRED RIFAMYCIN RESISTANCE; HIV-RELATED TUBERCULOSIS; PLASMA-CONCENTRATIONS; RIFAMPICIN; INDUCTION; MIDAZOLAM; TWICE; MOXIFLOXACIN; RIFABUTIN; REGIMENS AB Rifapentine (RPT) is an antituberculosis drug that may shorten treatment duration when substituted for rifampin (RIF). The maximal tolerated daily dose of RP T and its potential for cytochrome 3A4 induction and autoinduction at clinically relevant doses are unknown. In this phase I, dose-escalation study among healthy volunteers, daily doses as high as a prespecified maximum of 20 mg/kg/day were well tolerated. Steady-state RP T concentrations increased with dose from 5 to 15 mg/kg, but area under the plasma concentration-time curve (AUC(0-24)) and maximum concentration (C-max) were similar in the 15- and 20-mg/kg cohorts. Although RP T pharmacokinetics (PK) appeared to be time-dependent, accumulation occurred with daily dosing. The mean AUC(0-12) of oral midazolam (MDZ), a cytochrome 3A (CYP3A) probe drug, was reduced by 93% with the coadministration of RPT and by 74% with the coadministration of RIF (P < 0.01). Changes in the oral clearance of MDZ did not vary by RP T dose. In conclusion, RP T was tolerated at doses as high as 20 mg/kg/day, its PK were less than dose-proportional, and its CYP3A induction was robust. C1 [Dooley, K. E.; Lu, Y.; Hubbard, W. C.; Fuchs, E. J.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Dooley, K. E.; Nuermberger, E. L.; Melia, M. T.; Dorman, S. E.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA. [Bliven-Sizemore, E. E.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Weiner, M.] Vet Adm Med Ctr, Div Med & Infect Dis, San Antonio, TX USA. [Burman, W. J.] Denver Publ Hlth, Denver, CO USA. RP Dooley, KE (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. EM kdooley1@jhmi.edu FU Centers for Disease Control and Prevention; CDC Foundation; National Institutes of Health National Center for Research Resources [UL1 RR025005]; NIAID [P30 50410, K23AI080842]; Sanofi-Aventis; [1S10 RR 27733] FX The study team is grateful to the individuals who participated in this study. We appreciate the efforts of the research team at the Drug Development Unit at Johns Hopkins, notably Stephanie Everts and Elizabeth Purdy. We acknowledge the contributions of Namandje Bumpus and Teresa Parsons from the Clinical Pharmacology Analytical Laboratory at Johns Hopkins to the development of the RPT and RIF (and metabolite) assays, and we thank Angela Kashuba and Stephanie Malone at the University of North Carolina for quantifying MDZ and its metabolite. We also acknowledge Carla Jeffries of the Centers for Disease Control and Prevention for her assistance with graphics. We appreciate the thoughtful input and comments of Chad Heilig and Andy Vernon from the Centers for Disease Control and Prevention and Theresa Shapiro from Johns Hopkins. This study was sponsored by the Centers for Disease Control and Prevention and the CDC Foundation and was supported by the following grants: Institutional Clinical and Translational Science Award National Institutes of Health National Center for Research Resources UL1 RR025005, NIAID P30 50410 (UNC Center for AIDS Research (MDZ assays)), and K23AI080842 (K. E. D.). The ABI-Sciex API5500 Quadrupole-Linear Ion Trap console used for quantification of rifapentine and rifampin was purchased from Grant 1S10 RR 27733 awarded to W. C. H. The Waters Acquity ultraperformance liquid chromatography interfaced with the API5500 was purchased with funds from Pendleton Enterprises awarded to Craig W. Hendrix. Rifapentine (Priftin; Anagni, Italy) was provided by Sanofi-Aventis. NR 37 TC 24 Z9 25 U1 2 U2 22 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0009-9236 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD MAY PY 2012 VL 91 IS 5 BP 881 EP 888 DI 10.1038/clpt.2011.323 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 929FT UT WOS:000303047400022 PM 22472995 ER PT J AU Rice, TW Rubinson, L Uyeki, TM Vaughn, FL John, BB Miller, RR Higgs, E Randolph, AG Smoot, BE Thompson, BT AF Rice, Todd W. Rubinson, Lewis Uyeki, Timothy M. Vaughn, Frances L. John, Benjamin B. Miller, Russell R., II Higgs, Elizabeth Randolph, Adrienne G. Smoot, B. Elizabeth Thompson, B. Taylor CA NHLBI ARDS Network TI Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States SO CRITICAL CARE MEDICINE LA English DT Article DE bacterial coinfection; critical illness; mortality; pandemic H1N1 influenza ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE; H1N1 VIRUS; A(H1N1) INFECTION; ILL PATIENTS; VENTILATION; PNEUMONIA; FAILURE; MEXICO AB Objectives: The contribution of bacterial coinfection to critical illness associated with 2009 influenza A virus infection remains uncertain. The objective of this study was to determine whether bacterial coinfection increased the morbidity and mortality of 2009 influenza A. Design: Retrospective and prospective cohort study. Setting: Thirty-five adult U. S. intensive care units over the course of 1 yr. Patients: Six hundred eighty-three critically ill adults with confirmed or probable 2009 influenza A. Interventions: None. Measurements and Main Results: A confirmed or probable case was defined as a positive 2009 influenza A test result or positive test for influenza A that was otherwise not subtyped. Bacterial coinfection was defined as documented bacteremia or any presumed bacterial pneumonia with or without positive respiratory tract culture within 72 hrs of intensive care unit admission. The mean age was 45 +/- 16 yrs, mean body mass index was 32.5 +/- 11.1 kg/m(2), and mean Acute Physiology and Chronic Health Examination II score was 21 +/- 9, with 76% having at least one comorbidity. Of 207 (30.3%) patients with bacterial coinfection on intensive care unit admission, 154 had positive cultures with Staphylococcus aureus (n = 57) and Streptococcus pneumoniae (n = 19), the most commonly identified pathogens. Bacterial coinfected patients were more likely to present with shock (21% vs. 10%; p = .0001), require mechanical ventilation at the time of intensive care unit admission (63% vs. 52%; p = .005), and have longer duration of intensive care unit care (median, 7 vs. 6 days; p = .05). Hospital mortality was 23%; 31% in bacterial coinfected patients and 21% in patients without coinfection (p = .002). Immunosuppression (relative risk 1.57; 95% confidence interval 1.20-2.06; p = .0009) and Staphylococcus aureus at admission (relative risk 2.82; 95% confidence interval 1.76-4.51; p < .0001) were independently associated with increased mortality. Conclusions: Among intensive care unit patients with 2009 influenza A, bacterial coinfection diagnosed within 72 hrs of admission, especially with Staphylococcus aureus, was associated with significantly higher morbidity and mortality. (Crit Care Med 2012; 40: 1487-1498) C1 [Rice, Todd W.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Rubinson, Lewis] HHS ASPR OPEO, Natl Disaster Med Syst, Salt Lake City, UT USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Salt Lake City, UT USA. [Vaughn, Frances L.; John, Benjamin B.] HHS ASPR OPEO, Emergency Care Coordinat Ctr, Salt Lake City, UT USA. [Miller, Russell R., II] Intermt Med Ctr, Salt Lake City, UT USA. [Miller, Russell R., II] Univ Utah, Sch Med, Salt Lake City, UT USA. [Higgs, Elizabeth] NIAID, Div Clin Res, NIH, Boston, MA USA. [Randolph, Adrienne G.] Childrens Hosp, Boston, MA 02115 USA. [Smoot, B. Elizabeth] Harvard Univ, Sch Med, Boston, MA USA. [Thompson, B. Taylor] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Rice, TW (reprint author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. EM todd.rice@vanderbilt.edu OI Randolph, Adrienne/0000-0002-3084-3071 FU NHLBI [N01-HR-56179] FX Supported, in part, by NHLBI N01-HR-56179. NR 35 TC 66 Z9 72 U1 1 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD MAY PY 2012 VL 40 IS 5 BP 1487 EP 1498 DI 10.1097/CCM.0b013e3182416f23 PG 12 WC Critical Care Medicine SC General & Internal Medicine GA 930AE UT WOS:000303106900012 PM 22511131 ER PT J AU Scott, RA Chu, AY Grarup, N Manning, AK Hivert, MF Shungin, D Tonjes, A Yesupriya, A Barnes, D Bouatia-Naji, N Glazer, NL Jackson, AU Kutalik, Z Lagou, V Marek, D Rasmussen-Torvik, LJ Stringham, HM Tanaka, T Aadahl, M Arking, DE Bergmann, S Boerwinkle, E Bonnycastle, LL Bornstein, SR Brunner, E Bumpstead, SJ Brage, S Carlson, OD Chen, H Chen, YDI Chines, PS Collins, FS Couper, DJ Dennison, EM Dowling, NF Egan, JS Ekelund, U Erdos, MR Forouhi, NG Fox, CS Goodarzi, MO Grassler, J Gustafsson, S Hallmans, G Hansen, T Hingorani, A Holloway, JW Hu, FB Isomaa, B Jameson, KA Johansson, I Jonsson, A Jorgensen, T Kivimaki, M Kovacs, P Kumari, M Kuusisto, J Laakso, M Lecoeur, C Levy-Marchal, C Li, G Loos, RJF Lyssenko, V Marmot, M Marques-Vidal, P Morken, MA Muller, G North, KE Pankow, JS Payne, F Prokopenko, I Psaty, BM Renstrom, F Rice, K Rotter, JI Rybin, D Sandholt, CH Sayer, AA Shrader, P Schwarz, PEH Siscovick, DS Stancakova, A Stumvoll, M Teslovich, TM Waeber, G Williams, GH Witte, DR Wood, AR Xie, WJ Boehnke, M Cooper, C Ferrucci, L Froguel, P Groop, L Kao, WHL Vollenweider, P Walker, M Watanabe, RM Pedersen, O Meigs, JB Ingelsson, E Barroso, I Florez, JC Franks, PW Dupuis, J Wareham, NJ Langenberg, C AF Scott, Robert A. Chu, Audrey Y. Grarup, Niels Manning, Alisa K. Hivert, Marie-France Shungin, Dmitry Toenjes, Anke Yesupriya, Ajay Barnes, Daniel Bouatia-Naji, Nabila Glazer, Nicole L. Jackson, Anne U. Kutalik, Zoltan Lagou, Vasiliki Marek, Diana Rasmussen-Torvik, Laura J. Stringham, Heather M. Tanaka, Toshiko Aadahl, Mette Arking, Dan E. Bergmann, Sven Boerwinkle, Eric Bonnycastle, Lori L. Bornstein, Stefan R. Brunner, Eric Bumpstead, Suzannah J. Brage, Soren Carlson, Olga D. Chen, Han Chen, Yii-Der Ida Chines, Peter S. Collins, Francis S. Couper, David J. Dennison, Elaine M. Dowling, Nicole F. Egan, Josephine S. Ekelund, Ulf Erdos, Michael R. Forouhi, Nita G. Fox, Caroline S. Goodarzi, Mark O. Graessler, Juergen Gustafsson, Stefan Hallmans, Goeran Hansen, Torben Hingorani, Aroon Holloway, John W. Hu, Frank B. Isomaa, Bo Jameson, Karen A. Johansson, Ingegerd Jonsson, Anna Jorgensen, Torben Kivimaki, Mika Kovacs, Peter Kumari, Meena Kuusisto, Johanna Laakso, Markku Lecoeur, Cecile Levy-Marchal, Claire Li, Guo Loos, Ruth J. F. Lyssenko, Valeri Marmot, Michael Marques-Vidal, Pedro Morken, Mario A. Mueller, Gabriele North, Kari E. Pankow, James S. Payne, Felicity Prokopenko, Inga Psaty, Bruce M. Renstrom, Frida Rice, Ken Rotter, Jerome I. Rybin, Denis Sandholt, Camilla H. Sayer, Avan A. Shrader, Peter Schwarz, Peter E. H. Siscovick, David S. Stancakova, Alena Stumvoll, Michael Teslovich, Tanya M. Waeber, Gerard Williams, Gordon H. Witte, Daniel R. Wood, Andrew R. Xie, Weijia Boehnke, Michael Cooper, Cyrus Ferrucci, Luigi Froguel, Philippe Groop, Leif Kao, W. H. Linda Vollenweider, Peter Walker, Mark Watanabe, Richard M. Pedersen, Oluf Meigs, James B. Ingelsson, Erik Barroso, Ines Florez, Jose C. Franks, Paul W. Dupuis, Josee Wareham, Nicholas J. Langenberg, Claudia TI No Interactions Between Previously Associated 2-Hour Glucose Gene Variants and Physical Activity or BMI on 2-Hour Glucose Levels SO DIABETES LA English DT Article ID DIABETES PREVENTION PROGRAM; LIFE-STYLE INTERVENTION; COMMON VARIANTS; TYPE-2; RISK; MELLITUS; ENVIRONMENT; TRAITS; POLYMORPHISMS; PROGRESSION AB Gene-lifestyle interactions have been suggested to contribute to the development of type 2 diabetes. Glucose levels 2 h after a standard 75-g glucose challenge are used to diagnose diabetes and are associated with both genetic and lifestyle factors. However, whether these factors interact to determine 2-h glucose levels is unknown. We meta-analyzed single nucleotide polymorphism (SNP) X BMI and SNP x physical activity (PA) interaction regression models for five SNPs previously associated with 2-h glucose levels from up to 22 studies comprising 54,884 individuals without diabetes. PA levels were dichotomized, with individuals below the first quintile classified as inactive (20%) and the remainder as active (80%). BMI was considered a continuous trait. Inactive individuals had higher 2-h glucose levels than active individuals (beta = 0.22 mmol/L [95% CI 0.13-0.31], P = 1.63 X 10(-6)). All SNPs were associated with 2-h glucose (beta = 0.06-0.12 mmol/allele, P <= 1.53 X 10(-7)), but no significant interactions were found with PA (P > 0.18) or BMI (P >= 0.04). In this large study of gene-lifestyle interaction, we observed no interactions between genetic and lifestyle factors, both of which were associated with 2-h glucose. It is perhaps unlikely that top loci from genome-wide association studies will exhibit strong subgroup-specific effects, and may not, therefore, make the best candidates for the study of interactions. Diabetes 61:1291-1296, 2012 C1 [Scott, Robert A.; Barnes, Daniel; Brage, Soren; Ekelund, Ulf; Forouhi, Nita G.; Loos, Ruth J. F.; Wareham, Nicholas J.; Langenberg, Claudia] Addenbrookes Hosp, Inst Metab Sci, MRC, Epidemiol Unit, Cambridge, England. [Chu, Audrey Y.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA. [Chu, Audrey Y.; Kao, W. H. Linda] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Grarup, Niels; Hansen, Torben; Sandholt, Camilla H.; Pedersen, Oluf] Univ Copenhagen, Novo Nordisk Fdn, Ctr Basic Metab Res, Fac Hlth Sci, Copenhagen, Denmark. [Manning, Alisa K.; Chen, Han; Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Grarup, Niels; Hansen, Torben; Sandholt, Camilla H.; Pedersen, Oluf] Hagedorn Res Inst, Gentofte, Denmark. [Hivert, Marie-France] Univ Sherbrooke, Dept Med, Sherbrooke, PQ J1K 2R1, Canada. [Shungin, Dmitry; Renstrom, Frida; Franks, Paul W.] Lund Univ, Genet & Mol Epidemiol Unit, Dept Clin Sci, Malmo, Sweden. [Shungin, Dmitry; Franks, Paul W.] Umea Univ, Dept Publ Hlth & Clin Med, Genet Epidemiol & Clin Res Grp, Umea, Sweden. [Shungin, Dmitry; Johansson, Ingegerd] Umea Univ, Dept Odontol, Umea, Sweden. [Toenjes, Anke; Stumvoll, Michael] Univ Leipzig, Dept Med, Leipzig, Germany. [Toenjes, Anke; Stumvoll, Michael] Univ Leipzig, Integriertes Forsch & Behandlungszentrum IFB Adip, Leipzig, Germany. [Yesupriya, Ajay; Dowling, Nicole F.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Bouatia-Naji, Nabila; Lecoeur, Cecile; Froguel, Philippe] Inst Pasteur, CNRS, UMR 8199, F-59019 Lille, France. [Bouatia-Naji, Nabila; Lecoeur, Cecile; Levy-Marchal, Claire; Froguel, Philippe] Univ Lille Nord France, Lille, France. [Glazer, Nicole L.] Boston Univ, Dept Med Prevent Med & Epidemiol, Boston, MA 02215 USA. [Jackson, Anne U.; Stringham, Heather M.; Teslovich, Tanya M.; Boehnke, Michael] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA. [Kutalik, Zoltan; Marek, Diana; Bergmann, Sven] Univ Lausanne, Dept Med Genet, Lausanne, Switzerland. [Kutalik, Zoltan; Marek, Diana; Bergmann, Sven] Swiss Inst Bioinformat, Lausanne, Switzerland. [Lagou, Vasiliki; Prokopenko, Inga] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England. [Lagou, Vasiliki; Prokopenko, Inga] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England. [Rasmussen-Torvik, Laura J.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Tanaka, Toshiko; Ferrucci, Luigi] NIA, Clin Res Branch, Baltimore, MD 21224 USA. [Aadahl, Mette; Jorgensen, Torben] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark. [Arking, Dan E.] Johns Hopkins Univ, Inst Med Genet, Baltimore, MD USA. [Arking, Dan E.] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX USA. [Bonnycastle, Lori L.; Chines, Peter S.; Collins, Francis S.; Erdos, Michael R.; Morken, Mario A.] NHGRI, NIH, Bethesda, MD 20892 USA. [Bornstein, Stefan R.; Graessler, Juergen; Schwarz, Peter E. H.] Univ Dresden, Med Fac Carl Gustav Carus, Dept Med 3, Dresden, Germany. [Brunner, Eric; Hingorani, Aroon; Kivimaki, Mika; Kumari, Meena; Marmot, Michael] UCL, Dept Epidemiol & Publ Hlth, London, England. [Bumpstead, Suzannah J.] Wellcome Trust Sanger Inst, Cambridge, England. [Carlson, Olga D.; Egan, Josephine S.] NIA, Clin Invest Lab, Baltimore, MD 21224 USA. [Chen, Yii-Der Ida; Goodarzi, Mark O.; Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA. [Couper, David J.] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA. [Dennison, Elaine M.; Jameson, Karen A.; Sayer, Avan A.; Cooper, Cyrus] Univ Southampton, MRC, Lifecourse Epidemiol Unit, Southampton, Hants, England. [Fox, Caroline S.; Dupuis, Josee] NHLBI, Framingham Heart Study, Framingham, MA USA. [Fox, Caroline S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. [Goodarzi, Mark O.] Cedars Sinai Med Ctr, Div Endocrinol Diabet & Metab, Los Angeles, CA 90048 USA. [Gustafsson, Stefan; Ingelsson, Erik] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Hallmans, Goeran] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden. [Hansen, Torben] Univ So Denmark, Fac Hlth Sci, Odense, Denmark. [Hu, Frank B.; Renstrom, Frida; Franks, Paul W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Isomaa, Bo] Folkhalsan Res Ctr, Helsinki, Finland. [Isomaa, Bo] Dept Social Serv & Hlth Care, Pietarsaari, Finland. [Jonsson, Anna; Lyssenko, Valeri; Groop, Leif] Lund Univ, Diabet & Endocrinol Unit, Dept Clin Sci, Malmo, Sweden. [Jorgensen, Torben] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark. [Kovacs, Peter] Univ Leipzig, Interdisciplinary Ctr Clin Res, Leipzig, Germany. [Kuusisto, Johanna; Laakso, Markku; Stancakova, Alena] Univ Eastern Finland, Kuopio, Finland. [Kuusisto, Johanna; Laakso, Markku; Stancakova, Alena] Kuopio Univ Hosp, SF-70210 Kuopio, Finland. [Levy-Marchal, Claire] Hop Robert Debre, INSERM, CIC EC 05, F-75019 Paris, France. [Li, Guo] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Li, Guo] Univ Washington, Dept Med, Seattle, WA USA. [Marques-Vidal, Pedro] CHU Vaudois, Inst Social & Prevent Med IUMSP, CH-1011 Lausanne, Switzerland. [Mueller, Gabriele] Univ Dresden, Inst Med Informat & Biometry, Med Fac Carl Gustav Carus, Dresden, Germany. [North, Kari E.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [North, Kari E.] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC USA. [Pankow, James S.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Payne, Felicity; Barroso, Ines] Wellcome Trust Sanger Inst, Metab Dis Grp, Cambridge, England. [Psaty, Bruce M.] Univ Washington, Dept Epidemiol Serv, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Med Serv, Seattle, WA 98195 USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA 98121 USA. [Rice, Ken] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Rybin, Denis] Boston Univ, Data Coordinating Ctr, Boston, MA 02215 USA. [Shrader, Peter; Meigs, James B.; Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Shrader, Peter; Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Siscovick, David S.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Waeber, Gerard; Vollenweider, Peter] CHUV, Dept Internal Med, Lausanne, Switzerland. [Witte, Daniel R.] Steno Diabet Ctr, DK-2820 Gentofte, Denmark. [Wood, Andrew R.; Xie, Weijia] Peninsula Coll Med & Dent, Exeter, Devon, England. [Cooper, Cyrus] Univ Oxford, Botnar Res Ctr, Oxford, England. [Froguel, Philippe] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Genom Common Dis, London, England. [Walker, Mark] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Watanabe, Richard M.] Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90033 USA. [Watanabe, Richard M.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Pedersen, Oluf] Univ Copenhagen, Fac Hlth Sci, Inst Biomed Sci, Copenhagen, Denmark. [Pedersen, Oluf] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark. [Barroso, Ines] Univ Cambridge, Metab Res Labs, Cambridge, England. [Barroso, Ines] Addenbrookes Hosp, NIHR Cambridge Biomed Res Ctr, Cambridge, England. [Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Florez, Jose C.] Harvard & Massachusetts Inst Technol, Broad Inst, Cambridge, MA USA. [Florez, Jose C.] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA. RP Scott, RA (reprint author), Addenbrookes Hosp, Inst Metab Sci, MRC, Epidemiol Unit, Cambridge, England. EM robert.scott@mrc-epid.cam.ac.uk RI Prokopenko, Inga/H-3241-2014; Grarup, Niels/K-2807-2015; BOUATIA-NAJI, NABILA/D-5863-2013; Schwarz, Peter/B-5127-2013; Li, Guo/E-5613-2012; Holloway, John/B-5424-2009; Rice, Kenneth/A-4150-2013; Brage, Soren/C-6415-2013; Colaus, PsyColaus/K-6607-2013; Lagou, Vasiliki/N-8451-2013; Witte, Daniel/C-1722-2008; Marques-Vidal, Pedro/C-9449-2009; OI Forouhi, Nita/0000-0002-5041-248X; Chen, Han/0000-0002-9510-4923; Jorgensen, Torben/0000-0001-9453-2830; Marmot, Michael/0000-0002-2431-6419; Payne, Felicity/0000-0003-4228-581X; Pankow, James/0000-0001-7076-483X; Bergmann, Sven/0000-0002-6785-9034; Prokopenko, Inga/0000-0003-1624-7457; Grarup, Niels/0000-0001-5526-1070; Schwarz, Peter/0000-0001-6317-7880; Shungin, Dmitry/0000-0001-7900-5856; Bouatia-Naji, Nabila/0000-0001-5424-2134; Holloway, John/0000-0001-9998-0464; Rice, Kenneth/0000-0001-5779-4495; Brage, Soren/0000-0002-1265-7355; Witte, Daniel/0000-0002-0769-2922; Rybin, Denis/0000-0002-3657-4829; Barnes, Daniel/0000-0002-3781-7570; Marques-Vidal, Pedro/0000-0002-4548-8500; Kivimaki, Mika/0000-0002-4699-5627; Aihie Sayer, Avan/0000-0003-1283-6457; Dupuis, Josee/0000-0003-2871-3603; Kumari, Meena/0000-0001-9716-1035 FU British Heart Foundation [RG/07/008/23674]; Medical Research Council [MC_U106179473, G0100222, G0701863, G0902037, G1002084, G19/35, G8802774, MC_U106179471, MC_UP_A100_1003, MC_UP_A620_1014, MC_UP_A620_1015]; NCATS NIH HHS [UL1 TR000124]; NCRR NIH HHS [UL1 RR024148, UL1 RR025741]; NHLBI NIH HHS [T32 HL007575]; NIDDK NIH HHS [K24 DK080140, P30 DK020572, P30 DK063491, R01 DK072041] NR 28 TC 5 Z9 5 U1 0 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD MAY PY 2012 VL 61 IS 5 BP 1291 EP 1296 DI 10.2337/db11-0973 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 930XW UT WOS:000303179100042 PM 22415877 ER PT J AU Miller, CH Benson, J Ellingsen, D Driggers, J Payne, A Kelly, FM Soucie, JM Hooper, WC AF Miller, C. H. Benson, J. Ellingsen, D. Driggers, J. Payne, A. Kelly, F. M. Soucie, J. M. Hooper, W. Craig CA Hemophilia Inhibitor Res Study Inv TI F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity SO HAEMOPHILIA LA English DT Article DE F8 mutation; F9 mutation; factor IX; factor VIII; haemophilia; inhibitors ID FACTOR-VIII GENE; RISK-FACTORS; UNITED-STATES; HIGHEST RISK; FACTOR-IX; MILD; POLYMORPHISMS AB Both genetic and treatment-related risk factors contribute to the development of inhibitors in haemophilia. An inhibitor surveillance system piloted at 12 US sites has the goal of assessing risk factors through prospective data collection. This report examines the relationship of genotype and race/ethnicity to history of inhibitor in a large cohort of US haemophilia patients. Mutation analysis was performed on 676 haemophilia A (HA) and 153 haemophilia B (HB) patients by sequencing, Multiplex Ligation-dependent Probe Amplification, and PCR for inversions in F8 introns 22 (inv22) and 1 (inv1). Two HB patients with deletions had history of inhibitor. In severe HA, frequency of history of inhibitor was: large deletion 57.1%, splice site 35.7%, inv22 26.8%, nonsense 24.5%, frameshift 12.9%, inv1 11.1% and missense 9.5%. In HA, 19.6% of 321 White non-Hispanics (Whites), 37.1% of 35 Black non-Hispanics (Blacks) and 46.9% of 32 Hispanics had history of inhibitor (P = 0.0003). Mutation types and novel mutation rates were similar across ethnicities. When F8 haplotypes were constructed, Whites and Hispanics showed only H1 and H2. Within H1, history of inhibitor was 12.4% in Whites, 40.0% in Blacks (P = 0.009) and 32.4% in Hispanics (P = 0.002). Inhibitor frequency is confirmed to vary by mutation type and race in a large US population. White patients with history of inhibitor did not exhibit rare F8 haplotypes. F8 gene analysis did not reveal a cause for the higher inhibitor frequencies in Black and Hispanic patients. C1 [Miller, C. H.; Benson, J.; Ellingsen, D.; Driggers, J.; Payne, A.; Kelly, F. M.; Soucie, J. M.; Hooper, W. Craig; Hemophilia Inhibitor Res Study Inv] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Miller, CH (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS D-02, Atlanta, GA 30333 USA. EM cmiller2@cdc.gov OI Miller, Connie H/0000-0002-3989-7973 FU CDC Foundation through Pfizer Inc.; Novo Nordisk; CSL Behring FX The work was supported by the CDC Foundation through a grant from Pfizer Inc. The authors thank the patients who participated and the study coordinators and administrators at the sites: Pam Bryant, Deirdre Cooper-Blacketer, Young Chong, Becky Dudley, Margaret Geary, Rebecca Hauke, Ann Forsberg, Jan Kuhn, Michael Lammer, Jamie Leonard, Wendy Mitsuyama, Debbie Nelson, Mindy Nolte, Angie Riedel, Brenda Riske, Kendra Sanders, Julie Thomas, Michiyo Tomita, and David Waters. The authors also acknowledge the contributions made to haemophilia care and to this project by the late Robert Janco.; CLK has acted as a paid consultant to Inspiration Biopharmaceuticals and has received research funding from Novo Nordisk and CSL Behring. SRL has served as a consultant to Novo Nordisk A/S. BMW has acted as a paid consultant to Bayer and Novo Nordisk. Other authors stated that they had no interests which might be perceived as posing a conflict of interest or bias. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 31 TC 46 Z9 46 U1 1 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1351-8216 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2012 VL 18 IS 3 BP 375 EP 382 DI 10.1111/j.1365-2516.2011.02700.x PG 8 WC Hematology SC Hematology GA 931DE UT WOS:000303194200065 PM 22103590 ER PT J AU Carpenter, SL Soucie, JM Sterner, S Presley, R AF Carpenter, S. L. Soucie, J. Michael Sterner, S. Presley, R. CA HTCN Investigators TI Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database SO HAEMOPHILIA LA English DT Article DE ethnicity; factor VIII; haemophilia A; Hispanic; inhibitors; UDC ID RISK-FACTORS; FACTOR-VIII; POLYMORPHISMS; RACE/ETHNICITY; POPULATIONS; GENES; MALES AB Neutralizing inhibitors develop in 2030% of patients with severe factor VIII (FVIII) deficiency. It is well established that Blacks have a higher prevalence of inhibitors than Whites. This is the first study to definitively demonstrate increased inhibitor prevalence in the Hispanic population. We compared inhibitor prevalence among various racial and ethnic groups in a cross-sectional analysis of 5651 males with severe haemophilia A that participated in the Universal Data Collection project sponsored by the Centers for Disease Control and Prevention. We used logistic regression analysis to control for potential confounding variables. We assigned as Hispanic those participants who were white and labelled themselves Hispanic. The prevalence of high-titre inhibitors in the Hispanic participants was 24.5% compared to 16.4% for White non-Hispanic patients (OR 1.4, 95% CI 1.1, 1.7). Possibilities as to the underlying cause of increased inhibitor prevalence in minority ethnic populations include polymorphisms in the FVIII molecule, HLA subtypes and differing inflammatory responses. A better understanding may lead to tailored treatment programmes, or other therapies, to decrease or prevent inhibitor development. C1 [Carpenter, S. L.] Childrens Mercy Hosp, Dept Pediat, Kansas City, MO 64108 USA. [Soucie, J. Michael; Presley, R.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA USA. [Sterner, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA. RP Carpenter, SL (reprint author), Childrens Mercy Hosp, Dept Pediat, 2401 Gillham Rd, Kansas City, MO 64108 USA. EM slcarpenter@cmh.edu RI Kerlin, Bryce/E-3369-2011 OI Kerlin, Bryce/0000-0002-1756-8271 FU Universal Data Collection Working Group; Centers for Disease Control; Bleeding Disorder Complications through Regional Hemophilia Treatment Centers FX The authors acknowledge the contributions of Kristina Kypuros, MD to the early part of this project. The authors also acknowledge the support of the Universal Data Collection Working Group and the Centers for Disease Control for their help in designing and completing this research and for the use of the UDC data. The analyses in this study and writing of the manuscript were supported by the Grant/Cooperative Agreement Prevention of Bleeding Disorder Complications through Regional Hemophilia Treatment Centers. We also thank the patients, staff members and physicians of the Hemophilia Treatment Centers who contributed to the UDC database and whose contributions were critical to the completion of this work. NR 29 TC 18 Z9 20 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1351-8216 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2012 VL 18 IS 3 BP e260 EP e265 DI 10.1111/j.1365-2516.2011.02739.x PG 6 WC Hematology SC Hematology GA 931DE UT WOS:000303194200041 PM 22250850 ER PT J AU Stonebraker, JS Bolton-Maggs, PHB Soucie, JM Walker, I Brooker, M AF Stonebraker, J. S. Bolton-Maggs, P. H. B. Soucie, J. Michael Walker, I. Brooker, M. TI A study of variations in the reported haemophilia B prevalence around the world SO HAEMOPHILIA LA English DT Article DE epidemiology; haemophilia B; prevalence AB . The objectives of this article were to study the reported prevalence of haemophilia B (HB) on a country-by-country basis and to analyse whether the prevalence of HB varied by national economy. The prevalence of HB is the proportion of diagnosed, reported cases of HB in a population at a specific point of time. We collected data on the HB prevalence for 105 countries from the World Federation of Hemophilia annual global surveys. Our results showed that the HB prevalence varied considerably among countries, even among the wealthiest of countries. The HB prevalence (per 100 000 males) for the highest income countries was 2.69 +/- 1.61 (mean +/- SD), whereas the prevalence for the rest of the world was 1.20 +/- 1.33 (mean +/- SD). Ireland had the highest reported HB prevalence of 8.07 per 100 000 males. There was a strong trend of increasing HB prevalence (per 100 000 males) over time. Prevalence data reported from the WFH compared well with prevalence data from the literature. The WFH annual global surveys have some limitations, but they are the best available source of worldwide haemophilia data. Prevalence data are extremely valuable information for the planning efforts of national healthcare agencies in setting priorities and allocating resources for the treatment of HB. C1 [Stonebraker, J. S.] N Carolina State Univ, Coll Management, Raleigh, NC 27695 USA. [Bolton-Maggs, P. H. B.] Manchester Royal Infirm, Dept Clin Haematol, Manchester M13 9WL, Lancs, England. [Soucie, J. Michael] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Walker, I.] McMaster Univ, Hamilton, ON, Canada. [Brooker, M.] World Federat Hemophilia, Montreal, PQ, Canada. RP Stonebraker, JS (reprint author), N Carolina State Univ, Coll Management, Raleigh, NC 27695 USA. EM jeff_stonebraker@ncsu.edu FU Baxter FX PHBBM has received support from Baxter to attend international meetings in 2008 and 2010. The other authors declare no conflicting interests. NR 10 TC 29 Z9 29 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1351-8216 J9 HAEMOPHILIA JI Haemophilia PD MAY PY 2012 VL 18 IS 3 BP e91 EP e94 DI 10.1111/j.1365-2516.2011.02588.x PG 4 WC Hematology SC Hematology GA 931DE UT WOS:000303194200017 PM 21649801 ER PT J AU Rowe, AK Rowe, SY Holloway, KA Ivanovska, V Muhe, L Lambrechts, T AF Rowe, Alexander K. Rowe, Samantha Y. Holloway, Kathleen A. Ivanovska, Verica Muhe, Lulu Lambrechts, Thierry TI Does shortening the training on Integrated Management of Childhood Illness guidelines reduce its effectiveness? A systematic review SO HEALTH POLICY AND PLANNING LA English DT Review DE Child health; developing country; quality improvement; systematic review; training ID QUALITY-OF-CARE; HEALTH WORKER ADHERENCE; MULTIFACETED INTERVENTION; RANDOMIZED-TRIAL; SICK CHILDREN; UNDER-FIVES; STRATEGY; TANZANIA; IMCI; BANGLADESH AB Objective Implementation of the Integrated Management of Childhood Illness (IMCI) strategy with an 11-day training course for health workers improves care for ill children in outpatient settings in developing countries. The 11-day course duration is recommended by the World Health Organization, which developed IMCI. Our aim was to determine if shortening the training (to reduce cost) reduces its effectiveness. Methods We conducted a systematic review to compare IMCI's effectiveness with standard training (duration epsilon 11 days) versus shortened training (5-10 days). Studies were identified from a search of MEDLINE, two existing systematic reviews, and by contacting investigators. We included published or unpublished studies that evaluated IMCI's effectiveness in developing countries and reported quantitative measures of health worker practices related to managing ill children under 5 years old in public or private health facilities. Summary measures were the median of effect sizes for all outcomes from a given study, and the percentage of patients needing oral antimicrobials or rehydration who were treated according to IMCI guidelines. Findings Twenty-nine studies were included. Direct comparisons from three studies showed little difference between standard and shortened training. Indirect comparisons from 26 studies revealed that effect sizes for standard training versus no IMCI were greater than shortened training versus no IMCI. Across all comparisons, differences ranged from -3 to +23 percentage-points, and our best estimate was a 2 to 16 percentage-point advantage for standard training. No result was statistically significant. After IMCI training (of any duration), 34% of ill children needing oral antimicrobials or rehydration were not receiving these treatments according to IMCI guidelines. Conclusions Based on limited evidence, standard IMCI training seemed more effective than shortened training, although the difference might be small. As sizable performance gaps often existed after IMCI training, countries should consider implementing other interventions to support health workers after training, regardless of training duration. C1 [Rowe, Alexander K.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30341 USA. [Muhe, Lulu; Lambrechts, Thierry] WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland. RP Rowe, AK (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Mailstop F22,4770 Buford Highway, Atlanta, GA 30341 USA. EM axr9@cdc.gov FU WHO's Department of Child and Adolescent Health and Development FX SY Rowe and K Herman were partly supported by WHO's Department of Child and Adolescent Health and Development. NR 80 TC 9 Z9 10 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1080 J9 HEALTH POLICY PLANN JI Health Policy Plan. PD MAY PY 2012 VL 27 IS 3 BP 179 EP 193 DI 10.1093/heapol/czr033 PG 15 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 930ST UT WOS:000303160800001 PM 21515912 ER PT J AU Dong, C Zafrullah, M Mixson-Hayden, T Dai, X Liang, JH Meng, JH Kamili, S AF Dong, Chen Zafrullah, Mohammad Mixson-Hayden, Tonya Dai, Xing Liang, Jiuhong Meng, Jihong Kamili, Saleem TI Suppression of interferon-alpha signaling by hepatitis E virus SO HEPATOLOGY LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; ORF3 PROTEIN; STAT1 PHOSPHORYLATION; VIRAL REPLICATION; BETA-INTERFERON; INHIBITION; INDUCTION; TRANSDUCTION; ACTIVATION; INFECTION AB The interferon (IFN) system is integral to the host response against viruses, and many viruses have developed strategies to overcome its antiviral effects. The effects of hepatitis E virus (HEV), the causative agent of hepatitis E, on IFN signaling have not been investigated primarily because of the nonavailability of an efficient in vitro culture system or small animal models of infection. We report here the generation of A549 cell lines persistently infected with genotype 3 HEV, designated as HEV-A549 cells and the effects HEV has on IFN-amediated Janus kinasesignal transducer and activator of transcription (JAKSTAT) signaling. Treatment of HEV-A549 cells with 250, 500, and 1000 U/mL of IFN-a for 72 hours showed a dose-dependent reduction in HEV RNA levels by 10%, 20%, and 50%, respectively. IFN-astimulated genes coding for the antiviral proteins dsRNA-activated protein kinase (PKR) and 2',5'-oligoadenylate synthetase (2',5'-OAS) were down-regulated in IFN-atreated HEV-A549 cells. HEV infection also prevented IFN-ainduced phosphorylation of STAT1. Regulation of STAT1 by HEV was specific, as phosphorylation of STAT2, tyrosine kinase (Tyk) 2, and Jak1 by IFN-a was unaltered. Additionally, STAT1 levels were markedly increased in HEV-A549 cells compared with naive A549 cells. Furthermore, binding of HEV open reading frame (ORF)3 protein to STAT1 in HEV-A549 cells was observed. HEV ORF3 protein alone inhibited IFN-ainduced phosphorylation of STAT1 and down-regulated the IFN-astimulated genes encoding PKR, 2',5'-OAS, and myxovirus resistance A. Conclusion: HEV inhibits IFN-a signaling through the regulation of STAT1 phosphorylation in A549 cells. These findings have implications for the development of new strategies against hepatitis E. (HEPATOLOGY 2012 ) C1 [Dong, Chen; Zafrullah, Mohammad; Mixson-Hayden, Tonya; Dai, Xing; Meng, Jihong; Kamili, Saleem] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Dong, Chen; Liang, Jiuhong; Meng, Jihong] Southeast Univ, Sch Med, Nanjing, Jiangsu, Peoples R China. RP Meng, JH (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jihongmeng@163.com; skamili@cdc.gov NR 42 TC 31 Z9 32 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD MAY PY 2012 VL 55 IS 5 BP 1324 EP 1332 DI 10.1002/hep.25530 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 929GN UT WOS:000303049400003 PM 22183878 ER PT J AU Grasperge, BJ Reif, KE Morgan, TD Sunyakumthorn, P Bynog, J Paddock, CD Macaluso, KR AF Grasperge, Britton J. Reif, Kathryn E. Morgan, Timothy D. Sunyakumthorn, Piyanate Bynog, Joseph Paddock, Christopher D. Macaluso, Kevin R. TI Susceptibility of Inbred Mice to Rickettsia parkeri SO INFECTION AND IMMUNITY LA English DT Article ID SPOTTED-FEVER GROUP; MOUNTAIN WOOD TICK; UNITED-STATES; MURINE MODEL; CELL-LINE; INFECTION; PATHOGENESIS; INTERFERON; PEACOCKII; RESPONSES AB Rickettsia parkeri, a member of the spotted fever group Rickettsia, is the causative agent of American boutonneuse fever in humans. Despite the increased recognition of human cases, limited information is available regarding the infection of invertebrate and vertebrate hosts for this emerging tick-borne disease. Toward the development of a viable transmission model and to further characterize the pathology associated with R. parkeri infection, inbred mouse strains (A/J, BALB/c, C3H/HeJ, and C3H/HeN) were intravenously and intradermally inoculated with 105 low-passage-number R. parkeri (Portsmouth strain), and infection, gross pathology, and histopathology were scored. Additionally, a quantitative real-time PCR (qPCR) was performed to estimate rickettsial load in heart, lung, spleen, and liver tissues of infected mice at 19 days postinoculation. Of the A/J, BALB/c, and C3H/HeN mice, none displayed universal pathology consistent with sustained infection. Compared to age-matched control mice, the intravenously inoculated C3H/HeJ mice exhibited marked facial edema and marked splenomegaly upon gross examination, while the intradermally inoculated mice developed characteristic eschar-like lesions. The C3H/HeJ mice also exhibited the greatest concentrations of rickettsial DNA from heart, lung, liver, and spleen samples when examined by qPCR. The similarity of the pathology of human disease and sustained infection suggests that the C3H/HeJ strain of mice is a promising candidate for subsequent experiments to examine the tick transmission, dissemination, and pathology of R. parkeri rickettsiosis. C1 [Grasperge, Britton J.; Reif, Kathryn E.; Sunyakumthorn, Piyanate; Bynog, Joseph; Macaluso, Kevin R.] Louisiana State Univ, Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA. [Reif, Kathryn E.] Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA. [Reif, Kathryn E.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA. [Morgan, Timothy D.] Mississippi State Univ, Coll Vet Med, Dept Pathobiol & Populat Med, Starkville, MS USA. [Sunyakumthorn, Piyanate] Mahidol Univ, Mahidol Oxford Trop Med Res Programme, Bangkok 10700, Thailand. [Paddock, Christopher D.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. RP Macaluso, KR (reprint author), Louisiana State Univ, Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA. EM kmacaluso@vetmed.lsu.edu OI Grasperge, Britton/0000-0001-5592-9413 FU National Institutes of Health [AI077784] FX This research was supported by the National Institutes of Health (grant AI077784). NR 25 TC 10 Z9 10 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD MAY PY 2012 VL 80 IS 5 BP 1846 EP 1852 DI 10.1128/IAI.00109-12 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 925VX UT WOS:000302791100025 PM 22392926 ER PT J AU B'Hymer, C Mathias, P Krieg, E Cheever, KL Toennis, CA Clark, JC Kesner, JS Gibson, RL Butler, MA AF B'Hymer, Clayton Mathias, Patricia Krieg, Edward, Jr. Cheever, Kenneth L. Toennis, Christine A. Clark, John C. Kesner, James S. Gibson, Roger L. Butler, Mary Ann TI (2-Methoxyethoxy)acetic acid: a urinary biomarker of exposure for jet fuel JP-8 SO INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Article DE Urinary biomarkers; Jet propulsion fuel 8; JP-8; (2-methoxyethoxy)acetic acid; MEAA ID AIR-FORCE PERSONNEL; S-PHENYLMERCAPTURIC ACID; MASS-SPECTROMETRY; DERMAL EXPOSURE; BIS(2-METHOXYETHYL) ETHER; CREATININE; METABOLISM; BENZENE; SAMPLES; QUANTIFICATION AB To demonstrate the utility of the urinary metabolite (2-methoxyethoxy)acetic acid (MEAA) as a biomarker of exposure. 2-(2-methoxyethoxy)ethanol [diethylene glycol monomethyl ether] is an anti-icing agent used in the formulation of JP-8, and it is added at a known uniform 0.1% (v/v) concentration to each batch lot. JP-8 is a kerosene-based fuel containing different compounds that vary in the content of every batch/lot of fuel; thus, MEAA has the potential to be a more specific and a consistent quantitative biomarker for JP-8 exposure. MEAA was used to measure exposure of jet propulsion fuel 8 (JP-8) in United States Air Force (USAF) personnel working at six airbases within the United States. Post-shift urine specimens from various personnel including high (n = 98), moderate (n = 38), and low (n = 61) exposure workgroup categories were collected and analyzed by a gas chromatographic-mass spectrometric test method. The three exposure groups were evaluated for the number per group positive for MEAA, and a statistical analysis consisted of pair-wise t-tests for unequal variances was used to test for the differences in mean MEAA concentrations between the exposure groups. The number of samples detected as positive for MEAA exposure, that is, those above the test method's limit of detection (LOD = 0.1 mu g/ml), were 92 (93.9%), 13 (34.2%), and 2 (3.3%) for the high, moderate, and low exposure workgroup categories, respectively. The mean urinary MEAA level was significantly greater in the high exposure category (6.8 mu g/ml), compared to the moderate (0.42 mu g/ml) and the low (0.07 mu g/ml) exposure categories. The maximum concentration of urinary MEAA was 110 mu g/ml for the high exposure category, while 4.8 mu g/ml and 0.2 mu g/ml maximum levels were found in the moderate and low exposure categories, respectively. This study demonstrated that urinary MEAA can be used as an accurate biomarker of exposure for JP-8 workers and clearly distinguished the differences in JP-8 exposure by workgroup category. C1 [B'Hymer, Clayton; Mathias, Patricia; Krieg, Edward, Jr.; Cheever, Kenneth L.; Toennis, Christine A.; Clark, John C.; Kesner, James S.; Butler, Mary Ann] NIOSH, US Dept HHS, Ctr Dis Control & Prevent, Div Appl Res & Technol,Taft Lab, Cincinnati, OH 45226 USA. [Gibson, Roger L.] Uniform Serv Univ, Prevent Med & Biometr Dept, Bethesda, MD 20814 USA. RP B'Hymer, C (reprint author), NIOSH, US Dept HHS, Ctr Dis Control & Prevent, Div Appl Res & Technol,Taft Lab, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM cbhymer@cdc.gov NR 45 TC 2 Z9 2 U1 0 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-0131 J9 INT ARCH OCC ENV HEA JI Int. Arch. Occup. Environ. Health PD MAY PY 2012 VL 85 IS 4 BP 413 EP 420 DI 10.1007/s00420-011-0687-7 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 933PU UT WOS:000303375300009 PM 21809101 ER PT J AU Hall, HI Gray, KM Tang, T Li, JM Shouse, L Mermin, J AF Hall, H. Irene Gray, Kristen Mahle Tang, Tian Li, Jianmin Shouse, Luke Mermin, Jonathan TI Retention in Care of Adults and Adolescents Living With HIV in 13 US Areas SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT National HIV Prevention Conference CY AUG 16, 2011 CL Atlanta, GA DE HIV; standard of care; health care disparities ID ANTIRETROVIRAL THERAPY; MEDICAL-CARE; SEXUAL TRANSMISSION; UNITED-STATES; VIRAL LOAD; OF-CARE; VIRUS; METAANALYSIS; ENGAGEMENT; PREVENTION AB Background: Monitoring immunologic and virologic responses to antiretroviral therapy in HIV-1-infected patients is an important component of treatment in the United States. However, little population-based information is available on whether HIV-infected persons receive the recommended tests or continuous care. Methods: Using data from 13 areas reporting relevant HIV-related tests to national HIV surveillance, we determined retention in care in persons older than 12 years living with HIV at the end of 2009. We assessed retention in care, defined as >= 2 CD4 or viral load tests at least 3 months apart in the past year, by demographic, clinical, and risk characteristics and calculated prevalence ratios and 95% confidence intervals. We also assessed the percentage established in care within 12 months after HIV diagnosis in 2008 (>= 2 tests, >= 3 months apart). Results: Among 100,375 persons living with HIV, 45% had >= 2 tests at least 3 months apart. A higher percentage of whites were retained in care (50%) compared with blacks/African Americans (41%, prevalence ratio: 0.83, 95% confidence interval: 0.82 to 0.84) and Hispanics/Latinos (40%, prevalence ratio: 0.90, 95% CI: 0.87 to 0.92). Compared with heterosexual women (50%), fewer men who have sex with men (48%), heterosexual men (45%), and male (37%) and female (43%) injection drug users had >= 2 tests. Approximately 64% established care within 12 months of diagnosis. Conclusions: Less than half of persons living with HIV had laboratory evidence of ongoing clinical care and only two thirds established care after diagnosis. Further assessments determining modifiable barriers to accessing care could assist with achieving public health targets. C1 [Hall, H. Irene; Gray, Kristen Mahle; Li, Jianmin; Shouse, Luke; Mermin, Jonathan] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Tang, Tian] ICF Int, Atlanta, GA USA. RP Hall, HI (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, MS E-47,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ixh1@cdc.gov RI Mermin, Jonathan/J-9847-2012 NR 36 TC 73 Z9 73 U1 3 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2012 VL 60 IS 1 BP 77 EP 82 DI 10.1097/QAI.0b013e318249fe90 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 930BZ UT WOS:000303112200019 PM 22267016 ER PT J AU Glick, SN Morris, M Foxman, B Aral, SO Manhart, LE Holmes, KK Golden, MR AF Glick, Sara Nelson Morris, Martina Foxman, Betsy Aral, Sevgi O. Manhart, Lisa E. Holmes, King K. Golden, Matthew R. TI A Comparison of Sexual Behavior Patterns Among Men Who Have Sex With Men and Heterosexual Men and Women SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE men who have sex with men; heterosexuals; sexual behavior; HIV; STI ID HIV-INFECTION; UNITED-STATES; CONCURRENT PARTNERSHIPS; OLDER PARTNERS; RISK BEHAVIOR; BLACK-MEN; PREVALENCE; DISPARITIES; SEATTLE; TRANSMISSION AB Objective: Men who have sex with men (MSM) have higher rates of HIV and other sexually transmitted infections than women and heterosexual men. This elevated risk persists across age groups and reflects biological and behavioral factors; yet, there have been few direct comparisons of sexual behavior patterns between these populations. Methods: We compared sexual behavior patterns of MSM and male and female heterosexuals aged 18-39 using 4 population-based random digit dialing surveys. A 1996-1998 survey in 4 US cities and 2 Seattle surveys (2003 and 2006) provided estimates for MSM; a 2003-2004 Seattle survey provided data about heterosexual men and women. Results: Sexual debut occurred earlier among MSM than heterosexuals. MSM reported longer cumulative lifetime periods of new partner acquisition than heterosexuals and a more gradual decline in new partnership formation with age. Among MSM, 86% of 18- to 24-year-olds and 72% of 35- to 39-year-olds formed a new partnership during the previous year, compared with 56% of heterosexual men and 34% of women at 18-24 years, and 21% and 10%, respectively, at 35-39 years. MSM were also more likely to choose partners >5 years older and were 2-3 times as likely as heterosexuals to report recent concurrent partnerships. MSM reported more consistent condom use during anal sex than heterosexuals reported during vaginal sex. Conclusions: MSM have longer periods of partnership acquisition, a higher prevalence of partnership concurrency, and more age disassortative mixing than heterosexuals. These factors likely help to explain higher HIV/sexually transmitted infections rates among MSM, despite higher levels of condom use. C1 [Glick, Sara Nelson] George Washington Univ, Dept Epidemiol & Biostat, Washington, DC 20037 USA. [Morris, Martina] Univ Washington, Dept Sociol, Seattle, WA 98195 USA. [Morris, Martina] Univ Washington, Dept Stat, Seattle, WA 98195 USA. [Foxman, Betsy] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Aral, Sevgi O.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Manhart, Lisa E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Holmes, King K.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Holmes, King K.; Golden, Matthew R.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Golden, Matthew R.] HIV STD Program, Seattle, WA USA. RP Glick, SN (reprint author), George Washington Univ, Dept Epidemiol & Biostat, 2100-W Penn Ave NW,8th Floor, Washington, DC 20037 USA. EM snglick@gwu.edu RI Morris, Martina/I-7510-2012; OI Foxman, Betsy/0000-0001-6682-238X FU University of Washington from the National Institutes of Health, U.S. Public Health Service [T32 AI007140]; Public Health-Seattle King County; Center for Molecular and Clinical Epidemiology of Infectious Diseases, University of Michigan School of Public Health; University of Washington Center for AIDS and STD; Centers for Disease Control and Prevention; NIH [K23 AI01846]; NIMH [MH54320] FX Supported by University of Washington STD/AIDS Research Training Program (T32 AI007140 to S. N. Glick) from the National Institutes of Health, U.S. Public Health Service. The Seattle Sex Survey RDD was funded by Public Health-Seattle & King County, the Center for Molecular and Clinical Epidemiology of Infectious Diseases, University of Michigan School of Public Health, and the University of Washington Center for AIDS and STD. The 2003 Seattle MSM RDD was supported by a Comprehensive STD Prevention System Syphilis Elimination grant from the Centers for Disease Control and Prevention and the 2006 RDD was supported by a grant to M. R. Golden (NIH K23 AI01846).; The Urban Men's Health Study was conducted under the direction of Joe Catania and Ron Stall with support from NIMH (MH54320). NR 38 TC 37 Z9 37 U1 4 U2 18 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2012 VL 60 IS 1 BP 83 EP 90 DI 10.1097/QAI.0b013e318247925e PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 930BZ UT WOS:000303112200020 PM 22522237 ER PT J AU Abimbola, TO Marston, BJ Date, AA Blandford, JM Sangrujee, N Wiktor, SZ AF Abimbola, Taiwo O. Marston, Barbara J. Date, Anand A. Blandford, John M. Sangrujee, Nalinee Wiktor, Stefan Z. TI Cost-Effectiveness of Tuberculosis Diagnostic Strategies to Reduce Early Mortality Among Persons With Advanced HIV Infection Initiating Antiretroviral Therapy SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; tuberculosis; tuberculosis diagnosis; cost; cost-effectiveness; sub-Saharan Africa ID SUB-SAHARAN AFRICA; RESOURCE-LIMITED SETTINGS; SOUTH-AFRICA; INCOME COUNTRIES; TREATMENT PROGRAM; ADULTS; OUTCOMES; PREVALENCE; DISEASE; CULTURE AB Background: In sub-Saharan Africa, patients with advanced HIV experience high mortality during the first few months of antiretroviral therapy (ART), largely attributable to tuberculosis (TB). We evaluated the cost-effectiveness of TB diagnostic strategies to reduce this early mortality. Methods: We developed a decision analytic model to estimate the incremental cost, deaths averted, and cost-effectiveness of 3 TB diagnostic algorithms. The model base case represents current practice (symptoms screening, sputum smear, and chest radiography) in many resource-limited countries in sub-Saharan Africa. We compared the current practice with World Health Organization (WHO)-recommended practice with culture and WHO-recommended practice with the Xpert mycobacterium tuberculosis and resistance to rifampicin test and considered relevant medical costs from a health system perspective using the timeframe of the first 6 months of ART. We conducted univariate and probabilistic sensitivity analyses on all parameters in the model. Results: When considering TB diagnosis and treatment and ART costs, the cost per patient was $850 for current practice, $809 for the algorithm with Xpert test, and $879 for the algorithm with culture. Our results showed that both WHO-recommended algorithms avert more deaths among TB cases than does the current practice. The algorithm with Xpert test was least costly at reducing early mortality compared with the current practice. Sensitivity analyses indicated that cost-effectiveness findings were stable. Conclusions: Our analysis showed that culture or Xpert were cost-effective at reducing early mortality during the first 6 months of ART compared with the current practice. Thus, our findings provide support for ongoing efforts to expand TB diagnostic capacity. C1 [Abimbola, Taiwo O.; Marston, Barbara J.; Date, Anand A.; Blandford, John M.; Sangrujee, Nalinee; Wiktor, Stefan Z.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Abimbola, TO (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, MS-E30,1600 Clifton Rd, Atlanta, GA 30333 USA. EM tabimbola@cdc.gov NR 49 TC 21 Z9 21 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2012 VL 60 IS 1 BP E1 EP E7 DI 10.1097/QAI.0b013e318246538f PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 930BZ UT WOS:000303112200001 PM 22240465 ER PT J AU Abimbola, TO Marston, BJ AF Abimbola, Taiwo O. Marston, Barbara J. TI The Cost-Effectiveness of Cotrimoxazole in People With Advanced HIV Infection Initiating Antiretroviral Therapy in Sub-Saharan Africa SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; cost-effectiveness; cost; cotrimoxazole; antiretroviral therapy; opportunistic infection ID RESOURCE-LIMITED SETTINGS; COTE-DIVOIRE; HIV-1-INFECTED ADULTS; TRIMETHOPRIM-SULFAMETHOXAZOLE; INCOME COUNTRIES; EARLY MORTALITY; SOUTH-AFRICA; PROPHYLAXIS; UGANDA; COHORT AB Background: In sub-Saharan Africa, high mortality rates have been reported among patients with advanced HIV infection initiating antiretroviral therapy (ART). We evaluated the cost-effectiveness of expanding access to cotrimoxazole (CTX) for persons with HIV in averting mortality during the first 6 months of ART. We also evaluated possible cost savings related to prevention of specific opportunistic infections (OIs). Methods: We developed a decision-analytic model to estimate the incremental cost, deaths averted, and incremental cost-effectiveness ratio. The model compared 2 scenarios for providing CTX and evaluated potential benefits of increased CTX coverage in reducing deaths and cases of OI. The base case scenario represents an estimated current level of CTX coverage among adults initiating ART in low-income countries (65%). The comparator is 97% coverage (excluding only those with contraindications to CTX). We conducted sensitivity analyses on all parameters in the model. Results: Full coverage reduced deaths from 94 to 72 per 1000 patients, averting 22 deaths during the first 6 months of ART compared with the base case. The incremental cost of moving from base case to full coverage was estimated at $3.29 per person on ART and $146.91 per death averted over 6 months. Additional benefits from averted OI cases would likely be realized as well as savings from averted OI treatment costs. Conclusions: Our findings suggest that expanding CTX coverage is a cost-effective approach to reducing mortality among patients who present with advanced HIV and initiate ART. The expansion of coverage may also yield benefits for OIs. C1 [Abimbola, Taiwo O.] Ctr Dis Control & Prevent, Hlth Econ Syst & Integrat Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Abimbola, TO (reprint author), Ctr Dis Control & Prevent, Hlth Econ Syst & Integrat Branch, Div Global HIV AIDS, Ctr Global Hlth, MS-E30,1600 Clifton Rd, Atlanta, GA 30333 USA. EM tabimbola@cdc.gov NR 47 TC 9 Z9 8 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2012 VL 60 IS 1 BP E8 EP E14 DI 10.1097/QAI.0b013e3182478dc0 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 930BZ UT WOS:000303112200002 PM 22240461 ER PT J AU Dowda, M Pfeiffer, KA Lobelo, F Porter, DE Pate, RR AF Dowda, Marsha Pfeiffer, Karin A. Lobelo, Felipe Porter, Dwayne E. Pate, Russell R. TI Cardiorespiratory Fitness and Proximity to Commercial Physical Activity Facilities Among 12th Grade Girls SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Fitness; Geographic Information Systems; Physical activity ID HIGH-SCHOOL GIRLS; ADOLESCENT GIRLS; CHILDREN; ENVIRONMENT; HEALTH; YOUTH; VALIDITY; STUDENTS; AGE AB Purpose: To investigate the relationship between proximity to commercial physical activity (PA) facilities and cardiorespiratory fitness of 12th grade girls. Methods: Adolescent girls (n = 786, 60% African American, mean age = 17.6 +/- .6 years) performed a submaximal fitness test (Physical Work Capacity 170 test). Commercial PA facilities were mapped and counted within a.75-mile street-network buffer around girls' homes using Geographic Information Systems. Sedentary activities and vigorous physical activity (>= 6 metabolic equivalents) were determined by the average number of 30-minute blocks reported per day on the 3-Day Physical Activity Recall. Mixed model regressions were calculated using school as a random variable. Results: Girls had higher weight-relative Physical Work Capacity 170 test scores if there was a commercial PA facility (n = 186, 12.4 +/- 4.2 kg m/min/kg) within a.75-mile street-network buffer of home as compared with girls without a nearby facility (n = 600, 11.2 +/- 3.6 kg m/min/kg). After adjusting for demographic variables, sports participation, sedentary behaviors, and vigorous physical activity, having one or more commercial PA facilities within a.75-mile street-network buffer of homes was significantly related to cardiorespiratory fitness. Conclusions: Both with and without adjustment for covariates, the presence of a commercial PA facility within a.75-mile street-network buffer of a girl's home was associated with higher cardiorespiratory fitness. (C) 2012 Society for Adolescent Health and Medicine. All rights reserved. C1 [Dowda, Marsha; Pate, Russell R.] Univ S Carolina, Dept Exercise Sci, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. [Pfeiffer, Karin A.] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA. [Lobelo, Felipe] Ctr Dis Control & Prevent, Div Nutr Phys Activ & Obes, Atlanta, GA USA. [Porter, Dwayne E.] Univ S Carolina, Dept Environm Hlth Sci, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. RP Dowda, M (reprint author), Univ S Carolina, Dept Exercise Sci, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. EM mdowda@mailbox.sc.edu RI lobelo, felipe/B-9148-2013; OI Lobelo, Felipe/0000-0003-4185-7193 FU National Heart, Lung, and Blood Institute, National Institutes of Health, United States [R01HL057775] FX The authors thank LaVerne Shuler for administration of the study and Gaye Groover Christmus, M.P.H., for editing the manuscript. This study was funded by grant number R01HL057775 from the National Heart, Lung, and Blood Institute, National Institutes of Health, United States. NR 40 TC 3 Z9 3 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAY PY 2012 VL 50 IS 5 BP 497 EP 502 DI 10.1016/j.jadohealth.2011.09.018 PG 6 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 930HP UT WOS:000303128600013 PM 22525114 ER PT J AU Ouyang, LJ Grosse, SD Fox, MH Bolen, J AF Ouyang, Lijing Grosse, Scott D. Fox, Michael H. Bolen, Julie TI A National Profile of Health Care and Family Impacts of Children With Muscular Dystrophy and Special Health Care Needs in the United States SO JOURNAL OF CHILD NEUROLOGY LA English DT Article DE muscular dystrophy; National Survey of Children with Special Health Care Needs; medical home; family impact; Duchenne; Emery-Dreifuss ID FINANCIAL BURDEN; POPULATION; EXPENDITURES AB We used the 2005-2006 National Survey of Children with Special Health Care Needs to compare 3 types of outcomes between children with and those without parental reported muscular dystrophy: (1) functional limitations; (2) health care experiences in terms of the 5 components of a medical home; and (3) family impacts, including financial or out-of-pocket costs and parental employment and time use. We used weighted logistic regression to examine their associations with muscular dystrophy after adjustment for socio-demographic characteristics. Among children with special health care needs, children with reported muscular dystrophy were much more likely to have difficulties with ambulation and self-care. They were more likely to have family members who reported financial problems, reduced or stopped employment, and spent more than 10 hours weekly providing or coordinating care. Muscular dystrophy was not associated with the likelihood of having a medical home after adjustment for socioeconomic status and other socio-demographic characteristics. C1 [Ouyang, Lijing; Fox, Michael H.; Bolen, Julie] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Grosse, Scott D.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Ouyang, LJ (reprint author), 1600 Clifton Rd NE,Mail Stop E-88, Atlanta, GA 30329 USA. EM louyang@cdc.gov FU Intramural CDC HHS [CC999999] NR 21 TC 6 Z9 6 U1 2 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0883-0738 J9 J CHILD NEUROL JI J. Child Neurol. PD MAY PY 2012 VL 27 IS 5 BP 569 EP 576 DI 10.1177/0883073811420719 PG 8 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 931RW UT WOS:000303238000003 PM 21954427 ER PT J AU Magnuson, ML Satzger, RD Alcaraz, A Brewer, J Fetterolf, D Harper, M Hrynchuk, R McNally, MF Montgomery, M Nottingham, E Peterson, J Rickenbach, M Seidel, JL Wolnik, K AF Magnuson, Matthew L. Satzger, R. Duane Alcaraz, Armando Brewer, Jason Fetterolf, Dean Harper, Martin Hrynchuk, Ronald McNally, Mary F. Montgomery, Madeline Nottingham, Eric Peterson, James Rickenbach, Michael Seidel, Jimmy L. Wolnik, Karen TI Guidelines for the Identification of Unknown Samples for Laboratories Performing Forensic Analyses for Chemical Terrorism SO JOURNAL OF FORENSIC SCIENCES LA English DT Article DE forensic science; chemical terrorism; unknown; unknown samples; identification; sample acceptance; analysis; reporting ID CHROMATOGRAPHY-MASS SPECTROMETRY; CRITERIA AB Since the early 1990s, the FBI Laboratory has sponsored Scientific Working Groups to improve discipline practices and build consensus among the forensic community. The Scientific Working Group on the Forensic Analysis of Chemical, Biological, Radiological and Nuclear Terrorism developed guidance, contained in this document, on issues forensic laboratories encounter when accepting and analyzing unknown samples associated with chemical terrorism, including laboratory capabilities and analytical testing plans. In the context of forensic analysis of chemical terrorism, this guidance defines an unknown sample and addresses what constitutes definitive and tentative identification. Laboratory safety, reporting issues, and postreporting considerations are also discussed. Utilization of these guidelines, as part of planning for forensic analysis related to a chemical terrorism incident, may help avoid unfortunate consequences not only to the public but also to the laboratory personnel. C1 [Magnuson, Matthew L.] US EPA, Natl Homeland Secur Res Ctr, Off Res & Dev, Cincinnati, OH 45268 USA. [Satzger, R. Duane; Wolnik, Karen] US FDA, Forens Chem Ctr, Cincinnati, OH 45237 USA. [Alcaraz, Armando] Lawrence Livermore Natl Lab, Forens Sci Ctr, Livermore, CA 94551 USA. [Brewer, Jason; Fetterolf, Dean; Montgomery, Madeline; Rickenbach, Michael] Fed Bur Invest Lab, Quantico, VA 22135 USA. [Harper, Martin] NIOSH, Dept Hlth & Human Serv, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Hrynchuk, Ronald] Royal Canadian Mounted Police, Natl Forens Serv, Winnipeg, MB R3N OE7, Canada. [McNally, Mary F.] USA, Dept Def, RDECOM, Aberdeen Proving Ground, MD 21010 USA. [Nottingham, Eric] US EPA, Natl Enforcement Invest Ctr, Denver Fed Ctr, Lakewood, CO 80225 USA. [Peterson, James] Fed Bur Invest, Aberdeen Proving Ground, MD 21010 USA. [Seidel, Jimmy L.] US EPA, Off Criminal Enforcement Forens & Training, Forens Operat Program, Denver, CO 80225 USA. RP Magnuson, ML (reprint author), US EPA, Natl Homeland Secur Res Ctr, Off Res & Dev, 26 W Martin Luther King Dr, Cincinnati, OH 45268 USA. EM magnuson.matthew@epa.gov NR 21 TC 5 Z9 5 U1 0 U2 17 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-1198 J9 J FORENSIC SCI JI J. Forensic Sci. PD MAY PY 2012 VL 57 IS 3 BP 636 EP 642 DI 10.1111/j.1556-4029.2011.02014.x PG 7 WC Medicine, Legal SC Legal Medicine GA 928QX UT WOS:000302999000009 PM 22211294 ER PT J AU Ahluwalia, IB D'Angelo, D Morrow, B McDonald, JA AF Ahluwalia, Indu B. D'Angelo, Denise Morrow, Brian McDonald, Jill A. TI Association between Acculturation and Breastfeeding among Hispanic Women: Data from the Pregnancy Risk Assessment and Monitoring System SO JOURNAL OF HUMAN LACTATION LA English DT Article DE breastfeeding; acculturation; Hispanic; PRAMS ID UNITED-STATES; MEXICAN-AMERICANS; HEALTH; INITIATION; FORMULA; CARE; DURATION; LANGUAGE AB Background: Breastfeeding rates are typically higher among Hispanic women; however, they vary by acculturation status in that those more acculturated are less likely to breastfeed than those who are less acculturated. This study examined the association between acculturation and breastfeeding behaviors using population-based data. Methods: Data (N = 8942) from the Pregnancy Risk Assessment Monitoring System (PRAMS) were used for analysis. Acculturation status was determined using self-reported Hispanic ethnicity and the language in which the women responded to the PRAMS survey, either English or Spanish. Hispanic women who responded to the survey in Spanish were categorized as less acculturated than those who responded in English. Breastfeeding indicators used were: initiation, duration to >= 10 weeks, and exclusive breastfeeding to >= 10 weeks. Results: The prevalence rates of breastfeeding initiation, duration, and exclusive breastfeeding to >= 10 weeks were significantly higher among less acculturated than among highly acculturated. More acculturated were less likely to initiate breastfeeding (prevalence ratio [PR] = 0.88; 95% CI, 0.86-0.90), less likely to breastfeed =>= 10 weeks (PR = 0.77; 95% CI, 0.72-0.82), and less likely to report exclusive breastfeeding to >= 10 weeks (PR =, 0.70; 95% CI, 0.58-0.85). The relationship between breastfeeding continuation and acculturation persisted after adjusting for covariates in that more acculturated were less likely to breastfeed to >= 10 weeks (adjusted prevalence ratio [APR] = 0.81; 95% CI, 0.75-0.87), as did the relationship between exclusivity and acculturation; more acculturated were less likely to report exclusive breastfeeding (APR = 0.69; 95% CI, 0.55-0.87). Conclusions: Breastfeeding promotion efforts must include culturally/linguistically supportive services to assure that women are able to make optimal infant feeding decisions. C1 [Ahluwalia, Indu B.; D'Angelo, Denise; Morrow, Brian; McDonald, Jill A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Ahluwalia, IB (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mail Stop K-22, Atlanta, GA 30341 USA. EM Iahluwalia@cdc.gov NR 26 TC 24 Z9 24 U1 3 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0890-3344 J9 J HUM LACT JI J. Hum. Lact. PD MAY PY 2012 VL 28 IS 2 BP 167 EP 173 DI 10.1177/0890334412438403 PG 7 WC Nursing; Obstetrics & Gynecology; Pediatrics SC Nursing; Obstetrics & Gynecology; Pediatrics GA 930GO UT WOS:000303125900015 PM 22526345 ER PT J AU Tseng, HF Liu, A Sy, L Marcy, SM Fireman, B Weintraub, E Baggs, J Weinmann, S Baxter, R Nordin, J Daley, MF Jackson, L Jacobsen, SJ AF Tseng, H. F. Liu, A. Sy, L. Marcy, S. M. Fireman, B. Weintraub, E. Baggs, J. Weinmann, S. Baxter, R. Nordin, J. Daley, M. F. Jackson, L. Jacobsen, S. J. CA Vaccine Safety Datalink VSD Team TI Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study SO JOURNAL OF INTERNAL MEDICINE LA English DT Article DE adult vaccination; case-centered method; herpes zoster vaccine; self-controlled case series; varicella zoster virus ID HERPES-ZOSTER; INFLUENZA VACCINATION; BELLS-PALSY; CASE SERIES; VIRUS; OLDER; ASSOCIATION; SYSTEM; RISK AB . Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, Baggs J, Weinmann S, Baxter R, Nordin J, Daley MF, Jackson L, Jacobsen SJ, for the Vaccine Safety Datalink (VSD) Team (Kaiser Permanente, Pasadena, CA; Kaiser Permanente, Oakland, CA; Centers for Disease Control and Prevention, Atlanta, GA; Kaiser Permanente, Portland, OR; HealthPartners Research Foundation, Minneapolis, MN; Kaiser Permanente, Denver, CO; and Group Health Cooperative of Puget Sound, Seattle, WA; USA). Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med 2012; 271: 510520. Objectives. The aim of this study was to examine a large cohort of adults who received the zoster vaccine for evidence of an increased risk of prespecified adverse events requiring medical attention. Design. Two self-comparison approaches, including a case-centred approach and a self-controlled case series (SCCS) analysis were used. Setting. Eight managed-care organizations participating in the Vaccine Safety Datalink project in the United States. Subjects. A total of 193 083 adults aged 50 and older receiving a zoster vaccine from 1 January 2007 to 31 December 2008 were included. Main outcome measures. Prespecified adverse events were identified by aggregated International Classification of Diseases, Ninth Revision (ICD-9) codes in automated health plan datasets. Results. The risk of allergic reaction was significantly increased within 17 days of vaccination [relative risk = 2.13, 95% confidence interval (CI): 1.872.40 by case-centred method and relative rate = 2.32, 95% CI: 1.852.91 by SCCS]. No increased risk was found for the following adverse event groupings: cerebrovascular events; cardiovascular events; meningitis; encephalitis; and encephalopathy; and Ramsay-Hunt syndrome and Bells palsy. Conclusions. The results of this study support the findings from the prelicensure clinical trials, providing reassurance that the zoster vaccine is generally safe and well-tolerated with a small increased risk of allergic reactions in 17 days after vaccination. C1 [Tseng, H. F.] Kaiser Permanente, So Calif Permanente Med Grp, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Fireman, B.; Baxter, R.] Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA. [Weintraub, E.; Baggs, J.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. [Weinmann, S.] Kaiser Permanente, Portland, OR USA. [Nordin, J.] HealthPartners Res Fdn, Minneapolis, MN USA. [Daley, M. F.] Kaiser Permanente, Denver, CO USA. [Jackson, L.] Grp Hlth Cooperat Puget Sound, Seattle, WA USA. RP Tseng, HF (reprint author), Kaiser Permanente, So Calif Permanente Med Grp, Dept Res & Evaluat, 100 S Los Robles Ave,2nd Floor, Pasadena, CA 91101 USA. EM Hung-Fu.x.Tseng@kp.org OI Baggs, James/0000-0003-0757-4683; Jacobsen, Steven/0000-0002-8174-8533 FU Centers for Disease Control and Prevention (CDC) [200-2002-00732] FX This study was funded through a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732 from the Centers for Disease Control and Prevention (CDC). The authors thank David McClure and Lei Qian for their comments on statistical methods, Sungching Glenn for her assistance with programming, and Theresa Im, Felicia Bixler, Sarah Fisher and Zendi Solano for their assistance with medical record reviews. Dr. Hung Fu Tseng had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 24 TC 23 Z9 23 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0954-6820 J9 J INTERN MED JI J. Intern. Med. PD MAY PY 2012 VL 271 IS 5 BP 510 EP 520 DI 10.1111/j.1365-2796.2011.02474.x PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 930SR UT WOS:000303160600012 PM 22026504 ER PT J AU Pfeiffer, CM Hughes, JP Lacher, DA Bailey, RL Berry, RJ Zhang, M Yetley, EA Rader, JI Sempos, CT Johnson, CL AF Pfeiffer, Christine M. Hughes, Jeffery P. Lacher, David A. Bailey, Regan L. Berry, R. J. Zhang, Mindy Yetley, Elizabeth A. Rader, Jeanne I. Sempos, Christopher T. Johnson, Clifford L. TI Estimation of Trends in Serum and RBC Folate in the U.S. Population from Pre- to Postfortification Using Assay-Adjusted Data from the NHANES 1988-2010 SO JOURNAL OF NUTRITION LA English DT Article ID TOTAL HOMOCYSTEINE CONCENTRATIONS; FOLIC-ACID FORTIFICATION; BIO-RAD RADIOASSAY; UNITED-STATES; ROUND-TABLE; MICROBIOLOGIC ASSAY; VITAMIN-B-12 STATUS; NATIONAL-HEALTH; BLOOD FOLATE; LC-MS/MS AB The NHANES has monitored folate status of the U.S. population from prefortification (1988-1994) to postfortification (1999-2010) by measuring serum and RBC folate concentrations. The Bio-Rad radioassay (BR) was used from 1988 to 2006, and the microbiologic assay (MBA) was used from 2007 to 2010. The MBA produces higher concentrations than the BR and is considered to be more accurate. Thus, to bridge assay differences and to examine folate trends over time, we adjusted the BR results to be comparable to the MBA results. Postfortification, assay-adjusted serum and RBC folate concentrations were 2.5 times and 1.5 times prefortification concentrations, respectively, and showed a significant linear trend (P < 0.001) to slightly lower concentrations during 1999-2010. The postfortification prevalence of low serum (<10 nmol/L) or RBC (<340 nmol/L) folate concentrations was <= 1%, regardless of demographic subgroup, compared with 24% for serum folate and 3.5% for RBC folate prefortification, with substantial variation among demographic subgroups, The central 95% reference intervals for serum and RBC folate varied by demographic subgroup during both pre- and post-fortification periods. Age and dietary supplement use had the greatest effects on prevalence estimates of low folate concentrations during the prefortification period. In summary, the MBA-equivalent blood folate concentrations in the U.S. population showed first a sharp increase from pre- to postfortification, then showed a slight decrease (17% for serum and 12% for RBC folate) during the 12-y postfortification period. The MBA-equivalent pre- and postfortification reference concentrations will inform countries that plan folic acid fortification or that need to evaluate its impact. J. Nutr. 142: 886-893, 2012. C1 [Pfeiffer, Christine M.; Zhang, Mindy] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Hughes, Jeffery P.; Lacher, David A.; Johnson, Clifford L.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Bailey, Regan L.; Yetley, Elizabeth A.; Sempos, Christopher T.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Berry, R. J.] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Rader, Jeanne I.] US FDA, College Pk, MD USA. RP Pfeiffer, CM (reprint author), CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM cpfeiffer@cdc.gov OI Berry, Robert/0000-0002-7162-5046 FU Office of Dietary Supplements, NIH FX Supported by funding from the Office of Dietary Supplements, NIH. The findings and conclusions in this report are those of the authors and do not necessarily represent the official views or positions of the CDC and Prevention/Agency for Toxic Substances and Disease Registry, the NIH, or the Department of Health and Human Services. NR 29 TC 67 Z9 70 U1 1 U2 12 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD MAY PY 2012 VL 142 IS 5 BP 886 EP 893 DI 10.3945/jn.111.156919 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 929TX UT WOS:000303089700012 PM 22437563 ER PT J AU Pfeiffer, CM Hughes, JP Durazo-Arvizu, RA Lacher, DA Sempos, CT Zhang, M Yetley, EA Johnson, CL AF Pfeiffer, Christine M. Hughes, Jeffery P. Durazo-Arvizu, Ramon A. Lacher, David A. Sempos, Christopher T. Zhang, Mindy Yetley, Elizabeth A. Johnson, Clifford L. TI Changes in Measurement Procedure from a Radioassay to a Microbiologic Assay Necessitate Adjustment of Serum and RBC Folate Concentrations in the US Population from the NHANES 1988-2010 SO JOURNAL OF NUTRITION LA English DT Article ID BIO-RAD RADIOASSAY; WHOLE-BLOOD FOLATE; LC-MS/MS; INTERNATIONAL STANDARD; ROUND-TABLE; VITAMIN-B-12; BIOMARKERS; HISTORY AB The NHANES measured serum and RBC folate concentrations by using a radioassay during prefortification (1988-1994) and postfortification (1999-2006) periods followed by the use of a microbiologic assay (MBA) from 2007-2010. The MBA produces higher concentrations than does the radioassay and is considered to be more accurate. To allow for accurate long-term trending (1988-2010), we evaluated different regression models (linear, piecewise linear, and fractional polynomial) to assay-adjust the radioassay results to be comparable to the MBA results. The data used to derive the regression models originated from 2 crossover studies in which the 2 assays were applied to a set of 325 serum and 171 whole-blood samples. Fractional polynomial regression of logarithmically transformed data provided the best fit for serum folate. Linear regression of logarithmically transformed whole-blood data provided an equally good fit compared with the other models and was the simplest to apply for RBC folate. Prefortification serum and RBC folate geometric mean concentrations increased after adjustment from 13.0 to 16.7 nmol/L and from 403 to 747 nmol/L, respectively. Postfortification serum folate concentrations increased from similar to 30 to similar to 43 nmol/L, and RBC folate concentrations increased from similar to 600 to similar to 1100 nmol/L after adjustment, with some variation across survey cycles. The presented regression equations allow the estimation of more accurate prevalence estimates and long-term trends in blood folate concentrations in the U.S. population by using results that are equivalent to the MBA. This information will be useful to public health officials in the United States who are dealing with folic acid fortification issues. J. Nutr. 142: 894-900, 2012. C1 [Hughes, Jeffery P.; Lacher, David A.; Johnson, Clifford L.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Pfeiffer, Christine M.; Zhang, Mindy] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Durazo-Arvizu, Ramon A.] Loyola Univ, Dept Prevent Med & Epidemiol, Chicago, IL 60611 USA. [Sempos, Christopher T.; Yetley, Elizabeth A.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. RP Pfeiffer, CM (reprint author), CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. EM cpfeiffer@cdc.gov FU Office of Dietary Supplements, NIH FX Supported by funding from the Office of Dietary Supplements, NIH. The findings and conclusions in this report are those of the authors and do not necessarily represent the official views or positions of the CDC/Agency for Toxic Substances and Disease Registry, the NIH, or the Department of Health and Human Services. NR 24 TC 12 Z9 12 U1 0 U2 4 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD MAY PY 2012 VL 142 IS 5 BP 894 EP 900 DI 10.3945/jn.111.156901 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 929TX UT WOS:000303089700013 PM 22437557 ER PT J AU Balaban, V Stauffer, WM Hammad, A Afgarshe, M Abd-Alla, M Ahmed, Q Memish, ZA Saba, J Harton, E Palumbo, G Marano, N AF Balaban, Victor Stauffer, William M. Hammad, Adnan Afgarshe, Mohamud Abd-Alla, Mohamed Ahmed, Qanta Memish, Ziad A. Saba, Janan Harton, Elizabeth Palumbo, Gabriel Marano, Nina TI Protective Practices and Respiratory Illness Among US Travelers to the 2009 Hajj SO JOURNAL OF TRAVEL MEDICINE LA English DT Article ID FRENCH PILGRIMS; INFECTION; SYMPTOMS AB Background. All mass gatherings can place travelers at risk for infectious diseases, but the size and density of the annual Hajj pilgrimage to the Kingdom of Saudi Arabia (KSA) present important public health and infection control challenges. This survey of protective practices and respiratory illness among US travelers to the 2009 Hajj was designed to evaluate whether recommended behavioral interventions (hand hygiene, wearing a face mask, cough etiquette, social distancing, and contact avoidance) were effective at mitigating illness among travelers during the 2009 Hajj. Methods. US residents from Minnesota and Michigan completed anonymous surveys prior to and following travel to the 2009 Hajj. Surveys assessed demographics, knowledge, attitudes, and practices (KAP) related to influenza A(H1N1), vaccination, health-seeking behaviors, sources of health information, protective behaviors during the Hajj, and respiratory illness during and immediately after the Hajj. Results. Pre- and post-travel surveys were completed by 186 participants. Respiratory illness was reported by 76 (41.3%) respondents; 144 (77.4%) reported engaging in recommended protective behaviors during the Hajj. Reduced risk of respiratory illness was associated with practicing social distancing, hand hygiene, and contact avoidance. Pilgrims who reported practicing more recommended protective measures during the Hajj reported either less occurrence or shorter duration of respiratory illness. Noticing influenza A(H1N1) health messages during the Hajj was associated with more protective measures and with shorter duration of respiratory illness. Conclusions. Recommended protective behaviors were associated with less respiratory illness among US travelers to the 2009 Hajj. Influenza A(H1N1) communication and education in KSA during the Hajj may also have been an effective component of efforts to mitigate illness. Evaluations of communication efforts and preventive measures are important in developing evidence-based public health plans to prevent and mitigate disease outbreaks at the Hajj and other mass gatherings. C1 [Balaban, Victor; Stauffer, William M.; Harton, Elizabeth; Palumbo, Gabriel; Marano, Nina] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Stauffer, William M.] Univ Minnesota, Div Infect Dis & Int Med, Minneapolis, MN USA. [Hammad, Adnan; Saba, Janan] ACCESS, Dearborn, MI USA. [Afgarshe, Mohamud] Gargar Urgent Care & Clin, Minneapolis, MN USA. [Abd-Alla, Mohamed] Med Coll Wisconsin, Div Infect Dis, Milwaukee, WI 53226 USA. [Ahmed, Qanta] SUNY Stony Brook, Winthrop Univ Hosp, Div Pulm & Crit Care Med, Dept Med, Mineola, NY 11501 USA. [Memish, Ziad A.] Minist Hlth, Riyadh, Saudi Arabia. RP Balaban, V (reprint author), Ctr Dis Control & Prevent, Field Serv & Evaluat Branch, Div TB Eliminat, 1600 Clifton Rd,MS E-10, Atlanta, GA 30333 USA. EM vbalaban@cdc.gov NR 24 TC 15 Z9 23 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1195-1982 J9 J TRAVEL MED JI J. Travel Med. PD MAY-JUN PY 2012 VL 19 IS 3 BP 163 EP 168 DI 10.1111/j.1708-8305.2012.00602.x PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 931EJ UT WOS:000303197900006 PM 22530823 ER PT J AU Hornig, M Briese, T Licinio, J Khabbaz, RF Altshuler, LL Potkin, SG Schwemmle, M Siemetzki, U Mintz, J Honkavuori, K Kraemer, HC Egan, MF Whybrow, PC Bunney, WE Lipkin, WI AF Hornig, M. Briese, T. Licinio, J. Khabbaz, R. F. Altshuler, L. L. Potkin, S. G. Schwemmle, M. Siemetzki, U. Mintz, J. Honkavuori, K. Kraemer, H. C. Egan, M. F. Whybrow, P. C. Bunney, W. E. Lipkin, W. I. TI Absence of evidence for bornavirus infection in schizophrenia, bipolar disorder and major depressive disorder SO MOLECULAR PSYCHIATRY LA English DT Article DE Borna disease virus; infection; schizophrenia; affective disorders; pathogenesis ID PROVENTRICULAR DILATATION DISEASE; PRENATAL EXPOSURE; SERUM ANTIBODIES; VIRUS-INFECTION; RATING-SCALE; HUMAN BLOOD; INFLUENZA; RNA; RELIABILITY; PSYCHOSIS AB In 1983, reports of antibodies in subjects with major depressive disorder (MDD) to an as-yet uncharacterized infectious agent associated with meningoencephalitis in horses and sheep led to molecular cloning of the genome of a novel, negative-stranded neurotropic virus, Borna disease virus (BDV). This advance has enabled the development of new diagnostic assays, including in situ hybridization, PCR and serology based on recombinant proteins. Since these assays were first implemented in 1990, more than 80 studies have reported an association between BDV and a wide range of human illnesses that include MDD, bipolar disorder (BD), schizophrenia (SZ), anxiety disorder, chronic fatigue syndrome, multiple sclerosis, amyotrophic lateral sclerosis, dementia and glioblastoma multiforme. However, to date there has been no blinded case-control study of the epidemiology of BDV infection. Here, in a United States-based, multi-center, yoked case-control study with standardized methods for clinical assessment and blinded serological and molecular analysis, we report the absence of association of psychiatric illness with antibodies to BDV or with BDV nucleic acids in serially collected serum and white blood cell samples from 396 subjects, a study population comprised of 198 matched pairs of patients and healthy controls (52 SZ/control pairs, 66 BD/control pairs and 80 MDD/control pairs). Our results argue strongly against a role for BDV in the pathogenesis of these psychiatric disorders. Molecular Psychiatry (2012) 17, 486-493; doi:10.1038/mp.2011.179; published online 31 January 2012 C1 [Hornig, M.; Briese, T.; Siemetzki, U.; Honkavuori, K.; Lipkin, W. I.] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10032 USA. [Hornig, M.; Briese, T.; Lipkin, W. I.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA. [Licinio, J.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia. [Khabbaz, R. F.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Altshuler, L. L.; Mintz, J.; Whybrow, P. C.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Potkin, S. G.; Bunney, W. E.] Univ Calif Irvine, Irvine, CA USA. [Schwemmle, M.] Univ Freiburg Klinikum, Dept Virol, Freiburg, Germany. [Kraemer, H. C.] Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Egan, M. F.] Merck & Co Inc, Clin Neurosci, N Wales, PA USA. RP Hornig, M (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, 722 W 168th St,17th Floor, New York, NY 10032 USA. EM mady.hornig@columbia.edu; wil2001@columbia.edu RI Potkin, Steven/A-2021-2013; Licinio, Julio/L-4244-2013; OI Licinio, Julio/0000-0001-6905-5884; Potkin, Steven/0000-0003-1028-1013 FU NIH [MH57467] FX This study was supported by NIH award MH57467 (WIL). We thank Meera Bhat for data derived from linkage to the United States Census Bureau database, and Vishal Kapoor for assistance with Western immunoblot analyses. NR 41 TC 33 Z9 34 U1 2 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD MAY PY 2012 VL 17 IS 5 BP 486 EP 493 DI 10.1038/mp.2011.179 PG 8 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 930BN UT WOS:000303110800003 PM 22290118 ER PT J AU Creanga, AA Sabel, JC Ko, JY Wasserman, CR Shapiro-Mendoza, CK Taylor, P Barfield, W Cawthon, L Paulozzi, LJ AF Creanga, Andreea A. Sabel, Jennifer C. Ko, Jean Y. Wasserman, Cathy R. Shapiro-Mendoza, Carrie K. Taylor, Polly Barfield, Wanda Cawthon, Laurie Paulozzi, Leonard J. TI Maternal Drug Use and Its Effect on Neonates A Population-Based Study in Washington State SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID ABSTINENCE SYNDROME; SUBSTANCE USE; PREGNANCY; ABUSE; WOMEN; EPIDEMIOLOGY; COMORBIDITY; PREVALENCE; DISORDERS; METHADONE AB OBJECTIVE: To estimate the effect of maternal illicit and prescription drug use on neonates in Washington State between 2000 and 2008. METHODS: We used state-linked birth certificate and hospital discharge (mother and neonate) data to calculate prenatal drug exposure and neonatal abstinence syndrome rates, and compared state neonatal abstinence syndrome rates with national-level data from the Nationwide Inpatient Sample. We identified the drugs of exposure, examined predictors of drug exposure and neonatal abstinence syndrome, and assessed perinatal outcomes among drug-exposed and neonatal abstinence syndrome-diagnosed neonates compared with unexposed neonates. RESULTS: Drug exposure and neonatal abstinence syndrome rates increased significantly between 2000 and 2008, neonatal abstinence syndrome rates being consistently higher than national figures (3.3 compared with 2.8 per 1,000 births in 2008; P<.05). The proportion of neonatal abstinence syndrome-diagnosed neonates exposed prenatally to opioids increased from 26.4% in 2000 to 41.7% in 2008 (P<.05). Compared with unexposed neonates, drug-exposed and neonatal abstinence syn- drome-diagnosed neonates had a lower mean birth weight, longer birth hospitalization, were more likely to be born preterm, experience feeding problems, and have respiratory conditions (all P<.001). CONCLUSION: Maternal use of illicit and prescription drugs was associated with considerable neonatal morbidity and significantly higher rates of drug exposure and neonatal abstinence syndrome in recent years. Data suggest that opioid analgesics contributed to the increase in prenatal drug exposure and neonatal abstinence syndrome in Washington State. In accordance with current guidelines, our findings emphasize the need for clinicians to screen pregnant women for illicit and prescription drug use and minimize use of opioid analgesics during pregnancy. C1 [Creanga, Andreea A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Epidem Intelligence Serv,Off Workforce & Career D, Atlanta, GA 30341 USA. Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. Washington State Dept Hlth & Social & Hlth Serv, Olympia, WA USA. RP Creanga, AA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Epidem Intelligence Serv,Off Workforce & Career D, 4770 Buford Highway NE,Mail Stop K-23, Atlanta, GA 30341 USA. EM acreanga@cdc.gov NR 35 TC 28 Z9 28 U1 3 U2 22 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD MAY PY 2012 VL 119 IS 5 BP 924 EP 933 DI 10.1097/AOG.0b013e31824ea276 PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 930OW UT WOS:000303150000007 PM 22525903 ER PT J AU Secor, WE AF Secor, W. Evan TI The effects of schistosomiasis on HIV/AIDS infection, progression and transmission SO CURRENT OPINION IN HIV AND AIDS LA English DT Review DE coinfection; female urogenital schistosomiasis; HIV-1; schistosomiasis ID HUMAN-IMMUNODEFICIENCY-VIRUS; CLADE-C INFECTION; GENITAL SCHISTOSOMIASIS; MANSONI INFECTION; HAEMATOBIUM INFECTION; RHESUS MACAQUES; RURAL ZIMBABWE; T-CELLS; HIV; COINFECTION AB Purpose of review The recent findings pertaining to the public health impact of schistosomiasis on the epidemiology of HIV/AIDS are summarized. Recent findings Both empiric data and mathematical models support the hypothesis that schistosome infections lead to increased susceptibility to infection with HIV-1, a more rapid progression to disease through more vigorous viral replication and immunosuppression, and a higher likelihood of transmitting the infection to others through both vertical and horizontal routes. Different species of schistosome infection vary in the magnitude of their effects on these mechanisms with Schistosoma haematobium playing a greater role for increased susceptibility and transmission because of its association with urogenital disease. Summary Schistosomiasis appears to be a cofactor in the spread and progression of HIV/AIDS in areas wherein both diseases are endemic; increased emphasis on treatment of schistosome infections in persons at risk of HIV/AIDS should be pursued. C1 Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30329 USA. RP Secor, WE (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE MS-D65, Atlanta, GA 30329 USA. EM was4@cdc.gov NR 45 TC 33 Z9 35 U1 4 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1746-630X J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD MAY PY 2012 VL 7 IS 3 BP 254 EP 259 DI 10.1097/COH.0b013e328351b9e3 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 925TA UT WOS:000302783200008 PM 22327410 ER PT J AU Simon, SL Coleman, CN Noska, MA Bowman, T AF Simon, Steven L. Coleman, C. Norman Noska, Michael A. Bowman, Thomas TI RESPONSE OF THE US DEPARTMENT OF HEALTH AND HUMAN SERVICES IN PROTECTING CIVILIAN AMERICANS IN JAPAN DURING THE FUKUSHIMA NUCLEAR CRISIS SO HEALTH PHYSICS LA English DT Article DE operational topics; emergency planning; exposure, radiation; radiation safety; emergency response AB Following the earthquake and tsunami in northern Japan on 11 March 2011 and the ensuing damage to the Fukushima Daiichi Nuclear Power Plant complex, a request by the U. S. Ambassador to Japan to the U. S. Department of Health and Human Services (DHHS) Assistant Secretary for Preparedness and Response (ASPR) resulted in deployment of a five-person team of subject matter experts to the U. S. Embassy. The primary purpose of the deployment was to provide the U. S. Embassy in Tokyo with guidance on health and medical issues related to potential radiation exposure of U. S. citizens in Japan, including employees of the U. S. Department of State at consulates in Japan and American citizens living in or visiting Japan. At the request of the Government of Japan (GOJ), the deployed health team also assisted Japanese experts in their public health response to the radiation incident. Over a 3-wk period in Japan and continuing for weeks after their return to the U. S., the team provided expertise in the areas of medical and radiation oncology; health physics; assessment of radiation dose and cancer risk, particularly to U. S. citizens living in Tokyo and the surrounding areas; food and water contamination and the acceptable limits; countermeasures to exposure such as potassium iodide (KI); the use of KI and an offered donation from the United States;, evacuation and re-entry issues; and health/emergency-related communication strategies. This paper describes the various strategies used and observations made by the DHHS team during the first 2 mo after the Fukushima crisis began. Health Phys. 102(5):570-579; 2012 C1 [Simon, Steven L.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Coleman, C. Norman] Dept Hlth & Human Serv, Off Preparedness & Emergency Operat, Washington, DC USA. [Noska, Michael A.] US FDA, Silver Spring, MD USA. [Bowman, Thomas] Ctr Dis Control & Prevent, Div Strateg Natl Stockpile, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. RP Simon, SL (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. EM ssimon@mail.nih.gov FU DHHS; NIH; NCI; NCI Division of Cancer Epidemiology FX The authors are appreciative of support from the DHHS and individual agencies they represent and especially Dr. Nicole Lurie, the DHHS Assistant Secretary for Preparedness and Response. In addition, the authors are appreciative of the support from the Directors of the NIH, NCI, and the NCI Division of Cancer Epidemiology, the FDA Office of International Programs, and the FDA Office of Crisis Management for their logistic support. The authors gratefully acknowledge the dedication and expertise of a team member, Jana Telfer of the CDC, in the area of risk communications. NR 24 TC 3 Z9 3 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0017-9078 EI 1538-5159 J9 HEALTH PHYS JI Health Phys. PD MAY PY 2012 VL 102 IS 5 BP 570 EP 579 DI 10.1097/HP.0b013e31824c79e5 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 925VG UT WOS:000302789300014 ER PT J AU Miller, CW AF Miller, Charles W. TI THE FUKUSHIMA RADIOLOGICAL EMERGENCY AND CHALLENGES IDENTIFIED FOR FUTURE PUBLIC HEALTH RESPONSES SO HEALTH PHYSICS LA English DT Article DE operational topics; emergencies, radiological; emergency planning; public information AB On 11 March 2011, northern Japan was rocked by first a magnitude 9.0 earthquake off the eastern coast and then an ensuing tsunami. The Fukushima Daiichi Nuclear Power Plant complex was hit by these twin disasters, and a cascade of events was initiated that led to radionuclide releases causing widespread radioactive contamination of residential areas, agricultural land, and coastal waters. Radioactive material from Japan was subsequently transmitted to locations around the globe, including the U. S. The levels of radioactive material that arrived in the U. S. were never large enough to be a concern for health effects, but the presence of this material in the environment was enough to create a public health emergency in the U. S. The radiation safety and public health communities in the U. S. are identifying challenges they faced in responding to this incident. This paper discusses three of those challenges: (1) The growing shortage of trained radiation subject matter experts in the field of environmental transport and dosimetry of radionuclides; (2) the need to begin expressing all radiation-related quantities in terms of the International System of Units; and (3) the need to define when a radiation dose is or is not one of "public health concern.'' This list represents only a small subset of the list of challenges being identified by public health agencies that responded to the Fukushima incident. However, these three challenges are fundamental to any radiological emergency response. Addressing them will have a significant positive impact on how the U. S. responds to the next radiological emergency. Health Phys. 102(5):584-588; 2012 C1 Ctr Dis Control & Prevent, Radiat Studies Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Miller, CW (reprint author), Ctr Dis Control & Prevent, Radiat Studies Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway NE,Mailstop F58, Atlanta, GA 30341 USA. EM cmiller1@cdc.gov FU Intramural CDC HHS [CC999999] NR 14 TC 5 Z9 5 U1 0 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0017-9078 EI 1538-5159 J9 HEALTH PHYS JI Health Phys. PD MAY PY 2012 VL 102 IS 5 BP 584 EP 588 DI 10.1097/HP.0b013e31824d0241 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 925VG UT WOS:000302789300016 PM 22469934 ER PT J AU Nasrullah, M Breiding, MJ Smith, W McCullum, I Soetebier, K Liang, JL Drenzek, C Miller, JR Copeland, D Walton, S Lance, S Averhoff, F AF Nasrullah, Muazzam Breiding, Matthew J. Smith, Wendy McCullum, Isaac Soetebier, Karl Liang, Jennifer L. Drenzek, Cherie Miller, Jeffrey R. Copeland, Daphne Walton, Sabrina Lance, Susan Averhoff, Francisco TI Response to 2009 pandemic influenza A H1N1 among public schools of Georgia, United States-fall 2009 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Pandemic influenza A H1N1; Non-pharmaceutical interventions (NPIs); Schools; Absenteeism; Respiratory illness ID NONPHARMACEUTICAL INTERVENTIONS; SOCIAL CONTACTS; CLOSURE; TRANSMISSION; HOUSEHOLDS; CHILDREN; SPREAD; SEASON; IMPACT AB Background: Little is known about the extent of implementation or the effectiveness of the Centers for Disease Control and Prevention's (CDC) recommended non-pharmaceutical interventions (NPIs) in schools to control the spread of 2009 pandemic influenza A H1N1 (pH1N1). Methods: A web-based, cross-sectional survey of all public K-12 schools in Georgia, USA was conducted about preparedness and response to pH1N1, and absenteeism and respiratory illness. Schools that reported >10% absenteeism and at least two times the normal level of respiratory illness in the same week were designated as having experienced significant respiratory illness and absenteeism (SRIA) during that week. Results: Of 2248 schools surveyed, 704 (31.3%) provided sufficient data to include in our analysis. Participating schools were spread throughout Georgia, USA and were similar to non-participating schools. Of 704 schools, 160 (22.7%) reported at least 1 week of SRIA. Most schools reported implementing the CDC recommendations for the control of pH1N1, and only two schools reported canceling or postponing activities. Schools that communicated with parents about influenza in the summer, had shorter school days, and were located in urban areas were less likely to experience SRIA. Conclusions: Most Georgia schools in the United States adopted the CDC recommendations for pH1N1 mitigation and few disruptions of school activities were reported. Early and timely communication with parents, as well as shorter school days, may have been effective in limiting the effect of pH1N1 on schools. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. C1 [Nasrullah, Muazzam; Breiding, Matthew J.; McCullum, Isaac; Liang, Jennifer L.; Miller, Jeffrey R.; Copeland, Daphne; Walton, Sabrina; Lance, Susan; Averhoff, Francisco] NIOSH, Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. [Smith, Wendy; Soetebier, Karl; Drenzek, Cherie] Georgia Dept Community Hlth, Div Publ Hlth DPH, Atlanta, GA USA. RP Nasrullah, M (reprint author), NIOSH, Ctr Dis Control & Prevent CDC, 1600 Clifton Rd,Mailstop E46, Atlanta, GA 30333 USA. EM snasrullah@cdc.gov FU Georgia Department of Education, Atlanta, Georgia; CDC FX The authors thank Garry McGiboney and Marilyn Watson from the Georgia Department of Education, Atlanta, Georgia, for their valuable input and support of this project.; The study was supported by CDC as part of the pandemic H1N1 response. NR 22 TC 2 Z9 2 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAY PY 2012 VL 16 IS 5 BP E382 EP E390 DI 10.1016/j.ijid.2012.01.010 PG 9 WC Infectious Diseases SC Infectious Diseases GA 925TI UT WOS:000302784000012 PM 22424896 ER PT J AU Ku, BK Kulkarni, P AF Ku, Bon Ki Kulkarni, Pramod TI Comparison of diffusion charging and mobility-based methods for measurement of aerosol agglomerate surface area SO JOURNAL OF AEROSOL SCIENCE LA English DT Article DE Diffusion charging; Aerosol surface area; Agglomerates; Tandem mobility-mass approach; Mobility diameter; BET method ID VOLUME DISTRIBUTIONS; ONLINE MEASUREMENT; TITANIUM-DIOXIDE; ULTRAFINE; PARTICLES; MASS; MORPHOLOGY; EXPOSURE; NUMBER; TIO2 AB We compare different approaches to measure surface area of aerosol agglomerates. The objective was to compare field methods, such as mobility and diffusion charging based approaches, with laboratory approach, such as Brunauer, Emmett, Teller (BET) method used for bulk powder samples. To allow intercomparison of various surface area measurements, we defined 'geometric surface area' of agglomerates (assuming agglomerates are made up of ideal spheres), and compared various surface area measurements to the geometric surface area. Four different approaches for measuring surface area of agglomerate particles in the size range of 60-350 nm were compared using (i) diffusion charging-based sensors from three different manufacturers, (ii) mobility diameter of an agglomerate, (iii) mobility diameter of an agglomerate assuming a linear chain morphology with uniform primary particle size, and (iv) surface area estimation based on tandem mobility-mass measurement and microscopy. Our results indicate that the tandem mobility-mass measurement, which can be applied directly to airborne particles unlike the BET method, agrees well with the BET method. It was also shown that the three diffusion charging-based surface area measurements of silver agglomerates were similar within a factor of 2 and were lower than those obtained from the tandem mobility-mass and microscopy method by a factor of 3-10 in the size range studied. Surface area estimated using the mobility diameter depended on the structure or morphology of the agglomerate with significant underestimation at high fractal dimensions approaching 3. Published by Elsevier Ltd. C1 [Ku, Bon Ki; Kulkarni, Pramod] NIOSH, Ctr Dis Control & Prevent CDC, Cincinnati, OH 45226 USA. RP Ku, BK (reprint author), NIOSH, Ctr Dis Control & Prevent CDC, 4676 Columbia Pkwy,MS-R3, Cincinnati, OH 45226 USA. EM BKu@cdc.gov FU National Institute for Occupational Safety and Health through the Nanotechnology Research Center [CAN 927ZBCL] FX The authors would like to thank Drs. Art Miller and Emanuele Cauda at NIOSH for helpful suggestions, and Ellen Galloway for editorial assistance. This work was funded by the National Institute for Occupational Safety and Health through the Nanotechnology Research Center program (Project CAN 927ZBCL). NR 37 TC 10 Z9 10 U1 0 U2 24 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-8502 J9 J AEROSOL SCI JI J. Aerosol. Sci. PD MAY PY 2012 VL 47 BP 100 EP 110 DI 10.1016/j.jaerosci.2012.01.002 PG 11 WC Engineering, Chemical; Engineering, Mechanical; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA 926QR UT WOS:000302846500010 PM 26692585 ER PT J AU Zou, W Lin, WJ Hise, KB Chen, HC Keys, C Chen, JJ AF Zou, Wen Lin, Wei-Jiun Hise, Kelley B. Chen, Hung-Chia Keys, Christine Chen, James J. TI Prediction System for Rapid Identification of Salmonella Serotypes Based on Pulsed-Field Gel Electrophoresis Fingerprints SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID HIGH-DIMENSIONAL DATA; FOODBORNE PATHOGENS; MULTIPLEX; SWINE; PCR AB A classification model is presented for rapid identification of Salmonella serotypes based on pulsed-field gel electrophoresis (PFGE) fingerprints. The classification model was developed using random forest and support vector machine algorithms and was then applied to a database of 45,923 PFGE patterns, randomly selected from all submissions to CDC PulseNet from 2005 to 2010. The patterns selected included the top 20 most frequent serotypes and 12 less frequent serotypes from various sources. The prediction accuracies for the 32 serotypes ranged from 68.8% to 99.9%, with an overall accuracy of 96.0% for the random forest classification, and ranged from 67.8% to 100.0%, with an overall accuracy of 96.1% for the support vector machine classification. The prediction system improves reliability and accuracy and provides a new tool for early and fast screening and source tracking of outbreak isolates. It is especially useful to get serotype information before the conventional methods are done. Additionally, this system also works well for isolates that are serotyped as "unknown" by conventional methods, and it is useful for a laboratory where standard serotyping is not available. C1 [Zou, Wen; Chen, Hung-Chia; Chen, James J.] US FDA, Div Personalized Nutr & Med, Natl Ctr Toxicol Res, Jefferson, AR USA. [Lin, Wei-Jiun] Feng Chia Univ, Dept Appl Math, Taichung 40724, Taiwan. [Hise, Kelley B.] Ctr Dis Control & Prevent, PulseNet Database Unit, Enter Dis Lab Branch, Div Foodborne Waterborne & Environm Dis,Natl Ctr, Atlanta, GA USA. [Keys, Christine] US FDA, Div Microbiol, Off Regulatory Sci, Ctr Food Safety & Appl Nutr, College Pk, MD USA. RP Zou, W (reprint author), US FDA, Div Personalized Nutr & Med, Natl Ctr Toxicol Res, Jefferson, AR USA. EM wen.zou@fda.hhs.gov FU Oak Ridge Institute for Science and Education FX Wei-Jiun Lin and Hung-Chia Chen acknowledge support of a fellowship from the Oak Ridge Institute for Science and Education, administered through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration. NR 27 TC 18 Z9 19 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2012 VL 50 IS 5 BP 1524 EP 1532 DI 10.1128/JCM.00111-12 PG 9 WC Microbiology SC Microbiology GA 927II UT WOS:000302900500005 PM 22378901 ER PT J AU Quinlivan, ML Jensen, NJ Radford, KW Schmid, DS AF Quinlivan, Mark L. Jensen, Nancy J. Radford, Kay W. Schmid, D. Scott TI Novel Genetic Variation Identified at Fixed Loci in ORF62 of the Oka Varicella Vaccine and in a Case of Vaccine-Associated Herpes Zoster SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID COMPLETE DNA-SEQUENCES; VIRUS-STRAINS; SAFETY PROFILE; HEALTHY-CHILDREN; PARENTAL VIRUS; CARE FACILITY; SKIN-LESIONS; RECOMBINATION; TRANSMISSION; GENOTYPES AB The live attenuated Oka varicella vaccine (vOka), derived from clade 2 wild-type (wt) virus pOka, is used for routine childhood immunization in several countries, including the United States, which has caused dramatic declines in the incidence of varicella. vOka can cause varicella, establish latency, and reactivate to cause herpes zoster (HZ). Three loci in varicella-zoster virus (VZV) open reading frame 62 (ORF62) (106262, 107252, and 108111) are used to distinguish vOka from wt VZV. A fourth position (105705) is also fixed for the vOka allele in nearly all vaccine batches. These 4 positions and two vOka mutations (106710 and 107599) reportedly absent from Varivax were analyzed on Varivax-derived ORF62 TOPO TA clones. The wt allele was detected at positions 105705 and 107252 on 3% and 2% of clones, respectively, but was absent at positions 106262 and 108111. Position 106710 was fixed for the wt allele, whereas the vOka allele was present on 18.4% of clones at position 107599. We also evaluated the 4 vOka markers in an isolate obtained from a case of vaccine-caused HZ. The isolate carried the vOka allele at positions 105705, 106262, and 108111. However, at position 107252, the wt allele was present. Thus, all of the ORF62 vOka markers previously regarded as fixed occur as the wt allele in a small percentage of vOka strains. Characterization of all four vOka markers in ORF62 and of the clade 2 subtype marker in ORF38 is now necessary to confirm vOka adverse events. C1 [Quinlivan, Mark L.; Jensen, Nancy J.; Radford, Kay W.; Schmid, D. Scott] Ctr Dis Control & Prevent, Div Viral Dis Measles Mumps Rubella & Herpesvirus, Off Infect Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Schmid, DS (reprint author), Ctr Dis Control & Prevent, Div Viral Dis Measles Mumps Rubella & Herpesvirus, Off Infect Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. EM sschmid@cdc.gov NR 51 TC 6 Z9 6 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2012 VL 50 IS 5 BP 1533 EP 1538 DI 10.1128/JCM.06630-11 PG 6 WC Microbiology SC Microbiology GA 927II UT WOS:000302900500006 PM 22378912 ER PT J AU Steinau, M Onyekwuluje, JM Scarbrough, MZ Unger, ER Dillner, J Zhou, TQ AF Steinau, Martin Onyekwuluje, Juanita M. Scarbrough, Mariela Z. Unger, Elizabeth R. Dillner, Joakim Zhou, Tiequn TI Performance of Commercial Reverse Line Blot Assays for Human Papillomavirus Genotyping SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID BROAD-SPECTRUM; PCR AB The performance of three line blot assays (LBAs), the Linear Array HPV genotyping assay (LA) (Roche Diagnostics), INNO-LiPA HPV Genotyping Extra (LiPA) (Innogenetics), and the reverse hybridization assay (RH) (Qiagen), was evaluated using quantitated whole genomic human papillomavirus (HPV) plasmids (types 6, 11, 16, 18, 31, 33, 35, 39, 51, 52, 56, 58, 59, and 68b) as well as epidemiologic samples. In a plasmid titration series, LiPA and RH did not detect 50 international units (IU) of HPV type 18 (HPV18) in the presence of 5 x 10(4) IU or more of HPV16. HPV DNA (1 to 6 types) in the plasmid challenges at 50 IU or genome equivalents (GE) were identified with an accuracy of 99.9% by LA, 97.3% by LiPA, and 95.4% by RH, with positive reproducibility of 99.8% (kappa = 0.992), 88.2% (kappa = 0.928), and 88.1% (kappa = 0.926), respectively. Two instances of mistyping occurred with LiPA. Of the 120 epidemiologic samples, 76 were positive for high-risk types by LA, 90 by LiPA, and 69 by RH, with a positive reproducibility of 87.3% (kappa = 0.925), 83.9% (kappa = 0.899), and 90.2% (kappa = 0.942), respectively. Although the assays had good concordance in the clinical samples, the greater accuracy and specificity in the plasmid panel suggest that LA has an advantage for internationally comparable genotyping studies. C1 [Steinau, Martin; Onyekwuluje, Juanita M.; Scarbrough, Mariela Z.; Unger, Elizabeth R.] Ctr Dis Control & Prevent, WHO Human Papillomavirus Lab Network Global Refer, Chron Viral Dis Branch, Div High Consequence Pathogens, Atlanta, GA USA. [Steinau, Martin; Onyekwuluje, Juanita M.; Scarbrough, Mariela Z.; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis Pathol, Atlanta, GA USA. [Dillner, Joakim] WHO Human Papillomavirus Lab Network Global Refer, Malmo, Sweden. [Dillner, Joakim] Karolinska Inst, Dept Lab Med, Stockholm, Sweden. [Dillner, Joakim] Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden. [Dillner, Joakim] Karolinska Inst, Dept Biostat, Stockholm, Sweden. [Zhou, Tiequn] World Hlth Org, Qual Safety & Stand Team, Immunizat Vaccines & Biol Dept, Geneva, Switzerland. RP Steinau, M (reprint author), Ctr Dis Control & Prevent, WHO Human Papillomavirus Lab Network Global Refer, Chron Viral Dis Branch, Div High Consequence Pathogens, Atlanta, GA USA. EM MSteinau@cdc.gov OI Unger, Elizabeth/0000-0002-2925-5635 FU WHO; Bill and Melinda Gates Foundation FX This work was supported by the WHO via a project funded by the Bill and Melinda Gates Foundation. NR 10 TC 15 Z9 15 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2012 VL 50 IS 5 BP 1539 EP 1544 DI 10.1128/JCM.06576-11 PG 6 WC Microbiology SC Microbiology GA 927II UT WOS:000302900500007 PM 22357500 ER PT J AU Diaz, MH Bai, Y Malania, L Winchell, JM Kosoy, MY AF Diaz, Maureen H. Bai, Ying Malania, Lile Winchell, Jonas M. Kosoy, Michael Y. TI Development of a Novel Genus-Specific Real-Time PCR Assay for Detection and Differentiation of Bartonella Species and Genotypes SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CAT-SCRATCH DISEASE; SP-NOV.; INFECTIONS; HENSELAE; WILD; TRANSMISSION; THAILAND; RODENTS; AGENT; SPP. AB The genus Bartonella includes numerous species with varied host associations, including several that infect humans. Development of a molecular diagnostic method capable of detecting the diverse repertoire of Bartonella species while maintaining genus specificity has been a challenge. We developed a novel real-time PCR assay targeting a 301-bp region of the ssrA gene of Bartonella and demonstrated specific amplification in over 30 Bartonella species, subspecies, and strains. Subsequent analysis of ssrA sequences was sufficient to discriminate Bartonella species and provided phylogenetic data consistent with that of gltA, a commonly used gene for differentiating Bartonella genotypes. Using this assay, we identified Bartonella DNA in 29% and 47% of blood specimens from elk in Wyoming and cattle in the Republic of Georgia, respectively. Sequence analysis of a subset of genotypes from elk specimens revealed a cluster most closely related to Bartonella capreoli, and genotypes from cattle were identified as Bartonella bovis, both Bartonella species commonly found in wild and domestic ruminants. Considering the widespread geographic distribution and infectivity potential to a variety of hosts, this assay may be an effective diagnostic method for identification of Bartonella infections in humans and have utility in Bartonella surveillance studies. C1 [Diaz, Maureen H.; Winchell, Jonas M.] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Atlanta, GA USA. [Bai, Ying; Malania, Lile; Kosoy, Michael Y.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Malania, Lile] Natl Ctr Dis Control & Publ Hlth, Tbilisi, Rep of Georgia. RP Diaz, MH (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Atlanta, GA USA. EM MDiaz1@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX This work was supported in part by an appointment to the Emerging Infectious Diseases Fellowship Program administered by the Association of Public Health Laboratories and funded by the Centers for Disease Control and Prevention (CDC). Funding was also provided by the Global Disease Detection program at the CDC. NR 26 TC 26 Z9 29 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2012 VL 50 IS 5 BP 1645 EP 1649 DI 10.1128/JCM.06621-11 PG 5 WC Microbiology SC Microbiology GA 927II UT WOS:000302900500023 PM 22378904 ER PT J AU Cowan, LS Hooks, DP Christianson, S Sharma, MK Alexander, DC Guthrie, JL Jamieson, FB Supply, P Allix-Beguec, C Cruz, L Desmond, E Kramer, R Lugo, S Rudrik, J AF Cowan, Lauren S. Hooks, Delaina P. Christianson, Sara Sharma, Meenu K. Alexander, David C. Guthrie, Jennifer L. Jamieson, Frances B. Supply, Philip Allix-Beguec, Caroline Cruz, Laura Desmond, Ed Kramer, Rebecca Lugo, Sonia Rudrik, James TI Evaluation of Mycobacterial Interspersed Repetitive-Unit-Variable-Number Tandem-Repeat Genotyping as Performed in Laboratories in Canada, France, and the United States SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Letter ID MIRU-VNTRPLUS; TUBERCULOSIS C1 [Cowan, Lauren S.; Hooks, Delaina P.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Christianson, Sara; Sharma, Meenu K.] Publ Hlth Agcy Canada, Natl Reference Ctr Mycobacteriol, Winnipeg, MB, Canada. [Alexander, David C.; Guthrie, Jennifer L.; Jamieson, Frances B.] Ontario Agcy Hlth Protect & Promot, Toronto, ON, Canada. [Supply, Philip] Univ Lille Nord France, CNRS UMR 8204, INSERM U1019, Inst Pasteur Lille,CIIL, Lille, France. [Allix-Beguec, Caroline] Genoscreen, Lille, France. [Cruz, Laura; Desmond, Ed] Calif Dept Publ Hlth, Richmond, CA USA. [Kramer, Rebecca; Lugo, Sonia; Rudrik, James] Michigan Dept Community Hlth, Lansing, MI USA. RP Cowan, LS (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. EM los4@cdc.gov RI Jamieson, Frances/B-2040-2013; OI Guthrie, Jennifer/0000-0001-8565-203X NR 9 TC 5 Z9 5 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAY PY 2012 VL 50 IS 5 BP 1830 EP 1831 DI 10.1128/JCM.00168-12 PG 2 WC Microbiology SC Microbiology GA 927II UT WOS:000302900500069 PM 22505766 ER PT J AU Lee, R AF Lee, Rosalyn TI COMMUNITY VIOLENCE EXPOSURE AND ADOLESCENT SUBSTANCE USE: DOES MONITORING AND POSITIVE PARENTING MODERATE RISK IN URBAN COMMUNITIES? SO JOURNAL OF COMMUNITY PSYCHOLOGY LA English DT Article ID DRUG-USE; PROTECTIVE FACTORS; NATIONAL SAMPLE; USE DISORDERS; FAMILY; ALCOHOL; DEPENDENCE; BEHAVIORS; DELINQUENCY; ASSOCIATION AB This study investigates whether monitoring and positive parenting moderate the relationship between community violence exposure (CVE) and youth substance use. Analyses utilized a subsample (N = 2197) of a cross-sectional, ethnically diverse, urban school district sample. Dependent variables were any past year alcohol or drug use (AOD) and binge drinking. Independent variables were CVE, perceptions of parental monitoring, and positive parenting. Sixty-four percent of the sample witnessed beatings, 16.5% witnessed stabbings or shootings; 45% and 19.5% reported AOD consumption and binge drinking, respectively. After controlling for confounders, logistic regression models indicated that CVE was significantly and positively related to AOD and binge drinking. Parental monitoring was inversely related to AOD and binge drinking. Significant interactions between CVE and parenting variables were not found. Additional research is needed to identify factors at multiple levels of the social ecology that buffer the impact of community violence on adolescent substance use. C1 [Lee, Rosalyn] US Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Lee, R (reprint author), CDC NCIPC DVP, 4770 Buford Hwy NE,MS F64, Atlanta, GA 30341 USA. EM rdl3@cdc.gov NR 38 TC 10 Z9 10 U1 1 U2 16 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0090-4392 J9 J COMMUNITY PSYCHOL JI J. Community Psychol. PD MAY PY 2012 VL 40 IS 4 BP 406 EP 421 DI 10.1002/jcop.20520 PG 16 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Social Work SC Public, Environmental & Occupational Health; Psychology; Social Work GA 927WE UT WOS:000302940300002 ER PT J AU Pugh, KH Zarus, GM AF Pugh, Katherine H. Zarus, Gregory M. TI The Burden of Environmental Disease in the United States SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article ID PARTICULATE AIR-POLLUTION; PUBLIC-HEALTH; MORTALITY; EXPOSURE; ASTHMA; COSTS; LEAD; CHILDREN; CANCER; WORK C1 [Pugh, Katherine H.; Zarus, Gregory M.] Agcy Tox Subst & Dis Registry, Atlanta, GA 30341 USA. RP Pugh, KH (reprint author), Agcy Tox Subst & Dis Registry, 4770 Buford Hwy NE,MS F-59, Atlanta, GA 30341 USA. EM khpugh@cdc.gov NR 30 TC 1 Z9 1 U1 1 U2 6 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAY PY 2012 VL 74 IS 9 BP 30 EP 34 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 929UF UT WOS:000303090500005 PM 22590849 ER PT J AU Blake, R Peters, J AF Blake, Rob Peters, Jay TI Model Aquatic Health Code (MAHC) and International Swimming Pool and Spa Code (ISPSC) SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article C1 [Blake, Rob] Environm Hlth Serv Branch, Atlanta, GA 30341 USA. [Peters, Jay] Int Code Council, Washington, DC USA. RP Blake, R (reprint author), Environm Hlth Serv Branch, 4770 Buford Highway NE,Mailstop F-60, Atlanta, GA 30341 USA. EM RGBlake@cdc.gov FU CLC NIH HHS [NIH0010192010] NR 7 TC 1 Z9 1 U1 0 U2 2 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAY PY 2012 VL 74 IS 9 BP 36 EP 39 PG 4 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 929UF UT WOS:000303090500006 PM 22590850 ER PT J AU Lau, DT Dwyer, LL AF Lau, Denys T. Dwyer, Lisa L. TI Inappropriate Medication in Home Health Care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Letter ID OLDER-ADULTS; LIFE C1 [Lau, Denys T.] Univ Illinois, Coll Pharm, Chicago, IL 60612 USA. [Dwyer, Lisa L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Long Term Care Stat Branch, Hyattsville, MD 20782 USA. RP Lau, DT (reprint author), Univ Illinois, Coll Pharm, 833 S Wood St,M-C 871, Chicago, IL 60612 USA. EM DTLau@uic.edu FU NIA NIH HHS [K01 AG027295, K01 AG027295-06] NR 6 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2012 VL 27 IS 5 BP 490 EP 490 DI 10.1007/s11606-012-1992-x PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 926YM UT WOS:000302869300004 PM 22331400 ER PT J AU Popovic, T Araujo, J AF Popovic, Tanja Araujo, John TI Access to Scientific Information: From Counting to Accountability SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Editorial Material C1 [Popovic, Tanja; Araujo, John] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Popovic, T (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM tpopovic@cdc.gov NR 13 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2012 VL 18 IS 3 BP 228 EP 232 DI 10.1097/PHH.0b013e318223b159 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 923TQ UT WOS:000302642800011 PM 22473115 ER PT J AU Shrestha, RK Sansom, SL Farnham, PG AF Shrestha, Ram K. Sansom, Stephanie L. Farnham, Paul G. TI Comparison of Methods for Estimating the Cost of Human Immunodeficiency Virus-Testing Interventions SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article; Proceedings Paper CT 3rd Biennial Conference of the American-Society-of-Health-Economists CY JUN 20-23, 2010 CL Ithaca, NY SP Amer Soc Hlth Economists DE cost analysis methods; economic evaluation; HIV testing ID COMMUNITY-BASED ORGANIZATIONS; UNDIAGNOSED HIV-INFECTION; HEALTH-CARE SETTINGS; PARTNER-NOTIFICATION; REFERRAL SERVICES; UNITED-STATES; TRANSGENDER COMMUNITIES; SOCIAL NETWORKS; PREVENTION; DIAGNOSES AB Context: The Centers for Disease Control and Prevention (CDC), Division of HIV/AIDS Prevention, spends approximately 50% of its $325 million annual human immunodeficiency virus (HIV) prevention funds for HIV-testing services. An accurate estimate of the costs of HIV testing in various settings is essential for efficient allocation of HIV prevention resources. Objectives: To assess the costs of HIV-testing interventions using different costing methods. Design, Settings, and Participants: We used the microcosting-direct measurement method to assess the costs of HIV-testing interventions in nonclinical settings, and we compared these results with those from 3 other costing methods: microcosting-staff allocation, where the labor cost was derived from the proportion of each staff person's time allocated to HIV testing interventions; gross costing, where the New York State Medicaid payment for HIV testing was used to estimate program costs, and program budget, where the program cost was assumed to be the total funding provided by Centers for Disease Control and Prevention. Main Outcome Measures: Total program cost, cost per person tested, and cost per person notified of new HIV diagnosis. Results: The median costs per person notified of a new HIV diagnosis were $12 475, $15 018, $2697, and $20 144 based on microcosting-direct measurement, microcosting-staff allocation, gross costing, and program budget methods, respectively. Compared with the microcosting-direct measurement method, the cost was 78% lower with gross costing, and 20% and 61% higher using the microcosting-staff allocation and program budget methods, respectively. Conclusions: Our analysis showed that HIV-testing program cost estimates vary widely by costing methods. However, the choice of a particular costing method may depend on the research question being addressed. Although program budget and gross-costing methods may be attractive because of their simplicity, only the microcosting-direct measurement method can identify important determinants of the program costs and provide guidance to improve efficiency. C1 [Shrestha, Ram K.; Sansom, Stephanie L.; Farnham, Paul G.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Shrestha, RK (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Mail Stop E48,1600 Clifton Rd, Atlanta, GA 30333 USA. EM rshrestha@cdc.gov NR 48 TC 5 Z9 5 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2012 VL 18 IS 3 BP 259 EP 267 DI 10.1097/PHH.0b013e31822b2077 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 923TQ UT WOS:000302642800015 PM 22473119 ER PT J AU Baty, SA D'Souza, A Sunenshine, R Bisgard, K Erhart, LM AF Baty, Steven A. D'Souza, Aarikha Sunenshine, Rebecca Bisgard, Kris Erhart, Laura M. TI Variations in Positive Predictive Values for Rapid Influenza Tests for 2009 Pandemic Influenza A (pH1N1)-Arizona, April-October 2009 SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE 2009 pandemic influenza A (H1N1); positive predictive value; rapid influenza diagnostic test; influenza ID H1N1 VIRUS; DIAGNOSTIC-TESTS; SENSITIVITY; PERFORMANCE AB Context: Rapid influenza diagnostic tests (RIDTs) are used for influenza screening, clinical decision making, and influenza surveillance. In August 2009, a hospital reported increased false-positive RIDT results to the Arizona Department of Health Services. Because of reported RIDT low sensitivities (40%-62%) for 2009 pandemic influenza A (pH1N1), the hospital's report raised further concerns about the specificity and clinical utility of RIDTs. Objective: To determine the positive predictive value (PPV) of RIDTs compared with real-time reverse transcription-polymerase chain reaction assay (rRT-PCR) using Centers for Disease Control and Prevention (CDC) protocols and primers as a standard. Design: A standardized survey collected information including RIDT brand/lot number, training of personnel performing test, type of laboratory, swab and specimen type, time from collection to testing, sample storage, and viral transport medium. Setting: Arizona. Participants: Seven Arizona laboratories submitted positive RIDT clinical samples to Arizona State Public Health Laboratory (ASPHL) for confirmatory rRT-PCR testing. Main Outcome Measure: The PPV was calculated on the basis of rRT-PCR-positive results for April through October. Results: Results from 600 specimens using 1 of 4 RIDTs were available. Median pH1N1 PPV was 80% (range: 62%-91%) when calculated by RIDT brand. A significant difference in PPV was identified between the 2 largest facilities, which used the same RIDT brand, BinaxNOW Influenza A&B, (Laboratories A, 33% and B, 92%, [P < .01]). The facilities reported similar testing practices except lot numbers used and timing of testing. Laboratory A used lot 003684 and performed testing within 1 hour of collection; Laboratory B used multiple lots, excluding lot 003684, and performed testing within 24 hours. Laboratory A switched RIDT brands and noted a significant PPV increase from 33% to 91% (P < .01). Conclusions: Wide PPV variability combined with documented low sensitivity among RIDTs for pH1N1 diagnosis increases concerns about their specificity and clinical and epidemiologic utility for influenza. C1 [Baty, Steven A.; D'Souza, Aarikha; Erhart, Laura M.] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Baty, Steven A.; Sunenshine, Rebecca; Bisgard, Kris] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sunenshine, Rebecca] Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA. RP Baty, SA (reprint author), Arizona Dept Hlth Serv, 150 N 18th Ave, Phoenix, AZ 85007 USA. EM Steven.Baty@us.army.mil NR 10 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2012 VL 18 IS 3 BP 268 EP 271 DI 10.1097/PHH.0b013e3182214730 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 923TQ UT WOS:000302642800016 PM 22473120 ER PT J AU Iqbal, S Clower, JH Saha, S Boehmer, TK Mattson, C Yip, FY Cobb, RD Flanders, WD AF Iqbal, Shahed Clower, Jacquelyn H. Saha, Shubhayu Boehmer, Tegan K. Mattson, Christine Yip, Fuyuen Y. Cobb, Robert D. Flanders, W. D. TI Residential Carbon Monoxide Alarm Prevalence and Ordinance Awareness SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE carbon monoxide; carbon monoxide poisoning; environmental health; epidemiology; health policy; prevalence; prevention ID UNITED-STATES; PREVENTION; DEATHS AB Objective: Unintentional carbon monoxide (CO) poisoning is a leading cause of poisoning in the United States. Most poisoning cases occur in residential settings and a working CO alarm may prevent many of these events. The use of a CO alarm is mandated in many parts of the country; however, little is known about the compliance and adoption of such ordinances at the population level. This study determined the prevalence of residential CO alarm and awareness of a 2001 CO alarm ordinance in Mecklenburg County, North Carolina in 2009. Methods: A random sample of households stratified by housing type (eg, single-family homes, multifamily homes) was included in a cross-sectional survey conducted. One adult respondent from each household was administered a questionnaire that included information on sociodemographic and household characteristics, presence of a CO alarm, and CO alarm ordinance awareness. Data were analyzed using multivariate stratified conditional logistic regression. Results: Among 214 participating households (response rate, 23.4%), 145 (67.8%) reported having a working CO alarm and 79 (36.9%) of the respondents were aware of the CO alarm ordinance. Respondents who were aware of the ordinance had 9 times higher odds (95% confidence interval, 3.3-25.9) of having a CO alarm than those who were unaware. Also, households with an attached garage had more than 2 times higher odds (95% confidence interval, 1.0-6.2) of having a CO alarm than those without an attached garage. Awareness of the CO alarm ordinance was not associated with any sociodemographic (eg, age, sex, race, education, income) or household (eg, home ownership, home construction year) characteristics. Conclusions: Carbon monoxide alarm prevalence in Mecklenburg County households was higher than the national average and was associated with CO alarm ordinance awareness. Public health efforts might benefit from regulations aimed at population-level adoption of preventive health behaviors. C1 [Iqbal, Shahed; Mattson, Christine] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Saha, Shubhayu] Ctr Dis Control & Prevent, Prevent Effectiveness Fellowship Program, Sci Educ & Profess Dev Off, Atlanta, GA USA. [Clower, Jacquelyn H.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, CaZador, Atlanta, GA USA. [Flanders, W. D.] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA. [Mattson, Christine] Ctr Dis Control & Prevent, Behav & Clin Surveillance Branch, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Cobb, Robert D.] Mecklenburg Cty Hlth Dept, Charlotte, NC USA. [Flanders, W. D.] Emory Univ, Atlanta, GA 30322 USA. RP Iqbal, S (reprint author), 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA. EM SIqbal@cdc.gov NR 25 TC 3 Z9 3 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAY-JUN PY 2012 VL 18 IS 3 BP 272 EP 278 DI 10.1097/PHH.0b013e318221b1d1 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 923TQ UT WOS:000302642800017 PM 22473121 ER PT J AU Tian, H Lin, JMS Reeves, WC AF Tian, Hao Lin, Jin-Mann S. Reeves, William C. TI Utilization of two web-based continuing education courses evaluated by Markov chain model SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID MEDICAL-EDUCATION; CONTROLLED-TRIAL; CME; OUTCOMES; WEBSITE AB Objectives To evaluate the web structure of two web-based continuing education courses, identify problems and assess the effects of web site modifications. Design Markov chain models were built from 2008 web usage data to evaluate the courses' web structure and navigation patterns. The web site was then modified to resolve identified design issues and the improvement in user activity over the subsequent 12 months was quantitatively evaluated. Measurements Web navigation paths were collected between 2008 and 2010. The probability of navigating from one web page to another was analyzed. Results The continuing education courses' sequential structure design was clearly reflected in the resulting actual web usage models, and none of the skip transitions provided was heavily used. The web navigation patterns of the two different continuing education courses were similar. Two possible design flaws were identified and fixed in only one of the two courses. Over the following 12 months, the drop-out rate in the modified course significantly decreased from 41% to 35%, but remained unchanged in the unmodified course. The web improvement effects were further verified via a second-order Markov chain model. Conclusions The results imply that differences in web content have less impact than web structure design on how learners navigate through continuing education courses. Evaluation of user navigation can help identify web design flaws and guide modifications. This study showed that Markov chain models provide a valuable tool to evaluate web-based education courses. Both the results and techniques in this study would be very useful for public health education and research specialists. C1 [Tian, Hao; Lin, Jin-Mann S.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Lin, Jin-Mann S.; Reeves, William C.] Ctr Dis Control & Prevent, Publ Hlth Surveillance Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Tian, H (reprint author), Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd,MS A-15, Atlanta, GA 30333 USA. EM ejq7@cdc.gov NR 20 TC 0 Z9 0 U1 0 U2 9 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD MAY PY 2012 VL 19 IS 3 BP 489 EP 494 DI 10.1136/amiajnl-2011-000287 PG 6 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA 925TE UT WOS:000302783600024 PM 21976027 ER PT J AU Park, RM Stayner, LT Petersen, MR Finley-Couch, M Hornung, R Rice, C AF Park, Robert M. Stayner, Leslie T. Petersen, Martin R. Finley-Couch, Melissa Hornung, Richard Rice, Carol TI Cadmium and lung cancer mortality accounting for simultaneous arsenic exposure SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID RESPIRATORY CANCER; BATTERY WORKERS; RECOVERY PLANT; UNITED-STATES; SMELTER; WHITES; COHORT; NICKEL AB Objectives Prior investigations identified an association between airborne cadmium and lung cancer but questions remain regarding confounding by arsenic, a well-established lung carcinogen. Methods A cadmium smelter population exhibiting excess lung cancer was re-analysed using a retrospective exposure assessment for arsenic (As), updated mortality (1940-2002), a revised cadmium (Cd) exposure matrix and improved work history information. Results Cumulative exposure metrics for both cadmium and arsenic were strongly associated making estimation of their independent effects difficult. Standardised mortality ratios (SMRs) were modelled with Poisson regression with the contribution of arsenic to lung cancer risk constrained by exposure-response estimates previously reported. The results demonstrate (1) a statistically significant effect of Cd independent of As (SMR=3.2 for 10 mg-year/m(3) Cd, p = 0.012), (2) a substantial healthy worker effect for lung cancer (for unexposed workers, SMR = 0.69) and (3) a large deficit in lung cancer mortality among Hispanic workers (SMR = 0.27, p = 0.009), known to have low lung cancer rates. A supralinear dose-rate effect was observed (contribution to risk with increasing exposure intensity has declining positive slope). Lung cancer mortality was somewhat better predicted using a cadmium burden metric with a half-life of about 20-25 years. Conclusions These findings support an independent effect for cadmium in risk of lung cancer mortality. 1/1000 excess lifetime risk of lung cancer death is predicted from an airborne exposure of about 2.4 mu g/m(3) Cd. C1 [Park, Robert M.] NIOSH, Risk Evaluat Branch, Educ & Informat Div, Cincinnati, OH 45226 USA. [Stayner, Leslie T.] Univ Illinois, Sch Publ Hlth, Dept Epidemiol, Chicago, IL USA. [Petersen, Martin R.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Finley-Couch, Melissa] Patheon Pharmaceut Inc, Reading, OH USA. [Hornung, Richard] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH USA. [Rice, Carol] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA. RP Park, RM (reprint author), NIOSH, Risk Evaluat Branch, Educ & Informat Div, 4676 Columbia Pkwy,C-15, Cincinnati, OH 45226 USA. EM rhp9@cdc.gov FU Intramural CDC HHS [CC999999] NR 27 TC 18 Z9 18 U1 0 U2 6 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD MAY PY 2012 VL 69 IS 5 BP 303 EP 309 DI 10.1136/oemed-2011-100149 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 926YO UT WOS:000302869600001 PM 22271639 ER PT J AU Larson, TC Lewin, M Gottschall, EB Antao, VC Kapil, V Rose, CS AF Larson, Theodore C. Lewin, Michael Gottschall, E. Brigitte Antao, Vinicius C. Kapil, Vikas Rose, Cecile S. TI Associations between radiographic findings and spirometry in a community exposed to Libby amphibole SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID RESOLUTION COMPUTED-TOMOGRAPHY; INDUCED PLEURAL FIBROSIS; LUNG-FUNCTION; CHEST RADIOGRAPHS; FUNCTIONAL CONSEQUENCES; PULMONARY-FUNCTION; ASBESTOS EXPOSURE; ABNORMALITIES; MONTANA; PLAQUES AB Background Among asbestos-exposed individuals, abnormal spirometry is usually associated with parenchymal abnormalities or diffuse pleural thickening. Localised pleural thickening (LPT), the most common abnormality associated with asbestos exposure, is typically thought to be a marker of exposure with little clinical consequence. Our objective was to determine if abnormal spirometry is associated with LPT independent of other abnormalities, using data from community-based screening conducted in Libby, Montana. Methods Subjects were a subset of screening participants comprising persons with interpretable spirometry and chest radiograph results (n = 6475). Chest radiographs were independently evaluated by two or three B readers, and participants were classified by mutually exclusive categories of spirometry outcome: normal, restriction, obstruction or mixed defect. Results Restrictive spirometry was strongly associated with parenchymal abnormalities (OR 2.9; 95% CI 1.4 to 6.0) and diffuse pleural thickening (OR 4.1; 95% CI 2.1 to 7.8). Controlling for the presence of these abnormalities as well as age, smoking status and other covariates, restrictive spirometry was also associated with LPT (OR 1.4; 95% CI 1.1 to 1.8). The risk of restrictive spirometric findings correlated with the severity of LPT. Conclusions In this large community-based screening cohort, restrictive spirometry is significantly associated with LPT, indicating that this abnormality may result in lung function impairment. Physicians treating patients exposed to Libby amphibole should be aware that LPT may have functional consequences. C1 [Larson, Theodore C.; Lewin, Michael; Antao, Vinicius C.] Agcy Tox Subst & Dis Registry, Div Hlth Studies, Atlanta, GA 30341 USA. [Gottschall, E. Brigitte; Rose, Cecile S.] Univ Colorado, Denver, CO 80202 USA. [Kapil, Vikas] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Kapil, Vikas] Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. RP Larson, TC (reprint author), Agcy Tox Subst & Dis Registry, Div Hlth Studies, 4770 Buford Highway,MS F57, Atlanta, GA 30341 USA. EM thl3@cdc.gov RI Antao, Vinicius/B-5395-2013 OI Antao, Vinicius/0000-0002-8201-9973 FU US Department of Health and Human Services FX This study was financed by intramural funds from the US Department of Health and Human Services 200 Independence Avenue, S.W. Washington, D.C. 20201. NR 38 TC 18 Z9 18 U1 0 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 EI 1470-7926 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD MAY PY 2012 VL 69 IS 5 BP 361 EP 366 DI 10.1136/oemed-2011-100316 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 926YO UT WOS:000302869600009 PM 22383589 ER PT J AU Kharrazi, M Pearl, M Yang, J DeLorenze, GN Bean, CJ Callaghan, WM Grant, A Lackritz, E Romero, R Satten, GA Simhan, H Torres, AR Westover, JB Yolken, R Williamson, DM AF Kharrazi, Martin Pearl, Michelle Yang, Juan DeLorenze, Gerald N. Bean, Christopher J. Callaghan, William M. Grant, Althea Lackritz, Eve Romero, Roberto Satten, Glen A. Simhan, Hyagriv Torres, Anthony R. Westover, Jonna B. Yolken, Robert Williamson, Dhelia M. TI California Very Preterm Birth Study: design and characteristics of the population- and biospecimen bank-based nested case-control study SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE Study design; California Very Preterm Birth Study ID TUMOR-NECROSIS-FACTOR; SINGLE-NUCLEOTIDE POLYMORPHISMS; CYTOKINE GENE POLYMORPHISMS; PROGESTERONE-RECEPTOR GENE; THAN-G POLYMORPHISM; FACTOR-ALPHA GENE; PREMATURE-RUPTURE; AFRICAN-AMERICANS; FETAL MEMBRANES; THROMBOPHILIC POLYMORPHISMS AB Very preterm birth (VPTB) is a leading cause of infant mortality, morbidity and racial disparity in the US. The underlying causes of VPTB are multiple and poorly understood. The California Very Preterm Birth Study was conducted to discover maternal and infant genetic and environmental factors associated with VPTB. This paper describes the study design, population, data and specimen collection, laboratory methods and characteristics of the study population. Using a large, population-based cohort created through record linkage of livebirths delivered from 2000 to 2007 in five counties of southern California, and existing data and banked specimens from state-wide prenatal and newborn screening, 1100 VPTB cases and 796 control mother-infant pairs were selected for study (385/200 White, 385/253 Hispanic and 330/343 Black cases/controls, respectively). Medical record abstraction of cases was conducted at over 50 hospitals to identify spontaneous VPTB, improve accuracy of gestational age, obtain relevant clinical data and exclude cases that did not meet eligibility criteria. VPTB was defined as birth at <32 weeks in Whites and Hispanics and <34 weeks in Blacks. Approximately 55% of all VPTBs were spontaneous and 45% had medical indications or other exclusions. Of the spontaneous VPTBs, approximately 41% were reported to have chorioamnionitis. While the current focus of the California Very Preterm Birth Study is to assess the role of candidate genetic markers on spontaneous VPTB, its design enables the pursuit of other research opportunities to identify social, clinical and biological determinants of different types of VPTB with the ultimate aim of reducing infant mortality, morbidity and racial disparities in these health outcomes in the US and elsewhere. C1 [Kharrazi, Martin] Calif Dept Publ Hlth, Program Res & Demonstrat Sect, Genet Dis Screening Program, Richmond, CA 94804 USA. [Pearl, Michelle; Yang, Juan] Sequoia Fdn, La Jolla, CA USA. [DeLorenze, Gerald N.] Kaiser Permanente, Div Res, Oakland, CA USA. [Bean, Christopher J.; Grant, Althea] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. [Callaghan, William M.; Lackritz, Eve; Satten, Glen A.; Williamson, Dhelia M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Romero, Roberto] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Perinatol Res Branch, NIH, Detroit, MI USA. [Simhan, Hyagriv] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Torres, Anthony R.; Westover, Jonna B.] Utah State Univ, Ctr Persons Disabil, Logan, UT 84322 USA. [Yolken, Robert] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Kharrazi, M (reprint author), Calif Dept Publ Hlth, Program Res & Demonstrat Sect, Genet Dis Screening Program, 850 Marina Bay Pkwy,Room F175,Mail Stop 8200, Richmond, CA 94804 USA. EM marty.kharrazi@cdph.ca.gov OI Satten, Glen/0000-0001-7275-5371 FU Centers for Disease Control and Prevention; March of Dimes Birth Defects Foundation [21-FY05-1248]; Tobacco Related Disease Research Program [8RT-0115] FX This study was funded in part by the Centers for Disease Control and Prevention and the March of Dimes Birth Defects Foundation (project #21-FY05-1248). Project Baby's Breath, which created the initial prenatal specimen bank used by this study, was funded by the Tobacco Related Disease Research Program (grant #8RT-0115) (Drs Martin Kharrazi and Gerald N. DeLorenze, Co-PIs). Drs John Harris and Gary Shaw were responsible for the creation of the second prenatal specimen bank. Dr George Cunningham was responsible for the creation of the newborn specimen bank. California Birth Defects Monitoring Program staff (Jennifer Nicholson, Brandy Stephenson, Butch Arciaga and Cori DeTarr) conducted hospital abstraction under the supervision of Barbara Warmerdam. Steve Graham and Oren Bergman conducted record linkage of the screening and vital records data files. Megan Wier contributed to the study design and the conduct of the study in its early phases. Angela DiLaura and Marissa Root assisted with project coordination. Dr Michael S. Kramer gave valuable input on the early development of the abstraction form and F. Carol Bruce gave feedback on the conduct of the study. NR 86 TC 6 Z9 6 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 EI 1365-3016 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD MAY PY 2012 VL 26 IS 3 BP 250 EP 263 DI 10.1111/j.1365-3016.2011.01252.x PG 14 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA 921IL UT WOS:000302471200009 PM 22471684 ER PT J AU Tokars, JI Lewis, P DeStefano, F Wise, M Viray, M Morgan, O Gargiullo, P Vellozzi, C AF Tokars, Jerome I. Lewis, Paige DeStefano, Frank Wise, Matthew Viray, Melissa Morgan, Oliver Gargiullo, Paul Vellozzi, Claudia TI The Risk of Guillain-Barre Syndrome Associated with Influenza A (H1N1) 2009 Monovalent Vaccine and 2009-2010 Seasonal Influenza Vaccines: Results from Self-Controlled Analyses SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE Influenza vaccine; Guillain-Barre Syndrome; Vaccine adverse events; Self controlled analyses ID SAFETY DATALINK PROJECT; UNITED-STATES; CASE SERIES; SURVEILLANCE; IMMUNIZATION; KINGDOM; SYSTEM AB Purpose The Centers for Disease Control and Prevention Emerging Infections Program implemented active, population-based surveillance for Guillain-Barre syndrome (GBS) following H1N1 vaccines in 10 states/metropolitan areas. We report additional analyses of these data using self-controlled methods, which avoid potential confounding from person-level factors and co-morbidities. Methods Surveillance officers identified GBS cases with symptom onset during October 2009-April 2010 and ascertained receipt of H1N1 vaccines. We calculated self-controlled relative risks by comparing the number of cases with onset during a risk interval 1-42 days after vaccination with cases with onset during fixed (days 43-84) or variable (days 43-end of study period) control intervals. We calculated attributable risks by applying statistically significant relative risks to an independent estimate of GBS incidence. Results Fifty-nine GBS cases received H1N1 vaccine with or without seasonal vaccine. The relative risk was 2.1 (95% CI 1.2, 3.5) by the variable-window and 3.0 (95% CI 1.4, 6.4) by the fixed-window analyses. The corresponding attributable risks per million doses administered were 1.5 (95% CI 0.3, 3.4) and 2.8 (95% CI 0.6, 7.4). Conclusions These attributable risks are similar to those of some previous formulations of seasonal influenza vaccine (about one to two cases per million doses administered), suggesting a low risk of GBS following the H1N1 vaccine that is not clearly higher than that of seasonal influenza vaccines. Published 2012. This article is a US Government work and is in the public domain in the USA. C1 [Tokars, Jerome I.; Lewis, Paige; DeStefano, Frank; Wise, Matthew; Viray, Melissa; Vellozzi, Claudia] Ctr Dis Control & Prevent CDC, Div Healthcare Qual Promot, Atlanta, GA USA. [Wise, Matthew] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Morgan, Oliver] CDC, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Gargiullo, Paul] CDC, Influenza Div, Atlanta, GA 30333 USA. RP Tokars, JI (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd,MS A-20, Atlanta, GA 30333 USA. EM jit1@cdc.gov NR 28 TC 27 Z9 27 U1 0 U2 3 PU WILEY PERIODICALS, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD MAY PY 2012 VL 21 IS 5 BP 546 EP 552 DI 10.1002/pds.3220 PG 7 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 927YL UT WOS:000302946400010 PM 22407672 ER PT J AU Kretzschmar, M Satterwhite, C Leichliter, J Berman, S AF Kretzschmar, Mirjam Satterwhite, Catherine Leichliter, Jami Berman, Stuart TI Effects of Screening and Partner Notification on Chlamydia Positivity in the United States: A Modeling Study SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; TRACHOMATIS INFECTIONS; SEX PARTNERS; GONORRHEA; REINFECTION; PROGRAMS; WOMEN; MEN AB Objectives: Model impact of increasing screening and partner notification (PN) on chlamydia positivity. Methods: We used a stochastic simulation model describing pair formation and dissolution in an age-structured heterosexual population. The model accounts for steady, casual, and concurrent partnerships and a highly sexually active core group. The model used existing sexual behavior data from the United States and was validated using chlamydia positivity data from Region X (Alaska, Idaho, Oregon, Washington). A screening program with a coverage rate of 20% was implemented among women aged 15 to 24 years. After 10 years, we increased screening coverage to 35%, 50%, and 65% and partner treatment rates from 20% to 40% and 55%. Finally, we included male screening (aged 15-24, screening coverage: 20% and 35%, partner treatment: 25% and 40%). We analyzed the effects on chlamydia positivity in women and the frequency of reinfection 6 months after treatment. Results: The model described the decline in positivity observed from 1988 to 1997 in Region X, given screening coverage of 20% and a 25% partner treatment rate. Increasing screening coverage from 35% to 65% resulted in incremental decreases in positivity as did increasing the PN rate; a 23% reduction in positivity was achieved by either increasing screening by 3-fold or PN by 2-fold. Adding male screening to the program had less impact than increasing screening coverage or PN among women. Increased PN and treatment reduced reinfection rates considerably. Conclusions: Increasing efforts in PN may contribute at least as much to control of chlamydia infection as increasing screening coverage rates. C1 [Kretzschmar, Mirjam] RIVM, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands. [Kretzschmar, Mirjam] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands. [Satterwhite, Catherine; Leichliter, Jami; Berman, Stuart] CDC, Div STD Prevent, Atlanta, GA 30333 USA. RP Kretzschmar, M (reprint author), RIVM, Ctr Infect Dis Control, POB 1, NL-3720 BA Bilthoven, Netherlands. EM mirjam.kretzschmar@rivm.nl NR 36 TC 9 Z9 9 U1 3 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAY PY 2012 VL 39 IS 5 BP 325 EP 331 DI 10.1097/OLQ.0b013e31824e52c2 PG 7 WC Infectious Diseases SC Infectious Diseases GA 926ZE UT WOS:000302872500001 PM 22504590 ER PT J AU Hoover, KW Butler, M Workowski, KA Follansbee, S Gratzer, B Hare, CB Johnston, B Theodore, JL Tao, GY Smith, BD Chorba, T Kent, CK AF Hoover, Karen W. Butler, Mary Workowski, Kimberly A. Follansbee, Stephen Gratzer, Beau Hare, C. Bradley Johnston, Barbara Theodore, John L. Tao, Guoyu Smith, Bryce D. Chorba, Terence Kent, Charlotte K. CA Evaluation Grp Adherence STD TI Low Rates of Hepatitis Screening and Vaccination of HIV-Infected MSM in HIV Clinics SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID C VIRUS-INFECTION; VIRAL-HEPATITIS; MEDICINE ASSOCIATION; SEXUAL TRANSMISSION; DISEASES SOCIETY; UNITED-STATES; B-VIRUS; MEN; HEALTH; GUIDELINES AB Background: HIV-infected men who have sex with men (MSM) are at increased risk of viral hepatitis because of similar behavioral risk factors for acquisition of these infections. Our objective was to estimate adherence to HIV management guidelines that recommend screening HIV-infected persons for hepatitis A, B, and C infection, and vaccinating for hepatitis A and B if susceptible. Methods: We evaluated hepatitis prevention services received by a random sample of HIV-infected MSM in 8 HIV clinics in 6 US cities. We abstracted medical records of all visits made by the patients to the clinic during the period from 2004 to 2007, to estimate hepatitis screening and vaccination rates overall and by clinic site. Results: Medical records of 1329 patients who had 14,831 visits from 2004 to 2006 were abstracted. Screening rates for hepatitis A, B, and C were 47%, 52%, and 54%, respectively. Among patients who were screened and found to be susceptible, 29% were vaccinated for hepatitis A and 25% for hepatitis B. The percentage of patients screened and vaccinated varied significantly by clinic. Conclusions: Awareness of hepatitis susceptibility and hepatitis coinfection status in HIV-infected patients is essential for optimal clinical management. Despite recommendations for hepatitis screening and vaccination of HIV-infected MSM, rates were suboptimal at all clinic sites. These low rates highlight the importance of routine review of adherence to recommended clinical services. Such reviews can prompt the development and implementation of simple and sustainable interventions to improve the quality of care. C1 [Hoover, Karen W.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Butler, Mary] Battelle Ctr Publ Hlth Res & Evaluat, Seattle, WA USA. [Workowski, Kimberly A.] Emory Univ, Sch Med, Atlanta, GA USA. [Follansbee, Stephen] Kaiser Permanente, San Francisco, CA USA. [Gratzer, Beau] Howard Brown Hlth Ctr, Chicago, IL USA. [Gratzer, Beau] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Hare, C. Bradley] San Francisco Gen Hosp, Med Ctr, San Francisco, CA 94110 USA. [Johnston, Barbara; Theodore, John L.] St Vincent Catholic Med Ctr, New York, NY USA. RP Hoover, KW (reprint author), Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE MS E-80, Atlanta, GA 30333 USA. EM khoover@cdc.gov NR 30 TC 21 Z9 21 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAY PY 2012 VL 39 IS 5 BP 349 EP 353 DI 10.1097/OLQ.0b013e318244a923 PG 5 WC Infectious Diseases SC Infectious Diseases GA 926ZE UT WOS:000302872500008 PM 22504597 ER PT J AU Stanaway, JD Wald, A Martin, ET Gottlieb, SL Magaret, AS AF Stanaway, Jeffrey D. Wald, Anna Martin, Emily T. Gottlieb, Sami L. Magaret, Amalia S. TI Case-Crossover Analysis of Condom Use and Herpes Simplex Virus Type 2 Acquisition SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID GENITAL HERPES; RISK-REDUCTION; ADOLESCENT POPULATION; INFECTION; TRANSMISSION; PREVENTION; HSV-2; WOMEN; SEROCONVERSION; PARTNERS AB Background: Although growing evidence suggests that condoms offer moderate protection against herpes simplex virus type 2 (HSV-2), inability to control for unknown or unmeasured confounders associated with sexual activity may reduce the accuracy of the estimates. The case-crossover design offers increased control of individual-level confounders, and was thus used with the aim of producing a more accurate estimate of the effect of condom use on HSV-2 acquisition. Methods: Data were pooled from 6 prospective studies that measured HSV-2 status at enrollment and over follow-up, and included periodic self-reported condom use and sexual activity. Sexual activity contemporaneous with acquisition was assigned to a case period; earlier sexual activity was assigned to a control period. Conditional logistic regression was used to assess differences in behavior during the case and control periods. Results: One hundred ninety-one eligible participants acquired HSV-2 during follow-up. This approach detected a 3.6% increase in the odds of HSV-2 acquisition with each unprotected act (odds ratio = 1.036; 95% confidence interval: 1.021-1.052), but no increase in the odds of acquisition associated with protected acts (odds ratio = 1.008; 95% confidence interval: 0.987-1.030). Conclusions: This analysis suggests that condoms offer significant protection against HSV-2 transmission. C1 [Wald, Anna] Univ Washington, Harborview Med Ctr, Virol Res Clin, Dept Epidemiol, Seattle, WA 98104 USA. [Wald, Anna; Magaret, Amalia S.] Univ Washington, Dept Lab Med, Seattle, WA 98104 USA. [Wald, Anna] Univ Washington, Dept Med, Seattle, WA 98104 USA. [Wald, Anna] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA. [Martin, Emily T.] Wayne State Univ, Dept Pharm Practice, Detroit, MI USA. [Gottlieb, Sami L.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Magaret, Amalia S.] Fred Hutchinson Canc Res Ctr, Program Biostat, Seattle, WA 98104 USA. RP Wald, A (reprint author), Univ Washington, Harborview Med Ctr, Virol Res Clin, Dept Epidemiol, Mailstop 359928,325 9th Ave, Seattle, WA 98104 USA. EM annawald@u.washington.edu RI Wald, Anna/B-6272-2012 OI Wald, Anna/0000-0003-3486-6438 FU National Institutes of Health [AI-30731, K24 AI 071113] FX Supported by National Institutes of Health Grant AI-30731 and K24 AI 071113. NR 30 TC 8 Z9 8 U1 3 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAY PY 2012 VL 39 IS 5 BP 388 EP 393 DI 10.1097/OLQ.0b013e318248aa8a PG 6 WC Infectious Diseases SC Infectious Diseases GA 926ZE UT WOS:000302872500017 PM 22504606 ER PT J AU McRee, AL Gottlieb, SL Reiter, PL Dittus, PJ Halpern, CT Brewer, NT AF McRee, Annie-Laurie Gottlieb, Sami L. Reiter, Paul L. Dittus, Patricia J. Halpern, Carolyn Tucker Brewer, Noel T. TI Human Papillomavirus Vaccine Discussions: An Opportunity for Mothers to Talk With Their Daughters About Sexual Health SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID PARENT-ADOLESCENT COMMUNICATION; HPV VACCINE; RISK BEHAVIORS; CONDOM USE; AFRICAN-AMERICAN; PERSPECTIVES; PATTERNS; VISITS; ACCEPTABILITY; COMMITTEE AB Purpose: Mother-daughter communication about sex is associated with healthier behavior during adolescence. We sought to characterize mothers' communication with their daughters about human papillomavirus (HPV) vaccine and the potential for these discussions to provide an opportunity for talking about sexual health. Methods: During December 2009, we conducted an online survey with a nationally representative sample of US mothers of girls aged 11 to 14 years (n = 900; response rate = 66%). We used 3 complimentary approaches to assess HPV vaccine as an opportunity for mother-daughter communication about sex. Estimates are weighted. Results: Sixty-five percent of mothers reported talking with their daughters about HPV vaccine, of whom 41% said that doing so led to a conversation about sex. Mothers who had talked with their daughters about HPV vaccine were more likely than those who had not to have also talked with their daughters about sex (92% vs. 74%, OR = 3.25, CI = 1.57-6.68, P < 0.05), in multivariate analyses. Among mothers who talked about sex when they talked about HPV vaccine, many felt that HPV vaccine provided a good reason to do so (64%) or that it made it easier to start a conversation (33%). Conclusions: HPV vaccine discussions provide a cue to mother-daughter communication about sex that is as important as some more widely recognized cues. Discussions about HPV vaccine are an acceptable opportunity for mothers to talk with their daughters at an age when communication about sex is most influential. It may be possible for parents to capitalize on HPV vaccine discussions already happening in many families to promote sexual health. C1 [McRee, Annie-Laurie; Brewer, Noel T.] UNC Gillings Sch Global Publ Hlth, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC 27599 USA. [McRee, Annie-Laurie; Halpern, Carolyn Tucker] UNC Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27599 USA. [Gottlieb, Sami L.; Dittus, Patricia J.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Reiter, Paul L.] Ohio State Univ, Coll Med, Div Canc Prevent & Control, Columbus, OH 43210 USA. [Reiter, Paul L.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Brewer, Noel T.] UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. RP McRee, AL (reprint author), UNC Gillings Sch Global Publ Hlth, Dept Hlth Behav & Hlth Educ, 325 Rosenau Hall,CB 7440, Chapel Hill, NC 27599 USA. EM almcree@email.unc.edu RI McRee, Annie/J-3077-2013 FU Centers for Disease Control and Prevention (CDC) [02577-10]; American Cancer Society [MSRG-06-259-01-CPPB]; Lineberger Comprehensive Cancer Center [R25 CA57726]; Graduate School at UNC-Chapel Hill FX Supported by a grant from the Centers for Disease Control and Prevention (CDC, 02577-10) with additional support for project staff from the American Cancer Society (MSRG-06-259-01-CPPB) and the Cancer Control Education Program at Lineberger Comprehensive Cancer Center (R25 CA57726). Dr. McRee's time on the study was further supported by the Jessie Ball duPont Dissertation Completion Fellowship from the Graduate School at UNC-Chapel Hill. NR 37 TC 9 Z9 10 U1 4 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAY PY 2012 VL 39 IS 5 BP 394 EP 401 DI 10.1097/OLQ.0b013e318248aaa0 PG 8 WC Infectious Diseases SC Infectious Diseases GA 926ZE UT WOS:000302872500018 PM 22504607 ER PT J AU Schulte, PA Kuempel, ED Zumwalde, RD Geraci, CL Schubauer-Berigan, MK Castranova, V Hodson, L Murashov, V Dahm, MM Ellenbecker, M AF Schulte, Paul A. Kuempel, Eileen D. Zumwalde, Ralph D. Geraci, Charles L. Schubauer-Berigan, Mary K. Castranova, Vincent Hodson, Laura Murashov, Vladimir Dahm, Matthew M. Ellenbecker, Michael TI Focused actions to protect carbon nanotube workers SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Review DE cancer; mode of action; nanotechnology; risk management ID POORLY SOLUBLE PARTICLES; INHALATION EXPOSURE; EPITHELIAL-CELLS; ENGINEERED NANOMATERIALS; EPIDEMIOLOGIC-RESEARCH; MEDICAL-SURVEILLANCE; ASBESTOS FIBERS; IN-VITRO; INFLAMMATION; MICE AB There is still uncertainty about the potential health hazards of carbon nanotubes (CNTs) particularly involving carcinogenicity. However, the evidence is growing that some types of CNTs and nanofibers may have carcinogenic properties. The critical question is that while the carcinogenic potential of CNTs is being further investigated, what steps should be taken to protect workers who face exposure to CNTs, current and future, if CNTs are ultimately found to be carcinogenic? This paper addresses five areas to help focus action to protect workers: (i) review of the current evidence on the carcinogenic potential of CNTs; (ii) role of physical and chemical properties related to cancer development; (iii) CNT doses associated with genotoxicity in vitro and in vivo; (iv) workplace exposures to CNT; and (v) specific risk management actions needed to protect workers. Am. J. Ind. Med. 55:395411, 2012. Published 2012. This article is a U.S. Government work and is in the public domain in the USA. C1 [Schulte, Paul A.; Kuempel, Eileen D.; Zumwalde, Ralph D.; Geraci, Charles L.; Schubauer-Berigan, Mary K.; Castranova, Vincent; Hodson, Laura; Murashov, Vladimir; Dahm, Matthew M.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Ellenbecker, Michael] Univ Massachusetts Lowell, Dept Work Environm, Lowell, MA USA. RP Schulte, PA (reprint author), NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,MS C-14, Cincinnati, OH 45226 USA. EM pschulte@cdc.gov RI Hodson, Laura/F-4585-2011; Dahm, Matthew/I-2131-2012; Schubauer-Berigan, Mary/B-3149-2009; Murashov, Vladimir/K-5481-2012 OI Schubauer-Berigan, Mary/0000-0002-5175-924X; NR 112 TC 17 Z9 17 U1 1 U2 32 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD MAY PY 2012 VL 55 IS 5 BP 395 EP 411 DI 10.1002/ajim.22028 PG 17 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 925XD UT WOS:000302794500001 PM 22392774 ER PT J AU Calvert, GM Luckhaupt, S Lee, SJ Cress, R Schumacher, P Shen, R Tak, S Deapen, D AF Calvert, Geoffrey M. Luckhaupt, Sara Lee, Soo-Jeong Cress, Rosemary Schumacher, Pam Shen, Rui Tak, SangWoo Deapen, Dennis TI Lung cancer risk among construction workers in California, 1988-2007 SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE cancer; lung; surveillance; construction; occupational; roofer; welder; laborer; race ID HEALTH INTERVIEW SURVEY; OCCUPATIONAL GROUPS; COHORT MORTALITY; SMOKING; RATES; EPIDEMIOLOGY; INDUSTRY; ROOFERS AB Background Although lung cancer risks can vary by race/ethnicity and by construction occupation, these risks have not been examined extensively. Methods This study analyzed 110,937 lung cancer cases identified from the California Cancer Registry between 1988 and 2007. Mean age at diagnosis, proportion diagnosed at an advanced stage, and proportion with 3-year survival were calculated for lung cancer cases employed in the construction industry. Case-control methodology was also used to assess the risk of lung cancer. Morbidity odds ratios (MORs) were estimated by conditional logistic regression. Results Construction workers were found to have a significantly elevated risk for all lung cancer combined (MOR = 1.57) and for each lung cancer histologic subtype examined. All construction occupations, except managers/ engineers and supervisors, had a significantly elevated risk for all lung cancer combined. Roofers and welders had the highest risks for total lung cancer and for each of the histologic subtypes. Construction workers in each of the four race/ ethnicity groups also had significantly increased lung cancer risks. Compared to nonconstruction workers, construction workers were diagnosed at an earlier age, at a more advanced stage, and had significantly lower 3-year survival, though differences were modest. Conclusion These findings justify additional reductions in carcinogenic exposures in construction, and increased support for smoking cessation programs at construction sites. Am. J. Ind. Med. 55: 412-422, 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Calvert, Geoffrey M.; Luckhaupt, Sara; Schumacher, Pam; Shen, Rui; Tak, SangWoo] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Lee, Soo-Jeong] Univ Calif San Francisco, Sch Nursing, Dept Community Hlth Syst, San Francisco, CA 94143 USA. [Cress, Rosemary] Calif Canc Registry, Canc Surveillance Sect, Sacramento, CA USA. [Deapen, Dennis] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. RP Calvert, GM (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA. EM jac6@cdc.gov NR 38 TC 7 Z9 7 U1 2 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD MAY PY 2012 VL 55 IS 5 BP 412 EP 422 DI 10.1002/ajim.22010 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 925XD UT WOS:000302794500002 PM 22237930 ER PT J AU Arias, I Thacker, SB Monroe, JA AF Arias, Ileana Thacker, Stephen B. Monroe, Judith A. TI The Value of Public Health Services and Systems Research SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material C1 [Arias, Ileana; Thacker, Stephen B.] CDC, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Monroe, Judith A.] CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA. RP Arias, I (reprint author), CDC, Off Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE,Mail Stop D14, Atlanta, GA 30333 USA. EM iarias@cdc.gov RI Scutchfield, F. Douglas/F-9959-2013 NR 5 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2012 VL 42 IS 5 SU 1 BP S82 EP S83 DI 10.1016/j.amepre.2012.01.023 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 925TU UT WOS:000302785300009 PM 22502930 ER PT J AU Scutchfield, FD Perez, DJ Monroe, JA Howard, AF AF Scutchfield, F. Douglas Perez, Debra Joy Monroe, Judith A. Howard, Alex F. TI New Public Health Services and Systems Research Agenda Directions for the Next Decade SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID PERFORMANCE C1 [Scutchfield, F. Douglas; Howard, Alex F.] Univ Kentucky, Natl Coordinating Ctr Publ Hlth Serv & Syst Res, Coll Publ Hlth, Lexington, KY 40536 USA. [Perez, Debra Joy] Robert Wood Johnson Fdn, Princeton, NJ 08540 USA. [Monroe, Judith A.] CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA. RP Scutchfield, FD (reprint author), Univ Kentucky, Natl Coordinating Ctr Publ Hlth Serv & Syst Res, Coll Publ Hlth, 111 Washington Ave,Room 212, Lexington, KY 40536 USA. EM Scutch@uky.edu RI Scutchfield, F. Douglas/F-9959-2013 NR 29 TC 14 Z9 14 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2012 VL 42 IS 5 SU 1 BP S1 EP S5 DI 10.1016/j.amepre.2012.01.027 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 925TU UT WOS:000302785300001 PM 22502922 ER PT J AU Lee, T Lee, EG Kim, SW Chisholm, WP Kashon, M Harper, M AF Lee, Taekhee Lee, Eun Gyung Kim, Seung Won Chisholm, William P. Kashon, Michael Harper, Martin TI Quartz Measurement in Coal Dust with High-Flow Rate Samplers: Laboratory Study SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE coal dust; CIP10-R; FSP10; FTIR; GK2; 69; high-flow rate sampler; quartz; silica; XRD ID ANALYTICAL TESTING PROGRAM; X-RAY-DIFFRACTION; ALPHA-QUARTZ; PAT PROGRAM; AIRBORNE DUSTS; PERFORMANCE; SILICA AB A laboratory study was performed to measure quartz in coal dust using high-flow rate samplers (CIP10-R, GK2.69 cyclone, and FSP10 cyclone) and low-flow rate samplers [10-mm nylon and Higgins-Dewell type (BGI4L) cyclones] and to determine whether an increased mass collection from high-flow rate samplers would affect the subsequent quartz measurement by Fourier transform infrared (FTIR) and X-ray diffraction (XRD) analytical procedures. Two different sizes of coal dusts, mass median aerodynamic diameter 4.48 mu m (Coal Dust A) and 2.33 mu m (Coal Dust B), were aerosolized in a calm air chamber. The mass of coal dust collected by the samplers was measured gravimetrically, while the mass of quartz collected by the samplers was determined by FTIR (NIOSH Manual of Analytical Method 7603) and XRD (NIOSH Manual of Analytical Method 7500) after one of two different indirect preparations. Comparisons between high-flow rate samplers and low-flow rate samplers were made by calculating mass concentration ratios of coal dusts, net mass ratios of coal dusts, and quartz net mass. Mass concentrations of coal dust from the FSP10 cyclone were significantly higher than those from other samplers and mass concentrations of coal dust from 10-mm nylon cyclone were significantly lower than those from other samplers, while the CIP10-R, GK2.69, and BGI4L samplers did not show significant difference in the comparison of mass concentration of coal dusts. The BGI4L cyclone showed larger mass concentration of similar to 9% compared to the 10-mm nylon cyclone. All cyclones provided dust mass concentrations that can be used in complying with the International Standard Organization standard for the determination of respirable dust concentration. The amount of coal dust collected from the high-flow rate samplers was found to be higher with a factor of 2-8 compared to the low-flow rate samplers but not in direct proportion of increased flow rates. The high-flow rate samplers collected more quartz compared to low-flow rate samplers in the range of 2-10. There was no significant difference between the per cent (%) quartz in coal dust between the FTIR and XRD analyses. The findings of this study indicated that the increased mass of quartz collected with high-flow rate samplers would provide precise analytical results (i.e. significantly above the limit of detection and/or limit of quantification) compared to the mass collected with low-flow rate samplers, especially in environments with low concentrations of quartz or where short sampling times are desired. C1 [Lee, Taekhee; Lee, Eun Gyung; Kim, Seung Won; Chisholm, William P.; Harper, Martin] NIOSH, Exposure Assessment Branch, HELD, Ctr Dis Control & Prevent CDC, Morgantown, WV 26505 USA. [Kashon, Michael] NIOSH, Biostat & Epidemiol Branch, HELD, Ctr Dis Control & Prevent CDC, Morgantown, WV 26505 USA. RP Lee, T (reprint author), NIOSH, Exposure Assessment Branch, HELD, Ctr Dis Control & Prevent CDC, Morgantown, WV 26505 USA. EM fwc8@cdc.gov RI Kim, Seung Won/G-1843-2010 OI Kim, Seung Won/0000-0003-2960-5866 FU National Institute for Occupational Safety and Health (CAN) [0927ZGFR] FX National Institute for Occupational Safety and Health project [Respirable silica measurements with high-flow rate samplers (CAN# 0927ZGFR)]. NR 31 TC 15 Z9 16 U1 1 U2 18 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD MAY PY 2012 VL 56 IS 4 BP 413 EP 425 DI 10.1093/annhyg/mer111 PG 13 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 926BP UT WOS:000302806600005 PM 22186376 ER PT J AU Jain, S Benoit, SR Skarbinski, J Bramley, AM Finelli, L AF Jain, Seema Benoit, Stephen R. Skarbinski, Jacek Bramley, Anna M. Finelli, Lyn CA 2009 Pandemic Influenza A H1N1 Virus Hospitalizations Invest Team TI Influenza-Associated Pneumonia Among Hospitalized Patients With 2009 Pandemic Influenza A (H1N1) Virus-United States, 2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID IMMUNIZATION PRACTICES ACIP; ADVISORY-COMMITTEE; RISK-FACTORS; RESPIRATORY-FAILURE; SEASONAL INFLUENZA; YOUNG-CHILDREN; INFECTION; MORTALITY; RECOMMENDATIONS; SURVEILLANCE AB Background. Pneumonia was a common complication among hospitalized patients with 2009 pandemic influenza A H1N1 [pH1N1] in the United States in 2009. Methods. Through 2 national case series conducted during spring and fall of 2009, medical records were reviewed. A pneumonia case was defined as a hospitalized person with laboratory-confirmed pH1N1 virus and a chest radiographic report consistent with pneumonia based on agreement among 3 physicians. Results. Of 451 patients with chest radiographs performed, 195 (43%) had pneumonia (spring, 106 of 237 [45%]; fall, 89 of 214 [42%]). Compared with 256 patients without pneumonia, these 195 patients with pneumonia were more likely to be admitted to the intensive care unit (52% vs 16%), have acute respiratory distress syndrome (ARDS; 26% vs 2%), have sepsis (18% vs 3%), and die (17% vs 2%; P < .0001). One hundred eighteen (61%) of the patients with pneumonia had >= 1 underlying condition. Bacterial infections were reported in 13 patients with pneumonia and 2 patients without pneumonia. Patients with pneumonia, when compared with patients without pneumonia, were equally likely to receive influenza antiviral agents (78% vs 79%) but less likely to receive antiviral agents within < 2 days of illness onset (28% vs 50%; P < .0001). Conclusions. Hospitalized patients with pH1N1 and pneumonia were at risk for severe outcomes including ARDS, sepsis, and death; antiviral treatment was often delayed. In the absence of accurate pneumonia diagnostics, patients hospitalized with suspected influenza and lung infiltrates on chest radiography should receive early and aggressive treatment with antibiotics and influenza antiviral agents. C1 [Jain, Seema; Benoit, Stephen R.; Skarbinski, Jacek; Bramley, Anna M.; Finelli, Lyn; 2009 Pandemic Influenza A H1N1 Virus Hospitalizations Invest Team] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Jain, S (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A32, Atlanta, GA 30333 USA. EM bwc8@cdc.gov FU Centers for Disease Control and Prevention FX This investigation was supported by the Centers for Disease Control and Prevention. NR 52 TC 29 Z9 31 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2012 VL 54 IS 9 BP 1221 EP 1229 DI 10.1093/cid/cis197 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 926BG UT WOS:000302805700006 PM 22437239 ER PT J AU Desai, R Lopman, BA Shimshoni, Y Harris, JP Patel, MM Parashar, UD AF Desai, Rishi Lopman, Benjamin A. Shimshoni, Yair Harris, John P. Patel, Manish M. Parashar, Umesh D. TI Use of Internet Search Data to Monitor Impact of Rotavirus Vaccination in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID SURVEILLANCE; DISEASE AB Google-based Internet query share (IQS) for rotavirus search terms correlated well with US rotavirus laboratory detections from 2004 to 2010 (r = 0.88; P < .001), capturing the reduction observed during postvaccine years (2008-2010). IQS analysis could become an inexpensive and reliable supplement for monitoring the impact of rotavirus vaccination in the United States. C1 [Desai, Rishi; Lopman, Benjamin A.; Patel, Manish M.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Shimshoni, Yair] Google Labs, Tel Aviv, Israel. [Harris, John P.] Hlth Protect Agcy, London, England. RP Desai, R (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd NE,MS-A34, Atlanta, GA 30333 USA. EM rdesai1@cdc.gov NR 16 TC 12 Z9 12 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2012 VL 54 IS 9 BP CP8 EP CP11 DI 10.1093/cid/cis121 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 926BG UT WOS:000302805700005 PM 22423140 ER PT J AU Li, S Chao, A Li, Z Moore, CA Liu, YH Zhu, JH Erickson, JD Hao, L Berry, RJ AF Li, Song Chao, Ann Li, Zhu Moore, Cynthia A. Liu, Yinghui Zhu, Jianghui Erickson, J. David Hao, Ling Berry, Robert J. TI Folic Acid Use and Nonsyndromic Orofacial Clefts in China A Prospective Cohort Study SO EPIDEMIOLOGY LA English DT Article ID NEURAL-TUBE DEFECTS; LIFE-STYLE FACTORS; ORAL CLEFTS; BIRTH-DEFECTS; MULTIVITAMIN SUPPLEMENTATION; HIGH-PREVALENCE; NORTHERN CHINA; FOLATE STATUS; RISK; PREVENTION AB Background: Questions remain about the effectiveness, dose, and timing of folic acid in preventing orofacial clefts. Case-control studies report conflicting results. There have been no cohort studies of orofacial clefts and the use of folic acid without other vitamins. Methods: In a prospective cohort of 240,244 women enrolled between 1993 and 1995 in 1 northern and 2 southern provinces in China, we examined the risk of nonsyndromic cleft lip with or without cleft palate (CL/P) and cleft palate alone (CP) in relation to maternal use of 400 mu g of folic acid without other vitamins. Results: Daily use of 400 mu g of folic acid without other vitamins, started before the last menstrual period (LMP), was associated with reduced risk of CL/P with adjusted rate ratio (aRR) of 0.69 (95% confidence interval = 0.55-0.87). The greatest reduction in risk was observed in the north among daily users who began taking folic acid pills before LMP (aRR = 0.21 [0.10-0.44]); in the south there was marginal reduction in risk (aRR = 0.81 [0.63-1.05]). No evidence of reduced CL/P risk was observed among women who started folic acid pills on or after their LMP. No persuasive evidence for reduction in CP risk was seen with folic acid pill use at any time. Conclusion: Daily maternal consumption of 400 mu g of folic acid without other vitamins, started before mother's LMP, was associated with a reduced risk of CL/P in babies born in a high-prevalence region of China. C1 [Chao, Ann; Moore, Cynthia A.; Erickson, J. David; Berry, Robert J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Li, Song] Peking Univ, Dept Pediat, Hosp 3, Beijing 100871, Peoples R China. [Li, Zhu; Liu, Yinghui; Zhu, Jianghui; Hao, Ling] Peking Univ, Hlth Sci Ctr, Natl Ctr Maternal & Infant Hlth, Dept Hlth Care Epidemiol, Beijing 100871, Peoples R China. RP Berry, RJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM RJBerry@cdc.gov OI Berry, Robert/0000-0002-7162-5046 FU U.S. Centers for Disease Control and Prevention [U11/CCU015586-02]; Peking University [U11/CCU015586-02] FX Supported by Cooperative Agreement award U11/CCU015586-02 between the U.S. Centers for Disease Control and Prevention and Peking University, to provide surveillance, research, and health services evaluation directed toward the prevention of birth defects. The authors reported no other financial interests related to this research. NR 39 TC 15 Z9 19 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1044-3983 J9 EPIDEMIOLOGY JI Epidemiology PD MAY PY 2012 VL 23 IS 3 BP 423 EP 432 DI 10.1097/EDE.0b013e31824d0349 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 925TF UT WOS:000302783700010 PM 22415108 ER PT J AU Hadgu, A Nordbo, SA Skjeldestad, FE AF Hadgu, Alula Nordbo, Svein Arne Skjeldestad, Finn Egil TI One in 16 Quadrillion Importance of Blinding in Research Reproducibility SO EPIDEMIOLOGY LA English DT Letter ID ACID AMPLIFICATION TESTS; CHLAMYDIA-TRACHOMATIS; OVARIAN-CANCER; SERUM C1 [Hadgu, Alula] Ctr Dis Control & Prevent, Div STD Prevent, Stat & Data Management Branch, Atlanta, GA 30333 USA. [Nordbo, Svein Arne] Norwegian Univ Sci & Technol, Dept Med Microbiol, Inst Lab Med Childrens & Womens Hlth, N-7034 Trondheim, Norway. [Skjeldestad, Finn Egil] Norwegian Inst Publ Hlth, Dept Infect Dis Epidemiol, Oslo, Norway. RP Hadgu, A (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Stat & Data Management Branch, Atlanta, GA 30333 USA. EM axh1@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1044-3983 J9 EPIDEMIOLOGY JI Epidemiology PD MAY PY 2012 VL 23 IS 3 BP 503 EP 504 DI 10.1097/EDE.0b013e31824da327 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 925TF UT WOS:000302783700024 PM 22475835 ER PT J AU Teo, CG AF Teo, C. -G. TI Fatal outbreaks of jaundice in pregnancy and the epidemic history of hepatitis E SO EPIDEMIOLOGY AND INFECTION LA English DT Review DE Hepatitis E; immunization (vaccination); public health microbiology; virus infection; water-borne infection ID NON-B-HEPATITIS; ACUTE VIRAL-HEPATITIS; E VIRUS-INFECTION; ACUTE YELLOW ATROPHY; ENTERICALLY-TRANSMITTED HEPATITIS; WATER-BORNE HEPATITIS; FECAL-ORAL MODE; NON-A; FULMINANT-HEPATITIS; CLINICAL CHARACTERISTICS AB Space-time clustering of people who fall acutely ill with jaundice, then slip into coma and death, is an alarming phenomenon, more markedly so when the victims are mostly or exclusively pregnant. Documentation of the peculiar, fatal predisposition of pregnant women during outbreaks of jaundice identifies hepatitis E and enables construction of its epidemic history. Between the last decade of the 18th century and the early decades of the 20th century, hepatitis E-like outbreaks were reported mainly from Western Europe and several of its colonies. During the latter half of the 20th century, reports of these epidemics, including those that became serologically confirmed as hepatitis E, emanated from, first, the eastern and southern Mediterranean littoral and, thereafter, Southern and Central Asia, Eastern Europe, and the rest of Africa. The dispersal has been accompanied by a trend towards more frequent and larger-scale occurrences. Epidemic and endemic hepatitis E still beset people inhabiting Asia and Africa, especially pregnant women and their fetuses and infants. Their relief necessitates not only accelerated access to potable water and sanitation but also vaccination against hepatitis E. C1 Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Teo, CG (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Mailstop A33,1600 Clifton Rd, Atlanta, GA 30333 USA. EM CTeo@cdc.gov NR 309 TC 35 Z9 36 U1 1 U2 11 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAY PY 2012 VL 140 IS 5 BP 767 EP 787 DI 10.1017/S0950268811002925 PG 21 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 919ZV UT WOS:000302371600001 PM 22273541 ER PT J AU Iser, BPM Lima, HCAV De Moraes, C De Almeida, RPA Watanabe, LT Alves, SLA Lemos, APS Gorla, MCO Goncalves, MG Dos Santos, DA Sobel, J AF Iser, B. P. M. Lima, H. C. A. V. De Moraes, C. De Almeida, R. P. A. Watanabe, L. T. Alves, S. L. A. Lemos, A. P. S. Gorla, M. C. O. Goncalves, M. G. Dos Santos, D. A. Sobel, J. TI Outbreak of Neisseria meningitidis C in workers at a large food-processing plant in Brazil: challenges of controlling disease spread to the larger community SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Community outbreaks; epidemiology; Neisseria meningitidis; public health; surveillance ID FIELD GEL-ELECTROPHORESIS; REAL-TIME PCR; MENINGOCOCCAL DISEASE; SEROGROUP-C; VACCINATION; POLYSACCHARIDE; IDENTIFICATION; PREVENTION; DNA AB An outbreak of meningococcal disease (MD) with severe morbidity and mortality was investigated in midwestern Brazil in order to identify control measures. A MD case was defined as isolation of Neisseria meningitidis, or detection of polysaccharide antigen in a sterile site, or presence of clinical purpura fulminans, or an epidemiological link with a laboratory-confirmed case-patient, between June and August 2008. In 8 out of 16 MD cases studied, serogroup C ST103 complex was identified. Five (31%) cases had neurological findings and five (31%) died. The attack rate was 12 cases/100 000 town residents and 60 cases/100 000 employees in a large local food-processing plant. We conducted a matched case-control study of eight primary laboratory-confirmed cases (1: 4). Factors associated with illness in single variable analysis were work at the processing plant [matched odds ratio (mOR) 22, 95% confidence interval (CI) 2.3-207.7, P<0.01], and residing <1 year in Rio Verde (mOR 7, 95% CI 1.11-43.9, P<0.02). Mass vaccination (> 10 000 plant employees) stopped propagation in the plant, but not in the larger community. C1 [Lemos, A. P. S.; Gorla, M. C. O.] Adolfo Lutz Inst, Dept Bacteriol, Div Med Biol, Sao Paulo, Brazil. [Goncalves, M. G.] Adolfo Lutz Inst, Dept Immunol, Div Med Biol, Sao Paulo, Brazil. [Sobel, J.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. EM betine.iser@saude.gov.br FU U.S. Center for Disease Control; United Nations Educational, Scientific and Cultural Organization; Brazilian Ministry of Health; U.S. Center for Disease Prevention FX The U.S. Centers for Disease Control and Prevention in cooperation with the United Nations Educational, Scientific and Cultural Organization and Brazilian Ministry of Health provided support for the Field Epidemiology Training Programme. NR 36 TC 9 Z9 10 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAY PY 2012 VL 140 IS 5 BP 906 EP 915 DI 10.1017/S0950268811001610 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 919ZV UT WOS:000302371600019 PM 21875453 ER PT J AU Niwa, H Lasker, BA Hinrikson, HP Franzen, CG Steigerwalt, AG Whitney, AM Brown, JM AF Niwa, H. Lasker, B. A. Hinrikson, H. P. Franzen, C. G. Steigerwalt, A. G. Whitney, A. M. Brown, J. M. TI Characterization of human clinical isolates of Dietzia species previously misidentified as Rhodococcus equi SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES LA English DT Article ID SP-NOV.; RETICULATED PAPILLOMATOSIS; IDENTIFICATION; PATIENT; MARIS; CONFLUENT; PATHOGEN AB In this study, 16 human clinical isolates of Dietzia species previously misidentified as Rhodococcus equi were evaluated using phenotypic methods, including traditional and commercial (API Coryne) biochemical tests, antimicrobial susceptibility testing, and 16S rRNA gene and gyrB gene sequencing. Positive results for both the hydrolysis of adenine and Christie-Atkins-Munch-Petersen (CAMP) reaction allowed for differentiation between the Dietzia isolates and the type strain of Rhodococcus equi; however, traditional and commercial phenotypic profiles could not be used to reliably identify Dietzia species. The analysis of 16S rRNA gene and gyrB gene sequences could discriminate all Dietzia strains from the type strain of R. equi. Most Dietzia species had distinct 16S rRNA gene and gyrB gene sequences; however, the 16S rRNA gene sequences of the type strains of D. schimae and D. cercidiphylli were identical to D. maris and D. natronolimnaea, respectively. Based on comparative sequence analysis, five clinical isolates clustered with D. maris/D. schimae and nine with D. natronolimnaea/D. cercidiphylli. The two remaining isolates were found to be most closely related to the D. cinnamea/D. papillomatosis clade. Even though molecular analyses were not sufficiently discriminative to accurately identify all Dietzia species, the method was able to reliably identify isolates that were previously misidentified by phenotypic methods to the genus level. C1 [Niwa, H.; Lasker, B. A.; Hinrikson, H. P.; Franzen, C. G.; Steigerwalt, A. G.; Whitney, A. M.; Brown, J. M.] Ctr Dis Control & Prevent CDC, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Niwa, H.] Japan Racing Assoc, Equine Res Inst, Epizoot Res Ctr, Div Microbiol, Shimotsuke, Japan. RP Brown, JM (reprint author), Ctr Dis Control & Prevent CDC, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Mail Stop G-34,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jmb6@cdc.gov FU Japan Racing Association FX This study was supported by a research fellowship grant from the Japan Racing Association to H.N. We thank Gerald Pellegrini and Benjamin Moser for supporting this study. We acknowledge the assistance of Ainsley Nicholson of the Division of High-Consequence Pathogens and Pathology (DHCPP) Genomics Unit, Centers for Disease Control and Prevention (CDC). NR 37 TC 7 Z9 7 U1 0 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0934-9723 J9 EUR J CLIN MICROBIOL JI Eur. J. Clin. Microbiol. Infect. Dis. PD MAY PY 2012 VL 31 IS 5 BP 811 EP 820 DI 10.1007/s10096-011-1379-7 PG 10 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 921ML UT WOS:000302481600025 PM 21892735 ER PT J AU Oh, JY Cunningham, MC Beldavs, ZG Tujo, J Moore, SW Thomas, AR Cieslak, PR AF Oh, John Y. Cunningham, Margaret C. Beldavs, Zintars G. Tujo, Jennifer Moore, Stephen W. Thomas, Ann R. Cieslak, Paul R. TI Statewide Validation of Hospital-Reported Central Line-Associated Bloodstream Infections: Oregon, 2009 SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID CARE-ASSOCIATED INFECTIONS; SURVEILLANCE; HEALTH; RECOMMENDATIONS; SYSTEMS; COST AB BACKGROUND. Mandatory reporting of healthcare-associated infections is common, but underreporting by hospitals limits meaningful interpretation. OBJECTIVE. To validate mandatory intensive care unit (ICU) central line-associated bloodstream infection (CLABSI) reporting by Oregon hospitals. DESIGN. Blinded comparison of ICU CLABSI determination by hospitals and health department-based external reviewers with group adjudication. SETTING. Forty-four Oregon hospitals required by state law to report ICU CLABSIs. PARTICIPANTS. Seventy-six patients with ICU CLABSIs and a systematic sample of 741 other patients with ICU-related bacteremia episodes. METHODS. External reviewers examined medical records and determined CLABSI status. All cases with CLABSI determinations discordant from hospital reporting were adjudicated through formal discussion with hospital staff, a process novel to validation of CLABSI reporting. RESULTS. Hospital representatives and external reviewers agreed on CLABSI status in 782 (96%) of 817 bacteremia episodes (kappa = 0.77 [ 95% confidence interval (CI), 0.70-0.84]). Among the 27 episodes identified as CLABSIs by external reviewers but not reported by hospitals, the final status was CLABSI in 16 (59%). The measured sensitivities of hospital ICU CLABSI reporting were 72% (95% CI, 62%-81%) with adjudicated CLABSI determination as the reference standard and 60% (95% CI, 51%-69%) with external review alone as the reference standard ( P = .07). Validation increased the statewide ICU CLABSI rate from 1.21 (95% CI, 0.95-1.51) to 1.54 (95% CI, 1.25-1.88) CLABSIs/1,000 central line-days; ICU CLABSI rates increased by more than 1.00 CLABSI/1,000 central line-days in 6 (14%) hospitals. CONCLUSIONS. Validating hospital CLABSI reporting improves accuracy of hospital-based CLABSI surveillance. Discussing discordant findings improves the quality of validation. C1 [Oh, John Y.; Cunningham, Margaret C.; Beldavs, Zintars G.; Moore, Stephen W.; Thomas, Ann R.; Cieslak, Paul R.] Oregon Hlth Author, Publ Hlth Div, Portland, OR USA. [Oh, John Y.; Cunningham, Margaret C.; Beldavs, Zintars G.; Moore, Stephen W.; Thomas, Ann R.; Cieslak, Paul R.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Tujo, Jennifer] Multnomah Cty Hlth Dept, Communicable Dis Off, Portland, OR USA. RP Cieslak, PR (reprint author), 800 NE Oregon St, Portland, OR 97232 USA. EM paul.r.cieslak@state.or.us FU CDC ARRA HAI ELC [280683] FX This study was supported by CDC ARRA HAI ELC grant 280683. NR 25 TC 16 Z9 16 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAY PY 2012 VL 33 IS 5 BP 439 EP 445 DI 10.1086/665317 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 925DJ UT WOS:000302740600001 PM 22476268 ER PT J AU Arnold, KE Thompson, ND AF Arnold, Kathryn E. Thompson, Nicola D. TI Building Data Quality and Confidence in Data Reported to the National Healthcare Safety Network SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Editorial Material ID SURVEILLANCE C1 [Arnold, Kathryn E.; Thompson, Nicola D.] Ctr Dis Control & Prevent, Surveillance Branch, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Arnold, KE (reprint author), Ctr Dis Control & Prevent, Surveillance Branch, Div Healthcare Qual Promot, 1600 Clifton Rd,Mailstop A 24, Atlanta, GA 30333 USA. EM kea3@cdc.gov NR 11 TC 5 Z9 5 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAY PY 2012 VL 33 IS 5 BP 446 EP 448 DI 10.1086/665311 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 925DJ UT WOS:000302740600002 PM 22476269 ER PT J AU Berrios-Torres, SI Mu, Y Edwards, JR Horan, TC Fridkin, SK AF Berrios-Torres, Sandra I. Mu, Yi Edwards, Jonathan R. Horan, Teresa C. Fridkin, Scott K. TI Improved Risk Adjustment in Public Reporting: Coronary Artery Bypass Graft Surgical Site Infections SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID NOSOCOMIAL INFECTIONS; CARDIAC-SURGERY; WOUND-INFECTION; SURVEILLANCE; VALIDATION; SYSTEM; INDEX; RATES; MEDIASTINITIS; OPERATIONS AB OBJECTIVE. The objective was to develop a new National Healthcare Safety Network (NHSN) risk model for sternal, deep incisional, and organ/space (complex) surgical site infections (SSIs) following coronary artery bypass graft (CABG) procedures, detected on admission and readmission, consistent with public reporting requirements. PATIENTS AND SETTING. A total of 133,503 CABG procedures with 4,008 associated complex SSIs reported by 293 NHSN hospitals in the United States. METHODS. CABG procedures performed from January 1, 2006, through December 31, 2008, were analyzed. Potential SSI risk factors were identified by univariate analysis. Multivariate analysis with forward stepwise logistic regression modeling was used to develop the new model. The c-index was used to compare the predictive power of the new and NHSN risk index models. RESULTS. Multivariate analysis independent risk factors included ASA score, procedure duration, female gender, age, and medical school affiliation. The new risk model has significantly improved predictive performance over the NHSN risk index (c-index, 0.62 and 0.56, respectively). CONCLUSIONS. Traditionally, the NHSN surveillance system has used a risk index to provide procedure-specific risk-stratified SSI rates to hospitals. A new CABG sternal, complex SSI risk model developed by multivariate analysis has improved predictive performance over the traditional NHSN risk index and is being considered for endorsement as a measure for public reporting. C1 [Berrios-Torres, Sandra I.; Mu, Yi; Edwards, Jonathan R.; Horan, Teresa C.; Fridkin, Scott K.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Berrios-Torres, SI (reprint author), 1600 Clifton Rd NE MS A-31, Atlanta, GA 30329 USA. EM zbn6@cdc.gov NR 37 TC 16 Z9 16 U1 0 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAY PY 2012 VL 33 IS 5 BP 463 EP 469 DI 10.1086/665313 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 925DJ UT WOS:000302740600005 PM 22476272 ER PT J AU Green, CF Davidson, CS Panlilio, AL Jensen, PA Jin, Y Gibbs, SG Scarpino, PV AF Green, Christopher F. Davidson, Craig S. Panlilio, Adelisa L. Jensen, Paul A. Jin, Yan Gibbs, Shawn G. Scarpino, Pasquale V. TI Effectiveness of Selected Surgical Masks in Arresting Vegetative Cells and Endospores When Worn by Simulated Contagious Patients SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID N95 RESPIRATORS; FACE MASKS; EFFICIENCY; BACTERIA AB OBJECTIVE. The objective of this study was to quantify the effectiveness of selected surgical masks in arresting vegetative cells and endospores in an experimental model that simulated contagious patients. SETTING. Laboratory. METHODS. Five commercially available surgical masks were tested for their ability to arrest infectious agents. Surgical masks were placed over the nose and mouth of mannequin head forms (Simulaids adult model Brad CPR torso). The mannequins were retrofitted with a nebulizer attached to an automated breathing simulator calibrated to a tidal volume of 500 mL/breath and a breathing rate of 20 breaths/min, for a minute respiratory volume of 10 L/min. Aerosols of endospores or vegetative cells were generated with a modified microbiological research establishment-type 6-jet collision nebulizer, while air samples were taken with all-glass impinger (AGI-30) samplers downstream of the point source. All experiments were conducted in a horizontal bioaerosol chamber. RESULTS. Mean arrestance of bioaerosols by the surgical masks ranged from 48% to 68% when the masks were challenged with endospores and from 66% to 76% when they were challenged with vegetative cells. When the arrestance of endospores was evaluated, statistical differences were observed between some pairs, though not all, of the models evaluated. There were no statistically significant differences in arrestance observed between models of surgical masks challenged with vegetative cells. CONCLUSIONS. The arrestance of airborne vegetative cells and endospores by surgical masks worn by simulated contagious patients supports surgical mask use as one of the recommended cough etiquette interventions to limit the transmission of airborne infectious agents. C1 [Gibbs, Shawn G.] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Environm Agr & Occupat Hlth, Omaha, NE 68198 USA. [Green, Christopher F.] Univ Cincinnati, Clermont Coll, Sci Math & Engn Div, Batavia, OH USA. [Davidson, Craig S.; Scarpino, Pasquale V.] Univ Cincinnati, Dept Civil & Environm Engn, Cincinnati, OH 45221 USA. [Panlilio, Adelisa L.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Preparedness Detect & Control Infect Dis, Atlanta, GA USA. [Jensen, Paul A.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Jin, Yan] Univ Cincinnati, Dept Math Sci, Cincinnati, OH 45221 USA. RP Gibbs, SG (reprint author), Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Environm Agr & Occupat Hlth, 985110 Nebraska Med Ctr, Omaha, NE 68198 USA. EM sgibbs@unmc.edu FU Department of Health and Human Services, Centers for Disease Control and Prevention (CDC) FX This work was supported financially by the Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). Mention of products or services and use of trade names and commercial sources is for identification only and does not constitute endorsement by the CDC or the University of Cincinnati. NR 28 TC 2 Z9 2 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAY PY 2012 VL 33 IS 5 BP 487 EP 494 DI 10.1086/665321 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 925DJ UT WOS:000302740600008 PM 22476275 ER PT J AU Dharan, NJ Fry, AM Kieke, BA Coleman, L Meece, J Vandermause, M Gubareva, LV Klimov, AI Belongia, EA AF Dharan, Nila J. Fry, Alicia M. Kieke, Burney A. Coleman, Laura Meece, Jennifer Vandermause, Mary Gubareva, Larisa V. Klimov, Alexander I. Belongia, Edward A. TI Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Antiviral; influenza; oseltamivir effectiveness; resistance ID NEURAMINIDASE INHIBITORS; VIRUS; SUSCEPTIBILITY; ZANAMIVIR; H5N1 AB Nineteen patients with oseltamivir-resistant seasonal influenza A (H1N1) infections were randomized to receive oseltamivir or placebo. Nasopharyngeal swabs were obtained, and clinical and virologic outcomes were compared, stratified by early or late treatment. Neuraminidase inhibition assay and pyrosequencing for H275Y confirmed resistance. Twelve (63%) patients received oseltamivir; 8 (67%) received late treatment. Seven (37%) patients received placebo; 6 (86%) presented >48 hours after onset. Time to 50% decrease in symptom severity, complete symptom resolution, and first negative culture were shortest among the early treatment group. While sample size prohibits a strong conclusion, future studies should evaluate for similar trends. C1 [Dharan, Nila J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Influenza Div, Atlanta, GA USA. [Kieke, Burney A.; Coleman, Laura; Meece, Jennifer; Vandermause, Mary; Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA. RP Dharan, NJ (reprint author), New Jersey Med Sch UMDNJ, 185 S Orange Ave,MSB I-689, Newark, NJ 07103 USA. EM DharanNJ@UMDNJ.edu; Belongia.Edward@marshfieldclinic.org NR 16 TC 5 Z9 6 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2012 VL 6 IS 3 BP 153 EP 158 DI 10.1111/j.1750-2659.2011.00312.x PG 6 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 924TW UT WOS:000302715200014 PM 22118629 ER PT J AU Gambaryan, AS Lomakina, NF Boravleva, EY Kropotkina, EA Mashin, VV Krasilnikov, IV Klimov, AI Rudenko, LG AF Gambaryan, Alexandra S. Lomakina, Natalia F. Boravleva, Elizaveta Y. Kropotkina, Ekaterina A. Mashin, Vadim V. Krasilnikov, Igor V. Klimov, Alexander I. Rudenko, Larisa G. TI Comparative safety, immunogenicity, and efficacy of several anti-H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine) SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE H5N1; live attenuated influenza vaccine ID AMINO-ACID-RESIDUES; AVIAN INFLUENZA; VIRUS-VACCINE; A VIRUS; HEMAGGLUTININ PROTEIN; ATTENUATED INFLUENZA; BALB/C MICE; REASSORTANT; ACTIVATION; CANDIDATE AB Objective Parallel testing of inactivated (split and whole virion) and live vaccine was conducted to compare the immunogenicity and protective efficacy against homologous and heterosubtypic challenge by H5N1 highly pathogenic avian influenza virus. Method Four experimental live vaccines based on two H5N1 influenza virus strains were tested; two of them had hemagglutinin (HA) of A/Vietnam/1203/04 strain lacking the polybasic HA cleavage site, and two others had hemagglutinins from attenuated H5N1 virus A/Chicken/Kurgan/3/05, with amino acid substitutions of Asp54/Asn and Lys222/Thr in HA1 and Val48/Ile and Lys131/Thr in HA2 while maintaining the polybasic HA cleavage site. The neuraminidase and non-glycoprotein genes of the experimental live vaccines were from H2N2 cold-adapted master strain A/Leningrad/134/17/57 (VN-Len and Ku-Len) or from the apathogenic H6N2 virus A/Gull/Moscow/3100/2006 (VN-Gull and Ku-Gull). Inactivated H5N1 and H1N1 and live H1N1 vaccine were used for comparison. All vaccines were applied in a single dose. Safety, immunogenicity, and protectivity against the challenge with HPAI H5N1 virus A/Chicken/Kurgan/3/05 were estimated. Results All experimental live H5 vaccines tested were apathogenic as determined by weight loss and conferred more than 90% protection against lethal challenge with A/Chicken/Kurgan/3/05 infection. Inactivated H1N1 vaccine in mice offered no protection against challenge with H5N1 virus, while live cold-adapted H1N1 vaccine reduced the mortality near to zero level. Conclusions The high yield, safety, and protectivity of VN-Len and Ku-Len made them promising strains for the production of inactivated and live vaccines against H5N1 viruses. C1 [Gambaryan, Alexandra S.] RAMS, MP Chumakov Inst Poliomyelitis & Viral Encephalit, Moscow 142782, Moscow Region, Russia. [Lomakina, Natalia F.] RAAS, YR Kovalenko All Russian Res Inst Expt Vet, Moscow, Russia. [Mashin, Vadim V.; Krasilnikov, Igor V.] Russian Minist Hlth, NPO Microgen, Moscow, Russia. [Klimov, Alexander I.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Rudenko, Larisa G.] RAMS, Expt Med Res Inst, St Petersburg, Russia. RP Gambaryan, AS (reprint author), RAMS, MP Chumakov Inst Poliomyelitis & Viral Encephalit, PO Inst Poliomyelitis, Moscow 142782, Moscow Region, Russia. EM alexandra.gambaryan@gmail.com RI Gambaryan, Alexandra/E-2667-2014; Rudenko, Larisa/B-5169-2015 OI Rudenko, Larisa/0000-0002-0107-9959 FU Russian Foundation for Basic Research [11-04-00517] FX We thank Dr C. C. Yamnikova (Ivanovsky Institute of Virology, RAMS, Moscow, Russia) for providing H5N1 influenza viruses A/Chicken/Kurgan/3/05 and Dr R. Donis (Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA) for providing A/Vietnam/1203/04-PR8/CDC-RG strain. Also, we would like to thank Dr Michael Shaw (Influenza Division, Centers for Disease Control and Prevention) for fruitful and constructive discussion as well as for his help during the paper preparation. This study was supported by research grants 11-04-00517 from the Russian Foundation for Basic Research. NR 34 TC 7 Z9 11 U1 0 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2012 VL 6 IS 3 BP 188 EP 195 DI 10.1111/j.1750-2659.2011.00291.x PG 8 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 924TW UT WOS:000302715200018 PM 21951678 ER PT J AU Chadha, MS Broor, S Gunasekaran, P Potdar, VA Krishnan, A Chawla-Sarkar, M Biswas, D Abraham, AM Jalgaonkar, SV Kaur, H Klimov, A Lal, RB Moen, A Kant, L Mishra, AC AF Chadha, Mandeep S. Broor, Shobha Gunasekaran, Palani Potdar, Varsha A. Krishnan, Anand Chawla-Sarkar, Mamta Biswas, Dipankar Abraham, Asha M. Jalgaonkar, Suresh V. Kaur, Harpreet Klimov, Alexander Lal, Renu B. Moen, Ann Kant, Lalit Mishra, Akhilesh C. TI Multisite virological influenza surveillance in India: 2004-2008 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE India; influenza strains; multisite surveillance; vaccine strains ID VIRUSES; EPIDEMIOLOGY; PATTERNS; A(H1N1); HUMANS; PUNE AB Background Influenza surveillance is important to identify circulating, emerging/reemerging strains and unusual epidemiological trends. With these objectives, a multisite human influenza surveillance network was initiated in India in 2004. Methods Epidemiologic data and throat swabs for laboratory testing were collected from patients with influenza-like illness (ILI) and severe acute respiratory infections (SARI). Virus isolation was carried out in Madin-Darby canine kidney cells and strains identified by hemagglutination inhibition assay. Meteorological data were collected. Results From September 2004 to December 2008, 617 (4 43%) of 13928 cases yielded isolates: 27.8% were influenza A(H1N1), 29.8% were type A(H3N2), and 42.3% were type B. The yearly type and subtype distribution varied significantly from site to site. Peak influenza activity was observed from June to August in Delhi, Pune, and Kolkata and October to December in Chennai. Maximum influenza activity was seen during the rains in Delhi, Pune, Chennai, and Kolkata in correlation with virus isolations. Multivariate analysis of ILI cases showed chill/rigors, cough, fatigue, and ILI in family, correlated positively with isolation. Genetic analysis of Indian isolates revealed that viruses matched with vaccine strains by and large. Overlapping between circulating and vaccine component strains of consecutive years was also observed. Conclusions Seasonal influenza A(H1N1), H3N2, and type B co-circulated in all regions without any particular pattern of movement of any subtype. Year-round limited influenza activity with peaks during rains was observed. Genetic drifts and varying seasonality in different parts of the country suggest that a staggered timing of vaccination may be appropriate for India. C1 [Chadha, Mandeep S.; Potdar, Varsha A.; Mishra, Akhilesh C.] Natl Inst Virol, Pune 411001, Maharashtra, India. [Broor, Shobha; Krishnan, Anand] All India Inst Med Sci, New Delhi, India. [Gunasekaran, Palani] King Inst Prevent Med & Res, Madras, Tamil Nadu, India. [Chawla-Sarkar, Mamta] Natl Inst Cholera & Enter Dis, Kolkata, India. [Biswas, Dipankar] Reg Med Res Ctr, Dibrugarh, Assam, India. [Abraham, Asha M.] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India. [Jalgaonkar, Suresh V.] Indira Gandhi Govt Med Coll, Nagpur, Maharashtra, India. [Kaur, Harpreet; Kant, Lalit] Indian Council Med Res, New Delhi, India. [Klimov, Alexander; Lal, Renu B.; Moen, Ann] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Mishra, AC (reprint author), Natl Inst Virol, 20-A Dr Ambedkar Rd, Pune 411001, Maharashtra, India. EM acm1750@gmail.com RI Krishnan, Anand/D-8537-2012; OI Krishnan, Anand/0000-0002-9173-7811 FU DHHS-CDC [5U50C1024407]; Indian Council of Medical Research, New Delhi FX Authors acknowledge contributions of the staff of Regional and Referral centers. This study was funded by DHHS-CDC Co - operative Agreement Grant Number: 5U50C1024407 and Indian Council of Medical Research, New Delhi. NR 29 TC 25 Z9 25 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2012 VL 6 IS 3 BP 196 EP 203 DI 10.1111/j.1750-2659.2011.00293.x PG 8 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 924TW UT WOS:000302715200019 PM 21955356 ER PT J AU Fry, AM Hancock, K Patel, M Gladden, M Doshi, S Blau, DM Sugerman, D Veguilla, V Lu, XH Noland, H Bai, YH Maroufi, A Kao, A Kriner, P Lopez, K Ginsberg, M Jain, S Olsen, SJ Katz, JM AF Fry, Alicia M. Hancock, Kathy Patel, Minal Gladden, Matthew Doshi, Saumil Blau, Dianna M. Sugerman, David Veguilla, Vic Lu, Xiuhua Noland, Heather Bai, Yaohui Maroufi, Azarnoush Kao, Annie Kriner, Paula Lopez, Karla Ginsberg, Michele Jain, Seema Olsen, Sonja J. Katz, Jacqueline M. CA Influenza Serology Working Grp TI The first cases of 2009 pandemic influenza A (H1N1) virus infection in the United States: a serologic investigation demonstrating early transmission SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE 2009 pandemic influenza A (H1N1); influenza; serology; Southern California; transmission ID ASSAYS; RATES AB Background The first two laboratory-confirmed cases of 2009 pandemic influenza A (H1N1) virus (H1N1pdm09) infection were detected in San Diego (SD) and Imperial County (IC) in southern California, April 2009. Objectives To describe H1N1pdm09 infections and transmission early in the 2009 H1N1 pandemic. Patients/Methods We identified index case-patients from SD and IC with polymerase chain reaction (PCR)-confirmed H1N1pdm09 infections and investigated close contacts for a subset of case-patients from April 17-May 6, 2009. Acute and convalescent serum was collected. Serologic evidence for H1N1pdm09 infection was determined by microneutralization and hemagglutination inhibition assays. Results Among 75 close contacts of seven index case-patients, three reported illness onset prior to patient A or B, including two patient B contacts and a third with no links to patient A or B. Among the 69 close contacts with serum collected >14 days after the onset of index case symptoms, 23 (33%) were seropositive for H1N1pdm09, and 8 (35%) had no fever, cough, or sore throat. Among 15 household contacts, 8 (53%) were seropositive for H1N1pdm09. The proportion of contacts seropositive for H1N1pdm09 was highest in persons aged 5-24 years (50%) and lowest in persons aged 50 years (13%) (P = 0 07). Conclusions By the end of April 2009, before H1N1pdm09 was circulating widely in the community, a third of persons with close contact to confirmed H1N1pdm09 cases had H1N1pdm09 infection in SD and IC. Three unrelated clusters during March 21-30 suggest that transmission of H1N1pdm09 had begun earlier in southern California. C1 [Fry, Alicia M.; Hancock, Kathy; Patel, Minal; Gladden, Matthew; Doshi, Saumil; Blau, Dianna M.; Sugerman, David; Veguilla, Vic; Lu, Xiuhua; Noland, Heather; Bai, Yaohui; Jain, Seema; Olsen, Sonja J.; Katz, Jacqueline M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Maroufi, Azarnoush; Kao, Annie; Ginsberg, Michele] Hlth & Human Serv Agcy, San Diego, CA USA. RP Fry, AM (reprint author), 1600 Clifton Rd,MS A-20, Atlanta, GA 30333 USA. EM afry@cdc.gov NR 14 TC 3 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2012 VL 6 IS 3 BP e48 EP e53 DI 10.1111/j.1750-2659.2012.00339.x PG 6 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 924TW UT WOS:000302715200011 PM 22353441 ER PT J AU Jules, A Grijalva, CG Zhu, YW Talbot, KH Williams, JV Dupont, WD Edwards, KM Schaffner, W Shay, DK Griffin, MR AF Jules, Astride Grijalva, Carlos G. Zhu, Yuwei Talbot, Keipp H. Williams, John V. Dupont, William D. Edwards, Kathryn M. Schaffner, William Shay, David K. Griffin, Marie R. TI Estimating age-specific influenza-related hospitalization rates during the pandemic (H1N1) 2009 in Davidson Co, TN SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE A(H1N1)pdm09 virus; capture-recapture; hospitalization rates; surveillance-sampling ID CAPTURE-RECAPTURE METHODS; UNITED-STATES; SURVEILLANCE; CHILDREN; BURDEN; 1ST AB Background In April 2009, a pandemic caused by a novel influenza strain, the A(H1N1) pdm09 virus, started. Few age-specific estimates of hospitalizations associated with the first year of circulation of the pandemic virus are available. Objectives To estimate age-specific hospitalization rates associated with laboratory-confirmed A(H1N1) pdm09 virus in Davidson County, TN, from May 2009 to March 2010. Patients/methods Two separate strategies were applied: capture-recapture and surveillance-sampling methods. For the capture-recapture estimates, we linked data collected via two independent prospective population-based surveillance systems: The Influenza Vaccine Effectiveness Network (Flu-VE) tested consenting county patients hospitalized with respiratory symptoms at selected hospitals using real-time reverse transcriptase polymerase chain reaction (rRT-PCR); the Emerging Infections Program identified county patients with positive influenza tests in all area hospitals. For the surveillance-sampling estimates, we applied the age-specific proportions of influenza-positive patients (from Flu-VE) to the number of acute respiratory illness hospitalizations obtained from the Tennessee Hospital Discharge Data system. Results With capture-recapture, we estimated 0 89 (95% CI, 0.72-1.49), 0.62 (0.42-1.11), 1.78 (0.99-3.63), and 0.76 (0.50-1.76) hospitalizations per 1000 residents aged < 5, 5-17, 18-49, and 50 years, respectively. Surveillance-sampling estimated rates were 0.78 (0.46-1.22), 0.32 (0.14-0.69), 0.99 (0.64-1.52), and 1.43 (0.80-2.48) hospitalizations per 1000 residents aged < 5, 5-17, 18-49, and 50 years, respectively. In all age-groups combined, we estimated approximately 1 influenza-related hospitalization per 1000 residents. Conclusions Two independent methods provided consistent results on the burden of pandemic virus in Davidson County and suggested that the overall incidence of A(H1N1) pdm09-associated hospitalization was 1 per 1000 county residents. C1 [Jules, Astride; Grijalva, Carlos G.; Schaffner, William; Griffin, Marie R.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. [Zhu, Yuwei; Dupont, William D.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA. [Talbot, Keipp H.; Griffin, Marie R.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. [Williams, John V.; Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. [Williams, John V.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA. [Shay, David K.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Griffin, Marie R.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA. RP Griffin, MR (reprint author), Vanderbilt Univ, Sch Med, Dept Prevent Med, Suite 2600,1500 21st Ave S, Nashville, TN 37212 USA. EM marie.griffin@vanderbilt.edu RI Dupont, William/I-4430-2012; Williams, John/F-6962-2010; OI Williams, John/0000-0001-8377-5175; Shay, David/0000-0001-9619-4820 FU Flu-VE network; Centers for Disease Control and Prevention; Vanderbilt University [U01 IP000184, U50/CCU 4161 23]; CDC; NIAID [1K23AI074863-01]; VaxInnate; Sanofi Pasteur; Wyeth (Pfizer) FX Dr. Astride Jules wrote the first draft and contributed to statistical analyses. Dr. Carlos G. Grijalva contributed to statistical analysis, and drafting and review of paper. Dr. Yuwei Zhu contributed to data management, statistical analysis, and drafting and review of paper. Dr. Keipp H. Talbot reviewed the paper. Dr. John V. Williams provided laboratory technical assistance, and drafted and reviewed the paper. Professor William D. Dupont contributed to statistical analyses. Professor Kathryn M. Edwards, Professor William Schaffner, and Dr. David K. Shay drafted and reviewed the paper. Professor Marie R. Griffin provided funding through the Flu-VE network, and drafted and reviewed the paper.; This study was funded by the Centers for Disease Control and Prevention through cooperative agreements with Vanderbilt University (U01 IP000184and U50/CCU 4161 23). Internal CDC funds were used to support CDC investigators and to provide laboratory validation of RT-PCR methods at the enrolling site laboratories. Dr. Talbot received salary support from the NIAID (1K23AI074863-01).; H. Keipp Talbot received research funds from VaxInnate, Sanofi Pasteur, and Wyeth (Pfizer). John V. Williams is associated with the Scientific Advisory Board of Quidel, and William Schaffner is a consultant to Novartis, GSK, Sanofi Pasteur, Dynavax, Pfizer; Member, Data Safety Monitoring Boards of Merck. NR 27 TC 9 Z9 9 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAY PY 2012 VL 6 IS 3 BP e63 EP e71 DI 10.1111/j.1750-2659.2012.00343.x PG 9 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 924TW UT WOS:000302715200013 PM 22360812 ER PT J AU Patel, P Bennett, B Sullivan, T Parker, MM Heffelfinger, JD Sullivan, PS AF Patel, Pragna Bennett, Berry Sullivan, Timothy Parker, Monica M. Heffelfinger, James D. Sullivan, Patrick S. CA CDC AHI Study Grp TI Rapid HIV screening: Missed opportunities for HIV diagnosis and prevention SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE HIV; Rapid tests; Acute HIV infection; Early HIV infection; Fourth-generation ID INFECTION; TRANSMISSION; PERFORMANCE; RATES AB Background: Although rapid HIV tests increase the number of persons who are aware of their HIV status, they may fail to detect early HIV infection. Objectives: To evaluate the sensitivity for early HIV infection of several rapid tests and third-and fourth-generation assays compared with nucleic acid amplification testing (NAAT). Study design: Sensitivity for early HIV infection was evaluated using 62 NAAT-positive/WB-negative or indeterminate specimens from the CDC Acute HIV Infection study. Specimens underwent third-generation testing with Genetic Systems 1/2 + O (R) and rapid testing with Multispot HIV-1/HIV-2. A subset was also tested with four FDA-approved rapid tests and Determine HIV-1 Antigen/Antibody Rapid Test (R) and Architect HIV Antigen/Antibody Combo (R), both fourth-generation tests. Results: Of 99,111 specimens screened from April 2006 to March 2008, 62 met the definition for early HIV infection (60 NAAT-positive/seronegative and 2 NAAT-positive/Western blot indeterminate). Third-generation testing correctly detected antibody in 34 specimens (55%; 95% confidence interval (CI): 42-67); Multispot detected antibody in 16 (26%; 95% CI: 16-38). Of the 62 specimens, 33 (53%) had sufficient quantity for further testing. Rapid test sensitivities for early HIV infection ranged from 22-33% compared with 55-57% for the third-generation assay and 76-88% for the fourth-generation tests. Conclusions: Many rapid HIV tests failed to detect half of the early HIV infection cases in whom antibody was present. Programs that screen high-incidence populations with rapid tests should consider supplemental testing with NAAT or other antigen-based tests. These data support the need for more sensitive antigen-based point-of-care screening tests for early HIV infection. Published by Elsevier B.V. C1 [Patel, Pragna; Heffelfinger, James D.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Bennett, Berry] Florida Bur Labs, Retrovirol Sect, Jacksonville, FL USA. [Sullivan, Timothy; Parker, Monica M.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. [Sullivan, Patrick S.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. RP Patel, P (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-45, Atlanta, GA 30333 USA. EM plp3@cdc.gov OI Sullivan, Timothy/0000-0003-3144-9188; Sullivan, Patrick/0000-0002-7728-0587 FU CDC [1UA1 PS000063] FX This study was supported by grant 1UA1 PS000063 from the CDC. NR 16 TC 31 Z9 32 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD MAY PY 2012 VL 54 IS 1 BP 42 EP 47 DI 10.1016/j.jcv.2012.01.022 PG 6 WC Virology SC Virology GA 922NX UT WOS:000302555500009 PM 22381919 ER PT J AU Viner, K Perella, D Lopez, A Bialek, S Newbern, C Pierre, R Spells, N Watson, B AF Viner, Kendra Perella, Dana Lopez, Adriana Bialek, Stephanie Newbern, Claire Pierre, Rodrerica Spells, Niya Watson, Barbara TI Transmission of Varicella Zoster Virus From Individuals With Herpes Zoster or Varicella in School and Day Care Settings SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; AIRBORNE TRANSMISSION; IMPLEMENTATION; VACCINATION; DNA AB Background. Because the varicella incidence has declined following varicella vaccine licensure, herpes zoster (HZ) cases may play a larger role in varicella zoster virus (VZV) transmission. We investigated how HZ and varicella cases contribute to the varicella incidence in schools and day care centers. Methods. Surveillance data collected in Philadelphia during September 2003-June 2010 were analyzed. A varicella case was considered to be sporadic if it was reported from a school or day care facility >6 weeks after or >= 10 days before other reports of VZV transmission. A varicella case was considered to be secondary if it occurred 10-21 days after report of a case of HZ or sporadic varicella. Analysis compared VZV transmission from individuals with HZ or sporadic varicella, stratified by varicella vaccination status and disease severity. Results. Of 290 HZ cases reported, 27 (9%) resulted in 84 secondary varicella cases. Of 1358 sporadic varicella cases reported, 205 (15%) resulted in 564 secondary varicella cases. Approximately half of the HZ and sporadic varicella cases resulted in single secondary cases. The proportion of individuals who had secondary cases with mild disease was similar for those exposed to HZ and those exposed to varicella (70% and 72%, respectively). VZV transmission was highest from unvaccinated individuals with sporadic varicella (P < .01). Conclusions. VZV transmission from individuals with HZ contributes to varicella morbidity. More research is needed to understand risk factors and guide recommendations for preventing VZV transmission from individuals with HZ. C1 [Viner, Kendra; Perella, Dana; Newbern, Claire; Pierre, Rodrerica; Spells, Niya; Watson, Barbara] Philadelphia Dept Publ Hlth, Varicella Act Surveillance Program, Div Dis Control, Philadelphia, PA 19146 USA. [Lopez, Adriana; Bialek, Stephanie] Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Ctr Dis Control & Prevent, Atlanta, GA USA. RP Viner, K (reprint author), Philadelphia Dept Publ Hlth, Varicella Act Surveillance Program, Div Dis Control, 500 S Broad St, Philadelphia, PA 19146 USA. EM kendra.viner@phila.gov FU Centers of Disease Control and Prevention [3U0 1IP000019]; Philadelphia Department of Public Health for active varicella surveillance and epidemiological studies FX This work was supported by the Centers of Disease Control and Prevention through a cooperative agreement (grant 3U0 1IP000019) with the Philadelphia Department of Public Health for active varicella surveillance and epidemiological studies. NR 14 TC 10 Z9 10 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2012 VL 205 IS 9 BP 1336 EP 1341 DI 10.1093/infdis/jis207 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 921QI UT WOS:000302491800003 PM 22454467 ER PT J AU Bresee, JS Marcus, R Venezia, RA Keene, WE Morse, D Thanassi, M Brunett, P Bulens, S Beard, RS Dauphin, LA Slutsker, L Bopp, C Eberhard, M Hall, A Vinje, J Monroe, SS Glass, RI AF Bresee, Joseph S. Marcus, Ruthanne Venezia, Richard A. Keene, William E. Morse, Dale Thanassi, Mark Brunett, Patrick Bulens, Sandra Beard, R. Suzanne Dauphin, Leslie A. Slutsker, Laurence Bopp, Cheryl Eberhard, Mark Hall, Aron Vinje, Jan Monroe, Stephan S. Glass, Roger I. CA US Acute Gastroenteritis Etiology TI The Etiology of Severe Acute Gastroenteritis Among Adults Visiting Emergency Departments in the United States SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID FOODBORNE DISEASE OUTBREAKS; SENTINEL GENERAL PRACTICES; VIRUS-LIKE PARTICLES; ROTAVIRUS INFECTION; HUMAN CALICIVIRUS; IMMUNE-RESPONSES; FECAL SPECIMENS; STOOL CULTURES; RECTAL SWABS; CHILDREN AB Background. Acute gastroenteritis (AGE) remains a common cause of clinic visits and hospitalizations in the United States, but the etiology is rarely determined. Methods. We performed a prospective, multicenter emergency department-based study of adults with AGE. Subjects were interviewed on presentation and 3-4 weeks later. Serum samples, rectal swab specimens, and/or whole stool specimens were collected at presentation, and serum was collected 3-4 weeks later. Fecal specimens were tested for a comprehensive panel of viral, bacterial, and parasitic pathogens; serum was tested for calicivirus antibodies. Results. Pathogens were detected in 25% of 364 subjects, including 49% who provided a whole stool specimen. The most commonly detected pathogens were norovirus (26%), rotavirus (18%), and Salmonella species (5.3%). Pathogens were detected significantly more often from whole stool samples versus a rectal swab specimen alone. Nine percent of subjects who provided whole stool samples had >1 pathogen identified. Conclusions. Viruses, especially noroviruses, play a major role as agents of severe diarrhea in adults. Further studies to confirm the unexpectedly high prevalence of rotaviruses and to explore the causes of illness among patients from whom a pathogen cannot be determined are needed. Studies of enteric pathogens should require the collection of whole stool samples. C1 [Bresee, Joseph S.; Bulens, Sandra; Beard, R. Suzanne; Dauphin, Leslie A.; Hall, Aron; Vinje, Jan; Monroe, Stephan S.; Glass, Roger I.] Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Albany, NY USA. [Marcus, Ruthanne] Connecticut Emerging Infect Program, Albany, NY USA. [Venezia, Richard A.] Albany Med Ctr, Albany, NY USA. [Keene, William E.] Dept Human Serv, Oregon Publ Hlth Div, Albany, NY USA. [Morse, Dale] New York Dept Hlth, Albany, NY USA. [Thanassi, Mark] Yale New Haven Med Ctr, Dept Emergency Med, New Haven, CT 06504 USA. [Brunett, Patrick] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Slutsker, Laurence; Bopp, Cheryl] Div Bacterial & Mycot Dis, Foodborne & Diarrheal Dis Branch, Atlanta, GA USA. [Eberhard, Mark] Ctr Dis Control, Natl Ctr Infect Dis, Div Parasit Dis, Off Director, Atlanta, GA 30333 USA. RP Bresee, JS (reprint author), Ctr Dis Control & Prevent, MS A-20,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jbresee@cdc.gov OI Vinje, Jan/0000-0002-1530-3675; Monroe, Stephan/0000-0002-5424-716X FU National Center for Infectious Diseases, CDC FX This work was supported by the National Center for Infectious Diseases, CDC. NR 48 TC 53 Z9 56 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2012 VL 205 IS 9 BP 1374 EP 1381 DI 10.1093/infdis/jis206 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 921QI UT WOS:000302491800007 PM 22454468 ER PT J AU Bangert, M Bricio-Moreno, L Gore, S Rajam, G Ades, EW Gordon, SB Kadioglu, A AF Bangert, Mathieu Bricio-Moreno, Laura Gore, Suzanna Rajam, Gowrisankar Ades, Edwin W. Gordon, Stephen B. Kadioglu, Aras TI P4-Mediated Antibody Therapy in an Acute Model of Invasive Pneumococcal Disease SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS; STREPTOCOCCUS-PNEUMONIAE; ANTIINFLAMMATORY ACTIVITY; BACTERIAL-MENINGITIS; SURFACE ADHESIN; HAEMOPHILUS-INFLUENZAE; PASSIVE IMMUNOTHERAPY; INFECTIOUS-DISEASES; MALAWIAN ADULTS; MORTALITY AB New treatments against severe bacterial infections are needed because the response to antibiotic treatment is slow in acute settings and is becoming less effective owing to the emergence of antibiotic-resistant pathogens. P4-mediated antibody therapy offers a unique treatment strategy that combines exogenous immunoglobulin with the immunoactivating peptide P4. In an acute model of pneumococcal disease, mice were infected with Streptococcus pneumoniae and treated intravenously or intranasally with P4 and intravenous immunoglobulin (IVIG). Survival of P4-IVIG-treated mice increased from 0% to 60% among those that received intravenous treatment and from 0% to 100% among those that received intranasal treatment. Importantly, intranasal administration of P4 at an early stage of infection prevented the onset of bacteremia and sepsis. Increased survival was associated with reduced bacterial burden in affected tissues and with recruitment and activation of professional phagocytes, as manifested by increased expression of Fc-gamma receptors. In vitro studies involving P4-stimulated alveolar, peritoneal, and J774.2 murine macrophages showed an increased ability of these immune cells to phagocytose pneumococci independent of capsule. The use of adjunct antibody therapies to treat infectious diseases shows promise. C1 [Bangert, Mathieu; Gordon, Stephen B.] Univ Liverpool Liverpool Sch Trop Med, Resp Infect Grp, Atlanta, GA USA. [Rajam, Gowrisankar; Ades, Edwin W.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. [Bangert, Mathieu; Bricio-Moreno, Laura; Gore, Suzanna; Kadioglu, Aras] Univ Liverpool, Inst Infect & Global Hlth, Dept Clin Infect Microbiol & Immunol, Liverpool L69 3BX, Merseyside, England. RP Bangert, M (reprint author), Univ Liverpool Liverpool Sch Trop Med, Resp Infect Grp, Pembroke Pl, Liverpool L35 QA, Merseyside, England. EM m.bangert@liverpool.ac.uk RI Bricio-Moreno, Laura/E-1449-2012; kadioglu, aras/E-1458-2012; OI Gordon, Stephen/0000-0001-6576-1116; Bangert, Mathieu/0000-0003-1320-8145 FU Crossley Barnes Fellowship; NIHR Biomedical Research Centre in Microbial Diseases FX This work was funded by the Crossley Barnes Fellowship and the NIHR Biomedical Research Centre in Microbial Diseases, with infrastructural support from the NWDA. NR 46 TC 11 Z9 11 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2012 VL 205 IS 9 BP 1399 EP 1407 DI 10.1093/infdis/jis223 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 921QI UT WOS:000302491800010 PM 22457294 ER PT J AU Baty, SA Gibney, KB Staples, JE Patterson, AB Levy, C Lehman, J Wadleigh, T Feld, J Lanciotti, R Nugent, CT Fischer, M AF Baty, Steven A. Gibney, Katherine B. Staples, J. Erin Patterson, Andrean Bunko Levy, Craig Lehman, Jennifer Wadleigh, Tricia Feld, Jamie Lanciotti, Robert Nugent, C. Thomas Fischer, Marc TI Evaluation for West Nile Virus (WNV) RNA in Urine of Patients Within 5 Months of WNV Infection SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter ID ASSAY C1 [Baty, Steven A.; Levy, Craig] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Baty, Steven A.; Gibney, Katherine B.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Gibney, Katherine B.; Staples, J. Erin; Lehman, Jennifer; Lanciotti, Robert; Fischer, Marc] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO USA. [Patterson, Andrean Bunko; Wadleigh, Tricia; Feld, Jamie] Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA. [Wadleigh, Tricia; Feld, Jamie] Ctr Dis Control & Prevent, Off State Tribal Local & Territorial Support, Atlanta, GA USA. [Nugent, C. Thomas] Gen Probe Inc, San Diego, CA USA. RP Fischer, M (reprint author), CDC, Arboviral Dis Branch, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM mxf2@cdc.gov OI Gibney, Katherine/0000-0001-5851-5339 NR 5 TC 17 Z9 17 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2012 VL 205 IS 9 BP 1476 EP 1477 DI 10.1093/infdis/jis221 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 921QI UT WOS:000302491800023 PM 22438324 ER PT J AU Hall, JE Walters, ML Basile, KC AF Hall, Jeffrey E. Walters, Mikel L. Basile, Kathleen C. TI Intimate Partner Violence Perpetration by Court-Ordered Men: Distinctions Among Subtypes of Physical Violence, Sexual Violence, Psychological Abuse, and Stalking SO JOURNAL OF INTERPERSONAL VIOLENCE LA English DT Article DE domestic violence; batterers; stalking ID MODELS; ASSAULT; SAMPLE; TESTS; FIT AB This study continues previous work documenting the structure of violence perpetrated by males against their female intimate partners. It assesses the construct validity of a measurement model depicting associations among eight subtypes of perpetration: moderate physical violence, severe physical violence, forced or coerced sexual violence, sexual violence where consent was not possible, emotional/verbal psychological abuse, dominance/isolation psychological abuse, interactional contacts/surveillance related stalking, and stalking involving mediated contacts. Data were obtained from a sample of 340 men arrested for physical assault of a female spouse or partner, and court ordered into batterer intervention programs. Men were surveyed before starting the intervention. Confirmatory factor analyses (CFA) supported the validity of model as evidenced by good model to data fit and satisfaction of requirements for fit statistics. In addition, the eight factor solution was characterized by a slightly better model to data fit than a four factor higher order solution described in the author's previous work. Latent variable correlations across the broader categories of intimate partner violence (IPV) revealed that the violence subtypes were mostly moderately positively correlated and ranged from .381 (emotional/verbal psychological abuse with interactional contacts/surveillance related stalking) to .795 (dominance/isolation psychological with abuse with forced sex). Future studies should determine whether there are distinct risk factors and health outcomes associated with each of the eight IPV perpetration subtypes and identify possible patterns of co-occurrence. C1 [Hall, Jeffrey E.; Walters, Mikel L.; Basile, Kathleen C.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA USA. RP Hall, JE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, 4770 Buford Highway NE,Mailstop F63, Atlanta, GA USA. EM jhall2@cdc.gov NR 28 TC 6 Z9 6 U1 2 U2 22 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0886-2605 J9 J INTERPERS VIOLENCE JI J. Interpers. Violence PD MAY PY 2012 VL 27 IS 7 BP 1374 EP 1395 DI 10.1177/0886260511425249 PG 22 WC Criminology & Penology; Family Studies; Psychology, Applied SC Criminology & Penology; Family Studies; Psychology GA 919YB UT WOS:000302367000010 PM 22203640 ER PT J AU Covassin, T Elbin, RJ Sarmiento, K AF Covassin, Tracey Elbin, R. J. Sarmiento, Kelly TI Educating Coaches About Concussion in Sports: Evaluation of the CDC's "Heads Up: Concussion in Youth Sports" Initiative SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE concussions; youth coaches; CDC Heads Up ID 2ND IMPACT SYNDROME; 2ND-IMPACT SYNDROME; EPIDEMIOLOGY AB BACKGROUND: Concussions remain a serious public health concern. It is important that persons involved in youth sports, particularly coaches, be made aware and educated on the signs and symptoms of concussion. This study assessed the perceptions of youth sport coaches who have received the Centers for Disease Control and Prevention's (CDC's) Heads Up: Concussion in Youth Sports materials in preventing, recognizing, and responding to concussions. METHODS: A 22-item survey was developed with questions pertaining to demographics, awareness of sports-related concussion, and the usefulness of the CDC's "Heads Up: Concussion in Youth Sports'' initiative and materials. A total of 340 youth sport coaches completed the survey, for a response rate of 34.0%. RESULTS: All youth sport coaches reported having the "Heads Up'' materials for approximately 6 months before completing the survey. Seventy-seven percent of youth sports coaches reported being better able to identify athletes who may have a concussion, with 50% reported having learned something new about concussion after reviewing the materials. Sixty-three percent of youth sport coaches viewed concussions as being more serious, while 72% of coaches reporting that they are now educating others on concussion. CONCLUSION: The "Heads Up'' materials demonstrated that youth sports coaches' were able to appropriately prevent, recognize, and respond to sports-related concussions after reviewing the materials. Future studies should concentrate on evaluating the impact of concussion policies, laws and media coverage on coaches' awareness and prevention, recognition, and response to concussions using a rigorous design including a control group. C1 [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA. [Elbin, R. J.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA 15261 USA. [Sarmiento, Kelly] Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Covassin, T (reprint author), Michigan State Univ, Dept Kinesiol, 105 IM Sport Circle, E Lansing, MI 48824 USA. EM covassin@msu.edu; rje13@pitt.edu; egz8@cdc.gov NR 13 TC 36 Z9 36 U1 3 U2 23 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD MAY PY 2012 VL 82 IS 5 BP 233 EP 238 DI 10.1111/j.1746-1561.2012.00692.x PG 6 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 923NI UT WOS:000302625600005 PM 22494094 ER PT J AU Burke, RL Kronmann, KC Daniels, CC Meyers, M Byarugaba, DK Dueger, E Klein, TA Evans, BP Vest, KG AF Burke, R. L. Kronmann, K. C. Daniels, C. C. Meyers, M. Byarugaba, D. K. Dueger, E. Klein, T. A. Evans, B. P. Vest, K. G. TI A Review of Zoonotic Disease Surveillance Supported by the Armed Forces Health Surveillance Center SO ZOONOSES AND PUBLIC HEALTH LA English DT Review DE Zoonotic; surveillance; US military; human-animal interface ID REPUBLIC-OF-KOREA; BRIDGES TRAINING AREA; INFLUENZA-A VIRUS; GYEONGGI PROVINCE; SMALL MAMMALS; SEROLOGICAL SURVEILLANCE; INFECTION SURVEILLANCE; COXIELLA-BURNETII; MURINE TYPHUS; SCRUB TYPHUS AB The Armed Forces Health Surveillance Center (AFHSC), Division of Global Emerging Infections Surveillance and Response System conducts disease surveillance through a global network of US Department of Defense research laboratories and partnerships with foreign ministries of agriculture, health and livestock development in over 90 countries worldwide. In 2010, AFHSC supported zoonosis survey efforts were organized into four main categories: (i) development of field assays for animal disease surveillance during deployments and in resource limited environments, (ii) determining zoonotic disease prevalence in high-contact species which may serve as important reservoirs of diseases and sources of transmission, (iii) surveillance in high-risk human populations which are more likely to become exposed and subsequently infected with zoonotic pathogens and (iv) surveillance at the humananimal interface examining zoonotic disease prevalence and transmission within and between human and animal populations. These efforts have aided in the detection, identification and quantification of the burden of zoonotic diseases such as anthrax, brucellosis, Crimean Congo haemorrhagic fever, dengue fever, Hantaan virus, influenza, Lassa fever, leptospirosis, melioidosis, Q fever, Rift Valley fever, sandfly fever Sicilian virus, sandfly fever Naples virus, tuberculosis and West Nile virus, which are of military and public health importance. Future zoonotic surveillance efforts will seek to develop local capacity for zoonotic surveillance focusing on high risk populations at the humananimal interface. C1 [Burke, R. L.; Vest, K. G.] Armed Forces Hlth Surveillance Ctr, Silver Spring, MD 20904 USA. [Kronmann, K. C.] Adjacent Abbassia Fever Hosp, Naval Med Res Unit 3, Cairo, Egypt. [Daniels, C. C.] DoD Vet Food Anal & Diagnost Lab, San Antonio, TX USA. [Meyers, M.; Evans, B. P.] Armed Forces Res Inst Med Sci, Bangkok 10400, Thailand. [Byarugaba, D. K.] Makerere Univ, Sch Vet Med, Kampala, Uganda. [Dueger, E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dueger, E.] Global Dis Detect Reg Ctr, Naval Med Res Unit 3, Cairo, Egypt. [Klein, T. A.] US Army Yongsan Garrison Force Hlth Protect & Pre, Seoul, South Korea. RP Burke, RL (reprint author), Armed Forces Hlth Surveillance Ctr, 11800 Tech Rd,Suite 200, Silver Spring, MD 20904 USA. EM ronald.l.burke@amedd.army.mil RI Valle, Ruben/A-7512-2013 FU US Department of Defense FX We thank Dr Elisabeth Fichet-Calvet for her expert knowledge and advice on studying rodents in West Africa, Dr Lisa Hensley for providing expertise on testing for Lassa virus, and Ms Shirley Cameron Nimo Paintsil for her tireless work in developing and executing protocols for studies in Ghana. We also thank Dr Heung-Chul Kim, 65th Medical Brigade, Dr Jin Won Song, Korea University, and Dr Joon-Seok Chae, Seoul National University, for their technical support with the Korean surveillance. Funding for these efforts was provided by the US Department of Defense. NR 58 TC 6 Z9 7 U1 3 U2 35 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1863-1959 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD MAY PY 2012 VL 59 IS 3 BP 164 EP 175 DI 10.1111/j.1863-2378.2011.01440.x PG 12 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA 923KX UT WOS:000302619300002 PM 22128834 ER PT J AU Murphree, R Dunn, JR Schaffner, W Jones, TF AF Murphree, R. Dunn, J. R. Schaffner, W. Jones, T. F. TI La Crosse Encephalitis Surveillance using Single Versus Paired Serologic Testing SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE La Crosse virus; encephalitis; serologic tests; surveillance ID VIRUS-INFECTIONS; TENNESSEE AB We evaluated the validity of single versus paired serologic testing for La Crosse virus (LACV) encephalitis surveillance. Compared with paired serology, a single positive IgG or IgM immunoflourescent antibody titre appears useful for LACV encephalitis surveillance with sensitivity, 75%; specificity, 98%; positive predictive value, 95%; and overall test efficiency 92%. C1 [Murphree, R.; Dunn, J. R.; Jones, T. F.] Tennessee Dept Hlth, Communicable & Environm Dis Serv, Nashville, TN 37243 USA. [Murphree, R.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Schaffner, W.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. RP Murphree, R (reprint author), Tennessee Dept Hlth, Communicable & Environm Dis Serv, 425 5th Ave N,1st Floor,Cordell Hull Bldg, Nashville, TN 37243 USA. EM zle9@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1863-1959 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD MAY PY 2012 VL 59 IS 3 BP 181 EP 183 DI 10.1111/j.1863-2378.2011.01433.x PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA 923KX UT WOS:000302619300004 PM 21848528 ER PT J AU Yonas, MA Nowalk, MP Zimmerman, RK Ahmed, F Albert, SM AF Yonas, Michael A. Nowalk, Mary Patricia Zimmerman, Richard K. Ahmed, Faruque Albert, Steven M. TI Examining Structural and Clinical Factors Associated with Implementation of Standing Orders for Adult Immunization SO JOURNAL FOR HEALTHCARE QUALITY LA English DT Article DE adult immunizations; mixed methods; research; standing orders; survey design AB A proven method to increase vaccination rates in primary care is a standing orders program (SOP) for nonphysician staff to assess and vaccinate eligible individuals without a specific written physician order. This study describes a mixed methods approach to examining physicians' beliefs and attitudes about and adoption of SOPs for adult immunizations, specifically, influenza and pneumococcal polysaccharide vaccine. Focus groups and in-depth interviews of physicians, nurses, practice managers, and the medical director of a managed care health plan were conducted. Results were used to enrich a concise survey based on the Awareness-to-Adherence model of physician behavior and previous research, which was mailed to 1,640 general internists and family physicians nationwide. Barriers to SOPs identified through qualitative methods were lack of interest in changing the status quo, a physician-dominated hierarchy, and fear of malpractice. Facilitators included having an electronic medical record and a practice culture that was open to change. The survey (response rate 67%) confirmed the facilitators and further identified patient, physician, and practice factors that served as barriers to establishing and maintaining SOPs. This mixed methods approach provided the opportunity to develop a tailored and practice-oriented survey for examining the contextual factors influencing clinical providers' decisions to implement SOPs for adult immunization. C1 [Ahmed, Faruque] Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. EM may24@pitt.edu OI Zimmerman, Richard/0000-0001-5941-6092; Albert, Steven/0000-0001-6786-9956 FU Centers for Disease Control and Prevention; Association for Prevention Teaching and Research [5 U50 CD300-860-21] FX This study was supported by the Centers for Disease Control and Prevention and the Association for Prevention Teaching and Research, Grant No. 5 U50 CD300-860-21. Its contents are the responsibility of the authors and do not necessarily reflect the official views of the CDC or the APTR. NR 24 TC 3 Z9 3 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1062-2551 EI 1945-1474 J9 J HEALTHC QUAL JI J. Healthc. Qual. PD MAY-JUN PY 2012 VL 34 IS 3 BP 34 EP 42 DI 10.1111/j.1945-1474.2011.00144.x PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA V36ON UT WOS:000209221100004 PM 22059731 ER PT J AU Farnham, PG Sansom, SL Hutchinson, AB AF Farnham, Paul G. Sansom, Stephanie L. Hutchinson, Angela B. TI How Much Should We Pay for a New HIV Diagnosis? A Mathematical Model of HIV Screening in US Clinical Settings SO MEDICAL DECISION MAKING LA English DT Article DE HIV; AIDS; cost-effectiveness analysis; cost-utility analysis; economic aspects of disease; economics health ID ACTIVE ANTIRETROVIRAL THERAPY; ADJUSTED LIFE-YEAR; UNITED-STATES; COST-EFFECTIVENESS; EMERGENCY-DEPARTMENT; PREVENTION PROGRAMS; SEXUAL TRANSMISSION; PERSONS AWARE; MEN; METAANALYSIS AB Objective. To develop a model to assist clinical setting decision makers in determining how much they can spend on human immunodeficiency virus (HIV) screening and still be cost-effective. Design. The authors developed a simple mathematical model relating the program cost per new HIV diagnosis to the cost per HIV infection averted and the cost per quality-adjusted life year (QALY) saved by screening. They estimated outcomes based on behavioral changes associated with awareness of HIV infection and applied the model to US sexually transmitted disease clinics. Methods. The authors based the cost per new HIV diagnosis (2009 US dollars) on the costs of testing and the proportion of persons who tested positive. Infections averted were calculated from the reduction in annual transmission rates between persons aware and unaware of their infections. The authors defined program costs from the sexually transmitted disease clinic perspective and treatment costs and QALYs saved from the societal perspective. They undertook numerous sensitivity analyses to determine the robustness of the base case results. Results. In the base case, the cost per new HIV diagnosis was $2528, the cost per infection averted was $40,516, and the cost per QALY saved was less than zero, or cost-saving. Given the model inputs, the cost per new diagnosis could increase to $22,909 to reach the cost-saving threshold and to $63,053 for the cost-effectiveness threshold. All sensitivity analyses showed that the cost-effectiveness results were consistent for extensive variation in the values of model inputs. Conclusions. HIV screening in a clinical setting is cost-effective for a wide range of testing costs, variations in positivity rates, reductions in HIV transmissions, and variation in the receipt of test results. C1 [Farnham, Paul G.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Farnham, PG (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-48, Atlanta, GA 30333 USA. EM pgf1@cdc.gov NR 48 TC 14 Z9 14 U1 1 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X EI 1552-681X J9 MED DECIS MAKING JI Med. Decis. Mak. PD MAY-JUN PY 2012 VL 32 IS 3 BP 459 EP 469 DI 10.1177/0272989X11431609 PG 11 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 951ET UT WOS:000304704300009 PM 22247422 ER PT J AU Streicker, DG Lemey, P Velasco-Villa, A Rupprecht, CE AF Streicker, Daniel G. Lemey, Philippe Velasco-Villa, Andres Rupprecht, Charles E. TI Rates of Viral Evolution Are Linked to Host Geography in Bat Rabies SO PLOS PATHOGENS LA English DT Article ID RNA VIRUSES; DIVERSITY; SUBSTITUTION; PHYLOGENIES; INFLUENZA; INFECTION; DYNAMICS; ECOLOGY; LEVEL; MODES AB Rates of evolution span orders of magnitude among RNA viruses with important implications for viral transmission and emergence. Although the tempo of viral evolution is often ascribed to viral features such as mutation rates and transmission mode, these factors alone cannot explain variation among closely related viruses, where host biology might operate more strongly on viral evolution. Here, we analyzed sequence data from hundreds of rabies viruses collected from bats throughout the Americas to describe dramatic variation in the speed of rabies virus evolution when circulating in ecologically distinct reservoir species. Integration of ecological and genetic data through a comparative Bayesian analysis revealed that viral evolutionary rates were labile following historical jumps between bat species and nearly four times faster in tropical and subtropical bats compared to temperate species. The association between geography and viral evolution could not be explained by host metabolism, phylogeny or variable selection pressures, and instead appeared to be a consequence of reduced seasonality in bat activity and virus transmission associated with climate. Our results demonstrate a key role for host ecology in shaping the tempo of evolution in multi-host viruses and highlight the power of comparative phylogenetic methods to identify the host and environmental features that influence transmission dynamics. C1 [Streicker, Daniel G.] Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA. [Streicker, Daniel G.; Velasco-Villa, Andres; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Rabies Program, Atlanta, GA USA. [Lemey, Philippe] Katholieke Univ Leuven, Dept Microbiol & Immunol, Louvain, Belgium. RP Streicker, DG (reprint author), Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA. EM dstrike@uga.edu OI Streicker, Daniel/0000-0001-7475-2705 FU University of Georgia; National Science Foundation [DEB-1020966]; European Research Council under the European Community [278443, 260864] FX DGS was funded by a University of Georgia Dissertation Completion Award (http://www.grad.uga.edu/) and National Science Foundation Grant DEB-1020966 (http://www.nsf.gov/). The research leading to these results has received funding from the European Research Council under the European Community's Seventh Framework Programme (FP7/2007-2013) Grant agreements 278443 and 260864 (http://erc.europa.eu/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 33 Z9 33 U1 2 U2 33 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD MAY PY 2012 VL 8 IS 5 AR e1002720 DI 10.1371/journal.ppat.1002720 PG 9 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 959OS UT WOS:000305322900053 PM 22615575 ER PT J AU Horney, J Zotti, ME Williams, A Hsia, J AF Horney, Jennifer Zotti, Marianne E. Williams, Amy Hsia, Jason TI Cluster Sampling with Referral to Improve the Efficiency of Estimating Unmet Needs among Pregnant and Postpartum Women after Disasters SO WOMENS HEALTH ISSUES LA English DT Article AB Introduction and Background: Women of reproductive age, in particular women who are pregnant or fewer than 6 months postpartum, are uniquely vulnerable to the effects of natural disasters, which may create stressors for care-givers, limit access to prenatal/postpartum care, or interrupt contraception. Traditional approaches (e. g., newborn records, community surveys) to survey women of reproductive age about unmet needs may not be practical after disasters. Finding pregnant or postpartum women is especially challenging because fewer than 5% of women of reproductive age are pregnant or postpartum at any time. Methods: From 2009 to 2011, we conducted three pilots of a sampling strategy that aimed to increase the proportion of pregnant and postpartum women of reproductive age who were included in postdisaster reproductive health assessments in Johnston County, North Carolina, after tornadoes, Cobb/Douglas Counties, Georgia, after flooding, and Bertie County, North Carolina, after hurricane-related flooding. Results: Using this method, the percentage of pregnant and postpartum women interviewed in each pilot increased from 0.06% to 21%, 8% to 19%, and 9% to 17%, respectively. Conclusion and Discussion: Two-stage cluster sampling with referral can be used to increase the proportion of pregnant and postpartum women included in a postdisaster assessment. This strategy may be a promising way to assess unmet needs of pregnant and postpartum women in disaster-affected communities. Published by Elsevier Inc. C1 [Horney, Jennifer] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. [Zotti, Marianne E.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. [Williams, Amy] Ctr Dis Control & Prevent, Off Noncommunicable Dis Injury & Environm Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth,Appl Sci Branch, Atlanta, GA USA. [Hsia, Jason] Ctr Dis Control & Prevent, Off Noncommunicable Dis Injury & Environm Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth,Global Tobacco Control Branch, Atlanta, GA USA. RP Horney, J (reprint author), Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Campus Box 8165,400 Roberson, Chapel Hill, NC 27599 USA. EM jen.horney@unc.edu FU Intramural CDC HHS [CC999999] NR 18 TC 4 Z9 5 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAY-JUN PY 2012 VL 22 IS 3 BP E253 EP E257 DI 10.1016/j.whi.2012.01.002 PG 5 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA V33SR UT WOS:000209039000002 PM 22365134 ER PT J AU Pattamadilok, S Incomserb, P Primsirikunawut, A Lukebua, A Rota, PA Sawanpanyalert, P AF Pattamadilok, Sirima Incomserb, Patcha Primsirikunawut, Athiwat Lukebua, Atchariya Rota, Paul A. Sawanpanyalert, Pathom TI Genetic characterization of measles viruses that circulated in Thailand from 1998 to 2008 SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE measles; genotype ID MOLECULAR EPIDEMIOLOGY; UNITED-STATES; GENOTYPE; JAPAN; IDENTIFICATION; IMPORTATION; ELIMINATION; RUBELLA; CHINA; RNA AB During the period between 1998 and 2008, 48 representative measles viruses (MeVs) circulating in Thailand were subjected to genetic characterization. Three genotypes, G2, D5, and D9 were detected. The results suggested that measles genotype D5, which has been circulating since at least 1998, is the endemic genotype in Thailand. Genotype G2 was detected between 1998 and 2001. In addition, almost all of the MeVs detected throughout the country in 2008 were genotype D9. This is the first report of genotype D9 in Thailand. This report provides important baseline data about measles genotypes in Thailand and this information will be needed to help verify measles elimination in Thailand. J. Med. Virol. 84:804813, 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Pattamadilok, Sirima] Minist Publ Hlth, Natl Inst Hlth, Dept Med Sci, Neural & Circulatory Syst Virus Lab, Muang 11000, Nonthaburi, Thailand. [Rota, Paul A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Pattamadilok, S (reprint author), Minist Publ Hlth, Natl Inst Hlth, Dept Med Sci, Neural & Circulatory Syst Virus Lab, Tivanonda Rd, Muang 11000, Nonthaburi, Thailand. EM sirima.p@dmsc.mail.go.th FU WHO/HQ, Geneva, Switzerland FX We are grateful to Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health for collecting samples and information on cases. We would like to express our sincere thanks to Mr. David A. Featherstone, WHO/HQ, Geneva, Switzerland for financial support and guidance. Finally many thanks to staff of the Neural and Circulatory Virus Systems Laboratory, Department of Medical Sciences, Ministry of Public Health, Thailand. NR 37 TC 1 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0146-6615 J9 J MED VIROL JI J. Med. Virol. PD MAY PY 2012 VL 84 IS 5 BP 804 EP 813 DI 10.1002/jmv.23249 PG 10 WC Virology SC Virology GA 909MT UT WOS:000301569500013 PM 22431030 ER PT J AU Kancherla, V Amendah, DD Grosse, SD Yeargin-Allsopp, M Braun, KVN AF Kancherla, Vijaya Amendah, Djesika D. Grosse, Scott D. Yeargin-Allsopp, Marshalyn Braun, Kim Van Naarden TI Medical expenditures attributable to cerebral palsy and intellectual disability among Medicaid-enrolled children SO RESEARCH IN DEVELOPMENTAL DISABILITIES LA English DT Article DE Cost and cost analysis; Cerebral palsy; Delivery of health care; Intellectual disability; Health expenditures; Medicaid ID PRIVATELY INSURED POPULATION; HEALTH-CARE UTILIZATION; SICKLE-CELL-DISEASE; UNITED-STATES; PREVALENCE; COMORBIDITIES; EPIDEMIOLOGY; ILLNESS; PROGRAM; AUTISM AB This study estimated medical expenditures attributable to cerebral palsy (CP) among children enrolled in Medicaid, stratified by the presence of co-occurring intellectual disability (ID), relative to children without CP or ID. The MarketScan (R) Medicaid Multi-State database was used to identify children with CP for 2003-2005 by using the International Classification of Diseases, Ninth Revision: Clinical Modification (ICD-9-CM) code 343.xx. Children with ID were identified for 2005 by using ICD-9-CM code 317.xx-319.xx. Children without CP or ID during the same period served as control subjects. Medical expenditures were estimated for case and control children for 2005. The difference between the average expenditures for children with and without CP was used as a proxy for attributable expenditures for the condition. The attributable expenditures of co-occurring ID were calculated similarly as the difference in average expenditures among children with CP with and without ID. A total of 9927 children with CP were identified. Among them, 2022 (20.3%) children had co-occurring ID recorded in medical claims. Children with CP but without ID incurred medical expenditures that were $15,047 higher than those of control children without CP or ID. By contrast, children with CP and co-occurring ID incurred costs that were $41,664 higher, compared with control children, and $26,617 more than children with CP but without ID. Administrative data from a large, multistate database demonstrated high medical expenditures for publicly insured children with CP. Expenditures approximately tripled for children with CP and co-occurring ID. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Kancherla, Vijaya; Yeargin-Allsopp, Marshalyn; Braun, Kim Van Naarden] Ctr Dis Control & Prevent, Dev Disabil Branch, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Amendah, Djesika D.] African Populat & Hlth Res Ctr, Nairobi, Kenya. [Grosse, Scott D.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Kancherla, V (reprint author), Ctr Dis Control & Prevent, Dev Disabil Branch, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM VKancherla@cdc.gov RI Kancherla, Vijaya/K-3100-2012 NR 33 TC 15 Z9 15 U1 1 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0891-4222 J9 RES DEV DISABIL JI Res. Dev. Disabil. PD MAY-JUN PY 2012 VL 33 IS 3 BP 832 EP 840 DI 10.1016/j.ridd.2011.12.001 PG 9 WC Education, Special; Rehabilitation SC Education & Educational Research; Rehabilitation GA 902CH UT WOS:000301015700007 PM 22245730 ER PT J AU Khatib, RA Skarbinski, J Njau, JD Goodman, CA Elling, BF Kahigwa, E Roberts, JM MacArthur, JR Gutman, JR Kabanywanyi, AM Smith, EE Somi, MF Lyimo, T Mwita, A Genton, B Tanner, M Mills, A Mshinda, H Bloland, PB Abdulla, SM Kachur, SP AF Khatib, Rashid A. Skarbinski, Jacek Njau, Joseph D. Goodman, Catherine A. Elling, Berty F. Kahigwa, Elizeus Roberts, Jacquelin M. MacArthur, John R. Gutman, Julie R. Kabanywanyi, Abdunoor M. Smith, Ernest E. Somi, Masha F. Lyimo, Thomas Mwita, Alex Genton, Blaise Tanner, Marcel Mills, Anne Mshinda, Hassan Bloland, Peter B. Abdulla, Salim M. Kachur, S. Patrick TI Routine delivery of artemisinin-based combination treatment at fixed health facilities reduces malaria prevalence in Tanzania: an observational study SO MALARIA JOURNAL LA English DT Article DE Malaria; Artemisinin-based combination therapy; Transmission reduction; Malaria ID PLASMODIUM-FALCIPARUM MALARIA; INSECTICIDE-TREATED NETS; SULFADOXINE-PYRIMETHAMINE; RURAL TANZANIA; ARTEMETHER-LUMEFANTRINE; UNCOMPLICATED MALARIA; THERAPEUTIC-EFFICACY; HOUSEHOLD SURVEYS; TREATMENT POLICY; ARTESUNATE AB Background: Artemisinin-based combination therapy (ACT) has been promoted as a means to reduce malaria transmission due to their ability to kill both asexual blood stages of malaria parasites, which sustain infections over long periods and the immature derived sexual stages responsible for infecting mosquitoes and onward transmission. Early studies reported a temporal association between ACT introduction and reduced malaria transmission in a number of ecological settings. However, these reports have come from areas with low to moderate malaria transmission, been confounded by the presence of other interventions or environmental changes that may have reduced malaria transmission, and have not included a comparison group without ACT. This report presents results from the first large-scale observational study to assess the impact of case management with ACT on population-level measures of malaria endemicity in an area with intense transmission where the benefits of effective infection clearance might be compromised by frequent and repeated re-infection. Methods: A pre-post observational study with a non-randomized comparison group was conducted at two sites in Tanzania. Both sites used sulphadoxine-pyrimethamine (SP) monotherapy as a first-line anti-malarial from mid-2001 through 2002. In 2003, the ACT, artesunate (AS) co-administered with SP (AS + SP), was introduced in all fixed health facilities in the intervention site, including both public and registered non-governmental facilities. Population-level prevalence of Plasmodium falciparum asexual parasitaemia and gametocytaemia were assessed using light microscopy from samples collected during representative household surveys in 2001, 2002, 2004, 2005 and 2006. Findings: Among 37,309 observations included in the analysis, annual asexual parasitaemia prevalence in persons of all ages ranged from 11% to 28% and gametocytaemia prevalence ranged from <1% to 2% between the two sites and across the five survey years. A multivariable logistic regression model was fitted to adjust for age, socioeconomic status, bed net use and rainfall. In the presence of consistently high coverage and efficacy of SP monotherapy and AS + SP in the comparison and intervention areas, the introduction of ACT in the intervention site was associated with a modest reduction in the adjusted asexual parasitaemia prevalence of 5 percentage-points or 23% (p<0.0001) relative to the comparison site. Gametocytaemia prevalence did not differ significantly (p = 0.30). Interpretation: The introduction of ACT at fixed health facilities only modestly reduced asexual parasitaemia prevalence. ACT is effective for treatment of uncomplicated malaria and should have substantial public health impact on morbidity and mortality, but is unlikely to reduce malaria transmission substantially in much of sub-Saharan Africa where individuals are rapidly re-infected. C1 [Khatib, Rashid A.; Njau, Joseph D.; Elling, Berty F.; Kahigwa, Elizeus; Kabanywanyi, Abdunoor M.; Lyimo, Thomas; Abdulla, Salim M.; Kachur, S. Patrick] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Khatib, Rashid A.; Kabanywanyi, Abdunoor M.; Genton, Blaise; Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Skarbinski, Jacek; Roberts, Jacquelin M.; MacArthur, John R.; Gutman, Julie R.; Smith, Ernest E.; Bloland, Peter B.; Kachur, S. Patrick] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Njau, Joseph D.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Goodman, Catherine A.] Wellcome Trust Res Programme, Kenya Med Res Inst, Nairobi, Kenya. [Goodman, Catherine A.; Mills, Anne] London Sch Hyg & Trop Med, London WC1, England. [Elling, Berty F.] Karolinska Inst, Stockholm, Sweden. [Kahigwa, Elizeus] Swiss Dev Cooperat, Dar Es Salaam, Tanzania. [Somi, Masha F.] Australian Natl Univ, Australian Ctr Econ Res Hlth, Canberra, ACT, Australia. [Mwita, Alex] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania. [Mshinda, Hassan] Tanzania Commiss Sci & Technol, Dar Es Salaam, Tanzania. RP Khatib, RA (reprint author), Ifakara Hlth Inst, Dar Es Salaam, Tanzania. EM rkhatib@ihi.or.tz OI Mills, Anne/0000-0001-9863-9950 FU CDC; U.S. Agency for International Development; Wellcome TrustUnited States Centers for Disease Control and Prevention; United States Agency for International Development FX The Interdisciplinary Monitoring Project for Antimalarial Combination Therapy in Tanzania (IMPACT-Tz) operated from 2000-2006 as a collaborative implementation research platform resting on: Ifakara Health Institute, U.S. Centers for Disease Control and Prevention (CDC), London School of Hygiene and Tropical Medicine, and the Ministry of Health and Social Welfare including its National Malaria Control Programme, the Tanzania Essential Health Interventions Project and the Council Health Management Teams of Kilombero, Rufiji, and Ulanga Districts. Financial support for IMPACT-Tz came primarily from CDC, the U.S. Agency for International Development and the Wellcome Trust. The authors wish to thank the many investigators, data collectors and field supervisors who contributed to the collection and analyses of these data including: Baraka Amuri, Katia Bruxvoort, Jensen Charles, Bakari Kissa, Chrisostom Mahutanga, John Malugu, Honorati Masanja, Meredith McMorrow, Yahya Mkilindi, Agostino Mahundi, Eleuther Mwageni, Rose Nathan, Daniel Okenu, and John Wigayi. We also wish to acknowledge Tanzania Meteorological Agency for the rainfall data from the study area. We are especially grateful for the contributions of the Ministry of Health including the National Malaria Control Programme and the Council Health Management Teams of Rufiji, Kilombero and Ulanga Districts. Finally, we wish to acknowledge the community members who participated in or otherwise contributed to these studies. This manuscript is published with permission from Dr. Mwele Malecela, Director-General, National Institute for Medical Research. Funding from United States Centers for Disease Control and Prevention and United States Agency for International Development. NR 50 TC 18 Z9 18 U1 2 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD APR 30 PY 2012 VL 11 AR 140 DI 10.1186/1475-2875-11-140 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 058SA UT WOS:000312653100001 PM 22545573 ER PT J AU Riley, PL Zuber, A Vindigni, SM Gupta, N Verani, AR Sunderland, NL Friedman, M Zurn, P Okoro, C Patrick, H Campbell, J AF Riley, Patricia L. Zuber, Alexandra Vindigni, Stephen M. Gupta, Neeru Verani, Andre R. Sunderland, Nadine L. Friedman, Michael Zurn, Pascal Okoro, Chijioke Patrick, Heather Campbell, James TI Information systems on human resources for health: a global review SO HUMAN RESOURCES FOR HEALTH LA English DT Review DE Human resources information system; HRIS; Human resources for health; Literature review; Workforce surveillance; Workforce science; Global health AB Background: Although attainment of the health-related Millennium Development Goals relies on countries having adequate numbers of human resources for health (HRH) and their appropriate distribution, global understanding of the systems used to generate information for monitoring HRH stock and flows, known as human resources information systems (HRIS), is minimal. While HRIS are increasingly recognized as integral to health system performance assessment, baseline information regarding their scope and capability around the world has been limited. We conducted a review of the available literature on HRIS implementation processes in order to draw this baseline. Methods: Our systematic search initially retrieved 11 923 articles in four languages published in peer-reviewed and grey literature. Following the selection of those articles which detailed HRIS implementation processes, reviews of their contents were conducted using two-person teams, each assigned to a national system. A data abstraction tool was developed and used to facilitate objective assessment. Results: Ninety-five articles with relevant HRIS information were reviewed, mostly from the grey literature, which comprised 84 % of all documents. The articles represented 63 national HRIS and two regionally integrated systems. Whereas a high percentage of countries reported the capability to generate workforce supply and deployment data, few systems were documented as being used for HRH planning and decision-making. Of the systems examined, only 23 % explicitly stated they collect data on workforce attrition. The majority of countries experiencing crisis levels of HRH shortages (56 %) did not report data on health worker qualifications or professional credentialing as part of their HRIS. Conclusion: Although HRIS are critical for evidence-based human resource policy and practice, there is a dearth of information about these systems, including their current capabilities. The absence of standardized HRIS profiles (including documented processes for data collection, management, and use) limits understanding of the availability and quality of information that can be used to support effective and efficient HRH strategies and investments at the national, regional, and global levels. C1 [Riley, Patricia L.; Zuber, Alexandra; Verani, Andre R.; Sunderland, Nadine L.; Friedman, Michael; Okoro, Chijioke; Patrick, Heather] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Vindigni, Stephen M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Vindigni, Stephen M.] Univ Washington, Sch Med, Seattle, WA USA. [Gupta, Neeru; Zurn, Pascal] World Hlth Org, Dept Human Resources Hlth, Geneva, Switzerland. [Campbell, James] Inst Cooperac Social Integrare, Barcelona, Spain. RP Riley, PL (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, 1600 Clifton Rd,MS-E41, Atlanta, GA 30333 USA. EM pyr0@cdc.gov NR 27 TC 12 Z9 12 U1 3 U2 35 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-4491 J9 HUM RESOUR HEALTH JI Hum. Resour. Health PD APR 30 PY 2012 VL 10 AR 7 DI 10.1186/1478-4491-10-7 PG 12 WC Health Policy & Services; Industrial Relations & Labor SC Health Care Sciences & Services; Business & Economics GA 001MB UT WOS:000308463700001 PM 22546089 ER PT J AU Bateman, BT Shaw, KM Kuklina, EV Callaghan, WM Seely, EW Hernandez-Diaz, S AF Bateman, Brian T. Shaw, Kate M. Kuklina, Elena V. Callaghan, William M. Seely, Ellen W. Hernandez-Diaz, Sonia TI Hypertension in Women of Reproductive Age in the United States: NHANES 1999-2008 SO PLOS ONE LA English DT Article ID ANTIHYPERTENSIVE MEDICATION USE; MAJOR CONGENITAL-MALFORMATIONS; RISK-FACTORS; CHILDBEARING AGE; EARLY-PREGNANCY; PREVALENCE; DISPARITIES; TRENDS; US; DISORDERS AB Objective: To examine the epidemiology of hypertension in women of reproductive age. Methods: Using NHANES from 1999-2008, we identified 5,521 women age 20-44 years old. Hypertension status was determined using blood pressure measurements and/or self-reported medication use. Results: The estimated prevalence of hypertension in women of reproductive age was 7.7% (95% confidence interval (CI): 6.9%-8.5%). The prevalence of anti-hypertensive pharmacologic therapy was 4.2% (95% CI 3.5%-4.9%). The prevalence of hypertension was relatively stable across the study period; the age and race adjusted odds of hypertension in 2007-2008 did not differ significantly from 1999-2000 (odds ratio 1.2, CI 0.8 to 1.7, p = 0.45). Significant independent risk factors associated with hypertension included older age, non-Hispanic black race (compared to non-Hispanic whites), diabetes mellitus, chronic kidney disease, and higher body mass index. The most commonly used antihypertensive medications included diuretics, angiotensin-converting enzyme inhibitors (ACE), and beta blockers. Conclusion: Hypertension occurs in about 8% of women of reproductive age. There are remarkable differences in the prevalence of hypertension between racial/ethnic groups. Obesity is a risk factor of particular importance in this population because it affects over 30% of young women in the U. S., is associated with more than 4 fold increased risk of hypertension, and is potentially modifiable. C1 [Bateman, Brian T.] Harvard Univ, Massachusetts Gen Hosp, Div Obstet Anesthesia, Sch Med,Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA. [Shaw, Kate M.; Kuklina, Elena V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Seely, Ellen W.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA. [Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Bateman, BT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Div Obstet Anesthesia, Sch Med,Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA. EM BBateman@partners.org FU National Institutes of Health [GM007592] FX This work was supported by National Institutes of Health T32 training grant GM007592 (BTB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 23 Z9 24 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 30 PY 2012 VL 7 IS 4 AR e36171 DI 10.1371/journal.pone.0036171 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 959UL UT WOS:000305340200047 PM 22558371 ER PT J AU Djingarey, MH Barry, R Bonkoungou, M Tiendrebeogo, S Sebgo, R Kandolo, D Lingani, C Preziosi, MP Zuber, PLF Perea, W Hugonnet, S Tolve, NDD Tevi-Benissan, C Clark, TA Mayer, LW Novak, R Messonier, NE Berlier, M Toboe, D Nshimirimana, D Mihigo, R Aguado, T Diomande, F Kristiansen, PA Caugant, DA LaForce, FM AF Djingarey, Mamoudou H. Barry, Rodrigue Bonkoungou, Mete Tiendrebeogo, Sylvestre Sebgo, Rene Kandolo, Denis Lingani, Clement Preziosi, Marie-Pierre Zuber, Patrick L. F. Perea, William Hugonnet, Stephane Tolve, Nora Dellepiane de Rey Tevi-Benissan, Carole Clark, Thomas A. Mayer, Leonard W. Novak, Ryan Messonier, Nancy E. Berlier, Monique Toboe, Desire Nshimirimana, Deo Mihigo, Richard Aguado, Teresa Diomande, Fabien Kristiansen, Paul A. Caugant, Dominique A. LaForce, F. Marc TI Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience SO VACCINE LA English DT Article DE Africa; Meningitis epidemics; Burkina Faso; Mass immunization campaigns; Vaccine introduction; Communication and social mobilization; Meningococcal A conjugate vaccine ID REAL-TIME PCR; MENINGITIS AB A new Group A meningococcal (Men A) conjugate vaccine, MenAfriVac (TM), was prequalified by the World Health Organization (WHO) in June 2010. Because Burkina Faso has repeatedly suffered meningitis epidemics due to Group A Neisseria meningitidis special efforts were made to conduct a country-wide campaign with the new vaccine in late 2010 and before the onset of the next epidemic meningococcal disease season beginning in January 2011. In the ensuing five months (July-November 2010) the following challenges were successfully managed: (1) doing a large safety study and registering the new vaccine in Burkina Faso; (2) developing a comprehensive communication plan; (3) strengthening the surveillance system with particular attention to improving the capacity for real-time polymerase chain reaction (PCR) testing of spinal fluid specimens; (4) improving cold chain capacity and waste disposal; (5) developing and funding a sound campaign strategy; and (6) ensuring effective collaboration across all partners. Each of these issues required specific strategies that were managed through a WHO-led consortium that included all major partners (Ministry of Health/Burkina Faso, Serum Institute of India Ltd., UNICEF, Global Alliance for Vaccines and Immunization, Meningitis Vaccine Project, CDC/Atlanta, and the Norwegian Institute of Public Health/Oslo). Biweekly teleconferences that were led by WHO ensured that problems were identified in a timely fashion. The new meningococcal A conjugate vaccine was introduced on December 6, 2010, in a national ceremony led by His Excellency Blaise Compaore, the President of Burkina Faso. The ensuing 10-day national campaign was hugely successful, and over 11.4 million Burkinabes between the ages of 1 and 29 years (100% of target population) were vaccinated. African national immunization programs are capable of achieving very high coverage for a vaccine desired by the public, introduced in a well-organized campaign, and supported at the highest political level. The Burkina Faso success augurs well for further rollout of the Men A conjugate vaccine in meningitis belt countries. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Djingarey, Mamoudou H.; Barry, Rodrigue; Kandolo, Denis; Lingani, Clement; Toboe, Desire; Diomande, Fabien] WHO Intercountry Support Team, Ouagadougou, Burkina Faso. [Preziosi, Marie-Pierre; Zuber, Patrick L. F.; Perea, William; Hugonnet, Stephane; Tolve, Nora Dellepiane de Rey; Tevi-Benissan, Carole; Aguado, Teresa] WHO HQ, Geneva, Switzerland. [Clark, Thomas A.; Mayer, Leonard W.; Novak, Ryan; Messonier, Nancy E.; Diomande, Fabien] CDC, Atlanta, GA 30333 USA. [Preziosi, Marie-Pierre; Berlier, Monique; LaForce, F. Marc] PATH, Meningitis Vaccine Project, Washington, DC 20001 USA. [Preziosi, Marie-Pierre; Berlier, Monique; LaForce, F. Marc] PATH, Meningitis Vaccine Project, Ferney Voltaire, France. [Nshimirimana, Deo; Mihigo, Richard] WHO AFRO, Brazzaville, Congo. [Kristiansen, Paul A.; Caugant, Dominique A.] Norwegian Inst Publ Hlth, Oslo, Norway. RP LaForce, FM (reprint author), PATH, Meningitis Vaccine Project, 455 Massachusetts Ave NW, Washington, DC 20001 USA. EM fmlaforce@path.org NR 18 TC 52 Z9 53 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 30 PY 2012 VL 30 SU 2 BP B40 EP B45 DI 10.1016/j.vaccine.2011.12.073 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 956SP UT WOS:000305109700007 PM 22607898 ER PT J AU Abdulla, S Alonso, P Binka, F Graves, P Greenwood, B Leke, R Malik, E Marsh, K Meek, S Mendis, K Schapira, A Slutsker, L Tanner, M Valecha, N White, N Bosman, A Cibulskis, R d'Acremont, V Cunningham, J D'Souza, B Lines, J Mnzava, A Newman, R Rietveld, A Olemese, P Rietveld, A Ringwald, P AF Abdulla, Salim Alonso, Pedro Binka, Fred Graves, Patricia Greenwood, Brian Leke, Rose Malik, Elfatih Marsh, Kevin Meek, Sylvia Mendis, Kamini Schapira, Allan Slutsker, Larry Tanner, Marcel Valecha, Neena White, Nicholas Bosman, Andrea Cibulskis, Richard d'Acremont, Valerie Cunningham, Jane D'Souza, Bianca Lines, Jo Mnzava, Abraham Newman, Robert Rietveld, Aafje Olemese, Peter Rietveld, Aafje Ringwald, Pascal CA WHO Malaria Policy Advisory WHO Malaria Policy Advisory TI Inaugural meeting of the malaria policy advisory committee to the WHO: conclusions and recommendations SO MALARIA JOURNAL LA English DT Article DE Global; Malaria; Policy development; WHO; Drug resistance; Diagnostic tests; Mosquito control; Elimination; Surveillance; Chemoprevention AB The Malaria Policy Advisory Committee to the World Health Organization met for the first time from 31 January to 2 February 2012 in Geneva, Switzerland. This article provides a summary of the discussions, conclusions and recommendations from that meeting, as part of the newly launched Malaria Journal thematic series "WHO Malaria Policy Advisory Committee: Reports and Recommendations". Summaries are provided, referencing the relevant background documents, for the meeting sessions on global malaria control, drug resistance and containment, rapid diagnostic test procurement criteria, larviciding, classification of countries for elimination, estimating malaria cases and deaths, and seasonal malaria chemoprevention. Policy statements, position statements, and guidelines that will arise from the MPAC meeting conclusions and recommendations will be formally issued and disseminated to World Health Organization member states by the World Health Organization Global Malaria Programme. C1 [Bosman, Andrea; Cibulskis, Richard; d'Acremont, Valerie; D'Souza, Bianca; Lines, Jo; Mnzava, Abraham; Newman, Robert; Rietveld, Aafje; Olemese, Peter; Rietveld, Aafje; Ringwald, Pascal; WHO Malaria Policy Advisory; WHO Malaria Policy Advisory] WHO, Global Malaria Programme, CH-1211 Geneva 27, Switzerland. [Abdulla, Salim] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Alonso, Pedro] Ctr Int Hlth & Res, Barcelona, Spain. [Binka, Fred] Univ Ghana, Accra, Ghana. [Graves, Patricia] James Cook Univ, Cairns, Australia. [Greenwood, Brian; D'Souza, Bianca; Lines, Jo; Mnzava, Abraham] London Sch Hyg & Trop Med, London WC1, England. [Leke, Rose] Univ Yaounde, Yaounde, Cameroon. [Malik, Elfatih] Minist Hlth, Gezira, Sudan. [Marsh, Kevin] Kenya Govt Med Res Ctr, Kilifi, Kenya. [Meek, Sylvia] Malaria Consortium, London, England. [Slutsker, Larry] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tanner, Marcel] Swiss Trop Publ Hlth Inst, Basel, Switzerland. [Valecha, Neena] Natl Inst Malaria Res, New Delhi, India. [White, Nicholas] Mahidol Univ, Bangkok 10700, Thailand. [Cunningham, Jane] WHO, Special Programme Res & Training Trop Dis TDR, CH-1211 Geneva 27, Switzerland. RP Abdulla, S (reprint author), WHO, Global Malaria Programme, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. EM newmanr@who.int FU Bill & Melinda Gates Foundation FX The authors gratefully acknowledge the hard work of the many people who contributed to the background documents and other preparations for the inaugural MPAC meeting: WHO Global Malaria Programme staff, WHO staff from other departments, in particular the Special Programme for Research and Training in Tropical Diseases (TDR) and Immunization, Vaccines and Biologicals (IVB), vector control experts who participated in the larviciding interim position statement consultation, members of the TEG on chemotherapy, and the IPTc Taskforce. The authors also thank all the MPAC meeting participants and observers for their contributions during the meeting discussions. The inaugural MPAC meeting was supported in part by a grant from the Bill & Melinda Gates Foundation to the WHO Global Malaria Programme. NR 11 TC 0 Z9 0 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD APR 30 PY 2012 VL 11 AR 137 DI 10.1186/1475-2875-11-137 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 952AF UT WOS:000304761400001 ER PT J AU Feng, YY Karna, SR Dearen, TK Singh, DK Adhikari, LN Shrestha, A Xiao, LH AF Feng, Yaoyu Karna, Sandeep Raj Dearen, Theresa K. Singh, Dinesh Kumar Adhikari, Lekh Nath Shrestha, Aruna Xiao, Lihua TI Common occurrence of a unique Cryptosporidium ryanae variant in zebu cattle and water buffaloes in the buffer zone of the Chitwan National Park, Nepal SO VETERINARY PARASITOLOGY LA English DT Article DE Cryptosporidium; Molecular epidemiology; Cattle; Buffalo; Nepal; Zoonosis ID DEER-LIKE GENOTYPE; EASTERN UNITED-STATES; MOLECULAR CHARACTERIZATION; DAIRY-CATTLE; BUBALUS-BUBALIS; ZOONOTIC TRANSMISSION; GIARDIA-DUODENALIS; 1ST REPORT; PREVALENCE; CALVES AB There are very few studies on the diversity and public health significance of Cryptosporidium species in zebu cattle and water buffaloes in developing countries. In this study, PCR-restriction fragment length polymorphism and DNA sequence analyses of the small-subunit (SSU) rRNA gene were used to genotype Cryptosporidium specimens from 12 zebu cattle calves, 16 water buffalo calves, and four swamp deer (Cervus duvaucelii) collected from the buffer zone of the Chitwan National Park, Nepal. All Cryptosporidium specimens from cattle and buffaloes belonged to Cryptosporidium ryanae, whereas those from deer belonged to Cryptosporidium ubiquitum. Comparison of the SSU rRNA gene sequences obtained with those from earlier studies has identified a nucleotide substitution unique to all C. ryanae isolates from Nepal, in addition to some sequence heterogeneity among different copies of the gene. The finding of the dominance of a unique C ryanae variant in both zebu cattle and water buffaloes in Nepal indicates that there is unique cryptosporidiosis transmission in bovine animals in the study area, and cross-species transmission of some Cryptosporidium spp. can occur between related animal species sharing the same habitats. Published by Elsevier B.V. C1 [Dearen, Theresa K.; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. [Feng, Yaoyu] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, Lanhou, Peoples R China. [Feng, Yaoyu] E China Univ Sci & Technol, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China. [Karna, Sandeep Raj; Singh, Dinesh Kumar; Adhikari, Lekh Nath; Shrestha, Aruna] Inst Agr & Anim Sci, Rampur, Nepal. RP Xiao, LH (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. EM lxiao@cdc.gov RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU State Key Laboratory of Veterinary Etiological Biology, Lanzhou, China FX This work was supported by Open Funding Project of the State Key Laboratory of Veterinary Etiological Biology, Lanzhou, China. NR 44 TC 24 Z9 26 U1 0 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-4017 J9 VET PARASITOL JI Vet. Parasitol. PD APR 30 PY 2012 VL 185 IS 2-4 BP 309 EP 314 DI 10.1016/j.vetpar.2011.09.025 PG 6 WC Parasitology; Veterinary Sciences SC Parasitology; Veterinary Sciences GA 926OC UT WOS:000302839700039 PM 21996006 ER PT J AU Amek, N Bayoh, N Hamel, M Lindblade, KA Gimnig, JE Odhiambo, F Laserson, KF Slutsker, L Smith, T Vounatsou, P AF Amek, Nyaguara Bayoh, Nabie Hamel, Mary Lindblade, Kim A. Gimnig, John E. Odhiambo, Frank Laserson, Kayla F. Slutsker, Laurence Smith, Thomas Vounatsou, Penelope TI Spatial and temporal dynamics of malaria transmission in rural Western Kenya SO PARASITES & VECTORS LA English DT Article ID TREATED BED NETS; ENTOMOLOGIC INOCULATION RATES; ANOPHELES-GAMBIAE; MODEL; MORTALITY; VECTORS; VILLAGE; AFRICA; IDENTIFICATION; SEASONALITY AB Background: Understanding the relationship between Plasmodium falciparum malaria transmission and health outcomes requires accurate estimates of exposure to infectious mosquitoes. However, measures of exposure such as mosquito density and entomological inoculation rate (EIR) are generally aggregated over large areas and time periods, biasing the outcome-exposure relationship. There are few studies examining the extent and drivers of local variation in malaria exposure in endemic areas. Methods: We describe the spatio-temporal dynamics of malaria transmission intensity measured by mosquito density and EIR in the KEMRI/CDC health and demographic surveillance system using entomological data collected during 2002-2004. Geostatistical zero inflated binomial and negative binomial models were applied to obtain location specific (house) estimates of sporozoite rates and mosquito densities respectively. Model-based predictions were multiplied to estimate the spatial pattern of annual entomological inoculation rate, a measure of the number of infective bites a person receive per unit of time. The models included environmental and climatic predictors extracted from satellite data, harmonic seasonal trends and parameters describing space-time correlation. Results: Anopheles gambiae s.l was the main vector species accounting for 86 % (n = 2309) of the total mosquitoes collected with the remainder being Anopheles funestus. Sixty eight percent (757/1110) of the surveyed houses had no mosquitoes. Distance to water bodies, vegetation and day temperature were strongly associated with mosquito density. Overall annual point estimates of EIR were 6.7, 9.3 and 9.6 infectious bites per annum for 2002, 2003 and 2004 respectively. Monthly mosquito density and EIR varied over the study period peaking in May during the wet season each year. The predicted and observed densities of mosquitoes and EIR showed a strong seasonal and spatial pattern over the study area. Conclusions: Spatio-temporal maps of malaria transmission intensity obtained in this study are not only useful in understanding variability in malaria epidemiology over small areas but also provide a high resolution exposure surface that can be used to analyse the impact of transmission on malaria related and all-cause morbidity and mortality. C1 [Vounatsou, Penelope] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth EPH, CH-4002 Basel, Switzerland. [Amek, Nyaguara; Smith, Thomas; Vounatsou, Penelope] Univ Basel, Basel, Switzerland. [Amek, Nyaguara; Bayoh, Nabie; Hamel, Mary; Odhiambo, Frank; Laserson, Kayla F.] Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent CDC, Res & Publ Hlth Collaborat, Kisumu, Kenya. [Hamel, Mary; Lindblade, Kim A.; Gimnig, John E.; Slutsker, Laurence] Ctr Dis Control & Prevent, Atlanta, GA 30301 USA. RP Vounatsou, P (reprint author), Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth EPH, Socinstr 57, CH-4002 Basel, Switzerland. EM Penelope.Vounatsou@unibas.ch RI Smith, Thomas/B-5569-2015 OI Smith, Thomas/0000-0002-3650-9381 FU Swiss National Science Foundation [325200_118379]; Swiss-South African Joint Research Program [JRPIZLSZ3_122926] FX We are grateful to the KEMRI/CDC HDSS for providing the entomological data and to the MTIMBA principal investigators for conceiving the project. The analysis of the data was supported partly by Swiss National Science Foundation (Project Nr. 325200_118379) and a Swiss-South African Joint Research Program (Project No. JRPIZLSZ3_122926). The KEMRI/CDC HDSS is a member of the INDEPTH network. NR 34 TC 19 Z9 19 U1 0 U2 16 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD APR 28 PY 2012 VL 5 AR 86 DI 10.1186/1756-3305-5-86 PG 13 WC Parasitology SC Parasitology GA 993CB UT WOS:000307831000001 PM 22541138 ER PT J AU Catalano, RF Fagan, AA Gavin, LE Greenberg, MT Irwin, CE Ross, DA Shek, DTL AF Catalano, Richard F. Fagan, Abigail A. Gavin, Loretta E. Greenberg, Mark T. Irwin, Charles E., Jr. Ross, David A. Shek, Daniel T. L. TI Adolescent Health 3 Worldwide application of prevention science in adolescent health SO LANCET LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; MIDDLE-INCOME COUNTRIES; SOCIAL-DEVELOPMENT INTERVENTION; EARLY-CHILDHOOD INTERVENTION; COMPUTER-BASED INTERVENTION; NURSE HOME VISITATION; GROWTH CURVE ANALYSES; 15-YEAR FOLLOW-UP; PAST BASE-LINE; SUBSTANCE USE AB The burden of morbidity and mortality from non-communicable disease has risen worldwide and is accelerating in low-income and middle-income countries, whereas the burden from infectious diseases has declined. Since this transition, the prevention of non-communicable disease as well as communicable disease causes of adolescent mortality has risen in importance. Problem behaviours that increase the short-term or long-term likelihood of morbidity and mortality, including alcohol, tobacco, and other drug misuse, mental health problems, unsafe sex, risky and unsafe driving, and violence are largely preventable. In the past 30 years new discoveries have led to prevention science being established as a discipline designed to mitigate these problem behaviours. Longitudinal studies have provided an understanding of risk and protective factors across the life course for many of these problem behaviours. Risks cluster across development to produce early accumulation of risk in childhood and more pervasive risk in adolescence. This understanding has led to the construction of developmentally appropriate prevention policies and programmes that have shown short-term and long-term reductions in these adolescent problem behaviours. We describe the principles of prevention science, provide examples of efficacious preventive interventions, describe challenges and potential solutions to take efficacious prevention policies and programmes to scale, and conclude with recommendations to reduce the burden of adolescent mortality and morbidity worldwide through preventive intervention. C1 [Catalano, Richard F.] Univ Washington, Sch Social Work, Social Dev Res Grp, Seattle, WA 98195 USA. [Fagan, Abigail A.] Univ S Carolina, Dept Criminol & Criminal Justice, Columbia, SC 29208 USA. [Gavin, Loretta E.] US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Greenberg, Mark T.] Penn State Univ, Prevent Res Ctr, University Pk, PA 16802 USA. [Irwin, Charles E., Jr.] Univ Calif San Francisco, Dept Pediat, Div Adolescent Med, San Francisco, CA USA. [Ross, David A.] London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, Infect Dis Epidemiol Dept, London WC1, England. [Shek, Daniel T. L.] Hong Kong Polytech Univ, Dept Appl Social Sci, Hunghom, Hong Kong, Peoples R China. RP Catalano, RF (reprint author), Univ Washington, Sch Social Work, Social Dev Res Grp, 9725 3rd Ave NE,Suite 401, Seattle, WA 98195 USA. EM catalano@uw.edu RI Shek, Daniel/N-9576-2014 OI Shek, Daniel/0000-0003-3359-6229 FU Intramural CDC HHS [CC999999] NR 115 TC 140 Z9 140 U1 7 U2 56 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD APR 28 PY 2012 VL 379 IS 9826 BP 1653 EP 1664 DI 10.1016/S0140-6736(12)60238-4 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 934OB UT WOS:000303452600039 PM 22538180 ER PT J AU Grimsby, JL Porneala, BC Vassy, JL Yang, QH Florez, JC Dupuis, J Liu, TB Yesupriya, A Chang, MH Ned, RM Dowling, NF Khoury, MJ Meigs, JB AF Grimsby, Jonna L. Porneala, Bianca C. Vassy, Jason L. Yang, Quanhe Florez, Jose C. Dupuis, Josee Liu, Tiebin Yesupriya, Ajay Chang, Man-Huei Ned, Renee M. Dowling, Nicole F. Khoury, Muin J. Meigs, James B. CA MAGIC Investigators TI Race-ethnic differences in the association of genetic loci with HbA(1c) levels and mortality in US adults: the third National Health and Nutrition Examination Survey (NHANES III) SO BMC MEDICAL GENETICS LA English DT Article ID IRON-DEFICIENCY ANEMIA; HISPANIC WHITE ADULTS; HEMOGLOBIN A(1C); CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; HUMAN GENOME; GLYCATED HEMOGLOBIN; RACIAL-DIFFERENCES; PLASMA-GLUCOSE; A1C LEVELS AB Background: Hemoglobin A(1c) (HbA(1c)) levels diagnose diabetes, predict mortality and are associated with ten single nucleotide polymorphisms (SNPs) in white individuals. Genetic associations in other race groups are not known. We tested the hypotheses that there is race-ethnic variation in 1) HbA(1c)-associated risk allele frequencies (RAFs) for SNPs near SPTA1, HFE, ANK1, HK1, ATP11A, FN3K, TMPRSS6, G6PC2, GCK, MTNR1B; 2) association of SNPs with HbA(1c) and 3) association of SNPs with mortality. Methods: We studied 3,041 non-diabetic individuals in the NHANES (National Health and Nutrition Examination Survey) III. We stratified the analysis by race/ethnicity (NHW: non-Hispanic white; NHB: non-Hispanic black; MA: Mexican American) to calculate RAF, calculated a genotype score by adding risk SNPs, and tested associations with SNPs and the genotype score using an additive genetic model, with type 1 error = 0.05. Results: RAFs varied widely and at six loci race-ethnic differences in RAF were significant (p < 0.0002), with NHB usually the most divergent. For instance, at ATP11A, the SNP RAF was 54% in NHB, 18% in MA and 14% in NHW (p < .0001). The mean genotype score differed by race-ethnicity (NHW: 10.4, NHB: 11.0, MA: 10.7, p < .0001), and was associated with increase in HbA(1c) in NHW (beta = 0.012 HbA(1c) increase per risk allele, p = 0.04) and MA (beta = 0.021, p = 0.005) but not NHB (beta = 0.007, p = 0.39). The genotype score was not associated with mortality in any group (NHW: OR (per risk allele increase in mortality) = 1.07, p = 0.09; NHB: OR = 1.04, p = 0.39; MA: OR = 1.03, p = 0.71). Conclusion: At many HbA(1c) loci in NHANES III there is substantial RAF race-ethnic heterogeneity. The combined impact of common HbA(1c)-associated variants on HbA(1c) levels varied by race-ethnicity, but did not influence mortality. C1 [Grimsby, Jonna L.; Porneala, Bianca C.; Vassy, Jason L.; Florez, Jose C.; Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Grimsby, Jonna L.; Vassy, Jason L.; Florez, Jose C.; Meigs, James B.] Harvard Univ, Sch Med, Boston, MA USA. [Yang, Quanhe; Yesupriya, Ajay; Chang, Man-Huei; Ned, Renee M.; Dowling, Nicole F.; Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Florez, Jose C.] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA. [Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Florez, Jose C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Dupuis, Josee] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Dupuis, Josee] NHLBI, Framingham Heart Study, Framingham, MA USA. RP Meigs, JB (reprint author), Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. EM jmeigs@partners.org OI Dupuis, Josee/0000-0003-2871-3603 FU American Diabetes Association Mentored Post-Doctoral Fellowship Award; National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) [R01 DK078616]; NIDDK [K24 DK080140]; NIDDK Research Career Award [K23 DK65978]; Massachusetts General Hospital Physician Scientist Development Award; Doris Duke Charitable Foundation Clinical Scientist Development Award FX The data are from the NHANES III Public Use and Genetic Data Sets (http://www.cdc.gov/nchs/nhanes/genetics/genetic.htm). Supported by an American Diabetes Association Mentored Post-Doctoral Fellowship Award (Dr. Grimsby), National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK078616 (Dr Meigs), NIDDK K24 DK080140 (Dr Meigs), NIDDK Research Career Award K23 DK65978 (Dr Florez), a Massachusetts General Hospital Physician Scientist Development Award, and a Doris Duke Charitable Foundation Clinical Scientist Development Award (Dr Florez). The MAGIC Investigators are listed in the on-line supplement. We thank Sekar Kathiresan MD, for assistance in obtaining the NHANES III DNA that we used for genotyping, and Peter Shrader MS for analytic assistance. NR 56 TC 17 Z9 18 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2350 J9 BMC MED GENET JI BMC Med. Genet. PD APR 27 PY 2012 VL 13 AR 30 DI 10.1186/1471-2350-13-30 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 000GA UT WOS:000308373300001 PM 22540250 ER PT J AU Iriemenam, NC Shah, M Gatei, W van Eijk, AM Ayisi, J Kariuki, S Vanden Eng, J Owino, SO Lal, AA Omosun, YO Otieno, K Desai, M ter Kuile, FO Nahlen, B Moore, J Hamel, MJ Ouma, P Slutsker, L Shi, YP AF Iriemenam, Nnaemeka C. Shah, Monica Gatei, Wangeci van Eijk, Anna M. Ayisi, John Kariuki, Simon Vanden Eng, Jodi Owino, Simon O. Lal, Ashima A. Omosun, Yusuf O. Otieno, Kephas Desai, Meghna ter Kuile, Feiko O. Nahlen, Bernard Moore, Julie Hamel, Mary J. Ouma, Peter Slutsker, Laurence Shi, Ya Ping TI Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya SO MALARIA JOURNAL LA English DT Article DE Malaria in pregnancy; SP resistance; Kenya; dhfr; dhps ID INTERMITTENT PREVENTIVE TREATMENT; TREATED BED NETS; DIHYDROFOLATE-REDUCTASE; DIHYDROPTEROATE SYNTHASE; MALARIA PREVENTION; COMPETITIVE RELEASE; PLACENTAL MALARIA; NORTHERN TANZANIA; CONTROLLED-TRIAL; POINT MUTATION AB Background: Resistance to sulphadoxine-pyrimethamine (SP) in Plasmodium falciparum parasites is associated with mutations in the dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) genes and has spread worldwide. SP remains the recommended drug for intermittent preventive treatment for malaria in pregnancy (IPTp) and information on population prevalence of the SP resistance molecular markers in pregnant women is limited. Methods: Temporal trends of SP resistance molecular markers were investigated in 489 parasite samples collected from pregnant women at delivery from three different observational studies between 1996 and 2009 in Kenya, where SP was adopted for both IPTp and case treatment policies in 1998. Using real-time polymerase chain reaction, pyrosequencing and direct sequencing, 10 single-nucleotide polymorphisms (SNPs) of SP resistance molecular markers were assayed. Results: The prevalence of quintuple mutant (dhfr N51I/C59R/S108N and dhps A437G/K540E combined genotype) increased from 7 % in the first study (1996-2000) to 88 % in the third study (2008-2009). When further stratified by sample collection year and adoption of IPTp policy, the prevalence of the quintuple mutant increased from 2.4 % in 1998 to 44.4 % three years after IPTp policy adoption, seemingly in parallel with the increase in percentage of SP use in pregnancy. However, in the 1996-2000 study, more mutations in the combined dhfr/dhps genotype were associated with SP use during pregnancy only in univariable analysis and no associations were detected in the 2002-2008 and 2008-2009 studies. In addition, in the 2008-2009 study, 5.3 % of the parasite samples carried the dhps triple mutant (A437G/K540E/A581G). There were no differences in the prevalence of SP mutant genotypes between the parasite samples from HIV+ and HIV- women over time and between paired peripheral and placental samples. Conclusions: There was a significant increase in dhfr/dhps quintuple mutant and the emergence of new genotype containing dhps 581 in the parasites from pregnant women in western Kenya over 13 years. IPTp adoption and SP use in pregnancy only played a minor role in the increased drug-resistant parasites in the pregnant women over time. Most likely, other major factors, such as the high prevalence of resistant parasites selected by the use of SP for case management in large non-pregnant population, might have contributed to the temporally increased prevalence of SP resistant parasites in pregnant women. Further investigations are needed to determine the linkage between SP drug resistance markers and efficacy of IPTp-SP. C1 [Iriemenam, Nnaemeka C.; Shah, Monica; Gatei, Wangeci; Vanden Eng, Jodi; Lal, Ashima A.; Omosun, Yusuf O.; Desai, Meghna; Nahlen, Bernard; Hamel, Mary J.; Slutsker, Laurence; Shi, Ya Ping] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30329 USA. [Iriemenam, Nnaemeka C.; Shah, Monica; Lal, Ashima A.; Omosun, Yusuf O.] VA Med Ctr, Atlanta Res & Educ Fdn, Decatur, GA USA. [van Eijk, Anna M.; ter Kuile, Feiko O.] Univ Amsterdam, Acad Med Ctr, Dept Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands. [Ayisi, John; Kariuki, Simon; Otieno, Kephas; Desai, Meghna; Ouma, Peter] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Owino, Simon O.; Moore, Julie] Univ Georgia, Dept Infect Dis, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA. [van Eijk, Anna M.; ter Kuile, Feiko O.] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England. RP Shi, YP (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE,MS D67, Atlanta, GA 30329 USA. EM yps0@cdc.gov OI Omosun, Yusuf/0000-0003-4759-6254; ter Kuile, Feiko/0000-0003-3663-5617 FU American Society for Microbiology (ASM); Centers for Disease Control and Prevention (CDC); Office of Antimicrobial Resistance, Centers for Disease Control and Prevention [921ZJQH] FX We show appreciation to all the participating women for their involvement in the current study. Our thanks also extend to the many staff in Kenya who conducted the malaria in pregnancy studies, including sample and data collection and data management, during the three different study periods. NC Iriemenam was supported by the American Society for Microbiology (ASM) and Centers for Disease Control and Prevention (CDC) Postdoctoral Fellowship (ASM/CDC Research Fellowship Program). We thank the director of the Kenyan Medical Research Institute for his approval of publishing this article. This study was supported by intramural funding from the Office of Antimicrobial Resistance, Centers for Disease Control and Prevention (Project ID#921ZJQH). NR 65 TC 38 Z9 38 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD APR 27 PY 2012 VL 11 AR 134 DI 10.1186/1475-2875-11-134 PG 15 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 968IO UT WOS:000305972400001 PM 22540158 ER PT J AU Krauland, MG Hotopp, JCD Riley, DR Daugherty, SC Marsh, JW Messonnier, NE Mayer, LW Tettelin, H Harrison, LH AF Krauland, Mary G. Hotopp, Julie C. Dunning Riley, David R. Daugherty, Sean C. Marsh, Jane W. Messonnier, Nancy E. Mayer, Leonard W. Tettelin, Herve Harrison, Lee H. TI Whole Genome Sequencing to Investigate the Emergence of Clonal Complex 23 Neisseria meningitidis Serogroup Y Disease in the United States SO PLOS ONE LA English DT Article ID HIDDEN MARKOV MODEL; MENINGOCOCCAL DISEASE; GENETIC-CHARACTERIZATION; PILIN GLYCOSYLATION; SIGNAL PEPTIDES; PAN-GENOME; RNA GENES; ALIGNMENT; VACCINE; IDENTIFICATION AB In the United States, serogroup Y, ST-23 clonal complex Neisseria meningitidis was responsible for an increase in meningococcal disease incidence during the 1990s. This increase was accompanied by antigenic shift of three outer membrane proteins, with a decrease in the population that predominated in the early 1990s as a different population emerged later in that decade. To understand factors that may have been responsible for the emergence of serogroup Y disease, we used whole genome pyrosequencing to investigate genetic differences between isolates from early and late N. meningitidis populations, obtained from meningococcal disease cases in Maryland in the 1990s. The genomes of isolates from the early and late populations were highly similar, with 1231 of 1776 shared genes exhibiting 100% amino acid identity and an average pi(N) = 0.0033 and average pi(S) = 0.0216. However, differences were found in predicted proteins that affect pilin structure and antigen profile and in predicted proteins involved in iron acquisition and uptake. The observed changes are consistent with acquisition of new alleles through horizontal gene transfer. Changes in antigen profile due to the genetic differences found in this study likely allowed the late population to emerge due to escape from population immunity. These findings may predict which antigenic factors are important in the cyclic epidemiology of meningococcal disease. C1 [Krauland, Mary G.; Marsh, Jane W.; Harrison, Lee H.] Univ Pittsburgh, Sch Med, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15260 USA. [Krauland, Mary G.; Marsh, Jane W.; Harrison, Lee H.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Hotopp, Julie C. Dunning; Riley, David R.; Daugherty, Sean C.; Tettelin, Herve] Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA. [Messonnier, Nancy E.; Mayer, Leonard W.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA USA. RP Krauland, MG (reprint author), Univ Pittsburgh, Sch Med, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15260 USA. EM mgk8@pitt.edu RI Dunning Hotopp, Julie/E-7762-2010 OI Dunning Hotopp, Julie/0000-0003-3862-986X FU Centers for Disease Control and Prevention; Sanofi Pasteur FX This study was supported by a cooperative agreement from the Centers for Disease Control and Prevention and a grant from Sanofi Pasteur. Sanofi Pasteur had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 56 TC 10 Z9 10 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 27 PY 2012 VL 7 IS 4 AR e35699 DI 10.1371/journal.pone.0035699 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 959TJ UT WOS:000305336000048 PM 22558202 ER PT J AU Milton, JN Sebastiani, P Solovieff, N Hartley, SW Bhatnagar, P Arking, DE Dworkis, DA Casella, JF Barron-Casella, E Bean, CJ Hooper, WC DeBaun, MR Garrett, ME Soldano, K Telen, MJ Ashley-Koch, A Gladwin, MT Baldwin, CT Steinberg, MH Klings, ES AF Milton, Jacqueline N. Sebastiani, Paola Solovieff, Nadia Hartley, Stephen W. Bhatnagar, Pallav Arking, Dan E. Dworkis, Daniel A. Casella, James F. Barron-Casella, Emily Bean, Christopher J. Hooper, W. Craig DeBaun, Michael R. Garrett, Melanie E. Soldano, Karen Telen, Marilyn J. Ashley-Koch, Allison Gladwin, Mark T. Baldwin, Clinton T. Steinberg, Martin H. Klings, Elizabeth S. TI A Genome-Wide Association Study of Total Bilirubin and Cholelithiasis Risk in Sickle Cell Anemia SO PLOS ONE LA English DT Article ID CORONARY-HEART-DISEASE; GILBERTS-SYNDROME; UGT1A1-ASTERISK-28 ALLELE; PROMOTER POLYMORPHISMS; ALPHA-THALASSEMIA; HYDROXYUREA THERAPY; UGT1A1 POLYMORPHISM; PLASMA BILIRUBIN; BETA-THALASSEMIA; HYPERBILIRUBINEMIA AB Serum bilirubin levels have been associated with polymorphisms in the UGT1A1 promoter in normal populations and in patients with hemolytic anemias, including sickle cell anemia. When hemolysis occurs circulating heme increases, leading to elevated bilirubin levels and an increased incidence of cholelithiasis. We performed the first genome-wide association study (GWAS) of bilirubin levels and cholelithiasis risk in a discovery cohort of 1,117 sickle cell anemia patients. We found 15 single nucleotide polymorphisms (SNPs) associated with total bilirubin levels at the genome-wide significance level (p value <5x10(-8)). SNPs in UGT1A1, UGT1A3, UGT1A6, UGT1A8 and UGT1A10, different isoforms within the UGT1A locus, were identified (most significant rs887829, p = 9.08x10(-25)). All of these associations were validated in 4 independent sets of sickle cell anemia patients. We tested the association of the 15 SNPs with cholelithiasis in the discovery cohort and found a significant association (most significant p value 1.15x10(-4)). These results confirm that the UGT1A region is the major regulator of bilirubin metabolism in African Americans with sickle cell anemia, similar to what is observed in other ethnicities. C1 [Milton, Jacqueline N.; Sebastiani, Paola; Solovieff, Nadia; Hartley, Stephen W.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA. [Dworkis, Daniel A.; Baldwin, Clinton T.; Steinberg, Martin H.; Klings, Elizabeth S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Klings, Elizabeth S.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Bhatnagar, Pallav; Arking, Dan E.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA. [Casella, James F.; Barron-Casella, Emily] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Hematol, Baltimore, MD 21205 USA. [Bean, Christopher J.; Hooper, W. Craig] Ctr Dis Control & Prevent, Clin & Mol Hemostasis Lab Branch, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [DeBaun, Michael R.] Vanderbilt Univ Sch Med, Nashville, TN USA. [Garrett, Melanie E.; Soldano, Karen; Telen, Marilyn J.; Ashley-Koch, Allison] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Gladwin, Mark T.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. [Gladwin, Mark T.] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA USA. RP Milton, JN (reprint author), Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA. EM klingon@bu.edu RI Bhatnagar, Pallav/A-1280-2013; OI Ashley-Koch, Allison/0000-0001-5409-9155; Dworkis, Daniel/0000-0003-0706-5117; Steinberg, Martin/0000-0001-8800-8020; sebastiani, paola/0000-0001-6419-1545 FU National Institutes of Health/ National Heart, Lung and Blood Institute [1RC2HL101212] FX This study was funded by National Institutes of Health/ National Heart, Lung and Blood Institute grant # 1RC2HL101212. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 58 TC 18 Z9 19 U1 1 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 27 PY 2012 VL 7 IS 4 AR e34741 DI 10.1371/journal.pone.0034741 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 959TJ UT WOS:000305336000016 PM 22558097 ER PT J AU Atherly, DE Lewis, KDC Tate, J Parashar, UD Rheingans, RD AF Atherly, Deborah E. Lewis, Kristen D. C. Tate, Jacqueline Parashar, Umesh D. Rheingans, Richard D. TI Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030 SO VACCINE LA English DT Article DE Rotavirus vaccines; Cost-effectiveness; Health impact ID 8 LATIN-AMERICAN; COST-EFFECTIVENESS; CARIBBEAN COUNTRIES; CHILDHOOD DIARRHEA; UNITED-STATES; CHILDREN; GASTROENTERITIS; MORTALITY; REDUCTION; EFFICACY AB Rotavirus is the leading cause of diarrheal disease in children under 5 years of age. It is responsible for more than 450,000 deaths each year, with more than 90% of these deaths occurring in low-resource countries eligible for support by the GAVI Alliance. Significant efforts made by the Alliance and its partners are providing countries with the opportunity to introduce rotavirus vaccines into their national immunization programs, to help prevent childhood illness and death. We projected the cost-effectiveness and health impact of rotavirus vaccines in GAVI-eligible countries, to assist decision makers in prioritizing resources to achieve the greatest health benefits for their populations. A decision-analytic model was used to project the health outcomes and direct costs of a birth cohort in the target population, with and without a rotavirus vaccine. Current data on disease burden, vaccine efficacy, immunization rates, and costs were used in the model. Vaccination in GAVI-eligible countries would prevent 2.46 million childhood deaths and 83 million disability-adjusted life years (DALYs) from 2011 to 2030, with annual reductions of 180,000 childhood deaths at peak vaccine uptake. The cost per DALY averted is $42 for all GAVI countries combined, over the entire period. Rotavirus vaccination would be considered very cost-effective for the entire cohort of GAVI countries, and in each country individually, as cost-effectiveness ratios are less than the gross domestic product (GDP) per capita. Vaccination is most cost-effective and has the greatest impact in regions with high rotavirus mortality. Rotavirus vaccination in GAVI-eligible countries is very cost-effective and is projected to substantially reduce childhood mortality in this population. (C) 2012 Published by Elsevier Ltd. C1 [Atherly, Deborah E.; Lewis, Kristen D. C.] PATH, Rotavirus Vaccine Program, Seattle, WA USA. [Tate, Jacqueline; Parashar, Umesh D.] Ctr Dis Control & Prevent, Viral Enter Epidemiol Team, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Rheingans, Richard D.] Univ Florida, Gainesville, FL USA. RP Atherly, DE (reprint author), PATH, Rotavirus Vaccine Program, 2201 Westlake Ave, Seattle, WA USA. EM datherly@path.org FU PATH; GAVI Alliance FX This study was funded by PATH's Rotavirus Vaccine Program under a grant from the GAVI Alliance. NR 59 TC 36 Z9 37 U1 2 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 27 PY 2012 VL 30 SU 1 BP A7 EP A14 DI 10.1016/j.vaccine.2011.12.096 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 953EQ UT WOS:000304850100003 PM 22520139 ER PT J AU Banyai, K Laszlo, B Duque, J Steele, AD Nelson, EAS Gentsch, JR Parashar, UD AF Banyai, Krisztian Laszlo, Brigitta Duque, Jazmin Steele, A. Duncan Nelson, E. Anthony S. Gentsch, Jon R. Parashar, Umesh D. TI Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: Insights for understanding the impact of rotavirus vaccination programs SO VACCINE LA English DT Article DE G type; P type; Prevalence; Surveillance; Molecular epidemiology ID 1ST 2 YEARS; CHILDHOOD DIARRHEA; YOUNG-CHILDREN; DOUBLE-BLIND; GASTROENTERITIS; INFANTS; EFFICACY; DISEASE; SURVEILLANCE; SAFETY AB Recently, two rotavirus vaccines have been recommended for routine immunization of infants worldwide. These vaccines proved efficacious during clinical trials and field use in both developing and developed countries, and appear to provide good protection against a range of rotavirus genotypes, including some that are not included in the vaccines. However, since conclusive data that the vaccines will protect against a wide variety of rotavirus strains are still lacking and since vaccines may exert some selection pressure, a detailed picture of global strain prevalence from the pre-rotavirus vaccine era is important to evaluate any potential changes in circulating strains observed after widespread introduction of rotavirus vaccines. Thus, we systematically reviewed rotavirus genotyping studies spanning a 12-year period from 1996 to 2007. In total, similar to 110,000 strains were genotyped from 100 reporting countries. Five genotypes (G1-G4, and G9) accounted for 88% of all strains, although extensive geographic and temporal differences were observed. For example, the prevalence of G1 strains declined from 2000 onward, while G3 strains re-emerged, and G9 and G12 strains emerged during the same period. When crude strain prevalence data were weighted by region based on the region's contribution to global rotavirus mortality, the importance of genotypes G1 and G9 strains that were more prevalent in regions with low mortality was reduced and conversely the importance of G8 strains that were more prevalent in African settings with greater contribution to global rotavirus mortality was increased. This study provides the most comprehensive, up-to-date information on rotavirus strain surveillance in the pre-rotavirus vaccine era and will provide useful background to examine the impact of rotavirus vaccine introduction on future strain prevalence. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Banyai, Krisztian; Laszlo, Brigitta] Hungarian Acad Sci, Vet Med Res Inst, H-1143 Budapest, Hungary. [Banyai, Krisztian] Natl Ctr Epidemiol, Div Virol, Budapest, Hungary. [Laszlo, Brigitta] Univ Debrecen, Dept Med Microbiol, Med & Hlth Sci Ctr, Debrecen, Hungary. [Duque, Jazmin; Gentsch, Jon R.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Steele, A. Duncan] PATH, Seattle, WA USA. [Nelson, E. Anthony S.] Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Hong Kong, Peoples R China. RP Banyai, K (reprint author), Hungarian Acad Sci, Vet Med Res Inst, Hungaria Krt 21, H-1143 Budapest, Hungary. EM bkrota@hotmail.com OI Duque, Jazmin/0000-0003-3484-276X; Nelson, Edmund Anthony Severn/0000-0002-2521-3403; Banyai, Krisztian/0000-0002-6270-1772 FU Global Alliance for Vaccines and Immunisation (GAVI) FX Contributors: KB., B.L., and J.D. participated in literature search, data collection, analysis, and preparation of figures and tables. KB., A.D.S., E.A.S.N., J.R.G., and U.D.P. designed the study: K.B., J.R.G. and U.D.P. drafted the first version of the paper. All authors participated in the completion of the final version. Conflict of interest statement: The authors declare no conflicts of interest. Funding: Support for this project was provided by Program for Appropriate Technology in Health (PATH) through funding from the Global Alliance for Vaccines and Immunisation (GAVI). The views expressed by the authors do not necessarily reflect the views of GAVI and/or PATH. The authors were personally salaried by their institutions during the period of writing of this paper. NR 43 TC 126 Z9 130 U1 0 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 27 PY 2012 VL 30 SU 1 BP A122 EP A130 DI 10.1016/j.vaccine.2011.09.111 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 953EQ UT WOS:000304850100018 PM 22520121 ER PT J AU Anh, DD Trang, NV Thiem, VD Nguyen, THA Mao, ND Wang, YH Jiang, BM Hien, ND Luan, LT AF Dang Duc Anh Nguyen Van Trang Vu Dinh Thiem Nguyen Thi Hien Anh Nguyen Duc Mao Wang, Yuhuan Jiang, Baoming Nguyen Dang Hien Le Thi Luan CA Rotavin-M1 Vaccine Trial Grp TI A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children SO VACCINE LA English DT Article DE Rotavirus vaccine; Rotavin-M1; Vietnam; Safety; Immunogenicity; Vaccine dose; Rotarix (TM) ID ROUTINE INFANT VACCINES; AFRICAN INFANTS; UNITED-STATES; DOUBLE-BLIND; 2 DOSAGES; DIARRHEA; RIX4414; TRIAL; EXPERIENCE; BURDEN AB We tested a candidate live, oral, rotavirus vaccine (Rotavin-M1 (TM)) derived from an attenuated GIP [8] strain (KH0118-2003) isolated from a child in Vietnam. The vaccine was tested first for safety in 29 healthy adults. When deemed safe, it was further tested for safety and immunogenicity in 160 infants (4 groups) aged 6-12 weeks in a dose and schedule ranging study. The vaccine was administered in low titer (10(6.0) FFU/dose) on a 2-dose schedule given 2 months apart (Group 2L) and on a 3-dose schedule given 1 month apart (Group 3L) and in high titer (10(6.3) FFU/dose) in 2 doses 2 months apart (Group 2H) and in 3 doses 1 month apart (Group 3H). For comparison, 40 children (group Rotarix (TM)) were given 2 doses of the lyophilized Rotarix (TM) vaccine (10(6.5) CCID50/dose) 1 month apart. All infants were followed for 30 days after each dose for clinical adverse events including diarrhea, vomiting, fever, abdominal pain, irritability and intussusception. Immunogenicity was assessed by IgA seroconversion and viral shedding was monitored for 7 days after administration of each dose. Two doses of Rotavin-M1 (10(6.3) FFU/dose) were well tolerated in adults. Among infants (average 8 weeks of age at enrollment), administration of Rotavin-M1 was safe and did not lead to an increased rate of fever, diarrhea, vomiting or irritability compared to Rotarix (TM), indicating that the candidate vaccine virus had been fully attenuated by serial passages. No elevation of levels of serum transaminase, blood urea, or blood cell counts were observed. The highest rotavirus IgA seroconversion rate (73%, 95%CI (58-88%)) was achieved in group 2H (2 doses 1 10(6.3) FFU/dose, 2 months apart). The 2 dose schedules performed slightly better than the 3 dose schedules and the higher titer doses performed slightly better than the lower titer doses. These rates of seroconversion were similar to that of the Rotarix (TM) group (58%, 95%CI (42-73%)). However more infants who received Rotarix (TM) (65%) shed virus in their stool after the first dose than those who received Rotavin-M1 (44-48%) (p < 0.05) and the percent shedding decreased after subsequent doses of either vaccine. Rotavin-M1 vaccine is safe and immunogenic in Vietnamese infants. A trial in progress will assess the safety, immunogenicity and efficacy of Rotavin-M1 (2 doses at 10(6.3) FFU/dose) in a larger number of infants. The trial registration numbers are NCT01375907 and NCT01377571. (C)2011 Elsevier Ltd. All rights reserved. C1 [Dang Duc Anh; Nguyen Van Trang; Vu Dinh Thiem; Nguyen Thi Hien Anh] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam. [Wang, Yuhuan; Jiang, Baoming] Ctr Dis Control & Prevent, CDC, Atlanta, GA USA. [Nguyen Dang Hien; Le Thi Luan] Ctr Res & Prod Vaccines & Biol, Hanoi, Vietnam. RP Anh, DD (reprint author), Natl Inst Hyg & Epidemiol, Hanoi, Vietnam. EM ducanh@nihe.org.vn; bxj4@cdc.gov FU Ministry of Science and Technology, Government of Vietnam [KC.10.33/06-10] FX Conflict of interest: Drs Anh, Trang, Thiem, Hien-Anh, Mao, Wang and Jiang have no conflict of interest. Financial support: The Ministry of Science and Technology, KC.10.33/06-10, Government of Vietnam. Ethical approval: The study and protocol (No. 962/CN-BYT-September 29, 2009) were approved by the Ethics Committees of the National Institute of Hygiene and Epidemiology and the Ministry of Health, Government of Vietnam. NR 29 TC 1 Z9 1 U1 2 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 27 PY 2012 VL 30 SU 1 BP A114 EP A121 DI 10.1016/j.vaccine.2011.07.118 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 953EQ UT WOS:000304850100017 ER PT J AU Laserson, KF Nyakundi, D Feikin, DR Nyambane, G Cook, E Oyieko, J Ojwando, J Rivers, SB Ciarlet, M Neuzil, KM Breiman, RF AF Laserson, Kayla F. Nyakundi, Daveline Feikin, Daniel R. Nyambane, Geoffrey Cook, Earnest Oyieko, Janet Ojwando, Joel Rivers, Stephen B. Ciarlet, Max Neuzil, Kathleen M. Breiman, Robert F. TI Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq (R), in Kenya, including among HIV-infected and HIV-exposed infants SO VACCINE LA English DT Article DE Rotavirus; Pentavalent rotavirus vaccine; RotaTeq (R); Safety; HIV; Adverse events; Serious adverse events; Intussusception ID CHILDREN; DIARRHEA; EFFICACY; INTUSSUSCEPTION; GASTROENTERITIS; MORTALITY; DISEASE; MOTHERS; BORN AB Two multicenter Phase III trials were conducted in five countries from March 2007 to March 2009 to evaluate the safety and efficacy of the pentavalent rotavirus vaccine (PRV), RotaTeq (R), in Africa and Asia. In this report, we evaluate the safety of this vaccine, including among HIV-infected and HIV-exposed infants, in Kenya. 1308 Infants were randomized 1:1 to receive 3 doses of PRV/placebo at approximately 6, 10, and 14 weeks of age. HIV counseling and testing were offered to all participants. A positive PCR result indicated HIV infection: the presence of HIV antibody in PCR-negative children indicated HIV exposure without HIV infection. All serious adverse events (SAE) within 14 days of any dose, and vaccine-related SAEs, intussusception, and deaths occurring at any time during the study, were reported ("SAE surveillance"). In addition, 297 participants were followed for 42 days after any dose for any adverse event (AE), regardless of severity ("intensive safety surveillance"). The safety evaluation was stratified by HIV status. SAEs were reported in 20/649 vaccine recipients (3.1%) and 21/643 placebo recipients (3.3%) within 14 days following vaccination (p = 0.9). The most common SAE in the vaccinated group was pneumonia (1.7%). No individual SAE was significantly more common among vaccine vs. placebo recipients. Seventy-two deaths were reported, 38 (5.9%) and 34 (5.3%) among vaccine and placebo recipients, respectively (p=0.66). No cases of intussusception were reported. During intensive safety surveillance, 137/147(93.2%) vaccine recipients and 147/150(98.0%) placebo recipients experienced one or more AEs (risk ratio = 0.95: 95% CI: 0.91-1.0; p = 0.05). 88.5% of the infants were tested for HIV infection; 21/581 (3.6%) children in the vaccine group and 17/577 (2.9%) in the placebo group were HIV-infected. Among the 37 HIV-infected infants with full safety follow-up, 5/21 (23.8%) vaccine recipients and 2/16 (12.5%) placebo recipients reported an SAE (p = 0.67). In total, 12 deaths occurred among identified HIV-infected infants: 8 (38%) receiving vaccine vs. 4 (23.5%) receiving placebo (RR=1.6, 95% CI: 0.59-4.5). Among the 21 HIV-infected infants in the vaccine group, 2 of 8 deaths were gastroenteritis-related; among the 17 HIV-infected infants in the placebo group, 3 of 4 deaths were gastroenteritis-related. There were no significant differences in serious or non-serious AEs, including vaccine-related SAEs, between the 88 HIV-exposed vaccine recipients vs. the 89 HIV-exposed placebo recipients. PRV appears to be a safe intervention against rotavirus gastroenteritis among infants in Kenya. AEs, including serious AEs, were not associated with receipt of vaccine. Further, SAEs were not significantly more common among HIV-infected or HIV-exposed participants; however, the low number of HIV-infected infants did not provide sufficient power to fully assess safety in HIV- infected vaccine recipients. Published by Elsevier Ltd. C1 [Feikin, Daniel R.; Breiman, Robert F.] Ctr Dis Control & Prevent, Int Emerging Infect Program, Atlanta, GA USA. [Laserson, Kayla F.; Breiman, Robert F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Rivers, Stephen B.; Ciarlet, Max] Merck Res Labs, N Wales, PA USA. [Neuzil, Kathleen M.] PATH, Rotavirus Vaccine Program, Seattle, WA USA. RP Laserson, KF (reprint author), KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya. EM klaserson@ke.cdc.gov FU PATH; GAVI Alliance; Merck Co., Inc. FX The trial (Merck protocol V260-015) was funded by PATH's Rotavirus Vaccine Program with a grant from the GAVI Alliance; the trial was co-sponsored by Merck & Co., Inc. This study, under protocol V260-015, was designed, managed, conducted, and analyzed by the co-sponsors in collaboration with the site investigators and under the supervision and advice of the Data and Safety Monitoring Board. We wish to thank the study participants and their families, and the entire study team. We wish to acknowledge the assistance from the KEMRI/CDC HIV laboratory for all HIV diagnostic testing, and the CDC GAP team for assistance in linking the study participants to appropriate HIV care and treatment. We are grateful to Michael J. Dallas and Donna Hyatt at Merck for numerous additional data analyses, and we also thank Michele L. Coia, and Margaret Nelson, also at Merck. We appreciate the support received from Kristen Lewis, J.C. Victor, and A. Duncan Steele at PATH. This manuscript is published with the permission of the Director, KEMRI. KEMRI/CDC is a member of the INDEPTH Network. NR 32 TC 8 Z9 9 U1 0 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 27 PY 2012 VL 30 SU 1 BP A61 EP A70 DI 10.1016/j.vaccine.2011.09.026 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 953EQ UT WOS:000304850100010 PM 22520138 ER PT J AU Miles, MG Lewis, KDC Kang, G Parashar, UD Steele, AD AF Miles, Melody G. Lewis, Kristen D. C. Kang, Gagandeep Parashar, Umesh D. Steele, A. Duncan TI A systematic review of rotavirus strain diversity in India, Bangladesh, and Pakistan SO VACCINE LA English DT Review DE Rotavirus; India; Bangladesh; Pakistan; VP7; VP4; Serotype; Genotype ID GROUP-A ROTAVIRUS; HOSPITAL-BASED SURVEILLANCE; SOUTH-INDIA; ACUTE DIARRHEA; GENOMIC DIVERSITY; EASTERN INDIA; MOLECULAR EPIDEMIOLOGY; DEVELOPING-COUNTRIES; CONTROLLED-TRIAL; CHILD-MORTALITY AB Of the estimated half-million deaths from rotavirus globally each year, approximately one-third (N=160,000 deaths) occur in the Indian subcontinent (defined as India, Bangladesh, and Pakistan). Two commercial vaccines are available for use and recommended by WHO, although the prohibitive vaccine price has limited their introduction into routine childhood immunization programs. New rotavirus vaccines are in late clinical development, including two advanced candidates in India. As significant shifts in rotavirus strain diversity have occurred in the past three decades and questions remain regarding whether strain replacement may occur following introduction of rotavirus vaccines, it is important to understand the temporal and regional strain diversity profile before vaccine introduction. We reviewed 33 peer-reviewed manuscripts from the Indian subcontinent and found that the most common G-types (G1-4) and P-types (P[4] and P[8]) globally accounted for three-fourths of all strains in the subcontinent. However, strains varied by region, and temporal analysis showed the decline of G3 and G4 in recent years and the emergence of G9 and G12. Our findings underscore the large diversity of rotavirus strains in the Indian subcontinent and highlight the need to conduct surveillance on a regional scale to better understand strain diversity before and after rotavirus vaccine introduction. (C) 2012 Published by Elsevier Ltd. C1 [Miles, Melody G.; Lewis, Kristen D. C.; Steele, A. Duncan] PATH, Seattle, WA USA. [Kang, Gagandeep] Christian Med Coll & Hosp, Dept Gastrointestinal Sci, Vellore, Tamil Nadu, India. [Parashar, Umesh D.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Steele, AD (reprint author), POB 900922, Seattle, WA 98109 USA. EM duncan.steele@gatesfoundation.org NR 67 TC 21 Z9 21 U1 0 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 27 PY 2012 VL 30 SU 1 BP A131 EP A139 DI 10.1016/j.vaccine.2011.10.002 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 953EQ UT WOS:000304850100019 PM 22520122 ER PT J AU Neuzil, KM Parashar, UD Steele, AD AF Neuzil, Kathleen M. Parashar, Umesh D. Steele, A. Duncan TI Rotavirus vaccines for children in developing countries: Understanding the science, maximizing the impact, and sustaining the effort Preface SO VACCINE LA English DT Editorial Material C1 [Neuzil, Kathleen M.; Steele, A. Duncan] PATH, Rotavirus Vaccine Program, Seattle, WA USA. [Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Epidemiol Branch, Atlanta, GA USA. RP Neuzil, KM (reprint author), PATH, Rotavirus Vaccine Program, Seattle, WA USA. EM kneuzil@path.org NR 31 TC 4 Z9 4 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 27 PY 2012 VL 30 SU 1 BP A1 EP A2 DI 10.1016/j.vaccine.2011.10.108 PG 2 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 953EQ UT WOS:000304850100001 PM 22520117 ER PT J AU Patel, M Steele, AD Parashar, UD AF Patel, Manish Steele, A. Duncan Parashar, Umesh D. TI Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines SO VACCINE LA English DT Article DE Rotavirus; Vaccines; Diarrhea; Oral polio vaccine; Immunogenicity; Co-administration ID 1ST 2 YEARS; CHOLERA VACCINE; AFRICAN INFANTS; DOUBLE-BLIND; CVD 103-HGR; IMMUNOGENICITY; SAFETY; EFFICACY; LIVE; GASTROENTERITIS AB In recent years, two live, oral rotavirus vaccines have been successfully tested in developing and industrialized countries, and both vaccines are now recommended by the World Health Organization for all children worldwide. Both immunogenicity and efficacy of these rotavirus vaccines has been lower in developing compared to industrialized settings. We reviewed the data on the effect of trivalent OPV on the immunogenicity and efficacy of two rotavirus vaccines currently recommended by the WHO. While rotavirus vaccines have not affected immune responses to OPV, in general, the immune responses (i.e., antibody levels) to rotavirus vaccination were lower when rotavirus vaccines were co-administered with OPV. Limited data suggests that the interference is greater after the first dose of OPV, presumably because the first dose is associated with greatest intestinal replication of vaccine polio virus strains, and this interference is largely overcome with subsequent rotavirus vaccine doses. Despite the lower immunogenicity, one large efficacy study in middle income Latin American countries showed no decrease in protective efficacy of rotavirus vaccine in infants receiving concurrent OPV. While these data are encouraging and support simultaneous administration of rotavirus vaccines and OPV, additional evidence should be gathered as rotavirus vaccines are used more widely in developing country settings, where OPV is routinely used, rather than inactivated polio vaccine. Published by Elsevier Ltd. C1 [Patel, Manish; Parashar, Umesh D.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Steele, A. Duncan] Rotavirus Vaccine Program PATH, Seattle, WA USA. RP Patel, M (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM aul3@cdc.gov NR 40 TC 19 Z9 19 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 27 PY 2012 VL 30 SU 1 BP A30 EP A35 DI 10.1016/j.vaccine.2011.11.093 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 953EQ UT WOS:000304850100006 PM 22520134 ER PT J AU Tate, JE Steele, AD Bines, JE Zuber, PLF Parashar, UD AF Tate, Jacqueline E. Steele, A. Duncan Bines, Julie E. Zuber, Patrick L. F. Parashar, Umesh D. TI Research priorities regarding rotavirus vaccine and intussusception: A meeting summary SO VACCINE LA English DT Article DE Intussusception; Rotavirus vaccine ID RHESUS ROTAVIRUS; US CHILDREN; INFANTS; SAFETY; EFFICACY; HOSPITALIZATIONS; GASTROENTERITIS; REDUCTION; AUSTRALIA; AGE AB Currently available rotavirus vaccines have been associated with a small increased risk of intussusception (similar to 1-2 cases per 100,000 vaccinated infants) in some populations. In response to this newly emerging data on intussusception related to current rotavirus vaccines, a group of technical experts convened by the Program for Applied Technology in Health met to review the data, establish what gaps in knowledge exist, and identify what future research is needed. This manuscript outlines the evidence that is currently available and the research agenda that was generated during this meeting. It also highlights the need for countries that are using or considering introducing the rotavirus vaccine to evaluate both the benefits and risks of vaccination. Published by Elsevier Ltd. C1 [Tate, Jacqueline E.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Steele, A. Duncan] PATH, Rotavirus Vaccine Program, Seattle, WA USA. [Bines, Julie E.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia. [Bines, Julie E.] Royal Childrens Hosp, Melbourne, Vic, Australia. [Bines, Julie E.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Zuber, Patrick L. F.] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. RP Tate, JE (reprint author), 1600 Clifton Rd NE,MS-A47, Atlanta, GA 30333 USA. EM jqt8@cdc.gov NR 49 TC 16 Z9 16 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD APR 27 PY 2012 VL 30 SU 1 BP A179 EP A184 DI 10.1016/j.vaccine.2011.08.110 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 953EQ UT WOS:000304850100025 PM 22520129 ER PT J AU Gaur, P Ranjan, P Sharma, S Patel, JR Bowzard, JB Rahman, SK Kumari, R Gangappa, S Katz, JM Cox, NJ Lal, RB Sambhara, S Lal, SK AF Gaur, Pratibha Ranjan, Priya Sharma, Shipra Patel, Jenish R. Bowzard, J. Bradford Rahman, Shah K. Kumari, Rashmi Gangappa, Shivaprakash Katz, Jacqueline M. Cox, Nancy J. Lal, Renu B. Sambhara, Suryaprakash Lal, Sunil K. TI Influenza A Virus Neuraminidase Protein Enhances Cell Survival through Interaction with Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) Protein SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PANCREATIC ADENOCARCINOMA CELLS; PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; NF-KAPPA-B; KINASE; ACTIVATION; BETA; SRC; OVEREXPRESSION; INFECTIONS; EXPRESSION AB The influenza virus neuraminidase (NA) protein primarily aids in the release of progeny virions from infected cells. Here, we demonstrate a novel role for NA in enhancing host cell survival by activating the Src/Akt signaling axis via an interaction with carcinoembryonic antigen-related cell adhesion molecule 6/cluster of differentiation 66c (C6). NA/C6 interaction leads to increased tyrosyl phosphorylation of Src, FAK, Akt, GSK3 beta, and Bcl-2, which affects cell survival, proliferation, migration, differentiation, and apoptosis. siRNA-mediated suppression of C6 resulted inadown-regulation of activated Src, FAK, and Akt, increased apoptosis, and reduced expression of viral proteins and viral titers in influenza virus-infected human lung adenocarcinoma epithelial and normal human bronchial epithelial cells. These findings indicate that influenza NA not only aids in the release of progeny virions, but also cell survival during viral replication. C1 [Gaur, Pratibha; Sharma, Shipra; Rahman, Shah K.; Kumari, Rashmi; Lal, Sunil K.] Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 110067, India. [Ranjan, Priya; Patel, Jenish R.; Bowzard, J. Bradford; Gangappa, Shivaprakash; Katz, Jacqueline M.; Cox, Nancy J.; Lal, Renu B.; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30033 USA. RP Lal, SK (reprint author), Int Ctr Genet Engn & Biotechnol, Virol Grp, Aruna Asaf Ali Rd, New Delhi 110067, India. EM sunillal@icgeb.res.in OI Patel, Jenish/0000-0001-5310-8160 FU International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi; Department of Biotechnology, India; Centers for Disease Control (CDC), Atlanta FX This work was supported by internal funds from the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, a research grant from the Department of Biotechnology, India (to S. K. L.), and a training and research grant from the Centers for Disease Control (CDC), Atlanta (to S. K. L.). NR 35 TC 10 Z9 10 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 27 PY 2012 VL 287 IS 18 BP 15109 EP 15117 DI 10.1074/jbc.M111.328070 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 941XU UT WOS:000304003200072 PM 22396546 ER PT J AU Mortamais, M Chevrier, C Philippat, C Petit, C Calafat, AM Ye, XY Silva, MJ Brambilla, C Eijkemans, MJC Charles, MA Cordier, S Slama, R AF Mortamais, Marion Chevrier, Cecile Philippat, Claire Petit, Claire Calafat, Antonia M. Ye, Xiaoyun Silva, Manori J. Brambilla, Christian Eijkemans, Marinus J. C. Charles, Marie-Aline Cordier, Sylvaine Slama, Remy TI Correcting for the influence of sampling conditions on biomarkers of exposure to phenols and phthalates: a 2-step standardization method based on regression residuals SO ENVIRONMENTAL HEALTH LA English DT Article DE Biomarker; Endocrine Disruptor; Phenols; Phthalate esters; Pregnancy; Sampling conditions ID BISPHENOL-A; URINARY CONCENTRATIONS; PREGNANT-WOMEN; DIETHYL PHTHALATE; MEASUREMENT ERROR; US POPULATION; METABOLITES; VARIABILITY; SERUM; OUTCOMES AB Background: Environmental epidemiology and biomonitoring studies typically rely on biological samples to assay the concentration of non-persistent exposure biomarkers. Between-participant variations in sampling conditions of these biological samples constitute a potential source of exposure misclassification. Few studies attempted to correct biomarker levels for this error. We aimed to assess the influence of sampling conditions on concentrations of urinary biomarkers of select phenols and phthalates, two widely-produced families of chemicals, and to standardize biomarker concentrations on sampling conditions. Methods: Urine samples were collected between 2002 and 2006 among 287 pregnant women from Eden and Pelagie cohorts, from which phthalates and phenols metabolites levels were assayed. We applied a 2-step standardization method based on regression residuals. First, the influence of sampling conditions (including sampling hour, duration of storage before freezing) and of creatinine levels on biomarker concentrations were characterized using adjusted linear regression models. In the second step, the model estimates were used to remove the variability in biomarker concentrations due to sampling conditions and to standardize concentrations as if all samples had been collected under the same conditions (e. g., same hour of urine collection). Results: Sampling hour was associated with concentrations of several exposure biomarkers. After standardization for sampling conditions, median concentrations differed by - 38 % for 2,5-dichlorophenol to +80 % for a metabolite of diisodecyl phthalate. However, at the individual level, standardized biomarker levels were strongly correlated (correlation coefficients above 0.80) with unstandardized measures. Conclusions: Sampling conditions, such as sampling hour, should be systematically collected in biomarker-based studies, in particular when the biomarker half-life is short. The 2-step standardization method based on regression residuals that we proposed in order to limit the impact of heterogeneity in sampling conditions could be further tested in studies describing levels of biomarkers or their influence on health. C1 [Mortamais, Marion; Philippat, Claire; Slama, Remy] INSERM, Team Environm Epidemiol Appl Reprod & Resp Hlth, Inst Albert Bonniot, U823, Grenoble, France. [Mortamais, Marion] INSERM, U1061, Montpellier, France. [Chevrier, Cecile; Petit, Claire; Cordier, Sylvaine] INSERM, U625, Rennes, France. [Philippat, Claire; Brambilla, Christian; Slama, Remy] Grenoble Univ, Inst Albert Bonniot, U823, Grenoble, France. [Calafat, Antonia M.; Ye, Xiaoyun; Silva, Manori J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Eijkemans, Marinus J. C.] UMC, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands. [Charles, Marie-Aline] Inserm & INED Joint Res Grp, Paris, France. [Charles, Marie-Aline] INSERM, CESP, U1018, Villejuif, France. RP Slama, R (reprint author), INSERM, Team Environm Epidemiol Appl Reprod & Resp Hlth, Inst Albert Bonniot, U823, Grenoble, France. EM remy.slama@ujf-grenoble.fr RI Philippat, Claire/N-2423-2013; BRAMBILLA, CHRISTIAN/K-2285-2013; Slama, Remy/M-1755-2013; Chevrier, Cecile/J-9170-2015; Cordier, Sylvaine/F-7919-2013 OI Slama, Remy/0000-0002-8980-8529; FU French Agency for Environmental and Occupational Health Safety (ANSES); Foundation for medical research (FRM); Eden cohort is funded by the Foundation for medical research (FRM), Inserm; IReSP; Nestle; French Ministry of health; National Research Agency (ANR); Univ. Paris-Sud; Institute of health monitoring (InVS); AFSSET; MGEN; AFSSA (ANSES); ANSES; Ministry of Health, Ministry of Labor; ANR; InVS; Inserm; Regional Council of Brittany; AVENIR grant from Inserm FX This work was supported by the French Agency for Environmental and Occupational Health Safety (ANSES). Eden cohort is funded by the Foundation for medical research (FRM), Inserm, IReSP, Nestle, French Ministry of health, National Research Agency (ANR), Univ. Paris-Sud, Institute of health monitoring (InVS), AFSSET, MGEN, AFSSA (ANSES). Pelagie cohort was funded by ANSES, Ministry of Health, Ministry of Labor, ANR, InVS, Inserm, and the Regional Council of Brittany. The team of Environmental Epidemiology (Inserm U823) is supported by an AVENIR grant from Inserm. The findings and conclusion in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 44 TC 9 Z9 9 U1 0 U2 24 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-069X J9 ENVIRON HEALTH-GLOB JI Environ. Health PD APR 26 PY 2012 VL 11 AR 29 DI 10.1186/1476-069X-11-29 PG 14 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 068AG UT WOS:000313336300001 PM 22537080 ER PT J AU Woolpert, T Staples, JE Faix, DJ Nett, RJ Kosoy, OI Biggerstaff, BJ Johnson, BW Sracic, M Fischer, M AF Woolpert, Tabitha Staples, J. Erin Faix, Dennis J. Nett, Randall J. Kosoy, Olga I. Biggerstaff, Brad J. Johnson, Barbara W. Sracic, Michael Fischer, Marc TI Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine SO VACCINE LA English DT Article DE Japanese encephalitis; Japanese encephalitis vaccines; Vaccines; Immunization ID IC51; PHASE-3; POINTS; SAFETY; TRIAL AB Background:There are no data on the use of inactivated Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) as a booster among individuals who previously received inactivated mouse brain-derived JE vaccine (JE-MB). Methods: Military personnel who received >= 3 doses of JE-MB or were JE vaccine-naive were vaccinated with 2 doses of JE-VC on days 0 and 28. Serum neutralizing antibodies were measured pre-vaccination and 28 days after each dose. Non-inferiority was evaluated for seroprotection rate and geometric mean titer (GMT) between previously vaccinated participants post-dose 1 and vaccine-naive participants post-dose 2. Results: Fifty-three previously vaccinated and 70 JE vaccine-naive participants were enrolled. Previously vaccinated participants had significantly higher GMTs pre-vaccination, post-dose 1, and post-dose 2. Seroprotection rates among previously vaccinated participants post-dose 1 (44/44, 100%) were noninferior to those achieved in previously naive participants post-dose 2 (53/57, 93%). The GMT was significantly higher in previously vaccinated participants post-dose 1 (GMT 315; 95% CI 191-520) compared to previously naive participants post-dose 2 (GMT 79; 95% CI 54-114). Conclusions: Among military personnel previously vaccinated with >= 3 doses of JE-MB, a single dose of JE-VC adequately boosts neutralizing antibody levels and provides at least short-term protection. Additional studies are needed to confirm these findings in other populations and determine the duration of protection following a single dose of JE-VC in prior recipients of JE-MB. Published by Elsevier Ltd. C1 [Fischer, Marc] Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Sracic, Michael] US Marine Corps, Marine Expeditionary Unit 13, Camp Pendleton, CA 92055 USA. [Woolpert, Tabitha; Faix, Dennis J.] USN, Dept Operat Infect Dis, Hlth Res Ctr, San Diego, CA 92106 USA. RP Fischer, M (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM mfischer@cdc.gov FU Military Vaccine Agency [MILVAX 10-1-111] FX This work was supported by the Military Vaccine Agency's Medical Infectious Disease Research Program (MILVAX 10-1-111). NR 18 TC 11 Z9 12 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 26 PY 2012 VL 30 IS 20 BP 3090 EP 3096 DI 10.1016/j.vaccine.2012.02.063 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 932PK UT WOS:000303302800007 PM 22406277 ER PT J AU Engelgau, MM Karan, A Mahal, A AF Engelgau, Michael M. Karan, Anup Mahal, Ajay TI The Economic impact of Non-communicable Diseases on households in India SO GLOBALIZATION AND HEALTH LA English DT Article ID HEART-DISEASE; CARDIOVASCULAR-DISEASE; MORTALITY-RATES; HEALTH-CARE; BURDEN; COUNTRIES; DECREASE; DECLINE; DEATH; ASIA AB Background: In India, Non Communicable Diseases (NCDs) and injuries account for an estimated 62% of the total age-standardized burden of forgone Disability Adjusted Life Years (DALYs). Public and private financing of clinical services to reduce the NCD burden is a major challenge. Methods: We used National Sample Survey Organization (NSSO) survey data from 1995-96 and 2004 covering nearly 200 thousand households to assess healthcare utilization patterns and out of pocket health spending by disease category. For this purpose, self-reported diseases and conditions were categorized into NCDs and non-NCDs. Survey data were used to assess how households financed their overall health expenditures and related this pattern to specific health conditions. We measured catastrophic spending on NCD-related hospitalization, defined as occurring when health expenditures exceeded 40% of a household's ability to pay, that is, household consumption spending less combined survival consumption expenditure; and impoverishment when per capita expenditure within the household decreased to below the poverty line once health spending was netted out. Results: The share of NCDs in out of pocket health expenses incurred by households increased over time, from 31.6 percent in 1995-96 to 47.3 percent in 2004. In both years, own savings and income were the most important source of financing for many health conditions, typically between 40-60 percent of all spending, whereas 30-35 percent was from borrowing. The odds of catastrophic hospitalization expenditures for cancer was nearly 170% greater and for CVD and injuries 22 percent greater than the odds due to communicable diseases. Impoverishment patterns were similar. Conclusions: Out of pocket expenses for treating NCDs rose sharply over the period from 1995-96 to 2004. When NCDs are present, the financial risks to which Indians households are exposed are significant. C1 [Mahal, Ajay] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia. [Engelgau, Michael M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Karan, Anup] Univ Oxford, Dept Publ Hlth, Oxford, England. [Karan, Anup] Publ Hlth Fdn India, New Delhi, India. RP Mahal, A (reprint author), Monash Univ, Sch Publ Hlth & Prevent Med, 99 Commercial Rd, Melbourne, Vic 3004, Australia. EM ajay.mahal@monash.edu FU Department for International Development (DFID), United Kingdom; PHFI-Wellcome Trust-UKC FX This study was supported in whole by the Department for International Development (DFID), United Kingdom, through a Trust Fund to the World Bank supporting health studies in India. Anup Karan was supported by the PHFI-Wellcome Trust-UKC under the Future Faculty Programme. Neither DFID, nor PHFI or the Wellcome Trust had any role in the study design, data collection, data analysis, interpretation, or write up. NR 18 TC 27 Z9 27 U1 0 U2 14 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1744-8603 J9 GLOBALIZATION HEALTH JI Global. Health PD APR 25 PY 2012 VL 8 AR 9 DI 10.1186/1744-8603-8-9 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 965DF UT WOS:000305745900001 PM 22533895 ER PT J AU McDonald, LC Lessa, F Sievert, D Wise, M Herrera, R Gould, C Malpiedi, P Dudeck, M Srinivasan, A Fridkin, S Cardo, D AF McDonald, L. Clifford Lessa, Fernanda Sievert, Dawn Wise, Matt Herrera, Rosa Gould, Carolyn Malpiedi, Paul Dudeck, Maggie Srinivasan, Arjun Fridkin, Scott Cardo, Denise TI Vital Signs: Preventing Clostridium difficile Infections SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID DISEASE; AMERICA; STRAIN C1 [McDonald, L. Clifford; Lessa, Fernanda; Sievert, Dawn; Wise, Matt; Herrera, Rosa; Gould, Carolyn; Malpiedi, Paul; Dudeck, Maggie; Srinivasan, Arjun; Fridkin, Scott; Cardo, Denise] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP McDonald, LC (reprint author), CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM cmcdonald1@cdc.gov NR 18 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 25 PY 2012 VL 307 IS 16 BP 1684 EP 1687 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 930OA UT WOS:000303147500008 ER PT J AU Barfield, WD AF Barfield, Wanda D. TI Improving Systems in Perinatal Care Quality, Not Quantity SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID LOW-BIRTH-WEIGHT; NEED C1 Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Barfield, WD (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,MS K-20, Atlanta, GA 30341 USA. EM wbarfield@cdc.gov NR 15 TC 2 Z9 2 U1 0 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 25 PY 2012 VL 307 IS 16 BP 1750 EP 1751 DI 10.1001/jama.2012.538 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 930OA UT WOS:000303147500030 PM 22535861 ER PT J AU Wicker, JA Whiteman, MC Beasley, DWC Davis, CT McGee, CE Lee, JC Higgs, S Kinney, RM Huang, CYH Barrett, ADT AF Wicker, Jason A. Whiteman, Melissa C. Beasley, David W. C. Davis, C. Todd McGee, Charles E. Lee, J. Ching Higgs, Stephen Kinney, Richard M. Huang, Claire Y. -H. Barrett, Alan D. T. TI Mutational analysis of the West Nile virus NS4B protein SO VIROLOGY LA English DT Article DE West Nile virus; Flavivirus; NS4B protein; Attenuated phenotype; Temperature sensitivity ID YELLOW-FEVER VIRUS; DENGUE-VIRUS; ALPHA/BETA-INTERFERON; VISCEROTROPIC STRAIN; REPLICATION; FLAVIVIRUS; INHIBITION; PHENOTYPE; VIRULENCE; VACCINE AB West Nile virus NS4B is a small hydrophobic nonstructural protein approximately 27 kDa in size whose function is poorly understood. Amino acid substitutions were introduced into the NS4B protein primarily targeting two distinct regions; the N-terminal domain (residues 35 through 60) and the central hydrophobic domain (residues 95 through 120). Only the NS4B P38G substitution was associated with both temperature-sensitive and small-plaque phenotypes. Importantly, this mutation was found to attenuate neuroinvasiveness greater than 10,000,000-fold and lower viremia titers compared to the wild-type NY99 virus in a mouse model. Full genome sequencing of the NS4B P38G mutant virus revealed two unexpected mutations at NS4B T116I and NS3 N480H (P38G/T116I/N480H), however, neither mutation alone was temperature sensitive or attenuated in mice. Following incubation of P38G/T116I/N480H at 41 degrees C, five mutants encoding compensatory substitutions in the NS4B protein exhibited a reduction in the temperature-sensitive phenotype and reversion to a virulent phenotype in the mouse model. (C) 2011 Published by Elsevier Inc. C1 [Wicker, Jason A.; Whiteman, Melissa C.; Beasley, David W. C.; Davis, C. Todd; McGee, Charles E.; Barrett, Alan D. T.] Univ Texas Med Branch, Dept Pathol, Sealy Ctr Vaccine Dev, Ctr Biodef & Emerging Infect Dis,Sealy Ctr Struct, Galveston, TX 77555 USA. [Wicker, Jason A.; Whiteman, Melissa C.; Beasley, David W. C.; Davis, C. Todd; McGee, Charles E.; Lee, J. Ching; Barrett, Alan D. T.] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA. [Wicker, Jason A.; Beasley, David W. C.; Barrett, Alan D. T.] Univ Texas Med Branch, Dept Microbiol & Immunol, Sealy Ctr Vaccine Dev, Ctr Biodef & Emerging Infect Dis,Sealy Ctr Struct, Galveston, TX 77555 USA. [Lee, J. Ching] Univ Texas Med Branch, Dept Biochem & Mol Biol, Sealy Ctr Vaccine Dev, Ctr Biodef & Emerging Infect Dis,Sealy Ctr Struct, Galveston, TX 77555 USA. [Higgs, Stephen] Kansas State Univ, Biosecur Res Inst, Manhattan, KS 66506 USA. [Kinney, Richard M.; Huang, Claire Y. -H.] Ctr Dis Control & Prevent, Div Vector Borne Viral Dis, Publ Hlth Serv, US Dept HHS, Ft Collins, CO 80521 USA. RP Barrett, ADT (reprint author), Univ Texas Med Branch, Dept Pathol, Sealy Ctr Vaccine Dev, Ctr Biodef & Emerging Infect Dis,Sealy Ctr Struct, Galveston, TX 77555 USA. EM abarrett@utmb.edu RI Lee, James/A-7849-2009 FU NIH [T32AI 7526]; Clayton Foundation for Research; Robert A. Welch Foundation FX We would like to thank Shinji Makino for helpful discussions related to this work. JAW is supported by NIH T32AI 7526 and this work was supported, in part, by the Clayton Foundation for Research. JCL is supported by the Robert A. Welch Foundation. NR 45 TC 25 Z9 25 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD APR 25 PY 2012 VL 426 IS 1 BP 22 EP 33 DI 10.1016/j.virol.2011.11.022 PG 12 WC Virology SC Virology GA 909LH UT WOS:000301565500004 PM 22314017 ER PT J AU Ford, ES AF Ford, Earl S. TI Ideal Cardiovascular Health Start Young, Finish Strong SO CIRCULATION LA English DT Editorial Material DE Editorials; pediatrics; population; prevention; risk factors ID AMERICAN-HEART-ASSOCIATION; TRENDS; ADOLESCENTS; PREVALENCE; DISEASE; PROMOTION; MORTALITY; EDUCATION; CHILDREN; OBESITY C1 Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,MS K67, Atlanta, GA 30341 USA. EM eford@cdc.gov FU Intramural CDC HHS [CC999999] NR 20 TC 5 Z9 5 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD APR 24 PY 2012 VL 125 IS 16 BP 1955 EP 1957 DI 10.1161/CIRCULATIONAHA.112.102327 PG 3 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 981GP UT WOS:000306955300012 PM 22452833 ER PT J AU Purdy, MA Lara, J Khudyakov, YE AF Purdy, Michael A. Lara, James Khudyakov, Yury E. TI The Hepatitis E Virus Polyproline Region Is Involved in Viral Adaptation SO PLOS ONE LA English DT Article ID INTRINSICALLY UNSTRUCTURED PROTEINS; MOLECULAR RECOGNITION FEATURES; WEB SERVER; HYPERVARIABLE REGION; DISORDERED PROTEINS; SECONDARY STRUCTURE; ENERGY CONTENT; PREDICTION; BINDING; INFECTION AB Genomes of hepatitis E virus (HEV), rubivirus and cutthroat virus (CTV) contain a region of high proline density and low amino acid (aa) complexity, named the polyproline region (PPR). In HEV genotypes 1, 3 and 4, it is the only region within the non-structural open reading frame (ORF1) with positive selection (4-10 codons with dN/dS>1). This region has the highest density of sites with homoplasy values >0.5. Genotypes 3 and 4 show similar to 3-fold increase in homoplastic density (HD) in the PPR compared to any other region in ORF1, genotype 1 does not exhibit significant HD (p>0.0001). PPR sequence divergence was found to be 2-fold greater for HEV genotypes 3 and 4 than for genotype 1. The data suggest the PPR plays an important role in host-range adaptation. Although the PPR appears to be hypervariable and homoplastic, it retains as much phylogenetic signal as any other similar sized region in the ORF1, indicating that convergent evolution operates within the major HEV phylogenetic lineages. Analyses of sequence-based secondary structure and the tertiary structure identify PPR as an intrinsically disordered region (IDR), implicating its role in regulation of replication. The identified propensity for the disorder-to-order state transitions indicates the PPR is involved in protein-protein interactions. Furthermore, the PPR of all four HEV genotypes contains seven putative linear binding motifs for ligands involved in the regulation of a wide number of cellular signaling processes. Structure-based analysis of possible molecular functions of these motifs showed the PPR is prone to bind a wide variety of ligands. Collectively, these data suggest a role for the PPR in HEV adaptation. Particularly as an IDR, the PPR likely contributes to fine tuning of viral replication through protein-protein interactions and should be considered as a target for development of novel anti-viral drugs. C1 [Purdy, Michael A.; Lara, James; Khudyakov, Yury E.] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD TB Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Purdy, MA (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD TB Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM mup3@cdc.gov FU Division of Viral Hepatitis, Center for Disease Control FX This research was funded completely with programmatic funds from the Division of Viral Hepatitis, Center for Disease Control. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors conceived of this project, conducted experiments as conceived and analyzed the data. No outside influence was used to modify our data or conclusions in any way. NR 66 TC 23 Z9 24 U1 3 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 24 PY 2012 VL 7 IS 4 AR e35974 DI 10.1371/journal.pone.0035974 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 959VE UT WOS:000305343200073 PM 22545153 ER PT J AU Hall, HI Holtgrave, DR Maulsby, C AF Hall, H. Irene Holtgrave, David R. Maulsby, Catherine TI HIV transmission rates from persons living with HIV who are aware and unaware of their infection SO AIDS LA English DT Article ID UNITED-STATES; ANTIRETROVIRAL THERAPY; SEXUAL TRANSMISSION; MEDICAL-CARE; PREVENTION; ENGAGEMENT; RETENTION; SPECTRUM; LINKAGE; VIRUS AB Transmission rate modeling estimated secondary infections from those aware and unaware of their HIV infection. An estimated 49% of transmissions were from the 20% of persons living with HIV unaware of their infection. About eight transmissions would be averted per 100 persons newly aware of their infection; with more infections averted the higher the percentage of persons with viral suppression who can be linked to care. Improving all stages of HIV care would substantially reduce transmission rates. C1 [Hall, H. Irene] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Holtgrave, David R.; Maulsby, Catherine] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA. RP Hall, HI (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, MS E-47,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ixh1@cdc.gov NR 20 TC 113 Z9 114 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD APR 24 PY 2012 VL 26 IS 7 BP 893 EP 896 DI 10.1097/QAD.0b013e328351f73f PG 4 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 926EB UT WOS:000302813000017 PM 22313960 ER PT J AU Zhang, Y Xu, ST Wang, HL Zhu, Z Ji, YX Liu, CY Zhang, XJ Sun, LW Zhou, JH Lu, PS Hu, Y Feng, DX Zhang, ZY Wang, CY Fang, XQ Zheng, HY Liu, L Sun, XD Tang, W Wang, Y Liu, Y Gao, H Tian, H Ma, JT Gu, SY Wang, S Feng, Y Bo, F Liu, JF Si, Y Zhou, SJ Ma, YY Wu, SW Zhou, SD Li, FC Ding, ZR Yang, ZH Rota, PA Featherstone, D Jee, Y Bellini, WJ Xu, WB AF Zhang, Yan Xu, Songtao Wang, Huiling Zhu, Zhen Ji, Yixin Liu, Chunyu Zhang, Xiaojie Sun, Liwei Zhou, Jianhui Lu, Peishan Hu, Ying Feng, Daxing Zhang, Zhenying Wang, Changyin Fang, Xueqiang Zheng, Huanying Liu, Leng Sun, Xiaodong Tang, Wei Wang, Yan Liu, Yan Gao, Hui Tian, Hong Ma, Jiangtao Gu, Suyi Wang, Shuang Feng, Yan Bo, Fang Liu, Jianfeng Si, Yuan Zhou, Shujie Ma, Yuyan Wu, Shengwei Zhou, Shunde Li, Fangcai Ding, Zhengrong Yang, Zhaohui Rota, Paul A. Featherstone, David Jee, Youngmee Bellini, William J. Xu, Wenbo TI Single Endemic Genotype of Measles Virus Continuously Circulating in China for at Least 16 Years SO PLOS ONE LA English DT Article ID REPUBLIC-OF-CHINA; GENETIC-CHARACTERIZATION; MOLECULAR EPIDEMIOLOGY; UNITED-STATES; ELIMINATION AB The incidence of measles in China from 1991 to 2008 was reviewed, and the nucleotide sequences from 1507 measles viruses (MeV) isolated during 1993 to 2008 were phylogenetically analyzed. The results showed that measles epidemics peaked approximately every 3 to 5 years with the range of measles cases detected between 56,850 and 140,048 per year. The Chinese MeV strains represented three genotypes; 1501 H1, 1 H2 and 5 A. Genotype H1 was the predominant genotype throughout China continuously circulating for at least 16 years. Genotype H1 sequences could be divided into two distinct clusters, H1a and H1b. A 4.2% average nucleotide divergence was found between the H1a and H1b clusters, and the nucleotide sequence and predicted amino acid homologies of H1a viruses were 92.3%-100% and 84.7%-100%, H1b were 97.1%-100% and 95.3%-100%, respectively. Viruses from both clusters were distributed throughout China with no apparent geographic restriction and multiple co-circulating lineages were present in many provinces. Cluster H1a and H1b viruses were co-circulating during 1993 to 2005, while no H1b viruses were detected after 2005 and the transmission of that cluster has presumably been interrupted. Analysis of the nucleotide and predicted amino acid changes in the N proteins of H1a and H1b viruses showed no evidence of selective pressure. This study investigated the genotype and cluster distribution of MeV in China over a 16-year period to establish a genetic baseline before MeV elimination in Western Pacific Region (WPR). Continuous and extensive MeV surveillance and the ability to quickly identify imported cases of measles will become more critical as measles elimination goals are achieved in China in the near future. This is the first report that a single endemic genotype of measles virus has been found to be continuously circulating in one country for at least 16 years. C1 [Zhang, Yan; Xu, Songtao; Wang, Huiling; Zhu, Zhen; Ji, Yixin; Xu, Wenbo] China Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, WHO WPRO Reg Reference Measles Lab, Beijing, Peoples R China. [Liu, Chunyu] Chinese Acad Med Sci, Inst Pathogen Biol, Beijing 100730, Peoples R China. [Liu, Chunyu] Peking Union Med Coll, Beijing 100021, Peoples R China. [Zhang, Xiaojie; Sun, Liwei] Changchun Childrens Hosp, Changchun, Jilin, Peoples R China. [Zhou, Jianhui; Wang, Shuang] Jilin Prov Ctr Dis Control & Prevent, Changchun, Jilin, Peoples R China. [Lu, Peishan; Hu, Ying] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China. [Feng, Daxing; Zhang, Zhenying] Henan Prov Ctr Dis Control & Prevent, Zhengzhou, Henan, Peoples R China. [Wang, Changyin; Fang, Xueqiang] Shandong Prov Ctr Dis Control & Prevent, Jinan, Shandong, Peoples R China. [Zheng, Huanying; Liu, Leng] Guangdong Prov Ctr Dis Control & Prevent, Guangzhou, Guangdong, Peoples R China. [Sun, Xiaodong; Tang, Wei] Shanghai Prov Ctr Dis Control & Prevent, Shanghai, Peoples R China. [Wang, Yan] Liaoning Prov Ctr Dis Control & Prevent, Shenyang, Liaoning, Peoples R China. [Liu, Yan] Hebei Prov Ctr Dis Control & Prevent, Baoding, Hebei, Peoples R China. [Gao, Hui] Shanxi Prov Ctr Dis Control & Prevent, Taiyuan, Shanxi, Peoples R China. [Tian, Hong] Tianjin Prov Ctr Dis Control & Prevent, Tianjin, Peoples R China. [Ma, Jiangtao] Ningxia Prov Ctr Dis Control & Prevent, Ningxia, Peoples R China. [Gu, Suyi] Innermongolia Prov Ctr Dis Control & Prevent, Hohhot, Innermongolia, Peoples R China. [Feng, Yan] Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou, Zhejiang, Peoples R China. [Bo, Fang] Heilongjiang Prov Ctr Dis Control & Prevent, Haerbin, Heilongjiang, Peoples R China. [Liu, Jianfeng] Gansu Prov Ctr Dis Control & Prevent, Lanzhou, Gansu, Peoples R China. [Si, Yuan] Shannxi Prov Ctr Dis Control & Prevent, Xian, Shannxi, Peoples R China. [Zhou, Shujie] Anhui Prov Ctr Dis Control & Prevent, Hefei, Anhui, Peoples R China. [Ma, Yuyan] Guangxi Prov Ctr Dis Control & Prevent, Nanning, Guangxi, Peoples R China. [Wu, Shengwei] Guizhou Prov Ctr Dis Control & Prevent, Guiyang, Guizhou, Peoples R China. [Zhou, Shunde] Jiangxi Prov Ctr Dis Control & Prevent, Nanchang, Jiangxi, Peoples R China. [Li, Fangcai] Hunan Prov Ctr Dis Control & Prevent, Changsha, Hunan, Peoples R China. [Ding, Zhengrong] Yunnan Prov Ctr Dis Control & Prevent, Kunming, Yunnan, Peoples R China. [Yang, Zhaohui] Hubei Prov Ctr Dis Control & Prevent, Wuhan, Hubei, Peoples R China. [Rota, Paul A.; Bellini, William J.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Featherstone, David] WHO, CH-1211 Geneva, Switzerland. [Jee, Youngmee] WHO, Western Pacific Reg Off, Expanded Programme Immunizat, Manila, Philippines. RP Xu, WB (reprint author), China Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, WHO WPRO Reg Reference Measles Lab, Beijing, Peoples R China. EM wenbo_xu1@yahoo.com.cn FU WHO; WHO headquarters, WPRO, US CDC FX This study was supported by the grants of WHO fund for WPRO Measles Regional Reference Laboratory. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank all the provincial and prefecture measles laboratory staffs and epidemiologists in mainland China for providing clinical specimens, isolates and epidemiologic data; We thank WHO headquarters, WPRO, US CDC for the technical and financial support. We also acknowledge anonymous reviewers for comments that improved the manuscript. NR 29 TC 10 Z9 17 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 20 PY 2012 VL 7 IS 4 AR e34401 DI 10.1371/journal.pone.0034401 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 959UD UT WOS:000305339200013 PM 22532829 ER PT J AU Prithiviraj, J Hill, V Jothikumar, N AF Prithiviraj, Jothikumar Hill, Vincent Jothikumar, Narayanan TI Rapid detection of microbial DNA by a novel isothermal genome exponential amplification reaction (GEAR) assay SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Molecular; Isothermal amplification; Nucleic acids; Diagnosis; Real-time monitoring ID DISPLACEMENT AMPLIFICATION; CHAIN-REACTION; POLYMERASE; SPECIMENS; INVITRO AB In this study we report the development of a simple target-specific isothermal nucleic acid amplification technique, termed genome exponential amplification reaction (GEAR). Escherichia coli was selected as the microbial target to demonstrate the GEAR technique as a proof of concept. The GEAR technique uses a set of four primers; in the present study these primers targeted 5 regions on the 16S rRNA gene of E. coli. The outer forward and reverse Tab primer sequences are complementary to each other at their 5' end, whereas their 3' end sequences are complementary to their respective target nucleic acid sequences. The GEAR assay was performed at a constant temperature 60 degrees C and monitored continuously in a real-time PCR instrument in the presence of an intercalating dye (SYTO 9). The GEAR assay enabled amplification of as few as one colony forming units of E. coli per reaction within 30 min. We also evaluated the GEAR assay for rapid identification of bacterial colonies cultured on agar media directly in the reaction without DNA extraction. Cells from E. coli colonies were picked and added directly to GEAR assay master-mix without prior DNA extraction. DNA in the cells could be amplified, yielding positive results within 15 min. Published by Elsevier Inc. C1 [Hill, Vincent; Jothikumar, Narayanan] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Waterborne Dis Prevent Branch, Atlanta, GA 30329 USA. [Prithiviraj, Jothikumar] Georgia Tech, Inst Bioengn & Biosci, Atlanta, GA 30332 USA. RP Jothikumar, N (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Waterborne Dis Prevent Branch, 1600 Clifton Rd NE,Mail Stop D-66, Atlanta, GA 30329 USA. EM jin2@cdc.gov RI Hill, Vincent/G-1789-2012 OI Hill, Vincent/0000-0001-7069-7737 NR 20 TC 4 Z9 4 U1 1 U2 20 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD APR 20 PY 2012 VL 420 IS 4 BP 738 EP 742 DI 10.1016/j.bbrc.2012.03.055 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 936VW UT WOS:000303619100008 PM 22450319 ER PT J AU Raisch, DW Feeney, P Goff, DC Narayan, KMV O'Connor, PJ Zhang, P Hire, DG Sullivan, MD AF Raisch, Dennis W. Feeney, Patricia Goff, David C., Jr. Narayan, K. M. Venkat O'Connor, Patrick J. Zhang, Ping Hire, Don G. Sullivan, Mark D. TI Baseline comparison of three health utility measures and the feeling thermometer among participants in the action to control cardiovascular risk in diabetes trial SO CARDIOVASCULAR DIABETOLOGY LA English DT Article DE Diabetes mellitus; Type 2/* complications /physiopathology/psychology; Health status indicators; Randomized controlled clinical trial; Humans; Regression analysis; Glycemic control ID QUALITY-OF-LIFE; PREFERENCE-BASED MEASURE; VISUAL ANALOG SCALES; COST-EFFECTIVENESS; RHEUMATOID-ARTHRITIS; STANDARD GAMBLE; VALUING HEALTH; CLINICAL-TRIAL; BODY-MASS; INDEX AB Background: Health utility (HU) measures are used as overall measures of quality of life and to determine quality adjusted life years (QALYs) in economic analyses. We compared baseline values of three HUs including Short Form 6 Dimensions (SF-6D), and Health Utilities Index, Mark II and Mark III (HUI2 and HUI3) and the feeling thermometer (FT) among type 2 diabetes participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. We assessed relationships between HU and FT values and patient demographics and clinical variables. Methods: ACCORD was a randomized clinical trial to test if intensive controls of glucose, blood pressure and lipids can reduce the risk of major cardiovascular disease (CVD) events in type 2 diabetes patients with high risk of CVD. The health-related quality of life (HRQOL) sub-study includes 2,053 randomly selected participants. Interclass correlations (ICCs) and agreement between measures by quartile were used to evaluate relationships between HU's and the FT. Multivariable regression models specified relationships between patient variables and each HU and the FT. Results: The ICCs were 0.245 for FT/SF-6D, 0.313 for HUI3/SF-6D, 0.437 for HUI2/SF-6D, 0.338 for FT/HUI2, 0.337 for FT/HUI3 and 0.751 for HUI2/HUI3 (P < 0.001 for all). Common classification by quartile was found for the majority (62%) of values between HUI2 and HUI3, which was significantly (P < 0.001) higher than between other HUs and the FT: SF-6D/HUI3 = 40.8%, SF-6D/HUI2 = 40.9%, FT/HUI3 = 35.0%, FT/HUI2 = 34.9%, and FT/SF-6D = 31.9%. Common classification was higher between SF-6D/HUI2 and SF-6D/HUI3 (P < 0.001) than between FT/SF-6D, FT/HUI2, and FT/HUI3. The mean difference in HU values per patient ranged from -0.024 +/- 0.225 for SF-6D/HUI3 to -0.124 +/- 0.133 for SF-6D/ HUI2. Regression models were significant; clinical and demographic variables explained 6.1% (SF-6D) to 7.7% (HUI3) of the variance in HUs. Conclusions: The agreements between the different HUs were poor except for the two HUI measures; therefore HU values derived different measures may not be comparable. The FT had low agreement with HUs. The relationships between HUs and demographic and clinical measures demonstrate how severity of diabetes and other clinical and demographic factors are associated with HUs and FT measures. C1 [Raisch, Dennis W.] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA. [Raisch, Dennis W.] Clin Res Pharm Coordinating Ctr, VA Cooperat Studies Program, Albuquerque, NM USA. [Feeney, Patricia; Goff, David C., Jr.; Hire, Don G.] Wake Forest Univ Hlth Sci, Winston Salem, NC 27157 USA. [Narayan, K. M. Venkat] Emory Univ, Sch Publ Hlth, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [O'Connor, Patrick J.] HealthPartners Res Fdn, Minneapolis, MN USA. [Zhang, Ping] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Sullivan, Mark D.] Univ Washington, Seattle, WA 98195 USA. RP Raisch, DW (reprint author), Univ New Mexico, Hlth Sci Ctr, 1 Univ New Mexico, Albuquerque, NM 87131 USA. EM draisch@salud.unm.edu RI Narayan, K.M. Venkat /J-9819-2012 OI Narayan, K.M. Venkat /0000-0001-8621-5405 FU National Heart, Lung, and Blood Institute FX The study was funded by the National Heart, Lung, and Blood Institute, who provided financial support throughout the conduct of the study. Except for PF and DH, the authors are no longer financially supported by the funding agency. NR 51 TC 5 Z9 5 U1 2 U2 14 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2840 J9 CARDIOVASC DIABETOL JI Cardiovasc. Diabetol. PD APR 19 PY 2012 VL 11 AR 35 DI 10.1186/1475-2840-11-35 PG 9 WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism SC Cardiovascular System & Cardiology; Endocrinology & Metabolism GA 973LV UT WOS:000306362500001 PM 22515638 ER PT J AU Smith, JH Papania, M Knaus, D Brooks, P Haas, DL Mair, R Barry, J Tompkins, SM Tripp, RA AF Smith, Jennifer Humberd Papania, Mark Knaus, Darin Brooks, Paula Haas, Debra L. Mair, Raydel Barry, James Tompkins, S. Mark Tripp, Ralph A. TI Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose SO VACCINE LA English DT Article DE Influenza; Vaccine; Dose-sparing; Ferret; Aerosol ID IMMUNE-RESPONSES; VIRUS-INFECTION; ANTIBODY; SERUM; IMMUNIZATION; CHALLENGE; CHILDREN; EFFICACY; AEROSOL; SAFETY AB Live-attenuated influenza vaccine (LAIV) is delivered to vaccine recipients using a nasal spray syringe. LAIV delivered by this method is immunogenic at current doses; however, improvements in nasal delivery might allow for significant dose reduction. We investigated LAIV vaccination in ferrets using a high efficiency nebulizer designed for nasal delivery. LAIV nasal aerosol elicited high levels of serum neutralizing antibodies and protected ferrets from homologous virus challenge at conventional (10(7) TCID50) and significantly reduced (10(3) TCID50) doses. Aerosol LAIV also provided a significant level of subtype-specific cross-protection. These results demonstrate the dose-sparing potential of nebulizer-based nasal aerosol LAIV delivery. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Tripp, Ralph A.] Univ Georgia, Anim Hlth Res Ctr, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA. [Mair, Raydel] Ctr Dis Control & Prevent CDC, Meningitis Lab, Atlanta, GA 30333 USA. [Papania, Mark] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. [Knaus, Darin; Barry, James] Creare Res & Dev Inc, Hanover, NH 03755 USA. RP Tripp, RA (reprint author), Univ Georgia, Anim Hlth Res Ctr, Coll Vet Med, Dept Infect Dis, 111 Carlton St, Athens, GA 30602 USA. EM ratripp@uga.edu RI Tompkins, Stephen/A-3317-2008; OI Tompkins, Stephen/0000-0002-1523-5588; Tripp, Ralph/0000-0002-2924-9956 FU CDC SBIR [1021RR211316, HHSN266200700006C] FX These studies were supported by CDC SBIR award #1021RR211316 and HHSN266200700006C. MedImmune provided the LAIV vaccines used in the study along with technical input on the study protocols. The nebulizers used in this study were designed and manufactured by Creare, Inc. (Hanover, NH) under Small Business Innovation Research contracts with the Centers for Disease Control and Prevention (CDC). Creare, Inc. and CDC share multiple patents for the nebulizer design and the technology has been commercially licensed to AerovectRx, Inc. Dr. Papania, Dr. Barry, and Dr. Knaus are co-inventors of the technology and thus have a financial interest in the nebulizer devices. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 40 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD APR 19 PY 2012 VL 30 IS 19 BP 3026 EP 3033 DI 10.1016/j.vaccine.2011.10.092 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 934FM UT WOS:000303429100017 PM 22075083 ER PT J AU Swanson, SJ Phares, CR Mamo, B Smith, KE Cetron, MS Stauffer, WM AF Swanson, Stephen J. Phares, Christina R. Mamo, Blain Smith, Kirk E. Cetron, Martin S. Stauffer, William M. TI Albendazole Therapy and Enteric Parasites in United States-Bound Refugees SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID TRANSMITTED HELMINTH INFECTIONS; NEGLECTED TROPICAL DISEASES; PRE-DEPARTURE TREATMENT; SUB-SAHARAN AFRICA; INTESTINAL PARASITES; MONTAGNARD REFUGEES; HOOKWORM INFECTION; SUDANESE REFUGEES; HIGH-PREVALENCE; EFFICACY AB Background Beginning on May 1, 1999, the Centers for Disease Control and Prevention (CDC) recommended presumptive treatment of refugees for intestinal parasites with a single dose of albendazole (600 mg), administered overseas before departure for the United States. Methods We conducted a retrospective cohort study involving 26,956 African and Southeast Asian refugees who were screened by means of microscopical examination of stool specimens for intestinal parasites on resettlement in Minnesota between 1993 and 2007. Adjusted prevalence ratios for intestinal nematodes, schistosoma species, giardia, and entamoeba were calculated among refugees who migrated before versus those who migrated after the CDC recommendation of presumptive predeparture albendazole treatment. Results Among 4370 untreated refugees, 20.8% had at least one stool nematode, most commonly hookworm (in 9.2%). Among 22,586 albendazole-treated refugees, only 4.7% had one or more nematodes, most commonly trichuris (in 3.9%). After adjustment for sex, age, and region, albendazole-treated refugees were less likely than untreated refugees to have any nematodes (prevalence ratio, 0.19), ascaris (prevalence ratio, 0.06), hookworm (prevalence ratio, 0.07), or trichuris (prevalence ratio, 0.27) but were not less likely to have giardia or entamoeba. Schistosoma ova were identified exclusively among African refugees and were less prevalent among those treated with albendazole (prevalence ratio, 0.60). After implementation of the albendazole protocol, the most common pathogens among 17,011 African refugees were giardia (in 5.7%), trichuris (in 5.0%), and schistosoma (in 1.8%); among 5575 Southeast Asian refugees, only giardia remained highly prevalent (present in 17.2%). No serious adverse events associated with albendazole use were reported. Conclusions Presumptive albendazole therapy administered overseas before departure for the United States was associated with a decrease in the prevalence of intestinal nematodes among newly arrived African and Southeast Asian refugees. C1 [Swanson, Stephen J.] Epidem Intelligence Serv, Atlanta, GA USA. [Phares, Christina R.; Cetron, Martin S.; Stauffer, William M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Swanson, Stephen J.; Mamo, Blain; Smith, Kirk E.] Minnesota Dept Hlth, St Paul, MN USA. [Swanson, Stephen J.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Swanson, Stephen J.; Stauffer, William M.] Univ Minnesota, Minneapolis, MN USA. RP Swanson, SJ (reprint author), Hennepin Cty Med Ctr, Dept Pediat, 701 Pk Ave,G7, Minneapolis, MN 55415 USA. EM stephen.swanson@hcmed.org NR 41 TC 20 Z9 21 U1 0 U2 3 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 19 PY 2012 VL 366 IS 16 BP 1498 EP 1507 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 927UE UT WOS:000302934800007 PM 22512482 ER PT J AU Huho, BJ Killeen, GF Ferguson, HM Tami, A Lengeler, C Charlwood, JD Kihonda, A Kihonda, J Kachur, SP Smith, TA Abdulla, SMK AF Huho, Bernadette J. Killeen, Gerard F. Ferguson, Heather M. Tami, Adriana Lengeler, Christian Charlwood, J. Derek Kihonda, Aniset Kihonda, Japhet Kachur, S. Patrick Smith, Thomas A. Abdulla, Salim M. K. TI Artemisinin-based combination therapy does not measurably reduce human infectiousness to vectors in a setting of intense malaria transmission SO MALARIA JOURNAL LA English DT Article DE Malaria; Artemisinin-based combination therapy; Transmission reduction; Malaria ID PLASMODIUM-FALCIPARUM MALARIA; PAPUA-NEW-GUINEA; SUB-SAHARAN AFRICA; RURAL TANZANIA; SULFADOXINE-PYRIMETHAMINE; ANOPHELES-GAMBIAE; SOUTHERN TANZANIA; HUMAN-POPULATIONS; 6-DOSE REGIMEN; MOSQUITOS AB Background: Artemisinin-based combination therapy (ACT) for treating malaria has activity against immature gametocytes. In theory, this property may complement the effect of terminating otherwise lengthy malaria infections and reducing the parasite reservoir in the human population that can infect vector mosquitoes. However, this has never been verified at a population level in a setting with intense transmission, where chronically infectious asymptomatic carriers are common and cured patients are rapidly and repeatedly re-infected. Methods: From 2001 to 2004, malaria vector densities were monitored using light traps in three Tanzanian districts. Mosquitoes were dissected to determine parous and oocyst rates. Plasmodium falciparum sporozoite rates were determined by ELISA. Sulphadoxine-pyrimethamine (SP) monotherapy was used for treatment of uncomplicated malaria in the contiguous districts of Kilombero and Ulanga throughout this period. In Rufiji district, the standard drug was changed to artesunate co-administered with SP (AS + SP) in March 2003. The effects of this change in case management on malaria parasite infection in the vectors were analysed. Results: Plasmodium falciparum entomological inoculation rates exceeded 300 infective bites per person per year at both sites over the whole period. The introduction of AS + SP in Rufiji was associated with increased oocyst prevalence (OR [95% CI] = 3.9 [2.9-5.3], p < 0.001), but had no consistent effect on sporozoite prevalence (OR [95% CI] = 0.9 [0.7-1.2], p = 0.5). The estimated infectiousness of the human population in Rufiji was very low prior to the change in drug policy. Emergence rates and parous rates of the vectors varied substantially throughout the study period, which affected estimates of infectiousness. The latter consequently cannot be explained by the change in drug policy. Conclusions: In high perennial transmission settings, only a small proportion of infections in humans are symptomatic or treated, so case management with ACT may have little impact on overall infectiousness of the human population. Variations in infection levels in vectors largely depend on the age distribution of the mosquito population. Benefits of ACT in suppressing transmission are more likely to be evident where transmission is already low or effective vector control is widely implemented. C1 [Huho, Bernadette J.; Killeen, Gerard F.; Ferguson, Heather M.; Kihonda, Aniset; Kihonda, Japhet; Kachur, S. Patrick; Abdulla, Salim M. K.] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Huho, Bernadette J.; Lengeler, Christian; Smith, Thomas A.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Killeen, Gerard F.; Charlwood, J. Derek] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [Ferguson, Heather M.] Univ Glasgow, Div Infect & Immun, Glasgow G12 8TA, Lanark, Scotland. [Tami, Adriana] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol, NL-9713 AV Groningen, Netherlands. [Tami, Adriana] Royal Trop Inst, NL-1105 AZ Amsterdam, Netherlands. [Kachur, S. Patrick] US Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Huho, Bernadette J.; Lengeler, Christian; Smith, Thomas A.] Univ Basel, CH-4003 Basel, Switzerland. RP Kachur, SP (reprint author), Ifakara Hlth Inst, Dar Es Salaam, Tanzania. EM spk0@cdc.gov RI Smith, Thomas/B-5569-2015; OI Smith, Thomas/0000-0002-3650-9381; Ferguson, Heather/0000-0002-9625-5176 FU Swiss National Science Foundation [3270-059541-99]; Malaria Transmission Intensity and Mortality Burden Across Africa (MTIMBA) project through MIM/TDR initiative; Malaria Transmission Intensity and Mortality Burden Across Africa (MTIMBA) project through RBM initiative; Wellcome Trust [076806]; Centre for Disease Control and Prevention, USA through the Interdisciplinary Monitoring Programme for Antimalarial Combination Therapy in Tanzania (IMPACT) project; CDC, United States Agency for International Development FX Adult mosquito surveys were partly funded by the Swiss National Science Foundation (Grant number 3270-059541-99) and by the Malaria Transmission Intensity and Mortality Burden Across Africa (MTIMBA) project through MIM/TDR and RBM initiatives. GFK was supported by a Wellcome Trust Research Career Development Fellowship (076806) and SPK by the Centre for Disease Control and Prevention, USA through the Interdisciplinary Monitoring Programme for Antimalarial Combination Therapy in Tanzania (IMPACT) project. The Interdisciplinary Monitoring Project for Antimalarial Combination Therapy in Tanzania (IMPACT) operated as a multiyear implementation research evaluation platform comprising the US Centers for Disease Control and Prevention (CDC), Ifakara Health Institute, the National Institute for Medical Research, Muhimbili University College of Health Sciences, the London School of Hygiene and Tropical Medicine (UK) and the Tanzanian Ministry of Health and Social Welfare, including its National Malaria Control Programme, the Tanzania Essential Health Interventions Project, and the Council Health Management Teams of Rufiji, Morogoro, Mvomeru, Kilombero and Ulanga Districts. IMPACT was primarily supported by funding from the CDC, United States Agency for International Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 52 TC 9 Z9 9 U1 1 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD APR 18 PY 2012 VL 11 AR 118 DI 10.1186/1475-2875-11-118 PG 12 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 033HF UT WOS:000310784200001 PM 22513162 ER PT J AU Fontecha, GA Mendoza, M Banegas, E Poorak, M De Oliveira, AM Mancero, T Udhayakumar, V Lucchi, NW Mejia, RE AF Fontecha, Gustavo A. Mendoza, Meisy Banegas, Engels Poorak, Mitra De Oliveira, Alexandre M. Mancero, Tamara Udhayakumar, Venkatachalam Lucchi, Naomi W. Mejia, Rosa E. TI Comparison of molecular tests for the diagnosis of malaria in Honduras SO MALARIA JOURNAL LA English DT Article ID POLYMERASE-CHAIN-REACTION; PLASMODIUM-FALCIPARUM; MIXED INFECTIONS; MULTIPLEX PCR; VIVAX; PARASITES; IDENTIFICATION; MICROSCOPY; ASSAY AB Background: Honduras is a tropical country with more than 70% of its population living at risk of being infected with either Plasmodium vivax or Plasmodium falciparum. Laboratory diagnosis is a very important factor for adequate treatment and management of malaria. In Honduras, malaria is diagnosed by both, microscopy and rapid diagnostic tests and to date, no molecular methods have been implemented for routine diagnosis. However, since mixed infections, and asymptomatic and low-parasitaemic cases are difficult to detect by light microscopy alone, identifying appropriate molecular tools for diagnostic applications in Honduras deserves further study. The present study investigated the utility of different molecular tests for the diagnosis of malaria in Honduras. Methods: A total of 138 blood samples collected as part of a clinical trial to assess the efficacy of chloroquine were used: 69 microscopically confirmed P. falciparum positive samples obtained on the day of enrolment and 69 follow-up samples obtained 28 days after chloroquine treatment and shown to be malaria negative by microscopy. Sensitivity and specificity of microscopy was compared to an 18 s ribosomal RNA gene-based nested PCR, two single-PCR reactions designed to detect Plasmodium falciparum infections, one single-PCR to detect Plasmodium vivax infections, and one multiplex one-step PCR reaction to detect both parasite species. Results: Of the 69 microscopically positive P. falciparum samples, 68 were confirmed to be P. falciparum-positive by two of the molecular tests used. The one sample not detected as P. falciparum by any of the molecular tests was shown to be P. vivax-positive by a reference molecular test indicating a misdiagnosis by microscopy. The reference molecular test detected five cases of P. vivax/P. falciparum mixed infections, which were not recognized by microscopy as mixed infections. Only two of these mixed infections were recognized by a multiplex test while a P. vivax-specific polymerase chain reaction (PCR) detected three of them. In addition, one of the day 28 samples, previously determined to be malaria negative by microscopy, was shown to be P. vivax-positive by three of the molecular tests specific for this parasite. Conclusions: Molecular tests are valuable tools for the confirmation of Plasmodium species and in detecting mixed infections in malaria endemic regions. C1 [Poorak, Mitra; De Oliveira, Alexandre M.; Udhayakumar, Venkatachalam; Lucchi, Naomi W.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Fontecha, Gustavo A.] UNAH, MEIZ Microbiol Sch, Tegucigalpa, Honduras. [Mendoza, Meisy; Banegas, Engels; Mejia, Rosa E.] Minist Hlth, Natl Malaria Lab, Tegucigalpa, Honduras. [Mancero, Tamara] PAHO, Tegucigalpa, Honduras. [Poorak, Mitra; Udhayakumar, Venkatachalam; Lucchi, Naomi W.] Atlanta Res & Educ Fdn, Decatur, GA USA. RP Lucchi, NW (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM NLucchi@cdc.gov RI maria, ana /G-8106-2014 FU United States Agency for International Development (USAID) through Amazon Malaria Initiative (AMI); Atlanta Research and Education Foundation FX We would like to thank the United States Agency for International Development (USAID) through the Amazon Malaria Initiative (AMI) for the financial support. NL and MP were supported by the Atlanta Research and Education Foundation. NR 23 TC 10 Z9 10 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD APR 18 PY 2012 VL 11 AR 119 DI 10.1186/1475-2875-11-119 PG 5 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 982CN UT WOS:000307019400001 PM 22513192 ER PT J AU Ackers, ML Greenberg, AE Lin, CY Bartholow, BN Goodman, AH Longhi, M Gurwith, M AF Ackers, Marta-Louise Greenberg, Alan E. Lin, Carol Y. Bartholow, Bradford N. Goodman, Adrian Hirsch Longhi, Michael Gurwith, Marc TI High and Persistent HIV Seroincidence in Men Who Have Sex with Men across 47 US Cities SO PLOS ONE LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; IMMUNODEFICIENCY-VIRUS VACCINE; NEW-YORK-CITY; RISK BEHAVIOR; UNITED-STATES; YOUNG MEN; SAN-FRANCISCO; HOMOSEXUAL-MEN; SUBSTANCE USE; DRUG-USE AB Objective: To provide HIV seroincidence data among men who have sex with men (MSM) in the United States and to identify predictive factors for seroconversion. Methods: From 1998-2002, 4684 high-risk MSM, age 18-60 years, participated in a randomized, placebo-controlled HIV vaccine efficacy trial at 56 U. S. clinical trial sites. Demographics, behavioral data, and HIV status were assessed at baseline and 6 month intervals. Since no overall vaccine efficacy was detected, data were combined from both trial arms to calculate HIV incidence based on person-years (py) of follow-up. Predictors of seroconversion, adjusted hazards ratio (aHR), were evaluated using a Cox proportional hazard model with time-varying covariates. Results: Overall, HIV incidence was 2.7/100 py and was relatively uniform across study sites and study years. HIV incidence was highest among young men and men reporting unprotected sex, recreational drug use, and a history of a sexually transmitted infection. Independent predictors of HIV seroconversion included: age 18-30 years (aHR = 2.4; 95% CI 1.4,4.0), having >10 partners (aHR = 2.4; 95% CI 1.7,3.3), having a known HIV-positive male sex partner (aHR = 1.6; 95% CI 1.2, 2.0), unprotected anal intercourse with HIV positive/unknown male partners (aHR = 1.7; 95% CI 1.3, 2.3), and amphetamine (aHR = 1.6; 95% CI 1.1, 2.1) and popper (aHR = 1.7; 95% CI 1.3, 2.2) use. Conclusions: HIV seroincidence was high among MSM despite repeated HIV counseling and reported declines in sexual risk behaviors. Continuing development of new HIV prevention strategies and intensification of existing efforts will be necessary to reduce the rate of new HIV infections, especially among young men. C1 [Ackers, Marta-Louise; Greenberg, Alan E.; Lin, Carol Y.; Bartholow, Bradford N.] Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div HIV AIDS Prevent, Epidemiol Branch, Atlanta, GA USA. [Lin, Carol Y.] Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div HIV AIDS Prevent, Quantitat Sci & Data Management Branch, Atlanta, GA USA. [Goodman, Adrian Hirsch; Longhi, Michael; Gurwith, Marc] VaxGen Inc, Brisbane, CA USA. RP Ackers, ML (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA. EM mda6@cdc.gov FU VaxGen, Inc.; US Centers for Disease Control and Prevention FX This work was supported by VaxGen, Inc., and US Centers for Disease Control and Prevention. No funding bodies had any role in the study design, data collection, analysis, decision to publish or preparation of the manuscript. NR 56 TC 23 Z9 25 U1 3 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 18 PY 2012 VL 7 IS 4 AR e34972 DI 10.1371/journal.pone.0034972 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 959XD UT WOS:000305350600049 PM 22529964 ER PT J AU Eisen, RJ Borchert, JN Mpanga, JT Atiku, LA MacMillan, K Boegler, KA Montenieri, JA Monaghan, A Gage, KL AF Eisen, Rebecca J. Borchert, Jeff N. Mpanga, Joseph T. Atiku, Linda A. MacMillan, Katherine Boegler, Karen A. Montenieri, John A. Monaghan, Andrew Gage, Kenneth L. TI Flea Diversity as an Element for Persistence of Plague Bacteria in an East African Plague Focus SO PLOS ONE LA English DT Article ID WESTERN USAMBARA MOUNTAINS; EARLY-PHASE TRANSMISSION; SOUTHWESTERN UNITED-STATES; YERSINIA-PESTIS; ENDEMIC REGION; NILE REGION; NEW-MEXICO; TANZANIA; CLIMATE; UGANDA AB Plague is a flea-borne rodent-associated zoonotic disease that is caused by Yersinia pestis and characterized by long quiescent periods punctuated by rapidly spreading epidemics and epizootics. How plague bacteria persist during inter-epizootic periods is poorly understood, yet is important for predicting when and where epizootics are likely to occur and for designing interventions aimed at local elimination of the pathogen. Existing hypotheses of how Y. pestis is maintained within plague foci typically center on host abundance or diversity, but little attention has been paid to the importance of flea diversity in enzootic maintenance. Our study compares host and flea abundance and diversity along an elevation gradient that spans from low elevation sites outside of a plague focus in the West Nile region of Uganda (similar to 725-1160 m) to higher elevation sites within the focus (similar to 1380-1630 m). Based on a year of sampling, we showed that host abundance and diversity, as well as total flea abundance on hosts was similar between sites inside compared with outside the plague focus. By contrast, flea diversity was significantly higher inside the focus than outside. Our study highlights the importance of considering flea diversity in models of Y. pestis persistence. C1 [Eisen, Rebecca J.; Borchert, Jeff N.; MacMillan, Katherine; Boegler, Karen A.; Montenieri, John A.; Gage, Kenneth L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Mpanga, Joseph T.; Atiku, Linda A.] Uganda Virus Res Inst, Entebbe, Uganda. [Monaghan, Andrew] Natl Ctr Atmospher Res, Boulder, CO 80307 USA. RP Eisen, RJ (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. EM dyn2@cdc.gov OI Monaghan, Andrew/0000-0002-8170-2359 FU Centers for Disease Control and Prevention's Climate and Health Program; US Agency for International Development Emerging Pandemic Threats Program FX This study was funded by the Centers for Disease Control and Prevention's Climate and Health Program and the US Agency for International Development Emerging Pandemic Threats Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 9 Z9 11 U1 0 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 18 PY 2012 VL 7 IS 4 AR e35598 DI 10.1371/journal.pone.0035598 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 959XD UT WOS:000305350600103 PM 22530057 ER PT J AU Wilczynski, JA Ives, R Peters, S Henderson, T House, J Hill, V Schneeberger, C Xiao, LH Dearen, T Webeck, J AF Wilczynski, Jo Ann Ives, Rebecca Peters, Susan Henderson, Tiffany House, Jennifer Hill, Vincent Schneeberger, Chandra Xiao, Lihua Dearen, Theresa Webeck, Jenna TI Outbreak of Cryptosporidiosis Associated With a Firefighting Response-Indiana and Michigan, June 2011 (Reprinted from MMWR, vol 61, pg 153-156, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Webeck, Jenna] CDC, Atlanta, GA 30333 USA. [Wilczynski, Jo Ann] Branch Hillsdale St Joseph Community Hlth Agcy, Coldwater, MI USA. [Peters, Susan; Henderson, Tiffany] Michigan Dept Community Hlth, Lansing, MI USA. [House, Jennifer] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. [Hill, Vincent; Schneeberger, Chandra; Xiao, Lihua; Dearen, Theresa] Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Ives, Rebecca] Michigan State Univ, E Lansing, MI 48824 USA. RP Webeck, J (reprint author), CDC, Atlanta, GA 30333 USA. EM jwebeck@cdc.gov RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 18 PY 2012 VL 307 IS 15 BP 1574 EP 1576 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 927GU UT WOS:000302896100008 ER PT J AU Zhang, ZF Fang, J Gillespie, C Wang, GJ Hong, YL Yoon, PW AF Zhang, Zefeng Fang, Jing Gillespie, Cathleen Wang, Guijing Hong, Yuling Yoon, Paula W. TI Age-Specific Gender Differences in In-Hospital Mortality by Type of Acute Myocardial Infarction SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE CORONARY SYNDROMES; CHARLSON COMORBIDITY INDEX; SEX-DIFFERENCES; ST-ELEVATION; CLINICAL PRESENTATION; UNSTABLE ANGINA; HEART-DISEASE; CASE-FATALITY; HIGH-RISK; OUTCOMES AB Younger women hospitalized with an acute myocardial infarction (MI) have a poorer prognosis than men. Whether this is true for patients with acute ST-segment elevation MI (STEMI) and non-STEMI (NSTEMI) is not extensively studied. Using the Market Scan 2004 to 2007 Commercial and Medicare supplemental admission databases, we assessed gender differences in in-hospital mortality according to age in 91,088 patients (35,899 with STEMI, 55,189 with NSTEMI) who were 18 to 89 years old and had acute MI as their primary diagnosis. Patients with STEMI had significantly higher in-hospital mortality than those with NSTEMI (4.35% vs 3.53%, p < 0.0001). Compared to men women were older, had higher co-morbidity scores, and were less likely to undergo revascularization during hospitalization in the STEMI and NSTEMI populations. In patients with STEMI the unadjusted women-to-men odds ratio for in-hospital mortality was 2.29 (95% confidence interval 1.48 to 3.55) for the 18- to 49-year age group, 1.68 (1.28 to 2.21) for 50 to 59, 1.48 (1.17 to 1.88) for 60 to 69, 1.28 (1.06 to 1.57) for 70 to 79, and 1.01 (0.83 to 1.23) for 80 to 89. Corresponding unadjusted odds ratios were 1.51 (0.87 to 2.61), 1.46 (1.11 to 1.92), 1.29 (1.04 to 1.61), 0.83 (0.70 to 0.99) and 0.82 (0.70 to 0.94) for patients with NSTEMI. After adjustment for potential confounding factors, excess risk for in-hospital mortality in younger women versus their men counterparts (<60 years old) persisted in STEMI. In patients with NSTEMI the difference between younger women and younger men was not statistically significant; however, older women (>= 70 years old) had better survival than men. In conclusion, higher risk of in-hospital mortality in younger women compared to younger men is more evident in patients with STEMI. Published by Elsevier Inc. (Am J Cardiol 2012;109:1097-1103) C1 [Zhang, Zefeng; Fang, Jing; Gillespie, Cathleen; Wang, Guijing; Hong, Yuling; Yoon, Paula W.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. RP Zhang, ZF (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. EM zzhang3@cdc.gov OI Gillespie, Cathleen/0000-0003-1878-1055 NR 30 TC 49 Z9 51 U1 0 U2 6 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 15 PY 2012 VL 109 IS 8 BP 1097 EP 1103 DI 10.1016/j.amjcard.2011.12.001 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 931NP UT WOS:000303226900003 PM 22245410 ER PT J AU Prineas, RJ Le, A Soliman, EZ Zhang, ZM Howard, VJ Ostchega, Y Howard, G AF Prineas, Ronald J. Le, Anh Soliman, Elsayed Z. Zhang, Zhu-Ming Howard, Virginia J. Ostchega, Yechiam Howard, George CA Reasons Geographic Racial TI United States National Prevalence of Electrocardiographic Abnormalities in Black and White Middle-Age (45- to 64-Year) and Older (>= 65-Year) Adults (from the Reasons for Geographic and Racial Differences in Stroke Study) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID PARTICIPANTS; MORTALITY; RISK; MEN AB A United States national sample of 20,962 participants (57% women, 44% blacks) from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study provided general population estimates for electrocardiographic (ECG) abnormalities among black and white men and women. The participants were recruited from 2003 to 2007 by random selection from a commercially available nationwide list, with oversampling of blacks and those from the stroke belt, with a cooperation rate of 49%. The measurement of risk factors and 12-lead electrocardiograms (centrally coded using Minnesota code criteria) showed 28% had >= 1 major ECG abnormality. The prevalence of abnormalities was greater (>= 35%) for those >= 65 years old, with no differences between blacks and whites. However, among men <65 years, blacks had more major abnormalities than whites, most notably for atrial fibrillation, major Q waves, and left ventricular hypertrophy. Men generally had more ECG abnormalities than women. The most common ECG abnormalities were T-wave abnormalities. The average heart rate-corrected QT interval was longer in women than in men, similar in whites and blacks, and increased with age. However, the average heart rate was greater in women than in men and in blacks than in whites and decreased with age. The prevalence of ECG abnormalities was related to the presence of hypertension, diabetes, blood pressure, and age. In conclusion, black men and women in the United States have a significantly greater prevalence of ECG abnormalities than white men and women at age 45 to 64 years; however, these proportions, although larger, tended to equalize or reverse after age 65. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;109:1223-1228) C1 [Prineas, Ronald J.; Soliman, Elsayed Z.; Zhang, Zhu-Ming] Wake Forest Univ, Bowman Gray Sch Med, Div Publ Hlth Sci, Dept Epidemiol & Prevent, Winston Salem, NC 27106 USA. [Le, Anh; Howard, George] Univ Alabama Birmingham, Birmingham Sch Publ Hlth, Dept Biostat, Birmingham, AL USA. [Howard, Virginia J.] Univ Alabama Birmingham, Birmingham Sch Publ Hlth, Dept Epidemiol, Birmingham, AL USA. [Ostchega, Yechiam] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Prineas, RJ (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Div Publ Hlth Sci, Dept Epidemiol & Prevent, Winston Salem, NC 27106 USA. EM rprineas@wfubmc.edu FU National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services (Bethesda, Maryland) [U01 NS041588] FX This work was supported by a cooperative agreement grant U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services (Bethesda, Maryland). Representatives from the funding institute were involved in the review of the report but were not directly involved in the collection, management, analysis, or interpretation of the data. Dr. Howard, study primary investigator, had full access to all the data and takes responsibility for the integrity of the data and accuracy of the data analysis. NR 16 TC 17 Z9 19 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 15 PY 2012 VL 109 IS 8 BP 1223 EP 1228 DI 10.1016/j.amjcard.2011.11.061 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 931NP UT WOS:000303226900024 PM 22245412 ER PT J AU Lu, PJ Nuorti, JP AF Lu, Peng-Jun Nuorti, J. Pekka TI Uptake of Pneumococcal Polysaccharide Vaccination Among Working-age Adults With Underlying Medical Conditions, United States, 2009 SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE adult; asthma; pneumococcal vaccines; smoking; vaccination ID HIGH-RISK ADULTS; RACIAL/ETHNIC DIFFERENCES; SELF-REPORT; IMMUNIZATION PRACTICES; ELDERLY OUTPATIENTS; CONJUGATE VACCINE; INFLUENZA; VALIDATION; PREVENTION; VALIDITY AB Since 1997, the Advisory Committee on Immunization Practices has recommended the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for nonelderly adults with certain medical conditions. In 2008, the Committee added asthma and cigarette smoking to the list of indications for PPSV23 vaccination. Using data from the 2009 National Health Interview Survey, the authors assessed PPSV23 uptake in people with established and new indications. To identify factors independently associated with receiving PPSV23, they used multivariable logistic regression and predictive marginal analyses. In 2009, a total of 35.2 million adults 18-64 years of age (18.6%) had established PPSV23 indications; adding asthma and smoking to the list of indications increased the high-risk population to 71.6 million people (37.9%). Overall, 26.1% of people with established indications for PPSV23 and 17.4% of people with any indication (those previously established, as well as asthma and smoking) had received the vaccine; overall coverage among persons 50-64 years of age was significantly higher than that among persons 18-49 years of age (34.6% vs. 16.7%; P < 0.001) and for all specific indications except cancer. For persons who had asthma or who smoked but had no other indications, rates of coverage were 12.3% and 8.5%, respectively. In persons who had established indications, being older, white, and unemployed and having more physician visits, a prior hospitalization, a regular physician, and health insurance were independently associated with PPSV23 receipt. PPSV23 uptake varies substantially by age and indication but remains low overall, with approximately 59 million unvaccinated high-risk working-age adults. Effective strategies to increase pneumococcal vaccination coverage among at-risk groups are needed. C1 [Lu, Peng-Jun] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Nuorti, J. Pekka] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30333 USA. RP Lu, PJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, 1600 Clifton Rd NE,Mail Stop A-19, Atlanta, GA 30333 USA. EM lhp8@cdc.gov NR 37 TC 11 Z9 11 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD APR 15 PY 2012 VL 175 IS 8 BP 827 EP 837 DI 10.1093/aje/kwr376 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 926BM UT WOS:000302806300012 PM 22403807 ER PT J AU Adalio, CJ White, SF Fowler, KA Sinclair, S Pine, DS Blair, RJR AF Adalio, Christopher J. White, Stuart F. Fowler, Katherine A. Sinclair, Stephen Pine, Daniel S. Blair, R. J. R. TI Youth with Disruptive Behavior Disorders and Callous-Unemotional Traits Show Impaired Neural Representation of Expected Value SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat DE Disruptive Behavior Disorder; Conduct Disorder; Decision-making; fMRl C1 [Adalio, Christopher J.; White, Stuart F.; Sinclair, Stephen; Blair, R. J. R.] NIMH, Unit Affect Cognit Neurosci, Bethesda, MD 20892 USA. [Fowler, Katherine A.] Epidem Intelligence Serv, CDC, Atlanta, GA USA. [Pine, Daniel S.] NIMH, Sect Dev & Affect Neurosci, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 232 BP 71S EP 72S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466000227 ER PT J AU Pearce, BD Fisch, MC Hubbard, S Rivera, HN Wilkins, PP Hasenkamp, W Gross, R Bliwise, N Jones, JJ Duncan, EJ AF Pearce, Brad D. Fisch, Marylynn C. Hubbard, Sydney Rivera, Hilda N. Wilkins, Patricia P. Hasenkamp, Wendy Gross, Robin Bliwise, Nancy Jones, Jeffrey J. Duncan, Erica J. TI Chronic Toxoplasma Gondii Infection Affects Cognition and Acoustic Startle Latency in Schizophrenia and Controls SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat DE schizophrenia; Toxoplasma gondii; acoustic startle; cognition C1 [Pearce, Brad D.; Fisch, Marylynn C.; Hubbard, Sydney] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Rivera, Hilda N.; Wilkins, Patricia P.; Jones, Jeffrey J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hasenkamp, Wendy; Gross, Robin; Duncan, Erica J.] Emory Univ, Atlanta VA, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 4 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 265 BP 82S EP 82S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466000260 ER PT J AU Mansergh, G Valdiserri, RO Yakovchenko, V Koh, H AF Mansergh, Gordon Valdiserri, Ronald O. Yakovchenko, Vera Koh, Howard TI Aligning Resources to Fight HIV/AIDS in the United States: Funding to States Through the US Department of Health and Human Services SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE AIDS; budget; federal; funding; government; HIV; United States ID HIV-PREVENTION RESOURCES; ALLOCATIONS AB Background: In response to the first U. S. National HIV/AIDS Strategy released in July 2010, we assessed how HIV/AIDS funding is spent by the Department of Health and Human Services (HHS) and how these resources align geographically with the HIV/AIDS epidemic according to various measures. Methods: Estimated FY2010 spending information was gathered from HHS agencies, including state/territory-level spending by prevention, care, and treatment services of the Centers for Disease Control and Prevention (CDC), Health Resources and Services Administration (HRSA), and Substance Abuse and Mental Health Services Administration (SAMHSA) - as well as Centers for Medicare and Medicaid Services (CMS). HHS funding is presented descriptively by state in the context of living HIV and AIDS case numbers and rates. Results: Nearly US$ 16 billion went to discretionary and entitlement spending, 77% of which supported or provided care and treatment by CMS (Medicare, Medicaid) and HRSA; the remainder to research, prevention, and other activities. For states and territories overall, funding was highly correlated with living AIDS case numbers (R-2 = .88) as well as living HIV case numbers (R-2 = .84); funding was far less correlated with case rates (per 100,000 population) for AIDS (R-2 = .35) or HIV (R-2 = .42). Conclusions: HHS HIV/AIDS funding, overall, is well correlated with the number of HIV/AIDS cases in each state/territory. Future assessments should capture information on who is being served, where, and how. C1 [Mansergh, Gordon] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Mansergh, Gordon; Valdiserri, Ronald O.; Yakovchenko, Vera; Koh, Howard] US Dept HHS, Off Assistant Secretary Hlth, Washington, DC 20201 USA. RP Mansergh, G (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Mailstop E37, Atlanta, GA 30333 USA. EM gmansergh@cdc.gov NR 18 TC 8 Z9 8 U1 2 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2012 VL 59 IS 5 BP 516 EP 522 DI 10.1097/QAI.0b013e318245cc05 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 917BQ UT WOS:000302147400018 PM 22156922 ER PT J AU Herbst, JH Glassman, M Carey, JW Painter, TM Gelaude, DJ Fasula, AM Raiford, JL Freeman, AE Harshbarger, C Viall, AH Purcell, DW AF Herbst, Jeffrey H. Glassman, Marlene Carey, James W. Painter, Thomas M. Gelaude, Deborah J. Fasula, Amy M. Raiford, Jerris L. Freeman, Arin E. Harshbarger, Camilla Viall, Abigail H. Purcell, David W. TI Operational Research to Improve HIV Prevention in the United States SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Review DE combination prevention; HIV/AIDS prevention; operational research; treatment as prevention ID COMMUNITY-BASED ORGANIZATIONS; ANTIRETROVIRAL TREATMENT; CARE; INFECTION; INTERVENTIONS; TRANSMISSION; STRATEGIES; SEX; MEN; THERAPY AB The HIV/AIDS epidemic in the United States continues despite several recent noteworthy advances in HIV prevention. Contemporary approaches to HIV prevention involve implementing combinations of biomedical, behavioral, and structural interventions in novel ways to achieve high levels of impact on the epidemic. Methods are needed to develop optimal combinations of approaches for improving efficiency, effectiveness, and scalability. This article argues that operational research offers promise as a valuable tool for addressing these issues. We define operational research relative to domestic HIV prevention, identify and illustrate how operational research can improve HIV prevention, and pose a series of questions to guide future operational research. Operational research can help achieve national HIV prevention goals of reducing new infections, improving access to care and optimization of health outcomes of people living with HIV, and reducing HIV-related health disparities. C1 [Herbst, Jeffrey H.; Glassman, Marlene; Carey, James W.; Painter, Thomas M.; Gelaude, Deborah J.; Fasula, Amy M.; Raiford, Jerris L.; Freeman, Arin E.; Harshbarger, Camilla; Viall, Abigail H.; Purcell, David W.] Ctr Dis Control & Prevent CDC, DHAP, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Herbst, JH (reprint author), Ctr Dis Control & Prevent, Operat Res Team, Prevent Res Branch, Div HIV AIDS Prevent,Natl Ctr HIV AIDS Viral Hepa, 1600 Clifton Rd NE,Mailstop E-37, Atlanta, GA 30333 USA. EM jherbst@cdc.gov OI Purcell, David/0000-0001-8125-5168 FU Centers for Disease Control and Prevention, Atlanta, GA FX Supported by Centers for Disease Control and Prevention, Atlanta, GA. NR 59 TC 9 Z9 9 U1 2 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2012 VL 59 IS 5 BP 530 EP 536 DI 10.1097/QAI.0b013e3182479077 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 917BQ UT WOS:000302147400020 PM 22217681 ER PT J AU Spira, TJ Ellerbrock, TV AF Spira, Thomas J. Ellerbrock, Tedd V. TI Commentary on Greig et al, "Similar Mortality and Reduced Loss to Follow-Up in Integrated Compared With Vertical Programs Providing Antiretroviral Treatment in Sub-Saharan Africa" SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Editorial Material ID SERVICES C1 [Spira, Thomas J.; Ellerbrock, Tedd V.] Ctr Dis Control & Prevent, HIV Care & Treatment Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. RP Spira, TJ (reprint author), Ctr Dis Control & Prevent, HIV Care & Treatment Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. NR 7 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD APR 15 PY 2012 VL 59 IS 5 BP E82 EP E84 DI 10.1097/QAI.0b013e31824c1985 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 917BQ UT WOS:000302147400001 PM 22330609 ER PT J AU Roberge, RJ Kim, JH Benson, SM AF Roberge, Raymond J. Kim, Jung-Hyun Benson, Stacey M. TI Absence of consequential changes in physiological, thermal and subjective responses from wearing a surgical mask SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY LA English DT Article DE Surgical mask; Thermal burden; Physiological impact; Subjective perceptions ID HEALTH-CARE WORKERS; RESPIRATOR USE; HEART-RATE; N95; INFLUENZA; DISCOMFORT; PROTECTION; COMFORT; HUMANS; IMPACT AB Twenty subjects treadmill exercised at 5.6 km/h for 1 h with and without wearing a surgical mask while being monitored for heart rate, respiratory rate, oxygen saturation, transcutaneous CO2, SpO(2), core and skin temperatures, mask deadspace heat and relative humidity, and skin temperature under the mask. Rating scales were utilized for exertion and heat perceptions. Surgical mask use resulted in increases in heart rate (9.5 beats/min; p < 0.001), respiratory rate (1.6 breaths/min; p = 0.02), and transcutaneous carbon dioxide (2.17 mm Hg; p = 0.0006), and decreased temperature of uncovered facial skin (0.40 degrees C; p = 0.03). The 1.76 degrees C increase in temperature of the skin covered by the mask was associated with a mask deadspace apparent heat index of 52.9 degrees C. Perceptions of heat were neutral to slightly hot, and for exertion ranged from very, very light to fairly light. Surgical mask use for 1 h at a low-moderate work rate is not associated with clinically significant physiological impact or significant subjective perceptions of exertion or heat. Published by Elsevier B.V. C1 [Roberge, Raymond J.; Kim, Jung-Hyun; Benson, Stacey M.] NIOSH, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, Pittsburgh, PA USA. RP Roberge, RJ (reprint author), 626 Cochrans Mill Rd, Pittsburgh, PA 15206 USA. EM dtn0@cdc.gov NR 48 TC 9 Z9 9 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9048 J9 RESP PHYSIOL NEUROBI JI Respir. Physiol. Neuro. PD APR 15 PY 2012 VL 181 IS 1 BP 29 EP 35 DI 10.1016/j.resp.2012.01.010 PG 7 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 921CP UT WOS:000302455900005 PM 22326638 ER PT J AU Neil, KP Sodha, SV Lukwago, L O-Tipo, S Mikoleit, M Simington, SD Mukobi, P Balinandi, S Majalija, S Ayers, J Kagirita, A Wefula, E Asiimwe, F Kweyamba, V Talkington, D Shieh, WJ Adem, P Batten, BC Zaki, SR Mintz, E AF Neil, Karen P. Sodha, Samir V. Lukwago, Luswa O-Tipo, Shikanga Mikoleit, Matthew Simington, Sherricka D. Mukobi, Peter Balinandi, Stephen Majalija, Samuel Ayers, Joseph Kagirita, Atek Wefula, Edward Asiimwe, Frank Kweyamba, Vianney Talkington, Deborah Shieh, Wun-Ju Adem, Patricia Batten, Brigid C. Zaki, Sherif R. Mintz, Eric TI A Large Outbreak of Typhoid Fever Associated With a High Rate of Intestinal Perforation in Kasese District, Uganda, 2008-2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID RAPID DIAGNOSTIC-TESTS; ENTERICA SEROVAR TYPHI; DEVELOPING-COUNTRIES; SALMONELLA AB Background. Salmonella enterica serovar Typhi (Salmonella Typhi) causes an estimated 22 million typhoid fever cases and 216 000 deaths annually worldwide. In Africa, the lack of laboratory diagnostic capacity limits the ability to recognize endemic typhoid fever and to detect outbreaks. We report a large laboratory-confirmed outbreak of typhoid fever in Uganda with a high proportion of intestinal perforations (IPs). Methods. A suspected case of typhoid fever was defined as fever and abdominal pain in a person with either vomiting, diarrhea, constipation, headache, weakness, arthralgia, poor response to antimalarial medications, or IP. From March 4, 2009 to April 17, 2009, specimens for blood and stool cultures and serology were collected from suspected cases. Antimicrobial susceptibility testing and pulsed-field gel electrophoresis (PFGE) were performed on Salmonella Typhi isolates. Surgical specimens from patients with IP were examined. A community survey was conducted to characterize the extent of the outbreak. Results. From December 27, 2007 to July 30, 2009, 577 cases, 289 hospitalizations, 249 IPs, and 47 deaths from typhoid fever occurred; Salmonella Typhi was isolated from 27 (33%) of 81 patients. Isolates demonstrated multiple PFGE patterns and uniform susceptibility to ciprofloxacin. Surgical specimens from 30 patients were consistent with typhoid fever. Estimated typhoid fever incidence in the community survey was 8092 cases per 100 000 persons. Conclusions. This typhoid fever outbreak was detected because of an elevated number of IPs. Underreporting of milder illnesses and delayed and inadequate antimicrobial treatment contributed to the high perforation rate. Enhancing laboratory capacity for detection is critical to improving typhoid fever control. C1 [Neil, Karen P.; Sodha, Samir V.; Mikoleit, Matthew; Simington, Sherricka D.; Talkington, Deborah; Mintz, Eric] Ctr Dis Control & Prevent, CDC, Div Foodborne Waterborne & Environm Dis, NCEZID, Atlanta, GA 30333 USA. [Neil, Karen P.] Ctr Dis Control & Prevent, CDC, Epidem Intelligence Serv, Sci Educ & Profess Dev Off, Atlanta, GA 30333 USA. [Lukwago, Luswa] Minist Hlth, Kampala, Uganda. [O-Tipo, Shikanga; Balinandi, Stephen] Kenya Field Epidemiol & Lab Training Program, Nairobi, Kenya. [Majalija, Samuel] Makerere Univ, Sch Vet Med, Kampala, Uganda. [Ayers, Joseph] Catholic Med Mission Board, New York, NY USA. [Kagirita, Atek] Cent Publ Hlth Lab, Kampala, Uganda. [Shieh, Wun-Ju; Adem, Patricia; Batten, Brigid C.; Zaki, Sherif R.] CDC, NCEZID, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. RP Neil, KP (reprint author), Ctr Dis Control & Prevent, CDC, Div Foodborne Waterborne & Environm Dis, NCEZID, 1600 Clifton Rd NE,MS A38, Atlanta, GA 30333 USA. EM kneil@cdc.gov OI Mikoleit, Matthew/0000-0002-4582-6733 NR 33 TC 33 Z9 33 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2012 VL 54 IS 8 BP 1091 EP 1099 DI 10.1093/cid/cis025 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 915EW UT WOS:000302007900012 PM 22357703 ER PT J AU Lutterloh, E Likaka, A Sejvar, J Manda, R Naiene, J Monroe, SS Khaila, T Chilima, B Mallewa, M Kampondeni, SD Lowther, SA Capewell, L Date, K Townes, D Redwood, Y Schier, JG Nygren, B Barr, BT Demby, A Phiri, A Lungu, R Kaphiyo, J Humphrys, M Talkington, D Joyce, K Stockman, LJ Armstrong, GL Mintz, E AF Lutterloh, Emily Likaka, Andrew Sejvar, James Manda, Robert Naiene, Jeremias Monroe, Stephan S. Khaila, Tadala Chilima, Benson Mallewa, Macpherson Kampondeni, Sam D. Lowther, Sara A. Capewell, Linda Date, Kashmira Townes, David Redwood, Yanique Schier, Joshua G. Nygren, Benjamin Barr, Beth Tippett Demby, Austin Phiri, Abel Lungu, Rudia Kaphiyo, James Humphrys, Michael Talkington, Deborah Joyce, Kevin Stockman, Lauren J. Armstrong, Gregory L. Mintz, Eric TI Multidrug-Resistant Typhoid Fever With Neurologic Findings on the Malawi-Mozambique Border SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ENTERICA SEROVAR-TYPHI; SALMONELLA-TYPHI; NEUROPSYCHIATRIC MANIFESTATIONS; CEREBELLAR-ATAXIA; DRUG-RESISTANCE; SEROTYPE TYPHI; OUTBREAK; BACTEREMIA; CHILDREN; SUSCEPTIBILITY AB Background. Salmonella enterica serovar Typhi causes an estimated 22 million cases of typhoid fever and 216 000 deaths annually worldwide. We investigated an outbreak of unexplained febrile illnesses with neurologic findings, determined to be typhoid fever, along the Malawi-Mozambique border. Methods. The investigation included active surveillance, interviews, examinations of ill and convalescent persons, medical chart reviews, and laboratory testing. Classification as a suspected case required fever and >= 1 other finding (eg, headache or abdominal pain); a probable case required fever and a positive rapid immunoglobulin M antibody test for typhoid (TUBEX TF); a confirmed case required isolation of Salmonella Typhi from blood or stool. Isolates underwent antimicrobial susceptibility testing and subtyping by pulsed-field gel electrophoresis (PFGE). Results. We identified 303 cases from 18 villages with onset during March-November 2009; 214 were suspected, 43 were probable, and 46 were confirmed cases. Forty patients presented with focal neurologic abnormalities, including a constellation of upper motor neuron signs (n = 19), ataxia (n = 22), and parkinsonism (n 5 8). Eleven patients died. All 42 isolates tested were resistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole; 4 were also resistant to nalidixic acid. Thirty-five of 42 isolates were indistinguishable by PFGE. Conclusions. The unusual neurologic manifestations posed a diagnostic challenge that was resolved through rapid typhoid antibody testing in the field and subsequent blood culture confirmation in the Malawi national reference laboratory. Extending laboratory diagnostic capacity, including blood culture, to populations at risk for typhoid fever in Africa will improve outbreak detection, response, and clinical treatment. C1 [Capewell, Linda; Date, Kashmira; Nygren, Benjamin; Humphrys, Michael; Talkington, Deborah; Joyce, Kevin; Mintz, Eric] CDC, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Lutterloh, Emily; Lowther, Sara A.; Capewell, Linda; Date, Kashmira; Townes, David; Redwood, Yanique] CDC, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Likaka, Andrew; Manda, Robert; Khaila, Tadala; Chilima, Benson; Phiri, Abel; Lungu, Rudia; Kaphiyo, James] Minist Hlth, Lilongwe, Malawi. [Sejvar, James; Monroe, Stephan S.] CDC, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Naiene, Jeremias] Minist Saude, Maputo, Mozambique. [Mallewa, Macpherson] Malawi Liverpool Wellcome Trust Clin Res Program, Coll Med, Blantyre, Malawi. [Kampondeni, Sam D.] Queen Elizabeth Cent Hosp, Dept Radiol, Blantyre, Malawi. [Schier, Joshua G.] CDC, Div Environm Hazards & Hlth Effects, Atlanta, GA 30333 USA. [Barr, Beth Tippett; Demby, Austin] CDC, Global AIDS Program, Lilongwe, Malawi. [Stockman, Lauren J.; Armstrong, Gregory L.] CDC, Div Viral Dis, Atlanta, GA 30333 USA. RP Mintz, E (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, C-09,1600 Clifton Rd, Atlanta, GA 30333 USA. EM emintz@cdc.gov RI Schier, Joshua/F-9861-2013; OI Monroe, Stephan/0000-0002-5424-716X FU government of Malawi; government of Mozambique; CDC FX This work was supported by the governments of Malawi and Mozambique and by the CDC. NR 38 TC 34 Z9 34 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2012 VL 54 IS 8 BP 1100 EP 1106 DI 10.1093/cid/cis012 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 915EW UT WOS:000302007900013 PM 22357702 ER PT J AU Moran, GJ Krishnadasan, A Gorwitz, RJ Fosheim, GE Albrecht, V Limbago, B Talan, DA AF Moran, Gregory J. Krishnadasan, Anusha Gorwitz, Rachel J. Fosheim, Greg E. Albrecht, Valerie Limbago, Brandi Talan, David A. CA EMERGENCY ID NET Study Grp TI Prevalence of Methicillin-Resistant Staphylococcus aureus as an Etiology of Community-Acquired Pneumonia SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID PANTON-VALENTINE LEUKOCIDIN; INFECTIOUS-DISEASES-SOCIETY; CLINICAL PRESENTATION; EMERGENCY-DEPARTMENT; INFLUENZA SEASON; UNITED-STATES; ADULTS; GUIDELINES; MORTALITY AB Background. Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of skin infections. Recent case series describe severe community-acquired pneumonia (CAP) caused by MRSA, but the prevalence and risk factors are unknown. Methods. We prospectively enrolled adults hospitalized with CAP from 12 university-affiliated emergency departments during the winter-spring of 2006 and 2007. Clinical information and culture results were collected, and factors associated with MRSA were assessed. Results. Of 627 patients, 595 (95%) had respiratory (50%) and/or blood cultures (92%) performed. A pathogen was identified in 102 (17%); MRSA was identified in 14 (2.4%; range by site, 0%-5%) patients and in 5% of patients admitted to the intensive care unit. Two (14%) MRSA pneumonia patients died. All 9 MRSA isolates tested were pulsed-field type USA300. Features significantly associated with isolation of MRSA (as compared with any other or no pathogen) included patient history of MRSA; nursing home admission in the previous year; close contact in the previous month with someone with a skin infection; multiple infiltrates or cavities on chest radiograph; and comatose state, intubation, receipt of pressors, or death in the emergency department. Conclusions. Methicillin-resistant Staphylococcus aureus remains an uncommon cause of CAP. Detection of MRSA was associated with more severe clinical presentation. C1 [Moran, Gregory J.] Univ Calif Los Angeles, Olive View UCLA Med Ctr, Dept Emergency Med, Div Infect Dis, Sylmar, CA 91342 USA. [Moran, Gregory J.; Talan, David A.] Univ Calif Los Angeles, Olive View UCLA Med Ctr, David Geffen Sch Med, Div Infect Dis, Sylmar, CA 91342 USA. [Gorwitz, Rachel J.; Fosheim, Greg E.; Albrecht, Valerie; Limbago, Brandi] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Moran, GJ (reprint author), Univ Calif Los Angeles, Olive View UCLA Med Ctr, Dept Emergency Med, Div Infect Dis, 14445 Olive View Dr, Sylmar, CA 91342 USA. EM gmoran@ucla.edu FU Centers for Disease Control and Prevention [U01/CI000353]; Furiex; Ortho-McNeil; Cepheid; Agennix; Trius; Durata; Pfizer; Merck; Innovation Biosensors; Aggenix; Pinnacle FX This work was supported by the Centers for Disease Control and Prevention (cooperative agreement #U01/CI000353). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.; G. J. M. has received speaking honoraria from Forest, Cubist, and Merck, and has received research funding from Furiex, Ortho-McNeil, Cepheid, Agennix, Trius, and Durata. D. A. T. has served as a consultant for Forest, Merck, and Optimer, and has received research funding from Pfizer, Merck, Cepheid, Innovation Biosensors, Durata, Aggenix, Furiex, and Pinnacle. All other authors report no potential conflicts. NR 24 TC 48 Z9 51 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2012 VL 54 IS 8 BP 1126 EP 1133 DI 10.1093/cid/cis022 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 915EW UT WOS:000302007900017 PM 22438343 ER PT J AU Tohme, RA Holmberg, SD AF Tohme, Rania A. Holmberg, Scott D. TI Transmission of Hepatitis C Virus Infection Through Tattooing and Piercing: A Critical Review SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID PARENTERALLY TRANSMITTED HEPATITIS; INJECTION-DRUG USERS; RISK-FACTORS; BLOOD-DONORS; UNITED-STATES; VIRAL-HEPATITIS; GENOTYPE DISTRIBUTION; BODY PIERCINGS; LIVER-DISEASE; PRISON INMATE AB Tattoos and piercings are increasing, especially among youths, but the risk of hepatitis C virus (HCV) infection from these practices has not been adequately assessed and there are conflicting findings in the literature. We evaluated the risk of HCV infection from tattooing and piercing using the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Studies that specified the venue of tattooing and/or piercing showed no definitive evidence for an increased risk of HCV infection when tattoos and piercings were received in professional parlors. However, the risk of HCV infection is significant, especially among high-risk groups (adjusted odds ratio, 2.0-3.6), when tattoos are applied in prison settings or by friends. Prevention interventions are needed to avoid the transmission of hepatitis C from tattooing and piercing in prisons, homes, and other potentially nonsterile settings. Youths also should be educated on the need to have tattoos and piercings performed under sterile conditions to avoid HCV infection. C1 [Tohme, Rania A.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS, STD, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, TB Prevent NCHHSTP, Atlanta, GA 30333 USA. RP Tohme, RA (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS, STD, 1600 Clifton Rd NE,Mailstop G-37, Atlanta, GA 30333 USA. EM rtohme@cdc.gov FU Intramural CDC HHS [CC999999] NR 82 TC 32 Z9 32 U1 2 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2012 VL 54 IS 8 BP 1167 EP 1178 DI 10.1093/cid/cir991 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 915EW UT WOS:000302007900024 PM 22291098 ER PT J AU Rottinghaus, EK Ugbena, R Diallo, K Bassey, O Azeez, A DeVos, J Zhang, GQ Aberle-Grasse, J Nkengasong, J Yang, CF AF Rottinghaus, Erin K. Ugbena, Richard Diallo, Karidia Bassey, Orji Azeez, Aderemi DeVos, Joshua Zhang, Guoqing Aberle-Grasse, John Nkengasong, John Yang, Chunfu TI Dried Blood Spot Specimens Are a Suitable Alternative Sample Type for HIV-1 Viral Load Measurement and Drug Resistance Genotyping in Patients Receiving First-Line Antiretroviral Therapy SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMITTED HIV; WHOLE-BLOOD; CHILDBEARING WOMEN; SURVEILLANCE; ASSAY; PLASMA; PREVENTION; MUTATIONS; DIAGNOSIS AB Background. Antiretroviral therapy (ART) is being administered in developing nations at unprecedented numbers following the World Health Organization's (WHO) development of standardized first-line drug regimens. To ensure continued efficacy of these drug regimens, WHO recommends monitoring virological responses and development of human immunodeficiency virus (HIV) drug resistance (HIVDR) in HIV-infected patients in a prospective cohort. The current study compared dried fluid spot specimens with the reference standard plasma specimens as a practical tool for viral load (VL) and HIVDR genotyping in resource-limited settings. Methods. Dried blood spot (DBS), dried plasma spot (DPS), and plasma specimens were collected from 173 -patients receiving ART at 2 hospital sites in Abuja, Nigeria. HIV-1 VL analysis was performed using NucliSENS EasyQ HIV-1 v1.1 RUO test kits. Genotyping of the HIV-1 pol gene was performed using a broadly sensitive in-house assay. Results. Direct comparison of VL levels showed that DBS specimens, and not DPS specimens, gave results comparable to those of plasma specimens (P = .0619 and .0007, respectively); however, both DBS and DPS specimens had excellent correlation with plasma specimens in predicting virological failure (VL, >= 1000 copies/mL) in patients (kappa = 0.78 and 0.83, respectively). Of the 18 specimens with a plasma VL >= 1000 copies/mL, HIVDR genotyping rates were 100% in DBS and 38.9% in DPS specimens, and DBS specimens identified 61 of 65 HIVDR mutations (93.8%) identified in plasma specimens. Conclusions. Our results indicate that DBS specimens could be used for surveys to monitor HIVDR prevention failure in resource-limited settings. C1 [Rottinghaus, Erin K.; Diallo, Karidia; DeVos, Joshua; Zhang, Guoqing; Nkengasong, John; Yang, Chunfu] Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Aberle-Grasse, John] Ctr Dis Control & Prevent, Epidemiol & Strateg Informat Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Ugbena, Richard; Bassey, Orji] GAP CDC Nigeria, Abuja, Nigeria. [Azeez, Aderemi] Minist Hlth Nigeria, Abuja, Nigeria. RP Yang, CF (reprint author), Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV AIDS, Ctr Global Hlth, Stop A-11,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM cyang1@cdc.gov RI Yang, Chunfu/G-6890-2013; Zhang, Guoqing/C-9523-2014 FU US President's Emergency Plan for AIDS Relief; American Public Health Laboratory; US Centers for Disease Control and Prevention FX This study was supported in part by the US President's Emergency Plan for AIDS Relief. E. K. R. and G. Z. are the recipients of 2009-2011 and 2010-2011 Emerging Infectious Disease Fellowships, sponsored by the American Public Health Laboratory and the US Centers for Disease Control and Prevention, respectively. NR 36 TC 28 Z9 28 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2012 VL 54 IS 8 BP 1187 EP 1195 DI 10.1093/cid/cis015 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 915EW UT WOS:000302007900026 PM 22412066 ER PT J AU Campbell, JD Moore, D Degerman, R Kaharuza, F Were, W Muramuzi, E Odongo, G Wetaka, M Mermin, J Tappero, JW AF Campbell, James D. Moore, David Degerman, Richard Kaharuza, Frank Were, Willy Muramuzi, Emmy Odongo, George Wetaka, Milton Mermin, Jonathan Tappero, Jordan W. TI HIV-Infected Ugandan Adults Taking Antiretroviral Therapy With CD4 Counts > 200 Cells/mu L Who Discontinue Cotrimoxazole Prophylaxis Have Increased Risk of Malaria and Diarrhea SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID PNEUMOCYSTIS-CARINII-PNEUMONIA; HUMAN-IMMUNODEFICIENCY-VIRUS; OPPORTUNISTIC INFECTIONS; CONTROLLED-TRIAL; RURAL UGANDA; VIRAL LOAD; ADOLESCENTS; MORBIDITY; MORTALITY; COHORT AB Background. Cotrimoxazole prophylaxis prolongs survival and prevents opportunistic infections, malaria, and diarrhea in persons infected with human immunodeficiency virus (HIV). Many countries recommend that individuals taking antiretroviral therapy (ART) discontinue cotrimoxazole when CD4 counts are >200 cells/mu L. However, this practice has not been evaluated in sub-Saharan Africa. Methods. Patients in the Home-Based AIDS Care program in eastern Uganda initiated ART if they had a CD4 cell count <= 250 cells/mu L or World Health Organization stage III or IV HIV disease. In the program's fourth year, patients with CD4 counts >200 cells/mu L were randomly assigned, by household, to continue or discontinue cotrimoxazole. Consenting participants were followed for episodes of malaria and diarrhea. Results. At randomization, 836 eligible patients had been receiving ART for a mean of 3.7 years, with a median CD4 count of 489 cells/mu L; 94% had a viral load,400 copies/mu L. Among those continuing (n = 452) vs discontinuing (n 5 384) cotrimoxazole, 0.4 vs 12.2%, respectively, had at least 1 episode of malaria (P < .001), and 14% vs 25%, respectively, had at least 1 episode of diarrhea (P < .001). Compared to those remaining on cotrimoxazole, patients who discontinued had a relative risk of malaria of 32.5 (95% confidence interval [CI], 8.6-275.0; P < .001) and of diarrhea of 1.8 (95% CI, 1.3-2.4; P < .001). Conclusions. HIV-infected adults on ART with CD4 counts >200 cells/mu L who live in a malaria-endemic area of sub-Saharan Africa and who abruptly discontinue cotrimoxazole prophylaxis have an increased incidence of malaria and diarrhea compared with those who continue prophylaxis. C1 [Campbell, James D.] Uganda Virus Res Inst, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Ctr Dis Control & Prevent,CDC Uganda, Entebbe, Uganda. [Moore, David] Univ British Columbia, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V5Z 1M9, Canada. [Moore, David] Univ British Columbia, Dept Med, Fac Med, Vancouver, BC V5Z 1M9, Canada. [Degerman, Richard; Kaharuza, Frank; Were, Willy; Muramuzi, Emmy; Odongo, George; Wetaka, Milton; Tappero, Jordan W.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA USA. RP Campbell, JD (reprint author), Uganda Virus Res Inst, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Ctr Dis Control & Prevent,CDC Uganda, Nakiwogo Rd, Entebbe, Uganda. EM campbellj@ug.cdc.gov RI Mermin, Jonathan/J-9847-2012 FU CDC; Global AIDS Program FX This work was supported by the CDC, Global AIDS Program, under the US President's Emergency Plan for AIDS Relief. NR 14 TC 25 Z9 26 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2012 VL 54 IS 8 BP 1204 EP 1211 DI 10.1093/cid/cis013 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 915EW UT WOS:000302007900028 PM 22423133 ER PT J AU Chow, AW Benninger, MS Brook, I Brozek, JL Goldstein, EJC Hicks, LA Pankey, GA Seleznick, M Volturo, G Wald, ER File, TM AF Chow, Anthony W. Benninger, Michael S. Brook, Itzhak Brozek, Jan L. Goldstein, Ellie J. C. Hicks, Lauri A. Pankey, George A. Seleznick, Mitchel Volturo, Gregory Wald, Ellen R. File, Thomas M., Jr. TI IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ACUTE MAXILLARY SINUSITIS; ACUTE OTITIS-MEDIA; RESPIRATORY-TRACT INFECTIONS; PLACEBO-CONTROLLED TRIAL; RESISTANT STREPTOCOCCUS-PNEUMONIAE; COMMUNITY-ACQUIRED PNEUMONIA; RANDOMIZED CONTROLLED-TRIAL; PNEUMOCOCCAL CONJUGATE VACCINE; DIAGNOSED ACUTE RHINOSINUSITIS; GENERAL-PRACTICE POPULATION AB Evidence-based guidelines for the diagnosis and initial management of suspected acute bacterial rhinosinusitis in adults and children were prepared by a multidisciplinary expert panel of the Infectious Diseases Society of America comprising clinicians and investigators representing internal medicine, pediatrics, emergency medicine, otolaryngology, public health, epidemiology, and adult and pediatric infectious disease specialties. Recommendations for diagnosis, laboratory investigation, and empiric antimicrobial and adjunctive therapy were developed. C1 [Chow, Anthony W.] Univ British Columbia, Dept Med, Div Infect Dis, Vancouver, BC, Canada. [Benninger, Michael S.] Cleveland Clin, Otolaryngol Head & Neck Inst, Cleveland, OH USA. [Brook, Itzhak] Georgetown Univ, Sch Med, Dept Pediat, Washington, DC 20007 USA. [Brozek, Jan L.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada. [Brozek, Jan L.] McMaster Univ, Dept Med, Hamilton, ON, Canada. [Goldstein, Ellie J. C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Goldstein, Ellie J. C.] RM Alden Res Lab, Santa Monica, CA USA. [Hicks, Lauri A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Pankey, George A.] Ochsner Clin Fdn, Dept Infect Dis Res, New Orleans, LA USA. [Seleznick, Mitchel] Univ S Florida, Coll Med, Div Gen Internal Med, Tampa, FL USA. [Volturo, Gregory] Univ Massachusetts, Dept Emergency Med, Worcester, MA 01605 USA. [Wald, Ellen R.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA. [File, Thomas M., Jr.] NE Ohio Med Univ, Dept Infect Dis, Rootstown, OH USA. [File, Thomas M., Jr.] Summa Hlth Syst, Akron, OH USA. RP Chow, AW (reprint author), Univ British Columbia, Div Infect Dis, Dept Med, 769 Burley Pl, W Vancouver, BC V7T 2A2, Canada. EM tonychow@mail.ubc.ca FU Infectious Diseases Society of America; Pfizer; Merck-Frosst Canada; Core Health; Cempra; Boehringer Ingelheim; Gilead; Tibotec; Medicines Co.; Merck; Schering-Plough Pharm; Optimer Pharm; Theravance; Cubist; Astellas; Cerexa; Impex; Novexel; Novartis; Clinical Microbiology Institute; Genzyme; Nanopacific Holdings; Romark Laboratories GL; Viroxis Corp.; Warner Chilcott; Avidbiotics Corp; GLSynthesis; Immunome; Toltec Pharma LLC FX This work was supported by the Infectious Diseases Society of America.; A. W. C. has served as a consultant to Inimex, Migenix, Bayer, Merck, and Wyeth, has provided expert testimony for MEDACorp Clinical Advisors, has received honoraria for Inimex and MEDACorp, has received stocks/bonds from Inimex and Migenix, and has received consulting fees or honoraria from Pfizer, Merck-Frosst Canada, and Core Health. T. M. F. has served as a consultant to Bayer, GlaxoSmithKline, Forest, Nabriva Pharm, Merck, Daichi, Sankyo, Tetraphase, Pfizer, Cubist, and Astellas/Theravance; and has received research grants from Cempra, Pfizer, Boehringer Ingelheim, Gilead, Tibotec, and the Medicines Co. E. J. C. G. has served as a consultant to Theravance, Bayer, Merck, and Optimer; has received honoraria from Bayer, Merck, and Optimer; has served on advisory boards for Merck, Optimer, Bayer, Bio-K+, and Kindred; has served on the speakers' bureaus of Bayer, Merck, Sanofi Pasteur, and Forest Labs; has received research grants from Merck, Schering-Plough Pharm, Optimer Pharm, Theravance, Cubist, Pfizer, Astellas, Cerexa, Impex, Novexel, Novartis, Clinical Microbiology Institute, Genzyme, Nanopacific Holdings, Romark Laboratories GL, Viroxis Corp., Warner Chilcott, Avidbiotics Corp, GLSynthesis, Immunome, and Toltec Pharma LLC; and has received other remuneration from Schering-Plough, Pfizer, Astella/Theravance, Cubist, and Salix. G. A. P. has served as a consultant to Optimer. G. V. has served as a consultant to the National Heart, Lung, and Blood Institute (NHLBI) and Pfizer and has received honoraria from Boston Scientific and the NHLBI. M. S. has served as a consultant to Eli Lilly and Pfizer and has received honoraria from Boston Scientific and the NHLBI. All other authors report no potential conflicts. NR 217 TC 112 Z9 121 U1 2 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2012 VL 54 IS 8 BP E72 EP E112 DI 10.1093/cid/cis370 PG 41 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 915EW UT WOS:000302007900005 PM 22438350 ER PT J AU Charurat, M Nasidi, A Delaney, K Saidu, A Croxton, T Mondal, P Aliyu, GG Constantine, N Abimiku, A Carr, JK Vertefeuille, J Blattner, W AF Charurat, Man Nasidi, Abdulsalami Delaney, Kevin Saidu, Ahmed Croxton, Taelisha Mondal, Prosanta Aliyu, Gambo Gumel Constantine, Niel Abimiku, Alash'le Carr, Jean K. Vertefeuille, John Blattner, William TI Characterization of Acute HIV-1 Infection in High-Risk Nigerian Populations SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL COUNTS; ANTIRETROVIRAL THERAPY; SUBTYPE; IDENTIFICATION; TRANSMISSION; INDIVIDUALS; DYNAMICS; AFRICA; LOAD AB Background. Acute phase of human immunodeficiency virus (HIV) infection (AHI) may account for a significant proportion of HIV-1 transmission. We identified and characterized individuals in Nigeria with AHI. Methods. Individuals were tested using a combination of rapid HIV testing in mobile units and laboratory-based specimen pooling for nucleic acid amplification testing. Genome sequences were characterized. A linear segmented regression model was fit to serial viral load (VL) measurements to characterize early VL profiles. Results. Sixteen AHIs were identified from 28 655 persons screened. Specimens were genotyped: 7 (43.8%) were CRF02_AG, 6 (37.5%) were subtype G, 1 (6.3%) was CRF06_cpx, and 2 (12.5%) were unique recombinant forms. No antiretroviral resistance mutations were detected. The mean duration of high VL burden from peak to nadir was 76 days (95% confidence interval [CI], 58-93 days), and the mean rate of viremic control was -0.66 log(10) VL per month. The mean VL at set-point was 4.5 log(10) copies/mL (95% CI, 3.9-5.1 log(10) copies/mL). Conclusions. This study is the first to characterize AHI among Nigerians identified as HIV infected before seroconversion who would be otherwise missed by conventional HIV testing. Infections by HIV subtypes in Nigeria exhibit long periods of high viral burden, which can contribute to increased transmissibility. C1 [Charurat, Man] Univ Maryland, Sch Med, Div Epidemiol & Prevent, Inst Human Virol, Baltimore, MD 21201 USA. [Nasidi, Abdulsalami; Saidu, Ahmed] Nigerian Fed Minist Hlth, Abuja, Federal Capital, Nigeria. [Nasidi, Abdulsalami] Reach Care Fdn, Abuja, Federal Capital, Nigeria. [Delaney, Kevin] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Vertefeuille, John] Ctr Dis Control & Prevent, Global AIDS Program, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA USA. RP Charurat, M (reprint author), Univ Maryland, Sch Med, Div Epidemiol & Prevent, Inst Human Virol, 725 W Lombard St,N459, Baltimore, MD 21201 USA. EM mcharurat@ihv.umaryland.edu FU US Centers for Disease Control and Prevention, National Center for HIV/AIDS, Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention [200-2003-01716]; US National Institutes of Health [D43TW001041, R01AI074594] FX This work was supported by the US Centers for Disease Control and Prevention, National Center for HIV/AIDS, Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention (contract number 200-2003-01716). US National Institutes of Health grants (D43TW001041 and R01AI074594) provided research training support for this analysis. NR 27 TC 9 Z9 9 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD APR 15 PY 2012 VL 205 IS 8 BP 1239 EP 1247 DI 10.1093/infdis/jis103 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 914VL UT WOS:000301980800011 PM 22357663 ER PT J AU Chang, JT Shebl, FM Pfeiffer, RM Graubard, BI Biryahwaho, B Dollard, SC Mbulaiteye, SM AF Chang, Joanne T. Shebl, Fatma M. Pfeiffer, Ruth M. Graubard, Barry I. Biryahwaho, Benon Dollard, Sheila C. Mbulaiteye, Sam M. TI Investigating human herpesvirus 8 infection among adults in Uganda: A factor analysis approach SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Chang, Joanne T.] Univ Michigan, Natl Canc Inst, Ann Arbor, MI 48109 USA. [Shebl, Fatma M.] Yale Univ, Chron Dis Epidemiol Div, New Haven, CT USA. [Pfeiffer, Ruth M.; Graubard, Barry I.; Mbulaiteye, Sam M.] NCI, DCEG, Bethesda, MD 20892 USA. [Biryahwaho, Benon; Dollard, Sheila C.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 5487 DI 10.1158/1538-7445.AM2012-5487 PG 1 WC Oncology SC Oncology GA V43SR UT WOS:000209701602149 ER PT J AU Chokkalingam, AP Chun, D Hsu, LI Metayer, C Rabinowitz, DJ Zhang, M Wiemeis, JL Buffler, PA AF Chokkalingam, Anand P. Chun, Danielle Hsu, Ling-I Metayer, Catherine Rabinowitz, Daniel J. Zhang, Mindy Wiemeis, Joseph L. Buffler, Patricia A. TI Serological levels of folate at birth and risk of childhood acute lymphoblastic leukemia SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Chokkalingam, Anand P.; Chun, Danielle; Hsu, Ling-I; Metayer, Catherine; Buffler, Patricia A.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Rabinowitz, Daniel J.; Zhang, Mindy] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wiemeis, Joseph L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 676 DI 10.1158/1538-7445.AM2012-676 PG 1 WC Oncology SC Oncology GA V43SR UT WOS:000209701602135 ER PT J AU Sargent, LM Kashon, ML Hubbs, AF Lowry, DT Ruppert, M Senft, JR McKinstry, KT Tyson, TL Reynolds, SH AF Sargent, Linda M. Kashon, Michael L. Hubbs, Ann F. Lowry, David T. Ruppert, Michael Senft, Jamie R. McKinstry, Kimberly T. Tyson, Tyson L. Reynolds, Steven H. TI Amplification of mouse chromosome 4 in chemically induced and invasive mouse lung adenocarcinoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Sargent, Linda M.; Kashon, Michael L.; Hubbs, Ann F.; Lowry, David T.; McKinstry, Kimberly T.; Reynolds, Steven H.] NIOSH, CDC, Morgantown, WV USA. [Ruppert, Michael; Senft, Jamie R.] W Virginia Univ, Morgantown, WV 26506 USA. [Tyson, Tyson L.] NIOSH, Res Triangle Pk, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 2345 DI 10.1158/1538-7445.AM2012-2345 PG 2 WC Oncology SC Oncology GA V43SQ UT WOS:000209701504331 ER PT J AU Chow, AW Benninger, MS Brook, I Brozek, JL Goldstein, EJC Hicks, LA Pankey, GA Seleznick, M Volturo, G Wald, ER File, TM AF Chow, Anthony W. Benninger, Michael S. Brook, Itzhak Brozek, Jan L. Goldstein, Ellie J. C. Hicks, Lauri A. Pankey, George A. Seleznick, Mitchel Volturo, Gregory Wald, Ellen R. File, Thomas M., Jr. TI Executive Summary: IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID GRADE; RECOMMENDATIONS; CONSENSUS; QUALITY AB Evidence-based guidelines for the diagnosis and initial management of suspected acute bacterial rhinosinusitis in adults and children were prepared by a multidisciplinary expert panel of the Infectious Diseases Society of America comprising clinicians and investigators representing internal medicine, pediatrics, emergency medicine, otolaryngology, public health, epidemiology, and adult and pediatric infectious disease specialties. Recommendations for diagnosis, laboratory investigation, and empiric antimicrobial and adjunctive therapy were developed. C1 Univ British Columbia, Dept Med, Div Infect Dis, Vancouver, BC V7T 2A2, Canada. Cleveland Clin, Head & Neck Inst, Cleveland, OH USA. Georgetown Univ, Sch Med, Dept Pediat, Washington, DC USA. McMaster Univ, Dept Clin Epipemiol & Biostat, Hamilton, ON, Canada. McMaster Univ, Dept Med, Hamilton, ON, Canada. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. R M Alden Res Lab, Santa Monica, CA USA. Ctr Dis Control Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. Ochsner Clin Fdn, Dept Infect Dis Res, New Orleans, LA USA. Univ S Florida, Coll Med, Div Gen Inernal Med, Tampa, FL USA. Univ Massachusetts, Dept Emergency Med, Worcester, MA USA. Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediatr, Madison, WI USA. NE Ohio Med Univ, Dept Infect Dis, Rootstown, OH USA. Summa Hlth Syst, Akron, OH USA. RP Chow, AW (reprint author), Univ British Columbia, Dept Med, Div Infect Dis, 769 Burley Pl, Vancouver, BC V7T 2A2, Canada. EM tonychow@mail.ubc.ca NR 6 TC 6 Z9 10 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2012 VL 54 IS 8 BP 1041 EP 1045 DI 10.1093/cid/cir1043 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 915EW UT WOS:000302007900034 ER PT J AU Chang, YCE Yu, XX Zhang, Y Tie, YF Wang, YF Yashchuk, S Ghosh, AK Harrison, RW Weber, IT AF Chang, Yu-Chung E. Yu, XiaXia Zhang, Ying Tie, Yunfeng Wang, Yuan-Fang Yashchuk, Sofiya Ghosh, Arun K. Harrison, Robert W. Weber, Irene T. TI Potent Antiviral HIV-1 Protease Inhibitor GRL-02031 Adapts to the Structures of Drug Resistant Mutants with Its P1 '-Pyrrolidinone Ring SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; RESOLUTION CRYSTAL-STRUCTURES; TYPE-1 PROTEASE; ACTIVE-SITE; IN-VITRO; REVERSE-TRANSCRIPTASE; RETROVIRAL PROTEASES; KINETIC-ANALYSIS; BINDING-SITE; MUTATION AB GRL-02031 (1) is an HIV-1 protease (PR) inhibitor containing a novel P1' (R)-aminomethyl-2-pyrrolidinone group. Crystal structures at resolutions of 1.25-1.55 angstrom were analyzed for complexes of 1 with the PR containing major drug resistant mutations, PRI47V, PRL76V, PRV82A, and PRN88D. Mutations of I47V and V82A alter residues in the inhibitor-binding site, while L76V and N88D are distal mutations having no direct contact with the inhibitor. Substitution of a smaller amino acid in PRI47V and PRL76V and the altered charge of PRN88D are associated with significant local structural changes compared to the wild-type PR, while substitution of alanine in PRV82A, increases the size of the S1' subsite. The P1' pyrrolidinone group of 1 accommodates to these local changes by assuming two different conformations. Overall, the conformation and interactions of 1 with PR mutants resemble those of PRWT with similar inhibition constants in good agreement with the antiviral potency on multidrug resistant HIV-1. C1 [Chang, Yu-Chung E.; Wang, Yuan-Fang; Harrison, Robert W.; Weber, Irene T.] Georgia State Univ, Dept Biol, Mol Basis Dis Program, Atlanta, GA 30302 USA. [Yu, XiaXia; Harrison, Robert W.] Georgia State Univ, Dept Comp Sci, Mol Basis Dis Program, Atlanta, GA 30303 USA. [Zhang, Ying; Weber, Irene T.] Georgia State Univ, Dept Chem, Mol Basis Dis Program, Atlanta, GA 30303 USA. [Tie, Yunfeng] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Yashchuk, Sofiya; Ghosh, Arun K.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA. [Yashchuk, Sofiya; Ghosh, Arun K.] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA. RP Weber, IT (reprint author), Georgia State Univ, Dept Biol, Mol Basis Dis Program, POB 4010, Atlanta, GA 30302 USA. EM iweber@gsu.edu FU Georgia State University; Georgia Research Alliance; National Institutes of Health [GM062920, GM053386]; U.S. Department of Energy, Basic Energy Sciences, Office of Science [W-31-109-Eng-38] FX This work was supported in part by the Georgia State University Molecular Basis of Disease Program, the Georgia State University Research Program Enhancement Award in Bioinformatics, the Georgia Research Alliance, and the National Institutes of Health grants GM062920 and GM053386. We thank Ting-Yi Chiu and Jing Wang for assisting with construction of PRI47V. We thank the staff at the SER-CAT beamline at the Advanced Photon Source, Argonne National Laboratory, for assistance during X-ray data collection. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Basic Energy Sciences, Office of Science, under contract no. W-31-109-Eng-38. NR 57 TC 9 Z9 10 U1 1 U2 12 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD APR 12 PY 2012 VL 55 IS 7 BP 3387 EP 3397 DI 10.1021/jm300072d PG 11 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 923AT UT WOS:000302591100044 PM 22401672 ER PT J AU Sterling, TR Moro, R Villarino, ME AF Sterling, Timothy R. Moro, Ruth Villarino, M. Elsa TI Rifapentine and Isoniazid for Latent Tuberculosis REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Sterling, Timothy R.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Moro, Ruth; Villarino, M. Elsa] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Sterling, TR (reprint author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. EM timothy.sterling@vanderbilt.edu NR 1 TC 0 Z9 0 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 12 PY 2012 VL 366 IS 15 BP 1448 EP 1448 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 923GV UT WOS:000302608600017 ER PT J AU Ahluwalia, IB Harrison, L Ding, HL Austin, T D'Angelo, D Hastings, P Ruffo, N O'Neil, ME Jamieson, D Singleton, JA Bridges, CB AF Ahluwalia, Indu B. Harrison, Leslie Ding, Helen Austin, Toyia D'Angelo, Denise Hastings, Phil Ruffo, Nan O'Neil, Mary Elizabeth Jamieson, Denise Singleton, James A. Bridges, Carolyn B. TI Influenza Vaccination Coverage Among Pregnant Women-29 States and New York City, 2009-10 Season (Reprinted from MMWR, vol 61, pg 113, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Ahluwalia, Indu B.; Harrison, Leslie; Ding, Helen; Austin, Toyia; D'Angelo, Denise; Hastings, Phil; Ruffo, Nan; O'Neil, Mary Elizabeth] CDC, Pregnancy Risk Assessment Monitoring Team, Atlanta, GA 30333 USA. [Jamieson, Denise] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. [Bridges, Carolyn B.] CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. RP Ahluwalia, IB (reprint author), CDC, Pregnancy Risk Assessment Monitoring Team, Atlanta, GA 30333 USA. EM iahluwalia@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 11 PY 2012 VL 307 IS 14 BP 1477 EP 1479 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 922HN UT WOS:000302538100009 ER PT J AU Brucker, R Bui, T Kwan-Gett, T Stewart, L Hall, AJ Kinzer, MH AF Brucker, Rachel Bui, Tony Kwan-Gett, Tao Stewart, Laurie Hall, Aron J. Kinzer, Michael H. TI Notes From the Field: Norovirus Infections Associated With Frozen Raw Oysters-Washington, 2011 (Reprinted from MMWR, vol 61, pg 110, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID OUTBREAKS C1 [Kinzer, Michael H.] CDC, Atlanta, GA 30333 USA. [Brucker, Rachel; Bui, Tony; Kwan-Gett, Tao; Stewart, Laurie] Publ Hlth Seattle& King Cty, Washington, DC USA. RP Kinzer, MH (reprint author), CDC, Atlanta, GA 30333 USA. EM mkinzer@cdc.gov NR 4 TC 0 Z9 0 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 11 PY 2012 VL 307 IS 14 BP 1480 EP 1480 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 922HN UT WOS:000302538100010 ER PT J AU Balanzat, AM Hertlein, C Apezteguia, C Bonvehi, P Camera, L Gentile, A Rizzo, O Gomez-Carrillo, M Coronado, F Azziz-Baumgartner, E Chavez, PR Widdowson, MA AF Balanzat, Ana M. Hertlein, Christian Apezteguia, Carlos Bonvehi, Pablo Camera, Luis Gentile, Angela Rizzo, Oscar Gomez-Carrillo, Manuel Coronado, Fatima Azziz-Baumgartner, Eduardo Chavez, Pollyanna R. Widdowson, Marc-Alain TI An Analysis of 332 Fatalities Infected with Pandemic 2009 Influenza A (H1N1) in Argentina SO PLOS ONE LA English DT Article ID RESPIRATORY-DISTRESS SYNDROME; HOSPITALIZED-PATIENTS; A(H1N1) INFECTION; UNITED-STATES; EXPERIENCE; DEFINITIONS; CHILDREN; VIRUS; DEATH; ARDS AB Background: The apparent high number of deaths in Argentina during the 2009 pandemic led to concern that the influenza A H1N1pdm disease was different there. We report the characteristics and risk factors for influenza A H1N1pdm fatalities. Methods: We identified laboratory-confirmed influenza A H1N1pdm fatalities occurring during June-July 2009. Physicians abstracted data on age, sex, time of onset of illness, medical history, clinical presentation at admission, laboratory, treatment, and outcomes using standardize questionnaires. We explored the characteristics of fatalities according to their age and risk group. Results: Of 332 influenza A H1N1pdm fatalities, 226 (68%) were among persons aged <50 years. Acute respiratory failure was the leading cause of death. Of all cases, 249 (75%) had at least one comorbidity as defined by Advisory Committee on Immunization Practices. Obesity was reported in 32% with data and chronic pulmonary disease in 28%. Among the 40 deaths in children aged <5 years, chronic pulmonary disease (42%) and neonatal pathologies (35%) were the most common co-morbidities. Twenty (6%) fatalities were among pregnant or postpartum women of which only 47% had diagnosed comorbidities. Only 13% of patients received antiviral treatment within 48 hours of symptom onset. None of children aged <5 years or the pregnant women received antivirals within 48 h of symptom onset. As the pandemic progressed, the time from symptom-onset to medical care and to antiviral treatment decreased significantly among case-patients who subsequently died (p < 0.001). Conclusion: Persons with co-morbidities, pregnant and who received antivirals late were over-represented among influenza A H1N1pdm deaths in Argentina, though timeliness of antiviral treatment improved during the pandemic. C1 [Balanzat, Ana M.; Hertlein, Christian] Natl Minist Hlth Argentina, Buenos Aires, DF, Argentina. [Apezteguia, Carlos] Soc Argentina Terapia Intensiva, Buenos Aires, DF, Argentina. [Bonvehi, Pablo] Soc Argentina Infectol, Buenos Aires, Argentina. [Camera, Luis] Soc Argentina Med, Buenos Aires, DF, Argentina. [Gentile, Angela] Soc Argentina Pediat, Buenos Aires, DF, Argentina. [Rizzo, Oscar] Asociac Argentina Med Resp, Buenos Aires, DF, Argentina. [Gomez-Carrillo, Manuel] Asociac Argentina Microbiol, Buenos Aires, DF, Argentina. [Coronado, Fatima; Azziz-Baumgartner, Eduardo; Chavez, Pollyanna R.; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Balanzat, AM (reprint author), Natl Minist Hlth Argentina, Buenos Aires, DF, Argentina. EM balanzat@fibertel.com.ar OI Widdowson, Marc-Alain/0000-0002-0682-6933 FU Pan American Health Organization (PAHO)-Argentina FX This work was supported by the Pan American Health Organization (PAHO)-Argentina. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 7 Z9 7 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 10 PY 2012 VL 7 IS 4 AR e33670 DI 10.1371/journal.pone.0033670 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 959FE UT WOS:000305297500014 PM 22506006 ER PT J AU Nachman, KE Parker, JD AF Nachman, Keeve E. Parker, Jennifer D. TI Exposures to fine particulate air pollution and respiratory outcomes in adults using two national datasets: a cross-sectional study SO ENVIRONMENTAL HEALTH LA English DT Article DE Particulate matter; Asthma; Sinusitis; Air pollution; National Health Interview Survey (NHIS) ID ENVIRONMENTAL-HEALTH DISPARITIES; NORTH-AMERICAN CHILDREN; UNITED-STATES; ASTHMA DISPARITIES; EPIDEMIOLOGIC EVIDENCE; CHEMICAL-COMPOSITION; PULMONARY-FUNCTION; CHILDHOOD ASTHMA; ACID AEROSOLS; LUNG-FUNCTION AB Background: Relationships between chronic exposures to air pollution and respiratory health outcomes have yet to be clearly articulated for adults. Recent data from nationally representative surveys suggest increasing disparity by race/ethnicity regarding asthma-related morbidity and mortality. The objectives of this study are to evaluate the relationship between annual average ambient fine particulate matter (PM2.5) concentrations and respiratory outcomes for adults using modeled air pollution and health outcome data and to examine PM2.5 sensitivity across race/ethnicity. Methods: Respondents from the 2002-2005 National Health Interview Survey (NHIS) were linked to annual kriged PM2.5 data from the USEPA AirData system. Logistic regression was employed to investigate increases in ambient PM2.5 concentrations and self-reported prevalence of respiratory outcomes including asthma, sinusitis and chronic bronchitis. Models included health, behavioral, demographic and resource-related covariates. Stratified analyses were conducted by race/ethnicity. Results: Of nearly 110,000 adult respondents, approximately 8,000 and 4,000 reported current asthma and recent attacks, respectively. Overall, odds ratios (OR) for current asthma (0.97 (95% Confidence Interval: 0.87-1.07)) and recent attacks (0.90 (0.78-1.03)) did not suggest an association with a 10 mu g/m(3) increase in PM2.5. Stratified analyses revealed significant associations for non-Hispanic blacks [OR = 1.73 (1.17-2.56) for current asthma and OR = 1.76 (1.07-2.91) for recent attacks] but not for Hispanics and non-Hispanic whites. Significant associations were observed overall (1.18 (1.08-1.30)) and in non-Hispanic whites (1.31 (1.18-1.46)) for sinusitis, but not for chronic bronchitis. Conclusions: Non-Hispanic blacks may be at increased sensitivity of asthma outcomes from PM2.5 exposure. Increased chronic PM2.5 exposures in adults may contribute to population sinusitis burdens. C1 [Nachman, Keeve E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA. [Parker, Jennifer D.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Nachman, KE (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA. EM knachman@jhsph.edu NR 84 TC 15 Z9 18 U1 3 U2 30 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-069X J9 ENVIRON HEALTH-GLOB JI Environ. Health PD APR 10 PY 2012 VL 11 AR 25 DI 10.1186/1476-069X-11-25 PG 12 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 951KV UT WOS:000304720400001 PM 22490087 ER PT J AU Hudson, PN Self, J Weiss, S Braden, Z Xiao, YH Girgis, NM Emerson, G Hughes, C Sammons, SA Isaacs, SN Damon, IK Olson, VA AF Hudson, Paul N. Self, Joshua Weiss, Sonja Braden, Zachary Xiao, Yuhong Girgis, Natasha M. Emerson, Ginny Hughes, Christine Sammons, Scott A. Isaacs, Stuart N. Damon, Inger K. Olson, Victoria A. TI Elucidating the Role of the Complement Control Protein in Monkeypox Pathogenicity SO PLOS ONE LA English DT Article ID VACCINIA VIRUS; ENHANCED NEUTRALIZATION; SMALLPOX INHIBITOR; IMMUNE-RESPONSES; ENZYMES SPICE; CONGO BASIN; ACTIVATION; EXPRESSION; VIRULENCE; TRANSMISSION AB Monkeypox virus (MPXV) causes a smallpox-like disease in humans. Clinical and epidemiological studies provide evidence of pathogenicity differences between two geographically distinct monkeypox virus clades: the West African and Congo Basin. Genomic analysis of strains from both clades identified a similar to 10 kbp deletion in the less virulent West African isolates sequenced to date. One absent open reading frame encodes the monkeypox virus homologue of the complement control protein (CCP). This modulatory protein prevents the initiation of both the classical and alternative pathways of complement activation. In monkeypox virus, CCP, also known as MOPICE, is a similar to 24 kDa secretory protein with sequence homology to this superfamily of proteins. Here we investigate CCP expression and its role in monkeypox virulence and pathogenesis. CCP was incorporated into the West African strain and removed from the Congo Basin strain by homologous recombination. CCP expression phenotypes were confirmed for both wild type and recombinant monkeypox viruses and CCP activity was confirmed using a C4b binding assay. To characterize the disease, prairie dogs were intranasally infected and disease progression was monitored for 30 days. Removal of CCP from the Congo Basin strain reduced monkeypox disease morbidity and mortality, but did not significantly decrease viral load. The inclusion of CCP in the West African strain produced changes in disease manifestation, but had no apparent effect on disease-associated mortality. This study identifies CCP as an important immuno-modulatory protein in monkeypox pathogenesis but not solely responsible for the increased virulence seen within the Congo Basin clade of monkeypox virus. C1 [Hudson, Paul N.; Self, Joshua; Weiss, Sonja; Braden, Zachary; Emerson, Ginny; Hughes, Christine; Sammons, Scott A.; Damon, Inger K.; Olson, Victoria A.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, DHCPP, Atlanta, GA 30333 USA. [Hudson, Paul N.; Self, Joshua; Weiss, Sonja; Braden, Zachary; Emerson, Ginny; Hughes, Christine; Sammons, Scott A.; Damon, Inger K.; Olson, Victoria A.] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, DSR, NCEZID, Atlanta, GA USA. [Xiao, Yuhong; Girgis, Natasha M.; Isaacs, Stuart N.] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. RP Hudson, PN (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, DHCPP, Atlanta, GA 30333 USA. EM fst6@cdc.gov FU NIH [U01 AI066333] FX This work was funded by NIH grant U01 AI066333. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 45 TC 6 Z9 6 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 9 PY 2012 VL 7 IS 4 AR e35086 DI 10.1371/journal.pone.0035086 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 955JO UT WOS:000305014500044 PM 22496894 ER PT J AU De Marco, D Clementi, N Mancini, N Solforosi, L Moreno, GJ Sun, XJ Tumpey, TM Gubareva, LV Mishin, V Clementi, M Burioni, R AF De Marco, Donata Clementi, Nicola Mancini, Nicasio Solforosi, Laura Moreno, Guisella J. Sun, Xiangjie Tumpey, Terrence M. Gubareva, Larisa V. Mishin, Vasiliy Clementi, Massimo Burioni, Roberto TI A Non-VH1-69 Heterosubtypic Neutralizing Human Monoclonal Antibody Protects Mice against H1N1 and H5N1 Viruses SO PLOS ONE LA English DT Article ID INFLUENZA-A VIRUSES; OSELTAMIVIR-RESISTANT INFLUENZA; IMMUNIZATION PRACTICES ACIP; ADVISORY-COMMITTEE; UNITED-STATES; B-CELLS; S-OIV; INFECTION; HEMAGGLUTININ; EPITOPE AB Influenza viruses are among the most important human pathogens and are responsible for annual epidemics and sporadic, potentially devastating pandemics. The humoral immune response plays an important role in the defense against these viruses, providing protection mainly by producing antibodies directed against the hemagglutinin (HA) glycoprotein. However, their high genetic variability allows the virus to evade the host immune response and the potential protection offered by seasonal vaccines. The emergence of resistance to antiviral drugs in recent years further limits the options available for the control of influenza. The development of alternative strategies for influenza prophylaxis and therapy is therefore urgently needed. In this study, we describe a human monoclonal antibody (PN-SIA49) that recognizes a highly conserved epitope located on the stem region of the HA and able to neutralize a broad spectrum of influenza viruses belonging to different subtypes (H1, H2 and H5). Furthermore, we describe its protective activity in mice after lethal challenge with H1N1 and H5N1 viruses suggesting a potential application in the treatment of influenza virus infections. C1 [De Marco, Donata; Clementi, Nicola; Mancini, Nicasio; Solforosi, Laura; Moreno, Guisella J.; Clementi, Massimo; Burioni, Roberto] Univ Vita Salute San Raffaele, Lab Microbiol & Virol, Milan, Italy. [Sun, Xiangjie; Tumpey, Terrence M.; Gubareva, Larisa V.; Mishin, Vasiliy] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP De Marco, D (reprint author), Univ Vita Salute San Raffaele, Lab Microbiol & Virol, Milan, Italy. EM burioni.roberto@hsr.it RI Burioni, Roberto /F-2396-2012; Clementi, Massimo/F-6646-2013; Clementi, Nicola/G-8545-2014; OI Clementi, Nicola/0000-0002-1822-9861; Clementi, Massimo/0000-0002-7461-5898; MANCINI, Nicasio/0000-0003-0637-0910 FU UNIFLUVAC [10DF] FX This study was supported by the Italian Minister of Health Universal Influenza Vaccine, UNIFLUVAC, grant n. 10DF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 34 Z9 34 U1 2 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 4 PY 2012 VL 7 IS 4 AR e34415 DI 10.1371/journal.pone.0034415 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 953GO UT WOS:000304855200049 PM 22496802 ER PT J AU Wiedeman, J Plant, J Glaser, C Messenger, S Wadford, D Sheriff, H Fritz, C McKenzie, M Hammond, C Gordon, E Rupprecht, CE Petersen, BW AF Wiedeman, Jean Plant, Jennifer Glaser, Carol Messenger, Sharon Wadford, Debra Sheriff, Heather Fritz, Curtis McKenzie, Mary Hammond, Christina Gordon, Eric Rupprecht, Charles E. Petersen, Brett W. TI Recovery of a Patient From Clinical Rabies-California, 2011 (Reprinted from MMWR, vol 61, pg 61, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Petersen, Brett W.] CDC, Atlanta, GA 30333 USA. [Wiedeman, Jean; Plant, Jennifer] Univ Calif Davis, Med Ctr, Davis, CA USA. RP Petersen, BW (reprint author), CDC, Atlanta, GA 30333 USA. EM bpetersen@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 4 PY 2012 VL 307 IS 13 BP 1364 EP 1367 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 919AY UT WOS:000302294200009 ER PT J AU Steinhoff, MC Omer, SB Roy, E El Arifeen, S Raqib, R Dodd, C Breiman, RF Zaman, K AF Steinhoff, Mark C. Omer, Saad B. Roy, Eliza El Arifeen, Shams Raqib, Rubhana Dodd, Caitlin Breiman, Robert F. Zaman, K. TI Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial SO CANADIAN MEDICAL ASSOCIATION JOURNAL LA English DT Article ID FOR-GESTATIONAL-AGE; BIRTH-WEIGHT; VACCINE EFFECTIVENESS; PERINATAL OUTCOMES; ANTIGENIC MATCH; COMMUNITY TRIAL; VIRUS-INFECTION; UNITED-STATES; RURAL NEPAL; WOMEN AB Background: There are limited data about the effect of maternal influenza infection on fetuses and newborns. We performed a secondary analysis of data from the Mother'sGift project, a randomized study designed to test the effectiveness of inactivated influenza and pneumococcal vaccines during pregnancy. Methods: In the Mother'sGift project, 340 pregnant women in Bangladesh received either inactivated influenza vaccine or 23-valent pneumococcal polysaccharide vaccine (control). This study was performed from August 2004 through December 2005. We performed a secondary analysis of outcomes following maternal influenza immunization during two periods: when influenza virus was not circulating (September 2004 through January 2005) and when influenza virus was circulating (February through October 2005). We assessed gestational age, mean birth weight and the proportion of infants who were small for gestational age. Results: During the period with no circulating influenza virus, there were no differences in the incidence of respiratory illness with fever per 100 person-months among mothers and infants in the two groups (influenza vaccine: 3.9; control: 4.0; p > 0.9). The proportion of infants who were small for gestational age and the mean birth weight were similar between groups (small for gestational age: influenza vaccine 29.1%, control 34.3%; mean birth weight: influenza vaccine 3083 g, control 3053 g). During the period with circulating influenza virus, there was a substantial reduction in the incidence per 100 person-months of respiratory illness with fever among the mothers and infants who had received the influenza vaccine (influenza vaccine: 3.7; control: 7.2; p = 0.0003). During this period, the proportion of infants who were small for gestational age was lower in the influenza vaccine group than in the control group (25.9% v. 44.8%; p = 0.03). The mean birth weight was higher among infants whose mothers received the influenza vaccine than among those who received the control vaccine during this period (3178 g v. 2978 g; p = 0.02). Interpretation: During the period with circulating influenza virus, maternal immunization during pregnancy was associated with a lower proportion of infants who were small for gestational age and an increase in mean birth weight. These data need confirmation but suggest that prevention of influenza infection in pregnancy can influence intrauterine growth. C1 [Steinhoff, Mark C.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. [Steinhoff, Mark C.; Dodd, Caitlin] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. Kaiser Permanente, Ctr Hlth Res SE, Atlanta, GA USA. [Roy, Eliza; El Arifeen, Shams; Raqib, Rubhana; Zaman, K.] Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh. [Breiman, Robert F.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Steinhoff, MC (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. EM mark.steinhoff@cchmc.org RI Omer, Saad/K-1182-2012; OI Omer, Saad/0000-0002-5383-3474; Raqib, Rubhana/0000-0002-8116-4511 FU United States Agency for International Development; Wyeth Pharmaceuticals Inc.; Thrasher Research Fund; Aventis Pasteur; International Centre for Diarrheal Disease Research, Bangladesh; Bloomberg School of Public Health at Johns Hopkins University; National Foundation for Infectious Diseases (NFID); Merck Co. Inc.; Bill and Melinda Gates Foundation FX The Mother'sGift project was supported by the Bill and Melinda Gates Foundation; the United States Agency for International Development; Wyeth Pharmaceuticals Inc.; the Thrasher Research Fund; Aventis Pasteur; the International Centre for Diarrheal Disease Research, Bangladesh; and the Bloomberg School of Public Health at Johns Hopkins University.; Dr. Omer was awarded the Maurice R. Hilleman Early-Stage Career Investigator Award by the National Foundation for Infectious Diseases (NFID). The award was funded by an unrestricted educational grant to the NFID from Merck Co. Inc.; however, Dr. Omer had no direct interaction with Merck Co. Inc. NR 52 TC 87 Z9 89 U1 1 U2 9 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA SN 0820-3946 J9 CAN MED ASSOC J JI Can. Med. Assoc. J. PD APR 3 PY 2012 VL 184 IS 6 BP 645 EP 653 DI 10.1503/cmaj.110754 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 007NJ UT WOS:000308894700032 PM 22353593 ER PT J AU Hellinger, WC Bacalis, LP Kay, RS Thompson, ND Xia, GL Lin, YL Khudyakov, YE Perz, JF AF Hellinger, Walter C. Bacalis, Laura P. Kay, Robyn S. Thompson, Nicola D. Xia, Guo-Liang Lin, Yulin Khudyakov, Yury E. Perz, Joseph F. TI Health Care-Associated Hepatitis C Virus Infections Attributed to Narcotic Diversion SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID OPERATING-ROOM; UNITED-STATES; TRANSMISSION; ANESTHESIOLOGIST; PERSONNEL; PATIENT; WORKERS; SYSTEM; ORGAN; TIME AB Background: Three cases of genetically related hepatitis C virus (HCV) infection that were unattributable to infection control breaches were identified at a health care facility. Objective: To investigate HCV transmission from an HCV-infected health care worker to patients through drug diversion. Design: Cluster and look-back investigations. Setting: Acute care hospital and affiliated multispecialty clinic. Patients: Inpatients and outpatients during the period of HCV transmission. Measurements: Employee work and narcotic dispensing records, blood testing for HCV antibody and RNA, and sequencing of the NS5B gene and the hypervariable region 1 of the E2 gene. Results: 21 employees were recorded as being at work or as retrieving a narcotic from an automated dispensing cabinet in an area where a narcotic was administered to each of the 3 case patients; all employees provided blood samples for HCV testing. One employee was infected with HCV that had more than 95% NS5B sequence homology with the HCV strains of the 3 case patients. Quasi-species analysis showed close genetic relatedness with variants from each of the case patients and more than 97.9% nucleotide identity. The employee acknowledged parenteral opiate diversion. An investigation identified 6132 patients at risk for exposure to HCV because of the drug diversion. Of the 3929 living patients, 3444 (87.7%) were screened for infection. Two additional cases of genetically related HCV infection attributable to the employee were identified. Limitation: Of the living patients at risk for HCV exposure, 12.3% were not tested. Conclusion: Five cases of HCV infection occurring over 3 to 4 years were attributed to drug diversion by an HCV-infected health care worker. Studies of drug diversion and assessments of strategies to prevent narcotics tampering in all health care settings are needed. C1 [Hellinger, Walter C.] Mayo Clin, Div Infect Dis, Jacksonville, FL 32224 USA. Florida Dept Hlth, Tallahassee, FL USA. Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hellinger, WC (reprint author), Mayo Clin, Div Infect Dis, 4500 San Pablo Rd, Jacksonville, FL 32224 USA. EM helling@mayo.edu NR 31 TC 14 Z9 14 U1 0 U2 3 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 3 PY 2012 VL 156 IS 7 BP 477 EP U34 DI 10.7326/0003-4819-156-7-201204030-00002 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 921GP UT WOS:000302466400001 PM 22473434 ER PT J AU Hsu, J Santesso, N Mustafa, R Brozek, J Chen, YL Hopkins, JP Cheung, A Hovhannisyan, G Ivanova, L Flottorp, SA Saeterdal, I Wong, AD Tian, J Uyeki, TM Akl, EA Alonso-Coello, P Smaill, F Schunemann, HJ AF Hsu, Jonathan Santesso, Nancy Mustafa, Reem Brozek, Jan Chen, Yao Long Hopkins, Jessica P. Cheung, Adrienne Hovhannisyan, Gayane Ivanova, Liudmila Flottorp, Signe A. Saeterdal, Ingvil Wong, Arthur D. Tian, Jinhui Uyeki, Timothy M. Akl, Elie A. Alonso-Coello, Pablo Smaill, Fiona Schuenemann, Holger J. TI Antivirals for Treatment of Influenza A Systematic Review and Meta-analysis of Observational Studies SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID H1N1 VIRUS-INFECTION; CLINICALLY DIAGNOSED INFLUENZA; OSELTAMIVIR TREATMENT; SEASONAL INFLUENZA; ADULT PATIENTS; RISK-FACTORS; NEURAMINIDASE INHIBITORS; HOSPITALIZED ADULTS; PREGNANT-WOMEN; UNITED-STATES AB Background: Systematic reviews of randomized, controlled trials in patients with influenza suggest a lack of evidence about the effects of antiviral therapy on several patient-important outcomes of influenza. Purpose: To systematically review observational studies for benefits and harms of oseltamivir, zanamivir, amantadine, or rimantadine in the treatment of influenza. Data Sources: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, SIGLE, the Chinese Biomedical Literature Database, Panteleimon, and LILACS up to November 2010; contact with pharmaceutical companies; and reference lists. Study Selection: Observational studies in any language that compared single antiviral therapy with no therapy or other antiviral therapy, or that had no comparator, for influenza or influenza-like illness. Data Extraction: Two independent investigators extracted data. Confidence in the estimates of the obtained effects (quality of evidence) was assessed by using the Grading of Recommendations Assessment, Development, and Evaluation approach. Data Synthesis: 74 studies fulfilled the inclusion criteria. Meta-analyses of the few studies providing effects with adjustment for confounders suggest that, in high-risk populations, oral oseltamivir may reduce mortality (odds ratio, 0.23 [95% CI, 0.13 to 0.43]; low-quality evidence), hospitalization (odds ratio, 0.75 [CI, 0.66 to 0.89]; low-quality evidence), and duration of symptoms (33 hours [CI, 21 to 45 hours]; very low-quality evidence) compared with no treatment. Earlier treatment with oseltamivir was generally associated with better outcomes. Inhaled zanamivir may lead to shorter symptom duration (23 hours [CI, 17 to 28 hours]; moderate-quality evidence) and fewer hospitalizations (odds ratio, 0.66 [CI, 0.37 to 1.18]) but more complications than no treatment. Direct comparison of oral oseltamivir and inhaled zanamivir suggests no important differences in key outcomes. Data from 1 study suggest that oral amantadine may reduce mortality and pneumonia associated with influenza A. No included study evaluated rimantadine. Limitations: Mortality was assessed in high-risk patients, and generalizability is limited. The overall body of evidence is limited by risk for confounding and selection, reporting, and publication bias. Conclusion: Therapy with oral oseltamivir and inhaled zanamivir may provide a net benefit over no treatment of influenza. However, as with the randomized trials, the confidence in the estimates of the effects for decision making is low to very low. C1 [Schuenemann, Holger J.] McMaster Univ, WHO Collaborating Ctr Evidence Informed Policy Ma, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 4K1, Canada. Lanzhou Univ, Evidence Based Med Ctr, Lanzhou, Gansu, Peoples R China. Niagara Reg Publ Hlth, Thorold, ON, Canada. Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway. Univ Bergen, Bergen, Norway. Ctr Dis Control & Prevent, Atlanta, GA USA. SUNY Buffalo, Buffalo, NY 14260 USA. CIBERESP IIB Sant Pau, Iberoamer Cochrane Ctr, Barcelona, Spain. RP Schunemann, HJ (reprint author), McMaster Univ, WHO Collaborating Ctr Evidence Informed Policy Ma, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Room 2C16,1280 Main St W, Hamilton, ON L8N 4K1, Canada. EM schuneh@mcmaster.ca OI Mustafa, Reem/0000-0002-2091-0875 FU World Health Organization; McMaster University; Faculty of Health Sciences of McMaster University FX World Health Organization and McMaster University.; By agreement I2-APW-223 from the World Health Organization and by the Faculty of Health Sciences of McMaster University (internal grant to McMaster Healthcare Grading and Recommendations Center). NR 93 TC 97 Z9 104 U1 2 U2 19 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 3 PY 2012 VL 156 IS 7 BP 512 EP U95 DI 10.7326/0003-4819-156-7-201204030-00411 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA 921GP UT WOS:000302466400005 PM 22371849 ER PT J AU Nahar, MS Soliman, AS Colacino, JA Calafat, AM Battige, K Hablas, A Seifeldin, IA Dolinoy, DC Rozek, LS AF Nahar, Muna S. Soliman, Amr S. Colacino, Justin A. Calafat, Antonia M. Battige, Kristen Hablas, Ahmed Seifeldin, Ibrahim A. Dolinoy, Dana C. Rozek, Laura S. TI Urinary bisphenol A concentrations in girls from rural and urban Egypt: a pilot study SO ENVIRONMENTAL HEALTH LA English DT Article DE Egypt; Urban; Rural; Bisphenol A ID PERFORMANCE LIQUID-CHROMATOGRAPHY; ENDOCRINE-DISRUPTING CHEMICALS; BREAST-CANCER; ENVIRONMENTAL ESTROGENS; TEMPORAL VARIABILITY; HUMAN EXPOSURE; FOOD SIMULANT; MIGRATION; XENOESTROGENS; BPA AB Background: Exposure to endocrine active compounds, including bisphenol A (BPA), remains poorly characterized in developing countries despite the fact that behavioral practices related to westernization have the potential to influence exposure. BPA is a high production volume chemical that has been associated with metabolic dysfunction as well as behavioral and developmental effects in people, including children. In this pilot study, we evaluate BPA exposure and assess likely pathways of exposure among girls from urban and rural Egypt. Methods: We measured urinary concentrations of total (free plus conjugated) species of BPA in spot samples in urban (N = 30) and rural (N = 30) Egyptian girls, and compared these concentrations to preexisting data from age-matched American girls (N = 47) from the U. S. National Health and Nutrition Examination Survey (NHANES). We also collected anthropometric and questionnaire data regarding food storage behaviors to assess potential routes of exposure. Results: Urban and rural Egyptian girls exhibited similar concentrations of urinary total BPA, with median unadjusted values of 1.00 and 0.60 ng/mL, respectively. Concentrations of urinary BPA in this group of Egyptian girls (median unadjusted: 0.70 ng/mL) were significantly lower compared to age-matched American girls (median unadjusted: 2.60 ng/mL) according to NHANES 2009-2010 data. Reported storage of food in plastic containers was a significant predictor of increasing concentrations of urinary BPA. Conclusions: Despite the relatively low urinary BPA concentrations within this Egyptian cohort, the significant association between food storage behaviors and increasing urinary BPA concentration highlights the need to understand food and consumer product patterns that may be closing the gap between urban and rural lifestyles. C1 [Nahar, Muna S.; Colacino, Justin A.; Battige, Kristen; Dolinoy, Dana C.; Rozek, Laura S.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Soliman, Amr S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Soliman, Amr S.; Colacino, Justin A.; Rozek, Laura S.] Univ Michigan, Ctr Global Hlth, Ann Arbor, MI 48109 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Hablas, Ahmed; Seifeldin, Ibrahim A.] Tanta Canc Ctr, Tanta, Egypt. [Hablas, Ahmed; Seifeldin, Ibrahim A.] Gharbiah Canc Soc, Tanta, Egypt. [Rozek, Laura S.] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA. RP Dolinoy, DC (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. EM ddolinoy@umich.edu FU University of Michigan [R25 CA112383]; University of Michigan NIEHS P30 Core Center [P30 ES017885]; SPH Department of Environmental Health Sciences; NIH [ES017524]; NIEHS [T32 ES007062]; UM School of Public Health (SPH); [CA112383] FX This work was supported by the University of Michigan Cancer Epidemiology Education in Special Populations Program (R25 CA112383), the University of Michigan NIEHS P30 Core Center (P30 ES017885), with generous support from the UM School of Public Health (SPH) and the SPH Department of Environmental Health Sciences. Support for DCD was provided by NIH grant ES017524, support for KB was provided by Training Grant CA112383, and support for MSN and JAC was provided by NIEHS Institutional Training Grant T32 ES007062. We acknowledge Xiaoyun Ye, Xiaoliu Zhou and Ryan Hennings for measuring the urinary concentrations of BPA and Stacy Endres at NIEHS for her effort in part of the data collection. NR 61 TC 14 Z9 14 U1 1 U2 25 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-069X J9 ENVIRON HEALTH-GLOB JI Environ. Health PD APR 2 PY 2012 VL 11 AR 20 DI 10.1186/1476-069X-11-20 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 951KT UT WOS:000304720200001 PM 22472083 ER PT J AU Barradas, DT Kroelinger, CD Kogan, MD AF Barradas, Danielle T. Kroelinger, Charlan D. Kogan, Michael D. TI Medical Home Access Among American Indian and Alaska Native Children in 7 States: National Survey of Children's Health SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Medical home; Disparities; American Indians; National Survey of Children's Health ID CARE DISPARITIES; UNITED-STATES; YOUTH AB To describe the prevalence of medical home among American Indian and Alaska Native children (AIAN) compared to non-Hispanic white (NHW) children and identify areas for improvement in the provision of care within a medical home. Prevalence of medical home, defined as family-centered, comprehensive, coordinated, compassionate, culturally effective care, including a personal doctor or nurse and usual care location, was estimated using 2007 National Survey of Children's Health data. Analyses included 1-17 year-olds in states reporting AIAN race as a distinct category (Alaska, Arizona, Montana, New Mexico, North Dakota, Oklahoma, and South Dakota, n = 9,764). Associations between medical home and demographic (child's age, household education and income, and state) and health-related [child's insurance status, special health care need status, and past year Indian Health Service (IHS) utilization] characteristics were assessed among AIAN children. Overall, the prevalence of medical home was 27 % lower among AIAN children (42.6, 95 % CI = 34.4-50.8) than NHW children (58.3, 95 % CI = 56.2-60.4). Child's age (adjusted OR [aOR] = 2.7, 95 % CI = 1.3-5.6) was significantly associated with medical home. IHS utilization was associated with medical home among AIAN children with private insurance (aOR = 0.2, 95 % CI = 0.1-0.4), but not among uninsured or publicly insured children. Care coordination and family-centered care were noted areas for improvement among AIAN children. Less than half of AIAN children had a medical home. Future studies should further examine the intersection between insurance and IHS to determine if enhanced coordination is needed for this population, which is often served by multiple federally-funded health-related programs. C1 [Barradas, Danielle T.; Kroelinger, Charlan D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Kogan, Michael D.] Maternal & Child Hlth Bur, Hlth Resources & Serv Adm, Rockville, MD USA. RP Barradas, DT (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K-22, Atlanta, GA 30341 USA. EM dbarradas@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 5 Z9 5 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2012 VL 16 SU 1 BP S6 EP S13 DI 10.1007/s10995-012-0990-2 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 055JA UT WOS:000312410600002 PM 22466686 ER PT J AU Busacker, A Kasehagen, L AF Busacker, Ashley Kasehagen, Laurin TI Association of Residential Mobility with Child Health: An Analysis of the 2007 National Survey of Children's Health SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE National Survey of Children's Health; Residential mobility; Child health ID GEOGRAPHIC-MOBILITY; ORAL-HEALTH; CARE; INSTABILITY; ADOLESCENTS; RELOCATION; MORTALITY; BEHAVIOR; MOTHERS; STRESS AB To describe the association of residential mobility with child health. We conducted descriptive, bivariate, and multivariable analyses of data from 63,131 children, 6-17 years, from the 2007 National Survey of Children's Health. Logistic regression was used to explore the association of residential mobility with child health and measures of well-being. Analyses were carried out using SAS-callable SUDAAN to appropriately weight estimates and adjust for the complex sampling design. After adjusting for age, race/ethnicity, presence of a special health care need, family structure, parental education, poverty level, and health insurance status, children who moved >= 3 times were more likely to have poorer reported overall physical (AOR 1.21 [95 % CI: 1.01-1.46]) and oral health status (AOR 1.31 [95 % CI: 1.15-1.49]), and >= 1 moderate/severe chronic conditions (AOR 1.40 [95 % CI: 1.19-1.65]) than children who had no lifetime moves. When compared to children who had never moved, children who moved >= 3 times were more likely to be uninsured/have periods of no coverage (AOR 1.35; 95 % CI: 0.98-1.87) and lack a medical home (AOR 1.16, 95 % CI: 1.04-1.31). None of the outcomes were statistically significant for children who moved fewer than 3 times. Clinicians need to be aware that children who move frequently may lack stable medical homes and consistent coverage increasing their risk of poor health outcomes and aggravation of mild or underlying chronic conditions. Public health systems could provide the necessary link between parents and clinicians to ensure that continuous, coordinated care is established for children who move frequently. C1 [Kasehagen, Laurin] Univ Nebraska Med Ctr, Sect Child Hlth Policy, Dept Pediat, Omaha, NE 68198 USA. [Kasehagen, Laurin] Univ Nebraska Med Ctr, CityMatCH, Omaha, NE 68198 USA. [Busacker, Ashley; Kasehagen, Laurin] Ctr Dis Control & Prevent, MCH Epidemiol Program, ASB, DRH,NCCDPHP, Atlanta, GA 30341 USA. [Busacker, Ashley] Wyoming Dept Hlth, Cheyenne, WY USA. RP Kasehagen, L (reprint author), Univ Nebraska Med Ctr, Sect Child Hlth Policy, Dept Pediat, 982170 Nebraska Med Ctr, Omaha, NE 68198 USA. EM lkasehagen@unmc.edu NR 35 TC 12 Z9 12 U1 1 U2 12 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2012 VL 16 SU 1 BP S78 EP S87 DI 10.1007/s10995-012-0997-8 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 055JA UT WOS:000312410600010 PM 22527774 ER PT J AU Ogbuanu, C Goodman, D Kahn, K Noggle, B Long, C Bagchi, S Barradas, D Castrucci, B AF Ogbuanu, Chinelo Goodman, David Kahn, Katherine Noggle, Brendan Long, Cherie Bagchi, Suparna Barradas, Danielle Castrucci, Brian TI Factors Associated with Parent Report of Access to Care and the Quality of Care Received by Children 4 to 17 Years of Age in Georgia SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Children; Health care access; Health care quality; Health care utilization; National Survey of Children's Health ID HEALTH-CARE; UNITED-STATES; INSURANCE-COVERAGE; BEHAVIORAL-MODEL; US CHILDREN; DENTAL-CARE; SERVICES; SATISFACTION; DISPARITIES; IMPACT AB We examined factors associated with health care access and quality, among children in Georgia. Data from the 2007 National Survey of Children's Health were merged with the 2008 Area Resource File. The medically under-served area variable was appended to the merged file, restricting to Georgia children ages 4-17 years (N = 1,397). Study outcomes were past-year access to care, defined as utilization of preventive medical care and no occasion of delay or denial of needed care; and quality of care received, defined as compassionate, culturally-effective, and family-centered care which was categorized as higher, moderate, or lower. Analysis included binary and multinomial logit modeling. In our study population, 80.8 % were reported to have access to care. The quality of care distribution was: higher (39.4 %), moderate (30.6 %), and lower (30.0 %). Younger age (4-9 years) was positively associated with having access to care. Compared to children who had continuous and adequate private insurance, children who were never/intermittently insured or who had continuous and inadequate private insurance were less likely to have access. Compared to children who had continuous and adequate private insurance, there were lower odds of perceiving received care as higher/moderate versus lower quality among children who were never/intermittently insured or who had continuous and inadequate/adequate public insurance. Being in excellent/very good health and living in safe/supportive neighborhoods were positively associated with quality; non-white race/ethnicity and federal poverty level were negatively associated with quality. Assuring continuous, adequate insurance may positively impact health care access and quality. C1 [Ogbuanu, Chinelo; Kahn, Katherine; Noggle, Brendan; Long, Cherie; Bagchi, Suparna; Castrucci, Brian] Georgia Dept Community Hlth, Div Publ Hlth, Atlanta, GA USA. [Goodman, David; Barradas, Danielle] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Ogbuanu, C (reprint author), 2 Peachtree St NW,Suite 14-272, Atlanta, GA 30303 USA. EM chogbuanu@dhr.state.ga.us NR 42 TC 1 Z9 1 U1 1 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2012 VL 16 SU 1 BP S129 EP S142 DI 10.1007/s10995-012-1002-2 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 055JA UT WOS:000312410600015 PM 22466685 ER PT J AU Schieve, LA Rice, C Yeargin-Allsopp, M Boyle, CA Kogan, MD Drews, C Devine, O AF Schieve, Laura A. Rice, Catherine Yeargin-Allsopp, Marshalyn Boyle, Coleen A. Kogan, Michael D. Drews, Carolyn Devine, Owen TI Parent-Reported Prevalence of Autism Spectrum Disorders in US-Born Children: An Assessment of Changes within Birth Cohorts from the 2003 to the 2007 National Survey of Children's Health SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Autism; Prevalence; Birth population ID SPECIAL-EDUCATION; UNITED-STATES; TRENDS; MINNESOTA; DIAGNOSIS; AGE AB The prevalence of autism spectrum disorders (ASD) from the 2007 National Survey of Children's Health (NSCH) was twice the 2003 NSCH estimate for autism. From each NSCH, we selected children born in the US from 1990 to 2000. We estimated autism prevalence within each 1-year birth cohort to hold genetic and non-genetic prenatal factors constant. Prevalence differences across surveys thus reflect survey measurement changes and/or external identification effects. In 2003, parents were asked whether their child was ever diagnosed with autism. In 2007, parents were asked whether their child was ever diagnosed with an ASD and whether s/he currently had an ASD. For the 1997-2000 birth cohorts (children aged 3-6 years in 2003 and 7-10 years in 2007), relative increases between 2003 autism estimates and 2007 ASD estimates were 200-600 %. For the 1990-1996 birth cohorts (children aged 7-13 years in 2003) increases were lower; nonetheless, differences between 2003 estimates and 2007 "ever ASD'' estimates were >100 % for 6 cohorts and differences between 2003 estimates and 2007 "current ASD'' estimates were >80 % for 3 cohorts. The magnitude of most birth cohort-specific differences suggests continuing diagnosis of children in the community played a sizable role in the 2003-2007 ASD prevalence increase. While some increase was expected for 1997-2000 cohorts, because some children have later diagnoses coinciding with school entry, increases were also observed for children ages C7 years in 2003. Given past ASD subtype studies, the 2003 "autism'' question might have missed a modest amount (<= 33 %) of ASDs other than autistic disorder. C1 [Schieve, Laura A.; Rice, Catherine; Yeargin-Allsopp, Marshalyn; Boyle, Coleen A.; Devine, Owen] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Kogan, Michael D.] Maternal & Child Hlth Bur, Hlth Resources & Serv Adm, Rockville, MD 20857 USA. [Drews, Carolyn] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. RP Schieve, LA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, MS E-86,1600 Clifton Rd, Atlanta, GA 30333 USA. EM LSchieve@cdc.gov RI Rice, Catherine/D-6305-2016 NR 25 TC 21 Z9 21 U1 3 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2012 VL 16 SU 1 BP S151 EP S157 DI 10.1007/s10995-012-1004-0 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 055JA UT WOS:000312410600017 PM 22476793 ER PT J AU Kew, O AF Kew, Olen TI Reaching the last one per cent: progress and challenges in global polio eradication SO CURRENT OPINION IN VIROLOGY LA English DT Article ID VACCINE-DERIVED POLIOVIRUS; JANUARY 2010-SEPTEMBER 2011; POLIOMYELITIS ERADICATION; IMMUNODEFICIENT PATIENT; INFECTION; OUTBREAK; NIGERIA; INDIA; EMERGENCE; WORLDWIDE AB Since its launch in 1988, the World Health Organization's Global Polio Eradication Initiative has reduced worldwide polio incidence by >99%. The most dramatic progress was achieved up to the year 2000, the original eradication target date, but subsequent years have seen only limited progress in preventing the last 1% of cases. Recent gains in India and Nigeria have been offset by continued endemicity in Pakistan and Afghanistan, and repeated reseeding of wild poliovirus into polio-free areas has led to large outbreaks and re-established transmission. Although wild poliovirus type 2 was eradicated in 1999 and wild poliovirus type 3 may be nearing eradication, the continued emergence of circulating vaccine-derived polioviruses, especially type 2, presents ongoing challenges to stopping all poliovirus transmission. C1 Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Kew, O (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, G-10,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM OKew@cdc.gov NR 46 TC 23 Z9 23 U1 4 U2 22 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1879-6257 J9 CURR OPIN VIROL JI Curr. Opin. Virol. PD APR PY 2012 VL 2 IS 2 BP 188 EP 198 DI 10.1016/j.coviro.2012.02.006 PG 11 WC Virology SC Virology GA 051FX UT WOS:000312112700012 PM 22482715 ER PT J AU Adair, LS Thompson, AL Kayira, D Chasela, C Kacheche, Z Kamwendo, D Bentley, M Jamieson, D Allen, LH Shahab-Ferdows, S AF Adair, Linda S. Thompson, A. L. Kayira, D. Chasela, C. Kacheche, Z. Kamwendo, D. Bentley, M. Jamieson, D. Allen, L. H. Shahab-Ferdows, S. TI Maternal and infant predictors of CRP in exclusively breastfed infants born to HIV-infected Malawian mothers SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Adair, Linda S.; Thompson, A. L.; Bentley, M.] UNC, Chapel Hill, NC USA. [Kayira, D.; Chasela, C.; Kacheche, Z.; Kamwendo, D.] UNC Project, Lilongwe, Malawi. [Jamieson, D.] CDC, Atlanta, GA 30333 USA. [Allen, L. H.; Shahab-Ferdows, S.] ARS, USDA, Davis, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711304788 ER PT J AU Clayton, HB Scanlon, K Perrine, C Li, RW AF Clayton, Heather Breeze Scanlon, Kelley Perrine, Cria Li, Ruowei TI Do mother's self-reported reasons for introducing solid foods vary by age at introduction and socio-demographic characteristics? SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Clayton, Heather Breeze; Scanlon, Kelley; Perrine, Cria; Li, Ruowei] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711301284 ER PT J AU Du, SF Neiman, A Wang, HJ Zhang, B Popkin, BM AF Du, Shufa Neiman, Andrea Wang, Huijun Zhang, Bing Popkin, Barry M. TI Understanding the patterns and trends of potassium intake and sodium/potassium ratio in China, 1991-2009 SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Du, Shufa; Popkin, Barry M.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. [Neiman, Andrea] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Wang, Huijun; Zhang, Bing] Chinese CDC, Natl Inst Nutr & Food Safety, Beijing, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711305569 ER PT J AU Dwyer, JT Bailey, R Saldanha, L Holden, J Andrews, K Betz, J Gahche, J Hardy, C Milner, J Roseland, J AF Dwyer, Johanna T. Bailey, Regan Saldanha, Leila Holden, Joanne Andrews, Karen Betz, Joseph Gahche, Jaime Hardy, Constance Milner, John Roseland, Janet TI Progress in development of dietary supplement (DS) composition and label databases for research SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Dwyer, Johanna T.; Bailey, Regan; Saldanha, Leila; Betz, Joseph] Off Dietary Supplements, Bethesda, MD USA. [Milner, John] NCI, NIH, Bethesda, MD 20892 USA. [Holden, Joanne; Andrews, Karen; Roseland, Janet] USDA, Nutrient Data Lab, Beltsville, MD 20705 USA. [Gahche, Jaime] CDC, NCHS, Hysattsville, MD USA. [Hardy, Constance] US FDA, CFSAN, Silver Spring, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711301264 ER PT J AU Flax, VL Bentley, ME Chasela, C Kayira, D Hudgens, MG Kacheche, KG Chavula, C Jamieson, DJ van der Horst, C Adair, LS AF Flax, Valerie L. Bentley, Margaret E. Chasela, Charles Kayira, Dumbani Hudgens, Michael G. Kacheche, Kopekani G. Chavula, Charity Jamieson, Denise J. van der Horst, Charles Adair, Linda S. TI Patterns and predictors of growth in HIV-exposed 24-48-week-old Malawians receiving lipid-based nutrient supplements as a breastmilk replacement: results of the BAN study SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Flax, Valerie L.; Bentley, Margaret E.; Hudgens, Michael G.; van der Horst, Charles; Adair, Linda S.] UNC, Chapel Hill, NC USA. [Chasela, Charles; Kayira, Dumbani; Kacheche, Kopekani G.; Chavula, Charity] UNC Project, Lilongwe, Malawi. [Jamieson, Denise J.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711303839 ER PT J AU Grant, FKE Martorell, R Ayala-Flores, R Cole, CR Ramakrishnan, U Laird, RJ Patel, M Juliao, PC Quick, R Suchdev, PS AF Grant, Frederick Kobina Ebo Martorell, Reynaldo Ayala-Flores, Rafael Cole, Conrad R. Ramakrishnan, Usha Laird, Ruth J. Patel, Minal Juliao, Patricia C. Quick, Rob Suchdev, Parminder S. TI Selling Sprinkles as part of a health products package may reduce fever and diarrhea incidence but not respiratory illness in preschool children in western Kenya SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Grant, Frederick Kobina Ebo; Martorell, Reynaldo; Ramakrishnan, Usha] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Suchdev, Parminder S.] Emory Univ, Dept Pediat & Global Hlth, Atlanta, GA 30322 USA. [Ayala-Flores, Rafael; Laird, Ruth J.; Suchdev, Parminder S.] CDC, Nutr Branch, Atlanta, GA 30333 USA. [Patel, Minal; Juliao, Patricia C.; Quick, Rob] CDC, Waterborne Dis Prevent Branch, Atlanta, GA 30333 USA. [Cole, Conrad R.] Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH USA. RI Suchdev, Parmi/K-4851-2012; Ramakrishnan, Usha/L-8921-2016 NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711300220 ER PT J AU Hinkle, SN Sharma, AJ Swan, DW Schieve, LJ Stein, A Ramakrishnan, U AF Hinkle, Stefanie Nicole Sharma, Andrea J. Swan, Deanne W. Schieve, Laura J. Stein, Aryeh Ramakrishnan, Usha TI Gestational weight gain and child weight status at 5 years of age: differential effects by prepregnancy body mass index status SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Hinkle, Stefanie Nicole; Sharma, Andrea J.; Schieve, Laura J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Swan, Deanne W.; Stein, Aryeh; Ramakrishnan, Usha] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RI Hinkle, Stefanie/F-8253-2013; Ramakrishnan, Usha/L-8921-2016 OI Hinkle, Stefanie/0000-0003-4312-708X; NR 0 TC 0 Z9 0 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711300090 ER PT J AU Jordan-Bell, E Adair, L Flax, V Chasela, C Kayira, D Daza, E Tembo, M Chitsulo, P Jamieson, D van der Horst, C Bentley, M AF Jordan-Bell, Elizabeth Adair, Linda Flax, Valerie Chasela, Charles Kayira, Dumbani Daza, Eric Tembo, Martin Chitsulo, Phindile Jamieson, Denise van der Horst, Charles Bentley, Margaret TI Weight status in HIV-positive women after termination of a drug and lipid-based nutrient supplement intervention is predicted by food availability and health SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Jordan-Bell, Elizabeth; Adair, Linda; Flax, Valerie; Daza, Eric; van der Horst, Charles; Bentley, Margaret] UNC, Chapel Hill, NC USA. [Chasela, Charles; Kayira, Dumbani; Tembo, Martin; Chitsulo, Phindile] UNC Project, Lilongwe, Malawi. [Jamieson, Denise] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711302685 ER PT J AU Kuiper, HC Meyers, T Ribera, AM Muresan, MC Smith, AR Waters, CW Vesper, HW AF Kuiper, Heather C. Meyers, Tunde Ribera, Ashley M. Muresan, Marcela C. Smith, Antoinette R. Waters, Christina W. Vesper, Hubert W. TI Quantitative Analysis of Trans-Fatty Acids in Human Plasma SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Kuiper, Heather C.; Meyers, Tunde; Ribera, Ashley M.; Muresan, Marcela C.; Smith, Antoinette R.; Waters, Christina W.; Vesper, Hubert W.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711305313 ER PT J AU Li, HT Mei, ZG Ren, AG Serdula, M Cogswell, M Liu, JM AF Li, Hong-tian Mei, Zuguo Ren, Aiguo Serdula, Mary Cogswell, Mary Liu, Jian-meng TI Impact of iron-containing micronutrient supplementation on high hemoglobin concentration during pregnancy SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Li, Hong-tian; Ren, Aiguo; Liu, Jian-meng] Peking Univ, Hlth Sci Ctr, Inst Reprod & Child Hlth, Beijing 100871, Peoples R China. [Mei, Zuguo; Serdula, Mary; Cogswell, Mary] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711304180 ER PT J AU Liu, JM Mei, ZG Ye, RW Serdula, M Li, HT Cogswell, M AF Liu, Jian-meng Mei, Zuguo Ye, Rongwei Serdula, Mary Li, Hong-tian Cogswell, Mary TI Impact of iron-contained micronutrient supplementation on macrosomia and large for gestational age births SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Liu, Jian-meng; Ye, Rongwei; Li, Hong-tian] Peking Univ, Hlth Sci Ctr, Inst Reprod & Child Hlth, Beijing 100871, Peoples R China. [Mei, Zuguo; Serdula, Mary; Cogswell, Mary] Ctr Dis Control & Prevent, Div Nutr Phys Activ & Obes, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711304112 ER PT J AU Mei, ZG Pfeiffer, CM Looker, AC Flores-Ayala, RC Lacher, DA Mirel, LB Grummer-Strawn, LM AF Mei, Zuguo Pfeiffer, Christine M. Looker, Anne C. Flores-Ayala, Rafael C. Lacher, David A. Mirel, Lisa B. Grummer-Strawn, Laurence M. TI Serum soluble transferrin receptor concentrations in US preschool children and non-pregnant women of childbearing age from the National Health and Nutrition Examination Survey 2003-2008 SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Mei, Zuguo; Flores-Ayala, Rafael C.; Grummer-Strawn, Laurence M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Looker, Anne C.; Lacher, David A.; Mirel, Lisa B.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711300302 ER PT J AU Odewole, O Zakai, N Judd, S Berry, R Qi, YP McClellan, W Williamson, R Demilade, A Oakley, G AF Odewole, Oluwaseun Zakai, Neil Judd, Susan Berry, Robert Qi, Yan Ping McClellan, William Williamson, Rebecca Demilade, Adedinsewo Oakley, Godfrey TI Prevalence of Folate deficiency and Folate Deficiency Anemia in REGARDS 2003-2007 SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Odewole, Oluwaseun; McClellan, William; Williamson, Rebecca; Demilade, Adedinsewo; Oakley, Godfrey] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Zakai, Neil] Univ Vermont, Burlington, VT USA. [Judd, Susan] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA. [Berry, Robert; Qi, Yan Ping] Ctr Dis Control, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711300203 ER PT J AU Olsen, RJ Laucirica, DR Watkins, ME Feske, ML Garcia-Bustillos, JR Vu, C Cantu, C Shelburne, SA Fittipaldi, N Kumaraswami, M Shea, P Flores, AR Beres, SB Lovgren, M Tyrrell, GJ Efstratiou, A Low, DE Van Beneden, CA Musser, JM AF Olsen, Randall J. Laucirica, Daniel R. Watkins, Melanie E. Feske, Marsha L. Garcia-Bustillos, Jesus R. Chau Vu Cantu, Concepcion Shelburne, Samuel A. Fittipaldi, Nahuel Kumaraswami, Muthiah Shea, Patrick Flores, Anthony R. Beres, Stephen B. Lovgren, Maguerite Tyrrell, Gregory J. Efstratiou, Androulla Low, Donald E. Van Beneden, Chris A. Musser, James M. TI Polymorphisms in regulator of protease B (RopB) alter disease phenotype and strain virulence of serotype M3 Group A Streptococcus SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Olsen, Randall J.; Laucirica, Daniel R.; Watkins, Melanie E.; Feske, Marsha L.; Garcia-Bustillos, Jesus R.; Chau Vu; Cantu, Concepcion; Fittipaldi, Nahuel; Kumaraswami, Muthiah; Shea, Patrick; Beres, Stephen B.; Musser, James M.] Methodist Hosp, Res Inst, Houston, TX 77030 USA. [Shelburne, Samuel A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Flores, Anthony R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Lovgren, Maguerite; Tyrrell, Gregory J.] Univ Alberta, Edmonton, AB, Canada. [Efstratiou, Androulla] Hlth Protect Agcy, London, England. [Low, Donald E.] Univ Toronto, Toronto, ON, Canada. [Van Beneden, Chris A.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711301662 ER PT J AU Panicker, G Rajbhandari, I Unger, E AF Panicker, Gitika Rajbhandari, Ira Unger, Elizabeth TI Detection of antibodies to HPV vaccine types using a multiplexed immunoassay SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Panicker, Gitika; Rajbhandari, Ira; Unger, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711307058 ER PT J AU Park, S Blanck, HM Sherry, B Jones, SE Pan, LP AF Park, Sohyun Blanck, Heidi M. Sherry, Bettylou Jones, Sherry Everett Pan, Liping TI Non-Diet Soda Intake Independent of Weight Status Is Associated with Asthma among US Adolescents SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Park, Sohyun; Blanck, Heidi M.; Sherry, Bettylou; Jones, Sherry Everett; Pan, Liping] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711300643 ER PT J AU Park, S Blanck, HM Sherry, B Brener, N O'Toole, T AF Park, Sohyun Blanck, Heidi M. Sherry, Bettylou Brener, Nancy O'Toole, Terrence TI Factors Associated with Low Water Intake among US High School Students SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Park, Sohyun; Blanck, Heidi M.; Sherry, Bettylou; Brener, Nancy; O'Toole, Terrence] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711300440 ER PT J AU Perrine, CG Sullivan, KM Flores-Ayala, R Grummer-Strawn, LM AF Perrine, Cria G. Sullivan, Kevin M. Flores-Ayala, Rafael Grummer-Strawn, Laurence M. TI Contributors to iodine status among children in the US SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Perrine, Cria G.; Sullivan, Kevin M.; Flores-Ayala, Rafael; Grummer-Strawn, Laurence M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Sullivan, Kevin M.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711305152 ER PT J AU Saldanha, LG Dwyer, JT Holden, JM Andrews, KW Bailey, RL Betz, JM Gahche, JJ Hardy, CJ Milner, J Roseland, JM AF Saldanha, Leila G. Dwyer, Johanna T. Holden, Joanne M. Andrews, Karen W. Bailey, Regan L. Betz, Joseph M. Gahche, Jaime J. Hardy, Constance J. Milner, John Roseland, Janet M. TI Identifying non-vitamin & mineral bioactive (non-VM) ingredients for inclusion in Dietary Supplement (DS) Composition Databases SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Milner, John] NCI, NIH, Bethesda, MD 20892 USA. [Saldanha, Leila G.; Dwyer, Johanna T.; Bailey, Regan L.; Betz, Joseph M.] Off Dietary Supplements, Bethesda, MD USA. [Holden, Joanne M.; Andrews, Karen W.; Roseland, Janet M.] ARS, USDA, Beltsville, MD USA. [Gahche, Jaime J.] CDC, NHANES, NCHS, Hyattsville, MD USA. [Hardy, Constance J.] US FDA, CFSAN, College Pk, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711302966 ER PT J AU Tsang, B Ruth, LJ Sullivan, KM Williams, TN Suchdev, PS AF Tsang, Becky Ruth, Laird J. Sullivan, Kevin M. Williams, Tom N. Suchdev, Parminder S. TI Nutritional status of young children with inherited blood disorders in western Kenya SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Tsang, Becky; Sullivan, Kevin M.; Suchdev, Parminder S.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Ruth, Laird J.; Sullivan, Kevin M.; Suchdev, Parminder S.] Ctr Dis Control & Prevent, Nutr Branch, Atlanta, GA USA. [Williams, Tom N.] Ctr Geog Med Res Coast, Kilifi, Kenya. RI Suchdev, Parmi/K-4851-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711303958 ER PT J AU Unger, ER Miller, AH Jones, JF Drake, DF Tian, H Pagnoni, G AF Unger, Elizabeth R. Miller, Andrew H. Jones, James F. Drake, Daniel F. Tian, Hao Pagnoni, Giuseppe TI Decreased basal ganglia activation in Chronic Fatigue Syndrome subjects is associated with increased fatigue SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Unger, Elizabeth R.; Jones, James F.; Tian, Hao] Ctr Dis Control & Prevent, Atlanta, GA USA. [Miller, Andrew H.; Drake, Daniel F.] Emory Univ, Sch Med, Atlanta, GA USA. [Pagnoni, Giuseppe] Univ Modena & Reggio Emilia, Modena, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711303880 ER PT J AU Widen, EM Bentley, ME Chasela, C Kayira, D Tegha, G Kourtis, A Jamieson, D van der Horst, C Allen, L Shahab-Ferdows, S Adair, LS AF Widen, Elizabeth M. Bentley, M. E. Chasela, C. Kayira, D. Tegha, G. Kourtis, A. Jamieson, D. van der Horst, C. Allen, L. Shahab-Ferdows, S. Adair, L. S. TI Maternal and infant iron status in HIV-infected Malawian women and their exclusively breastfed infants SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Widen, Elizabeth M.; Bentley, M. E.; van der Horst, C.; Adair, L. S.] UNC CH, Chapel Hill, NC USA. [Chasela, C.; Kayira, D.; Tegha, G.] UNC Project, Lilongwe, Malawi. [Kourtis, A.; Jamieson, D.] CDC, Atlanta, GA 30333 USA. [Allen, L.; Shahab-Ferdows, S.] USDA ARS WHNRC, Davis, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711303540 ER PT J AU Widen, EM Bentley, M Kayira, D Chasela, C Kacheche, Z Tegha, G Kamwendo, D Jamieson, D Flax, V van der Horst, C Adair, L AF Widen, Elizabeth M. Bentley, Margaret Kayira, Dumbani Chasela, Charles Kacheche, Zebrone Tegha, Gerald Kamwendo, Debbie Jamieson, Denise Flax, Valerie van der Horst, Charles Adair, Linda TI Maternal body mass index modifies the impact of negative energy balance during lactation on infant weight and length gain in HIV-exposed, uninfected Malawian females SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Widen, Elizabeth M.; Bentley, Margaret; Flax, Valerie; van der Horst, Charles; Adair, Linda] UNC CH, Chapel Hill, NC USA. [Kayira, Dumbani; Chasela, Charles; Kacheche, Zebrone; Tegha, Gerald; Kamwendo, Debbie] UNC Project, Lilongwe, Malawi. [Jamieson, Denise] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711301331 ER PT J AU Yang, M Park, S Chun, OK AF Yang, Meng Park, Sohyun Chun, Ock K. TI Association between total water intake, micronutrient intakes and serum nutrient profile among US adults SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Yang, Meng; Chun, Ock K.] Univ Connecticut, Storrs, CT USA. [Park, Sohyun] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711305949 ER PT J AU Kim, SY England, L Sappenfield, W Wilson, HG Bish, CL Salihu, HM Sharma, AJ AF Kim, Shin Y. England, Lucinda Sappenfield, William Wilson, Hoyt G. Bish, Connie L. Salihu, Hamisu M. Sharma, Andrea J. TI Racial/Ethnic Differences in the Percentage of Gestational Diabetes Mellitus Cases Attributable to Overweight and Obesity, Florida, 2004-2007 SO PREVENTING CHRONIC DISEASE LA English DT Article ID RISK-FACTORS; WOMEN; ETHNICITY; PREGNANCY; POPULATION; STRATEGIES; DIAGNOSIS; OUTCOMES; WEIGHT; ADULTS AB Introduction Gestational diabetes mellitus (GDM) affects 3% to 7% of pregnant women in the United States, and Asian, black, American Indian, and Hispanic women are at increased risk. Florida, the fourth most populous US state, has a high level of racial/ethnic diversity, providing the opportunity to examine variations in the contribution of maternal body mass index (BMI) status to GDM risk. The objective of this study was to estimate the race/ethnicity-specific percentage of GDM attributable to overweight and obesity in Florida. Methods We analyzed linked birth certificate and maternal hospital discharge data for live, singleton deliveries in Florida from 2004 through 2007. We used logistic regression to assess the independent contributions of women's prepregnancy BMI status to their GDM risk, by race/ethnicity, while controlling for maternal age and parity. We then calculated the adjusted population-attributable fraction of GDM cases attributable to overweight and obesity. Results The estimated GDM prevalence was 4.7% overall and ranged from 4.0% among non-Hispanic black women to 9.9% among Asian/Pacific Islander women. The probability of GDM increased with increasing BMI for all racial/ethnic groups. The fraction of GDM cases attributable to overweight and obesity was 41.1% overall, 15.1% among Asians/Pacific Islanders, 39.1% among Hispanics, 41.2% among non-Hispanic whites, 50.4% among non-Hispanic blacks, and 52.8% among American Indians. Conclusion Although non-Hispanic black and American Indian women may benefit the most from prepregnancy reduction in obesity, interventions other than obesity prevention may be needed for women from other racial/ethnic groups. C1 [Kim, Shin Y.; England, Lucinda; Wilson, Hoyt G.; Bish, Connie L.; Sharma, Andrea J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Sappenfield, William] Florida Dept Hlth, Bur Family & Community Hlth, Div Family Hlth Serv, Tallahassee, FL USA. [Salihu, Hamisu M.] Univ S Florida, Dept Biostat & Epidemiol, Tampa, FL USA. RP Kim, SY (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS K-23, Atlanta, GA 30341 USA. EM skim1@cdc.gov OI Sharma, Andrea/0000-0003-0385-0011 NR 32 TC 6 Z9 6 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2012 VL 9 AR 110249 DI 10.5888/pcd9.110249 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 977HL UT WOS:000306647200009 ER PT J AU Kirtland, KA Zack, MM Caspersen, CJ AF Kirtland, Karen A. Zack, Matthew M. Caspersen, Carl J. TI State-Specific Synthetic Estimates of Health Status Groups Among Inactive Older Adults With Self-Reported Diabetes, 2000-2009 SO PREVENTING CHRONIC DISEASE LA English DT Article ID GLYCEMIC CONTROL; FUNCTIONAL DISABILITY; EXERCISE; US; ASSOCIATION; MELLITUS; COMORBIDITY; DISEASE; WOMEN; TRIAL AB Introduction Physical activity helps diabetic older adults who have physical impairments or comorbid conditions to control their disease. To enable state planners to select physical activity programs for these adults, we calculated synthetic state-specific estimates of inactive older adults with diabetes, categorized by defined health status groups. Methods Using data from the 2000 through 2009 National Health Interview Survey (NHIS) and the Behavioral Risk Factor Surveillance System (BRFSS), we calculated synthetic state-specific estimates of inactive adults with diabetes who were aged 50 years or older for 5 mutually exclusive health status groups: 1) homebound, 2) frail (functional difficulty in walking one-fourth mile, climbing 10 steps, standing for 2 hours, and stooping, bending, and kneeling), 3) functionally impaired (difficulty in 1 to 3 of these functions), 4) having 1 or more comorbid conditions (with no functional impairments), and 5) healthy (no impairments or comorbid conditions). We combined NHIS regional proportions for the health status groups of inactive, older diabetic adults with BRFSS data of older diabetic adults to estimate state-specific proportions and totals. Results State-specific estimates of health status groups among all older adults ranged from 2.2% to 3.0% for homebound, 5.8% to 8.8% for frail, 20.1% to 26.1% for impaired, 34.9% to 43.7% for having comorbid conditions, and 4.0% to 6.9% for healthy; the remainder were older active diabetic adults. Except for the homebound, the percentages in these health status groups varied significantly by region and state. Conclusion These state-specific estimates correspond to existing physical activity programs to match certain health status characteristics of groups and may be useful to program planners to meet the needs of inactive, older diabetic adults. C1 [Zack, Matthew M.; Caspersen, Carl J.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Kirtland, KA (reprint author), Northrop Grumman, 3375 NE Expressway NE, Atlanta, GA 30341 USA. EM gon6@cdc.gov RI Caspersen, Carl/B-2494-2009 NR 29 TC 2 Z9 2 U1 3 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2012 VL 9 AR 110221 DI 10.5888/pcd9.110221 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 977HL UT WOS:000306647200010 ER PT J AU Wen, XJ Kanny, D Thompson, WW Okoro, CA Town, M Balluz, LS AF Wen, Xiao-Jun Kanny, Dafna Thompson, William W. Okoro, Catherine A. Town, Machell Balluz, Lina S. TI Binge Drinking Intensity and Health-Related Quality of Life Among US Adult Binge Drinkers SO PREVENTING CHRONIC DISEASE LA English DT Article ID FACTOR SURVEILLANCE SYSTEM; EXCESSIVE ALCOHOL-CONSUMPTION; RISK; GENDER; HARMS; STATES; POLICY AB Introduction Binge drinking (men, >= 5 drinks, women, >= 4 on an occasion) accounts for more than half of the 7 9,000 annual deaths due to excessive alcohol use in the United States. The frequency of binge drinking is associated with poor health-related quality of life (HRQOL), but the association between binge drinking intensity and HRQOL is unknown. Our objective was to examine this association. Methods We used 2008-2010 Behavioral Risk Factor Surveillance System data and multivariate linear regression models to examine the association between binge drinking intensity (largest number of drinks consumed on any occasion) among US adult binge drinkers and 2 HRQOL indicators: number of physically and mentally unhealthy days. Results Among binge drinkers, the highest-intensity binge drinkers (women consuming >= 7 drinks and men consuming >= 8 drinks on any occasion) were more likely to report poor HRQOL than binge drinkers who reported lower levels of intensity (women who consumed 4 drinks and men who consumed 5 drinks on any occasion). On average, female binge drinkers reported more physically and mentally unhealthy days (2.8 d and 5.1 d, respectively) than male binge drinkers (2.5 d and 3.6 d, respectively). After adjustment for confounding factors, women who consumed >= 7 drinks on any occasion reported more mentally unhealthy days (6.3 d) than women who consumed 4 drinks (4.6 d). Compared with male binge drinkers across the age groups, female binge drinkers had a significantly higher mean number of mentally unhealthy days. Conclusion Our findings underscore the importance of implementing effective population-level strategies to prevent binge drinking and improve HRQOL. C1 [Kanny, Dafna] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Kanny, D (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS K-67, Atlanta, GA 30341 USA. EM dkk3@cdc.gov FU Medscape, LLC; Preventing Chronic Disease FX This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Preventing Chronic Disease. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. NR 30 TC 2 Z9 2 U1 0 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2012 VL 9 AR 110204 DI 10.5888/pcd9.110204 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 977HL UT WOS:000306647200007 ER PT J AU Will, JC Valderrama, AL Yoon, PW AF Will, Julie C. Valderrama, Amy L. Yoon, Paula W. TI Preventable Hospitalizations for Congestive Heart Failure: Establishing a Baseline to Monitor Trends and Disparities SO PREVENTING CHRONIC DISEASE LA English DT Article ID CARE-SENSITIVE CONDITIONS; QUALITY-OF-CARE; PRACTICE GUIDELINES; MANAGEMENT; OUTCOMES; UPDATE; DIAGNOSIS; ETHNICITY; MORTALITY; DISEASE AB Introduction Preventable hospitalization for congestive heart failure (CHF) is believed to capture the failure of the outpatient health care system to properly manage and treat CHF. In anticipation of changes in the national health care system, we report baseline rates of these hospitalizations and describe trends by race over 1 5 years. Methods We used National Hospital Discharge Survey data from 1 995 through 2009, which represent approximately 1% of hospitalizations in the United States each year. We calculated age-, sex-, and race-stratified rates and age-and sex-standardized rates for preventable CHF hospitalizations on the basis of the Agency for Healthcare Research and Quality's specifications, which use civilian population estimates from the US Census Bureau as the denominator for rates. Results Approximately three-fourths of the hospitalizations occurred among people aged 65 years or older. In each subgroup and period, rates were significantly higher (P < .05) for blacks than whites. Only black men aged 1 8 to 44 showed a linear increase (P = .004) in crude rates across time. Subpopulations aged 65 or older, except black men, showed a linear decrease (P < .05) in crude rates over time. Age-and sex-standardized rates showed a significant linear decrease in rates for whites (P = .01) and a borderline decrease for blacks (P = .06) Conclusion Before implementation of the Patient Protection and Affordable Care Act, we found that blacks were disproportionately affected by preventable CHF hospitalizations compared with whites. Our results confirm recent findings that preventable CHF hospitalization rates are declining in whites more than blacks. Alarmingly, rates for younger black men are on the rise. C1 [Will, Julie C.; Valderrama, Amy L.; Yoon, Paula W.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. RP Will, JC (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy NE,Mailstop F-72, Atlanta, GA 30341 USA. EM jxw6@cdc.gov RI Dalla Zuanna, Teresa/G-3133-2015 NR 28 TC 3 Z9 3 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD APR PY 2012 VL 9 AR 110260 DI 10.5888/pcd9.110260 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 977HL UT WOS:000306647200006 ER PT J AU Naumann, RB Dellinger, AM Anderson, ML Bonomi, AE Rivara, FP AF Naumann, Rebecca B. Dellinger, Ann M. Anderson, Melissa L. Bonomi, Amy E. Rivara, Frederick P. TI Healthcare utilization and costs among older adult female drivers and former drivers SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE Older adults; Mobility; Motor vehicle; Costs; Healthcare ID DRIVING CESSATION; DEPRESSIVE SYMPTOMS; PEOPLE AB Purpose: This study compared the healthcare utilization and costs for specific types of medical services among older adult women who currently drive and those who no longer drive. Methods: This study included 347 women aged 65 or older who were either former (had stopped driving) or current drivers, randomly sampled from a large U.S. health plan to participate in a telephone survey, and who had automated health records with healthcare utilization and cost data. Bivariate analyses and generalized linear modeling were used to examine associations between driving status and healthcare utilization and costs. Results: Adjusting for age, income, and marital status, former drivers were more likely than current drivers to use mental health care services (RR = 3.37; 95% Cl: 1.03, 10.98). Former drivers also tended to use more inpatient (RR=1.85; 95% Cl: 0.88, 3.87) and emergency services (RR=1.89; 95% Cl: 0.96, 3.70), but results did not reach statistical significance. Total annual healthcare costs in 2005 were almost twice as high for former drivers compared with current drivers ($13,046 vs. $7,054; mean difference = $5,992; 95% Cl: -$360, $12,344), although this relationship was not statistically significant (CR = 1.61; 95% Cl: 0.88, 2.96). Impact on Industry: Former drivers were more than three times as likely as current drivers to use mental health services, and tended to use more emergency and inpatient services. Further research on factors that potentially mediate the relationship between driving status and health service use is warranted. (C) 2012 National Safety Council and Elsevier Ltd. All rights reserved. C1 [Naumann, Rebecca B.; Dellinger, Ann M.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Anderson, Melissa L.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. [Bonomi, Amy E.] Ohio State Univ, Dept Human Dev & Family Sci, Columbus, OH 43210 USA. [Rivara, Frederick P.] Haborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA. RP Naumann, RB (reprint author), 4770 Buford Hwy NE,Mailstop F-62, Atlanta, GA 30341 USA. EM RNaumann@cdc.gov NR 13 TC 1 Z9 1 U1 2 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PD APR PY 2012 VL 43 IS 2 BP 141 EP 144 DI 10.1016/j.jsr.2012.01.001 PG 4 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 972GO UT WOS:000306265500008 PM 22710001 ER PT J AU Epstein, MP Duncan, R Broadaway, KA He, M Allen, AS Satten, GA AF Epstein, Michael P. Duncan, Richard Broadaway, K. Alaine He, Min Allen, Andrew S. Satten, Glen A. TI Stratification-Score Matching Improves Correction for Confounding by Population Stratification in Case-Control Association Studies SO GENETIC EPIDEMIOLOGY LA English DT Article DE population stratification; matching; case-control study; association ID GENOME-WIDE ASSOCIATION; GENETIC-ASSOCIATION; PROPENSITY SCORE; SAMPLING METHODS; RARE VARIANTS; BREAST-CANCER; RISK LOCI; DISEASE; DESIGNS AB Proper control of confounding due to population stratification is crucial for valid analysis of case-control association studies. Fine matching of cases and controls based on genetic ancestry is an increasingly popular strategy to correct for such confounding, both in genome-wide association studies (GWASs) as well as studies that employ next-generation sequencing, where matching can be used when selecting a subset of participants from a GWAS for rare-variant analysis. Existing matching methods match on measures of genetic ancestry that combine multiple components of ancestry into a scalar quantity. However, we show that including nonconfounding ancestry components in a matching criterion can lead to inaccurate matches, and hence to an improper control of confounding. To resolve this issue, we propose a novel method that assigns cases and controls to matched strata based on the stratification score (Epstein et al. [2007] Am J Hum Genet 80:921-930), which is the probability of disease given genomic variables. Matching on the stratification score leads to more accurate matches because case participants are matched to control participants who have a similar risk of disease given ancestry information. We illustrate our matching method using the African-American arm of the GAIN GWAS of schizophrenia. In this study, we observe that confounding due to stratification can be resolved by our matching approach but not by other existing matching procedures. We also use simulated data to show our novel matching approach can provide a more appropriate correction for population stratification than existing matching approaches. Genet. Epidemiol. 36:195-205, 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Epstein, Michael P.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA. [He, Min; Allen, Andrew S.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA. [Satten, Glen A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Epstein, MP (reprint author), Emory Univ, Sch Med, Dept Human Genet, 615 Michael St,Suite 301, Atlanta, GA 30322 USA. EM mpepste@emory.edu OI Satten, Glen/0000-0001-7275-5371 FU National Institutes of Health [HG003618, HL077663] FX Contract grant sponsor: National Institutes of Health; Contract grant numbers: HG003618; HL077663. NR 42 TC 7 Z9 7 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PD APR PY 2012 VL 36 IS 3 BP 195 EP 205 DI 10.1002/gepi.21611 PG 11 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA 932VX UT WOS:000303319700003 PM 22714934 ER PT J AU Nahar, N Uddin, M Gurley, ES Khan, MSU Hossain, MJ Sultana, R Luby, SP AF Nahar, Nazmun Uddin, Main Gurley, Emily S. Khan, M. Salah Uddin Hossain, M. Jahangir Sultana, Rebeca Luby, Stephen P. TI Pig illnesses and epidemics: a qualitative study on perceptions and practices of pig raisers in Bangladesh SO VETERINARIA ITALIANA LA English DT Article DE Bangladesh; Disease; Farmer; One Health; Perception; Pig; Qualitative research; Swine; Zoonosis ID NIPAH VIRUS; RISK-FACTORS; ENCEPHALITIS; MALAYSIA; HEALTH; EMERGENCE; OUTBREAK; FARMERS; WORKERS; SWINE AB Zoonoses in swine are increasingly becoming a global public health concern. Understanding how livestock farmers perceive animal illnesses will help to develop locally acceptable and effective public health intervention strategies to control and manage zoonoses. The authors describe Bangladeshi pig raisers' perception of pig illnesses and their behaviour towards sick pigs. We collected qualitative data from August 2007 to September 2008. Included in our study are backyard pig raisers from three districts, namely: Faridpur, Chapainobabgonj and Tangail and nomadic herders from six districts, namely: Mymensingh, Tangail, Sherpur, Sirajgonj, Bogra and Pabna. We conducted in-depth interviews (n = 34) and made observations of human interactions with pigs (n = 18). Pig raisers reported several illnesses that caused their pigs to suffer and die. They had close contact with sick pigs whilst caring for them. They slaughtered sick pigs and consumed and sold the pork if they thought that ate pig might die. They believed that pig illness could be transmitted among pigs but not between pigs and humans. The perception of pig raisers on pig illnesses and their behaviour towards sick pigs places them in close contact with potentially infectious pig secretions and excretions. Such exposure could favour zoonotic transmission of infectious diseases. A better surveillance system for pig diseases would provide an opportunity to identify the transmission of diseases, determine whether they pose a risk to humans, or whether they contribute to the emergence of diseases. C1 [Nahar, Nazmun; Uddin, Main; Gurley, Emily S.; Khan, M. Salah Uddin; Hossain, M. Jahangir; Sultana, Rebeca; Luby, Stephen P.] ICDDR B, Dhaka 1212, Bangladesh. [Luby, Stephen P.] Ctr Dis Control & Prevent, CDC, Atlanta, GA 30333 USA. RP Nahar, N (reprint author), ICDDR B, GPO Box 128, Dhaka 1212, Bangladesh. EM nahar.nazmun@yahoo.com RI Gurley, Emily/B-7903-2010 OI Gurley, Emily/0000-0002-8648-9403 FU Centers for Disease Control and Prevention (CDC), CoAg [5-U01-CI000298-03] FX This study was funded by the Centers for Disease Control and Prevention (CDC), CoAg Grant Number 5-U01-CI000298-03. NR 32 TC 3 Z9 4 U1 1 U2 9 PU IST ZOOPROFILATTICO SPERIMENTALE ABRUZZO & MOLISE G CAPORALE-IZS A&M PI TERAMO PA CAMPO BOARIO, TERAMO, 64100, ITALY SN 0505-401X J9 VET ITAL JI Vet. Ital. PD APR-JUN PY 2012 VL 48 IS 2 BP 157 EP 165 PG 9 WC Veterinary Sciences SC Veterinary Sciences GA 965LK UT WOS:000305769100004 PM 22718332 ER PT J AU Jimenez, P Conn, JE Wirtz, R Brochero, H AF Jimenez, Pilar Conn, Jan E. Wirtz, Robert Brochero, Helena TI Anopheles (Diptera: Culicidae) vectors of malaria in Puerto Carreno municipality, Vichada, Colombia SO BIOMEDICA LA Spanish DT Article DE Anopheles; malaria; biology; disease vectors; Colombia ID NYSSORHYNCHUS ALBITARSIS DIPTERA; POLYMERASE CHAIN-REACTION; PLASMODIUM-VIVAX; COMPLEX DIPTERA; BITING ACTIVITY; TRANSMISSION; BRAZIL; FALCIPARUM; BIONOMICS; MOSQUITOS AB Anopheles (Diptera: Culicidae) vectors of malaria in Puerto Carreno municipality, Vichada, Colombia Introduction. The study of the biological aspects of Anopheles spp., strengthens the entomological surveillance. Objective. To determine biological aspects and behavior of adult Anopheles mosquitoes in the urban area of Puerto Carreno municipality, Vichada, Colombia. Materials and methods. Wild anophelines were collected landing on humans both indoors and outdoors between 18:00h and 06:00h for 50 min/h during two consecutive nights/month for eight months in the urban area of Puerto Carreno. The biting rate activity, the natural infection by Plasmodium falciparum and P. vivax VK247 and VK210 using ELISA, and the annual entomological inoculation rate were determined for each species. The members of the Albitarsis complex were determined by amplificacion of the white gene by polymerase chain reaction. Results. In order of abundance the species found were An. darlingi (n=1,166), An. marajoara sensu stricto (n=152), An. braziliensis (n=59), An. albitarsis F (n=25), An. albitarsis sensu lato (n=16), An. argyritarsis (n=3) and An. oswaldoi sensu lato (n=2). An. darlingi showed two activity peaks between 21:00 to 22:00 and 05:00 to 06:00 hours outdoors and between 21:00 to 22:00 and 04:00 to 05:00 indoors. Natural infection of this species was found with P. vivax VK210 and its annual entomological inoculation rate was 2. Natural infection of An marajoara sensu stricto with P. falciparum was found, with an annual entomological inoculation rate of 5 and a peak biting activity between 18:00 to 19:00 hrs both indoors and outdoors. Conclusion. Transmission of malaria in the urban area of Puerto Carrel:), Vichada, can occur by An. darlingi and An. marajoara s. S. C1 [Jimenez, Pilar; Brochero, Helena] Univ Nacl Colombia, Fac Agron, Bogota, DC, Colombia. [Conn, Jan E.] New York State Dept Hlth, Wadsworth Ctr, Griffin Lab, Slingerlands, NY USA. [Conn, Jan E.] SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY USA. [Wirtz, Robert] Ctr Dis Control & Prevent, Entomol Branch, Atlanta, GA USA. Univ Nacl Colombia, Fac Agron, Lab Entomol, Bogota, Colombia. RP Brochero, H (reprint author), Univ Nacl Colombia, Fac Agron, Edificio 500,Oficina 201,Carrera 30 45-03, Bogota, DC, Colombia. EM embrochero@unal.edu.co FU NIAID NIH HHS [R01 AI5413, AI 2R01AIO54139, R01 AI054139, N01AI05413] NR 32 TC 6 Z9 7 U1 0 U2 1 PU INST NACIONAL SALUD PI BOGOTA D C PA AVENIDA CALLE 26 NO 51-60, APARTADO AEREO 80334 Y 80080, BOGOTA D C, 00000, COLOMBIA SN 0120-4157 J9 BIOMEDICA JI Biomedica PD APR PY 2012 VL 32 SU 1 BP 13 EP 21 PG 9 WC Tropical Medicine SC Tropical Medicine GA 950XC UT WOS:000304683700003 PM 23235809 ER PT J AU Nakata, A AF Nakata, Akinori TI Investigating the associations between work hours, sleep status, and self-reported health among full-time employees SO INTERNATIONAL JOURNAL OF PUBLIC HEALTH LA English DT Article DE Work hour; Sleep hour; Subjective sleep sufficiency; Sleep deprivation; Self-rated health ID JAPANESE MALE WORKERS; RATED HEALTH; JOB STRESS; PROSPECTIVE COHORT; OVERTIME WORK; MENTAL-HEALTH; GAZEL COHORT; FOLLOW-UP; DISTURBANCES; HYPERTENSION AB Objectives The extent to which work hours and sleep are associated with self-rated health (SRH) was investigated in full-time employees of small- and medium-scale businesses (SMBs) in a suburb of Tokyo. Methods A total of 2,579 employees (1,887 men and 692 women), aged 18-79 (mean 45) years, in 296 SMBs were surveyed using a self-administered questionnaire from August to December 2002. Work hours, sleep, and SRH were evaluated. Results Compared with those working 6-8 h/day, participants working > 8 to 10 h/day and > 10 h/day had significantly higher odds of suboptimal SRH [adjusted odds ratio (aOR) 1.36 and 1.87, respectively]. Similarly, compared with those sleeping 6+ h/day and sufficient sleep, participants with short sleep (< 6 h/day) and insufficient sleep had increased odds of suboptimal SRH (aOR 1.65 and aOR 2.03, respectively). Combinations of the longest work hours with short sleep (aOR 3.30) or insufficient sleep (aOR 3.40) exerted synergistic negative associations on SRH. Conclusions This study suggests that long work hours and poor sleep and its combination are associated with suboptimal SRH. C1 NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Nakata, A (reprint author), NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, MS-C24,4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM cji5@cdc.gov NR 40 TC 11 Z9 11 U1 3 U2 14 PU SPRINGER BASEL AG PI BASEL PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND SN 1661-8556 J9 INT J PUBLIC HEALTH JI Int. J. Public Health PD APR PY 2012 VL 57 IS 2 BP 403 EP 411 DI 10.1007/s00038-011-0242-z PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 947RA UT WOS:000304446000017 PM 21384225 ER PT J AU Arcidiacono, P Khwaja, A Ouyang, LJ AF Arcidiacono, Peter Khwaja, Ahmed Ouyang, Lijing TI Habit Persistence and Teen Sex: Could Increased Access to Contraception Have Unintended Consequences for Teen Pregnancies? SO JOURNAL OF BUSINESS & ECONOMIC STATISTICS LA English DT Article DE Contraceptive policy; Dynamic discrete choice ID 1ST INTERCOURSE; EMPIRICAL-ANALYSIS; UNITED-STATES; CHILDBEARING; MODELS; IMPACT; MALES; DECISIONS; COUNTRIES; EDUCATION AB We develop a dynamic discrete-choice model of teen sex and pregnancy that incorporates habit persistence. Habit persistence has two sources here. The first is a "fixed cost" of having sex, which relates to a moral or psychological barrier that has been crossed the first time one has sex. The second is a "transition cost," whereby once a particular relationship has progressed to sex, it is difficult to move back. We estimate significant habit persistence in teen sex, implying that the long-run effects of contraception policy may be different from their short-run counterparts, especially if the failure rate of contraception is sufficiently large. Programs that increase access to contraception are found to decrease teen pregnancies in the short run but increase them in the long run. C1 [Arcidiacono, Peter] Duke Univ, Dept Econ, Durham, NC 27708 USA. [Arcidiacono, Peter] NBER, Cambridge, MA 02138 USA. [Khwaja, Ahmed] Yale Univ, Sch Management, New Haven, CT 06510 USA. [Ouyang, Lijing] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Arcidiacono, P (reprint author), Duke Univ, Dept Econ, Durham, NC 27708 USA. EM psarcidi@econ.duke.edu; ahmed.khwaja@yale.edu; louyang@cdc.gov FU National Institute for Child Health and Human Development [R03 HD042817-01A1] FX We thank Jacob Klerman, Shannon Seitz, Jim Walker, and seminar participants at Carnegie Mellon, Clemson University, the IRP Summer Research Workshop, the University of Maryland, Northwestern University, and the winter and summer meetings of the Econometric Society. This research was partially funded by the National Institute for Child Health and Human Development (R03 HD042817-01A1). The views expressed are those of the authors and do not represent the opinions of the Centers for Disease Control and Prevention. NR 34 TC 11 Z9 11 U1 2 U2 13 PU AMER STATISTICAL ASSOC PI ALEXANDRIA PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA SN 0735-0015 J9 J BUS ECON STAT JI J. Bus. Econ. Stat. PD APR PY 2012 VL 30 IS 2 BP 312 EP 325 DI 10.1080/07350015.2011.652052 PG 14 WC Economics; Social Sciences, Mathematical Methods; Statistics & Probability SC Business & Economics; Mathematical Methods In Social Sciences; Mathematics GA 948DY UT WOS:000304485000014 ER PT J AU Diack, A Will, R Bishop, M Ritchie, D Brandel, JP Haik, S Tagliavini, F Van Duijn, C Belay, E Gambetti, P Schonberger, L Manson, J AF Diack, Abigail Will, Robert Bishop, Matthew Ritchie, Diane Brandel, Jean-Philippe Haik, Stephane Tagliavini, Fabrizio Van Duijn, Cornelia Belay, Ermias Gambetti, Pierluigi Schonberger, Lawrence Manson, Jean TI Modelling human TSE disease transmission SO PRION LA English DT Meeting Abstract C1 [Will, Robert; Bishop, Matthew; Ritchie, Diane] Natl CJD Res & Surveillance Unit, Edinburgh, Midlothian, Scotland. [Brandel, Jean-Philippe; Haik, Stephane] APHPCellule Natl Reference Malad Creutzfeldt Jako, Paris, France. [Tagliavini, Fabrizio] Ist Nazl Neurol Carlo Besta, Milan, Italy. [Van Duijn, Cornelia] Erasmus Univ, Sch Med, Rotterdam, Netherlands. [Gambetti, Pierluigi] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gambetti, Pierluigi] Natl Prion Dis Pathol Surveillance Ctr, Cleveland, OH USA. RI Belay, Ermias/A-8829-2013 NR 0 TC 0 Z9 0 U1 0 U2 5 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1933-6896 J9 PRION JI Prion PD APR-JUN PY 2012 VL 6 SU S BP 44 EP 45 PG 2 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 944WK UT WOS:000304234300092 ER PT J AU Maddox, R Gambetti, P Holman, R Blevins, J Schonberger, L Belay, E AF Maddox, Ryan Gambetti, Pierluigi Holman, Robert Blevins, Janis Schonberger, Lawrence Belay, Ermias TI Prion protein gene codon 129 polymorphism among confirmed sporadic prion disease cases by race and ethnicity, United States SO PRION LA English DT Meeting Abstract C1 [Maddox, Ryan; Holman, Robert; Schonberger, Lawrence; Belay, Ermias] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gambetti, Pierluigi; Blevins, Janis] Case Western Reserve Univ, Natl Prion Dis Pathol Surveillance Ctr, Cleveland, OH 44106 USA. RI Belay, Ermias/A-8829-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1933-6896 J9 PRION JI Prion PD APR-JUN PY 2012 VL 6 SU S BP 68 EP 68 PG 1 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 944WK UT WOS:000304234300142 ER PT J AU Anderson, SE Tapp, L Durgam, S Meade, BJ Jackson, LG Cohen, DE AF Anderson, Stacey E. Tapp, Loren Durgam, Srinivas Meade, B. Jean Jackson, Laurel G. Cohen, David E. TI The identification of a sensitizing component used in the manufacturing of an ink ribbon SO JOURNAL OF IMMUNOTOXICOLOGY LA English DT Article DE Polyvinyl butyral; local lymph node assay; occupational contact dermatitis; ink ribbon manufacturing ID ALLERGIC CONTACT-DERMATITIS; LYMPH-NODE ASSAY; OCCUPATIONAL DERMATITIS; PRINTING INDUSTRY; RESPONSES; EXPOSURE AB Skin diseases including dermatitis constitute approximate to 30% of all occupational illnesses, with a high incidence in the printing industry. An outbreak of contact dermatitis among employees at an ink ribbon manufacturing plant was investigated by scientists from the National Institute for Occupational Safety and Health (NIOSH). Employees in the process areas of the plant were exposed to numerous chemicals and many had experienced skin rashes, especially after the introduction of a new ink ribbon product. To identify the causative agent(s) of the occupational dermatitis, the murine local lymph node assay (LLNA) was used to identify the potential of the chemicals used in the manufacture of the ink ribbon to induce allergic contact dermatitis. Follow-up patch testing with the suspected allergens was conducted on exposed employees. Polyvinyl butyral, a chemical component used in the manufacture of the ink ribbon in question and other products, tested positive in the LLNA, with an EC3 of 3.6%, which identifies it as a potential sensitizer; however, no employees tested positive to this chemical during skin patch testing. This finding has implications beyond those described in this report because of occupational exposure to polyvinyl butyral outside of the printing industry. C1 [Anderson, Stacey E.; Meade, B. Jean; Jackson, Laurel G.] NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA. [Tapp, Loren; Durgam, Srinivas] NIOSH, Hazard Evaluat & Tech Assistance Branch, Cincinnati, OH 45226 USA. [Cohen, David E.] NYU, Med Ctr, Dept Dermatol, New York, NY 10016 USA. RP Anderson, SE (reprint author), NIOSH, Hlth Effects Lab Div, 1095 Willowdale Dr, Morgantown, WV 26505 USA. EM sanderson4@cdc.gov FU National Institute for Occupational Safety and Health FX Statistical support was provided by Charles Mueller; medical support was provided by Elena Page and Ayodele Adebayo; all work at the Hazard Evaluations and Technical Assistance Branch of the National Institute for Occupational Safety and Health. This work was performed and financially supported by the National Institute for Occupational Safety and Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. NR 25 TC 1 Z9 1 U1 0 U2 0 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1547-691X J9 J IMMUNOTOXICOL JI J. Immunotoxicol. PD APR-JUN PY 2012 VL 9 IS 2 BP 193 EP 200 DI 10.3109/1547691X.2011.654364 PG 8 WC Toxicology SC Toxicology GA 942ST UT WOS:000304068000008 PM 22375946 ER PT J AU Kalb, SR Baudys, J Rees, JC Smith, TJ Smith, LA Helma, CH Hill, K Kull, S Kirchner, S Dorner, MB Dorner, BG Pirkle, JL Barr, JR AF Kalb, Suzanne R. Baudys, Jakub Rees, Jon C. Smith, Theresa J. Smith, Leonard A. Helma, Charles H. Hill, Karen Kull, Skadi Kirchner, Sebastian Dorner, Martin B. Dorner, Brigitte G. Pirkle, James L. Barr, John R. TI De novo subtype and strain identification of botulinum neurotoxin type B through toxin proteomics SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY LA English DT Article DE Botulinum neurotoxin; Botulism; Mass spectrometry; Proteomics ID CLOSTRIDIUM-BOTULINUM; INFANT BOTULISM; JAPAN; DIFFERENTIATION; DIVERSITY; SEROTYPE AB Botulinum neurotoxins (BoNTs) cause the disease botulism, which can be lethal if untreated. There are seven known serotypes of BoNT, A-G, defined by their response to antisera. Many serotypes are distinguished into differing subtypes based on amino acid sequence, and many subtypes are further differentiated into toxin variants. Previous work in our laboratory described the use of a proteomics approach to distinguish subtype BoNT/A1 from BoNT/A2 where BoNT identities were confirmed after searching data against a database containing protein sequences of all known BoNT/A subtypes. We now describe here a similar approach to differentiate subtypes BoNT/B1, /B2, /B3, /B4, and /B5. Additionally, to identify new subtypes or hitherto unpublished amino acid substitutions, we created an amino acid substitution database covering every possible amino acid change. We used this database to differentiate multiple toxin variants within subtypes of BoNT/B1 and B2. More importantly, with our amino acid substitution database, we were able to identify a novel BoNT/B subtype, designated here as BoNT/B7. These techniques allow for subtype and strain level identification of both known and unknown BoNT/B rapidly with no DNA required. ' C1 [Kalb, Suzanne R.; Baudys, Jakub; Rees, Jon C.; Pirkle, James L.; Barr, John R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. [Smith, Theresa J.] USAMRIID, Ft Detrick, MD 21702 USA. [Smith, Leonard A.] MRMC, Off Chief Scientist, Ft Detrick, MD 21702 USA. [Helma, Charles H.; Hill, Karen] Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA. [Kull, Skadi; Kirchner, Sebastian; Dorner, Martin B.; Dorner, Brigitte G.] Robert Koch Inst, Ctr Biol Secur, Microbial Toxins ZBS3, D-13353 Berlin, Germany. RP Barr, JR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM jbarr@cdc.gov OI Kalb, Suzanne/0000-0002-8067-136X FU National Institute of Allergy And Infectious Diseases [B18-120] FX This research was partially supported through Interagency Agreement B18-120 from the National Institute of Allergy And Infectious Diseases. The opinions, interpretations, and recommendations are those of the authors and are not necessarily those of the Centers for Disease Control and Prevention, the US Army, the Robert Koch-Institut, the National Institute of Allergy and Infectious Diseases, or the National Institutes of Health. NR 24 TC 22 Z9 22 U1 0 U2 13 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1618-2642 J9 ANAL BIOANAL CHEM JI Anal. Bioanal. Chem. PD APR PY 2012 VL 403 IS 1 BP 215 EP 226 DI 10.1007/s00216-012-5767-3 PG 12 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 912YY UT WOS:000301839700016 PM 22395449 ER PT J AU Bowler, RM Harris, M Gocheva, V Wilson, K Kim, Y Davis, SI Bollweg, G Lobdell, DT Ngo, L Roels, HA AF Bowler, Rosemarie M. Harris, Matthew Gocheva, Vihra Wilson, Katherine Kim, Yangho Davis, Stephanie I. Bollweg, George Lobdell, Danelle T. Ngo, Long Roels, Harry A. TI Anxiety affecting parkinsonian outcome and motor efficiency in adults of an Ohio community with environmental airborne manganese exposure SO INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH LA English DT Article DE Generalized anxiety; Manganese; Environmental air/Epidemiology; UPDRS/Motor/Bradykinesia/ADL ID PLASMA-MASS SPECTROMETRY; LONG-TERM EXPOSURE; NERVOUS-SYSTEM; NEUROPSYCHIATRIC SYMPTOMS; BLOOD MANGANESE; WORKERS; DISORDERS; WELDERS; SEQUELAE; DISEASE AB Manganese (Mn) is a nutrient and neurotoxicant sometimes associated with mood, motor and neurological effects. Reports of health effects from occupational exposure to Mn are well known, but the reported links to environmental airborne Mn (Mn-Air) are less conclusive. Marietta, OH (USA) is a previously identified community with elevated Mn-Air from industrial emissions. Households were randomly selected in Marietta and the comparison town (Mount Vernon, OH). The responders were used to recruit on a voluntary basis 30- to 75-year-old residents, i.e. 100 in Marietta and 90 in Mount Vernon. They were administered the Unified Parkinson's Disease Rating Scale (UPDRS), motor efficiency, and mood tests, along with a comprehensive questionnaire including demographics, health and work history. Blood Mn (MnB), serum ferritin, and hepatic enzymes were measured. Results were compared with those of 90 residents from a demographically similar comparison town, Mount Vernon, OH, where Mn-Air from industrial emissions was not of concern. Mn-Air exposure indices were modeled for Marietta residents. The Mn-exposed participants resided on average 4.75 miles (range 1-11) from the Mn point source. Their modeled residential Mn-Air estimate ranged from 0.04 to 0.96 mu g/m(3) and was on average 0.18 mu g/m(3). The group means of MnB were similar for the Mn-exposed (9.65 mu g/L) and comparison (9.48 mu g/L) participants. The Marietta group reported more generalized anxiety on the Symptom Checklist-90-Revised (SCL-90-R) than the comparison group (p = 0.035). Generalized anxiety in Marietta was related to a cumulative exposure index (p = 0.002). based on modeled Mn-Air concentration and length of residence. Higher generalized anxiety scores were related to poorer performance on UPDRS tests [adjusted relative risk (95%CI): 2.18 (1.46-3.25) for motor-related activities of daily living, 3.44 (1.48-7.98) for bradykinesia, and 1.63 (1.06-2.53) for motor/movement]. Group differences in SCL-90-R generalized anxiety between the two towns and the observed relationship between exposure indices and generalized anxiety suggest an association between environmental Mn exposure and anxiety states. Whether this association is due to direct neurotoxic effects of Mn-Air or concern about the health effects of air pollution remains an open question. The results highlight the importance of measuring anxiety in relation to neuropsychological and neurological endpoints, and should be validated in other studies of Mn-exposed communities. (C) 2011 Elsevier GmbH. All rights reserved. C1 [Bowler, Rosemarie M.; Gocheva, Vihra] San Francisco State Univ, Dept Psychol, San Francisco, CA 94132 USA. [Harris, Matthew; Wilson, Katherine] Alliant Int Univ, San Francisco, CA USA. [Kim, Yangho] Univ Ulsan, Coll Med, Ulsan Univ Hosp, Ulsan 680749, South Korea. [Davis, Stephanie I.] Agcy Tox Subst & Dis Registry, Div Hlth Studies, Atlanta, GA USA. [Bollweg, George] US EPA, Reg Air & Radiat Div 5, Chicago, IL USA. [Lobdell, Danelle T.] US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA. [Ngo, Long] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. [Ngo, Long] Harvard Univ, Sch Med, Boston, MA USA. [Roels, Harry A.] Catholic Univ Louvain, Louvain Ctr Toxicol & Appl Pharmacol, B-1200 Brussels, Belgium. RP Bowler, RM (reprint author), 8371 Kent Dr, El Cerrito, CA 94530 USA. EM rbowl@sfsu.edu FU U.S. Environmental Protection Agency [83416001]; ATSDR Region 5, IL (Michelle Colledge, Health Consultation); Ohio Department of Health, Division of Prevention (Forrest Smith, Epidemiologist); Ohio Department of Health, Bureau of Environmental Health (Greg Stein, Robert Frey); Marietta City Health Department (Michael Brockett, Health Commissioner); Washington County Health Department (Kathleen Meckstroth, Health Commissioner); Knox County Health Department (Dennis Murray, Health Commissioner); Washington County Community Members (Eric Fitch, Biology Dept., Marietta College; Diane Dudzinski, Washington State Community College) FX The research described in this article has been funded wholly (or in part) by the U.S. Environmental Protection Agency through cooperative agreement number 83416001 to San Francisco State University.; This paper is dedicated to Dr. David Macarus who had the foresight to recognize the importance of this study. Unfortunately, Dr. Macarus died shortly after the approval of this project for funding. His efforts are acknowledged with gratitude. Special thanks is given to Dr. Alan Ducatman, West Virginia University Medical School, Community Medicine, for his generous intensive input in the health questionnaire, his availability for consultation on illnesses during the recruitment period, during the statistical analyses and preparation for the community presentations. Dr. Donna Mergler, Universite du Quebec a Montreal, is thanked for her generous consultation throughout this project and for her assistance in the early phase of the statistical analyses. Also acknowledged for valuable support to this study are: ATSDR Region 5, IL (Michelle Colledge, Health Consultation); Ohio Department of Health, Division of Prevention (Forrest Smith, Epidemiologist); Ohio Department of Health, Bureau of Environmental Health (Greg Stein, Robert Frey); Marietta City Health Department (Michael Brockett, Health Commissioner); Washington County Health Department (Kathleen Meckstroth, Health Commissioner); Knox County Health Department (Dennis Murray, Health Commissioner); Washington County Community Members (Eric Fitch, Biology Dept., Marietta College; Diane Dudzinski, Washington State Community College). NR 96 TC 13 Z9 13 U1 0 U2 6 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1438-4639 J9 INT J HYG ENVIR HEAL JI Int. J. Hyg. Environ. Health. PD APR PY 2012 VL 215 IS 3 BP 393 EP 405 DI 10.1016/j.ijheh.2011.10.005 PG 13 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 941KA UT WOS:000303960900019 PM 22112744 ER PT J AU Tsai, J Ford, ES Zhao, GX Li, CY Greenlund, KJ Croft, JB AF Tsai, James Ford, Earl S. Zhao, Guixiang Li, Chaoyang Greenlund, Kurt J. Croft, Janet B. TI Co-occurrence of obesity and patterns of alcohol use associated with elevated serum hepatic enzymes in US adults SO JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE Obesity; Abdominal obesity; Alcohol use; Transaminase; Aminotransferase; Alanine aminotransferase (ALT); Aspartate aminotransferase (AST); Gamma-glutamyl transferase (GGT) ID BODY-MASS INDEX; GAMMA-GLUTAMYL-TRANSFERASE; LIVER-DISEASE; ALANINE AMINOTRANSFERASE; DRINKING PATTERN; UNITED-STATES; RISK-FACTORS; PROSPECTIVE COHORT; AVERAGE VOLUME; CONSUMPTION AB The aim of this cross-sectional study was to present nationally representative findings on the co-occurrence of obesity and specific patterns of alcohol use associated with elevated serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gammaglutamyltransferase (GGT) among adults in the United States. We analyzed data from 8,373 adults aged >= 20 years who participated in the 2005-2008 National Health and Nutrition Examination Survey. We produced prevalence ratios by using the co-occurrence of obesity (i.e., body mass index >= 30.0 kg/m(2) or waist circumference >= 102 cm in men and >= 88 cm in women) and specific patterns of alcohol use (i.e., non-drinkers, non-excessive drinkers, and excessive drinkers) as a predictor; elevations in serum ALT, AST, and GGT were used as an outcome variable while adjusting for covariates in multivariate regression models. Approximately 34.7% of adult men and 38.6% of adult women in the United States had co-occurrence of obesity and any alcohol use, including 16.4% of men and 9.8% of women who had co-occurrence of obesity and excessive drinking during 2005-2008. When compared to male non-drinkers without obesity after multivariate adjustment, male excessive drinkers with obesity were 3.08 (95% CI: 1.80-5.28), 2.42 (95% CI: 1.80-3.26), and 3.15 (95% CI: 1.82-5.46) times more likely to exhibit elevated serum ALT, AST, and GGT, respectively. Similarly, when compared to female nondrinkers without obesity, female excessive drinkers with obesity were 2.36 (95% CI: 1.38-4.04), 3.27 (95% CI: 1.85-5.78), and 3.43 (95% CI: 2.19-5.40) times more likely to have elevated serum ALT, AST, and GGT, respectively. The co-occurrence of obesity and excessive drinking may place adults at an increased risk for potential liver injury. Our study findings provide support for evidence-based clinical and population-based interventions that integrate health behavior change among adults who have these co-occurring risk factors. C1 [Tsai, James; Ford, Earl S.; Zhao, Guixiang; Li, Chaoyang; Greenlund, Kurt J.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Tsai, J (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,Mail Stop K67, Atlanta, GA 30341 USA. EM jxt9@cdc.gov NR 79 TC 9 Z9 9 U1 1 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0160-7715 J9 J BEHAV MED JI J. Behav. Med. PD APR PY 2012 VL 35 IS 2 BP 200 EP 210 DI 10.1007/s10865-011-9353-5 PG 11 WC Psychology, Clinical SC Psychology GA 940BP UT WOS:000303865300009 PM 21626151 ER PT J AU Kenney, JL Adams, AP Gorchakov, R Leal, G Weaver, SC AF Kenney, Joan L. Adams, A. Paige Gorchakov, Rodion Leal, Grace Weaver, Scott C. TI Genetic and Anatomic Determinants of Enzootic Venezuelan Equine Encephalitis Virus Infection of Culex (Melanoconion) taeniopus SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID E2 ENVELOPE GLYCOPROTEIN; LENGTH CDNA-CLONE; ENCEPHALOMYELITIS VIRUS; VECTOR COMPETENCE; AEDES-TAENIORHYNCHUS; MOSQUITOS DIPTERA; MINUS-STRAND; RNA VIRUS; MULLER RATCHET; SOUTH-AMERICA AB Venezuelan equine encephalitis (VEE) is a re-emerging, mosquito-borne viral disease with the potential to cause fatal encephalitis in both humans and equids. Recently, detection of endemic VEE caused by enzootic strains has escalated in Mexico, Peru, Bolivia, Colombia and Ecuador, emphasizing the importance of understanding the enzootic transmission cycle of the etiologic agent, VEE virus (VEEV). The majority of work examining the viral determinants of vector infection has been performed in the epizootic mosquito vector, Aedes (Ochlerotatus) taeniorhynchus. Based on the fundamental differences between the epizootic and enzootic cycles, we hypothesized that the virus-vector interaction of the enzootic cycle is fundamentally different from that of the epizootic model. We therefore examined the determinants for VEEV IE infection in the enzootic vector, Culex (Melanoconion) taeniopus, and determined the number and susceptibility of midgut epithelial cells initially infected and their distribution compared to the epizootic virus-vector interaction. Using chimeric viruses, we demonstrated that the determinants of infection for the enzootic vector are different than those observed for the epizootic vector. Similarly, we showed that, unlike A. taeniorhynchus infection with subtype IC VEEV, C. taeniopus does not have a limited subpopulation of midgut cells susceptible to subtype IE VEEV. These findings support the hypothesis that the enzootic VEEV relationship with C. taeniopus differs from the epizootic virus-vector interaction in that the determinants appear to be found in both the nonstructural and structural regions, and initial midgut infection is not limited to a small population of susceptible cells. C1 Univ Texas Med Branch, Inst Human Infect & Immun, Ctr Trop Dis, Galveston, TX USA. Univ Texas Med Branch, Dept Pathol, Galveston, TX USA. RP Kenney, JL (reprint author), Ctr Dis Control & Prevent, Ft Collins, CO USA. EM sweaver@utmb.edu RI Weaver, Scott/D-6490-2011 FU NIH [AI071192, AI057156, AI077796]; James W. McLaughlin Fellowship; W.M. Keck Virus Imaging Training Fellowship FX This work was supported by NIH grants AI071192 and AI057156. JLK was supported by a James W. McLaughlin Fellowship and a W.M. Keck Virus Imaging Training Fellowship. APA was supported by an NIH K08 grant (AI077796). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 57 TC 11 Z9 11 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD APR PY 2012 VL 6 IS 4 AR e1606 DI 10.1371/journal.pntd.0001606 PG 12 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 935CP UT WOS:000303496800022 PM 22509419 ER PT J AU Tomashek, KM Gregory, CJ Sanchez, AR Bartek, MA Rivera, EJG Hunsperger, E Munoz-Jordan, JL Sun, W AF Tomashek, Kay M. Gregory, Christopher J. Sanchez, Aidsa Rivera Bartek, Matthew A. Rivera, Enid J. Garcia Hunsperger, Elizabeth Munoz-Jordan, Jorge L. Sun, Wellington TI Dengue Deaths in Puerto Rico: Lessons Learned from the 2007 Epidemic SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID LINKED-IMMUNOSORBENT-ASSAY; TRANSCRIPTASE-PCR ASSAY; WEST-NILE-VIRUS; HEMORRHAGIC-FEVER; SHOCK SYNDROME; RISK-FACTORS; ADULTS; INFECTIONS; DIAGNOSIS; TRANSFUSION AB Background: The incidence and severity of dengue in Latin America has increased substantially in recent decades and data from Puerto Rico suggests an increase in severe cases. Successful clinical management of severe dengue requires early recognition and supportive care. Methods: Fatal cases were identified among suspected dengue cases reported to two disease surveillance systems and from death certificates. To be included, fatal cases had to have specimen submitted for dengue diagnostic testing including nucleic acid amplification for dengue virus (DENV) in serum or tissue, immunohistochemical testing of tissue, and immunoassay detection of anti-DENV IgM from serum. Medical records from laboratory-positive dengue fatal case-patients were reviewed to identify possible determinants for death. Results: Among 10,576 reported dengue cases, 40 suspect fatal cases were identified, of which 11 were laboratory-positive, 14 were laboratory-negative, and 15 laboratory-indeterminate. The median age of laboratory-positive case-patients was 26 years (range 5 months to 78 years), including five children aged <15 years; 7 sought medical care at least once prior to hospital admission, 9 were admitted to hospital and 2 died upon arrival. The nine hospitalized case-patients stayed a mean of 15 hours (range: 3-48 hours) in the emergency department (ED) before inpatient admission. Five of the nine case-patients received intravenous methylprednisolone and four received non-isotonic saline while in shock. Eight case-patients died in the hospital; five had their terminal event on the inpatient ward and six died during a weekend. Dengue was listed on the death certificate in only 5 instances. Conclusions: During a dengue epidemic in an endemic area, none of the 11 laboratory-positive case-patients who died were managed according to current WHO Guidelines. Management issues identified in this case-series included failure to recognize warning signs for severe dengue and shock, prolonged ED stays, and infrequent patient monitoring. C1 [Tomashek, Kay M.; Gregory, Christopher J.; Sanchez, Aidsa Rivera; Hunsperger, Elizabeth; Munoz-Jordan, Jorge L.; Sun, Wellington] Ctr Dis Control & Prevent, Dengue Branch, DVBD, NCEZID,CDC, San Juan, PR USA. [Bartek, Matthew A.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Rivera, Enid J. Garcia] Puerto Rico Dept Hlth, San Juan, PR USA. RP Tomashek, KM (reprint author), Ctr Dis Control & Prevent, Dengue Branch, DVBD, NCEZID,CDC, San Juan, PR USA. EM ktomashek@cdc.gov NR 47 TC 19 Z9 19 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD APR PY 2012 VL 6 IS 4 AR e1614 DI 10.1371/journal.pntd.0001614 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 935CP UT WOS:000303496800030 PM 22530072 ER PT J AU Lauby, JL Marks, G Bingham, T Liu, KL Liau, A Stueve, A Millett, GA AF Lauby, Jennifer L. Marks, Gary Bingham, Trista Liu, Kai-Lih Liau, Adrian Stueve, Ann Millett, Gregorio A. TI Having Supportive Social Relationships is Associated with Reduced Risk of Unrecognized HIV Infection Among Black and Latino Men who Have Sex with Men SO AIDS AND BEHAVIOR LA English DT Article DE Social support; Unrecognized HIV infection; MSM; Mediation analysis ID AFRICAN-AMERICAN MEN; PHYSIOLOGICAL PROCESSES; UNDERLYING MECHANISMS; HIDDEN POPULATIONS; UNITED-STATES; CONDOM USE; HEALTH; DISEASE; GAY; EMPHASIS AB We examined the hypothesis that black and Latino men who have sex with men (MSM) who have supportive social relationships with other people are less likely to have unrecognized HIV infection compared with MSM of color who report lower levels of social support. We interviewed 1286 black and Latino MSM without known HIV infection in three metropolitan areas who were recruited using respondent driven sampling. Participants completed a computer-administered questionnaire and were tested for HIV. Unrecognized HIV infection was found in 118 men (9.2%). MSM who scored higher on the supportive relationship index had significantly lower odds of testing HIV-positive in the study. The mediation analysis identified two possible behavioral pathways that may partially explain this association: men who had strong supportive relationships were more likely to have had a test for HIV infection in the past 2 years and less likely to have recently engaged in high-risk sexual behavior. The findings illuminate the protective role of social relationships among MSM of color in our sample. C1 [Lauby, Jennifer L.] Public Hlth Management Corp, Philadelphia, PA 19102 USA. [Marks, Gary; Liau, Adrian; Millett, Gregorio A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Bingham, Trista] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Liu, Kai-Lih] New York City Dept Mental Hlth & Hyg, New York, NY USA. [Stueve, Ann] Educ Dev Ctr Inc, New York, NY USA. RP Lauby, JL (reprint author), Public Hlth Management Corp, 260 S Broad St,18th Floor, Philadelphia, PA 19102 USA. EM jennifer@phmc.org NR 35 TC 34 Z9 34 U1 2 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2012 VL 16 IS 3 BP 508 EP 515 DI 10.1007/s10461-011-0002-3 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 935GS UT WOS:000303507700003 PM 21805191 ER PT J AU Latkin, C Yang, C Tobin, K Roebuck, G Spikes, P Patterson, J AF Latkin, C. Yang, Cui Tobin, Karin Roebuck, Geoffrey Spikes, Pilgrim Patterson, Jocelyn TI Social Network Predictors of Disclosure of MSM Behavior and HIV-Positive Serostatus Among African American MSM in Baltimore, Maryland SO AIDS AND BEHAVIOR LA English DT Article DE HIV; Social networks; Disclosure; African American; Serostatus; MSM ID HETEROSEXUAL TRANSMISSION; RISK BEHAVIOR; BISEXUAL MEN; SEX; PARTNERS; MODEL AB This study examined correlates of disclosure of MSM behavior and seropositive HIV status to social network members among 187 African American MSM in Baltimore, MD. 49.7% of participants were HIV-positive, 64% of their social network members (excluding male sex partners) were aware of their MSM behavior, and 71.3% were aware of their HIV-positive status. Disclosure of MSM behavior to network members was more frequent among participants who were younger, had a higher level of education, and were HIV-positive. Attributes of the social network members associated with MSM disclosure included the network member being HIV-positive, providing emotional support, socializing with the participant, and not being a female sex partner. Participants who were younger were more likely to disclose their positive HIV status. Attributes of social network members associated with disclosure of positive serostatus included the network member being older, HIV-positive, providing emotional support, loaning money, and not being a male sex partner. C1 [Latkin, C.; Yang, Cui; Tobin, Karin; Roebuck, Geoffrey] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA. [Spikes, Pilgrim; Patterson, Jocelyn] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Latkin, C (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA. EM clatkin@jhsph.edu RI yang, cui /E-7403-2012 FU NCHHSTP CDC HHS [UR6 PS000355]; NICHD NIH HHS [K01 HD061269, K01 HD061269-04] NR 28 TC 19 Z9 19 U1 0 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2012 VL 16 IS 3 BP 535 EP 542 DI 10.1007/s10461-011-0014-z PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 935GS UT WOS:000303507700006 PM 21811844 ER PT J AU Sirivongrangson, P Lolekha, R Charoenwatanachokchai, A Siangphoe, U Fox, KK Jirarojwattana, N Bollen, L Yenyarsan, N Lokpichat, S Suksripanich, O McConnell, M AF Sirivongrangson, Pachara Lolekha, Rangsima Charoenwatanachokchai, Angkana Siangphoe, Umaporn Fox, Kimberley K. Jirarojwattana, Naiyana Bollen, Liesbeth Yenyarsan, Naruemon Lokpichat, Somchai Suksripanich, Orapin McConnell, Michelle TI HIV Risk Behavior Among HIV-Infected Men Who have Sex with Men in Bangkok, Thailand SO AIDS AND BEHAVIOR LA English DT Article DE HIV; MSM; Risk behaviors; STI ID SEXUALLY-TRANSMITTED INFECTIONS; SAN-FRANCISCO; TRANSMISSION; PREVALENCE; PARTNERS; DISEASES; STEADY; CHINA; WOMEN; KENYA AB We assessed prevalence of sexually transmitted infection (STIs), sexual risk behaviors, and factors associated with risk behaviors among HIV-infected MSM attending a public STI clinic serving MSM in Bangkok, Thailand. Between October 2005-October 2007, 154 HIV-infected MSM attending the clinic were interviewed about sexual risk behaviors and evaluated for STIs. Patients were examined for genital ulcers and had serologic testing for syphilis and PCR testing for chlamydia and gonorrhea. Results showed that sexual intercourse in the last 3 months was reported by 131 men. Of these, 32% reported anal sex without a condom. STIs were diagnosed in 41%. Factors associated with having sex without a condom were having a steady male partner, having a female partner and awareness of HIV status <1 month. Sexual risk behaviors and STIs were common among HIV-infected MSM in this study. This highlights the need for increased HIV prevention strategies for HIV-infected MSM. C1 [Lolekha, Rangsima; Siangphoe, Umaporn; Fox, Kimberley K.; Bollen, Liesbeth; Suksripanich, Orapin; McConnell, Michelle] Thailand MOPH US CDC Collaborat, Global AIDS Program, Nonthaburi 11000, Thailand. [Sirivongrangson, Pachara; Charoenwatanachokchai, Angkana; Jirarojwattana, Naiyana; Yenyarsan, Naruemon; Lokpichat, Somchai] Minist Publ Hlth MOPH, Bur AIDS TB STIs, Dept Dis Control, Bangkok, Thailand. [Fox, Kimberley K.; McConnell, Michelle] CDC, Global AIDS Program, Atlanta, GA 30333 USA. RP Lolekha, R (reprint author), Thailand MOPH US CDC Collaborat, Global AIDS Program, POB 139, Nonthaburi 11000, Thailand. EM RangsimaL@th.cdc.gov NR 29 TC 7 Z9 10 U1 1 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2012 VL 16 IS 3 BP 618 EP 625 DI 10.1007/s10461-011-9884-3 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 935GS UT WOS:000303507700015 PM 21274611 ER PT J AU Taylor, BS Chiasson, MA Scheinmann, R Hirshfield, S Humberstone, M Remien, RH Wolitski, RJ Wong, T AF Taylor, Barbara S. Chiasson, Mary Ann Scheinmann, Roberta Hirshfield, Sabina Humberstone, Mike Remien, Robert H. Wolitski, Richard J. Wong, Tom TI Results from Two Online Surveys Comparing Sexual Risk Behaviors in Hispanic, Black, and White Men Who Have Sex with Men SO AIDS AND BEHAVIOR LA English DT Article DE HIV; Men who have sex with men; Sexual behavior; Race; Ethnicity; Internet ID HIV-INFECTION; UNITED-STATES; YOUNG MEN; PARTNER CHARACTERISTICS; RACIAL DISPARITIES; SUBSTANCE USE; SAMPLE; TRANSMISSION; PREVALENCE; PREVENTION AB Many men who have sex with men (MSM) are among those who increasingly use the internet to find sexual partners. Few studies have compared behavior by race/ethnicity in internet-based samples of MSM. We examined the association of race/ethnicity with HIV risk-related behavior among 10,979 Hispanic, black, and white MSM recruited online. Significant variations by race/ethnicity were found in: age, income level, sexual orientation, number of lifetime male and female sexual partners, and rates of unprotected anal intercourse (UAI). Black and Hispanic men were more likely to report anal intercourse during the last sexual encounter, but white men were more likely to report UAI. In multivariate analysis, UAI was associated with HIV infection and sex with a main partner. Significant risk behavior variations by race/ethnicity were found. Research is needed to better target online interventions to MSM who engage in UAI or have other risk factors for transmitting or acquiring HIV. C1 [Taylor, Barbara S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Taylor, Barbara S.] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Chiasson, Mary Ann; Scheinmann, Roberta; Hirshfield, Sabina] Publ Hlth Solut, New York, NY USA. [Humberstone, Mike] Local Initiat Support Corp, New York, NY USA. [Remien, Robert H.] Columbia Univ, HIV Ctr Clin & Behav Studies, New York State Psychiat Inst, New York, NY USA. [Wolitski, Richard J.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Wong, Tom] Publ Hlth Agcy Canada, Ottawa, ON, Canada. RP Taylor, BS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,MSC 7881, San Antonio, TX 78229 USA. EM TaylorB4@uthscsa.edu FU NIAID NIH HHS [K23 AI081538, K23-AI081538-03]; NIDA NIH HHS [R03 DA018725, R03-DA018725-01]; NIMH NIH HHS [P30-MH43520, P30 MH043520]; PHS HHS [T32-A149821-06] NR 44 TC 5 Z9 5 U1 6 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2012 VL 16 IS 3 BP 644 EP 652 DI 10.1007/s10461-011-9983-1 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 935GS UT WOS:000303507700018 PM 21691760 ER PT J AU Mizuno, Y Borkowf, C Millett, GA Bingham, T Ayala, G Stueve, A AF Mizuno, Yuko Borkowf, Craig Millett, Gregorio A. Bingham, Trista Ayala, George Stueve, Ann TI Homophobia and Racism Experienced by Latino Men Who Have Sex with Men in the United States: Correlates of Exposure and Associations with HIV Risk Behaviors SO AIDS AND BEHAVIOR LA English DT Article DE Homophobia; Racism; HIV risk behaviors; Latino MSM ID SEXUALLY-TRANSMITTED-DISEASES; PSYCHOSOCIAL HEALTH-PROBLEMS; ISLANDER GAY MEN; 3 US CITIES; BLACK-MEN; SOCIAL DETERMINANTS; VIRAL-HEPATITIS; DISCRIMINATION; PREVENTION; HIV/AIDS AB Using cross-sectional data collected from 1081 Latino men who have sex with men (MSM) recruited with respondent-driven sampling (RDS) techniques from Los Angeles and New York, we examined the extent to which Latino MSM reported exposure to social discrimination (i.e., experienced both homophobia and racism, homophobia only, racism only, or neither homophobia nor racism). More than 40% of respondents experienced both homophobia and racism in the past 12 months. Los Angeles participants, those with lower income, and those who reported being HIV-positive were more likely to report experiencing both types of social discrimination. Adjusting for potential confounders, men exposed to both homophobia and racism were more likely than men exposed to neither form of discrimination to report unprotected receptive anal intercourse with a casual sex partner (AOR = 1.92, 95% CI, 1.18-3.24) and binge drinking (AOR = 1.42, 95% CI, 1.02-1.98). Our findings suggest the presence of a syndemic of adverse social experiences and call for more intervention research to address both homophobia and racism experienced among Latino MSM in the United States. C1 [Mizuno, Yuko] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Borkowf, Craig] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Millett, Gregorio A.] Ctr Dis Control & Prevent, Washington, DC USA. [Bingham, Trista] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA. [Ayala, George] Global Forum MSM & HIV, Oakland, CA USA. [Stueve, Ann] Educ Dev Ctr, New York, NY USA. RP Mizuno, Y (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mail Stop E37, Atlanta, GA 30333 USA. EM ymizuno@cdc.gov NR 25 TC 30 Z9 31 U1 3 U2 10 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2012 VL 16 IS 3 BP 724 EP 735 DI 10.1007/s10461-011-9967-1 PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 935GS UT WOS:000303507700027 PM 21630014 ER PT J AU de Perio, MA Wiegand, DM Evans, SM AF de Perio, Marie A. Wiegand, Douglas M. Evans, Stefanie M. TI Low Influenza Vaccination Rates Among Child Care Workers in the United States: Assessing Knowledge, Attitudes, and Behaviors SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Influenza; Vaccination; Child care; Occupational health; Immunization; Workers ID A H1N1 VIRUS; HOSPITALIZED-PATIENTS; INFECTION; IMMUNIZATION; PROGRAM; DEATHS; NURSES; MEXICO; STAFF AB Influenza can spread quickly among children and caregivers in child day care settings. Vaccination is the most effective method to prevent influenza. We determined 2009 pandemic influenza A (H1N1) (pH1N1) and seasonal influenza vaccination rates during the 2009-2010 influenza season among child care center employees, assessed knowledge and attitudes regarding the vaccines, and determined factors associated with vaccine receipt. Using a cross-sectional study design, from January 30-March 1, 2010, we surveyed 384 (95%) of 403 employees at 32 licensed child centers in the United States about personal and work characteristics, vaccine receipt, and knowledge and attitudes regarding each vaccine. Forty-five (11%) and eighty five (22%) respondents reported receiving the pH1N1 and seasonal influenza vaccines, respectively. The most common reasons cited for not getting either vaccine were "I don't think I need the vaccine," "I don't think the vaccine will keep me from getting the flu," and "the vaccine is not safe." Factors independently associated with receipt of either vaccine included belief in its efficacy, having positive attitudes towards it, and feeling external pressure to get it. Child care center employees had low rates of pH1N1 and seasonal influenza vaccination largely due to misconceptions about the need for and efficacy of the vaccine. Public health messages should address misconceptions about vaccines, and employers should consider methods to maximize influenza vaccination of employees as part of a comprehensive influenza prevention program. C1 [de Perio, Marie A.; Wiegand, Douglas M.; Evans, Stefanie M.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP de Perio, MA (reprint author), NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,R-10, Cincinnati, OH 45226 USA. EM mdeperio@cdc.gov FU Intramural CDC HHS [CC999999] NR 40 TC 8 Z9 8 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 J9 J COMMUN HEALTH JI J. Community Health PD APR PY 2012 VL 37 IS 2 BP 272 EP 281 DI 10.1007/s10900-011-9478-z PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 936KY UT WOS:000303590500003 PM 21938550 ER PT J AU Chapman, DP Wheaton, AG Perry, GS Sturgis, SL Strine, TW Croft, JB AF Chapman, Daniel P. Wheaton, Anne G. Perry, Geraldine S. Sturgis, Stephanie L. Strine, Tara W. Croft, Janet B. TI Household Demographics and Perceived Insufficient Sleep Among US Adults SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Sleep; Insufficient sleep; Sleep deprivation; Epidemiology ID QUALITY-OF-LIFE; DAYTIME SLEEPINESS; GENERAL-POPULATION; INSOMNIA; HEALTH; DISRUPTION; DISORDERS; DURATION; WOMEN; NEED AB It has become increasingly recognized that insufficient sleep is associated with adverse health outcomes. Studies have observed that sleep duration and daytime sleepiness varies by sex and marital status. Few studies have examined the impact of the number of children on sleep. To evaluate the association of marital status and number of children with insufficient sleep and in a large national sample. We analyzed data from the 2008 Behavioral Risk Factor Surveillance System (BRFSS) survey, a population-based telephone survey of non-institutionalized US adults (N = 395,407), in which respondents were asked, "During the past 30 days, for about how many days have you felt you did not get enough rest or sleep?" We used sex-specific, multivariate logistic regression analyses to assess the associations of marital status (married, previously married, never married) and the number of children in the household with frequent insufficient sleep (>= 14 days in past 30 days) after adjusting for age, race/ethnicity, and education. In this study population, 23% were never married, 60% were married, and 17% were previously married. Forty-three percent reported having children aged <18 years in the household. Married men (24.3%) were less likely to report frequent insufficient sleep than never married men (28.0%) or previously married men (28.8%). Never married women (33.4%) were more likely to report frequent insufficient sleep than currently married (29.0%) or previously married women (29.0%). The likelihood of frequent insufficient sleep increased in a linear fashion with the number of children in the household for all subgroups (P < 0.05) except among never married men. These findings suggest that the presence of children in the household often increases the frequency of insufficient rest or sleep among the adults with whom they reside. Thus, health care providers may wish to consider the presence of children under 18 years of age a potential "risk factor" for insufficient sleep when counseling adults in the household about the importance of sleep to overall health. C1 [Chapman, Daniel P.; Wheaton, Anne G.; Perry, Geraldine S.; Sturgis, Stephanie L.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30041 USA. [Strine, Tara W.] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance Program Off, Atlanta, GA 30041 USA. RP Chapman, DP (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop K-67, Atlanta, GA 30041 USA. EM DChapman@cdc.gov FU Intramural CDC HHS [CC999999]; ODCDC CDC HHS [3U50CD300860, U50 CD300860] NR 23 TC 8 Z9 8 U1 0 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 J9 J COMMUN HEALTH JI J. Community Health PD APR PY 2012 VL 37 IS 2 BP 344 EP 349 DI 10.1007/s10900-011-9451-x PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 936KY UT WOS:000303590500013 PM 21800186 ER PT J AU Rhea, S Ising, A Fleischauer, AT Deyneka, L Vaughan-Batten, H Waller, A AF Rhea, Sarah Ising, Amy Fleischauer, Aaron T. Deyneka, Lana Vaughan-Batten, Heather Waller, Anna TI Using Near Real-Time Morbidity Data to Identify Heat-Related Illness Prevention Strategies in North Carolina SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Heat-related illness; Prevention; Emergency department; North Carolina AB Timely public health interventions reduce heat-related illnesses (HRIs). HRI emergency department (ED) visit data provide near real-time morbidity information to local and state public health practitioners and may be useful in directing HRI prevention efforts. This study examined statewide HRI ED visits in North Carolina (NC) from 2008-2010 by age group, month, ED disposition, chief complaint, and triage notes. The mean number of HRI ED visits per day was compared to the maximum daily temperature. The percentage of HRI ED visits to all ED visits was highest in June (0.25%). 15-18 year-olds had the highest percentage of HRI visits and were often seen for sports-related heat exposures. Work-related HRI ED visits were more common than other causes in 19-45 year-olds. Individuals >= 65 years were more likely admitted to the hospital than younger individuals. The mean daily number of HRI ED visits increased by 1.4 for each 1 degrees F (degree Fahrenheit) increase from 90 degrees F to 98 degrees F and by 15.8 for each 1 degrees F increase from 98 degrees F to 100 degrees F. Results indicate that HRI prevention efforts in NC should be emphasized in early summer and targeted to adolescents involved in organized sports, young adults with outdoor occupations, and seniors. At a maximum daily temperature of 98 degrees F, there was a substantial increase in the average daily number of HRI ED visits. ED visit data provide timely, sentinel HRI information. Analysis of this near real-time morbidity data may assist local and state public health practitioners in identification of HRI prevention strategies that are especially relevant to their jurisdictions. C1 [Rhea, Sarah; Ising, Amy; Waller, Anna] Univ N Carolina, Dept Emergency Med, Carolina Ctr Hlth Informat, Chapel Hill, NC 27516 USA. [Fleischauer, Aaron T.] Ctr Dis Control & Prevent CDC, Raleigh, NC USA. [Fleischauer, Aaron T.; Deyneka, Lana; Vaughan-Batten, Heather] N Carolina Div Publ Hlth, Raleigh, NC USA. RP Rhea, S (reprint author), Univ N Carolina, Dept Emergency Med, Carolina Ctr Hlth Informat, 100 Market St, Chapel Hill, NC 27516 USA. EM srhea@email.unc.edu NR 15 TC 18 Z9 18 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 J9 J COMMUN HEALTH JI J. Community Health PD APR PY 2012 VL 37 IS 2 BP 495 EP 500 DI 10.1007/s10900-011-9469-0 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 936KY UT WOS:000303590500030 PM 21882040 ER PT J AU Thai, H Campo, DS Lara, J Dimitrova, Z Ramachandran, S Xia, GL Ganova-Raeva, L Teo, CG Lok, A Khudyakov, Y AF Hong Thai Campo, David S. Lara, James Dimitrova, Zoya Ramachandran, Sumathi Xia, Guoliang Ganova-Raeva, Lilia Teo, Chong-Gee Lok, Anna Khudyakov, Yury TI Convergence and coevolution of Hepatitis B virus drug resistance SO NATURE COMMUNICATIONS LA English DT Article ID NAIVE PATIENTS; NUCLEOSIDE; POLYMERASE; SELECTION; THERAPY; ANALOGS; TREES AB Treatment with lamivudine of patients infected with hepatitis B virus (HBV) results in a high rate of drug resistance, which is primarily associated with the rtM204I/V substitution in the HBV reverse transcriptase domain. Here we show that the rtM204I/V substitution, although essential, is insufficient for establishing resistance against lamivudine. The analysis of 639 HBV whole-genome sequences obtained from 11 patients shows that rtM204I/V is independently acquired by more than one intra-host HBV variant, indicating the convergent nature of lamivudine resistance. The differential capacity of HBV variants to develop drug resistance suggests that fitness effects of drug-resistance mutations depend on the genetic structure of the HBV genome. An analysis of Bayesian networks that connect rtM204I/V to many sites of HBV proteins confirms that lamivudine resistance is a complex trait encoded by the entire HBV genome rather than by a single mutation. These findings have implications for public health and offer a more general framework for understanding drug resistance. C1 [Hong Thai; Campo, David S.; Lara, James; Dimitrova, Zoya; Ramachandran, Sumathi; Xia, Guoliang; Ganova-Raeva, Lilia; Teo, Chong-Gee; Khudyakov, Yury] Ctr Dis Control & Prevent, Mol Epidemiol & Bioinformat Lab, Div Viral Hepatitis, Atlanta, GA 30329 USA. [Lok, Anna] Univ Michigan Hlth Syst, Div Gastroenterol & Hepatol, Dept Internal Med, Ann Arbor, MI 48109 USA. RP Thai, H (reprint author), Ctr Dis Control & Prevent, Mol Epidemiol & Bioinformat Lab, Div Viral Hepatitis, Atlanta, GA 30329 USA. EM guy8@cdc.gov RI Campo, David S./C-5072-2011; OI Campo, David S./0000-0002-8970-3436; Yang, Shuman/0000-0002-9638-0890 NR 27 TC 24 Z9 25 U1 0 U2 10 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD APR PY 2012 VL 3 AR 789 DI 10.1038/ncomms1794 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 934PB UT WOS:000303455200026 PM 22510694 ER PT J AU Homaira, N Luby, SP Alamgir, ASM Islam, K Paul, R Abedin, J Rahman, M Azim, T Podder, G Sohel, BM Brooks, A Fry, AM Widdowson, MA Bresee, J Rahman, M Azziz-Baumgartner, E AF Homaira, Nusrat Luby, Stephen P. Alamgir, A. S. M. Islam, Kariul Paul, Repon Abedin, Jaynal Rahman, Mustafizur Azim, Tasnim Podder, Goutam Sohel, Badrul Munir Brooks, Abdullah Fry, Alicia M. Widdowson, Marc-Alain Bresee, Joseph Rahman, Mahmudur Azziz-Baumgartner, Eduardo TI Influenza-associated mortality in 2009 in four sentinel sites in Bangladesh SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article ID UNITED-STATES; PANDEMIC INFLUENZA; CHILDHOOD DEATHS; A H1N1; PNEUMONIA; IMPACT; PREPAREDNESS; EPIDEMICS; UPDATE; VIRUS AB Objective To estimate influenza-associated mortality in Bangladesh in 2009. Methods In four hospitals in Bangladesh, respiratory samples were collected twice a month throughout 2009 from inpatients aged <5 years with severe pneumonia and from older inpatients with severe acute respiratory infection. The samples were tested for influenza virus ribonucleic acid (RNA) using polymerase chain reaction. The deaths in 2009 in five randomly selected unions (the smallest administrative units in Bangladesh) in each hospital's catchment area were then investigated using formal records and informal group discussions. The deaths of those who had reportedly died within 14 days of suddenly developing fever with cough and/or a sore throat were assumed to be influenza-associated. The rate of such deaths in 2009 in each of the catchment areas was then estimated from the number of apparently influenza-associated deaths in the sampled unions, the proportion of the sampled inpatients in the local hospital who tested positive for influenza virus RNA, and the estimated number of residents of the sampled unions. Findings Of the 2500 people known to have died in 2009 in all 20 study unions, 346(14%) reportedly had fever with cough and/or sore throat within 14 days of their deaths. The estimated mean annual influenza-associated mortality in these unions was 11 per 100 000 population: 1.5, 4.0 and 125 deaths per 100 000 among those aged < 5, 5-59 and > 59 years, respectively. Conclusion The highest burden of influenza-associated mortality in Bangladesh in 2009 was among the elderly. C1 [Homaira, Nusrat; Luby, Stephen P.; Islam, Kariul; Paul, Repon; Abedin, Jaynal; Rahman, Mustafizur; Azim, Tasnim; Podder, Goutam; Sohel, Badrul Munir; Brooks, Abdullah; Azziz-Baumgartner, Eduardo] Int Ctr Diarrhoeal Dis Res, Dhaka 1212, Bangladesh. [Alamgir, A. S. M.; Rahman, Mahmudur] Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh. [Fry, Alicia M.; Widdowson, Marc-Alain; Bresee, Joseph] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Homaira, N (reprint author), Int Ctr Diarrhoeal Dis Res, Dhaka 1212, Bangladesh. EM nhomaira@icddrb.org RI rahman, mustafizur/E-6918-2010; OI Widdowson, Marc-Alain/0000-0002-0682-6933 FU CDC's Influenza Division [1U01CI000628-01] FX This work was funded by the CDC's Influenza Division, under a cooperative agreement (1U01CI000628-01). NR 36 TC 17 Z9 17 U1 0 U2 1 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 EI 1564-0604 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD APR PY 2012 VL 90 IS 4 BP 272 EP 278 DI 10.2471/BLT.11.095653 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 932EL UT WOS:000303273100017 PM 22511823 ER PT J AU Feng, LZ Shay, DK Jiang, Y Zhou, H Chen, X Zheng, YD Jiang, LL Zhang, QJ Lin, H Wang, SJ Ying, YY Xu, YJ Wang, ND Feng, ZJ Viboud, C Yang, WZ Yu, HJ AF Feng, Luzhao Shay, David K. Jiang, Yong Zhou, Hong Chen, Xin Zheng, Yingdong Jiang, Lili Zhang, Qingjun Lin, Hong Wang, Shaojie Ying, Yanyan Xu, Yanjun Wang, Nanda Feng, Zijian Viboud, Cecile Yang, Weizhong Yu, Hongjie TI Influenza-associated mortality in temperate and subtropical Chinese cities, 2003-2008 SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article ID OF-DEATH STATISTICS; SEASONAL INFLUENZA; EXCESS MORTALITY; UNITED-STATES; TROPICAL SINGAPORE; PNEUMONIA; EPIDEMIC; IMPACT; HOSPITALIZATION; VACCINATION AB Objective To estimate influenza-associated mortality in urban China. Methods Influenza-associated excess mortality for the period 2003-2008 was estimated in three cities in temperate northern China and five cities in the subtropical south of the country. The estimates were derived from models based on negative binomial regressions, vital statistics and the results of weekly influenza virus surveillance. Findings Annual influenza-associated excess mortality, for all causes, was 18.0 (range: 10.9-32.7) deaths per 100 000 population in the northern cities and 11.3 (range: 7.3-1.7.8) deaths per 100000 in the southern cities. Excess mortality for, respiratory and circulatory disease was 12.4 (range: 7.4-22.2) and 8.8 (range: 5.5-13.6) deaths per 100 000 people in the northern and southern cities, respectively. Most (86%) deaths occurred among people aged 65 years. Influenza-associated excess mortality was higher in B-virus-dominant seasons than in seasons when A(H3N2) or A(H1N1) predominated, and more than half of all influenza-associated mortality was associated with influenza B virus. Conclusion Between 2003 and 2008, seasonal influenza, particularly that caused by the influenza B virus, was associated with substantial mortality in three cities in the temperate north of China and five cities in the subtropical south of the country: C1 [Jiang, Yong; Yu, Hongjie] Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing 102206, Peoples R China. [Shay, David K.; Zhou, Hong] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Zheng, Yingdong] Peking Univ, Sch Publ Hlth, Beijing 100871, Peoples R China. [Jiang, Lili] Shanghai Municipal Ctr Dis Control & Prevent, Shanghai, Peoples R China. [Zhang, Qingjun] Hubei Prov Ctr Dis Control & Prevent, Wuhan, Peoples R China. [Lin, Hong] Dalian Ctr Dis Control & Prevent, Dalian, Peoples R China. [Wang, Shaojie] Qingdao Ctr Dis Control & Prevent, Qingdao, Peoples R China. [Ying, Yanyan] Ningbo Ctr Dis Control & Prevent, Ningbo, Zhejiang, Peoples R China. [Xu, Yanjun] Guangdong Prov Ctr Dis Control & Prevent, Guangzhou, Guangdong, Peoples R China. [Wang, Nanda] Zhaoyuan Ctr Dis Control & Prevent, Yantai, Peoples R China. [Viboud, Cecile] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. RP Yu, HJ (reprint author), Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, 155 Changbai Rd, Beijing 102206, Peoples R China. EM yuhj@chinacdc.cn FU China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases FX This study was supported by the China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases. NR 34 TC 41 Z9 50 U1 1 U2 8 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD APR PY 2012 VL 90 IS 4 BP 279 EP 288 DI 10.2471/BLT.11.096958 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 932EL UT WOS:000303273100018 PM 22511824 ER PT J AU Cohen, AL Hyde, TB Verani, J Watkins, M AF Cohen, Adam L. Hyde, Terri B. Verani, Jennifer Watkins, Marqaret TI Integrating pneumonia prevention and treatment interventions with immunization services in resource-poor countries SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; INFLUENZAE TYPE-B; CHILDHOOD PNEUMONIA; CASE-MANAGEMENT; RESPIRATORY-INFECTIONS; HEALTH INTERVENTIONS; CHILDREN YOUNGER; AIR-POLLUTION; METAANALYSIS; MORTALITY AB Pneumonia is a leading cause of morbidity and mortality worldwide. Effective vaccine and non-vaccine interventions to prevent and control pneumonia are urgently needed to reduce the global burden of the disease. This paper explores practical strategies and policies for integrating interventions to prevent and treat pneumonia with routine immunization services, and it investigates the challenges involved in such integration. The primary pneumonia prevention and treatment strategies that are implemented during routine childhood immunization visits are vaccination of children against the disease, caretaker education and referral of children to medical services when necessary. C1 [Cohen, Adam L.; Verani, Jennifer] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Hyde, Terri B.; Watkins, Marqaret] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Cohen, AL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM dvjl@cdc.gov NR 33 TC 4 Z9 4 U1 1 U2 3 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD APR PY 2012 VL 90 IS 4 BP 289 EP 294 DI 10.2471/BLT.11.094029 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 932EL UT WOS:000303273100019 PM 22511825 ER PT J AU Razuri, H Romero, C Tinoco, Y Guezala, MC Ortiz, E Silva, M Reaves, E Williams, M Laguna-Torres, VA Halsey, ES Gomez, J Azziz-Baumgartner, E Widdowson, MA Bresee, J Moen, A Uyeki, TM Bennett, A Montgomery, JM Bausch, DG AF Razuri, Hugo Romero, Candice Tinoco, Yeny Guezala, Maria Claudia Ortiz, Ernesto Silva, Maria Reaves, Erik Williams, Maya Laguna-Torres, Victor Alberto Halsey, Eric S. Gomez, Jorge Azziz-Baumgartner, Eduardo Widdowson, Marc-Alain Bresee, Joe Moen, Ann Uyeki, Timothy M. Bennett, Andrew Montgomery, Joel M. Bausch, Daniel G. TI Population-based active surveillance cohort studies for influenza: lessons from Peru SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Editorial Material ID CHILDREN C1 [Razuri, Hugo; Romero, Candice; Tinoco, Yeny; Guezala, Maria Claudia; Ortiz, Ernesto; Silva, Maria; Reaves, Erik; Williams, Maya; Laguna-Torres, Victor Alberto; Halsey, Eric S.; Montgomery, Joel M.; Bausch, Daniel G.] US Naval Med Res Unit 6, Lima, Peru. [Gomez, Jorge] Minist Hlth, Gen Directorate Epidemiol, Lima, Peru. [Azziz-Baumgartner, Eduardo; Widdowson, Marc-Alain; Bresee, Joe; Moen, Ann; Uyeki, Timothy M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bennett, Andrew] Tulane Sch Publ Hlth & Trop Med, New Orleans, LA USA. RP Razuri, H (reprint author), US Naval Med Res Unit 6, Av Venezuela Cdra 36 S-N,Callao 2, Lima, Peru. EM hugo.razuri@med.navy.mil RI Razuri, Hugo/C-1542-2013; Valle, Ruben/A-7512-2013; OI Razuri, Hugo/0000-0003-4571-5520; Widdowson, Marc-Alain/0000-0002-0682-6933 NR 11 TC 9 Z9 10 U1 0 U2 1 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD APR PY 2012 VL 90 IS 4 BP 318 EP 320 DI 10.2471/BLT.11.097808 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 932EL UT WOS:000303273100024 PM 22511830 ER PT J AU Li, J German, R King, J Joseph, D Thompson, T Wu, XC Ajani, U Tai, E AF Li, Jun German, Robert King, Jessica Joseph, Djenaba Thompson, Trevor Wu, Xiao-Cheng Ajani, Umed Tai, Eric TI Recent trends in prostate cancer testing and incidence among men under age of 50 SO CANCER EPIDEMIOLOGY LA English DT Article DE Prostatic neoplasm; Cancer screening; SEER program; Incidence ID UNITED-STATES; RISK-FACTORS; YOUNG MEN; EPIDEMIOLOGY; SURVEILLANCE; METAANALYSIS; SMOKING; PROGRAM; COHORT AB Background: Information on prostate cancer testing and incidence among men under age 50 is scant. This study aims to describe trends of prostate cancer testing and incidence by demographic and clinical characteristics and identify potential correlations between prostate cancer testing and incidence. Methods: We examined prostate cancer testing and incidence rates among American men under age of 50 using data from the Behavioral Risk Factor Surveillance System (2002, 2004, 2006, and 2008) and data from the National Program of Cancer Registries and Surveillance, Epidemiology, and End Results programs (2001-2006). We conducted descriptive, logistic regression, and trend analyses using SUDAAN and SEER*Stat. Results: The prostate cancer incidence rate among black men was more than 2-fold that of white men. The overall prostate cancer incidence rate slightly increased from 2001 to 2006; however, the prevalence of prostate cancer testing declined over time. There was a borderline significant increase in prostate cancer incidence rate (APC = 3.5, 95% CI = 0.0, 7.0) for men aged 40-44. Well-differentiated prostate cancer incidence decreased significantly (APC = -24.7; 95% confidence interval (CI) = -34.9, -12.8) over time. Conclusions: We observed a large difference in prostate cancer incidence between blacks and whites under age 50. Similar patterns in prostate cancer testing and cancer incidence by race and ethnicity suggested prostate cancer testing might have influenced incidence to some extent in this young population. The different temporal patterns for prostate cancer testing and incidence, especially for men aged 40-44 years, suggested screening alone could not fully accounted for the increasing prostate cancer incidence rates. Decreasing trend of well-differentiated prostate cancer may be partially due to "Grade Inflation". Published by Elsevier Ltd. C1 [Li, Jun; German, Robert; King, Jessica; Joseph, Djenaba; Thompson, Trevor; Ajani, Umed; Tai, Eric] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Wu, Xiao-Cheng] Louisiana State Univ, Sch Publ Hlth, New Orleans, LA 70112 USA. RP Li, J (reprint author), CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. EM ffa2@cdc.gov; bobgerman2010@gmail.com; GZK3@cdc.gov; dvk5@cdc.gov; TKT2@cdc.gov; XWu@lsuhsc.edu; UAA0@cdc.gov; cvn5@cdc.gov NR 23 TC 12 Z9 14 U1 0 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1877-7821 J9 CANCER EPIDEMIOL JI Cancer Epidemiol. PD APR PY 2012 VL 36 IS 2 BP 122 EP 127 DI 10.1016/j.canep.2011.10.014 PG 6 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 931SY UT WOS:000303240800018 PM 22112545 ER PT J AU Faria, NR Hodges-Mameletzis, I Silva, JC Rodes, B Erasmus, S Paolucci, S Ruelle, J Pieniazek, D Taveira, N Trevino, A Goncalves, MF Jallow, S Xu, L Camacho, RJ Soriano, V Goubau, P de Sousa, JD Vandamme, AM Suchard, MA Lemey, P AF Faria, Nuno R. Hodges-Mameletzis, Ioannis Silva, Joana C. Rodes, Berta Erasmus, Smit Paolucci, Stefania Ruelle, Jean Pieniazek, Danuta Taveira, Nuno Trevino, Ana Goncalves, Maria F. Jallow, Sabelle Xu, Li Camacho, Ricardo J. Soriano, Vincent Goubau, Patrick de Sousa, Joao D. Vandamme, Anne-Mieke Suchard, Marc A. Lemey, Philippe TI Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID HIV-2 INFECTION; WEST-AFRICA; GUINEA-BISSAU; SUBTYPE-B; RESISTANCE MUTATIONS; SOOTY MANGABEYS; UNITED-STATES; COTE-DIVOIRE; IVORY-COAST; VIRAL LOAD AB Human immunodeficiency virus type 2 (HIV-2) emerged in West Africa and has spread further to countries that share socio-historical ties with this region. However, viral origins and dispersal patterns at a global scale remain poorly understood. Here, we adopt a Bayesian phylogeographic approach to investigate the spatial dynamics of HIV-2 group A (HIV-2A) using a collection of 320 partial pol and 248 partial env sequences sampled throughout 19 countries worldwide. We extend phylogenetic diffusion models that simultaneously draw information from multiple loci to estimate location states throughout distinct phylogenies and explicitly attempt to incorporate human migratory fluxes. Our study highlights that Guinea-Bissau, together with Cote d'Ivoire and Senegal, have acted as the main viral sources in the early stages of the epidemic. We show that convenience sampling can obfuscate the estimation of the spatial root of HIV-2A. We explicitly attempt to circumvent this by incorporating rate priors that reflect the ratio of human flow from and to West Africa. We recover four main routes of HIV-2A dispersal that are laid out along colonial ties: Guinea-Bissau and Cape Verde to Portugal, Cote d'Ivoire and Senegal to France. Within Europe, we find strong support for epidemiological linkage from Portugal to Luxembourg and to the UK. We demonstrate that probabilistic models can uncover global patterns of HIV-2A dispersal providing sampling bias is taken into account and we provide a scenario for the international spread of this virus. C1 [Faria, Nuno R.; de Sousa, Joao D.; Vandamme, Anne-Mieke; Lemey, Philippe] Katholieke Univ Leuven, Rega Inst, Louvain, Belgium. [Hodges-Mameletzis, Ioannis; Jallow, Sabelle] Univ Oxford, Weatherall Inst Mol Med, Oxford, England. [Silva, Joana C.; Goncalves, Maria F.; Camacho, Ricardo J.] Ctr Hosp Lisboa Ocidental, Mol Biol Lab, Lisbon, Portugal. [Rodes, Berta; Trevino, Ana; Soriano, Vincent] Hosp Carlos III, Dept Infect Dis, Madrid, Spain. [Erasmus, Smit; Xu, Li] Birmingham Heartlands Hosp, HPA Birmingham, Birmingham B9 5ST, W Midlands, England. [Paolucci, Stefania] Fdn IRCCS Policlin, San Matteo, Italy. [Ruelle, Jean; Goubau, Patrick] Catholic Univ Louvain, AIDS Reference Lab, B-1200 Brussels, Belgium. [Pieniazek, Danuta] Ctr Dis Control & Prevent, Incidence & Case Surveillance Branch, Atlanta, GA USA. [Taveira, Nuno] Fac Farm Lisboa, Unidade Retrovirus & Infeccoes Associadas, Ctr Patogenese Mol, Lisbon, Portugal. [Taveira, Nuno] Inst Super Ciencias Saude Egas Moniz, Ctr Invest Interdisciplinar Egas Moniz CiiEM, Monte De Caparica, Portugal. [Taveira, Nuno] Fac Med Lisbon, Inst Mol Med, Lisbon, Portugal. [Camacho, Ricardo J.; Vandamme, Anne-Mieke] Univ Nova Lisboa, Ctr Malaria & Outras Doencas Tropicais, Inst Higiene & Med Trop, P-1200 Lisbon, Portugal. [Suchard, Marc A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA. [Suchard, Marc A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Suchard, Marc A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. RP Faria, NR (reprint author), Katholieke Univ Leuven, Rega Inst, Louvain, Belgium. EM nuno.faria@rega.kuleuven.be RI Faria, Nuno/I-2975-2012; Vandamme, Anne Mieke/I-4127-2012; Cavaco-Silva, Joana/J-4708-2012; Taveira, Nuno/A-6252-2014; iMed.ULisboa, EEPHIV /B-4222-2014; iMed.ULisboa, iMed.ULisboa/C-6292-2014; Camacho, Ricardo/I-7629-2012; santos, sofia/I-1637-2012; OI Faria, Nuno/0000-0001-8839-2798; Vandamme, Anne Mieke/0000-0002-6594-2766; Taveira, Nuno/0000-0003-0176-5585; Camacho, Ricardo/0000-0002-9129-3237; Sousa, Joao/0000-0002-7604-3109; Rodrigues Faria, Nuno/0000-0002-9747-8822 FU Fundacao para a Ciencia e Tecnologia [SFRH/BD/64530/2009]; NIH [R01 GM86887]; European Union [FP7/2007-2013, 278433, 223131]; ERC [260864]; National Evolutionary Synthesis Center (NESCent) FX N. R. F. is supported by Fundacao para a Ciencia e Tecnologia (grant no. SFRH/BD/64530/2009). M. A. S. is supported by NIH R01 GM86887. We are grateful to Vitor Duque, Ana Trevino, Jose Miguel Pereira, Fausto Baldanti, Maurizio Zazzi, Carlo Perno, Catherine Brennan, Francoise Brun-Vezinet, Florence Damond, Diane Descamps, Gab Jung Kim, Sung Kim, Eric Arts, Carlo Torti, Robin Mukhopadhyaya, Anita Desai, Susmita Gurjan and Soo-Yon Rhee for valuable information concerning sampling dates and locations of the isolates, and Emmanuel Gilisseu for insight on the range of C. atys atys. The research leading to these results has received funding from the European Union Seventh Framework Programme [FP7/2007-2013] under grant agreement no. 278433 (PREDEMICS), grant agreement no. 223131 (CHAIN) and ERC grant agreement no. 260864. P. L. and M. A. S. acknowledge the support of the National Evolutionary Synthesis Center (NESCent) through a working group (Software for Bayesian Evolutionary Analysis). NR 77 TC 31 Z9 31 U1 1 U2 13 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 J9 J GEN VIROL JI J. Gen. Virol. PD APR PY 2012 VL 93 BP 889 EP 899 DI 10.1099/vir.0.038638-0 PN 4 PG 11 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA 929OF UT WOS:000303074500025 PM 22190015 ER PT J AU Festoff, B Li, CY Lynch, S AF Festoff, Barry Li, Chaoyang Lynch, Sharon TI Soluble Thrombomodulin Levels and Their Implications in Multiple Sclerosis SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Festoff, Barry; Lynch, Sharon] Univ Kansas, Med Ctr, Inst Neurol Disorders, Kansas City, MO USA. [Festoff, Barry] Univ Kansas, Med Ctr, Neurobiol Res VA Med Ctr 151, Kansas City, MO USA. [Li, Chaoyang] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA P05099 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204803083 ER PT J AU Gordon, P Mehal, J Holman, R Rowland, A Cheek, J AF Gordon, Paul Mehal, Jason Holman, Robert Rowland, Andrew Cheek, James TI Prevalence Estimates of Parkinson Disease among American Indian and Alaska Native People SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Gordon, Paul] Indian Hlth Serv, Mancos, CO USA. [Mehal, Jason; Holman, Robert] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rowland, Andrew] Univ New Mexico, Albuquerque, NM 87131 USA. [Cheek, James] Indian Hlth Serv, Albuquerque, NM USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA P07130 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204804157 ER PT J AU Horton, K Muravov, O AF Horton, Kevin Muravov, Oleg TI The National Amyotrophic Lateral Sclerosis (ALS) Registry: Overview and New Initiatives SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Horton, Kevin; Muravov, Oleg] Agcy Toxic Subst & Dis Registry, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA P01092 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204800151 ER PT J AU Ladha, S Ortega, E Sejvar, J Muley, S AF Ladha, Shafeeq Ortega, Erik Sejvar, James Muley, Suraj TI The Clinical and Electrophysiologic Features of AMAN in Southwestern Arizona and Northern Mexico SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Ladha, Shafeeq; Ortega, Erik] Barrow Neurol Inst, Phoenix, AZ 85013 USA. [Muley, Suraj] Barrow Neurol Inst, Paradise Valley, AZ USA. [Sejvar, James] Ctr Dis Control & Prevent, Atlanta, GA USA. RI Ladha, Shafeeq/A-4948-2010 OI Ladha, Shafeeq/0000-0003-1955-4292 NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA P06139 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204803376 ER PT J AU Nath, A Major, E Aksamit, A Calabrese, L Sejvar, J Kotton, C Barhams, M AF Nath, Avindra Major, Eugene Aksamit, Allen Calabrese, Leonard Sejvar, James Kotton, Camille Barhams, Maria TI Establishment of a Registry To Identify Cases of PML Using Uniform Diagnostic Criteria SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Nath, Avindra; Major, Eugene; Barhams, Maria] NINDS, NIH, Bethesda, MD 20892 USA. [Aksamit, Allen] Mayo Clin, Rochester, MN USA. [Calabrese, Leonard] Cleveland Clin, Cleveland, OH 44106 USA. [Sejvar, James] CDC, Decatur, GA USA. [Kotton, Camille] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA S08002 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204800420 ER PT J AU Nelson, AE Renner, JB Golightly, YM Schwartz, TA Kraus, VB Helmick, CG Jordan, JM AF Nelson, A. E. Renner, J. B. Golightly, Y. M. Schwartz, T. A. Kraus, V. B. Helmick, C. G. Jordan, J. M. TI DIFFERENCES IN MULTI-JOINT SYMPTOMATIC OSTEOARTHRITIS PHENOTYPES BY RACE AND GENDER: THE JOHNSTON COUNTY OSTEOARTHRITIS PROJECT SO OSTEOARTHRITIS AND CARTILAGE LA English DT Meeting Abstract CT World Congress on Osteoarthritis CY APR 26-29, 2012 CL Barcelona, SPAIN C1 [Nelson, A. E.; Renner, J. B.; Golightly, Y. M.; Jordan, J. M.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC USA. [Renner, J. B.] Univ N Carolina, Dept Radiol, Chapel Hill, NC USA. [Schwartz, T. A.] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Kraus, V. B.] Duke Univ Med Ctr, Durham, NC USA. [Helmick, C. G.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD APR PY 2012 VL 20 SU 1 BP S156 EP S156 PG 1 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 931MF UT WOS:000303223300336 ER PT J AU Beral, V Hermon, C Peto, R Reeves, G Brinton, L Marchbanks, P Negri, E Ness, R Peeters, PHM Vessey, M Calle, EE Gapstur, SM Patel, AV Dal Maso, L Talamini, R Chetrit, A Hirsh-Yechezkel, G Lubin, F Sadetzki, S Allen, N Bull, D Callaghan, K Crossley, B Gaitskell, K Goodill, A Green, J Key, T Moser, K Collins, R Doll, R Gonzalez, CA Lee, N Ory, HW Peterson, HB Wingo, PA Martin, N Pardthaisong, T Silpisornkosol, S Theetranont, C Boosiri, B Chutivongse, S Jimakorn, P Virutamasen, P Wongsrichanalai, C Tjonneland, A Titus-Ernstoff, L Byers, T Rohan, T Mosgaard, BJ Yeates, D Freudenheim, JL Chang-Claude, J Kaaks, R Anderson, KE Folsom, A Robien, K Rossing, MA Thomas, DB Weiss, NS Riboli, E Clavel-Chapelon, F Cramer, D Hankinson, SE Tworoger, SS Franceschi, S La Vecchia, C Magnusson, C Riman, T Weiderpass, E Wolk, A Schouten, LJ van den Brandt, PA Chantarakul, N Koetsawang, S Rachawat, D Palli, D Black, A de Gonzalez, AB Freedman, DM Hartge, P Hsing, AW Lacey, JV Hoover, RN Schairer, C Graff-Iversen, S Selmer, R Bain, CJ Green, AC Purdie, DM Siskind, V Webb, PM McCann, SE Hannaford, P Kay, C Binns, CW Lee, AH Zhang, M Ness, RB Nasca, P Coogan, PF Palmer, JR Rosenberg, L Kelsey, J Paffenbarger, R Whittemore, A Katsouyanni, K Trichopoulou, A Trichopoulos, D Tzonou, A Dabancens, A Martinez, L Molina, R Salas, O Goodman, MT Lurie, G Carney, ME Wilkens, LR Hartman, L Manjer, J Olsson, H Grisso, JA Morgan, M Wheeler, JE Casagrande, J Pike, MC Ross, RK Wu, AH Miller, AB Kumle, M Lund, E McGowan, L Shu, XO Zheng, W Farley, TMM Holck, S Meirik, O Risch, HA AF Beral, V. Hermon, C. Peto, R. Reeves, G. Brinton, L. Marchbanks, P. Negri, E. Ness, R. Peeters, P. H. M. Vessey, M. Calle, E. E. Gapstur, S. M. Patel, A. V. Dal Maso, L. Talamini, R. Chetrit, A. Hirsh-Yechezkel, G. Lubin, F. Sadetzki, S. Allen, N. Bull, D. Callaghan, K. Crossley, B. Gaitskell, K. Goodill, A. Green, J. Key, T. Moser, K. Collins, R. Doll, R. Gonzalez, C. A. Lee, N. Ory, H. W. Peterson, H. B. Wingo, P. A. Martin, N. Pardthaisong, T. Silpisornkosol, S. Theetranont, C. Boosiri, B. Chutivongse, S. Jimakorn, P. Virutamasen, P. Wongsrichanalai, C. Tjonneland, A. Titus-Ernstoff, L. Byers, T. Rohan, T. Mosgaard, B. J. Yeates, D. Freudenheim, J. L. Chang-Claude, J. Kaaks, R. Anderson, K. E. Folsom, A. Robien, K. Rossing, M. A. Thomas, D. B. Weiss, N. S. Riboli, E. Clavel-Chapelon, F. Cramer, D. Hankinson, S. E. Tworoger, S. S. Franceschi, S. La Vecchia, C. Magnusson, C. Riman, T. Weiderpass, E. Wolk, A. Schouten, L. J. van den Brandt, P. A. Chantarakul, N. Koetsawang, S. Rachawat, D. Palli, D. Black, A. de Gonzalez, A. Berrington Freedman, D. M. Hartge, P. Hsing, A. W. Lacey, J. V., Jr. Hoover, R. N. Schairer, C. Graff-Iversen, S. Selmer, R. Bain, C. J. Green, A. C. Purdie, D. M. Siskind, V. Webb, P. M. McCann, S. E. Hannaford, P. Kay, C. Binns, C. W. Lee, A. H. Zhang, M. Ness, R. B. Nasca, P. Coogan, P. F. Palmer, J. R. Rosenberg, L. Kelsey, J. Paffenbarger, R. Whittemore, A. Katsouyanni, K. Trichopoulou, A. Trichopoulos, D. Tzonou, A. Dabancens, A. Martinez, L. Molina, R. Salas, O. Goodman, M. T. Lurie, G. Carney, M. E. Wilkens, L. R. Hartman, L. Manjer, J. Olsson, H. Grisso, J. A. Morgan, M. Wheeler, J. E. Casagrande, J. Pike, M. C. Ross, R. K. Wu, A. H. Miller, A. B. Kumle, M. Lund, E. McGowan, L. Shu, X. O. Zheng, W. Farley, T. M. M. Holck, S. Meirik, O. Risch, H. A. CA Collaborative Grp Epidemiol Studie TI Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies SO PLOS MEDICINE LA English DT Article ID ORAL-CONTRACEPTIVE USE; REQUIRING PROLONGED OBSERVATION; EPITHELIAL OVARIAN; MASS INDEX; ANTHROPOMETRIC MEASURES; PROSPECTIVE COHORT; UNITED-STATES; RISK-FACTORS; POSTMENOPAUSAL WOMEN; HORMONAL FACTORS AB Background: Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p<0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p<0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m(2) increase in body mass index was 1.10 (95% CI, 1.07-1.13; p<0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p = 0.02) in ever-users of hormone therapy. Conclusions: Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade. C1 [Beral, V.; Hermon, C.; Reeves, G.; Allen, N.; Bull, D.; Callaghan, K.; Crossley, B.; Gaitskell, K.; Goodill, A.; Green, J.; Key, T.; Moser, K.] Canc Epidemiol Unit, Oxford, England. [Calle, E. E.; Gapstur, S. M.; Patel, A. V.] Amer Canc Soc, Atlanta, GA 30329 USA. [Dal Maso, L.; Talamini, R.] Aviano Canc Ctr, Pordenone, Italy. [Chetrit, A.; Hirsh-Yechezkel, G.; Lubin, F.; Sadetzki, S.] Gertner Inst, Canc & Radiat Epidemiol Unit, Tel Hashomer, Israel. [Peto, R.; Collins, R.; Doll, R.] Canc Res UK MRC BHF Clin Trial Serv Unit, Oxford, England. [Peto, R.; Collins, R.; Doll, R.] Epidemiol Studies Unit, Oxford, England. [Gonzalez, C. A.] Catalan Inst Oncol, Barcelona, Spain. [Marchbanks, P.; Lee, N.; Ory, H. W.; Peterson, H. B.; Wingo, P. A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Martin, N.; Pardthaisong, T.; Silpisornkosol, S.; Theetranont, C.] Chiang Mai Univ, Chiang Mai 50000, Thailand. [Boosiri, B.; Chutivongse, S.; Jimakorn, P.; Virutamasen, P.; Wongsrichanalai, C.] Chulalongkorn Univ, Bangkok, Thailand. [Tjonneland, A.] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark. [Titus-Ernstoff, L.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA. [Byers, T.] Colorado Sch Publ Hlth, Dept Epidemiol, Denver, CO USA. [Rohan, T.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Mosgaard, B. J.] Herlev Univ Hosp, Dept Obstet & Gynaecol, Copenhagen, Denmark. [Vessey, M.; Yeates, D.] Dept Publ Hlth, Oxford, England. [Freudenheim, J. L.] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA. [Chang-Claude, J.; Kaaks, R.] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany. [Anderson, K. E.; Folsom, A.; Robien, K.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA. [Rossing, M. A.; Thomas, D. B.; Weiss, N. S.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Riboli, E.] Univ London Imperial Coll Sci Technol & Med, London, England. [Clavel-Chapelon, F.] Paris S Univ, UMRS 1018, Inst Cancerol Gustave Roussy, Villejuif, France. [Clavel-Chapelon, F.] INSERM, U1018, Villejuif, France. [Cramer, D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Cambridge, MA 02138 USA. [Hankinson, S. E.; Tworoger, S. S.] Harvard Univ, Sch Med, Channing Lab Nurses Hlth Study, Cambridge, MA 02138 USA. [Franceschi, S.] Int Agcy Res Canc, F-69372 Lyon, France. [Negri, E.; La Vecchia, C.] Univ Milan, Ist Ric Farmacol Mario Negri, Milan, Italy. [Magnusson, C.; Riman, T.; Weiderpass, E.; Wolk, A.] Karolinska Inst, Stockholm, Sweden. [Schouten, L. J.; van den Brandt, P. A.] Maastricht Univ, Maastricht, Netherlands. [Chantarakul, N.; Koetsawang, S.; Rachawat, D.] Mahidol Univ, Bangkok 10700, Thailand. [Palli, D.] Canc Res & Prevent Inst, Mol & Nutr Epidemiol Unit, Florence, Italy. [Brinton, L.; Black, A.; de Gonzalez, A. Berrington; Freedman, D. M.; Hartge, P.; Hsing, A. W.; Lacey, J. V., Jr.; Hoover, R. N.; Schairer, C.] NCI, Bethesda, MD 20892 USA. [Graff-Iversen, S.; Selmer, R.] Norwegian Inst Publ Hlth, Oslo, Norway. [Bain, C. J.; Green, A. C.; Purdie, D. M.; Siskind, V.; Webb, P. M.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia. [Bain, C. J.; Green, A. C.; Purdie, D. M.; Siskind, V.; Webb, P. M.] Univ Queensland, Brisbane, Qld 4072, Australia. [McCann, S. E.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Hannaford, P.; Kay, C.] Royal Coll Gen Practitioners Oral Contracept Stud, London, England. [Binns, C. W.; Lee, A. H.; Zhang, M.] Curtin Univ Technol, Sch Publ Hlth, Perth, WA, Australia. [Ness, R. B.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [Nasca, P.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Boston, MA 02125 USA. [Coogan, P. F.; Palmer, J. R.; Rosenberg, L.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Kelsey, J.; Paffenbarger, R.; Whittemore, A.] Stanford Univ, Stanford, CA 94305 USA. [Katsouyanni, K.; Trichopoulou, A.; Trichopoulos, D.; Tzonou, A.] Univ Athens, Sch Med, GR-11527 Athens, Greece. [Dabancens, A.; Martinez, L.; Molina, R.; Salas, O.] Univ Chile, Santiago, Chile. [Goodman, M. T.; Lurie, G.; Carney, M. E.; Wilkens, L. R.] Univ Hawaii, Honolulu, HI 96822 USA. [Hartman, L.; Manjer, J.; Olsson, H.] Univ Hosp, Lund, Sweden. [Grisso, J. A.; Morgan, M.; Wheeler, J. E.] Univ Penn, Philadelphia, PA 19104 USA. [Peeters, P. H. M.] Univ Med Ctr Utrecht, Utrecht, Netherlands. [Casagrande, J.; Pike, M. C.; Ross, R. K.; Wu, A. H.] Univ So Calif, Los Angeles, CA USA. [Miller, A. B.] Univ Toronto, Toronto, ON, Canada. [Kumle, M.; Lund, E.] Univ Tromso, Tromso, Norway. [McGowan, L.] George Washington Univ, Washington, DC USA. [Shu, X. O.; Zheng, W.] Vanderbilt Univ, Nashville, TN USA. [Farley, T. M. M.; Holck, S.; Meirik, O.] WHO, UNDP, UNFPA, World Bank Special Programme Res Dev & Res Traini, CH-1211 Geneva, Switzerland. [Risch, H. A.] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA. RP Beral, V (reprint author), Canc Epidemiol Unit, Oxford, England. RI Brinton, Louise/G-7486-2015; Weiderpass, Elisabete/M-4029-2016; Schouten, Leo/G-3713-2012; Beral, Valerie/B-2979-2013; Binns, Colin/A-6012-2008; Negri, Eva/B-7244-2013; Webb, Penelope/D-5736-2013; Clavel-Chapelon, Francoise/G-6733-2014; Gonzalez, Carlos A/O-4651-2014 OI dal maso, luigino/0000-0001-6163-200X; La Vecchia, Carlo/0000-0003-1441-897X; PALLI, Domenico/0000-0002-5558-2437; Robien, Kim/0000-0002-2120-2280; Brinton, Louise/0000-0003-3853-8562; Weiderpass, Elisabete/0000-0003-2237-0128; Negri, Eva/0000-0001-9712-8526; Tworoger, Shelley/0000-0002-6986-7046; Magnusson, Cecilia/0000-0002-8567-6725; Webb, Penelope/0000-0003-0733-5930; Gonzalez, Carlos A/0000-0003-2822-9715 FU Cancer Research UK FX Funding for this collaborative reanalyis of original data was provided by Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 66 TC 5 Z9 5 U1 0 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD APR PY 2012 VL 9 IS 4 AR e1001200 DI 10.1371/journal.pmed.1001200 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 933VZ UT WOS:000303393800003 ER PT J AU Bloland, P Simone, P Burkholder, B Slutsker, L De Cock, KM AF Bloland, Peter Simone, Patricia Burkholder, Brent Slutsker, Laurence De Cock, Kevin M. TI The Role of Public Health Institutions in Global Health System Strengthening Efforts: The US CDC's Perspective SO PLOS MEDICINE LA English DT Editorial Material ID INTEGRATED MANAGEMENT; CHILDHOOD ILLNESS; EPIDEMIOLOGY; TANZANIA C1 [Bloland, Peter] Ctr Dis Control & Prevent, Div Publ Hlth Syst & Workforce Dev, Ctr Global Hlth, Atlanta, GA USA. [Burkholder, Brent] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. RP Bloland, P (reprint author), Ctr Dis Control & Prevent, Div Publ Hlth Syst & Workforce Dev, Ctr Global Hlth, Atlanta, GA USA. EM pbb1@cdc.gov NR 16 TC 17 Z9 17 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD APR PY 2012 VL 9 IS 4 AR e1001199 DI 10.1371/journal.pmed.1001199 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 933VZ UT WOS:000303393800002 PM 22509137 ER PT J AU Chen, WH Liu, YW Wang, HJ Hnizdo, E Sun, Y Su, LP Zhang, XK Weng, SF Bochmann, F Hearl, FJ Chen, JQ Wu, TC AF Chen, Weihong Liu, Yuewei Wang, Haijiao Hnizdo, Eva Sun, Yi Su, Liangping Zhang, Xiaokang Weng, Shaofan Bochmann, Frank Hearl, Frank J. Chen, Jingqiong Wu, Tangchun TI Long-Term Exposure to Silica Dust and Risk of Total and Cause-Specific Mortality in Chinese Workers: A Cohort Study SO PLOS MEDICINE LA English DT Article ID PARTICULATE AIR-POLLUTION; RESPIRABLE CRYSTALLINE SILICA; LUNG-CANCER; POTTERY WORKERS; UNITED-STATES; TIN MINERS; FOLLOW-UP; DISEASE; PARTICLES; INDUSTRY AB Background: Human exposure to silica dust is very common in both working and living environments. However, the potential long-term health effects have not been well established across different exposure situations. Methods and Findings: We studied 74,040 workers who worked at 29 metal mines and pottery factories in China for 1 y or more between January 1, 1960, and December 31, 1974, with follow-up until December 31, 2003 (median follow-up of 33 y). We estimated the cumulative silica dust exposure (CDE) for each worker by linking work history to a job-exposure matrix. We calculated standardized mortality ratios for underlying causes of death based on Chinese national mortality rates. Hazard ratios (HRs) for selected causes of death associated with CDE were estimated using the Cox proportional hazards model. The population attributable risks were estimated based on the prevalence of workers with silica dust exposure and HRs. The number of deaths attributable to silica dust exposure among Chinese workers was then calculated using the population attributable risk and the national mortality rate. We observed 19,516 deaths during 2,306,428 person-years of follow-up. Mortality from all causes was higher among workers exposed to silica dust than among non-exposed workers (993 versus 551 per 100,000 person-years). We observed significant positive exposure-response relationships between CDE (measured in milligrams/cubic meter-years, i.e., the sum of silica dust concentrations multiplied by the years of silica exposure) and mortality from all causes (HR 1.026, 95% confidence interval 1.023-1.029), respiratory diseases (1.069, 1.064-1.074), respiratory tuberculosis (1.065, 1.059-1.071), and cardiovascular disease (1.031, 1.025-1.036). Significantly elevated standardized mortality ratios were observed for all causes (1.06, 95% confidence interval 1.01-1.11), ischemic heart disease (1.65, 1.35-1.99), and pneumoconiosis (11.01, 7.67-14.95) among workers exposed to respirable silica concentrations equal to or lower than 0.1 mg/m(3). After adjustment for potential confounders, including smoking, silica dust exposure accounted for 15.2% of all deaths in this study. We estimated that 4.2% of deaths (231,104 cases) among Chinese workers were attributable to silica dust exposure. The limitations of this study included a lack of data on dietary patterns and leisure time physical activity, possible underestimation of silica dust exposure for individuals who worked at the mines/factories before 1950, and a small number of deaths (4.3%) where the cause of death was based on oral reports from relatives. Conclusions: Long-term silica dust exposure was associated with substantially increased mortality among Chinese workers. The increased risk was observed not only for deaths due to respiratory diseases and lung cancer, but also for deaths due to cardiovascular disease. C1 [Chen, Weihong; Liu, Yuewei; Wang, Haijiao; Weng, Shaofan; Chen, Jingqiong; Wu, Tangchun] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan 430074, Hubei, Peoples R China. [Chen, Weihong; Liu, Yuewei; Wu, Tangchun] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ Key Lab Environm & Hlth, Wuhan 430074, Hubei, Peoples R China. [Hnizdo, Eva; Hearl, Frank J.] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Sun, Yi; Bochmann, Frank] German Social Accid Insurance IFA, Inst Occupat Safety & Hlth, Dept Appl Epidemiol, St Augustin, Germany. [Su, Liangping] Wuhan Iron & Steel Corp, Daye Iron Mine Hosp, Huangshi, Hubei, Peoples R China. [Zhang, Xiaokang] Jingdezhen Hlth Bur, Jingdezhen, Jiangxi, Peoples R China. RP Chen, WH (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan 430074, Hubei, Peoples R China. EM wchen@mails.tjmu.edu.cn; wut@mails.tjmu.edu.cn RI Chen, Weihong/D-2177-2011; OI Chen, Weihong/0000-0001-8689-7311; Kaminski, Naftali/0000-0001-5917-4601 FU National Natural Scientific Foundation of China [30571553]; National Basic Research Program of China [2011CB503800]; Innovative Research Groups of the Natural Science Foundation of Hubei Province [2008CDA005]; Chinese Ministry of Health [1987-0792]; National Cancer Institute (USA); National Institute for Occupational Health and Safety (USA); German BG-Institute for Occupational Safety and Health [BIA1074] FX This research was supported by grants from the National Natural Scientific Foundation of China (30571553), National Basic Research Program of China (2011CB503800), Innovative Research Groups of the Natural Science Foundation of Hubei Province (2008CDA005), the Chinese Ministry of Health (1987-0792), the National Cancer Institute (USA, 1986), the National Institute for Occupational Health and Safety (USA, 1996), and the German BG-Institute for Occupational Safety and Health (BIA1074). The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the National Institute for Occupational Safety and Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 33 Z9 38 U1 4 U2 36 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD APR PY 2012 VL 9 IS 4 AR e1001206 DI 10.1371/journal.pmed.1001206 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 933VZ UT WOS:000303393800009 PM 22529751 ER PT J AU Sempos, CT Vesper, HW Phinney, KW Thienpont, LM Coates, PM AF Sempos, Christopher T. Vesper, Hubert W. Phinney, Karen W. Thienpont, Linda M. Coates, Paul M. CA VDSP TI Vitamin D status as an international issue: National surveys and the problem of standardization SO SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION LA English DT Article DE 25-hydroxyvitamin D; 3-epi-25-hydroxyvitamin D; Calibration; Commutability; CAP; DEQAS; Harmonization; NIST; CLSI; Standardization; Traceability ID TANDEM MASS-SPECTROMETRY; 25-HYDROXYVITAMIN D-3; HUMAN SERUM; ADULTS AB Wide spread variation in measurement results of total 25-hydroxyvitamin D (25(OH)D) confounds international efforts to develop evidence-based clinical guidelines. Accordingly, NIH Office of Dietary Supplements (ODS) in collaboration with CDC National Center for Environmental Health (NCEH), National Institute of Standards and Technology (NIST) and Ghent University established the Vitamin D Standardization Program (VDSP) in November 2010. VDSP objectives include: (1) standardize 25(OH)D concentration measurements in national health surveys around the world, (2) evaluate survey differences, (3) extend standardization efforts to assay manufacturers, and to clinical, commercial, and research laboratories, (4) promote standardization of emerging metabolites of vitamin D status, and (5) enable the use of standardized data in patient care and public health. An interlaboratory comparison study is being conducted to assess measurement variability among current assays. Participants include national health surveys from Australia, Canada, Germany, Ireland, Mexico, South Korea, UK and USA, 15 assay manufacturers, and two external quality assurance programs. CDC will implement a formal laboratory certification program. Standardization activities will use single-donor, fresh-frozen serum collected using the CLSI C37 protocol. Initial assay performance criteria, based on biological variability data, are <= 10 % imprecision and <= 5 % bias in relation to the reference values. An ancillary study on commutability of NIST SRM 972a, external quality assurance testing materials is included. To increase the comparability of existing data from different national surveys, master equations will be developed to facilitate the conversion of already existing national survey data to the NIST-Ghent University reference measurement procedures. C1 [Sempos, Christopher T.; Coates, Paul M.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Vesper, Hubert W.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Phinney, Karen W.] Natl Inst Stand & Technol, Div Analyt Chem, Gaithersburg, MD 20899 USA. [Thienpont, Linda M.] Univ Ghent, Fac Pharmaceut Sci, Analyt Chem Lab, B-9000 Ghent, Belgium. RP Sempos, CT (reprint author), NIH, Off Dietary Supplements, 6100 Execut Blvd,Rm 3B01, Bethesda, MD 20892 USA. EM semposch@mail.nih.gov; hvesper@cdc.gov RI Mensink, Gert/B-2447-2009; OI Mensink, Gert/0000-0001-6268-5998; Young, Ian/0000-0003-3890-3152; Van Uytfanghe, Katleen/0000-0001-8195-150X; Flynn, Albert/0000-0002-7072-4202 FU Medical Research Council [MC_U105960384, MC_U105960371] NR 28 TC 82 Z9 82 U1 0 U2 11 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0036-5513 J9 SCAND J CLIN LAB INV JI Scand. J. Clin. Lab. Invest. PD APR PY 2012 VL 72 SU 243 BP 32 EP 40 DI 10.3109/00365513.2012.681935 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 931VV UT WOS:000303248300006 PM 22536760 ER PT J AU Thienpont, LM Stepman, HCM Vesper, HW AF Thienpont, Linda M. Stepman, Hedwig C. M. Vesper, Hubert W. TI Standardization of measurements of 25-Hydroxyvitamin D3 and D2 SO SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION LA English DT Article DE Analytical performance goals; 3-epi-25-hydroxyvitamin D; total 25-hydroxyvitamin D; traceability; Vitamin D Standardization Program; VDSP; DEQAS ID TANDEM MASS-SPECTROMETRY; THYROID-FUNCTION TESTS; IFCC WORKING GROUP; VITAMIN-D STATUS; C-REACTIVE PROTEIN; HUMAN SERUM; D ASSAYS; C-3 EPIMERS; D-3; IMMUNOASSAYS AB The vitamin D status is increasingly assessed/monitored in different populations, research cohorts and individual patients. This is done by measuring the liver metabolites 25-hydroxyvitamin D3 and D2 as biomarkers. Recommendations for using specific serum concentrations of these biomarkers to assess a person's vitamin D status were done. This requires current vitamin D assays to be sufficiently accurate over time, location and laboratory procedures. In view of the fact that several studies demonstrated that current 25(OH)D measurement methods do not meet this prerequisite, standardization is needed. This paper rehearses the basic concept of standardization, in particular applied to measurements of 25-hydroxyvitamin D. Progress has been made by establishing a reference measurement system consisting of reference methods and reference materials. Coordinated efforts to improve the accuracy and standardize measurements are being performed by organizations such as the U.S. NIH, the CDC and Prevention, the NIST together with their national and international partners. Beyond describing the available reference measurement system and its use as calibration hierarchy to establish traceability of measurements with routine laboratory methods to the SI-unit, this report will also focus on other aspects considered essential for a successful and sustainable standardization, such as analytical issues related to the definition of the measurand and analytical performance goals. C1 [Thienpont, Linda M.; Stepman, Hedwig C. M.] Univ Ghent, Analyt Chem Lab, Fac Pharmaceut Sci, B-9000 Ghent, Belgium. [Vesper, Hubert W.] Ctr Dis Control & Prevent CDC, Div Sci Lab, Atlanta, GA 30341 USA. RP Thienpont, LM (reprint author), Univ Ghent, Analyt Chem Lab, Fac Pharmaceut Sci, Harelbekestr 72, B-9000 Ghent, Belgium. EM linda.thienpont@ugent.be NR 49 TC 28 Z9 30 U1 0 U2 5 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0036-5513 EI 1502-7686 J9 SCAND J CLIN LAB INV JI Scand. J. Clin. Lab. Invest. PD APR PY 2012 VL 72 SU 243 BP 41 EP 49 DI 10.3109/00365513.2012.681950 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 931VV UT WOS:000303248300007 PM 22536761 ER PT J AU Wheaton, AG Perry, GS Chapman, DP Croft, JB AF Wheaton, Anne G. Perry, Geraldine S. Chapman, Daniel P. Croft, Janet B. TI Sleep Disordered Breathing and Depression among US Adults: National Health and Nutrition Examination Survey, 2005-2008 SO SLEEP LA English DT Article DE Sleep disordered breathing; depression; obstructive sleep apnea ID POSITIVE AIRWAY PRESSURE; APNEA-HYPOPNEA SYNDROME; PSYCHOLOGICAL STATUS; DAYTIME SLEEPINESS; CPAP TREATMENT; ASSOCIATION; SYMPTOMS; CONSEQUENCES; MOOD; SYMPTOMATOLOGY AB Study Objective: To determine if symptoms of sleep disordered breathing (SDB) are associated with depression symptomology in a national sample. Design: National Health and Nutrition Examination Survey Setting: U. S., 2005-2008. Participants: 9,714 adults (>= 18 years) Measurements: Respondents were asked about frequency of snoring and snorting, gasping, or stopping breathing while asleep and completed the PHQ-9 (a 9-item depression screener). Odds ratios (OR) and 95% confidence intervals (CI) for SDB symptom-associated probable major depression (defined as a PHQ-9 score >= 10) were obtained from sex-specific logistic regression analyses adjusted for body mass index, age, race/ethnicity, and education. Results: Among men, 6.0% reported physician-diagnosed sleep apnea, 37.2% snored >= 5 nights/week, 7.1% snorted/stopped breathing >= 5 nights/week, and 5.0% had PHQ-9 scores >= 10. Among women, 3.1% reported sleep apnea, 22.4% snored >= 5 nights/week, 4.3% snorted/stopped breathing >= 5 nights/week, and 8.4% had PHQ-9 scores >= 10. Sleep apnea was associated with probable major depression (OR = 2.4; 95% CI: 1.5, 3.6 among men; OR = 5.2; 95% CI: 2.7, 9.9 among women). Snoring was not associated with depression symptoms in men or women. Snorting/stopping breathing = 5 nights/week compared to never was strongly associated with probable major depression in men (OR = 3.1; 95% CI: 1.8, 5.2) and women (OR = 3.0; 95% CI: 1.6, 5.4). Conclusion: Frequent snorting/stopping breathing was associated with probable major depression by the PHQ-9 in a national sample of adults. Additional research may be needed to determine whether regular screening for these conditions by mental health professionals and sleep specialists should be recommended. C1 [Wheaton, Anne G.; Perry, Geraldine S.; Chapman, Daniel P.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Wheaton, AG (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop K-67, Atlanta, GA 30341 USA. EM AWheaton@cdc.gov FU Association for Prevention Teaching and Research (APTR) [3U50CD300860]; Centers for Disease Control and Prevention (CDC) [3U50CD300860] FX Dr. Wheaton was supported through a cooperative agreement between the Association for Prevention Teaching and Research (APTR) and the Centers for Disease Control and Prevention (CDC), award number 3U50CD300860. NR 43 TC 26 Z9 27 U1 0 U2 6 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD APR 1 PY 2012 VL 35 IS 4 BP 461 EP 467 DI 10.5665/sleep.1724 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 930QO UT WOS:000303154400006 PM 22467983 ER PT J AU Turner, HA Finkelhor, D Ormrod, R Hamby, S Leeb, RT Mercy, JA Holt, M AF Turner, Heather A. Finkelhor, David Ormrod, Richard Hamby, Sherry Leeb, Rebecca T. Mercy, James A. Holt, Melissa TI Family Context, Victimization, and Child Trauma Symptoms: Variations in Safe, Stable, and Nurturing Relationships During Early and Middle Childhood SO AMERICAN JOURNAL OF ORTHOPSYCHIATRY LA English DT Article DE children; family relationships; violence exposure; childhood victimization; child trauma; child abuse; safe; stable; and nurturing relationships ID SCHOOL-AGE-CHILDREN; TELEPHONE SURVEY; PARENTING PRACTICES; HOUSEHOLD DYSFUNCTION; POLY-VICTIMIZATION; NONRESPONSE BIAS; ABUSE; RISK; MALTREATMENT; BEHAVIOR AB Based on a nationally representative sample of 2,017 children age 29 years, this study examines variations in safe, stable, and nurturing relationships (SSNRs), including several forms of family perpetrated victimization, and documents associations between these factors and child trauma symptoms. Findings show that many children were exposed to multiple forms of victimization within the family (such as physical or sexual abuse, emotional maltreatment, child neglect, sibling victimization, and witnessing family violence), as evidenced by substantial intercorrelations among the different forms of victimization. Moreover, victimization exposure was significantly associated with several indices of parental dysfunction, family adversity, residential instability, and problematic parenting practices. Of all SSNR variables considered, emotional abuse and inconsistent or hostile parenting emerged as having the most powerful independent effects on child trauma symptoms. Also, findings supported a cumulative risk model, whereby trauma symptom levels increased with each additional SSNR risk factor to which children were exposed. Implications for research and practice are discussed. C1 [Turner, Heather A.] Univ New Hampshire, Crimes Children Res Ctr, Horton Social Sci Ctr 126, Durham, NH 03824 USA. [Hamby, Sherry] Univ South, Sewanee, TN 37375 USA. [Leeb, Rebecca T.; Mercy, James A.; Holt, Melissa] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Turner, HA (reprint author), Univ New Hampshire, Crimes Children Res Ctr, Horton Social Sci Ctr 126, 20 Acad Way, Durham, NH 03824 USA. EM heather.turner@unh.edu FU federal sources; Office of Juvenile Justice and Delinquency Prevention, Office of Justice Programs, U.S. Department of Justice [2006-JW-BX-0003] FX In compliance with Section 507 of PL 104-208 (Stevens amendment), readers are advised that 100% of the funds for this program are derived from federal sources. This project was supported by grant 2006-JW-BX-0003 awarded by the Office of Juvenile Justice and Delinquency Prevention, Office of Justice Programs, U.S. Department of Justice. The total amount of federal funding is $2,848,809. Points of view or opinions in this article are those of the authors and do not necessarily represent the official position or policies of the U.S. Department of Justice or of the Centers for Disease Control and Prevention. NR 80 TC 22 Z9 22 U1 3 U2 18 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-9432 J9 AM J ORTHOPSYCHIAT JI Am. J. Orthopsychiatr. PD APR PY 2012 VL 82 IS 2 BP 209 EP 219 DI 10.1111/j.1939-0025.2012.01147.x PG 11 WC Psychiatry; Social Work SC Psychiatry; Social Work GA 926YI UT WOS:000302868700007 PM 22506523 ER PT J AU Laney, AS Tramma, S Petsonk, EL Attfield, MD AF Laney, A. S. Tramma, S. Petsonk, E. L. Attfield, M. D. TI The association between tobacco burden and "dirty chest'' is unlikely to follow a linear dose-response pattern SO BRITISH JOURNAL OF RADIOLOGY LA English DT Letter ID SMALL IRREGULAR OPACITIES; CIGARETTE-SMOKING; PNEUMOCONIOSIS; CLASSIFICATION; POPULATION; PREVALENCE C1 [Laney, A. S.; Tramma, S.; Petsonk, E. L.; Attfield, M. D.] Ctr Dis Control & Prevent, Surveillance Branch, Div Resp Dis Studies, NIOSH, Morgantown, WV 26505 USA. RP Laney, AS (reprint author), Ctr Dis Control & Prevent, Surveillance Branch, Div Resp Dis Studies, NIOSH, 1095 Willowdale Rd,Mail Stop HG900-2, Morgantown, WV 26505 USA. EM alaney@cdc.gov NR 15 TC 2 Z9 2 U1 0 U2 0 PU BRITISH INST RADIOLOGY PI LONDON PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND SN 0007-1285 J9 BRIT J RADIOL JI Br. J. Radiol. PD APR PY 2012 VL 85 IS 1012 BP 470 EP 471 DI 10.1259/bjr/27455728 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 916XV UT WOS:000302137400033 PM 22457407 ER PT J AU Soucie, JM AF Soucie, J. Michael TI Public health surveillance and data collection: general principles and impact on hemophilia care SO HEMATOLOGY LA English DT Article DE Surveillance; Data collection; Hemophilia; Comprehensive care; Public health ID RISK-FACTORS; MALES; DISORDERS; DISEASE; SYSTEM AB Public health surveillance is the ongoing collection, analysis, and dissemination of health related data to provide information that can be used to monitor and improve the health of populations. Such surveillance systems can be established in many settings to study a variety of populations and conditions. The most effective systems are designed around specific, well-defined objectives, collect data in a standardized fashion, analyze the data frequently, and disseminate the results to those who need to know the information. Surveillance has been used to determine the occurrence rates of hemophilia and to characterize the population affected by this rare but potentially serious congenital disorder. Data from surveillance systems have been used to identify risk factors for complications that, once identified, have been modified through public health interventions. The effectiveness of these interventions can be assessed by continued surveillance, thereby assuring improvement in care of people affected by hemophilia around the world. C1 Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Soucie, JM (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E64, Atlanta, GA 30333 USA. EM msoucie@cdc.gov FU Intramural CDC HHS [CC999999] NR 17 TC 2 Z9 2 U1 0 U2 2 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1024-5332 J9 HEMATOLOGY JI Hematology PD APR PY 2012 VL 17 SU 1 BP S144 EP S146 DI 10.1179/102453312X13336169156537 PG 3 WC Hematology SC Hematology GA 927OA UT WOS:000302916200040 PM 22507804 ER PT J AU Kay, MK Cartwright, EJ MacEachern, D McCullough, J Barzilay, E Mintz, E Duchin, JS MacDonald, K Turnsek, M Tarr, C Talkington, D Newton, A Marfin, AA AF Kay, Meagan K. Cartwright, Emily J. MacEachern, Dorothy McCullough, Joel Barzilay, Ezra Mintz, Eric Duchin, Jeffrey S. MacDonald, Kathryn Turnsek, Maryann Tarr, Cheryl Talkington, Deborah Newton, Anna Marfin, Anthony A. TI Vibrio mimicus Infection Associated with Crayfish Consumption, Spokane, Washington, 2010 SO JOURNAL OF FOOD PROTECTION LA English DT Article ID CHOLERAE STRAINS; PCR ASSAY AB We report a cluster of severe diarrheal disease caused by Vibrio mimicus infection among four persons who had consumed leftover crayfish the day after a private crayfish boil. Gastrointestinal illness caused by Vibrio mimicus has not been reported previously in Washington State. Three cases were laboratory confirmed by stool culture; using PCR, isolates were found to have ctx genes that encode cholera toxin (CT). Two of the cases were hospitalized under intensive care with a cholera-like illness. The illnesses were most likely caused by cross-contamination of cooked crayfish with uncooked crayfish; however, V. minuet's was not isolated nor were CT genes detected by PCR in leftover samples of frozen crayfish. Clinicians should be aware that V. mimicus can produce CT and that V. mimicus infection can cause severe illness. C1 [Kay, Meagan K.; Cartwright, Emily J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Atlanta, GA 30333 USA. [Kay, Meagan K.; Duchin, Jeffrey S.] Publ Hlth Seattle & King Co, Seattle, WA 98104 USA. [MacEachern, Dorothy; McCullough, Joel] Spokane Reg Hlth Dist, Spokane, WA 99201 USA. [MacDonald, Kathryn; Marfin, Anthony A.] Washington State Dept Hlth, Shoreline, WA 98155 USA. RP Kay, MK (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM meagan.kay@kingcounty.gov NR 11 TC 3 Z9 4 U1 4 U2 8 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X J9 J FOOD PROTECT JI J. Food Prot. PD APR PY 2012 VL 75 IS 4 BP 762 EP 764 DI 10.4315/0362-028X.JFP-11-410 PG 3 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 925IQ UT WOS:000302755300023 PM 22488068 ER PT J AU Nayak, AP Green, BJ Friend, S Beezhold, DH AF Nayak, Ajay P. Green, Brett J. Friend, Sherri Beezhold, Donald H. TI Development of monoclonal antibodies to recombinant terrelysin and characterization of expression in Aspergillus terreus SO JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Article ID MUSHROOM PLEUROTUS-OSTREATUS; LIPOPROTEIN-BINDING PROTEIN; ASP-HEMOLYSIN; STACHYBOTRYS-CHARTARUM; CYTOLYTIC PROTEIN; ESCHERICHIA-COLI; OTITIS-MEDIA; OSTREOLYSIN; FUMIGATUS; LOCALIZATION AB Aspergillus terreus is an emerging pathogen that mostly affects immunocompromised patients, causing infections that are often difficult to manage therapeutically. Current diagnostic strategies are limited to the detection of fungal growth using radiological methods or biopsy, which often does not enable species-specific identification. There is thus a critical need for diagnostic techniques to enable early and specific identification of the causative agent. In this study, we describe monoclonal antibodies (mAbs) developed to a previously described recombinant form of the haemolysin terrelysin. Sixteen hybridomas of various IgG isotypes were generated to the recombinant protein, of which seven demonstrated reactivity to the native protein in hyphal extracts. Cross-reactivity analysis using hyphal extracts from 29 fungal species, including 12 Aspergillus species and five strains of A. terreus, showed that three mAbs (13G10, 15B5 and 10G4) were A. terreus-specific. Epitope analysis demonstrated mAbs 13G10 and 10G4 recognize the same epitope, PSNEFE, while mAb 15B5 recognizes the epitope LYEGQFHS. Time-course studies showed that terrelysin expression was highest during early hyphal growth and dramatically decreased after mycelial expansion. Immunolocalization studies demonstrated that terrelysin was not only localized within the cytoplasm of hyphae but appeared to be more abundant at the hyphal tip. These findings were confirmed in cultures grown at room temperature as well as at 37 degrees C. Additionally, terrelysin was detected in the supernatant of A. terreus cultures. These observations suggest that terrelysin may be a candidate biomarker for A. terreus infection. C1 [Nayak, Ajay P.; Green, Brett J.; Beezhold, Donald H.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Nayak, Ajay P.] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26505 USA. [Friend, Sherri] NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Nayak, AP (reprint author), NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. EM fyg1@cdc.gov FU National Institute of Environmental Health Sciences [YI-ES0001-06] FX The findings and the conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. This work was supported in part by an InterAgency agreement with the National Institute of Environmental Health Sciences (YI-ES0001-06). NR 51 TC 4 Z9 7 U1 0 U2 3 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-2615 J9 J MED MICROBIOL JI J. Med. Microbiol. PD APR PY 2012 VL 61 IS 4 BP 489 EP 499 DI 10.1099/jmm.0.039511-0 PG 11 WC Microbiology SC Microbiology GA 927CJ UT WOS:000302884300005 PM 22160315 ER PT J AU Narciso, HE Pathela, P Morgenthau, BM Kansagra, SM May, L Scaccia, A Zucker, JR AF Narciso, Heather E. Pathela, Preeti Morgenthau, Beth Maldin Kansagra, Susan M. May, Linda Scaccia, Allison Zucker, Jane R. TI Description of a Large Urban School-Located 2009 Pandemic H1N1 Vaccination Campaign, New York City 2009-2010 SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE H1N1 influenza; Vaccination; Elementary schoolchildren ID INFLUENZA VACCINATION; CHILDREN; IMMUNIZATION; ADULTS; IMPACT AB In the spring of 2009, New York City (NYC) experienced the emergence and rapid spread of pandemic influenza A H1N1 virus (pH1N1), which had a high attack rate in children and caused many school closures. During the 2009 fall wave of pH1N1, a school-located vaccination campaign for elementary schoolchildren was conducted in order to reduce infection and transmission in the school setting, thereby reducing the impact of pH1N1 that was observed earlier in the year. In this paper, we describe the planning and outcomes of the NYC school-located vaccination campaign. We compared consent and vaccination data for three vaccination models (school nurse alone, school nurse plus contract nurse, team). Overall, > 1,200 of almost 1,600 eligible schools participated, achieving 26.8% consent and 21.5% first-dose vaccination rates, which did not vary significantly by vaccination model. A total of 189,902 doses were administered during two vaccination rounds to 115,668 students at 998 schools included in the analysis; vaccination rates varied by borough, school type, and poverty level. The team model achieved vaccination of more children per day and required fewer vaccination days per school. NYC's campaign is the largest described school-located influenza vaccination campaign to date. Despite substantial challenges, school-located vaccination is feasible in large, urban settings, and during a public health emergency. C1 [Pathela, Preeti; Morgenthau, Beth Maldin; Kansagra, Susan M.; Scaccia, Allison; Zucker, Jane R.] New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA. [Narciso, Heather E.] Univ Utah, Sch Med, Salt Lake City, UT USA. [May, Linda] New York City Off Adm Trials & Hearings, New York, NY USA. [Zucker, Jane R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Zucker, JR (reprint author), New York City Dept Hlth & Mental Hyg, 42-09 28th St,WS 5-97, Queens, NY 11101 USA. EM jzucker@health.nyc.gov FU Centers for Disease Control and Prevention [5U90TP221298-08, CDC-RFA-TP09-902-H1N109] FX This publication was supported by the Public Health Emergency Preparedness (PHEP) Cooperative Agreement (grant number: 5U90TP221298-08) and the Public Health Emergency Response Grant (funding opportunity number: CDC-RFA-TP09-902-H1N109) from the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC. NR 21 TC 3 Z9 3 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD APR PY 2012 VL 89 IS 2 BP 317 EP 328 DI 10.1007/s11524-011-9640-z PG 12 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 925HQ UT WOS:000302752300009 PM 22318374 ER PT J AU France, AM Bornschlegel, K Lazaroff, J Kennedy, J Balter, S AF France, Anne Marie Bornschlegel, Katherine Lazaroff, Julie Kennedy, Joseph Balter, Sharon TI Estimating the Prevalence of Chronic Hepatitis B Virus Infection-New York City, 2008 SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE Hepatitis B; Chronic; Prevalence; New York City ID UNITED-STATES AB Chronic hepatitis B virus (HBV) infection is a preventable cause of liver failure, cirrhosis, and liver cancer; estimated chronic HBV infection prevalence is 0.3-0.5% in the USA. Prevalence in New York City (NYC) is likely higher because foreign-born persons, who represent 36% of NYC's population versus 11% nationwide, bear a disproportionate burden of chronic HBV infection. However, because no comprehensive, population-based survey of chronic HBV infection has been conducted in NYC, a reliable prevalence estimate is unavailable. We used two approaches to estimate chronic HBV infection prevalence in NYC: (1) a census-based estimate, combining local and national prevalence data for specific populations, and (2) a surveillance-based estimate, using data from NYC's Department of Health and Mental Hygiene Hepatitis B Surveillance Registry and adjusting for out-migration and deaths. Results from both the census-based estimate and the surveillance-based estimate were similar, with an estimated prevalence of chronic HBV in NYC of 1.2%. This estimate is two to four times the estimated prevalence for the USA as a whole. According to the census-based estimate, > 93% of all cases in NYC are among persons who are foreign-born, and approximately half of those are among persons born in China. These findings underscore the importance of local data for tailoring programmatic efforts to specific foreign-born populations in NYC. In particular, Chinese-language programs and health education materials are critical. Reliable estimates are important for policymakers in local jurisdictions to better understand their own population's needs and can help target primary care services, prevention materials, and education. C1 [France, Anne Marie] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [France, Anne Marie] Off Workforce & Career Dev, Epidem Intelligence Serv, Atlanta, GA USA. [France, Anne Marie; Bornschlegel, Katherine; Lazaroff, Julie; Kennedy, Joseph; Balter, Sharon] New York City Dept Hlth & Mental Hyg, New York, NY USA. RP France, AM (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. EM hgj6@cdc.gov FU Centers for Disease Control and Prevention Emerging Infections Program FX This study was made possible in part by funding from the Centers for Disease Control and Prevention Emerging Infections Program. NR 17 TC 12 Z9 12 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD APR PY 2012 VL 89 IS 2 BP 373 EP 383 DI 10.1007/s11524-011-9653-7 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 925HQ UT WOS:000302752300014 PM 22246675 ER PT J AU Palma, RE Polop, JJ Owen, RD Mills, JN AF Palma, R. Eduardo Polop, Jaime J. Owen, Robert D. Mills, James N. TI ECOLOGY OF RODENT-ASSOCIATED HANTAVIRUSES IN THE SOUTHERN CONE OF SOUTH AMERICA: ARGENTINA, CHILE, PARAGUAY, AND URUGUAY SO JOURNAL OF WILDLIFE DISEASES LA English DT Review DE Argentina; Chile; ecology; hantavirus; host; Paraguay; rodents; Uruguay ID GENUS OLIGORYZOMYS RODENTIA; SOUTHWESTERN UNITED-STATES; TO-PERSON TRANSMISSION; 5 SIGMODONTINE RODENTS; LAGUNA NEGRA VIRUS; SIN-NOMBRE-VIRUS; PULMONARY SYNDROME; ANDES-VIRUS; SMALL MAMMALS; PHYLOGENETIC-RELATIONSHIPS AB Thirteen hantavirus genotypes, associated with at least 12 sigmodontine reservoir rodents, have been recognized in the four countries that represent the Southern Cone of South America. Host-virus relationships are not as well defined as in North America; several Southern Cone hantaviruses appear to share a common host and some viruses do not occur throughout the range of their host. Although hantavirus-host relationships in the Southern Cone are less strictly concordant with the single-host-single-virus pattern reported elsewhere, recent studies suggest that much of the ambiguity may result from an incomplete understanding of host and hantavirus systematics. Although some Southern Cone host species are habitat generalists, some sympatric species are habitat specialists, helping to explain bow some strict host-virus pairings may be maintained. In some cases, host population densities were higher in peridomestic habitats and prevalence of hantavirus infection was higher in host populations in peridomestic habitats. Seasonal and multiyear patterns in climate and human disturbance affect host population densities, prevalence of infection, and disease risk to humans. Unusually high hantavirus antibody prevalence in indigenous human populations may be associated with frequent and close contact with host rodents. Ongoing studies are improving our understanding of hantavirus-host ecology and providing tools that may predict human risk. C1 [Palma, R. Eduardo] Pontificia Univ Catolica Chile, Dept Ecol, CASEB, Santiago 6513677, Chile. [Palma, R. Eduardo] Pontificia Univ Catolica Chile, Ctr Estudios Avanzados Ecol & Biodiversidad, CASEB, Santiago 6513677, Chile. [Polop, Jaime J.] Univ Nacl Rio Cuarto, Dept Ciencias Nat, RA-5800 Cordoba, Argentina. [Owen, Robert D.] Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA. [Mills, James N.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Palma, RE (reprint author), Pontificia Univ Catolica Chile, Dept Ecol, CASEB, Alameda 340, Santiago 6513677, Chile. EM epalma@bio.puc.cl RI Palma, Eduardo/N-1416-2014 FU NIH [AI-45452]; Fondecyt-CASEB [1501-0001]; Fondecyt [1070331]; Fundacion Mundo Sano; Agencia Nacional de Investigaciones Cientificas y Tecnicas (FONCYT); National Institutes of Health (NIH) Fogarty International Center as part of the National Science Foundation [R01 TW006-986-01] FX We thank C. Jonsson, D. Goodin, L. Allen, and Y.-K. Chu for comments on the manuscript. S. Belmar and R. Cancino collaborated with the manuscript editing. Our research was funded by: NIH grant "Hantavirus ecology and disease Chile-Panama" ICIDR-NIH (AI-45452), Fondecyt-CASEB 1501-0001 (to REP), Fondecyt 1070331, Fundacion Mundo Sano and Agencia Nacional de Investigaciones Cientificas y Tecnicas (FONCYT; to JJP); National Institutes of Health (NIH) Fogarty International Center grant R01 TW006-986-01 (to C. Jonsson, RDO, and others), as part of the National Science Foundation/NIH Ecology of Infectious Diseases Program. Special thanks to Craig Manning for many hours of hard work in preparing the figure. NR 86 TC 17 Z9 18 U1 1 U2 12 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD APR PY 2012 VL 48 IS 2 BP 267 EP 281 PG 15 WC Veterinary Sciences SC Veterinary Sciences GA 922ZZ UT WOS:000302589000002 PM 22493103 ER PT J AU Ellis, CK Carroll, DS Lash, RR Peterson, AT Damon, IK Malekani, J Formenty, P AF Ellis, Christine K. Carroll, Darin S. Lash, Ryan R. Peterson, A. Townsend Damon, Inger K. Malekani, Jean Formenty, Pierre TI ECOLOGY AND GEOGRAPHY OF HUMAN MONKEYPDX CASE OCCURRENCES ACROSS AFRICA SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Ecologic niche modeling; epidemiology; georeferencing; monkeypox; point-radius method ID SPECIES DISTRIBUTIONS; CONGO BASIN; NICHE; VIRUS; DISEASE; TRANSMISSION; PREDICTION AB As ecologic niche modeling (ENM) evolves as a tool in spatial epidemiology and public health, selection of the most appropriate and informative environmental data sets becomes increasingly important. Here, we build on a previous ENM analysis of the potential distribution of human monkeypox in Africa by refining georeferencing criteria and using more-diverse environmental data to identify environmental parameters contributing to monkeypox distributional ecology. Significant environmental variables include annual precipitation, several temperature-related variables, primal), productivity, evapotranspiration, soil moisture, and pH. The potential distribution identified with this set of variables was broader than that identified in previous analyses but does not include areas recently found to hold monkeypox in southern Sudan. Our results emphasize the importance of selecting the most appropriate and informative environmental data sets for ENM analyses in pathogen transmission mapping. C1 [Peterson, A. Townsend] Univ Kansas, Biodivers Inst, Lawrence, KS 66045 USA. [Ellis, Christine K.] Wildlife Serv, USDA, Anim & Plant Hlth Inspect Serv, Natl Wildlife Res Ctr, Ft Collins, CO 80521 USA. [Carroll, Darin S.; Lash, Ryan R.; Damon, Inger K.] US Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30329 USA. [Malekani, Jean] Univ Kinshasa, Dept Biol, Kinshasa, Zaire. [Formenty, Pierre] WHO, CH-1202 Geneva, Switzerland. RP Peterson, AT (reprint author), Univ Kansas, Biodivers Inst, Lawrence, KS 66045 USA. EM town@ku.edu RI Lash, R. Ryan/E-4115-2013; Peterson, A. Townsend/I-5697-2013 OI Peterson, A. Townsend/0000-0003-0243-2379 NR 52 TC 13 Z9 13 U1 0 U2 2 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD APR PY 2012 VL 48 IS 2 BP 335 EP 347 PG 13 WC Veterinary Sciences SC Veterinary Sciences GA 922ZZ UT WOS:000302589000008 PM 22493109 ER PT J AU Loehman, RA Elias, J Douglass, RJ Kuenzi, AJ Mills, JN Wagoner, K AF Loehman, Rachel A. Elias, Joran Douglass, Richard J. Kuenzi, Amy J. Mills, James N. Wagoner, Kent TI PREDICTION OF PEROMYSCUS MANICULATUS (DEER MOUSE) POPULATION DYNAMICS IN MONTANA, USA, USING SATELLITE-DRIVEN VEGETATION PRODUCTIVITY AND WEATHER DATA SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Deer mice; hantavirus; MODIS; Peromyscus; prediction; satellites; trophic cascade ID SIN-NOMBRE-VIRUS; HANTAVIRUS-PULMONARY-SYNDROME; SOUTHWESTERN UNITED-STATES; GROSS PRIMARY PRODUCTION; NET PRIMARY PRODUCTION; CLIMATE-CHANGE; LONG-TERM; GENETIC IDENTIFICATION; RESERVOIR POPULATIONS; MICE AB Deer mice (Peromyscus maniculatus) are the main reservoir host for Sin Nombre virus, the primal), etiologic agent of hantavirus pulmonary syndrome in North America. Sequential changes in weather and plant productivity (trophic cascades) have been noted as likely catalysts of deer mouse population irruptions, and monitoring and modeling of these phenomena may allow for development of early-warning systems for disease risk. Relationships among weather variables, satellite-derived vegetation productivity, and deer mouse populations were examined for a grassland site east oldie Continental Divide and a sage-steppe site west of the Continental Divide in Montana, USA. We acquired monthly deer mouse population data for mid-1994 through 2007 from long-term study sites maintained for monitoring changes in hantavirus reservoir populations, and we compared these with monthly bioclimatology data from the same period and gross primary productivity data from the Moderate Resolution Imaging Spectroradiometer sensor for 2000-06. We used the Random Forests statistical learning technique to fit a series of predictive models based on temperature, precipitation, and vegetation productivity variables. Although we attempted several iterations of models, including incorporating lag effects and classifying rodent density by seasonal thresholds, our results showed no ability to predict rodent populations using vegetation productivity or weather data. We concluded that trophic cascade connections to rodent population levels may be weaker than originally supposed, may be specific to only certain climatic regions, or may not be detectable using remotely sensed vegetation productivity measures, although weather patterns and vegetation dynamics were positively correlated. C1 [Loehman, Rachel A.] US Forest Serv, Rocky Mt Res Stn Fire Sci Lab, Missoula, MT 59808 USA. [Elias, Joran] Univ Montana, Dept Math Sci, Missoula, MT 59801 USA. [Douglass, Richard J.; Kuenzi, Amy J.] Univ Montana, Dept Biol, Butte, MT 59701 USA. [Mills, James N.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathogenesis, Atlanta, GA 30333 USA. [Wagoner, Kent] Univ Tennessee, Off Inst Res & Assessment, Knoxville, TN 37996 USA. RP Loehman, RA (reprint author), US Forest Serv, Rocky Mt Res Stn Fire Sci Lab, 5775 W US Hwy 10, Missoula, MT 59808 USA. EM raloehman@fs.fed.us FU U.S. Centers for Disease Control [US3/CCU813599-07]; NTH from the INBRE-BRIN of the National Center for Research Resources [P20 RR16455-04]; NASA Headquarters [NGT5]; Numerical Terradynamic Simulation Group, University of Montana FX Funding for this project was from the U.S. Centers for Disease Control through Cooperative Agreement US3/CCU813599-07. Additional support for manuscript preparation was provided by NTH Grant P20 RR16455-04 from the INBRE-BRIN Program of the National Center for Research Resources. Further support for this research was provided by NASA Headquarters under Earth System Science Fellowship Grant NGT5. We thank Bill Semmens, Kevin Hughes, and Brent Lonner for making this work possible through their longitudinal data collection and processing; Faith Ann Heinsch and Qiaozhen Mu for assistance with acquiring and processing MODIS data; and the students and staff of the Numerical Terradynamic Simulation Group, University of Montana, for their support. NR 58 TC 8 Z9 8 U1 3 U2 31 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD APR PY 2012 VL 48 IS 2 BP 348 EP 360 PG 13 WC Veterinary Sciences SC Veterinary Sciences GA 922ZZ UT WOS:000302589000009 PM 22493110 ER PT J AU Boneva, RS Xu, SL Lin, JMS Haber, M Unger, E AF Boneva, Roumiana S. Xu, Songli Lin, Jin-Mann S. Haber, Micahel Unger, Elizabeth TI Hormonal Profiles of Women with Chronic Fatigue Syndrome Differ from those of Controls SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Boneva, Roumiana S.; Lin, Jin-Mann S.; Unger, Elizabeth] Ctr Dis Control & Prevent CDC, NCEZID, Atlanta, GA USA. [Xu, Songli] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Haber, Micahel] Emory Univ, Dept Biostat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2012 VL 21 IS 4 MA P31 BP 13 EP 13 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 926UE UT WOS:000302856600032 ER PT J AU Stanley, S Arriola, KJ Smith, S Hurlbert, M Ricci, C Escoffery, C AF Stanley, Sandte Arriola, Kimberly Jacob Smith, Shakiyla Hurlbert, Marc Ricci, Carolyn Escoffery, Cam TI An Inventory of Avon Foundation for Women Breast Cancer Patient Navigation Programs SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Stanley, Sandte] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Stanley, Sandte; Arriola, Kimberly Jacob; Smith, Shakiyla; Escoffery, Cam] Emory Univ, Atlanta, GA 30322 USA. [Hurlbert, Marc; Ricci, Carolyn] Avon Fdn Women, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2012 VL 21 IS 4 MA P85 BP 33 EP 33 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 926UE UT WOS:000302856600086 ER PT J AU Gelb, CA Polonec, L Chu, J Wayman, JJC Grella, LW AF Gelb, Cynthia A. Polonec, Lindsey Chu, Jennifer Wayman, Jennifer J. Clay Grella, Lauren Wine TI Common Beliefs and Misconceptions About Gynecologic Cancer: A Qualitative Study of US Women SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Gelb, Cynthia A.; Polonec, Lindsey] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Chu, Jennifer; Wayman, Jennifer J. Clay; Grella, Lauren Wine] Ogilvy Washington, Social Mkt, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2012 VL 21 IS 4 MA P97 BP 37 EP 38 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 926UE UT WOS:000302856600098 ER PT J AU Vaid, IG Wignington, C Borbely, D Manheim, D Cook, J AF Vaid, Isam G. Wignington, Charles Borbely, Deborah Manheim, Diane Cook, Jeffery TI The WISEWOMAN Program's Focus on Women at High Risk for Cardiovascular Disease: Individuals, Clinical Care Systems, and Community Partnerships SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Vaid, Isam G.; Wignington, Charles; Borbely, Deborah; Manheim, Diane; Cook, Jeffery] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Chamblee, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2012 VL 21 IS 4 MA P134 BP 51 EP 51 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 926UE UT WOS:000302856600135 ER PT J AU Cooper, CP Polonec, L Chu, J Wayman, JJC Grella, LW Gelb, CA AF Cooper, Crystale Purvis Polonec, Lindsey Chu, Jennifer Wayman, Jennifer J. Clay Grella, Lauren Wine Gelb, Cynthia A. TI Care Seeking for Gynecologic Cancer Symptoms SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Cooper, Crystale Purvis] Soltera Ctr Canc Prent & Control, Oro Valley, AZ USA. [Polonec, Lindsey; Gelb, Cynthia A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Chu, Jennifer; Wayman, Jennifer J. Clay; Grella, Lauren Wine] Ogilvy Washington, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2012 VL 21 IS 4 MA P142 BP 54 EP 54 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 926UE UT WOS:000302856600143 ER PT J AU Jim, CC Lee, JWY Groom, AV Espey, DK Saraiya, M Holve, S Bullock, A Howe, J Thierry, J AF Jim, Cheyenne C. Lee, Jennifer Wai-Yin Groom, Amy V. Espey, David K. Saraiya, Mona Holve, Steve Bullock, Ann Howe, Jean Thierry, Judith TI Human Papillomavirus Vaccination Practices Among Providers in Indian Health Service, Tribal and Urban Indian Healthcare Facilities SO JOURNAL OF WOMENS HEALTH LA English DT Article ID UNITED-STATES; AMERICAN-INDIANS; ALASKA-NATIVES; ATTITUDES; KNOWLEDGE; RISK; IMMUNIZATION; TRIALS AB Purpose: The human papillomavirus (HPV) vaccine is of particular importance in American Indian/Alaska Native women because of the higher rate of cervical cancer incidence compared to non-Hispanic white women. To better understand HPV vaccine knowledge, attitudes, and practices among providers working with American Indian/Alaska Native populations, we conducted a provider survey in Indian Health Service, Tribal and Urban Indian (I/T/U) facilities. Methods: During December 2009 and January 2010, we distributed an on-line survey to providers working in I/T/U facilities. We also conducted semistructured interviews with a subset of providers. Results: There were 268 surveys and 51 provider interviews completed. Providers were more likely to administer vaccine to 13-18-year-olds (96%) than to other recommended age groups (89% to 11-12-year-olds and 64% to 19-26-year-olds). Perceived barriers to HPV vaccination for 9-18-year-olds included parental safety and moral/religious concerns. Funding was the main barrier for 19-26-year-olds. Overall, providers were very knowledgeable about HPV, although nearly half of all providers and most obstetricians/gynecologists thought that a pregnancy test should precede vaccination. Sixty-four percent of providers of patients receiving the vaccine do not routinely discuss the importance of cervical cancer screening. Conclusions: Recommendations for HPV vaccination have been broadly implemented in I/T/U settings. Vaccination barriers identified by I/T/U providers are similar to those reported in other provider surveys. Provider education efforts should stress that pregnancy testing is not needed before vaccination and the importance of communicating the need for continued cervical cancer screening. C1 [Jim, Cheyenne C.; Groom, Amy V.] Ctr Dis Control & Prevent, Immunizat Serv Div, Program Operat Branch, Albuquerque, NM 87110 USA. [Lee, Jennifer Wai-Yin; Espey, David K.; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA USA. [Holve, Steve] Tuba City Reg Hlth Corp, Indian Hlth Serv, Tuba City, AZ USA. [Bullock, Ann] Cherokee Hosp, Indian Hlth Serv, Cherokee, NC USA. [Howe, Jean] No Navajo Med Ctr, Indian Hlth Serv, Shiprock, NM USA. [Thierry, Judith] Indian Hlth Serv, Off Clin & Prevent Serv, Rockville, MD USA. RP Jim, CC (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Program Operat Branch, 5300 Homestead Rd NE, Albuquerque, NM 87110 USA. EM cheyenne.jim@ihs.gov NR 27 TC 8 Z9 8 U1 2 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2012 VL 21 IS 4 BP 372 EP 378 DI 10.1089/jwh.2011.3417 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 926UE UT WOS:000302856600152 PM 22309210 ER PT J AU Naleway, AL Gold, R Drew, L Riedlinger, K Henninger, ML Gee, J AF Naleway, Allison L. Gold, Rachel Drew, Lois Riedlinger, Karen Henninger, Michelle L. Gee, Julianne TI Reported Adverse Events in Young Women Following Quadrivalent Human Papillomavirus Vaccination SO JOURNAL OF WOMENS HEALTH LA English DT Article ID AGED 13-17 YEARS; HPV VACCINE; UNITED-STATES; RECOMBINANT VACCINE; ATTITUDES; ACCEPTABILITY; KNOWLEDGE; ADOLESCENTS; BELIEFS; PREDICTORS AB Purpose: To assess and describe young women's experiences with their first dose of quadrivalent human papillomavirus vaccine (HPV4) (Gardasil (R)) in a large managed care organization. Methods: We collected survey and electronic medical record (EMR) data for 899 young women aged 11-26 receiving their first HPV4 injection from February through September 2008. Survey items included questions about adverse events, interactions with healthcare providers, and knowledge and attitudes toward HPV disease and HPV4. Results: Six hundred ninety-six (78%) participants reported pain at the injection site. Other common reactions included injection site bruising or discoloration (n = 155, 17%) or swelling (n = 127, 14%) and presyncope or syncope (n = 134, 15%). Overall, preteens and teens were more likely than adult participants to report vaccine adverse events. Most respondents, particularly in the adult age group, reported that their healthcare provider reviewed important information about HPV infection and about the risks and benefits of receiving the vaccine. Knowledge and attitudes about HPV and HPV4 also varied by age, with older women generally exhibiting more accurate knowledge about HPV and perceived susceptibility to cervical cancer. Conclusions: There were significant age differences in young women's experiences with their first HPV4 injection. These findings highlight the importance of age-appropriate education and provider communications about HPV disease and vaccination. C1 [Naleway, Allison L.; Gold, Rachel; Drew, Lois; Riedlinger, Karen; Henninger, Michelle L.] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR 97227 USA. [Gee, Julianne] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. RP Naleway, AL (reprint author), Kaiser Permanente NW, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. EM allison.naleway@kpchr.org OI Naleway, Allison/0000-0001-5747-4643 FU Centers for Disease Control and Prevention [200-2002-00732] FX Financial support for this study was provided in full by the Centers for Disease Control and Prevention (200-2002-00732) through America's Health Insurance Plans. The manuscript was reviewed and approved through the clearance process of the Centers for Disease Control and Prevention before submission. The findings and conclusions in this report are those of the authors and do not necessarily represent the official positions of the Centers for Disease Control and Prevention or America's Health Insurance Plans. We thank Jill Mesa, Carrie Meeks, JaNice Brewster, and Eresha Bluth for assistance with data collection and Dr. Matthew Daley for assistance with survey development. NR 42 TC 11 Z9 11 U1 0 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2012 VL 21 IS 4 BP 425 EP 432 DI 10.1089/jwh.2011.2895 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 926UE UT WOS:000302856600159 PM 22229713 ER PT J AU Holtz, TH Rustomjee, R Mthiyane, T AF Holtz, Timothy H. Rustomjee, Roxana Mthiyane, Thuli TI Diagnosis and treatment of pulmonary tuberculosis in patients with HIV Reply SO LANCET INFECTIOUS DISEASES LA English DT Letter ID INFECTION; ALGORITHM; MORTALITY C1 [Holtz, Timothy H.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Rustomjee, Roxana; Mthiyane, Thuli] MRC, Cape Town, South Africa. RP Holtz, TH (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM tkh3@th.cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD APR PY 2012 VL 12 IS 4 BP 268 EP 269 DI 10.1016/S1473-3099(12)70047-6 PG 2 WC Infectious Diseases SC Infectious Diseases GA 922AC UT WOS:000302518200011 ER PT J AU Roellig, DM Fang, QQ AF Roellig, Dawn M. Fang, Quentin Q. TI Detection of Anaplasma phagocytophilum in Ixodid Ticks from Equine-Inhabited Sites in the Southeastern United States SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Anaplasma phagocytophilum; Anaplasmosis; Ixodes scapularis; Surveillance; Ticks ID GRANULOCYTIC EHRLICHIOSIS; NORTHERN CALIFORNIA; HORSES; INFECTION; AGENT; GENE AB Anaplasma phagocytophilum is a vector-borne, obligate intracellular bacterium that invades the neutrophils and eosinophils of infected individuals, causing granulocytic anaplasmosis. Equine cases have previously been reported in the United States from California, Florida, and Connecticut, but limited surveillance studies in the Southeast have been conducted. The objective of this study was to determine A. phagocytophilum prevalence in Ixodes scapularis ticks at southeastern U.S. horse-inhabited sites to evaluate the potential risk for equine exposure to A. phagocytophilum-infected ticks in these areas. Samples of I. scapularis were collected from selected barrier islands and Georgia mainland sites where feral and domestic equine populations are present, respectively. Ticks were individually tested for infection by amplification of the A. phagocytophilum ankA gene. The collective prevalence of A. phagocytophilum in I. scapularis ticks was 20% (n=808). C1 [Roellig, Dawn M.; Fang, Quentin Q.] Georgia So Univ, Dept Biol Sci, Statesboro, GA 30460 USA. RP Roellig, DM (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis, 1600 Clifton Rd,MS-D65, Atlanta, GA 30329 USA. EM DMRoellig@cdc.gov FU College of Science and Technology; Georgia Southern University FX This study was partially funded by a College of Science and Technology Academic Excellence Grant and Graduate Student Professional Development Fund Grant awarded by Georgia Southern University. NR 13 TC 4 Z9 4 U1 0 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD APR PY 2012 VL 12 IS 4 BP 330 EP 332 DI 10.1089/vbz.2011.0757 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 925OC UT WOS:000302769700011 PM 22214269 ER PT J AU Lawson, CC Rocheleau, CM Whelan, EA Hibert, ENL Grajewski, B Spiegelman, D Rich-Edwards, JW AF Lawson, Christina C. Rocheleau, Carissa M. Whelan, Elizabeth A. Hibert, Eileen N. Lividoti Grajewski, Barbara Spiegelman, Donna Rich-Edwards, Janet W. TI Occupational exposures among nurses and risk of spontaneous abortion SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE antineoplastic agents; health personnel; occupational exposure; pregnancy ID HANDLING PARENTERAL ANTINEOPLASTICS; HEALTH-CARE WORKERS; REPRODUCTIVE OUTCOMES; PREGNANCY OUTCOMES; PROSPECTIVE COHORT; ANTICANCER DRUGS; ANESTHETIC-GASES; WOMEN; HAZARDS; CANCER AB OBJECTIVE: We investigated self-reported occupational exposure to antineoplastic drugs, anesthetic gases, antiviral drugs, sterilizing agents (disinfectants), and X-rays and the risk of spontaneous abortion in US nurses. STUDY DESIGN: Pregnancy outcome and occupational exposures were collected retrospectively from 8461 participants of the Nurses' Health Study II. Of these, 7482 were eligible for analysis using logistic regression. RESULTS: Participants reported 6707 live births, and 775 (10%) spontaneous abortions (<20 weeks). After adjusting for age, parity, shift work, and hours worked, antineoplastic drug exposure was associated with a 2-fold increased risk of spontaneous abortion, particularly with early spontaneous abortion before the 12th week, and 3.5-fold increased risk among nulliparous women. Exposure to sterilizing agents was associated with a 2-fold increased risk of late spontaneous abortion (12-20 weeks), but not with early spontaneous abortion. CONCLUSION: This study suggests that certain occupational exposures common to nurses are related to risks of spontaneous abortion. C1 [Lawson, Christina C.; Rocheleau, Carissa M.; Whelan, Elizabeth A.; Grajewski, Barbara] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Hibert, Eileen N. Lividoti] Harvard Univ, Sch Publ Hlth, Channing Lab, Dept Med, Boston, MA 02115 USA. [Rich-Edwards, Janet W.] Harvard Univ, Sch Publ Hlth, Connors Ctr Womens Hlth & Gender Biol, Boston, MA 02115 USA. [Spiegelman, Donna; Rich-Edwards, Janet W.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Spiegelman, Donna] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Lawson, CC (reprint author), NIOSH, CDC, 4676 Columbia Pkwy,R-15, Cincinnati, OH 45226 USA. EM clawson@cdc.gov FU Centers for Disease Control/National Institute for Occupational Safety and Health [200-2001-08007] FX This work was partially funded by contract no. 200-2001-08007 from the Centers for Disease Control/National Institute for Occupational Safety and Health. NR 51 TC 9 Z9 10 U1 3 U2 22 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD APR PY 2012 VL 206 IS 4 AR 327.e1 DI 10.1016/j.ajog.2011.12.030 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 918QS UT WOS:000302266000022 PM 22304790 ER PT J AU Chakraborty, A Khan, SU Hasnat, MA Parveen, S Islam, MS Mikolon, A Chakraborty, RK Ahmed, BN Ara, K Haider, N Zaki, SR Hoffmaster, AR Rahman, M Luby, SP Hossain, MJ AF Chakraborty, Apurba Khan, Salah Uddin Hasnat, Mohammed Abul Parveen, Shahana Islam, M. Saiful Mikolon, Andrea Chakraborty, Ranjit Kumar Ahmed, Be-Nazir Ara, Khorsed Haider, Najmul Zaki, Sherif R. Hoffmaster, Alex R. Rahman, Mahmudur Luby, Stephen P. Hossain, M. Jahangir TI Anthrax Outbreaks in Bangladesh, 2009-2010 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID BACILLUS-ANTHRACIS; CUTANEOUS ANTHRAX; MANAGEMENT; KAZAKSTAN AB During August 2009 October 2010, a multidisciplinary team investigated 14 outbreaks of animal and human anthrax in Bangladesh to identify the etiology, pathway of transmission, and social, behavioral, and cultural factors that led to these outbreaks. The team identified 140 animal cases of anthrax and 273 human cases of cutaneous anthrax. Ninety one percent of persons in whom cutaneous anthrax developed had history of butchering sick animals, handling raw meat, contact with animal skin, or were present at slaughtering sites. Each year, Bacillus anthracis of identical genotypes were isolated from animal and human cases. Inadequate livestock vaccination coverage, lack of awareness of the risk of anthrax transmission from animal to humans, social norms and poverty contributed to these outbreaks. Addressing these challenges and adopting a joint animal and human health approach could contribute to detecting and preventing such outbreaks in the future. C1 [Chakraborty, Apurba; Khan, Salah Uddin; Hasnat, Mohammed Abul; Parveen, Shahana; Islam, M. Saiful; Mikolon, Andrea; Haider, Najmul; Luby, Stephen P.; Hossain, M. Jahangir] Int Ctr Diarrheal Dis Res, Ctr Communicable Dis, Dhaka 1212, Bangladesh. [Chakraborty, Ranjit Kumar] Minist Fisheries & Livestock, Dept Livestock Serv, Dhaka, Bangladesh. [Ahmed, Be-Nazir; Ara, Khorsed; Rahman, Mahmudur] Inst Epidemiol Dis Control & Res, Dhaka 1212, Bangladesh. [Zaki, Sherif R.; Hoffmaster, Alex R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Chakraborty, A (reprint author), Int Ctr Diarrheal Dis Res, Ctr Communicable Dis, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh. EM achakraborty@icddrb.org; khansu@icddrb.org; hasnatvet1@gmail.com; shahana@icddrb.org; saiful@icddrb.org; amikolon@icddrb.org; chakraborty.ranjit@yahoo.com; benazir1959@gmail.com; khorsedara1957@yahoo.com; nazmulh@icddrb.org; sxz1@cdc.gov; amh9@cdc.gov; mrahman@citechco.net; sluby@icddrb.org; jhossain@icddrb.org RI Haider, Najmul/F-6083-2015 OI Haider, Najmul/0000-0002-5980-3460 FU CDC; Government of Bangladesh FX This study was supported by CDC and the Government of Bangladesh. The International Center for Diarrheal Disease Research, Bangladesh acknowledges with gratitude the commitment of the Government of Bangladesh and CDC to research efforts of the Centre. NR 32 TC 26 Z9 26 U1 3 U2 9 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2012 VL 86 IS 4 BP 703 EP 710 DI 10.4269/ajtmh.2012.11-0234 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 922AR UT WOS:000302519700024 PM 22492157 ER PT J AU Dahlgren, FS Holman, RC Paddock, CD Callinan, LS McQuiston, JH AF Dahlgren, F. Scott Holman, Robert C. Paddock, Christopher D. Callinan, Laura S. McQuiston, Jennifer H. TI Fatal Rocky Mountain Spotted Fever in the United States, 1999-2007 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID RISK-FACTORS; SURVEILLANCE; DOXYCYCLINE; CHILDREN; DISEASE; RICKETTSIOSES; THERAPY AB Death from Rocky Mountain spotted fever (RMSF) is preventable with prompt, appropriate treatment. Data from two independent sources were analyzed to estimate the burden of fatal RMSF and identify risk factors for fatal RMSF in the United States during 1999-2007. Despite increased reporting of RMSF cases to the Centers for Disease Control and Prevention, no significant changes in the estimated number of annual fatal RMSF cases were found. American Indians were at higher risk of fatal RMSF relative to whites (relative risk [RR] = 3.9), and children 5-9 years of age (RR = 6.0) and adults >= 70 years of age (RR = 3.0) were also at increased risk relative to other ages. Persons with cases of RMSF with an immunosuppressive condition were at increased risk of death (RR = 4.4). Delaying treatment of RMSF was also associated with increased deaths. These results may indicate a gap between recommendations and practice. C1 [Dahlgren, F. Scott] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vectorborne Infect Dis,Div High Consequence P, Natl Ctr Emerging & Zoonot Infect Dis,Off Directo, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA 30333 USA. RP Dahlgren, FS (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vectorborne Infect Dis,Div High Consequence P, Natl Ctr Emerging & Zoonot Infect Dis,Off Directo, 1600 Clifton Rd NE,Mailstop A30, Atlanta, GA 30333 USA. EM iot0@cdc.gov; rch1@cdc.gov; cdp9@cdc.gov; imj5@cdc.gov; fzh7@cdc.gov FU The Oak Ridge Institute for Science and Education; United States Department of Energy; Centers for Disease Control and Prevention FX This study was supported by The Oak Ridge Institute for Science and Education, the United States Department of Energy, and the Centers for Disease Control and Prevention. NR 54 TC 27 Z9 27 U1 0 U2 12 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD APR PY 2012 VL 86 IS 4 BP 713 EP 719 DI 10.4269/ajtmh.2012.11-0453 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 922AR UT WOS:000302519700026 PM 22492159 ER PT J AU Duong, HT Hoyt, AT Carmichael, SL Gilboa, SM Canfield, MA Case, A McNeese, ML Waller, DK AF Duong, Hao T. Hoyt, Adrienne T. Carmichael, Suzan L. Gilboa, Suzanne M. Canfield, Mark A. Case, Amy McNeese, Melanie L. Waller, Dorothy Kim CA Natl Birth Defects Prevention Stud TI Is Maternal Parity an Independent Risk Factor for Birth Defects? SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE nulliparity; multiparity; parity; congenital abnormalities; congenital heart defects ID ANTIHYPERTENSIVE MEDICATION USE; NEURAL-TUBE DEFECTS; CONGENITAL-MALFORMATIONS; METROPOLITAN ATLANTA; DIAPHRAGMATIC-HERNIA; ESOPHAGEAL ATRESIA; CLEFT-PALATE; ORAL CLEFTS; PREGNANCY; HYPOSPADIAS AB BACKGROUND Although associations between maternal parity and birth defects have been observed previously, few studies have focused on the possibility that parity is an independent risk factor for birth defects. We investigated the relation between levels of parity and a range of birth defects, adjusting each defect group for the same covariates. METHODS: We included infants who had an estimated delivery date between 1997 and 2007 and participated in the National Birth Defects Prevention Study, a multisite case-control study. Cases included infants or fetuses belonging to 38 phenotypes of birth defects (n = 17,908), and controls included infants who were unaffected by a major birth defect (n = 7173). Odds ratios (ORs) were adjusted for 12 covariates using logistic regression. RESULTS: Compared with primiparous mothers, nulliparous mothers were more likely to have infants with amniotic band sequence, hydrocephaly, esophageal atresia, hypospadias, limb reduction deficiencies, diaphragmatic hernia, omphalocele, gastroschisis, tetralogy of Fallot, and septal cardiac defects, with significant ORs (1.2 to 2.3). Compared with primiparous mothers, multiparous mothers had a significantly increased risk of omphalocele, with an OR of 1.5, but had significantly decreased risk of hypospadias and limb reduction deficiencies, with ORs of 0.77 and 0.77. CONCLUSIONS: Nulliparity was associated with an increased risk of specific phenotypes of birth defects. Most of the phenotypes associated with nulliparity in this study were consistent with those identified by previous studies. Research into biologic or environmental factors that are associated with nulliparity may be helpful in explaining some or all of these associations. Birth Defects Research (Part A) 94: 230-236, 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Duong, Hao T.; McNeese, Melanie L.; Waller, Dorothy Kim] Univ Texas Houston, Sch Publ Hlth, Houston Hlth Sci Ctr, Houston, TX 77030 USA. [Hoyt, Adrienne T.; Canfield, Mark A.; Case, Amy] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA. [Gilboa, Suzanne M.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Carmichael, Suzan L.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Waller, DK (reprint author), Univ Texas Houston, Sch Publ Hlth, Houston Hlth Sci Ctr, 1200 Hermann Pressler Dr,Suite E-619, Houston, TX 77030 USA. EM Kim.Waller@uth.tmc.edu FU CDC [5U01DD000494] FX Supported by the CDC-funded Texas Center for Birth Defects Research and Prevention by a Cooperative Agreement with the Centers for Disease Control and Prevention, Grant Number: 5U01DD000494, Centers for Birth Defects Research and Prevention. NR 51 TC 20 Z9 22 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD APR PY 2012 VL 94 IS 4 BP 230 EP 236 DI 10.1002/bdra.22889 PG 7 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 923GC UT WOS:000302606600005 PM 22371332 ER PT J AU Azziz-Baumgartner, E Luber, G Conklin, L Tosteson, TR Granade, HR Dickey, RW Backer, LC AF Azziz-Baumgartner, Eduardo Luber, George Conklin, Laura Tosteson, Thomas R. Granade, Hudson R. Dickey, Robert W. Backer, Lorraine C. TI Assessing the Incidence of Ciguatera Fish Poisoning with Two Surveys Conducted in Culebra, Puerto Rico, during 2005 and 2006 SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE ciguatera; ciguatera fish poisoning; ciguatoxins; incidence; poisoning; Puerto Rico; seafood ID VIRGIN-ISLANDS; UNITED-STATES; HEALTH AB BACKGROUND: Although ciguatera fish poisoning (CFP) is the most common seafood intoxication worldwide, its burden has been difficult to establish because there are no biomarkers to diagnose human exposure. OBJECTIVE: We explored the incidence of CFP, percentage of CFP case-patients with laboratory-confirmed ciguatoxic meal remnants, cost of CFP illness, and potential risk factors for CFP. METHODS: During 2005 and again during 2006, we conducted a census of all occupied households on the island of Culebra, Puerto Rico, where locally caught fish are a staple food. We defined CFP case-patients as persons with gastrointestinal symptoms (abdominal pain, vomiting, diarrhea, or nausea) and neurological symptoms (extremity paresthesia, arthralgia, myalgia, malaise, pruritus, headache, dizziness, metallic taste, visual disturbance, circumoral paresthesia, temperature reversal, or toothache) or systemic symptoms (e. g., bradycardia) within 72 hr of eating fish during the previous year. Participants were asked to save fish remnants eaten by case-patients for ciguatoxin analysis at the Food and Drug Administration laboratory in Dauphin Island, Alabama (USA). RESULTS: We surveyed 340 households during 2005 and 335 households during 2006. The estimated annual incidence of possible CFP was 4.0 per 1,000 person-years, and that of probable CFP was 7.5 per 1,000 person-years. One of three fish samples submitted by probable case-patients was positive for ciguatoxins. None of the case-patients required respiratory support. Households that typically consumed barracuda were more likely to report CFP (p = 0.02). CONCLUSIONS: Our estimates, which are consistent with previous studies using similar case findings, contribute to the overall information available to support public health decision making about CFP prevention. C1 [Azziz-Baumgartner, Eduardo; Luber, George; Conklin, Laura; Backer, Lorraine C.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Tosteson, Thomas R.] Univ Puerto Rico, Mayaguez, PR USA. [Granade, Hudson R.; Dickey, Robert W.] US FDA, Gulf Coast Seafood Lab, Dauphin Isl, AL USA. RP Azziz-Baumgartner, E (reprint author), 1600 Clifton Rd NE,MS A32, Atlanta, GA 30333 USA. EM Eha9@cdc.gov NR 25 TC 7 Z9 8 U1 0 U2 14 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD APR PY 2012 VL 120 IS 4 BP 526 EP 529 DI 10.1289/ehp.1104003 PG 4 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 921KJ UT WOS:000302476200021 PM 22275728 ER PT J AU Schecter, A Malik-Bass, N Calafat, AM Kato, K Colacino, JA Gent, TL Hynan, LS Harris, TR Malla, S Birnbaum, L AF Schecter, Arnold Malik-Bass, Noor Calafat, Antonia M. Kato, Kayoko Colacino, Justin A. Gent, Tyra L. Hynan, Linda S. Harris, T. Robert Malla, Sunitha Birnbaum, Linda TI Polyfluoroalkyl Compounds in Texas Children from Birth through 12 Years of Age SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE blood; children; infants; PFC; PFOA; PFOS; polyfluoroalkyl compounds; United States ID PERFLUOROOCTANOIC ACID PFOA; PERFLUORINATED COMPOUNDS; NATIONAL-HEALTH; SERUM CONCENTRATIONS; NHANES 1999-2000; SULFONATE PFOS; BLOOD-SAMPLES; US POPULATION; HUMAN-MILK; CHEMICALS AB BACKGROUND: For > 50 years, polyfluoroalkyl compounds (PFCs) have been used worldwide, mainly as surfactants and emulsifiers, and human exposure to some PFCs is widespread. OBJECTIVES: Our goal was to report PFC serum concentrations from a convenience sample of Dallas, Texas, children from birth to < 13 years of age, and to examine age and sex differences in PFC concentrations. METHODS: We analyzed 300 serum samples collected in 2009 for eight PFCs by online solid phase extraction-high performance liquid chromatography-isotope dilution-tandem mass spectrometry. RESULTS: Perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and perfluorononanoic acid (PFNA) were detected in > 92% of participants; the other PFCs measured were detected less frequently. Overall median concentrations of PFOS (4.1 ng/mL) were higher than those for PFOA (2.85 ng/mL), PFNA (1.2 ng/mL), and PFHxS (1.2 ng/mL). For PFOS, PFOA, PFNA, and PFHxS, we found no significant differences (p < 0.05) by sex, significantly increasing concentrations for all four chemicals by age, and significantly positive correlations between all four compounds. CONCLUSIONS: We found no significant differences in the serum concentrations of PFOS, PFOA, PFNA, and PFHxS by sex, but increasing concentrations with age. Our results suggest that these 300 Texas children from birth through 12 years of age continued to be exposed to several PFCs in late 2009, years after changes in production of some PFCs in the United States. C1 [Schecter, Arnold; Malik-Bass, Noor; Gent, Tyra L.; Harris, T. Robert; Malla, Sunitha] Univ Texas Sch Publ Hlth, Dallas, TX 75390 USA. [Calafat, Antonia M.; Kato, Kayoko] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Colacino, Justin A.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Hynan, Linda S.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci Biostat, Dallas, TX 75390 USA. [Hynan, Linda S.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Birnbaum, Linda] Natl Inst Environm Hlth Sci, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC USA. RP Schecter, A (reprint author), Univ Texas Sch Publ Hlth, 6011 Harry Hines Blvd,V8-112, Dallas, TX 75390 USA. EM arnold.schecter@utsouthwestern.edu OI Hynan, Linda/0000-0002-4642-7769 FU CDC; National Institute of Environmental Health Sciences (NIEHS), NIH [T32 ES007062] FX This study was supported primarily by the CDC and involved the CDC, CMC Dallas, the University of Texas Southwestern Medical Center, the University of Texas School of Public Health, Dallas Campus, and the National Institutes of Health (NIH). Support for J. Colacino was provided by an Institutional Training Grant from the National Institute of Environmental Health Sciences (NIEHS), NIH (T32 ES007062). NR 46 TC 25 Z9 25 U1 3 U2 37 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD APR PY 2012 VL 120 IS 4 BP 590 EP 594 DI 10.1289/ehp.1104325 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 921KJ UT WOS:000302476200032 PM 22182702 ER PT J AU Dooyema, CA Neri, A Lo, YC Durant, J Dargan, PI Swarthout, T Biya, O Gidado, SO Haladu, S Sani-Gwarzo, N Nguku, PM Akpan, H Idris, S Bashir, AM Brown, MJ AF Dooyema, Carrie A. Neri, Antonio Lo, Yi-Chun Durant, James Dargan, Paul I. Swarthout, Todd Biya, Oladayo Gidado, Saheed O. Haladu, Suleiman Sani-Gwarzo, Nasir Nguku, Patrick M. Akpan, Henry Idris, Sa'ad Bashir, Abdullahi M. Brown, Mary Jean TI Outbreak of Fatal Childhood Lead Poisoning Related to Artisanal Gold Mining in Northwestern Nigeria, 2010 SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE artisanal gold mining; childhood; environmental health; lead poisoning; nervous system ID CHILDREN; EXPOSURE; MEXICO; CITY AB BACKGROUND: In May 2010, a team of national and international organizations was assembled to investigate children's deaths due to lead poisoning in villages in northwestern Nigeria. OBJECTIVES: Our goal was to determine the cause of the childhood lead poisoning outbreak, investigate risk factors for child mortality, and identify children < 5 years of age in need of emergency chelation therapy for lead poisoning. METHODS: We administered a cross-sectional, door-to-door questionnaire in two affected villages, collected blood from children 2-59 months of age, and obtained soil samples from family compounds. Descriptive and bivariate analyses were performed with survey, blood lead, and environmental data. Multivariate logistic regression techniques were used to determine risk factors for childhood mortality. RESULTS: We surveyed 119 family compounds. Of 463 children < 5 years of age, 118 (25%) had died in the previous year. We tested 59% (204/345) of children < 5 years of age, and all were lead poisoned (>= 10 mu g/dL); 97% (198/204) of children had blood lead levels (BLLs) >= 45 mu g/dL, the threshold for initiating chelation therapy. Gold ore was processed inside two-thirds of the family compounds surveyed. In multivariate modeling, significant risk factors for death in the previous year from suspected lead poisoning included the age of the child, the mother's work at ore-processing activities, community well as primary water source, and the soil lead concentration in the compound. CONCLUSION: The high levels of environmental contamination, percentage of children < 5 years of age with elevated BLLs (97%, > 45 mu g/dL), and incidence of convulsions among children before death (82%) suggest that most of the recent childhood deaths in the two surveyed villages were caused by acute lead poisoning from gold ore-processing activities. Control measures included environmental remediation, chelation therapy, public health education, and control of mining activities. C1 [Dooyema, Carrie A.; Neri, Antonio; Brown, Mary Jean] Ctr Dis Control & Prevent, Hlth Homes & Lead Poisoning Prevent Branch, Natl Ctr Environm Hlth, Atlanta, GA USA. [Dooyema, Carrie A.; Lo, Yi-Chun] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Durant, James] Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [Dargan, Paul I.] Guys & St Thomas NHS Fdn Trust, London, England. [Dargan, Paul I.] Kings Hlth Partners, London, England. [Swarthout, Todd] Med Sans Frontieres, Amsterdam, Netherlands. [Biya, Oladayo; Gidado, Saheed O.; Haladu, Suleiman; Nguku, Patrick M.] Nigerian Field Epidemiol & Lab Training Program, Abuja, Nigeria. [Sani-Gwarzo, Nasir] Ctr Dis Control & Prevent, Abuja, Nigeria. [Akpan, Henry] Nigerian Fed Minist Hlth, Abuja, Nigeria. [Idris, Sa'ad; Bashir, Abdullahi M.] Zamfara State Minist Hlth, Gusau, Nigeria. RP Dooyema, CA (reprint author), 4770 Buford Highway,MS K-26, Chamblee, GA 30341 USA. EM igb7@cdc.gov FU CDC; CDC Nigeria; Nigerian Field Epidemiology and Laboratory Training Program FX Financial support was provided by the CDC Global Disease Detection Program, CDC Nigeria, and the Nigerian Field Epidemiology and Laboratory Training Program. NR 35 TC 45 Z9 46 U1 0 U2 25 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD APR PY 2012 VL 120 IS 4 BP 601 EP 607 DI 10.1289/ehp.1103965 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 921KJ UT WOS:000302476200034 PM 22186192 ER PT J AU Zhang, LN Yesupriya, A Hu, DJ Chang, MH Dowling, NF Ned, RM Udhayakumar, V Lindegren, ML Khudyakov, Y AF Zhang, Lyna Yesupriya, Ajay Hu, Dale J. Chang, Man-huei Dowling, Nicole F. Ned, Renee M. Udhayakumar, Venkatachalam Lindegren, Mary Lou Khudyakov, Yury TI Variants in ABCB1, TGFB1, and XRCC1 genes and susceptibility to viral hepatitis A infection in Mexican Americans SO HEPATOLOGY LA English DT Article ID A VIRUS-INFECTION; TRANSFORMING GROWTH FACTOR-BETA(1); NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; UNITED-STATES; OXIDATIVE STRESS; RISK-FACTORS; POLYMORPHISM; MDR1; SEROPREVALENCE AB Hepatitis A vaccination has dramatically reduced the incidence of hepatitis A virus (HAV) infection, but new infections continue to occur. To identify human genetic variants conferring a risk for HAV infection among the three major racial/ethnic populations in the United States, we assessed associations between 67 genetic variants (single nucleotide polymorphisms [SNPs]) among 31 candidate genes and serologic evidence of prior HAV infection using a population-based, cross-sectional study of 6,779 participants, including 2,619 non-Hispanic whites, 2,095 non-Hispanic blacks, and 2,065 Mexican Americans enrolled in phase 2 (1991-1994) of the Third National Health and Nutrition Examination Survey. Among the three racial/ethnic groups, the number (weighted frequency) of seropositivity for antibody to HAV was 958 (24.9%), 802 (39.2%), and 1540 (71.5%), respectively. No significant associations with any of the 67 SNPs were observed among non-Hispanic whites or non-Hispanic blacks. In contrast, among Mexican Americans, variants in two genes were found to be associated with an increased risk of HAV infection: TGFB1 rs1800469 (adjusted odds ratio [OR], 1.38; 95% confidence interval [CI], 1.14-1.68; P value adjusted for false discovery rate [FDR-P] = 0.017) and XRCC1 rs1799782 (OR, 1.57; 95% CI, 1.27-1.94; FDR-P = 0.0007). A decreased risk was found with ABCB1 rs1045642 (OR, 0.79; 95% CI, 0.71-0.89; FDR-P = 0.0007). Conclusion: Genetic variants in ABCB1, TGFB1, and XRCC1 appear to be associated with susceptibility to HAV infection among Mexican Americans. Replication studies involving larger population samples are warranted. (HEPATOLOGY 2012) C1 [Zhang, Lyna; Hu, Dale J.; Khudyakov, Yury] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Zhang, Lyna; Yesupriya, Ajay; Chang, Man-huei; Dowling, Nicole F.; Ned, Renee M.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Lindegren, Mary Lou] Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Zhang, LN (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS A33, Atlanta, GA 30333 USA. EM chn6@cdc.gov FU Centers for Disease Control and Prevention, Atlanta, GA FX Supported by the Centers for Disease Control and Prevention, Atlanta, GA. NR 52 TC 7 Z9 7 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD APR PY 2012 VL 55 IS 4 BP 1008 EP 1018 DI 10.1002/hep.25513 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 916AW UT WOS:000302069900004 PM 22135187 ER PT J AU Brinkman, MC Chuang, JC Gordon, SM Kim, H Kroeger, RR Polzin, GM Richter, PA AF Brinkman, Marielle C. Chuang, Jane C. Gordon, Sydney M. Kim, Hyoshin Kroeger, Robyn R. Polzin, Gregory M. Richter, Patricia A. TI Exposure to and deposition of fine and ultrafine particles in smokers of menthol and nonmenthol cigarettes SO INHALATION TOXICOLOGY LA English DT Article DE Menthol; nonmenthol; fine particles; ultrafine particles; particulate; 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone; NNK; benzo(a)pyrene; BaP; mouth level exposure; MLE; nicotine; cotinine; postpuff inhalation; topography; 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanol; NNAL; 1-hydroxypyrene; electrical low pressure impactor; SPA-D ID HUMAN RESPIRATORY-TRACT; MAINSTREAM SMOKE; SIZE DISTRIBUTION; AROMATIC-HYDROCARBONS; MASS-SPECTROMETRY; AMBIENT AIR; PUFF VOLUME; SHORT-TERM; TOBACCO; BIOMARKERS AB Introduction: Research on the deposition of mainstream smoke particulate in the respiratory tract of smokers is needed to understand how exposure may vary based on cigarette menthol content. Methods: We conducted a nine-participant crossover study in which smokers were randomly assigned to cigarettes differing primarily in menthol content. Participants smoked the test cigarettes ad libitum for one week, provided spot urine samples, and then smoked four test cigarettes in a laboratory session; this was repeated for the other test cigarette in week two. Fine and ultrafine particulate matter in exhaled breath were characterized, and smoking behavior was monitored. Participant-specific mainstream smoke, generated using each participant's topography data, was characterized. During home smoking, participants collected their spent test cigarette butts for estimates of mouth-level exposures (MLE) to mainstream nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Results: Participant-specific mainstream smoke NNK was higher (39%) and daily MLE to NNK was also higher (52%) when participants smoked the menthol cigarette. Nicotine was not significantly different. Participants retained more ultrafine particulate (43%) and fine particulate benzo(a) pyrene (43%) when smoking the menthol cigarette. There were no significant differences in the levels of urinary biomarkers for nicotine, NNK, or pyrene. Conclusion: This study demonstrates the use of noninvasive real-time techniques to measure exposure differences between cigarettes differing primarily in menthol content. Differences between NNK exposure, ultrafine particle and benzo(a) pyrene deposition, and smoking behavior were observed. Additional research using these techniques with cigarettes that differ only in menthol content is required to unequivocally attribute the exposure differences to presence or absence of menthol. C1 [Brinkman, Marielle C.; Chuang, Jane C.; Gordon, Sydney M.; Kim, Hyoshin; Kroeger, Robyn R.] Battelle Ctr Publ Hlth Res & Evaluat, Columbus, OH USA. [Polzin, Gregory M.; Richter, Patricia A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Brinkman, MC (reprint author), Battelle Mem Inst, 505 King Ave, Columbus, OH 43201 USA. EM brinkmmc@battelle.org FU Centers for Disease Control and Prevention (CDC) [HHS-P23320045006XI] FX The information in this document has been funded wholly or in part by the Centers for Disease Control and Prevention (CDC) under Contract HHS-P23320045006XI to Battelle Memorial Institute. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of CDC. Mention of trade names or commercial products is for informational purposes only and does not constitute endorsement or recommendation for use by the US Government, the US Department of Health and Human Services, or CDC. NR 72 TC 6 Z9 7 U1 2 U2 7 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0895-8378 J9 INHAL TOXICOL JI Inhal. Toxicol. PD APR PY 2012 VL 24 IS 5 BP 255 EP 269 DI 10.3109/08958378.2012.667218 PG 15 WC Toxicology SC Toxicology GA 922QU UT WOS:000302563800002 PM 22486344 ER PT J AU Bloss, E Chan, PC Cheng, NW Wang, KF Yang, SL Cegielski, P AF Bloss, E. Chan, P-C. Cheng, N-W. Wang, K-F. Yang, S-L. Cegielski, P. TI Increasing directly observed therapy related to improved tuberculosis treatment outcomes in Taiwan SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; directly observed therapy; treatment outcomes; Taiwan ID RANDOMIZED CONTROLLED-TRIAL; PULMONARY TUBERCULOSIS; PUBLIC-HEALTH AB SETTING: Directly observed therapy (DOT) is a core element of tuberculosis (TB) care and control efforts. In Taiwan, DOT was implemented in 2006, when the Stop TB Strategy was adopted as a national policy. OBJECT I V E : To quantify DOT among patients on anti-tuberculosis treatment and measure the association between proportion of DOT and TB treatment outcomes at a national level in Taiwan. DESIGN: We analyzed data prospectively collected on all new pulmonary TB cases reported to the national Web-based registry between 1 January 2007 and 30 June 2008. We compared treatment outcomes and proportion of DOT in multivariable analyses. RESULTS: Among 11 528 patients initiating anti-tuberculosis treatment, the proportion of days during which an official DOT observer witnessed treatment was >60% for 5150 (45%) patients and <= 60% for 4601 (40%) patients, whereas for 1777(15%) patients no days of DOT were recorded. Being older, male, having positive bacteriology results and a non-World Health Organization recommended treatment regimen at baseline were independently related to unsuccessful treatment outcomes and mortality. A dose-response effect was found between proportion of DOT and these outcomes. CONCLUSION: These findings highlight the importance of ensuring universal DOT in improving treatment outcomes among new pulmonary TB patients. C1 [Bloss, E.; Cheng, N-W.; Cegielski, P.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Chan, P-C.; Wang, K-F.; Yang, S-L.] Taiwan Ctr Dis Control, Taipei, Taiwan. RP Bloss, E (reprint author), CDC, Div TB Eliminat, Int Res & Programs Branch, 1600 Clifton Rd,MS E-10, Atlanta, GA 30333 USA. EM dpu2@cdc.gov NR 30 TC 11 Z9 11 U1 0 U2 2 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD APR PY 2012 VL 16 IS 4 BP 462 EP 467 DI 10.5588/ijtld.11.0121 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 919OA UT WOS:000302336300008 PM 22640512 ER PT J AU Bliven-Sizemore, EE Johnson, JL Goldberg, S Burman, WJ Villarino, ME Chaisson, RE AF Bliven-Sizemore, E. E. Johnson, J. L. Goldberg, S. Burman, W. J. Villarino, M. E. Chaisson, R. E. CA TB Clinical Trials Consortium TI Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE randomized clinical trial; thrice weekly intensive phase therapy; treatment failure ID HUMAN-IMMUNODEFICIENCY-VIRUS; SHORT-COURSE CHEMOTHERAPY; 2-YEAR FOLLOW-UP; PULMONARY TUBERCULOSIS; ANTIRETROVIRAL THERAPY; INTENSIVE PHASE; AFRICA; MOXIFLOXACIN; COHORT AB SETTING: Two international, multicenter Phase 2 clinical trials examining fluoroquinolone-containing regimens in adults with smear-positive pulmonary tuberculosis (TB), conducted from July 2003 to March 2007. Both trials enrolled human immunodeficiency virus (HIV) infected participants who were not receiving antiretroviral therapy (ART) at TB treatment initiation. OBJECTIVE: To assess the impact of HIV infection on TB treatment outcomes in Phase 2 clinical trials. DESIGN: Cross-protocol analysis comparing the safety, tolerability and outcomes of anti-tuberculosis treatment by HIV status. RESULTS: Of 750 participants who received at least one dose of study treatment, 123 (16%) were HIV-infected. Treatment completion rates were similar by HIV status (81% infected vs. 85% non-infected), as were rates of week 8 culture conversion (66% infected vs. 63% non-infected), and treatment failure (5% infected vs. 3% non-infected). Among HIV-infected participants, treatment failure detected using liquid media was more frequent in those treated thrice weekly (14% thrice weekly vs. 2% daily, P = 0.03). HIV-infected participants more frequently experienced an adverse event during the intensive phase treatment than non-HIV-infected participants (30% vs. 15%, P < 0.01). CONCLUSION: HIV-infected persons not receiving ART had more adverse events during the intensive phase of anti-tuberculosis treatment, but tolerated treatment well. Failure rates were higher among HIV-infected persons treated with thrice-weekly intensive phase therapy. C1 [Bliven-Sizemore, E. E.] Ctr Dis Control & Prevent, Div TB Eliminat, Clin Res Branch, Atlanta, GA 30333 USA. [Johnson, J. L.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Burman, W. J.] Denver Publ Hlth, Denver, CO USA. [Chaisson, R. E.] Johns Hopkins Univ, Baltimore, MD USA. RP Bliven-Sizemore, EE (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Clin Res Branch, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30333 USA. EM ebliven@cdc.gov OI Mayanja-Kizza, Harriet/0000-0002-9297-6208 FU Centers for Disease Control and Prevention; Bayer Pharmaceuticals; Global Alliance for Tuberculosis Drug Development FX Tuberculosis Clinical Trials Consortium Studies 27 and 28 were sponsored by the Centers for Disease Control and Prevention and Bayer Pharmaceuticals. Study 28 was also sponsored by The Global Alliance for Tuberculosis Drug Development. MFX and MFX placebo tablets were donated by Bayer Pharmaceuticals for both studies. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 25 TC 5 Z9 5 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD APR PY 2012 VL 16 IS 4 BP 473 EP 479 DI 10.5588/ijtld.11.0548 PG 7 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 919OA UT WOS:000302336300010 PM 22325844 ER PT J AU Lamunu, D Chapman, KN Nsubuga, P Muzanyi, G Mulumba, Y Mugerwa, MA Goldberg, S Bozeman, L Engle, M Saukkonen, J Mastranunzio, S Mayanja-Kizza, H Johnson, JL AF Lamunu, D. Chapman, K. N. Nsubuga, P. Muzanyi, G. Mulumba, Y. Mugerwa, M. A. Goldberg, S. Bozeman, L. Engle, M. Saukkonen, J. Mastranunzio, S. Mayanja-Kizza, H. Johnson, J. L. TI Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; non-participation; clinical trial; moxifloxacin; anti-tuberculosis agents ID RANDOMIZED CONTROLLED-TRIALS; CLINICAL-TRIALS; PARTICIPATION; RECRUITMENT; GUIDELINES; ATTITUDES; SELF AB SETTING: Clinical trials can provide a high standard of patient care and contribute to scientific knowledge; however, only a fraction of the patients screened participate and receive treatment as part of a trial. OBJECTIVE: To explore reasons why patients were not enrolled in an international tuberculosis (TB) treatment trial and to compare experiences among study sites. DESIGN: An analysis of reasons why patients were not enrolled was conducted among patients screened for a TB clinical trial at 26 sites in North and South America, Africa, and Europe. RESULTS: Staff at study sites screened 1119 potential candidates for the trial: 61% (n = 686) were not enrolled due to 1) failure to meet eligibility criteria (n = 405, 59%), 2) site's decision (n = 168, 24%), or 3) candidate's choice (n = 113, 16%). Study staff recorded a total of 144 reasons for why they believed patients chose not to participate, including concerns over research (28%), conflicts with work or school (21%), and lifestyle and family issues (20%). Socio-demographic and geographic factors also influenced participation. CONCLUSION: Increased evaluation of screening outcomes and of specific interventions, such as improved education and communication about trial procedures, may increase the efficiency of screening and enrollment in clinical trials. C1 [Lamunu, D.; Nsubuga, P.; Muzanyi, G.; Mulumba, Y.; Mugerwa, M. A.; Mastranunzio, S.; Mayanja-Kizza, H.; Johnson, J. L.] Uganda CWRU Res Collaborat, Kampala, Uganda. [Chapman, K. N.; Goldberg, S.; Bozeman, L.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Engle, M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Engle, M.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Saukkonen, J.] Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA. [Mayanja-Kizza, H.] Makerere Univ, Fac Med, Coll Hlth Sci, Dept Med, Kampala, Uganda. [Johnson, J. L.] Case Western Reserve Univ, Sch Med, Dept Med, Div Infect Dis, Cleveland, OH 44106 USA. [Johnson, J. L.] Univ Hosp Case Med Ctr, Cleveland, OH USA. RP Lamunu, D (reprint author), Uganda CWRU Res Collaborat, POB 663, Kampala, Uganda. EM DLamunu@mucwru.or.ug OI Mayanja-Kizza, Harriet/0000-0002-9297-6208 FU Tuberculosis Trials Consortium; United States Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Global Alliance for Tuberculosis Drug Development FX The authors thank the volunteers and site staff who participated in this study, P-J Feng and N Scott for their outstanding statistical and epidemiological support and assistance, W McKenzie for editorial review, and A Vernon for technical and editorial review. This study was supported by the Tuberculosis Trials Consortium and the United States Centers for Disease Control and Prevention.; Tuberculosis Clinical Trials Consortium Study 28 was supported by the Centers for Disease Control and Prevention and the Global Alliance for Tuberculosis Drug Development. MFX and MFX placebo tablets were donated by Bayer Pharmaceuticals. NR 17 TC 3 Z9 3 U1 1 U2 5 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD APR PY 2012 VL 16 IS 4 BP 480 EP 485 DI 10.5588/ijtld.11.0434 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 919OA UT WOS:000302336300011 PM 22640513 ER PT J AU Lyons, JL Scripko, PD Mukerji, SS Awosika, O Shieh, WJ Zaki, S DeLeon-Carnes, M Taylor, C Milner, D Johnson, JA Klein, JP AF Lyons, Jennifer L. Scripko, Patricia D. Mukerji, Shibani S. Awosika, Oluwole Shieh, Wun-Ju Zaki, Sherif DeLeon-Carnes, Marlene Taylor, Christopher Milner, Dan Johnson, Jennifer A. Klein, Joshua P. TI Propionibacterium acnes brain abscess in a patient with HIV-1 infection SO JOURNAL OF NEUROVIROLOGY LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; NEUROSURGERY C1 [Lyons, Jennifer L.; Scripko, Patricia D.; Mukerji, Shibani S.; Awosika, Oluwole; Klein, Joshua P.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Shieh, Wun-Ju; Zaki, Sherif; DeLeon-Carnes, Marlene] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Taylor, Christopher] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Taylor, Christopher] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Milner, Dan] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Johnson, Jennifer A.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Klein, Joshua P.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. RP Lyons, JL (reprint author), Brigham & Womens Hosp, Dept Neurol, 45 Francis St, Boston, MA 02115 USA. EM jlyons5@partners.org NR 13 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PD APR PY 2012 VL 18 IS 2 BP 148 EP 150 DI 10.1007/s13365-012-0088-z PG 3 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 926AF UT WOS:000302803000009 PM 22403028 ER PT J AU Knoeller, GE Mazurek, JM Moorman, JE AF Knoeller, Gretchen E. Mazurek, Jacek M. Moorman, Jeanne E. TI Characteristics Associated With Health Care Professional Diagnosis of Work-Related Asthma Among Individuals Who Describe Their Asthma as Being Caused or Made Worse by Workplace Exposures SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID SURVEILLANCE; QUALITY; ADULTS AB Objective: To identify factors associated with health care professional-diagnosed work-related asthma (WRA) among adults who describe their asthma as being caused or made worse by workplace exposures (possible WRA). Methods: We calculated prevalence ratios adjusted for age and sex using data from the 2006 to 2008 Behavioral Risk Factor Surveillance System Asthma Call-Back Survey from 37 states and the District of Columbia for ever-employed adults with current asthma and possible WRA. Results: An estimated 17.6% of ever-employed adults with current asthma and possible WRA had health care professional-diagnosed WRA. Health care professional-diagnosed WRA was associated with age, income, employment status, asthma control level, asthma attack, emergency department visit, hospitalization, urgent treatment, and changing/quitting a job due to asthma. Conclusions: Among ever-employed adults with possible WRA, health care professional-diagnosed WRA is associated with poorer asthma control and frequent unscheduled health care visits. C1 [Knoeller, Gretchen E.] NIOSH, Surveillance Branch, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Moorman, Jeanne E.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Knoeller, GE (reprint author), NIOSH, Surveillance Branch, Div Resp Dis Studies, Ctr Dis Control & Prevent, Mailstop HG 900,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM ipb8@cdc.gov NR 20 TC 9 Z9 9 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD APR PY 2012 VL 54 IS 4 BP 485 EP 490 DI 10.1097/JOM.06013e3182479f93 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 923AB UT WOS:000302589300016 PM 22453813 ER PT J AU Dodd, KA Bird, BH Metcalfe, MG Nichol, ST Albarino, CG AF Dodd, Kimberly A. Bird, Brian H. Metcalfe, Maureen G. Nichol, Stuart T. Albarino, Cesar G. TI Single-Dose Immunization with Virus Replicon Particles Confers Rapid Robust Protection against Rift Valley Fever Virus Challenge SO JOURNAL OF VIROLOGY LA English DT Article ID NSS PROTEIN; IN-VIVO; MICE; VACCINATION; INTERFERON; TRANSCRIPTION; EXPRESSION; INFECTION; EFFICACY; LACKING AB Rift Valley fever virus (RVFV) causes outbreaks of severe disease in people and livestock throughout Africa and the Arabian Peninsula. The potential for RVFV introduction outside the area of endemicity highlights the need for fast-acting, safe, and efficacious vaccines. Here, we demonstrate a robust system for the reverse genetics generation of a RVF virus replicon particle (VRPRVF) vaccine candidate. Using a mouse model, we show that VRPRVF immunization provides the optimal balance of safety and single-dose robust efficacy. VRPRVF can actively synthesize viral RNA and proteins but lacks structural glycoprotein genes, preventing spread within immunized individuals and reducing the risk of vaccine-induced pathogenicity. VRPRVF proved to be completely safe following intracranial inoculation of suckling mice, a stringent test of vaccine safety. Single-dose subcutaneous immunization with VRPRVF, although it is highly attenuated, completely protected mice against a virulent RVFV challenge dose which was 100,000-fold greater than the 50% lethal dose (LD50). Robust protection from lethal challenge was observed by 24 h postvaccination, with 100% protection induced in as little as 96 h. We show that a single subcutaneous VRPRVF immunization initiated a systemic antiviral state followed by an enhanced adaptive response. These data contrast sharply with the much-reduced survivability and immune responses observed among animals immunized with nonreplicating viral particles, indicating that replication, even if confined to the initially infected cells, contributes substantially to protective efficacy at early and late time points postimmunization. These data demonstrate that replicon vaccines successfully bridge the gap between safety and efficacy and provide insights into the kinetics of antiviral protection from RVFV infection. C1 [Dodd, Kimberly A.; Bird, Brian H.; Nichol, Stuart T.; Albarino, Cesar G.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Metcalfe, Maureen G.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Dodd, Kimberly A.] Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA. RP Bird, BH (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. EM che3@cdc.gov NR 41 TC 25 Z9 25 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD APR PY 2012 VL 86 IS 8 BP 4204 EP 4212 DI 10.1128/JVI.07104-11 PG 9 WC Virology SC Virology GA 917NU UT WOS:000302185400016 PM 22345465 ER PT J AU Kuklina, EV Kryscio, RJ AF Kuklina, Elena V. Kryscio, Richard J. TI Is spinal cord injury a new emerging risk factor for stroke? SO NEUROLOGY LA English DT Editorial Material ID CARDIOVASCULAR-DISEASE C1 [Kuklina, Elena V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Kryscio, Richard J.] Univ Kentucky, Coll Arts & Sci, Coll Publ Hlth, Dept Biostat, Lexington, KY 40506 USA. [Kryscio, Richard J.] Univ Kentucky, Coll Arts & Sci, Coll Publ Hlth, Dept Stat, Lexington, KY 40506 USA. RP Kuklina, EV (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. EM ekuklina@cdc.gov NR 10 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 IS 14 BP 1034 EP 1035 DI 10.1212/WNL.0b013e31824e8fc4 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 923KR UT WOS:000302618700004 PM 22377816 ER PT J AU Smith, EA Jacques-Carroll, L Walker, TY Sirotkin, B Murphy, TV AF Smith, Emily A. Jacques-Carroll, Lisa Walker, Tanja Y. Sirotkin, Barry Murphy, Trudy V. TI The National Perinatal Hepatitis B Prevention Program, 1994-2008 SO PEDIATRICS LA English DT Article DE hepatitis B; immunization programs; infant; newborn diseases; infectious disease transmission; pregnancy complications-infectious; United States ID VIRUS INFECTION; FOLLOW-UP; IMMUNIZATION PROGRAM; UNITED-STATES; VERTICAL TRANSMISSION; PROTECTIVE EFFICACY; SURFACE-ANTIGEN; CARRIER STATE; VACCINATION; INFANTS AB OBJECTIVE: To determine the trends and outcomes of the national Perinatal Hepatitis B Prevention Program (PHBPP) for infants born from 1994 to 2008. METHODS: PHBPPs in state and city public health jurisdictions annually submitted program outcome reports to the Centers for Disease Control and Prevention. The annual number of births to hepatitis B surface antigen (HBsAg)-positive women was estimated and used to evaluate the percentage of PHBPP-identified HBsAg-positive pregnant women. PHBPP reports were used to assess program objectives achieved, and infant outcomes by 12 to 24 months of age. RESULTS: From 1994 to 2008, the estimated number of annual births to HBsAg-positive women increased from 19 208 to 25 600 (P<.001). The annual number of PHBPP-managed infants increased (P<.001), comprising 40.8% to 50.5% of the estimated number. On average, 94.4% of PHBPP-managed infants received hepatitis B immunoglobulin and hepatitis B vaccine within 1 day of birth. The percentage of infants who completed the vaccine series by age 12 months decreased from 86.0% to 77.7% (P=.004), but the percentage who received postvaccination testing increased from 25.1% to 56.0% (P<.001). Incidence of chronic hepatitis B virus infection among tested infants decreased from 2.1% in 1999 to 0.8% in 2008 (P=.001). CONCLUSIONS: The PHBPP achieved substantial progress in preventing perinatal hepatitis B virus infection in the United States, despite an increasing number of at-risk infants. Significant gaps remain in identifying HBsAg-positive pregnant women, and completing management and assessment of their infants to ensure prevention of perinatal hepatitis B virus transmission. Pediatrics 2012;129:609-616 C1 [Smith, Emily A.] Ctr Dis Control & Prevent, NCHHSTP, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA 30329 USA. [Jacques-Carroll, Lisa] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30329 USA. [Sirotkin, Barry] Ctr Dis Control & Prevent, Off Infect Dis, Off Director, Atlanta, GA 30329 USA. RP Smith, EA (reprint author), Ctr Dis Control & Prevent, NCHHSTP, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, 1600 Clifton Rd NE,MS G-37, Atlanta, GA 30329 USA. EM esmith6@cdc.gov FU Centers for Disease Control and Prevention FX This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the Centers for Disease Control and Prevention. NR 45 TC 24 Z9 25 U1 0 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD APR PY 2012 VL 129 IS 4 BP 609 EP 616 DI 10.1542/peds.2011-2866 PG 8 WC Pediatrics SC Pediatrics GA 922IX UT WOS:000302541700037 PM 22451702 ER PT J AU Desai, R Haberling, D Holman, RC Singleton, RJ Cheek, JE Groom, AV Steiner, CA Parashar, UD Esposito, DH AF Desai, Rishi Haberling, Dana Holman, Robert C. Singleton, Rosalyn J. Cheek, James E. Groom, Amy V. Steiner, Claudia A. Parashar, Umesh D. Esposito, Douglas H. TI Impact of Rotavirus Vaccine on Diarrhea-Associated Disease Burden Among American Indian and Alaska Native Children SO PEDIATRICS LA English DT Article DE rotavirus; American Indian; Alaska Native; children; infants ID IMMUNIZATION PRACTICES ACIP; UNITED-STATES; ADVISORY-COMMITTEE; HOSPITALIZATIONS; GASTROENTERITIS; DISPARITIES; INFANTS; RECOMMENDATIONS; PREVENTION; DECLINE AB OBJECTIVE: Beginning in 2006, the Indian Health Service (IHS) began rotavirus vaccination of American Indian and Alaska Native (Al/AN) infants. To assess vaccine impact, we examined trends in IHS diarrhea-associated hospitalization and outpatient visits among Al/AN children in the pre- and postrotavirus vaccine era. METHODS: Diarrhea-associated hospitalizations and outpatient visits among Al/AN children <5 years of age during 2001 through 2010 were examined by gender, age group, and region for prevaccine years 2001-2006 and postvaccine years 2008, 2009, and 2010. To account for secular declining trends observed in prevaccine years, expected diarrhea-associated hospitalization and outpatient rates for postvaccine years were generated by using Poisson regression analysis of the 2001-2006 annual rates. RESULTS: Coverage with at least 1 dose of rotavirus vaccine among Al/AN infants aged 3 to 5 months in the first half of 2008, 2009, and 2010 ranged from 48% to 80% in various IHS regions. The prevaccine average annual diarrhea-associated hospitalization rates among Al/AN children <5 years of age was 63 per 10 000 persons (range: 57-75 per 10 000), and declined to 39, 31, and 27 per 10 000 in 2008, 2009, and 2010, respectively. Observed 2008, 2009, and 2010 rates were 24%, 37%, and 44% lower than expected rates, respectively. Decreases in diarrhea-associated hospitalizations and outpatient visits were observed in all IHS regions. CONCLUSIONS: Diarrhea-associated hospitalization and outpatient visit rates among Al/AN children have declined after implementation of rotavirus vaccination in Al/AN populations. Pediatrics 2012;129:e907-e913 C1 [Desai, Rishi; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Desai, Rishi; Esposito, Douglas H.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA. [Haberling, Dana; Holman, Robert C.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Groom, Amy V.] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30333 USA. [Singleton, Rosalyn J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Singleton, Rosalyn J.] US Dept HHS, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Ctr Dis Control & Prevent, Anchorage, AK USA. [Cheek, James E.; Groom, Amy V.] US Dept HHS, Div Epidemiol & Dis Prevent, Off Publ Hlth Support, Indian Hlth Serv, Albuquerque, NM USA. [Steiner, Claudia A.; Esposito, Douglas H.] US Dept HHS, Hlth Care Cost & Utilizat Project, Ctr Delivery Org & Markets, Agcy Hlth Care Res & Qual, Rockville, MD USA. RP Desai, R (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd NE,MS-A34, Atlanta, GA 30333 USA. EM rdesai1@cdc.gov NR 22 TC 5 Z9 5 U1 0 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2012 VL 129 IS 4 BP E907 EP E913 DI 10.1542/peds.2011-2537 PG 7 WC Pediatrics SC Pediatrics GA 922IX UT WOS:000302541700007 PM 22430454 ER PT J AU Shane, AL Hansen, NI Stoll, BJ Bell, EF Sanchez, PJ Shankaran, S Laptook, AR Das, A Walsh, MC Hale, EC Newman, NS Schrag, SJ Higgins, RD AF Shane, Andi L. Hansen, Nellie I. Stoll, Barbara J. Bell, Edward F. Sanchez, Pablo J. Shankaran, Seetha Laptook, Abbot R. Das, Abhik Walsh, Michele C. Hale, Ellen C. Newman, Nancy S. Schrag, Stephanie J. Higgins, Rosemary D. CA Eunice Kennedy Shriver Natl Inst TI Methicillin-Resistant and Susceptible Staphylococcus aureus Bacteremia and Meningitis in Preterm Infants SO PEDIATRICS LA English DT Article DE Staphylococcus aureus; methicillin resistant; infant; newborn ID INTENSIVE-CARE-UNIT; NEONATAL RESEARCH NETWORK; NECROTIZING ENTEROCOLITIS; PREGNANT-WOMEN; ONSET SEPSIS; INFECTIONS; TRANSMISSION; PROPHYLAXIS; EXPERIENCE; HEALTH AB BACKGROUND: Data are limited on the impact of methicillin-resistant Staphylococcus aureus (MRSA) on morbidity and mortality among very low birth weight (VLBW) infants with S aureus (SA) bacteremia and/or meningitis (B/M). METHODS: Neonatal data for VLBW infants (birth weight 401-1500 g) born January 1, 2006, to December 31, 2008, who received care at centers of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network were collected prospectively. Early-onset (<= 72 hours after birth) and late-onset (>72 hours) infections were defined by blood or cerebrospinal fluid cultures and antibiotic treatment of >= 5 days (or death <5 days with intent to treat). Outcomes were compared for infants with MRSA versus methicillin-susceptible S aureus (MSSA) B/M. RESULTS: Of 8444 infants who survived >3 days, 316 (3.7%) had SA B/M. Eighty-eight had MRSA (1% of all infants, 28% of infants with SA); 228 had MSSA (2.7% of all infants, 72% of infants with SA). No infant had both MRSA and MSSA B/M. Ninety-nine percent of MRSA infections were late-onset. The percent of infants with MRSA varied by center (P < .001) with 9 of 20 centers reporting no cases. Need for mechanical ventilation, diagnosis of respiratory distress syndrome, necrotizing enterocolitis, and other morbidities did not differ between infants with MRSA and MSSA. Mortality was high with both MRSA (23 of 88, 26%) and MSSA (55 of 228, 24%). CONCLUSIONS: Few VLBW infants had SA B/M. The 1% with MRSA had morbidity and mortality rates similar to infants with MSSA. Practices should provide equal focus on prevention and management of both MRSA and MSSA infections among VLBW infants. Pediatrics 2012;129:e914-e922 C1 [Shane, Andi L.; Stoll, Barbara J.; Hale, Ellen C.] Emory Univ Sch Med, Dept Pediat, Atlanta, GA 30322 USA. [Shane, Andi L.; Stoll, Barbara J.; Hale, Ellen C.] Childrens Healthcare Atlanta, Atlanta, GA USA. [Hansen, Nellie I.] RTI Int, Stat & Epidemiol Unit, Res Triangle Pk, NC USA. [Bell, Edward F.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA. [Sanchez, Pablo J.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA. [Shankaran, Seetha] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA. [Laptook, Abbot R.] Brown Univ, Women & Infants Hosp, Dept Pediat, Providence, RI 02908 USA. [Das, Abhik] RTI Int, Stat & Epidemiol Unit, Rockville, MD USA. [Walsh, Michele C.; Newman, Nancy S.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA. [Schrag, Stephanie J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. RP Shane, AL (reprint author), Emory Univ Sch Med, Dept Pediat, 2015 Uppergate Dr NE, Atlanta, GA 30322 USA. EM ashane@emory.edu FU National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) FX The National Institutes of Health and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) provided grant support for the Neonatal Research Network's (NRN) Generic Database Study. The funding source had no direct involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. Funded by the National Institutes of Health (NIH). NR 23 TC 28 Z9 28 U1 0 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2012 VL 129 IS 4 BP E914 EP E922 DI 10.1542/peds.2011-0966 PG 9 WC Pediatrics SC Pediatrics GA 922IX UT WOS:000302541700008 PM 22412036 ER PT J AU Goodson, JL Kulkarni, MA Vanden Eng, JL Wannemuehler, KA Cotte, AH Desrochers, RE Randriamanalina, B Luman, ET AF Goodson, James L. Kulkarni, Manisha A. Vanden Eng, Jodi L. Wannemuehler, Kathleen A. Cotte, Annett H. Desrochers, Rachelle E. Randriamanalina, Bakolalao Luman, Elizabeth T. TI Improved equity in measles vaccination from integrating insecticide-treated bednets in a vaccination campaign, Madagascar SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE measles; malaria; vaccination; insecticide-treated bed nets; integration; campaign; rougeole; paludisme; vaccination; moustiquaires impregnees d'insecticide; integration; campagne; Sarampion; Malaria; Vacunacion; Mosquiteras impregnadas con insecticida; Campana; Integracion ID COVERAGE; HEALTH; AFRICA; NETS; TOGO AB Objective To evaluate the effect of integrating ITN distribution on measles vaccination campaign coverage in Madagascar. Methods Nationwide cross-sectional survey to estimate measles vaccination coverage, nationally, and in districts with and without ITN integration. To evaluate the effect of ITN integration, propensity score matching was used to create comparable samples in ITN and non-ITN districts. Relative risks (RR) and 95% confidence intervals (CI) were estimated via log-binomial models. Equity ratios, defined as the coverage ratio between the lowest and highest household wealth quintile (Q), were used to assess equity in measles vaccination coverage. Results National measles vaccination coverage during the campaign was 66.9% (95% CI 63.0-70.7). Among the propensity score subset, vaccination campaign coverage was higher in ITN districts (70.8%) than non-ITN districts (59.1%) (RR = 1.3, 95% CI 1.1-1.6). Among children in the poorest wealth quintile, vaccination coverage was higher in ITN than in non-ITN districts (Q1; RR = 2.4, 95% CI 1.2-4.8) and equity for measles vaccination was greater in ITN districts (equity ratio = 1.0, 95% CI 0.8-1.3) than in non-ITN districts (equity ratio = 0.4, 95% CI 0.2-0.8). Conclusion Integration of ITN distribution with a vaccination campaign might improve measles vaccination coverage among the poor, thus providing protection for the most vulnerable and difficult to reach children. C1 [Goodson, James L.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Kulkarni, Manisha A.; Desrochers, Rachelle E.] HealthBridge Univ Ottawa, Ottawa, ON, Canada. [Randriamanalina, Bakolalao] Minist Hlth, Expanded Programme Immunizat, Antananarivo, Madagascar. RP Goodson, JL (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS-E05, Atlanta, GA 30333 USA. EM jgoodson@cdc.gov OI Kulkarni, Manisha/0000-0002-5084-4960 FU Canadian International Development Agency; United States Agency for International Development; Canadian Red Cross; United Nations Children's Fund FX The authors are grateful to the families who participated in this survey and to teams who worked under challenging field conditions to complete this survey. We would like to thank the many international partners who contributed to the implementation of the integrated campaign and its evaluation, including the Madagascar Ministry of Health, Family Planning and Social Protection, Madagascar Red Cross, CRESAN, Malaria No More, UNICEF, World Health Organization, Canadian International Development Agency, USAID, Canadian Red Cross, Institut National de la Statistique, Institut National de Sante Publique et Communautiare. Special thanks go to Dr. Izaka Rabeson, Dr. Bary Rakototiana and Mr. Fanja Ratsimbazafy of the Madagascar Red Cross for their logistical and administrative support and supervision in the field. In addition, we are grateful to Dr. Elizabeth Zell at the US Centers for Disease Control and Prevention for her valuable input on propensity score methods. The work was funded by the Canadian International Development Agency, United States Agency for International Development, Canadian Red Cross, and United Nations Children's Fund. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 29 TC 10 Z9 10 U1 0 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD APR PY 2012 VL 17 IS 4 BP 430 EP 437 DI 10.1111/j.1365-3156.2011.02953.x PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 915EA UT WOS:000302005600006 PM 22273490 ER PT J AU Rowe, AK Osterholt, DM Kouame, J Piercefield, E Herman, KM Onikpo, F Lama, M Deming, MS AF Rowe, Alexander K. Osterholt, Dawn M. Kouame, Julien Piercefield, Emily Herman, Karen M. Onikpo, Faustin Lama, Marcel Deming, Michael S. TI Trends in health worker performance after implementing the Integrated Management of Childhood Illness strategy in Benin SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE Benin; child health; developing country; health services research; Integrated Management of Childhood Illness; Benin; sante des enfants; pays en developpement; services de sante; gestion integree des maladies infantiles; Benin; salud infantil; paises en vias de desarrollo; investigacion en servicios sanitarios; Manejo Integrado de la Salud Infantil ID MALARIA; INTERVENTION; GUIDELINES; PREDICTORS; FACILITIES; ADHERENCE; CHILDREN; QUALITY AB Objective Training health workers to use Integrated Management of Childhood Illness (IMCI) guidelines can improve care for ill children in outpatient settings in developing countries. However, even after IMCI training, important performance gaps exist. One potential reason is that the effect of training can rapidly wane. Our aim was to determine if the performance of IMCI-trained health workers deteriorated over 3 years. Methods We studied two departments in Benin. First, we performed a record review of 32 IMCItrained health workers during the first year of IMCI implementation (2001-2002). Second, we analysed data from cross-sectional health facility surveys from 2001 to 2004 that represented the entire study area. Primary outcomes were the proportion of children under 5 years old with potentially lifethreatening illnesses who received either recommended or adequate treatment, and among all children, an index of overall guideline adherence. Secondary outcomes reflected the treatment of individual diseases. Outcomes were calculated monthly, and time trends were evaluated with regression modelling. Results The record review included 9393 consultations, and the surveys included 411 consultations performed by 105 health workers. For both data sources, performance trends were essentially flat for nearly all outcomes. Absolute levels of performance revealed substantial performance gaps. Conclusions We found no evidence that performance declined over 3 years after IMCI training. However, important performance gaps found immediately after IMCI training persisted and should be addressed. C1 [Rowe, Alexander K.; Osterholt, Dawn M.; Kouame, Julien; Piercefield, Emily; Herman, Karen M.] Ctr Dis Control & Prevent CDC, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Osterholt, Dawn M.] Cincinnati Childrens Hosp, Div Gen & Community Pediat Res, Cincinnati, OH USA. [Onikpo, Faustin] Minist Publ Hlth, Direct Dept Sante Publ Oueme & Plateau, Porto Novo, Benin. [Lama, Marcel] Africare Benin, Porto Novo, Benin. [Deming, Michael S.] CDC, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Rowe, AK (reprint author), Ctr Dis Control & Prevent, Mailstop A06,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM axr9@cdc.gov FU Africare; United States Agency for International Development's Africa Integrated Malaria Initiative FX We thank Francois Cokou for his assistance with data management. We acknowledge the support of Africare, the Managing Partner responsible for the implementation of the Africa Integrated Malaria Initiative in Benin with the Benin Ministry of Public Health. This project was funded by the United States Agency for International Development's Africa Integrated Malaria Initiative. NR 20 TC 6 Z9 6 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD APR PY 2012 VL 17 IS 4 BP 438 EP 446 DI 10.1111/j.1365-3156.2012.02976.x PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 915EA UT WOS:000302005600007 PM 22950471 ER PT J AU Beer, L Fagan, JL Garland, P Valverde, EE Bolden, B Brady, KA Courogen, M Hillman, D Neaigus, A Bertolli, J AF Beer, Linda Fagan, Jennifer L. Garland, Pamela Valverde, Eduardo E. Bolden, Barbara Brady, Kathleen A. Courogen, Maria Hillman, Daniel Neaigus, Alan Bertolli, Jeanne CA Never Care Project TI Medication-Related Barriers to Entering HIV Care SO AIDS PATIENT CARE AND STDS LA English DT Article ID ANTIRETROVIRAL THERAPY; CONSPIRACY BELIEFS; AFRICAN-AMERICANS; INFECTED PERSONS; POSITIVE PERSONS; GAY MEN; ADHERENCE; HEALTH; ACCEPTANCE; PREVENTION AB Early entry to HIV care and receipt of antiretroviral therapy improve the health of the individual and decrease the risk of transmission in the community. To increase the limited information on prospective decisions to enter care and how these decisions relate to beliefs about HIV medications, we analyzed interview data from the Never in Care Project, a multisite project conducted in Indiana, New Jersey, New York City, Philadelphia, and Washington State. From March 2008 through August 2010, we completed structured interviews with 134 persons with no evidence of HIV care entry, 48 of whom also completed qualitative interviews. Many respondents believed that HIV care entails the passive receipt of medications that may be harmful or unnecessary, resulting in reluctance to enter care. Respondents voiced concerns about prescription practices and preserving future treatment options, mistrust of medications and medical care providers, and ambivalence about the life-preserving properties of medications in light of an assumed negative impact on quality of life. Our results support the provision of information on other benefits of care (beyond medications), elicitation of concerns about medications, and assessment of psychosocial barriers to entering care. These tasks should begin at the time a positive test result is delivered and continue throughout the linkage-to-care process; for persons unwilling to enter care immediately, support should be provided in nonmedical settings. C1 [Beer, Linda; Fagan, Jennifer L.; Garland, Pamela; Valverde, Eduardo E.; Bertolli, Jeanne] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Garland, Pamela] P3S Corp, San Antonio, TX USA. [Bolden, Barbara] New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA. [Brady, Kathleen A.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Courogen, Maria] Washington State Dept Hlth, Olympia, WA USA. [Hillman, Daniel] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. [Neaigus, Alan] New York City Dept Hlth & Mental Hyg, New York, NY USA. RP Beer, L (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-46, Atlanta, GA 30333 USA. EM lbeer@cdc.gov FU Intramural CDC HHS [CC999999] NR 39 TC 9 Z9 9 U1 0 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD APR PY 2012 VL 26 IS 4 BP 214 EP 221 DI 10.1089/apc.2011.0407 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 918BX UT WOS:000302225000005 PM 22320266 ER PT J AU O'Hare, AM Batten, A Burrows, NR Pavkov, ME Taylor, L Gupta, I Todd-Stenberg, J Maynard, C Rodriguez, RA Murtagh, FEM Larson, EB Williams, DE AF O'Hare, Ann M. Batten, Adam Burrows, Nilka Rios Pavkov, Meda E. Taylor, Leslie Gupta, Indra Todd-Stenberg, Jeff Maynard, Charles Rodriguez, Rudolph A. Murtagh, Fliss E. M. Larson, Eric B. Williams, Desmond E. TI Trajectories of Kidney Function Decline in the 2 Years Before Initiation of Long-term Dialysis SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Trajectory; trajectories; acute kidney injury (AKI); predialysis ID STAGE RENAL-DISEASE; REPLACEMENT THERAPY; SAS PROCEDURE; FAILURE; OUTCOMES; RISK; END; PROGRESSION; DEATH; INCREASES AB Background: Little is known about patterns of kidney function decline leading up to the initiation of long-term dialysis. Study Design: Retrospective cohort study. Setting & Participants: 5,606 Veterans Affairs patients who initiated long-term dialysis in 2001-2003. Predictor: Trajectory of estimated glomerular filtration rate (eGFR) during the 2-year period before initiation of long-term dialysis. Outcomes & Measurements: Patient characteristics and care practices before and at the time of dialysis initiation and survival after initiation. Results: We identified 4 distinct trajectories of eGFR during the 2-year period before dialysis initiation: 62.8% of patients had persistently low level of eGFR <30 mL/min/1.73 m(2) (mean eGFR slope, 7.7 +/- 4.7 [SD] mL/min/1.73 m(2) per year), 24.6% had progressive loss of eGFR from levels of approximately 30-59 ml/min/1.73 m(2) (mean eGFR slope, 16.3 +/- 7.6 mL/min/1.73 m(2) per year), 9.5% had accelerated loss of eGFR from levels >60 mL/min/1.73 m(2) (mean eGFR slope, 32.3 +/- 13.4 mL/min/1.73 m(2) per year), and 3.1% experienced catastrophic loss of eGFR from levels >60 mL/min/1.73 m(2) within 6 months or less. Patients with steeper eGFR trajectories were more likely to have been hospitalized and have an inpatient diagnosis of acute kidney injury. They were less likely to have received recommended predialysis care and had a higher risk of death in the first year after dialysis initiation. Conclusions: There is substantial heterogeneity in patterns of kidney function loss leading up to the initiation of long-term dialysis perhaps calling for a more flexible approach toward preparing for end-stage renal disease. Am J Kidney Dis. 59(4):513-522. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [O'Hare, Ann M.; Rodriguez, Rudolph A.] Univ Washington, Seattle, WA 98195 USA. [O'Hare, Ann M.; Larson, Eric B.] Grp Hlth, Grp Hlth Res Inst, Seattle, WA USA. [Burrows, Nilka Rios; Pavkov, Meda E.; Williams, Desmond E.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Murtagh, Fliss E. M.] Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabilitat, London, England. RP O'Hare, AM (reprint author), VA Puget Sound Med Ctr, Div Nephrol Primary & Specialty Med Serv Line, Nephrol & Renal Dialysis Unit, Bldg 100,Rm 5B113,1660 S Columbian Way, Seattle, WA 98108 USA. EM ann.ohare@va.gov RI Maynard, Charles/N-3906-2015; Murtagh, Fliss/C-3216-2009 OI Maynard, Charles/0000-0002-1644-7814; Murtagh, Fliss/0000-0003-1289-3726 FU Centers for Disease Control and Prevention (CDC); VAPSHCS [07FED69212]; VA Puget Sound Health Services Research and Development Center of Excellence; National Institute on Aging [K 1K23AG28980] FX This work was supported by an Interagency Agreement between the Centers for Disease Control and Prevention (CDC) and VAPSHCS (07FED69212), the VA Puget Sound Health Services Research and Development Center of Excellence, and a Beeson Career Development Award from the National Institute on Aging to Dr O'Hare (K 1K23AG28980). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the CDC. NR 26 TC 80 Z9 82 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2012 VL 59 IS 4 BP 513 EP 522 DI 10.1053/j.ajkd.2011.11.044 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 916QE UT WOS:000302117500321 PM 22305760 ER PT J AU Banerjee, T Crews, D Wesson, D Saran, R Tilea, A Williams, D Burrows, N Powe, N AF Banerjee, Tanushree Crews, Deidra Wesson, Donald Saran, Rajiv Tilea, Anca Williams, Desmond Burrows, Nilka Powe, Neil TI DIETARY POTENTIAL RENAL ACID LOAD (PRAL) VARIES BY SOCIODEMOGRAPHICS AND CKD STATUS AMONG US ADULTS SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY MAY 09-13, 2012 CL Washington, DC SP Natl Kidney Fdn C1 [Banerjee, Tanushree; Powe, Neil] UCSF, San Francisco, CA USA. [Crews, Deidra] Johns Hopkins Univ, Baltimore, MD USA. [Saran, Rajiv; Tilea, Anca] Univ Michigan, Ann Arbor, MI 48109 USA. [Williams, Desmond; Burrows, Nilka] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2012 VL 59 IS 4 MA 23 BP A20 EP A20 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 916QE UT WOS:000302117500025 ER PT J AU Burrows, NR Hora, I Williams, D AF Burrows, Nilka Rios Hora, Israel Williams, Desmond TI INCREASING MEAN BODY MASS INDEX AMONG INCIDENT CASES OF END-STAGE RENAL DISEASE, BY DIABETES STATUS, UNITED STATES, 1996-2009 SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY MAY 09-13, 2012 CL Washington, DC SP Natl Kidney Fdn C1 [Burrows, Nilka Rios; Hora, Israel; Williams, Desmond] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2012 VL 59 IS 4 MA 43 BP A25 EP A25 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 916QE UT WOS:000302117500045 ER PT J AU Crews, D Light, L Shahinian, V Hedgeman, E Rios-Burrows, N Williams, D Powe, N AF Crews, Deidra Light, Laney Shahinian, Vahakn Hedgeman, Elizabeth Rios-Burrows, Nilka Williams, Desmond Powe, Neil CA CDC CKD Surveillance Team TI FOOD INSECURITY AND CKD IN THE UNITED STATES SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY MAY 09-13, 2012 CL Washington, DC SP Natl Kidney Fdn C1 [Crews, Deidra; Light, Laney] Johns Hopkins Univ, Baltimore, MD USA. [Shahinian, Vahakn; Hedgeman, Elizabeth] Univ Michigan, Ann Arbor, MI 48109 USA. [Rios-Burrows, Nilka; Williams, Desmond] Ctr Dis Control & Prevent, Atlanta, GA USA. [Powe, Neil] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2012 VL 59 IS 4 MA 57 BP A29 EP A29 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 916QE UT WOS:000302117500059 ER PT J AU Tilea, A Hedgeman, E Nair, S Pavkov, M Saydah, S Powe, N Saran, R AF Tilea, Anca Hedgeman, Elizabeth Nair, Seena Pavkov, Meda Saydah, Sharon Powe, Neil Saran, Rajiv CA CDC CKD Surveillance Syst TI CHRONIC KIDNEY DISEASE SURVEILLANCE FOR THE UNITED STATES: A US CENTERS FOR DISEASE CONTROL AND PREVENTION INITATIVE SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY MAY 09-13, 2012 CL Washington, DC SP Natl Kidney Fdn C1 Univ Michigan, Ann Arbor, MI 48109 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Ctr Dis Control & Prevent, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2012 VL 59 IS 4 MA 290 BP A87 EP A87 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 916QE UT WOS:000302117500292 ER PT J AU Yi, SH Kallen, AJ Jernigan, JA Patel, PR AF Yi, Sarah H. Kallen, Alexander J. Jernigan, John A. Patel, Priti R. CA CDC Dialysis BSI Prevention TI REDUCTION IN BLOODSTREAM INFECTION RATES IN OUTPATIENT HEMODIALYSIS CENTERS PARTICIPATING IN A CDC PREVENTION COLLABORATIVE SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY MAY 09-13, 2012 CL Washington, DC SP Natl Kidney Fdn C1 [Yi, Sarah H.; Kallen, Alexander J.; Jernigan, John A.; Patel, Priti R.; CDC Dialysis BSI Prevention] Ctr Dis Control & Prevent CDC, Div Healthcare Qual Promot, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2012 VL 59 IS 4 MA 304 BP A90 EP A90 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 916QE UT WOS:000302117500306 ER PT J AU Evon, DM Weiss, JJ Groessl, EJ Cabral, R AF Evon, Donna M. Weiss, Jeffrey J. Groessl, Erik J. Cabral, Rebecca TI ENGAGING HEALTH PSYCHOLOGISTS IN THE MANAGEMENT AND TREATMENT OF CHRONIC HEPATITIS C SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Evon, Donna M.] Univ N Carolina, Chapel Hill, NC 27599 USA. [Weiss, Jeffrey J.] Mt Sinai Sch Med, New York, NY USA. [Groessl, Erik J.] Univ Calif San Diego, VA San Diego, San Diego, CA 92103 USA. [Cabral, Rebecca] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. EM donna_evon@med.unc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S165 EP S165 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400641 ER PT J AU Khan, LK AF Khan, Laura Kettel TI BEGINNING THE PIPELINE OF EVIDENCE: USING THE SYSTEMATIC SCREENING AND ASSESSMENT METHOD SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Khan, Laura Kettel] CDC, DNPAO, Atlanta, GA 30341 USA. EM ldk7@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S55 EP S55 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400214 ER PT J AU Mercer, SL AF Mercer, Shawna L. TI STRENGTHENING THE EVIDENCE-BASE FOR CHILDHOOD OBESITY PREVENTION: LESSONS FROM THE COMMUNITY GUIDE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Mercer, Shawna L.] CDC, Atlanta, GA 30029 USA. EM SMercer@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S56 EP S56 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400216 ER PT J AU Peipins, L McCarty, F Hawkins, N Rodriguez, J Scholl, L Leadbetter, S AF Peipins, Lucy McCarty, Frances Hawkins, Nikki Rodriguez, Juan Scholl, Lawrence Leadbetter, Steven TI EXAMINING COGNITIVE AND AFFECTIVE INFLUENCES ON PERCEIVED RISK OF OVARIAN CANCER SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Peipins, Lucy; Hawkins, Nikki; Rodriguez, Juan; Leadbetter, Steven] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [McCarty, Frances] Georgia State Univ, Inst Publ Hlth, Atlanta, GA 30303 USA. [Scholl, Lawrence] ICF Macro, Calverton, MD USA. EM LBP6@CDC.GOV NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S91 EP S91 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400351 ER PT J AU Prue, C Baur, C McCormack, L Squiers, L Kelly, B Lynch, M Maddox, K Margolis, M Moultrie, R AF Prue, Christine Baur, Cynthia McCormack, Lauren Squiers, Linda Kelly, Bridget Lynch, Molly Maddox, Kathryn Margolis, Marjorie Moultrie, Rebecca TI SCIENTIFIC LITERACY OF H1N1 PANDEMIC FLU INFORMATION & PUBLIC PERSPECTIVES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Prue, Christine] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30084 USA. [Baur, Cynthia] Ctr Dis Control & Prevent, Off Associate Director Commun, Atlanta, GA 30084 USA. [Maddox, Kathryn] Chenega Govt Consulting, Chesapeake, VA USA. [McCormack, Lauren; Squiers, Linda; Kelly, Bridget; Lynch, Molly; Margolis, Marjorie; Moultrie, Rebecca] RTI Int, Hlth Commun Program, Res Triangle Pk, NC USA. EM cprue@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S145 EP S145 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400563 ER PT J AU Prue, C Simani, P Hibbs, B Saloni, S Leroy, Z Tumpey, A Karen, B Bryant, P Gaddes, R AF Prue, Christine Simani, Price Hibbs, Beth Saloni, Sapru Leroy, Zanie Tumpey, Abbigail Karen, Broder Bryant, Pamela Gaddes, Rachel TI CLINICIANS VIEWS ABOUT VACCINE ADVERSE EVENT REPORTING SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Prue, Christine; Hibbs, Beth; Leroy, Zanie; Tumpey, Abbigail; Karen, Broder; Bryant, Pamela] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30084 USA. [Simani, Price; Saloni, Sapru; Gaddes, Rachel] Hlth Commun Res, Rockville, MD USA. EM cprue@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S32 EP S32 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400123 ER PT J AU Violanti, JM Charles, LE Gu, JK Burchfiel, CM Andrew, ME Joseph, PN Dorn, JM AF Violanti, John M. Charles, Luenda E. Gu, Ja K. Burchfiel, Cecil M. Andrew, Michael E. Joseph, Parveen N. Dorn, Joan M. TI DEPRESSION SYMPTOMS AND CAROTID ARTERY INTIMA-MEDIA THICKNESS IN POLICE OFFICERS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Violanti, John M.; Dorn, Joan M.] SUNY Buffalo, Buffalo, NY 14214 USA. [Charles, Luenda E.; Gu, Ja K.; Burchfiel, Cecil M.; Andrew, Michael E.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Joseph, Parveen N.] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA. EM violanti@buffalo.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S157 EP S157 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400609 ER PT J AU Balaji, AB Eaton, DK Voetsch, AC Wiegand, RE Miller, KS Doshi, SR AF Balaji, Alexandra B. Eaton, Danice K. Voetsch, Andrew C. Wiegand, Ryan E. Miller, Kim S. Doshi, Sonal R. TI Association Between HIV-Related Risk Behaviors and HIV Testing Among High School Students in the United States, 2009 SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID IMMUNODEFICIENCY-VIRUS-INFECTION; SEXUALLY-TRANSMITTED-DISEASES; PRIMARY-CARE; AFRICAN-AMERICAN; YOUNG-ADULTS; AIDS RISK; ADOLESCENTS; YOUTH; COMMUNICATION; SERVICES AB Objective: To identify the human immunodeficiency virus (HIV)-related risk behaviors associated with HIV testing among US high school students who reported ever having sexual intercourse. Design: Secondary analysis of a cross-sectional study. Setting: The 2009 national Youth Risk Behavior Survey. Participants: A total of 7591 US high school students who reported ever having sexual intercourse. Main Exposures: Risk behaviors related to HIV. Main Outcome Measure: Having ever been tested for HIV. Results: Among the 7591 students who reported ever having sexual intercourse, 22.6% had been tested for HIV. Testing for HIV was most likely to be done among students who had ever injected any illegal drug (41.3%; adjusted odds ratio, 1.70; 95% CI, 1.14-2.56), had ever been physically forced to have sexual intercourse (36.2%; adjusted odds ratio, 1.43; 95% CI, 1.19-1.72), did not use a condom the last time they had sexual intercourse (28.7%; adjusted odds ratio, 1.28; 95% CI, 1.08-1.51), and had sexual intercourse with 4 or more persons during their life (34.7%; adjusted odds ratio, 2.32; 95% CI, 1.98-2.73). Conclusions: Most sexually active students, even among those who reported high-risk behaviors for HIV, have not been tested for HIV. New strategies for increasing HIV testing among the adolescent population, including encouraging routine voluntary HIV testing among those who are sexually active, are needed. C1 [Balaji, Alexandra B.; Eaton, Danice K.; Voetsch, Andrew C.; Wiegand, Ryan E.; Miller, Kim S.; Doshi, Sonal R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Balaji, AB (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-46, Atlanta, GA 30333 USA. EM dvi7@cdc.gov NR 56 TC 10 Z9 10 U1 2 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD APR PY 2012 VL 166 IS 4 BP 331 EP 336 DI 10.1001/archpediatrics.2011.1131 PG 6 WC Pediatrics SC Pediatrics GA 918UU UT WOS:000302277500005 PM 22213606 ER PT J AU Skoff, TH Cohn, AC Clark, TA Messonnier, NE Martin, SW AF Skoff, Tami H. Cohn, Amanda C. Clark, Thomas A. Messonnier, Nancy E. Martin, Stacey W. TI Early Impact of the US Tdap Vaccination Program on Pertussis Trends SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID PNEUMOCOCCAL CONJUGATE VACCINE; IMMUNIZATION PRACTICES ACIP; AGED 13-17 YEARS; UNITED-STATES; CHANGING EPIDEMIOLOGY; YOUNG INFANTS; HERD-IMMUNITY; BORDETELLA-PERTUSSIS; ADVISORY-COMMITTEE; PREVENTING TETANUS AB Objective: To evaluate the impact of the adolescent Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine) vaccination program on pertussis trends in the United States. Design: Retrospective analysis of nationally reported pertussis cases, January 1, 1990, through December 31, 2009. Setting: United States. Participants: Confirmed and probable pertussis cases. Intervention: The US Tdap vaccination program. Main Outcome Measure: Rate ratios of reported pertussis incidence (defined as incidence among 11- to 18-year-olds divided by the combined incidence in all other age groups) modeled through segmented regression analysis and age-specific trends in reported pertussis incidence over time. Results: A total of 200 401 pertussis cases were reported in the United States from 1990 to 2009. Overall incidence ranged from 1.0 to 8.8 per 100 000 persons (1991 and 2004, respectively). Slope coefficients (estimated annual rate of change in rate ratios) from segmented regression showed a steady increase in pertussis incidence among adolescents 11 to 18 years old compared with all other age groups before Tdap introduction (slope=0.22; P<.001), and a steep decreasing trend post introduction (slope=-0.48; P<.001), suggesting a direct impact of vaccination among adolescents. Indirect effects of adolescent vaccination were not observed among infants younger than 1 year. Conclusions: Changes in pertussis incidence in the United States from 2005 to 2009 revealed a divergence between 11- to 18-year-olds and other age groups, suggesting that targeted use of Tdap among adolescents reduced disease preferentially in this age group. Increased Tdap coverage in adolescents and adults is needed to realize the full direct and indirect benefits of vaccination. C1 [Skoff, Tami H.; Cohn, Amanda C.; Clark, Thomas A.; Messonnier, Nancy E.; Martin, Stacey W.] US Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Skoff, TH (reprint author), Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop C-25, Atlanta, GA 30333 USA. EM tlh9@cdc.gov NR 40 TC 40 Z9 41 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD APR PY 2012 VL 166 IS 4 BP 344 EP 349 DI 10.1001/archpediatrics.2011.1093 PG 6 WC Pediatrics SC Pediatrics GA 918UU UT WOS:000302277500007 PM 22213608 ER PT J AU Underwood, JM Townsend, JS Tai, E Davis, SP Stewart, SL White, A Momin, B Fairley, TL AF Underwood, J. Michael Townsend, Julie S. Tai, Eric Davis, Shane P. Stewart, Sherri L. White, Arica Momin, Behnoosh Fairley, Temeika L. TI Racial and Regional Disparities in Lung Cancer Incidence SO CANCER LA English DT Article DE lung neoplasm; tobacco; ethnic groups; epidemiology ID UNITED-STATES; CIGARETTE-SMOKING; AFRICAN-AMERICANS; ALASKA-NATIVES; NEVER-SMOKERS; LARGE COHORT; NAVAJO MEN; EPIDEMIOLOGY; PATTERNS; STAGE AB BACKGROUND: Lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer-related death in the United States (US). We examined data from 2004 to 2006 for lung cancer incidence rates by demographics, including race and geographic region, to identify potential health disparities. METHODS: Data from cancer registries affiliated with the Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries (NPCR), and the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results Program (SEER) were used for this study; representing 100% of the US population. Age-adjusted incidence rates and 95% confidence intervals for demographic (age, sex, race, ethnicity, and US Census region), and tumor (stage, grade, and histology) characteristics were calculated. RESULTS: During 2004 to 2006, 623,388 people (overall rate of 68.9 per 100,000) were diagnosed with lung cancer in the US. Lung cancer incidence rates were highest among men (86.2), Blacks (73.0), persons aged 70 to 79 years (431.1), and those living in the South (74.7). Among Whites, the highest lung cancer incidence rate was in the South (75.6); the highest rates among Blacks (88.9) and American Indians/Alaska Natives (65.4) in the Midwest, Asians/Pacific Islanders in the West (40.0), and Hispanics in the Northeast (40.3). CONCLUSIONS: Our findings of racial, ethnic, and regional disparities in lung cancer incidence suggest a need for the development and implementation of more effective culturally specific preventive and treatment strategies that will ultimately reduce the disproportionate burden of lung cancer in the US. Cancer 2012;118:1910-8. (C) 2011 American Cancer Society. C1 [Underwood, J. Michael; Townsend, Julie S.; Tai, Eric; Stewart, Sherri L.; White, Arica; Momin, Behnoosh; Fairley, Temeika L.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Davis, Shane P.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. [Underwood, J. Michael; White, Arica] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Underwood, JM (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,MS-K57, Atlanta, GA 30341 USA. EM jmunderwood@cdc.gov NR 62 TC 26 Z9 27 U1 4 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD APR 1 PY 2012 VL 118 IS 7 BP 1910 EP 1918 DI 10.1002/cncr.26479 PG 9 WC Oncology SC Oncology GA 910NR UT WOS:000301647000023 PM 21918961 ER PT J AU Edwards, SH Stribling, SL Pyatt, SD Kimberly, MM AF Edwards, Selvin H. Stribling, Shelton L. Pyatt, Susan D. Kimberly, Mary M. TI Reference Measurement Procedure for Total Glycerides by Isotope Dilution GC-MS SO CLINICAL CHEMISTRY LA English DT Article ID CHROMATOGRAPHY-MASS-SPECTROMETRY; CLINICAL MEASUREMENT; HUMAN SERUM; TRIGLYCERIDE; CHOLESTEROL; ENRICHMENTS; PLASMA; MODEL AB BACKGROUND: The CDC's Lipid Standardization Program established the chromotropic acid (CA) reference measurement procedure (RMP) as the accuracy base for standardization and metrological traceability for triglyceride testing. The CA RMP has several disadvantages, including lack of ruggedness. It uses obsolete instrumentation and hazardous reagents. To overcome these problems the CDC developed an isotope dilution GC-MS (ID-GC-MS) RMP for total glycerides in serum. METHODS: We diluted serum samples with Tris-HCl buffer solution and spiked 200-mu L aliquots with [C-13(3)]-glycerol. These samples were incubated and hydrolyzed under basic conditions. The samples were dried, derivatized with acetic anhydride and pyridine, extracted with ethyl acetate, and analyzed by ID-GC-MS. Linearity, imprecision, and accuracy were evaluated by analyzing calibrator solutions, 10 serum pools, and a standard reference material (SRM 1951b). RESULTS: The calibration response was linear for the range of calibrator concentrations examined (0-1.24 mmol/L) with a slope and intercept of 0.717 (95% CI, 0.7123-0.7225) and 0.3122 (95% CI, 0.3096-0.3140), respectively. The limit of detection was 14.8 mu mol/L. The mean %CV for the sample set (serum pools and SRM) was 1.2%. The mean %bias from NIST isotope dilution MS values for SRM 1951b was 0.7%. CONCLUSIONS: This ID-GC-MS RMP has the specificity and ruggedness to accurately quantify total glycerides in the serum pools used in the CDC's Lipid Standardization Program and demonstrates sufficiently acceptable agreement with the NIST primary RMP for total glyceride measurement. (C) 2011 American Association for Clinical Chemistry C1 [Edwards, Selvin H.; Pyatt, Susan D.; Kimberly, Mary M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Clin Chem Branch, Atlanta, GA 30341 USA. [Stribling, Shelton L.] Battelle Mem Inst, Atlanta, GA USA. RP Edwards, SH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Clin Chem Branch, 4770 Buford Hwy NE,MS-F25, Atlanta, GA 30341 USA. EM sedwards@cdc.gov FU Division for Heart and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC; National Heart Lung and Blood Institute FX Interagency Agreement with the National Heart Lung and Blood Institute and funding from the Division for Heart and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC. NR 28 TC 7 Z9 7 U1 4 U2 17 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD APR PY 2012 VL 58 IS 4 BP 768 EP 776 DI 10.1373/clinchem.2011.177063 PG 9 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 917NW UT WOS:000302185700020 PM 22273565 ER PT J AU Dombkowski, KJ Harrington, L Hanauer, D Kennedy, A Clark, S AF Dombkowski, Kevin J. Harrington, Laura Hanauer, David Kennedy, Allison Clark, Sarah TI Current and Potential Use of New Technologies for Reminder Notifications SO CLINICAL PEDIATRICS LA English DT Article ID CLINICAL-TRIAL; IMMUNIZATION; RATES; CARE C1 [Dombkowski, Kevin J.] Univ Michigan, Div Gen Pediat, Ann Arbor, MI 48109 USA. [Kennedy, Allison] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Dombkowski, KJ (reprint author), Univ Michigan, Div Gen Pediat, 300 N Ingalls, Ann Arbor, MI 48109 USA. EM kjd@med.umich.edu FU Centers for Disease Control and Prevention [1U01IP0000316] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Cooperative Agreement Number 1U01IP0000316 from the Centers for Disease Control and Prevention.; The findings and conclusions are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (the funding agency). NR 14 TC 8 Z9 8 U1 2 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 J9 CLIN PEDIATR JI Clin. Pediatr. PD APR PY 2012 VL 51 IS 4 BP 394 EP 397 DI 10.1177/0009922811420715 PG 4 WC Pediatrics SC Pediatrics GA 915FF UT WOS:000302008800014 PM 22333573 ER PT J AU Storm, JE Mazor, KA Aldous, KM Blount, BC Brodie, SE Serle, JB AF Storm, Jan E. Mazor, Kimberly A. Aldous, Kenneth M. Blount, Benjamin C. Brodie, Scott E. Serle, Janet B. TI Letter to the editor: "Review of the epidemiologic literature on residential exposure to perchloroethylene" by John A. Bukowski SO CRITICAL REVIEWS IN TOXICOLOGY LA English DT Letter ID VISUAL CONTRAST SENSITIVITY; ORGANIC-SOLVENTS; TETRACHLOROETHYLENE; CHILDREN C1 [Storm, Jan E.; Mazor, Kimberly A.] New York State Dept Hlth, Ctr Environm Hlth, Troy, NY USA. [Aldous, Kenneth M.] New York State Dept Hlth, Wadsworth Ctr, Troy, NY USA. [Blount, Benjamin C.] US Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Brodie, Scott E.; Serle, Janet B.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA. RP Storm, JE (reprint author), NYS DOH Ctr Environm Hlth, 547 River St, Troy, NY 12180 USA. EM jes19@health.state.ny.us NR 17 TC 0 Z9 0 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1040-8444 J9 CRIT REV TOXICOL JI Crit. Rev. Toxicol. PD APR PY 2012 VL 42 IS 4 BP 314 EP 317 DI 10.3109/10408444.2012.663745 PG 4 WC Toxicology SC Toxicology GA 919KE UT WOS:000302323400003 PM 22469066 ER PT J AU Herman, WH Edelstein, SL Ratner, RE Montez, MG Ackermann, RT Orchard, TJ Foulkes, MA Zhang, P Saudek, CD Brown, MB AF Herman, William H. Edelstein, Sharon L. Ratner, Robert E. Montez, Maria G. Ackermann, Ronald T. Orchard, Trevor J. Foulkes, Mary A. Zhang, Ping Saudek, Christopher D. Brown, Morton B. CA Diabet Prevention Program Res Grp TI The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention An intent-to-treat analysis of the DPP/DPPOS SO DIABETES CARE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; WEIGHT-LOSS; OUTCOMES; PROGRAM; US; EXERCISE; THERAPY; OBESITY; PEOPLE; ADULTS AB OBJECTIVE-The Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS) demonstrated that either intensive lifestyle intervention or metformin could prevent type 2 diabetes in high-risk adults for at least 10 years after randomization. We report the 10-year within-trial cost-effectiveness of the interventions. RESEARCH DESIGN AND METHODS-Data on resource utilization, cost, and quality of life were collected prospectively. Economic analyses were performed from health system and societal perspectives. RESULTS-Over 10 years, the cumulative, undiscounted per capita direct medical costs of the interventions, as implemented during the DPP, were greater for lifestyle ($4,601) than metformin ($2,300) or placebo ($769). The cumulative direct medical costs of care outside the DPP/DPPOS were least for lifestyle ($24,563 lifestyle vs. $25,616 metformin vs. $27,468 placebo). The cumulative, combined total direct medical costs were greatest for lifestyle and least for metformin ($29,164 lifestyle vs. $27,915 metformin vs. $28,236 placebo). The cumulative quality-adjusted life-years (QALYs) accrued over 10 years were greater for lifestyle (6.81) than metformin (6.69) or placebo (6.67). When costs and outcomes were discounted at 3%, lifestyle cost $10,037 per QALY, and metformin had slightly lower costs and nearly the same QALYs as placebo. CONCLUSIONS-Over 10 years, from a payer perspective, lifestyle was cost-effective and metformin was marginally cost-saving compared with placebo. Investment in lifestyle and metforrnin interventions for diabetes prevention in high-risk adults provides good value for the money spent. C1 [Herman, William H.; Brown, Morton B.] Univ Michigan, Ann Arbor, MI 48109 USA. [Edelstein, Sharon L.; Foulkes, Mary A.] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Ratner, Robert E.] Medstar Hlth Res Inst, Washington, DC USA. [Montez, Maria G.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ackermann, Ronald T.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Orchard, Trevor J.] Univ Pittsburgh, Pittsburgh, PA USA. [Zhang, Ping] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Saudek, Christopher D.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Herman, WH (reprint author), Univ Michigan, Ann Arbor, MI 48109 USA. OI orchard, trevor/0000-0001-9552-3215 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health; NIDDK; Indian Health Service; National Institute of Child Health and Human Development; National Institute on Aging; National Eye Institute; National Heart, Lung, and Blood Institute; Office of Research on Women's Health; National Institute on Minority Health and Health Disparities; Centers for Disease Control and Prevention; American Diabetes Association; Bristol-Myers Squibb; Parke-Davis FX During the DPPOS, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health provided funding to the clinical centers and the DPP Coordinating Center for the design and conduct of the study, and collection, management, analysis, and interpretation of the data. The Southwestern American Indian Centers were supported directly by the NIDDK, including its Intramural Research Program, and the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources, and the U.S. Department of Veterans Affairs supported data collection at many of the clinical centers. Funding was also provided by the National Institute of Child Health and Human Development; the National Institute on Aging; the National Eye Institute; the National Heart, Lung, and Blood Institute; the Office of Research on Women's Health; the National Institute on Minority Health and Health Disparities; the Centers for Disease Control and Prevention; and the American Diabetes Association.; Bristol-Myers Squibb and Parke-Davis provided additional funding and material support during the DPP. Lipha (Merck-Sante) provided medication and LifeScan Inc. donated materials during the DPP and the DPPOS. No other potential conflicts of interest relevant to this article were reported. NR 23 TC 84 Z9 84 U1 5 U2 20 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD APR PY 2012 VL 35 IS 4 BP 723 EP 730 DI 10.2337/dc11-1468 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 914OB UT WOS:000301959600012 ER PT J AU Barcelo, A Gregg, EW Gerzoff, RB Wong, R Flores, EP Ramirez-Zea, M Cafiero, E Altamirano, L Rivera, MA de Cosio, G de Maza, MD del Aguila, R Emanuel, E Gil, E Gough, E Jenkins, V Orellana, P Palma, R Palomo, R Pastora, M Pena, R Pineda, E Rodriguez, B Tacsan, L Thompson, L Villagra, L AF Barcelo, Alberto Gregg, Edward W. Gerzoff, Robert B. Wong, Roy Flores, Enrique Perez Ramirez-Zea, Manuel Cafiero, Elizabeth Altamirano, Lesbia Ascencio Rivera, Melanie de Cosio, Gerardo Dinorah de Maza, Martha del Aguila, Roberto Emanuel, Englebert Gil, Enrique Gough, Ethan Jenkins, Valerie Orellana, Patricia Palma, Ruben Palomo, Ruben Pastora, Martha Pena, Rodolfo Pineda, Elia Rodriguez, Bismark Tacsan, Luis Thompson, Loraine Villagra, Lucy CA CAMDI Collaborative Study Grp TI Prevalence of Diabetes and Intermediate Hyperglycemia Among Adults From the First Multinational Study of Noncommunicable Diseases in Six Central American Countries The Central America Diabetes Initiative (CAMDI) SO DIABETES CARE LA English DT Article ID IMPAIRED FASTING GLUCOSE; POPULATION AB OBJECTIVE-The increasing burdens of obesity and diabetes are two of the most prominent threats to the health of populations of developed and developing countries alike. The Central America Diabetes Initiative (CAMDI) is the first study to examine the prevalence of diabetes in Central America. RESEARCH DESIGN AND METHODS-The CAMDI survey was a cross-sectional survey based on a probabilistic sample of the noninstitutionalized population of five Central American populations conducted between 2003 and 2006. The total sample population was 10,822, of whom 7,234 (67%) underwent anthropometry measurement and a fasting blood glucose or 2-h oral glucose tolerance test. RESULTS-The total prevalence of diabetes was 8.5%, but was higher in Belize (12.9%) and lower in Honduras (5.4%). Of the screened population, 18.6% had impaired glucose tolerance/impaired fasting glucose. CONCLUSIONS-As this population ages, the prevalence of diabetes is likely to continue to rise in a dramatic and devastating manner. Preventive strategies must be quickly introduced. C1 [Barcelo, Alberto; Thompson, Loraine] PAHO, Washington, DC USA. [Gregg, Edward W.] US Ctr Dis Control & Prevent, Epidemiol & Stat Branch, Div Diabet Translat, Atlanta, GA USA. [Gerzoff, Robert B.] US Ctr Dis Control & Prevent, Epidemiol Branch, Off Smoking & Hlth, Atlanta, GA USA. [Wong, Roy] Caja Costarricense Seguro Social, Off Epidemiol Surveillance, San Jose, Costa Rica. [Flores, Enrique Perez] US Mexico Border, PAHO, Field Off, El Paso, TX USA. [Ramirez-Zea, Manuel] Inst Nutr Ctr Amer & Panama, Ctr Integral Prevenc Enfermedades Cron, Guatemala City, Guatemala. [Cafiero, Elizabeth] Harvard Univ, Sch Med, Dept Global Hlth & Populat, Boston, MA USA. [Altamirano, Lesbia] PAHO, Off Nicaragua, Managua, Nicaragua. [Ascencio Rivera, Melanie; Tacsan, Luis] Minist Hlth, Direcc Desarrollo Cient & Tecnol Salud, San Jose, Costa Rica. [de Cosio, Gerardo] PAHO, Off Belize, Belize City, Belize. [Dinorah de Maza, Martha] Diabet Assoc El Salvador, San Salvador, El Salvador. [del Aguila, Roberto] PAHO, Off Chile, Santiago, Chile. [Emanuel, Englebert; Gough, Ethan; Jenkins, Valerie] Minist Hlth, Dept Epidemiol, Belmopan, Belize. [Gil, Enrique] PAHO, Off Brazil, Brasilia, DF, Brazil. [Orellana, Patricia] Univ San Carlos, Dept Med, Guatemala City, Guatemala. [Palma, Ruben] Hosp Gen San Felipe, Fdn Diebet, Tegucigalpa, Honduras. [Palomo, Ruben] Minist Hlth, Dept Adult & Masculine Hlth, San Salvador, El Salvador. [Pastora, Martha] Minist Salud, Direcc Gen Serv Salud, Managua, Nicaragua. [Pena, Rodolfo; Rodriguez, Bismark] Univ Autonoma Nicaragua Leon, Ctr Invest Demog & Salud, Leon, Nicaragua. [Pineda, Elia] Univ Nacl Autonoma Honduras, Sch Nursing, Tegucigalpa, Honduras. [Villagra, Lucy] Univ Nacl Autonoma Nicaragua, Dept Endocrinol, Managua, Nicaragua. RP Barcelo, A (reprint author), PAHO, Washington, DC USA. EM barceloa@paho.org NR 9 TC 14 Z9 14 U1 2 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2012 VL 35 IS 4 BP 738 EP 740 DI 10.2337/dc11-1614 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 914OB UT WOS:000301959600014 PM 22323417 ER PT J AU Liu, LD Callinan, LS Holman, RC Blau, DM AF Liu, Lindy Callinan, Laura S. Holman, Robert C. Blau, Dianna M. TI Determinants for Autopsy after Unexplained Deaths Possibly Resulting from Infectious Causes, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID ACUTE RESPIRATORY SYNDROME; VIRTUAL AUTOPSY; PUBLIC-HEALTH; SURVEILLANCE; PATHOLOGY; ATTITUDES; DISEASE; SEPSIS; VIRUS; RATES AB We analyzed US multiple cause-of-death data for 2003-2006 for demographic and clinical determinants for autopsy in unexplained deaths possibly resulting from infectious causes. For 96,242 deaths, the definition for unexplained death was met and autopsy status was recorded. Most decedents were male, 40-49 years of age, and white. To identify factors associated with unexplained death, we used data from Arizona records. Multivariate analysis of Arizona records suggested that decedents of races other than white and black and decedents who had clinicopathologic syndromes in the cardiovascular, sepsis/shock, and multisyndrome categories recorded on the death certificate were least likely to have undergone autopsy; children with unexplained death were the most likely to have undergone autopsy. Improved understanding of unexplained deaths can provide opportunities for further studies, strengthen collaboration between investigators of unexplained deaths, and improve knowledge and awareness of infectious diseases of public health concern. C1 [Liu, Lindy; Callinan, Laura S.; Holman, Robert C.; Blau, Dianna M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Liu, LD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G32, Atlanta, GA 30333 USA. EM fuz3@cdc.gov NR 40 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2012 VL 18 IS 4 BP 549 EP 555 DI 10.3201/eid1804.111311 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 919MJ UT WOS:000302331600001 PM 22469466 ER PT J AU Luckhaupt, SE Sweeney, MH Funk, R Calvert, GM Nowell, M D'Mello, T Reingold, A Meek, J Yousey-Hindes, K Arnold, KE Ryan, P Lynfield, R Morin, C Baumbach, J Zansky, S Bennett, NM Thomas, A Schaffner, W Jones, T AF Luckhaupt, Sara E. Sweeney, Marie Haring Funk, Renee Calvert, Geoffrey M. Nowell, Mackenzie D'Mello, Tiffany Reingold, Arthur Meek, James Yousey-Hindes, Kimberly Arnold, Kathryn E. Ryan, Patricia Lynfield, Ruth Morin, Craig Baumbach, Joan Zansky, Shelley Bennett, Nancy M. Thomas, Ann Schaffner, William Jones, Timothy TI Influenza-associated Hospitalizations by Industry, 2009-10 Influenza Season, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID HEALTH-CARE PERSONNEL; H1N1 INFLUENZA; RISK-FACTORS; WORKERS AB In response to pandemic (H1N1) 2009, data were collected on work status and industry of employment of 3,365 adults hospitalized with laboratory-confirmed influenza during the 2009-10 influenza season in the United States. The proportion of workers hospitalized for influenza was lower than their proportion in the general population, reflecting underlying protective characteristics of workers compared with nonworkers. The most commonly represented sectors were transportation and warehousing; administrative and support and waste management and remediation services; health care; and accommodation and food service. C1 [Luckhaupt, Sara E.; Sweeney, Marie Haring; Calvert, Geoffrey M.] Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Funk, Renee; Nowell, Mackenzie; D'Mello, Tiffany] Ctr Dis Control & Prevent, Atlanta, GA USA. [Reingold, Arthur] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Meek, James; Yousey-Hindes, Kimberly] Yale Univ, New Haven, CT USA. [Arnold, Kathryn E.] Georgia Div Publ Hlth, Atlanta, GA USA. [Ryan, Patricia] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Lynfield, Ruth; Morin, Craig] Minnesota Dept Hlth, Minneapolis, MN USA. [Baumbach, Joan] New Mexico Dept Hlth, Santa Fe, NM USA. [Zansky, Shelley] New York State Dept Hlth, Albany, NY USA. [Bennett, Nancy M.] Univ Rochester, Rochester, NY USA. [Thomas, Ann] Oregon Publ Hlth Div, Portland, OR USA. [Schaffner, William] Vanderbilt Univ, Nashville, TN USA. [Jones, Timothy] Tennessee Dept Hlth, Nashville, TN USA. RP Luckhaupt, SE (reprint author), Ctr Dis Control & Prevent, 4676 Columbia Pkwy,Mailstop R17, Cincinnati, OH 45226 USA. EM pks8@cdc.gov OI Yousey-Hindes, Kimberly/0000-0002-9418-575X NR 17 TC 7 Z9 7 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2012 VL 18 IS 4 BP 556 EP 562 DI 10.3201/eid1804.110337 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 919MJ UT WOS:000302331600002 PM 22469504 ER PT J AU Gundi, VAKB Billeter, SA Rood, MP Kosoy, MY AF Gundi, Vijay A. K. B. Billeter, Sarah A. Rood, Michael P. Kosoy, Michael Y. TI Bartonella spp. in Rats and Zoonoses, Los Angeles, California, USA SO EMERGING INFECTIOUS DISEASES LA English DT Article ID CITRATE SYNTHASE GENE; RATTUS-NORVEGICUS; SP-NOV; INFECTIONS; RODENTS; DISEASE AB Bartonella spp. were detected in rats (Rattus norvegicus) trapped in downtown Los Angeles, California, USA. Of 200 rats tested, putative human pathogens, B. rochalimae and B. tribocorum were found in 37 (18.5%) and 115 (57.5%) rats, respectively. These bacteria among rodents in a densely populated urban area are a public health concern. C1 [Gundi, Vijay A. K. B.; Billeter, Sarah A.; Kosoy, Michael Y.] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. [Rood, Michael P.] Los Angeles Cty Dept Publ Hlth, Baldwin Pk, CA USA. RP Kosoy, MY (reprint author), Ctr Dis Control & Prevent, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM mck3@cdc.gov FU Emerging Infectious Diseases Fellowship Program; Centers for Disease and Control and Preventio FX This study was supported in part by an appointment to the Emerging Infectious Diseases Fellowship Program administered by the Association of Public Health Laboratories and funded by the Centers for Disease and Control and Prevention. NR 15 TC 19 Z9 19 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2012 VL 18 IS 4 BP 631 EP 633 DI 10.3201/eid1804.110816 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 919MJ UT WOS:000302331600012 PM 22469313 ER PT J AU Knust, B Medetov, ZB Kyraubayev, KB Bumburidi, Y Erickson, BR MacNeil, A Nichol, ST Bayserkin, BS Ospanov, KS AF Knust, Barbara Medetov, Zhumagul B. Kyraubayev, Kakimzhan B. Bumburidi, Yekaterina Erickson, Bobbie Rae MacNeil, Adam Nichol, Stuart T. Bayserkin, Baurzhan S. Ospanov, Kenes S. TI Crimean-Congo Hemorrhagic Fever, Kazakhstan, 2009-2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID AFRICA; VIRUS; RISK AB We evaluated Crimean-Congo hemorrhagic fever (CCHF) surveillance data from southern Kazakhstan during 2009-2010 and found both spatial and temporal association between reported tick bites and CCHF cases. Public health measures should center on preventing tick bites, increasing awareness of CCHF signs and symptoms, and adopting hospital infection control practices. C1 [Knust, Barbara; Bumburidi, Yekaterina; Erickson, Bobbie Rae; MacNeil, Adam; Nichol, Stuart T.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Medetov, Zhumagul B.; Kyraubayev, Kakimzhan B.; Bayserkin, Baurzhan S.; Ospanov, Kenes S.] Kazakhstan Minist Hlth, Alma Ata, Kazakhstan. RP Nichol, ST (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G14, Atlanta, GA 30333 USA. EM stn1@cdc.gov FU government of Kazakhstan; government of the United States FX Funding for this study was provided by the governments of Kazakhstan and the United States. NR 15 TC 6 Z9 7 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2012 VL 18 IS 4 BP 643 EP 645 DI 10.3201/eid1804.111503 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 919MJ UT WOS:000302331600016 PM 22469505 ER PT J AU Fittipaldi, N Olsen, RJ Beres, SB Van Beneden, C Musser, JM AF Fittipaldi, Nahuel Olsen, Randall J. Beres, Stephen B. Van Beneden, Chris Musser, James M. TI Genomic Analysis of emm59 Group A Streptococcus Invasive Strains, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID M-PROTEIN; PYOGENES; DISEASE AB Genomic analysis of type emm59 group A Streptococcus invasive strains isolated in the United States discovered higher than anticipated genetic heterogeneity among strains and identified a heretofore unrecognized monoclonal cluster of invasive infections in the San Francisco Bay area. Heightened monitoring for a potential shift in the epidemic behavior of emm59 group A Streptococcus is warranted. C1 [Fittipaldi, Nahuel; Olsen, Randall J.; Beres, Stephen B.; Musser, James M.] Methodist Hosp, Res Inst, Houston, TX 77030 USA. [Van Beneden, Chris] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Musser, JM (reprint author), Methodist Hosp Syst, Dept Pathol & Genom Med, 6565 Fannin St,B490, Houston, TX 77030 USA. EM jmmusser@tmhs.org FU Methodist Hospital System; Canadian Institutes of Health Research FX This work was funded by the Methodist Hospital System. N.F. is funded in part by the Canadian Institutes of Health Research. NR 13 TC 13 Z9 13 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2012 VL 18 IS 4 BP 650 EP 652 DI 10.3201/eid1804.111803 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 919MJ UT WOS:000302331600018 PM 22469010 ER PT J AU Marston, DA Horton, DL Ngeleja, C Hampson, K McElhinney, LM Banyard, AC Haydon, D Cleaveland, S Rupprecht, CE Bigambo, M Fooks, AR Lembo, T AF Marston, Denise A. Horton, Daniel L. Ngeleja, Chanasa Hampson, Katie McElhinney, Lorraine M. Banyard, Ashley C. Haydon, Daniel Cleaveland, Sarah Rupprecht, Charles E. Bigambo, Machunde Fooks, Anthony R. Lembo, Tiziana TI Ikoma Lyssavirus, Highly Divergent Novel Lyssavirus in an African Civet SO EMERGING INFECTIOUS DISEASES LA English DT Article ID RABIES; SERENGETI; VIRUS; ASSAY; BAT AB Evidence in support of a novel lyssavirus was obtained from brain samples of an African civet in Tanzania. Results of phylogenetic analysis of nucleoprotein gene sequences from representative Lyssavirus species and this novel lyssavirus provided strong empirical evidence that this is a new lyssavirus species, designated Ikoma lyssavirus. C1 [Fooks, Anthony R.] Anim Hlth & Vet Labs Agcy, Wildlife Zoonoses & Vector Borne Dis Res Grp, Addlestone KTI5 3NB, Surrey, England. [Ngeleja, Chanasa] Cent Vet Lab, Dar Es Salaam, Tanzania. [Hampson, Katie; Haydon, Daniel; Cleaveland, Sarah; Lembo, Tiziana] Univ Glasgow, Glasgow, Lanark, Scotland. [Rupprecht, Charles E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bigambo, Machunde] Lincoln Pk Zoo Tanzania Program, Arusha, Tanzania. RP Fooks, AR (reprint author), Anim Hlth & Vet Labs Agcy, Wildlife Zoonoses & Vector Borne Dis Res Grp, Addlestone KTI5 3NB, Surrey, England. EM tony.fooks@ahvla.gsi.gov.uk RI Horton, Daniel/D-9909-2011; Banyard, Ashley/C-7998-2011; McElhinney, Lorraine/C-7997-2011; Marston, Denise/D-7993-2011; APHA, Staff publications/E-6082-2010; Fooks, Anthony/F-5418-2010; OI Horton, Daniel/0000-0002-9126-2756; Banyard, Ashley/0000-0002-1286-9825; McElhinney, Lorraine/0000-0002-6022-348X; Marston, Denise/0000-0001-9215-088X; Hampson, Katie/0000-0001-5392-6884; Haydon, Daniel/0000-0002-1240-1886 FU Department for Environment, Food and Rural Affairs ROAME [SE0423/SV3500]; EU [228292]; Science and Technology Directorate (US Department of Homeland Security); Fogarty International Center; Lincoln Park Zoo (Chicago, IL, USA); Wellcome Trust; UBS Optimus Foundation; Medical Research Council FX This work was partially supported by The Department for Environment, Food and Rural Affairs ROAME SE0423/SV3500, by the EU FP7-funded Research Infrastructure Grant European Virus Archive (no. 228292), and by the Research and Policy for Infectious Disease Dynamics program of the Science and Technology Directorate (US Department of Homeland Security), and the Fogarty International Center. In Tanzania, the work was funded by Lincoln Park Zoo (Chicago, IL, USA), the Wellcome Trust, UBS Optimus Foundation, and the Medical Research Council. NR 15 TC 47 Z9 49 U1 0 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2012 VL 18 IS 4 BP 664 EP 667 DI 10.3201/eid1804.111553 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 919MJ UT WOS:000302331600022 PM 22469151 ER PT J AU Carson, PJ Borchardt, SM Custer, B Prince, HE Dunn-Williams, J Winkelman, V Tobler, L Biggerstaff, BJ Lanciotti, R Petersen, LR Busch, MP AF Carson, Paul J. Borchardt, Stephanie M. Custer, Brian Prince, Harry E. Dunn-Williams, Joan Winkelman, Valerie Tobler, Leslie Biggerstaff, Brad J. Lanciotti, Robert Petersen, Lyle R. Busch, Michael P. TI Neuroinvasive Disease and West Nile Virus Infection, North Dakota, USA, 1999-2008 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; NEW-YORK; EPIDEMIC; SEROPREVALENCE; ANTIBODIES AB To determine risk for West Nile virus (WNV) neuroinvasive disease in North Dakota, we tested plasma samples from blood donors for WNV IgG and compared infection rates with reported WNV neuroinvasive disease incidence. We estimate that 1 in 244 WNV infections leads to neuroinvasive disease; risk is substantially increased among men and older persons. C1 [Custer, Brian; Tobler, Leslie; Busch, Michael P.] Univ Calif San Francisco, Blood Syst Res Inst, San Francisco, CA 94118 USA. [Carson, Paul J.; Borchardt, Stephanie M.] Univ N Dakota, Sch Med & Hlth Sci, Grand Forks, ND 58201 USA. [Carson, Paul J.] Sanford Hlth, Fargo, ND USA. [Borchardt, Stephanie M.] Fargo Vet Affairs Med Ctr, Fargo, ND USA. [Borchardt, Stephanie M.] Wisconsin Dept Hlth, Madison, WI USA. [Prince, Harry E.] Focus Diagnost, Cypress, CA USA. [Dunn-Williams, Joan; Winkelman, Valerie] Creat Testing Solut, Tempe, AZ USA. [Biggerstaff, Brad J.; Lanciotti, Robert; Petersen, Lyle R.] Ctr Dis Control & Prevent, Ft Collins, CO USA. RP Busch, MP (reprint author), Univ Calif San Francisco, Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA. EM mbusch@bloodsystems.org FU Centers for Disease Control and Prevention [R01-CI-000214]; National Heart, Lung, and Blood Institute [RC2-HL-101632] FX This work was funded in part by grants from the Centers for Disease Control and Prevention (R01-CI-000214) and the National Heart, Lung, and Blood Institute (RC2-HL-101632). NR 15 TC 34 Z9 35 U1 0 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2012 VL 18 IS 4 BP 684 EP 686 DI 10.3201/eid1804.111313 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 919MJ UT WOS:000302331600028 PM 22469465 ER PT J AU Potter, P AF Potter, Polyxeni TI Military Magic or Nature's Fool SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, EID Journal, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, EID Journal, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD APR PY 2012 VL 18 IS 4 BP 709 EP 710 DI 10.3201/eid1804,AC1804 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 919MJ UT WOS:000302331600041 ER PT J AU Hebert, KA Wendel, AM Kennedy, SK Dannenberg, AL AF Hebert, Katherine A. Wendel, Arthur M. Kennedy, Sarah K. Dannenberg, Andrew L. TI Health impact assessment: A comparison of 45 local, national, and international guidelines SO ENVIRONMENTAL IMPACT ASSESSMENT REVIEW LA English DT Article DE Health impact assessment; Guidance; Techniques; Process; Equity; Health in all policy ID CONSENSUS AB This article provides a comparison of health impact assessment (HIA) guidelines from around the world and for multiple geographic scales. We identify commonalities and differences within HIA guides to discuss the plausibility of consensus guidelines and to inform guideline development The practice of HIA has grown over the last two decades with a concurrent growth of HIA guides. This study expands on earlier review work and includes guides published since 2007 (Mindell, Boltong and Forde, 2008). From April 2010 to October 2011, 45 HIA guides were identified through an internet search and review of previous research. Common characteristics, key features, and the HIA process were analyzed. The 45 documents recommended similar but not identical processes for conducting HIAs. These analyses suggest that guidelines for HIAs are similar in many areas of the world and that new HIA practitioners can use these findings to inform their approach. Further discussion is needed to determine if the approaches established in these guidelines are followed and if one set of common guidelines could be written for use in numerous countries and regions. (C) 2012 Elsevier Inc. All rights reserved. C1 [Hebert, Katherine A.; Wendel, Arthur M.; Kennedy, Sarah K.; Dannenberg, Andrew L.] Ctr Dis Control & Prevent CDC, Natl Ctr Environm Hlth, Hlth Community Design Initiat, Atlanta, GA 30341 USA. RP Wendel, AM (reprint author), 4770 Buford Highway,NE MS-K46, Atlanta, GA 30341 USA. EM jsx3@cdc.gov; dvq6@cdc.gov; heaton.sarah@gmail.com; adannenberg2@gmail.com NR 77 TC 16 Z9 17 U1 0 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0195-9255 J9 ENVIRON IMPACT ASSES JI Environ. Impact Assess. Rev. PD APR PY 2012 VL 34 BP 74 EP 82 DI 10.1016/j.eiar.2012.01.003 PG 9 WC Environmental Studies SC Environmental Sciences & Ecology GA 912WO UT WOS:000301832300009 ER PT J AU Fullerton, KE Scallan, E Kirk, MD Mahon, BE Angulo, FJ de Valk, H van Pelt, W Gauci, C Hauri, AM Majowicz, S O'Brien, SJ AF Fullerton, Kathleen E. Scallan, Elaine Kirk, Martyn D. Mahon, Barbara E. Angulo, Frederick J. de Valk, Henriette van Pelt, Wilfrid Gauci, Charmaine Hauri, Anja M. Majowicz, Shannon O'Brien, Sarah J. CA Int Collaboration Working Grp TI Case-Control Studies of Sporadic Enteric Infections: A Review and Discussion of Studies Conducted Internationally from 1990 to 2009 SO FOODBORNE PATHOGENS AND DISEASE LA English DT Review ID NATIONAL CASE-CONTROL; COLI O157-H7 INFECTION; CAMPYLOBACTER-JEJUNI INFECTION; MAJOR RISK-FACTORS; 5 FOODNET SITES; ESCHERICHIA-COLI; UNITED-STATES; SALMONELLA-ENTERITIDIS; INTESTINAL DISEASE; YOUNG-CHILDREN AB Epidemiologists have used case-control studies to investigate enteric disease outbreaks for many decades. Increasingly, case-control studies are also used to investigate risk factors for sporadic (not outbreak-associated) disease. While the same basic approach is used, there are important differences between outbreak and sporadic disease settings that need to be considered in the design and implementation of the case-control study for sporadic disease. Through the International Collaboration on Enteric Disease "Burden of Illness'' Studies (the International Collaboration), we reviewed 79 case-control studies of sporadic enteric infections caused by nine pathogens that were conducted in 22 countries and published from 1990 through to 2009. We highlight important methodological and study design issues (including case definition, control selection, and exposure assessment) and discuss how approaches to the study of sporadic enteric disease have changed over the last 20 years (e. g., making use of more sensitive case definitions, databases of controls, and computer-assisted interviewing). As our understanding of sporadic enteric infections grows, methods and topics for case-control studies are expected to continue to evolve; for example, advances in understanding of the role of immunity can be used to improve control selection, the apparent protective effects of certain foods can be further explored, and case-control studies can be used to provide population-based measures of the burden of disease. C1 [Fullerton, Kathleen E.] Ctr Dis Control & Prevent, Natl Surveillance Team, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis,Natl Ctr, Atlanta, GA 30333 USA. [Scallan, Elaine] Colorado Sch Publ Hlth, Aurora, CO USA. [Kirk, Martyn D.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia. [de Valk, Henriette] French Inst Publ Hlth Surveillance, St Maurice, France. [van Pelt, Wilfrid] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [Gauci, Charmaine] Univ Malta, Dept Publ Hlth, Msida, Malta. [Hauri, Anja M.] State Hesse, Hesse State Hlth Off, Dillenburg, Germany. [Majowicz, Shannon] Ctr Food Borne Environm & Zoonot Infect Dis, Guelph, ON, Canada. [O'Brien, Sarah J.] Univ Manchester, Hope Clin Acad Grp, Salford, Lancs, England. RP Fullerton, KE (reprint author), Ctr Dis Control & Prevent, Natl Surveillance Team, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis,Natl Ctr, 1600 Clifton Rd,MS C-09, Atlanta, GA 30333 USA. EM kfullerton@cdc.gov RI O'Brien, Sarah/D-4954-2012 FU Intramural CDC HHS [CC999999] NR 125 TC 5 Z9 5 U1 1 U2 15 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD APR PY 2012 VL 9 IS 4 BP 281 EP 292 DI 10.1089/fpd.2011.1065 PG 12 WC Food Science & Technology SC Food Science & Technology GA 916XU UT WOS:000302137300001 PM 22443481 ER PT J AU Deng, XL Ran, L Wu, SY Ke, BX He, DM Yang, XF Zhang, YH Ke, CW Klena, JD Yan, MY Feng, ZJ Kan, BA Liu, X Mikoleit, M Varma, JK AF Deng, Xiaoling Ran, Lu Wu, Shuyu Ke, Bixia He, Dongmei Yang, Xingfen Zhang, Yonghui Ke, Changwen Klena, John D. Yan, Meiying Feng, Zijian Kan, Biao Liu, Xin Mikoleit, Matthew Varma, Jay K. TI Laboratory-Based Surveillance of Non-typhoidal Salmonella Infections in Guangdong Province, China SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID ENTERICA SEROTYPE TYPHIMURIUM; QUALITY-ASSURANCE SYSTEM; NONTYPHOIDAL SALMONELLA; UNITED-STATES; ANTIMICROBIAL RESISTANCE; MULTIDRUG-RESISTANCE; FOODBORNE DISEASE; GLOBAL CHALLENGE; BURDEN; GASTROENTERITIS AB Salmonella is one of the most common foodborne pathogens in humans. Laboratory-based surveillance for non-typhoidal Salmonella infection was conducted in Guangdong Province, China to improve understanding about the disease burden and detection of dispersed outbreaks. Salmonella isolated from patients with diarrhea were sent from 16 sentinel hospitals to local public health laboratories for confirmation, serotyping, antimicrobial susceptibility testing, and pulsed-field gel electrophoresis (PFGE). PFGE patterns were analyzed to identify clusters representing potential outbreaks. Between September 2009 and October 2010, 352 (4%) Salmonella isolates were obtained from 9167 stool specimens. Salmonella enterica serotype Typhimurium (45%) and Salmonella enterica serotype Enteritidis (13%) were the most common serotypes, and multidrug resistance was high, especially in Salmonella Typhimurium isolates. PFGE patterns of obtained Salmonella isolates were found to be diverse, but a unique PFGE pattern comprising 53 Salmonella Typhimurium isolates were found to occur almost exclusively in infants. Epidemiologic studies are ongoing to determine whether a common exposure is the source of the Salmonella Typhimurium strain frequently isolated from infants. C1 [Deng, Xiaoling; Ke, Bixia; He, Dongmei; Yang, Xingfen; Zhang, Yonghui; Ke, Changwen] Guangdong Prov Ctr Dis Control & Prevent, Guangzhou 510300, Guangdong, Peoples R China. [Ran, Lu; Feng, Zijian] Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Beijing, Peoples R China. [Wu, Shuyu; Klena, John D.; Liu, Xin; Mikoleit, Matthew; Varma, Jay K.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Yan, Meiying; Kan, Biao] Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Natl Inst Communicable Dis Prevent & Control, Beijing, Peoples R China. RP Ke, CW (reprint author), Guangdong Prov Ctr Dis Control & Prevent, 176 Xingang W Rd, Guangzhou 510300, Guangdong, Peoples R China. EM kecw1965@yahoo.com.cn OI Mikoleit, Matthew/0000-0002-4582-6733 FU China-U.S. Collaborative Program on Emerging and Re-Emerging Infectious Diseases; WHO Global Foodborne Infections Network FX We are grateful for the participation and excellent work by sentinel hospitals in Guangdong Province. We also thank the China Field Epidemiology Training Program for technical support. In addition, we thank the technical experts from WHO Global Foodborne Infections Network, including Danilo M. A. Lo Fo Wong (WHO), Frederick J. Angulo and Patricia M. Griffin (CDC, United States), Jaap Wagenaar (Utrecht University, The Netherlands), Rene Hendriksen (National Food Institute, Denmark), Shaohua Zhao (Food and Drug Administration, United States) and Lai-King Ng (Public Health Agency of Canada, Canada). PulseNet International is acknowledged for their kind support in comparing Salmonella PFGE patterns in their database. This study was supported by the China-U.S. Collaborative Program on Emerging and Re-Emerging Infectious Diseases and WHO Global Foodborne Infections Network. NR 32 TC 19 Z9 22 U1 0 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD APR PY 2012 VL 9 IS 4 BP 305 EP 312 DI 10.1089/fpd.2011.1008 PG 8 WC Food Science & Technology SC Food Science & Technology GA 916XU UT WOS:000302137300004 PM 22356574 ER PT J AU Napier, RJ Shinnick, TM Kalman, D AF Napier, Ruth J. Shinnick, Thomas M. Kalman, Daniel TI Back to the future: host-targeted chemotherapeutics for drug-resistant TB SO FUTURE MICROBIOLOGY LA English DT Editorial Material DE Abl tyrosine kinase; antibiotic resistance; drug resistance; Gleevec; imatinib; MDR-TB; tuberculosis; XDR-TB ID FAMILY TYROSINE KINASES; SARCOMA-VIRUS; PHILADELPHIA-CHROMOSOME; IMATINIB MESYLATE; TUBERCULOSIS; ABL; GENE; LEUKEMIA; VACCINE; PATHOGENESIS C1 [Kalman, Daniel] Emory Univ, Dept Pathol & Lab Med, Microbiol & Mol Genet Grad Program, Atlanta, GA 30322 USA. Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. RP Kalman, D (reprint author), Emory Univ, Dept Pathol & Lab Med, Microbiol & Mol Genet Grad Program, Atlanta, GA 30322 USA. EM dkalman@emory.eau FU NIAID NIH HHS [R01 AI072462] NR 56 TC 1 Z9 1 U1 0 U2 3 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1746-0913 J9 FUTURE MICROBIOL JI Future Microbiol. PD APR PY 2012 VL 7 IS 4 BP 431 EP 435 DI 10.2217/FMB.12.19 PG 5 WC Microbiology SC Microbiology GA 917SN UT WOS:000302199000002 PM 22439718 ER PT J AU Saunders, RP Pate, RR Dowda, M Ward, DS Epping, JN Dishman, RK AF Saunders, R. P. Pate, R. R. Dowda, M. Ward, D. S. Epping, J. N. Dishman, R. K. TI Assessing sustainability of Lifestyle Education for Activity Program (LEAP) SO HEALTH EDUCATION RESEARCH LA English DT Article ID HIGH-SCHOOL GIRLS; RANDOMIZED CONTROLLED-TRIAL; PHYSICAL-ACTIVITY; HEALTH-PROGRAMS; IMPLEMENTATION; INTERVENTIONS; INNOVATIONS; PREVENTION; OUTCOMES AB Sustained intervention effects are needed for positive health impacts in populations; however, few published examples illustrate methods for assessing sustainability in health promotion programs. This paper describes the methods for assessing sustainability of the Lifestyle Education for Activity Program (LEAP). LEAP was a comprehensive school-based intervention that targeted change in instructional practices and the school environment to promote physical activity (PA) in high school girls. Previous reports indicated that significantly more girls in the intervention compared with control schools reported engaging in vigorous PA, and positive long-term effects on vigorous PA also were observed for girls in schools that most fully implemented and maintained the intervention 3 years following the active intervention. In this paper, the seven steps used to assess sustainability in LEAP are presented; these steps provide a model for assessing sustainability in health promotion programs in other settings. Unique features of the LEAP sustainability model include assessing sustainability of changes in instructional practices and the environment, basing assessment on an essential element framework that defined complete and acceptable delivery at the beginning of the project, using multiple data sources to assess sustainability, and assessing implementation longitudinally. C1 [Saunders, R. P.] Univ S Carolina, Arnold Sch Hlth, Dept Hlth Promot Educ & Behav, Columbia, SC 29208 USA. [Pate, R. R.; Dowda, M.] Univ S Carolina, Arnold Sch Hlth, Dept Exercise Sci, Columbia, SC 29208 USA. [Ward, D. S.] Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA. [Epping, J. N.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Act, Atlanta, GA 30329 USA. [Dishman, R. K.] Univ Georgia, Dept Exercise Sci, Athens, GA 30602 USA. RP Saunders, RP (reprint author), Univ S Carolina, Arnold Sch Hlth, Dept Hlth Promot Educ & Behav, Columbia, SC 29208 USA. EM rsaunders@sc.edu FU NHLBI NIH HHS [HL 57775] NR 26 TC 8 Z9 9 U1 3 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1153 J9 HEALTH EDUC RES JI Health Educ. Res. PD APR PY 2012 VL 27 IS 2 BP 319 EP 330 DI 10.1093/her/cyr111 PG 12 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA 915KL UT WOS:000302023400013 PM 22156233 ER PT J AU Auld, AF Ellerbrock, TV AF Auld, Andrew F. Ellerbrock, Tedd V. TI Commentary: Can mortality rates among adult antiretroviral therapy patients in Europe reach levels similar to those experienced in the general population? SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Editorial Material ID HIV; DEATH; RISK C1 [Auld, Andrew F.; Ellerbrock, Tedd V.] US Ctr Dis Control & Prevent CDC, Div Global HIV AIDS DGHA, Atlanta, GA 30333 USA. RP Auld, AF (reprint author), US Ctr Dis Control & Prevent CDC, Div Global HIV AIDS DGHA, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM ggv4@cdc.gov OI Auld, Andrew/0000-0001-5089-9163 NR 12 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD APR PY 2012 VL 41 IS 2 BP 445 EP 447 DI 10.1093/ije/dys023 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 921TJ UT WOS:000302500200021 PM 22395023 ER PT J AU Pfaller, MA Castanheira, M Lockhart, SR Ahlquist, AM Messer, SA Jones, RN AF Pfaller, M. A. Castanheira, M. Lockhart, S. R. Ahlquist, A. M. Messer, S. A. Jones, R. N. TI Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID INTENSIVE-CARE-UNIT; AZOLE ANTIFUNGAL AGENTS; NON-ALBICANS CANDIDEMIA; CRITICALLY-ILL PATIENTS; DOUBLE-BLIND TRIAL; INVASIVE CANDIDIASIS; RISK-FACTORS; CASPOFUNGIN RESISTANCE; FUNGAL-INFECTIONS; AMPHOTERICIN-B AB The echinocandin class of antifungal agents is considered to be the first-line treatment of bloodstream infections (BSI) due to Candida glabrata. Recent reports of BSI due to strains of C. glabrata resistant to both fluconazole and the echinocandins are of concern and prompted us to review the experience of two large surveillance programs, the SENTRY Antimicrobial Surveillance Program for the years 2006 through 2010 and the Centers for Disease Control and Prevention population-based surveillance conducted in 2008 to 2010. The in vitro susceptibilities of 1,669 BSI isolates of C. glabrata to fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin were determined by CLSI broth microdilution methods. Fluconazole MICs of >= 64 mu g/ml were considered resistant. Strains for which anidulafungin and caspofungin MICs were >= 0.5 mu g/ml and for which micafungin MICs were >= 0.25 mu g/ml were considered resistant. A total of 162 isolates (9.7%) were resistant to fluconazole, of which 98.8% were nonsusceptible to voriconazole (MIC >0.5 mu g/ml) and 9.3%, 9.3%, and 8.0% were resistant to anidulafungin, caspofungin, and micafungin, respectively. There were 18 fluconazole-resistant isolates that were resistant to one or more of the echinocandins (11.1% of all fluconazole-resistant isolates), all of which contained an acquired mutation in fks1 or fks2. By comparison, there were no echinocandin-resistant strains detected among 110 fluconazole-resistant isolates of C. glabrata tested in 2001 to 2004. These data document the broad emergence of coresistance over time to both azoles and echinocandins in clinical isolates of C. glabrata. C1 [Pfaller, M. A.; Castanheira, M.; Messer, S. A.; Jones, R. N.] JMI Labs, N Liberty, IA USA. [Lockhart, S. R.; Ahlquist, A. M.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Jones, R. N.] Tufts Univ, Sch Med, Boston, MA 02111 USA. RP Pfaller, MA (reprint author), JMI Labs, N Liberty, IA USA. EM mike-pfaller@jmilabs.com FU Pfizer Inc.; Astellas FX The antifungal global surveillance program which served as the source of data used in the development of the manuscript was supported in part by Pfizer Inc. and by Astellas. NR 62 TC 127 Z9 134 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2012 VL 50 IS 4 BP 1199 EP 1203 DI 10.1128/JCM.06112-11 PG 5 WC Microbiology SC Microbiology GA 917CC UT WOS:000302148700012 PM 22278842 ER PT J AU Angr, PK Taylor, TH Iademarco, MF Metchock, B Astles, JR Ridderhof, JC AF Angr, Pawan K. Taylor, Thomas H. Iademarco, Michael F. Metchock, Beverly Astles, J. Rex Ridderhof, John C. TI Performance of Tuberculosis Drug Susceptibility Testing in U.S. Laboratories from 1994 to 2008 SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID QUALITY-ASSURANCE PROGRAM; MYCOBACTERIUM-TUBERCULOSIS; RESISTANCE; NETWORK; ROUNDS AB We present a statistical summary of results from the Model Performance Evaluation Program (MPEP) for Mycobacterium tuberculosis Drug Susceptibility Testing, 1994 to 2008, implemented by the U.S. Centers for Disease Control and Prevention (CDC). During that period, a total of 57,733 test results for culture isolates were reported by 216 participating laboratories for the first-line antituberculosis drugs used in the United States-isoniazid (INH), rifampin (RMP), ethambutol (EMB), and pyrazinamide (PZA). Using Clinical Laboratory and Standards Institute (CLSI)-recommended concentrations for one or more of three methods, agar proportion (AP), BACTEC460 (Bactec), and MGIT-960 (MGIT), yielded overall agreement of 97.0% for first-line drugs. For susceptible strains, agreement was 98.4%; for resistant strains, agreement was 91.0%, with significantly lower accuracy (chisquare test, P < 0.0001). For resistant strains, overall agreement by methods was 91.3% for AP, 93.0% for Bactec, and 82.6% for MGIT and by drugs was 92.2% for INH, 91.5% for RMP, 79.0% for EMB, and 97.5% for PZA. For some strains, performance by method varied significantly. Use of duplicate strains in the same shipment and repeat strains over time revealed consistent performance even for strains with higher levels of interlaboratory discordance. No overall differences in performance between laboratories were observed based on volume of testing or type of facility (e.g., health department, hospital, independent). By all methods, decreased performance was observed for strains with low-level INH resistance, RMP resistance, and EMB-resistant strains. These results demonstrate a high level of performance in detection of drug-resistant M. tuberculosis in U.S. laboratories. C1 [Angr, Pawan K.] Ctr Dis Control & Prevent, Lab Syst Dev Branch, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA USA. [Taylor, Thomas H.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Iademarco, Michael F.; Metchock, Beverly] Ctr Dis Control & Prevent, Branch Lab, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Astles, J. Rex; Ridderhof, John C.] Ctr Dis Control & Prevent, Lab Sci, Policy & Practice Program Off, Off Surveillance,Epidemiol & Lab Serv, Atlanta, GA USA. RP Angr, PK (reprint author), Ctr Dis Control & Prevent, Lab Syst Dev Branch, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA USA. EM pangra@cdc.gov NR 28 TC 14 Z9 15 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2012 VL 50 IS 4 BP 1233 EP 1239 DI 10.1128/JCM.06479-11 PG 7 WC Microbiology SC Microbiology GA 917CC UT WOS:000302148700017 PM 22301024 ER PT J AU Theodore, MJ Anderson, RD Wang, X Katz, LS Vuong, JT Bell, ME Juni, BA Lowther, SA Lynfield, R MacNeil, JR Mayer, LW AF Theodore, M. Jordan Anderson, Raydel D. Wang, Xin Katz, Lee S. Vuong, Jeni T. Bell, Melissa E. Juni, Billie A. Lowther, Sara A. Lynfield, Ruth MacNeil, Jessica R. Mayer, Leonard W. TI Evaluation of New Biomarker Genes for Differentiating Haemophilus influenzae from Haemophilus haemolyticus SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID 16S RIBOSOMAL-RNA; NEONATAL INFECTIONS; IDENTIFICATION; PATHOGENESIS; PREVENTION; BACTERIA AB PCR detecting the protein D (hpd) and fuculose kinase (fucK) genes showed high sensitivity and specificity for identifying Haemophilus influenzae and differentiating it from H. haemolyticus. Phylogenetic analysis using the 16S rRNA gene demonstrated two distinct groups for H. influenzae and H. haemolyticus. C1 [Theodore, M. Jordan; Anderson, Raydel D.; Wang, Xin; Vuong, Jeni T.; MacNeil, Jessica R.; Mayer, Leonard W.] Ctr Dis Control & Prevent CDC, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA USA. [Juni, Billie A.; Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Lowther, Sara A.] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. [Katz, Lee S.; Bell, Melissa E.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Theodore, MJ (reprint author), Ctr Dis Control & Prevent CDC, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA USA. EM ale7@cdc.gov NR 28 TC 20 Z9 20 U1 0 U2 15 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2012 VL 50 IS 4 BP 1422 EP 1424 DI 10.1128/JCM.06702-11 PG 3 WC Microbiology SC Microbiology GA 917CC UT WOS:000302148700046 PM 22301020 ER PT J AU Jani, IV Sabatier, J Vubil, A Subbarao, S Bila, D de Sousa, A Mabunda, N Garcia, A Skaggs, B Ellenberger, D Ramos, A AF Jani, Ilesh V. Sabatier, Jennifer Vubil, Adolfo Subbarao, Shambavi Bila, Dulce de Sousa, Amina Mabunda, Nedio Garcia, Albert Skaggs, Beth Ellenberger, Dennis Ramos, Artur TI Evaluation of a High-Throughput Diagnostic System for Detection of HIV-1 in Dried Blood Spot Samples from Infants in Mozambique SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID IMMUNODEFICIENCY-VIRUS HIV; ANTIRETROVIRAL-THERAPY; PERFORMANCE; ASSAY; MORTALITY; INFECTION; AGREEMENT; CHILDREN; AFRICA; TESTS AB We performed a comparative analysis between Roche Amplicor HIV-1 DNA test and CAPTAQ assay for the detection of HIV in 830 dried blood spot (DBS) pediatric samples collected in Mozambique. Our results demonstrated no statistical difference between these assays. The CAPTAQ assay approached nearly 100% repeatability/accuracy. The increased throughput of testing with minimal operator interference in performing the CAPTAQ assay clearly demonstrated that this method is an improvement over the Roche Amplicor HIV-1 DNA test, version 1.5. C1 [Sabatier, Jennifer; Subbarao, Shambavi; Garcia, Albert; Ellenberger, Dennis; Ramos, Artur] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jani, Ilesh V.; Vubil, Adolfo; Bila, Dulce; de Sousa, Amina; Mabunda, Nedio] Inst Nacl Saude, Maputo, Mozambique. [Skaggs, Beth] Ctr Dis Control & Prevent, Maputo, Mozambique. RP Ellenberger, D (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM dellenberger@cdc.gov NR 17 TC 6 Z9 6 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2012 VL 50 IS 4 BP 1458 EP 1460 DI 10.1128/JCM.00107-12 PG 3 WC Microbiology SC Microbiology GA 917CC UT WOS:000302148700058 PM 22278838 ER PT J AU Pellegrini, GJ Graziano, JC Ragunathan, L Bhat, MA Hemashettar, BM Brown, JM AF Pellegrini, Gerald J., Jr. Graziano, James C. Ragunathan, Latha Bhat, Malini A. Hemashettar, Basavaraj M. Brown, June M. TI Scalp Abscess Due to Streptomyces cacaoi subsp cacaoi, First Report in a Human Infection SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article AB Streptomyces cacaoi subsp. cacaoi, a Gram-positive, branching filamentous bacteria, was isolated from a scalp infection in a patient from Pondicherry, India. Phenotypic tests identified the isolate as a Streptomyces species, but 16S rRNA sequence analysis provided the species identification required for tracking of this emerging pathogen. C1 [Pellegrini, Gerald J., Jr.; Graziano, James C.; Brown, June M.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Ragunathan, Latha; Bhat, Malini A.] Aarupadai Veedu Med Coll & Hosp, Dept Microbiol, Pondicherry, India. [Hemashettar, Basavaraj M.] Hitech Healthcare & Diagnost Ctr, Dept Microbiol, Belgaum, India. RP Brown, JM (reprint author), Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. EM jmb6@cdc.gov NR 9 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2012 VL 50 IS 4 BP 1484 EP 1486 DI 10.1128/JCM.06372-11 PG 3 WC Microbiology SC Microbiology GA 917CC UT WOS:000302148700066 PM 22278841 ER PT J AU Mehr, DR Phillips, CD Adepoju, L Moudouni, DK Stone, N Nwaiwu, O Frentzel, E Garfinkel, S AF Mehr, D. R. Phillips, C. D. Adepoju, L. Moudouni, D. K. Stone, N. Nwaiwu, O. Frentzel, E. Garfinkel, S. TI Asymptomatic Bacteriuria and Antibiotic Use in Nursing Homes. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Mehr, D. R.] Univ Missouri, Columbia, MO USA. [Phillips, C. D.; Adepoju, L.; Moudouni, D. K.; Nwaiwu, O.] Texas A&M Sci Ctr, College Stn, TX USA. [Frentzel, E.; Garfinkel, S.] Amer Inst Res, Chapel Hill, NC USA. [Stone, N.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S148 EP S149 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800431 ER PT J AU Aral, SO Blanchard, JF AF Aral, Sevgi O. Blanchard, James F. TI The Program Science initiative: improving the planning, implementation and evaluation of HIV/STI prevention programs SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article ID HIV PREVENTION; MALE CIRCUMCISION; TRIAL; MEN AB In this article, the authors describe the Program Science initiative in detail, discuss some of its recent accomplishments and explore its significance and timeliness in light of the HIV prevention challenges. The authors also describe the Program Science series being launched and present a preview of future articles. C1 [Aral, Sevgi O.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Blanchard, James F.] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada. RP Aral, SO (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,Mailstop E-02, Atlanta, GA 30333 USA. EM soa1@cdc.gov NR 11 TC 16 Z9 16 U1 2 U2 7 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD APR PY 2012 VL 88 IS 3 BP 157 EP 159 DI 10.1136/sextrans-2011-050389 PG 3 WC Infectious Diseases SC Infectious Diseases GA 919CK UT WOS:000302298200002 PM 22363021 ER PT J AU Tao, GY Hoover, KW Kent, CK AF Tao, Guoyu Hoover, Karen W. Kent, Charlotte K. TI Chlamydia Testing Patterns for Commercially Insured Women, 2008 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID UNITED-STATES AB Background: Annual chlamydia screening for sexually active women aged <= 25 years is recommended, and chlamydia testing rates have continuously increased. However, several studies have shown that many providers screen all women of reproductive age in public settings. Purpose: To examine chlamydia testing patterns in private settings for women and young women aged 15-44 years (hereafter referred to as women). Methods: A large commercial claims database was used to estimate the chlamydia testing rate for women aged 15-44 years who had reproductive health services in 2008. Such services and tests were identified using diagnostic and procedural codes in 2008. Results: Of 3.2 million women aged 15-44 years who had reproductive health services in 2008, 19.2% had at least a claim for a sexually transmitted disease (STD), 29.3% for pregnancy, and 81.2% for a gynecologic exam. Of those 3.2 million, 22.3% had chlamydia testing: 34.2% aged 15-25 years vs 18.3% aged 26-44 years. Of the 0.7 million who were tested, 65% were aged 26-44 years, and the reason for the healthcare visit in which their first chlamydia test was performed was an STD for 22.7% and pregnancy for 33.5%. Conclusions: In this population of insured women, young women are undertested and older women are overtested for chlamydia. Efforts to improve screening practices should be evaluated. (Am J Prev Med 2012;42(4):337-341) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Tao, Guoyu; Hoover, Karen W.; Kent, Charlotte K.] CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Tao, GY (reprint author), CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS-E80, Atlanta, GA 30333 USA. EM gat3@cdc.gov NR 19 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2012 VL 42 IS 4 BP 337 EP 341 DI 10.1016/j.amepre.2011.11.013 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 912LQ UT WOS:000301799900002 PM 22424245 ER PT J AU Zhuo, XH Zhang, P Selvin, E Hoerger, TJ Ackermann, RT Li, R Bullard, KM Gregg, EW AF Zhuo, Xiaohui Zhang, Ping Selvin, Elizabeth Hoerger, Thomas J. Ackermann, Ronald T. Li, Rui Bullard, Kai McKeever Gregg, Edward W. TI Alternative HbA1c Cutoffs to Identify High-Risk Adults for Diabetes Prevention A Cost-Effectiveness Perspective SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; WEIGHT-LOSS; TYPE-2; PROGRAM; HYPERTENSION; DIAGNOSIS; METFORMIN; HEMOGLOBIN; REDUCTION AB Background: New recommendations about the use of hemoglobin A1c (HbA1c) for diagnosing diabetes have stimulated a debate about the optimal HbA1c cutoff to identify prediabetes for preventive intervention. Purpose: To assess the cost effectiveness associated with the alternative HbA1c cutoffs for identifying prediabetes. Methods: A Markov simulation model was used to examine the cost effectiveness associated with a progressive 0.1% decrease in the HbA1c cutoff from 6.4% to 5.5%. The target population was the U.S. nondiabetic population aged >= 18 years. The simulation sample was created using the data of nondiabetic American adults from the National Health and Nutritional Examination Survey (NHANES 1999-2006). People identified as having prediabetes were assumed to receive a preventive intervention, with effectiveness the same as that in the Diabetes Prevention Program study under a high-cost intervention (HCI) scenario and in the Promoting a Lifestyle of Activity and Nutrition for Working to Alter the Risk of Diabetes study under a low-cost intervention (LCI) scenario. The analysis was conducted for a lifetime horizon from a healthcare system perspective. Results: Lowering the HbA1c cutoff would increase the health benefits of the preventive interventions at higher costs. For the HCI, lowering the HbA1c cutoff from 6.0% to 5.9% and from 5.9% to 5.8% would result in $27,000 and $34,000 per QALY gained, respectively. Continuing to decrease the cutoff from 5.8% to 5.7%, from 5.7% to 5.6%, and from 5.6% to 5.5% would cost $45,000, $58,000, and $96,000 per QALY gained, respectively. For the LCI, lowering the HbA1c cutoff from 6.0% to 5.9% and from 5.9% to 5.8% would result in $24,000 and $27,000 per QALY gained, respectively. Continuing to lower the cutoff from 5.8% to 5.7%, 5.7% to 5.6%, and 5.6% to 5.5% would cost $34,000, $43,000 and $70,000 per QALY gained, respectively. Conclusions: Lowering the HbA1c cutoff for prediabetes leads to less cost-effective preventive interventions. Assuming a conventional $ 50,000/QALY cost-effectiveness benchmark, the HbA1c cutoffs of 5.7% and higher were found to be cost effective. Lowering the cutoff from 5.7% to 5.6% also may be cost effective, however, if the costs of preventive interventions were to be lowered. (Am J Prev Med 2012;42(4):374-381) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Zhuo, Xiaohui; Zhang, Ping; Li, Rui; Bullard, Kai McKeever; Gregg, Edward W.] CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Selvin, Elizabeth] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Hoerger, Thomas J.] Res Triangle Int, Res Triangle Pk, NC USA. [Ackermann, Ronald T.] Indiana Univ, Div Gen Internal Med & Geriatr, Indianapolis, IN 46204 USA. RP Zhuo, XH (reprint author), CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K-10, Atlanta, GA 30341 USA. EM xzhuo@cdc.gov FU National Heart, Lung, and Blood Institute [N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022] FX This research uses data from the Atherosclerosis Risk in Communities Study (ARIC). ARIC study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. The authors thank the staff and participants of the ARIC study for their important contributions. NR 40 TC 10 Z9 10 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2012 VL 42 IS 4 BP 374 EP 381 DI 10.1016/j.amepre.2012.01.003 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 912LQ UT WOS:000301799900007 PM 22424250 ER PT J AU Labre, MP Herman, EJ Dumitru, GG Valenzuela, KA Cechman, CL AF Labre, Magdala P. Herman, Elizabeth J. Dumitru, Gema G. Valenzuela, Kristine A. Cechman, Christy L. TI Public Health Interventions for Asthma An Umbrella Review, 1990-2010 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID WRITTEN ACTION PLANS; SELF-MANAGEMENT; MULTICOMPONENT INTERVENTIONS; ENVIRONMENTAL FOCUS; EDUCATION-PROGRAMS; COST-EFFECTIVENESS; MULTI-TRIGGER; HOUSE-DUST; CHILDREN; TRIALS AB Context: Asthma is a chronic respiratory disease increasingly prevalent in the U.S., particularly among children and certain minority groups. This umbrella review sought to assess and summarize existing systematic reviews of asthma-related interventions that might be carried out or supported by state or community asthma control programs, and to identify gaps in knowledge. Evidence acquisition: Eleven databases were searched through September 2010, using terms related to four concepts: asthma, review, intervention, and NOT medication. Reviews of the effectiveness of medications, medical procedures, complementary and alternative medicine, psychological interventions, family therapy, and nutrients or nutritional supplements were excluded. Two coders screened each record and extracted data from the included reviews. Evidence synthesis: Data analysis was conducted from May to December 2010. Of 42 included reviews, 19 assessed the effectiveness of education and/or self-management, nine the reduction of indoor triggers, nine interventions to improve the provision of health care, and five examined other interventions. Several reviews found consistent evidence of effectiveness for self-management education, and one review determined that comprehensive home-based interventions including the reduction of multiple indoor asthma triggers are effective for children. Other reviews found limited or insufficient evidence because of study limitations. Conclusions: State or community asthma control programs should prioritize (1) implementing interventions for which the present review found evidence of effectiveness and (2) evaluating promising interventions that have not yet been adequately assessed. (Am J Prev Med 2012;42(4):403-410) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Herman, Elizabeth J.] CDC, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. [Labre, Magdala P.; Valenzuela, Kristine A.] SciMetrika, Res Triangle Pk, NC USA. [Cechman, Christy L.] CDC, Div Lib Sci & Serv, Chamblee, GA 30341 USA. RP Herman, EJ (reprint author), CDC, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F-58, Chamblee, GA 30341 USA. EM ehh9@cdc.gov FU Air Pollution and Respiratory Health Branch of the National Center for Environmental Health, CDC FX This work was supported by the Air Pollution and Respiratory Health Branch of the National Center for Environmental Health, CDC. The authors thank the following individuals from the Branch for their contribution to the review: Jeneita Bell, Dan Burrows, Gary Coil, Scott Damon, Theresa Harrington, Tursynbek Nurmagambetov, Paige Welch, Maureen Wilce, and Hatice Zahran. NR 60 TC 11 Z9 13 U1 6 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2012 VL 42 IS 4 BP 403 EP 410 DI 10.1016/j.amepre.2011.11.016 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 912LQ UT WOS:000301799900011 PM 22424254 ER PT J AU Hahn, RA Middleton, JC Elder, R Brewer, R Fielding, J Naimi, TS Toomey, TL Chattopadhyay, S Lawrence, B Campbell, CA AF Hahn, Robert A. Middleton, Jennifer Cook Elder, Randy Brewer, Robert Fielding, Jonathan Naimi, Timothy S. Toomey, Traci L. Chattopadhyay, Sajal Lawrence, Briana Campbell, Carla Alexia CA Community Preventive Serv Task TI Effects of Alcohol Retail Privatization on Excessive Alcohol Consumption and Related Harms A Community Guide Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID DISTILLED SPIRITS; PREVENTIVE-SERVICES; IOWA EXPERIENCE; GROCERY STORES; STATE MONOPOLY; SALES; DRINKING; WINE; AVAILABILITY; US AB Context: Excessive alcohol consumption is the third-leading cause of preventable death in the U.S. This systematic review is one in a series exploring effectiveness of interventions to reduce alcohol-related harms. Evidence acquisition: The focus of this review was on studies evaluating the effects of the privatization of alcohol retail sales on excessive alcohol consumption and related harms. Using Community Guide methods for conducting systematic reviews, a systematic search was conducted in multiple databases up to December 2010. Reference lists of acquired articles and review papers were also scanned for additional studies. Evidence synthesis: A total of 17 studies assessed the impact of privatizing retail alcohol sales on the per capita alcohol consumption, a well-established proxy for excessive alcohol consumption; 9 of these studies also examined the effects of privatization on the per capita consumption of alcoholic beverages that were not privatized. One cohort study in Finland assessed the impact of privatizing the sales of medium-strength beer (MSB) on self-reported alcohol consumption. One study in Sweden assessed the impact of re-monopolizing the sale of MSB on alcohol-related harms. Across the 17 studies, there was a 44.4% median increase in the per capita sales of privatized beverages in locations that privatized retail alcohol sales (interquartile interval: 4.5% to 122.5%). During the same time period, sales of nonprivatized alcoholic beverages decreased by a median of 2.2% (interquartile interval: -6.6% to -0.1%). Privatizing the sale of MSB in Finland was associated with a mean increase in alcohol consumption of 1.7 liters of pure alcohol per person per year. Re-monopolization of the sale of MSB in Sweden was associated with a general reduction in alcohol-related harms. Conclusions: According to Community Guide rules of evidence, there is strong evidence that privatization of retail alcohol sales leads to increases in excessive alcohol consumption. (Am J Prev Med 2012;42(4):418-427) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Hahn, Robert A.; Middleton, Jennifer Cook; Elder, Randy; Chattopadhyay, Sajal; Lawrence, Briana; Campbell, Carla Alexia] CDC, Community Guide Branch, Epidemiol & Anal Program Off, Atlanta, GA 30333 USA. [Brewer, Robert] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Fielding, Jonathan] Los Angeles Cty Dept Hlth Serv, Minneapolis, MN USA. [Toomey, Traci L.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Naimi, Timothy S.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Naimi, Timothy S.] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Hahn, RA (reprint author), CDC, Community Guide Branch, Epidemiol & Anal Program Off, 1600 Clifton Rd,Mailstop E-69, Atlanta, GA 30333 USA. EM rhahn@cdc.gov NR 55 TC 21 Z9 21 U1 2 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2012 VL 42 IS 4 BP 418 EP 427 DI 10.1016/j.amepre.2012.01.002 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 912LQ UT WOS:000301799900013 PM 22424256 ER PT J AU Okoro, CA Strine, TW Eke, PI Dhingra, SS Balluz, LS AF Okoro, Catherine A. Strine, Tara W. Eke, Paul I. Dhingra, Satvinder S. Balluz, Lina S. TI The association between depression and anxiety and use of oral health services and tooth loss SO COMMUNITY DENTISTRY AND ORAL EPIDEMIOLOGY LA English DT Article DE adults; anxiety; Behavioral Risk Factor Surveillance System; depression; oral health; population based; psychiatric disorders; surveillance ID FACTOR SURVEILLANCE SYSTEM; COMORBIDITY SURVEY REPLICATION; UNITED-STATES FINDINGS; DSM-IV DISORDERS; DENTAL ANXIETY; PERIODONTAL-DISEASE; BEHAVIOR; ADULTS; PREVALENCE; SEVERITY AB Objective: The purpose of this study is to examine the associations among depression, anxiety, use of oral health services, and tooth loss. Methods: Data were analysed for 80 486 noninstitutionalized adults in 16 states who participated in the 2008 Behavioral Risk Factor Surveillance System. Binomial and multinomial logistic regression analyses were used to estimate predicted marginals, adjusted prevalence ratios, adjusted odds ratios (AOR) and their 95% confidence intervals (CI). Results: The unadjusted prevalence for use of oral health services in the past year was 73.1% [standard error (SE), 0.3%]. The unadjusted prevalence by level of tooth loss was 56.1% (SE, 0.4%) for no tooth loss, 29.6% (SE, 0.3%) for 1-5 missing teeth, 9.7% (SE, 0.2%) for 6-31 missing teeth and 4.6% (SE, 0.1%) for total tooth loss. Adults with current depression had a significantly higher prevalence of nonuse of oral health services in the past year than those without this disorder (P < 0.001), after adjustment for age, sex, race/ethnicity, education, marital status, employment status, adverse health behaviours, chronic conditions, body mass index, assistive technology use and perceived social support. In logistic regression analyses employing tooth loss as a dichotomous outcome (0 versus 1) and as a nominal outcome (0 versus 1-5, 6-31, or all), adults with depression and anxiety were more likely to have tooth loss. Adults with current depression, lifetime diagnosed depression and lifetime diagnosed anxiety were significantly more likely to have had at least one tooth removed than those without each of these disorders (P < 0.001 for all), after fully adjusting for evaluated confounders (including use of oral health services). The adjusted odds of being in the 1-5 teeth removed, 6-31 teeth removed, or all teeth removed categories versus 0 teeth removed category were increased for adults with current depression versus those without (AOR = 1.35; 95% CI = 1.14-1.59; AOR = 1.83; 95% CI = 1.51-2.22; and AOR = 1.44; 95% CI = 1.11-1.86, respectively). The adjusted odds of being in the 1-5 teeth removed and 6-31 teeth removed categories versus 0 teeth removed category were also increased for adults with lifetime diagnosed depression or anxiety versus those without each of these disorders. Conclusion: Use of oral health services and tooth loss was associated with depression and anxiety after controlling for multiple confounders. C1 [Okoro, Catherine A.; Strine, Tara W.; Dhingra, Satvinder S.; Balluz, Lina S.] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Eke, Paul I.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Noncommunicable Dis Injury & Environm Hlth, Atlanta, GA 30333 USA. RP Okoro, CA (reprint author), Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance Program Off, Off Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE,MS E-97, Atlanta, GA 30333 USA. EM Cokoro@cdc.gov NR 49 TC 30 Z9 32 U1 1 U2 26 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0301-5661 J9 COMMUNITY DENT ORAL JI Community Dentist. Oral Epidemiol. PD APR PY 2012 VL 40 IS 2 BP 134 EP 144 DI 10.1111/j.1600-0528.2011.00637.x PG 11 WC Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational Health SC Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational Health GA 909NH UT WOS:000301570900005 PM 21883356 ER PT J AU Marchbanks, PA Curtis, KM Mandel, MG Wilson, HG Jeng, G Folger, SG McDonald, JA Daling, JR Bernstein, L Malone, KE Wingo, PA Simon, MS Norman, SA Strom, BL Ursin, G Weiss, LK Burkman, RT Spirtas, R AF Marchbanks, Polly A. Curtis, Kathryn M. Mandel, Michele G. Wilson, Hoyt G. Jeng, Gary Folger, Suzanne G. McDonald, Jill A. Daling, Janet R. Bernstein, Leslie Malone, Kathleen E. Wingo, Phyllis A. Simon, Michael S. Norman, Sandra A. Strom, Brian L. Ursin, Giske Weiss, Linda K. Burkman, Ronald T. Spirtas, Robert TI Oral contraceptive formulation and risk of breast cancer SO CONTRACEPTION LA English DT Article DE Oral contraceptives; Breast cancer; Hormones; Epidemiology; Case-control studies ID YOUNG-WOMEN; POTENCY AB Background: While evidence on the association between oral contraceptive (OC) use and breast cancer generally suggests little or no increased risk, the question of whether breast cancer risk varies by OC formulation remains controversial. Few studies have examined this issue because large samples and extensive OC histories are required. Study Design: We used data from a multicenter, population-based, case control investigation. Women aged 35-64 years were interviewed. To explore the association between OC formulation and breast cancer risk, we used conditional logistic regression to derive adjusted odds ratios, and we used likelihood ratio tests for heterogeneity to assess whether breast cancer risk varied by OC formulation. Key OC exposure variables were ever use, current or former use, duration of use and time since last use. To strengthen inferences about specific formulations, we restricted most analyses to the 2282 women with breast cancer and the 2424 women without breast cancer who reported no OC use or exclusive use of one OC. Results: Thirty-eight formulations were reported by the 2674 women who used one OC; most OC formulations were used by only a few women. We conducted multivariable analyses on the 10 formulations that were each used by at least 50 women and conducted supplemental analyses on selected formulations of interest based on recent research. Breast cancer risk did not vary significantly by OC formulation, and no formulation was associated with a significantly increased breast cancer risk. Conclusions: These results add to the small body of literature on the relationship between OC formulation and breast cancer. Our data are reassuring in that, among women 35-64 years of age, we found no evidence that specific OC formulations increase breast cancer risk. Published by Elsevier Inc. C1 [Marchbanks, Polly A.; Curtis, Kathryn M.; Mandel, Michele G.; Wilson, Hoyt G.; Jeng, Gary; Folger, Suzanne G.; McDonald, Jill A.; Wingo, Phyllis A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. [Daling, Janet R.; Malone, Kathleen E.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Duarte, CA USA. [Simon, Michael S.] Wayne State Univ, Karmanos Canc Inst, Div Hematol & Oncol, Detroit, MI USA. [Simon, Michael S.] Wayne State Univ, Karmanos Canc Inst, Populat Studies & Prevent Program, Detroit, MI USA. [Norman, Sandra A.; Strom, Brian L.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Norman, Sandra A.; Strom, Brian L.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Ursin, Giske] Canc Registry Norway, Oslo, Norway. [Ursin, Giske] Univ Oslo, Dept Nutr, Oslo, Norway. [Ursin, Giske] Univ So Calif, Los Angeles, CA USA. [Weiss, Linda K.] NCI, Off Canc Ctr, Bethesda, MD 20892 USA. [Burkman, Ronald T.] Tufts Univ, Sch Med, Dept Obstet & Gynecol, Springfield, MA 01199 USA. [Burkman, Ronald T.] Baystate Med Ctr, Springfield, MA USA. [Spirtas, Robert] George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC USA. RP Marchbanks, PA (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. EM pam2@cdc.gov FU National Institute of Child Health and Human Development; National Cancer institute; Emory University [N01-HD-3-3168]; Fred Hutchinson Cancer Research Center [N01-HD-2-3166]; Karmanos Cancer Institute at Wayne State University [N01-HD-3-3174]; University of Pennsylvania [N01-HD-3-3176]; University of Southern California [N01-HD-3-3175]; Centers for Disease Control and Prevention [Y01-HD-7022] FX This study was supported by the National Institute of Child Health and Human Development, with additional support from the National Cancer institute, through contracts with Emory University (N01-HD-3-3168), Fred Hutchinson Cancer Research Center (N01-HD-2-3166), Karmanos Cancer Institute at Wayne State University (N01-HD-3-3174), University of Pennsylvania (N01-HD-3-3176) and University of Southern California (N01-HD-3-3175) and through an intra-agency agreement with the Centers for Disease Control and Prevention (Y01-HD-7022). The Centers for Disease Control and Prevention contributed additional staff and computer support. Surveillance, Epidemiology and End Results (SEER) Programs of the National Cancer Institute provided assistance for study sites in Atlanta (N01-PC-67006), Detroit (N01-CN-65064), Los Angeles (N01-PC-67010) and Seattle (N01-CN-0532). NR 30 TC 13 Z9 13 U1 3 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD APR PY 2012 VL 85 IS 4 BP 342 EP 350 DI 10.1016/j.contraception.2011.08.007 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 915BY UT WOS:000301999100004 PM 22067757 ER PT J AU Stone, GS Henderson, AK Davis, SI Lewin, M Shimizu, I Krishnamurthy, R Bisgard, K Lee, R Jumaan, A Marziale, E Bryant, M Williams, C Mason, K Sirois, M Hori, M Chapman, J Bowman, DJ AF Stone, Gregory S. Henderson, Alden K. Davis, Stephanie I. Lewin, Michael Shimizu, Iris Krishnamurthy, Ramesh Bisgard, Kris Lee, Robin Jumaan, Aisha Marziale, Erin Bryant, Miranda Williams, Clayton Mason, Karen Sirois, Maria Hori, Makiko Chapman, Jonathan Bowman, David J. TI Lessons from the 2006 Louisiana Health and Population Survey SO DISASTERS LA English DT Article DE demography; disaster; displacement; Hurricane Katrina; Hurricane Rita; population estimate; survey methods ID RAPID ASSESSMENT; DATA-COLLECTION; SIZE; DISASTER; EMERGENCIES; CLUSTER; TRENDS AB The 2005 hurricane season caused extensive damage and induced a mass migration of approximately 1.1 million people from southern Louisiana in the United States. Current and accurate estimates of population size and demographics and an assessment of the critical needs for public services were required to guide recovery efforts. Since forecasts using pre-hurricane data may produce inaccurate estimates of the post-hurricane population, a household survey in 18 hurricane-affected parishes was conducted to provide timely and credible information on the size of these populations, their demographics and their condition. This paper describes the methods used, the challenges encountered, and the key factors for successful implementation. This post-disaster survey was unique because it identified the needs of the people in the affected parishes and quantified the number of people with these needs. Consequently, this survey established new population and health indicator baselines that otherwise would have not been available to guide the relief and recovery efforts in southern Louisiana. C1 [Stone, Gregory S.; Williams, Clayton] Louisiana Publ Hlth Inst, Hlth Syst Div, New Orleans, LA 70112 USA. [Shimizu, Iris] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Atlanta, GA USA. [Krishnamurthy, Ramesh] Ctr Dis Control & Prevent, Off Workforce & Career Dev, Atlanta, GA USA. [Bryant, Miranda] Populat Serv Int, Juba, Sudan. [Mason, Karen] Louisiana State Univ, Sch Publ Hlth, Baton Rouge, LA 70803 USA. [Sirois, Maria] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat, New Orleans, LA 70118 USA. [Hori, Makiko] Louisiana State Univ, Dept Sociol, Baton Rouge, LA 70803 USA. [Chapman, Jonathan] Louisiana Dept Hlth & Hosp, Bur Primary Care & Rural Hlth, Hlth Informat Serv, Baton Rouge, LA 70821 USA. RP Stone, GS (reprint author), Louisiana Publ Hlth Inst, Hlth Syst Div, 1515 Poydras St,Suite 1200, New Orleans, LA 70112 USA. EM gstone13@gmail.com NR 42 TC 0 Z9 0 U1 3 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0361-3666 J9 DISASTERS JI Disasters PD APR PY 2012 VL 36 IS 2 BP 270 EP 290 DI 10.1111/j.1467-7717.2011.01254.x PG 21 WC Planning & Development SC Public Administration GA 906KR UT WOS:000301344500006 PM 21992191 ER PT J AU Alisch, RS Barwick, BG Chopra, P Myrick, LK Satten, GA Conneely, KN Warren, ST AF Alisch, Reid S. Barwick, Benjamin G. Chopra, Pankaj Myrick, Leila K. Satten, Glen A. Conneely, Karen N. Warren, Stephen T. TI Age-associated DNA methylation in pediatric populations SO GENOME RESEARCH LA English DT Article ID PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; MAMMALIAN DNA; HUMAN COLON; CANCER; GENES; TUMORS; REPAIR; CELLS; EXPRESSION AB DNA methylation (DNAm) plays diverse roles in human biology, but this dynamic epigenetic mark remains far from fully characterized. Although earlier studies uncovered loci that undergo age-associated DNAm changes in adults, little is known about such changes during childhood. Despite profound DNAm plasticity during embryogenesis, monozygotic twins show indistinguishable childhood methylation, suggesting that DNAm is highly coordinated throughout early development. Here we examine the methylation of 27,578 CpG dinucleotides in peripheral blood DNA from a cross-sectional study of 398 boys, aged 3-17 yr, and find significant age-associated changes in DNAm at 2078 loci. These findings correspond well with pyrosequencing data and replicate in a second pediatric population (N = 78). Moreover, we report a deficit of age-related loci on the X chromosome, a preference for specific nucleotides immediately surrounding the interrogated CpG dinucleotide, and a primary association with developmental and immune ontological functions. Meta-analysis (N = 1158) with two adult populations reveals that despite a significant overlap of age-associated loci, most methylation changes do not follow a lifelong linear pattern due to a threefold to fourfold higher rate of change in children compared with adults; consequently, the vast majority of changes are more accurately modeled as a function of logarithmic age. We therefore conclude that age-related DNAm changes in peripheral blood occur more rapidly during childhood and are imperfectly accounted for by statistical corrections that are linear in age, further suggesting that future DNAm studies should be matched closely for age. C1 [Alisch, Reid S.; Barwick, Benjamin G.; Chopra, Pankaj; Myrick, Leila K.; Satten, Glen A.; Conneely, Karen N.; Warren, Stephen T.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA. [Satten, Glen A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Warren, Stephen T.] Emory Univ, Sch Med, Dept Biochem, Dept Pediat, Atlanta, GA 30322 USA. RP Warren, ST (reprint author), Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA. EM swarren@emory.edu RI perumal, murugiah/D-1565-2012; OI Satten, Glen/0000-0001-7275-5371 FU Emory Biomarker Service Center; Simons Foundation (SFARI); NIH [MH089606]; HHS [5T32GM008490-19] FX We thank Julie Mowrey and Brian Lynch for technical assistance and Cheryl Strauss for editorial comments. We also thank Dr. Teschendorff and Dr. Widschwendter for communicating specific samples included in their study; and Dr. Louis M. Kunkel, Dr. Isaac S. Kohane, Dr. Sek Won Kong, and Dr. Yuko Soneoka from Children's Hospital Boston. This work was supported in part by the Emory Biomarker Service Center, as well as a Simons Foundation (SFARI) award and NIH grant MH089606, both to S.T.W. B.G.B. was supported by HHS training grant no. 5T32GM008490-19. We are grateful to all of the families at the participating SFARI Simplex Collection (SSC) sites; as well as the principal investigators (A. Beaudet, R. Bernier, J. Constantino, E. Cook, E. Fombonne, D. Geschwind, D. Grice, A. Kiln, D. Ledbetter, C. Lord, C. Martin, D. Martin, R. Maxim, J. Miles, O. Ousley, B. Peterson, J. Piggot, C. Saulnier, M. State, W. Stone, J. Sutcliffe, C. Walsh, and E. Wijsman). We also appreciate the access to phenotypic data on the SFARI Base. Approved researchers can obtain the SSC population data set described in this study by applying at https://base.sfari.org. Disclaimer: The opinions and findings of this report are those of the authors and should not be taken as official positions or findings of the CDC. NR 48 TC 113 Z9 116 U1 3 U2 17 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1088-9051 J9 GENOME RES JI Genome Res. PD APR PY 2012 VL 22 IS 4 BP 623 EP 632 DI 10.1101/gr.125187.111 PG 10 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA 917UJ UT WOS:000302203800004 PM 22300631 ER PT J AU Gerding, J Price, J AF Gerding, Justin Price, Julianne TI Public Health Performance Management: Opportunities for Environmental Public Health SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article AB NEHA strives to provide up-to-date and relevant information on environmental health and to build partnerships in the profession. In pursuit of these goals, we feature a column from the Environmental Health Services Branch (EHSB) of the Centers for Disease Control and Prevention (CDC) in every issue of the Journal. In this column, EHSB and guest authors from across CDC will highlight a variety of concerns, opportunities, challenges, and successes that we all share in environmental public health. EHSB's objective is to strengthen the role of state, local, and national environmental health programs and professionals to anticipate, identify, and respond to adverse environmental exposures and the consequences of these exposures for human health. The services being developed through EHSB include access to topical, relevant, and scientific information; consultation; and assistance to environmental health specialists, sanitarians, and environmental health professionals and practitioners. The conclusions in this article are those of the author(s) and do not necessarily represent the views of the CDC. LCDR Justin Gerding is an environmental health officer in the CDC Environmental Health Services Branch. Julianne Price is the Florida Department of Health's Statewide Protocol for Assessing Community Excellence in Environmental Health (PACE EH) coordinator and an environmental specialist at the Indian River County Department's Division of Environmental Health. C1 [Gerding, Justin] CDC, Environm Hlth Serv Branch, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Gerding, J (reprint author), CDC, Environm Hlth Serv Branch, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-60, Atlanta, GA 30341 USA. EM jgerding@cdc.gov NR 4 TC 1 Z9 1 U1 1 U2 3 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD APR PY 2012 VL 74 IS 8 BP 30 EP 31 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 915RY UT WOS:000302046300005 PM 22533122 ER PT J AU Pies, C Parthasarathy, P Posner, SF AF Pies, Cheri Parthasarathy, Padmini Posner, Samuel F. TI Integrating the Life Course Perspective into a Local Maternal and Child Health Program SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Life Course Perspective; Birth outcomes; Social determinants of health; Health equity; Local health department ID LOW-BIRTH-WEIGHT; PRENATAL-CARE; UNITED-STATES; DISEASE; POPULATION; FRAMEWORK; DISPARITIES; PATTERNS; STRESS; FAMILY AB For many decades, early access to prenatal care has been considered the gold standard for improving birth outcomes. In Contra Costa County, a diverse urban and suburban county of over one million people in the San Francisco Bay Area, the Family Maternal and Child Health Programs of Contra Costa Health Services (CCHS) have seen high rates of early entry into prenatal care since 2000. Yet despite our best efforts to increase access to quality prenatal care, our rates of low birth weight and infant mortality, especially among African Americans, continue to be high. When we were introduced to the Life Course Perspective in 2003 as an organizational framework for our programmatic activities, we recognized that emerging scientific evidence in the literature demonstrated the importance of social and environmental factors in determining health and health equity, and supported a general impression in the field that prenatal care was not enough to improve birth outcomes. The Life Course Perspective suggests that many of the risk and protective factors that influence health and wellbeing across the lifespan also play an important role in birth outcomes and in health and quality of life beyond the initial years. In this article, we describe the Life Course Perspective and how one local Maternal and Child Health Program adopted and adapted this paradigm by creating and launching a Life Course Initiative to guide our programs and services. The Life Course Initiative implemented by CCHS is designed to reduce inequities in birth outcomes, improve reproductive potential, and change the health of future generations by introducing a longitudinal, integrated, and ecological approach to implementing maternal and child health programs. C1 [Pies, Cheri] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Parthasarathy, Padmini] Family Maternal Program, Martinez, CA 94553 USA. [Posner, Samuel F.] Ctr Dis Control & Prevent, Ctr Chron Dis & Hlth Promot, Atlanta, GA 30341 USA. [Parthasarathy, Padmini] Child Hlth Program, Martinez, CA 94553 USA. RP Pies, C (reprint author), Univ Calif Berkeley, Sch Publ Hlth, 279 Univ Hall, Berkeley, CA 94720 USA. EM cpies@berkeley.edu; padmini.parthasarathy@hsd.cccounty.us; shp5@cdc.gov OI Posner, Samuel/0000-0003-1574-585X NR 46 TC 9 Z9 12 U1 1 U2 12 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD APR PY 2012 VL 16 IS 3 BP 649 EP 655 DI 10.1007/s10995-011-0800-2 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 912KA UT WOS:000301795700013 PM 21630077 ER PT J AU MacDorman, MF Declercq, E Mathews, TJ Stotland, N AF MacDorman, Marian F. Declercq, Eugene Mathews, T. J. Stotland, Naomi TI Trends and Characteristics of Home Vaginal Birth After Cesarean Delivery in the United States and Selected States SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID HOSPITAL BIRTHS; PLANNED HOME; OUTCOMES; PATTERNS AB OBJECTIVE: To examine trends and characteristics of home vaginal birth after cesarean delivery (VBAC) in the United States and selected states from 1990-2008. METHODS: Birth certificate data were used to track trends in home and hospital VBACs from 1990-2008. Data on planned home VBAC were analyzed by sociodemographic and medical characteristics for the 25 states reporting this information in 2008 and compared with hospital VBAC data. RESULTS: In 2008, there were approximately 42,000 hospital VBACs and approximately 1,000 home VBACs in the United States, up from 664 in 2003 and 656 in 1990. The percentage of home births that were VBACs increased from less than 1% in 1996 to 4% in 2008, whereas the percentage of hospital births that were VBACs decreased from 3% in 1996 to 1% in 2008. Planned home VBACs had a lower risk profile than hospital VBACs with fewer births to teenagers, unmarried women, or smokers; fewer preterm or low-birth-weight deliveries; and higher maternal education levels. CONCLUSION: Recent increases in the proportion of U. S. women with a prior cesarean delivery mean that an increasing number of women are faced with the choice and associated risks of either VBAC or repeat cesarean delivery. Recent restrictions in hospital VBAC availability have coincided with increases in home VBACs; however, home VBAC remains rare, with approximately 1,000 occurrences in 2008. (Obstet Gynecol 2012;119:737-44) DOI: 10.1097/AOG.0b013e31824bb050 C1 [Stotland, Naomi] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94110 USA. Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA USA. Ctr Dis Control & Prevent, Reprod Stat Branch, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Stotland, N (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 1001 Potrero Ave 6D-1, San Francisco, CA 94110 USA. EM stotlandn@obgyn.ucsf.edu OI Declercq, Eugene/0000-0001-5411-3033 NR 35 TC 17 Z9 18 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2012 VL 119 IS 4 BP 737 EP 744 DI 10.1097/AOG.0b013e31824bb050 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 914SC UT WOS:000301971400008 PM 22433337 ER PT J AU Tyler, CP Whiteman, MK Zapata, LB Curtis, KM Hillis, SD Marchbanks, PA AF Tyler, Crystal P. Whiteman, Maura K. Zapata, Lauren B. Curtis, Kathryn M. Hillis, Susan D. Marchbanks, Polly A. TI Health Care Provider Attitudes and Practices Related to Intrauterine Devices for Nulliparous Women SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID CONTRACEPTION; PROVISION AB OBJECTIVE: To examine predictors of health care providers perceiving intrauterine devices (IUDs) as unsafe for nulliparous women and of infrequent provision of IUDs to nulliparous women. METHODS: We analyzed questionnaire data obtained during December 2009 to March 2010 from 635 office-based providers (physicians) and 1,323 Title X clinic providers (physicians, physician assistants, certified nurse midwives, nurse practitioners, and nurses). Using multi-variable logistic regression, we estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of the associations between patient, health care provider, and clinic and practice variables and provider misconceptions about the safety of IUDs for nulliparous women and with infrequent IUD provision. RESULTS: Approximately 30% of respondents had misconceptions about the safety of IUDs for nulliparous women. Factors associated with increased odds of misconceptions about the copper IUD and levonorgestrel-releasing IUD included: being an office-based family medicine physician (copper IUD adjusted OR 3.20, 95% CI 1.73-5.89; levonorgestrel-releasing IUD adjusted OR 2.03, 95% CI 1.10-3.76); not being trained in IUD insertion (copper IUD adjusted OR 4.72, 95% CI 2.32-9.61; levonorgestrel-releasing IUD adjusted OR 2.64, 95% CI 1.34-5.22); and nonavailability of IUDs on-site at their practice or clinic (copper IUD adjusted OR 2.18, 95% CI 1.20-3.95; levonorgestrel-releasing IUD adjusted OR 3.45, 95% CI 1.95-6.08). More than 60% of providers infrequently provided IUDs to nulliparous women. Nonavailability of IUDs on-site (copper IUD adjusted OR 1.78, 95% CI 1.01-3.14; levonorgestrel-releasing IUD adjusted OR 2.10, 95% CI 1.22-3.62) and provider misconceptions about safety (copper IUD adjusted OR 6.04, 95% CI 2.00-18.31; levonorgestrel-releasing IUD adjusted OR 6.91, 95% CI 3.01-15.85) were associated with infrequent IUD provision. CONCLUSION: Health care provider misconceptions about the safety of IUDs for nulliparous women are prevalent and are associated with infrequent provision. Improved health care provider education and IUD availability are needed to increase IUD use among nulliparous women. (Obstet Gynecol 2012;119:762-71) DOI: 10.1097/AOG.0b013e31824aca39 C1 Ctr Dis Control & Prevent, Epidem Intelligence Serv, Career Dev Div, Off Workforce & Career Dev,Natl Ctr Chron Dis Pre, Atlanta, GA USA. Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Tyler, CP (reprint author), 4770 Buford Highway,NE MS K-22, Atlanta, GA 30341 USA. EM ctyler@cdc.gov FU Division of Reproductive Health in the Centers for Disease Control and Prevention FX Supported by funding from the Division of Reproductive Health in the Centers for Disease Control and Prevention. NR 24 TC 59 Z9 59 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2012 VL 119 IS 4 BP 762 EP 771 DI 10.1097/AOG.0b013e31824aca39 PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 914SC UT WOS:000301971400011 PM 22433340 ER PT J AU Luo, HB Beckles, GLA Fang, XM Crews, JE Saaddine, JB Zhang, XZ AF Luo, Huabin Beckles, Gloria L. A. Fang, Xiangming Crews, John E. Saaddine, Jinan B. Zhang, Xinzhi TI Socioeconomic Status and Lifetime Risk for Workplace Eye Injury Reported by a US Population Aged 50 Years and Over SO OPHTHALMIC EPIDEMIOLOGY LA English DT Article DE Eye injury; Socioeconomic status; Education; Income; Vision; adults ID UNITED-STATES; OCULAR TRAUMA; WORK; EPIDEMIOLOGY; HEALTH; EDUCATION AB Purpose: To examine whether socioeconomic status, as measured by educational attainment and annual household income, is associated with lifetime risk for workplace eye injury in a large US population. Methods: In analyses of data from the Behavioral Risk Factor Surveillance System (2005-2007, N = 43,510), we used logistic regression analysis and propensity score matching to assess associations between socioeconomic measures and lifetime risk for workplace eye injury among those aged >= 50 years. Results: The lifetime prevalence of self-reported workplace eye injury was significantly higher among men (13.5%) than women (2.6%) (P < 0.001). After adjusting for age, race/ethnicity, eye care insurance, health status, and risk-taking behaviors, men with less than high school education (adjusted odds ratio [OR] = 2.24, 95% CI: 1.74-2.87) or high school education (adjusted OR = 1.92, 95% CI: 1.57-2.33) were more likely to report having had a lifetime workplace eye injury than those with more than a high school education. Men with an annual household income <$15,000 were also more likely to report having had a lifetime workplace eye injury than those whose income was >$50,000 (adjusted OR = 1.44, 95% CI: 1.07-1.95). After adjusting for other factors, no statistically significant associations between education, income, and lifetime workplace eye injury were found among women. Conclusions: Socioeconomic status was associated with lifetime risk for workplace eye injury among men but not women. Greater public awareness of individual and societal impacts of workplace eye injuries, especially among socioeconomically disadvantaged men, could help support efforts to develop a coordinated prevention strategy to minimize avoidable workplace eye injuries. C1 [Beckles, Gloria L. A.; Crews, John E.; Saaddine, Jinan B.; Zhang, Xinzhi] US Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Luo, Huabin] Mt Olive Coll, Mt Olive, NC USA. [Fang, Xiangming] China Agr Univ, Coll Econ & Management, Beijing 100094, Peoples R China. RP Zhang, XZ (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,K-10, Atlanta, GA 30341 USA. EM XZhang4@cdc.gov RI Fang, Xiangming/O-1653-2014 OI Fang, Xiangming/0000-0001-9922-8977 NR 32 TC 2 Z9 2 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0928-6586 J9 OPHTHAL EPIDEMIOL JI Ophthalmic Epidemiol. PD APR PY 2012 VL 19 IS 2 BP 103 EP 110 DI 10.3109/09286586.2011.639977 PG 8 WC Ophthalmology SC Ophthalmology GA 915ZY UT WOS:000302067400009 PM 22364578 ER PT J AU Green, LW Brancati, FL Albright, A AF Green, Lawrence W. Brancati, Frederick L. Albright, Ann CA Primary Prevention Diabet Working TI Primary prevention of type 2 diabetes: integrative public health and primary care opportunities, challenges and strategies SO FAMILY PRACTICE LA English DT Article DE Behavior; community; diabetes; lifestyle; primary care; primary prevention ID LIFE-STYLE INTERVENTION; IMPAIRED GLUCOSE-TOLERANCE; TOBACCO CONTROL; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; OBESITY CONTROL; FOLLOW-UP; MELLITUS; RISK; PROGRAMS AB Type 2 diabetes imposes a large and growing burden on the public's health. This burden, combined with the growing evidence for primary prevention from randomized controlled trials of structured lifestyle programs leads to recommendations to include caloric reduction, increased physical activity and specific assistance to patients in problem solving to achieve modest weight loss as well as pharmacotherapy. These recommendations demand exploration of new ways to implement such primary prevention strategies through more integrated community organization, medical practice and policy. The US experience with control of tobacco use and high blood pressure offers valuable lessons for policy, such as taxation on products, and for practice in a variety of settings, such as coordination of referrals for lifestyle supports. We acknowledge also some notable exceptions to their generalizability. This paper presents possible actions proposed by an expert panel, summarized in Table 1 as recommendations for immediate action, strategic action and research. The collaboration of primary care and public health systems will be required to make many of these recommendations a reality. This paper also provides information on the progress made in recent years by the Division of Diabetes Translation at the US Centers for Disease Control and Prevention (CDC) to implement or facilitate such integration of primary care and public health for primary prevention. C1 [Green, Lawrence W.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Sch Med, San Francisco, CA 94127 USA. [Brancati, Frederick L.] Johns Hopkins Univ, Sch Med, Dept Med & Epidemiol, Baltimore, MD USA. [Albright, Ann] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, US Dept HHS, Atlanta, GA USA. RP Green, LW (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, Sch Med, 66 Santa Paula Ave, San Francisco, CA 94127 USA. EM lwgreen@comcast.net FU Danya International, Inc.; Division of Diabetes Translation of the National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, US Department of Health and Human Services FX The authors wish to acknowledge Namratha Swamy, PhD, Jennifer Jones, Henry Wong, PhD, and Lauren Hess of Danya International, Inc. for their support in the coordination of the expert panel and preparation of the manuscript. We are indebted also to Dean Schillinger, MD, University of California at San Francisco and Chief, California Diabetes Program, California Department of Public Health. The content is solely the responsibility of the authors and does not necessarily represent the official position of the Centers for Disease Control and Prevention.; The convening of the panel and preparation of this report were supported by the Division of Diabetes Translation of the National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, US Department of Health and Human Services. NR 77 TC 8 Z9 8 U1 0 U2 20 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0263-2136 J9 FAM PRACT JI Fam. Pr. PD APR PY 2012 VL 29 SU 1 BP i13 EP i23 DI 10.1093/fampra/cmr126 PG 11 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 905TR UT WOS:000301298400003 PM 22399542 ER PT J AU Srinivasan, A Fishman, N AF Srinivasan, Arjun Fishman, Neil TI Antimicrobial Stewardship 2012: Science Driving Practice INTRODUCTION SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Editorial Material C1 [Srinivasan, Arjun] Ctr Dis Control & Prevent, Healthcare Associated Infect Prevent Programs & G, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Fishman, Neil] Univ Pennsylvania Hlth Syst, Philadelphia, PA USA. RP Srinivasan, A (reprint author), Ctr Dis Control & Prevent, Healthcare Associated Infect Prevent Programs & G, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A07, Atlanta, GA 30333 USA. EM beu8@cdc.gov NR 13 TC 8 Z9 8 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2012 VL 33 IS 4 SI SI BP 319 EP 321 DI 10.1086/664908 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 911KW UT WOS:000301716700001 PM 22418624 ER PT J AU Hines, CJ Hopf, NB Deddens, JA Silva, MJ Calafat, AM AF Hines, Cynthia J. Hopf, Nancy B. Deddens, James A. Silva, Manori J. Calafat, Antonia M. TI Occupational exposure to diisononyl phthalate (DiNP) in polyvinyl chloride processing operations SO INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Article DE Diisononyl phthalate; Occupational; Exposure assessment; Biological monitoring; Intake estimates; Polyvinyl chloride ID ISO-NONYLPHTHALATE DINP; ISONONYL PHTHALATE; HUMAN URINE; METABOLITE CONCENTRATIONS; DEVELOPMENTAL TOXICITY; RATS; ESTERS; REPRODUCTION; POPULATION; ABSORPTION AB Diisononyl phthalate (DiNP) is primarily used as a plasticizer in polyvinyl chloride (PVC) materials. While information is available on general population exposure to DiNP, occupational exposure data are lacking. We present DiNP metabolite urinary concentrations in PVC processing workers, estimate DiNP daily intake for these workers, and compare worker estimates to other populations. We assessed DiNP exposure in participants from two companies that manufactured PVC materials, a PVC film manufacturer (n = 25) and a PVC custom compounder (n = 12). A mid-shift and end-shift urine sample was collected from each participant and analyzed for the DiNP metabolite mono(carboxy-isooctyl) phthalate (MCiOP). Mixed models were used to assess the effect on MCiOP concentrations of a worker being assigned to (1) a task using DiNP and (2) a shift where DiNP was used. A simple pharmacokinetic model was used to estimate DiNP daily intake from the MCiOP concentrations. Creatinine-adjusted MCiOP urinary concentrations ranged from 0.42-80 mu g/g in PVC film and from 1.11-13.4 mu g/g in PVC compounding. PVC film participants who worked on a task using DiNP (n = 7) had the highest MCiOP geometric mean (GM) end-shift concentration (25.2 mu g/g), followed by participants who worked on a shift where DiNP was used (n = 11) (17.7 mu g/g) as compared to participants with no task (2.92 mu g/g) or shift (2.08 mu g/g) exposure to DiNP. The GM end-shift MCiOP concentration in PVC compounding participants (4.80 mu g/g) was comparable to PVC film participants with no task or shift exposure to DiNP. Because no PVC compounding participants were assigned to tasks using DINP on the day sampled, DiNP exposure in this company may be underestimated. The highest DiNP intake estimate was 26 mu g/kg/day. Occupational exposure to DiNP associated with PVC film manufacturing tasks were substantially higher (sixfold to tenfold) than adult general population exposures; however, all daily intake estimates were less than 25% of current United States or European acceptable or tolerable daily intake estimates. Further characterization of DiNP occupational exposures in other industries is recommended. C1 [Hines, Cynthia J.; Hopf, Nancy B.; Deddens, James A.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Hopf, Nancy B.] Inst Work & Hlth IST, Lausanne, Switzerland. [Deddens, James A.] Univ Cincinnati, Dept Math Sci, Cincinnati, OH 45221 USA. [Silva, Manori J.; Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Hines, CJ (reprint author), NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,R-14, Cincinnati, OH 45226 USA. EM chines@cdc.gov FU Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health; National Center for Environmental Health FX This work was supported by intramural research funds from the Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health and National Center for Environmental Health. NR 44 TC 6 Z9 11 U1 0 U2 25 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-0131 J9 INT ARCH OCC ENV HEA JI Int. Arch. Occup. Environ. Health PD APR PY 2012 VL 85 IS 3 BP 317 EP 325 DI 10.1007/s00420-011-0674-z PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 909OG UT WOS:000301573400009 PM 21701833 ER PT J AU Miller, KS Fasula, AM Lin, CY Levin, ML Wyckoff, SC Forehand, R AF Miller, Kim S. Fasula, Amy M. Lin, Carol Y. Levin, Martin L. Wyckoff, Sarah C. Forehand, Rex TI Ready, Set, Go: African American Preadolescents' Sexual Thoughts, Intentions, and Behaviors SO JOURNAL OF EARLY ADOLESCENCE LA English DT Article DE sexual behavior; sexual development; transitions ID PREVENTION PROGRAM; ADOLESCENTS; TRIAL AB Understanding of preadolescent sexuality is limited. To help fill this gap, we calculated frequencies, percentages, and confidence intervals for 1,096 preadolescents' reports of sexual thoughts, intentions, and sexual behavior. Cochran-Armitage trend tests accounted for age effects. Findings show that 9-year-olds are readying for sexual activity, with sexual readiness increasing between ages of 9 and 12. Sexual thoughts increased with age (p < .001): 46% of 9-year-olds and 70% of 12-year-olds were ready to learn about sex, and 14% of 9-year-olds and 41% of 12-year-olds thought about having sex. Few 9-year-olds anticipated sexual debut, but this increased with age (p < .05): 25% of 12-year-olds were ready for sex, and 20% anticipated initiating sex within a year. Our results indicate that preadolescents are initiating dating relationships and anticipating intercourse, and some have engaged in risk behaviors. Thus preadolescence is a critical time to implement prevention programs. C1 [Miller, Kim S.] Ctr Dis Control & Prevent, Global Aids Program, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Levin, Martin L.] Univ Memphis, Memphis, TN 38152 USA. [Wyckoff, Sarah C.] Univ N Carolina, Chapel Hill, NC USA. [Forehand, Rex] Univ Vermont, Burlington, VT 05405 USA. RP Miller, KS (reprint author), Ctr Dis Control & Prevent, Global Aids Program, Div Global HIV AIDS, 1600 Clifton Rd NE,Mailstop E-08, Atlanta, GA 30333 USA. EM kmiller@cdc.gov NR 27 TC 3 Z9 3 U1 1 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-4316 J9 J EARLY ADOLESCENCE JI J. Early Adolesc. PD APR PY 2012 VL 32 IS 2 BP 293 EP 307 DI 10.1177/0272431610393247 PG 15 WC Family Studies; Psychology, Developmental SC Family Studies; Psychology GA 912KO UT WOS:000301797100006 ER PT J AU Corral, I Landrine, H Hao, Y Zhao, LH Mellerson, JL Cooper, DL AF Corral, Irma Landrine, Hope Hao, Yongping Zhao, Luhua Mellerson, Jenelle L. Cooper, Dexter L. TI Residential segregation, health behavior and overweight/obesity among a national sample of African American adults SO JOURNAL OF HEALTH PSYCHOLOGY LA English DT Article DE context; diet; exercise; obesity; poverty; race ID MULTILEVEL LOGISTIC-REGRESSION; FAST-FOOD; NEIGHBORHOOD CHARACTERISTICS; PHYSICAL-ACTIVITY; UNITED-STATES; US; AVAILABILITY; DISPARITIES; ENVIRONMENTS; FRUIT AB We examined the role of residential segregation in 5+ daily fruit/vegetable consumption, exercise, and overweight/obesity among African Americans by linking data on the 11,142 African American adults in the 2000 Behavioral Risk Factor Surveillance System to 2000 census data on the segregation of metropolitan statistical areas (MSAs). Multi-level modeling revealed that after controlling for individual-level variables, MSA Segregation and Poverty contributed to fruit/vegetable consumption, MSA Poverty alone contributed to exercise, and MSA Segregation alone contributed to overweight/obesity. These findings highlight the need for research on the built-environments of the segregated neighborhoods in which most African Americans reside, and suggest that neighborhood disparities may contribute to health disparities. C1 [Corral, Irma] E Carolina Univ, Dept Psychiat Med, Greenville, NC 27834 USA. [Hao, Yongping; Zhao, Luhua] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mellerson, Jenelle L.; Cooper, Dexter L.] Amer Canc Soc, Atlanta, GA 30329 USA. RP Corral, I (reprint author), E Carolina Univ, Dept Psychiat Med, 600 Moye Blvd,Mail Stop 694, Greenville, NC 27834 USA. EM corrali@ecu.edu OI Corral, Irma/0000-0003-3840-9269 NR 35 TC 24 Z9 24 U1 1 U2 13 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1359-1053 J9 J HEALTH PSYCHOL JI J. Health Psychol. PD APR PY 2012 VL 17 IS 3 BP 371 EP 378 DI 10.1177/1359105311417191 PG 8 WC Psychology, Clinical SC Psychology GA 908UW UT WOS:000301519300007 PM 21844135 ER PT J AU Looker, AC Melton, LJ Borrud, LG Shepherd, JA AF Looker, A. C. Melton, L. J., III Borrud, L. G. Shepherd, J. A. TI Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Cross-sectional age patterns; Gender differences; Lumbar spine bone mineral density; NHANES; Osteoporosis; Race/ethnic differences ID FRACTURE RISK-ASSESSMENT; RACE/ETHNIC DIFFERENCES; POSTMENOPAUSAL WOMEN; OLDER MEN; OSTEOPOROSIS; HIP; DISCORDANCE; PREVALENCE; DIAGNOSIS; SITES AB This analysis examines lumbar spine bone mineral density (BMD) of US adults from NHANES 2005-2008 by age, sex, and race/ethnicity. Prevalence of low spine BMD and agreement between the prevalence of low BMD at the spine and femur neck in older adults are also assessed. Lumbar spine BMD data from a representative sample of the US population have not been previously available. We used data from the National Health and Nutrition Examination Survey 2005-2008 to examine demographic patterns in lumbar spine BMD among US adults age a parts per thousand yen20 years and the prevalence of low lumbar spine BMD in adults age a parts per thousand yen50 years. Agreement between the prevalence of low BMD at the femur neck and spine in older adults was also assessed. Dual-energy X-ray absorptiometry was used to measure lumbar spine and femur neck BMD. World Health Organization definitions were used to categorize skeletal status as normal, osteopenia, or osteoporosis. Compared to non-Hispanic whites, non-Hispanic blacks had higher and Mexican Americans had lower lumbar spine BMD. Lumbar spine BMD declined with age in women, but not in men. Approximately 4.7 million (10%) older US women and 1 million (3%) older men had lumbar spine osteoporosis in 2005-2008. Roughly one third of them differed in skeletal status at the spine and hip but most were normal at one site and osteopenic at the other. Only 3-10%, depending on sex, had osteoporosis at one skeletal site but not at the other skeletal site. Between 76% and 87% with discordant skeletal status had lumbar spine T-scores within 1 unit of the category threshold. These findings suggest that measuring either the femur neck or the lumbar spine will correctly classify the majority of individuals who present for care as osteoporotic or not. C1 [Looker, A. C.; Borrud, L. G.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Melton, L. J., III] Mayo Clin, Div Epidemiol, Coll Med, Rochester, MN USA. [Shepherd, J. A.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. RP Looker, AC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Room 4310,3311 Toledo Rd, Hyattsville, MD 20782 USA. EM Alooker@cdc.gov NR 42 TC 27 Z9 27 U1 0 U2 6 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD APR PY 2012 VL 23 IS 4 BP 1351 EP 1360 DI 10.1007/s00198-011-1693-z PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 912IM UT WOS:000301790500017 PM 21720893 ER PT J AU Lo, YC Turabelidze, G Lin, M Friedberg, Y AF Lo, Yi-Chun Turabelidze, George Lin, Mei Friedberg, Yelena TI Prevalence and Determinants of Recent HIV Testing Among Sexually Active Men Who Have Sex With Men in the St. Louis Metropolitan Area, Missouri, 2008 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID UNITED-STATES; RISK; PREVENTION; SURVEILLANCE; INFECTION; PROVIDERS; CITIES; CARE AB Background: New human immunodeficiency virus (HIV) diagnoses in the St. Louis metropolitan area, MO, occur predominantly among men who have sex with men (MSM). The Centers for Disease Control and Prevention recommends HIV testing at least annually for sexually active MSM. We examined prevalence and factors associated with recent HIV testing among MSM in the St. Louis area. Methods: The 2008 National HIV Behavioral Surveillance system recruited men in 21 US metropolitan areas through venue-based, time-space sampling. Men were interviewed for behavioral risks and testing history. The analysis included men in St. Louis who had engaged in male-male sex during the previous year and excluded men who had tested HIV-positive > 12 months before the interviews. Factors associated with testing during the previous 12 months were identified using log-binomial regression. Results: Among 339 MSM, 198 (58%) had been tested during the previous 12 months. MSM were more likely to have been tested if they were black (adjusted prevalence ratio [APR]: 1.6; 95% confidence interval [CI]: 1.0-2.5); had visited a health care provider during the previous 12 months (APR: 1.6; 95% CI: 1.3-2.1); or had ever disclosed same-sex attractions or male-male sex to health care providers (APR: 1.6; 95% CI: 1.2-2.0). Of the 141 men who were untested within 12 months, 89 (63%) attributed not testing to perceived low risk. Conclusions: Nearly half of sexually active MSM in this analysis had not been tested for HIV during the previous year. Annual visits to health care providers during which sexual risk is discussed are likely to promote testing among MSM. C1 [Lo, Yi-Chun; Turabelidze, George; Lin, Mei; Friedberg, Yelena] Missouri Dept Hlth & Senior Serv, Jefferson, AR USA. [Lo, Yi-Chun] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Lin, Mei] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Turabelidze, G (reprint author), Missouri Dept Hlth & Senior Serv, Eastern Dist Off, 220 S Jefferson, St Louis, MO 63103 USA. EM george.turabelidze@health.mo.gov NR 23 TC 10 Z9 10 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD APR PY 2012 VL 39 IS 4 BP 306 EP 311 DI 10.1097/OLQ.0b013e31824018d4 PG 6 WC Infectious Diseases SC Infectious Diseases GA 911UZ UT WOS:000301746400012 PM 22421699 ER PT J AU Silverberg, MJ Lau, B Justice, AC Engels, E Gill, MJ Goedert, JJ Kirk, GD D'Souza, G Bosch, RJ Brooks, JT Napravnik, S Hessol, NA Jacobson, LP Kitahata, MM Klein, MB Moore, RD Rodriguez, B Rourke, SB Saag, MS Sterling, TR Gebo, KA Press, N Martin, JN Dubrow, R AF Silverberg, Michael J. Lau, Bryan Justice, Amy C. Engels, Eric Gill, M. John Goedert, James J. Kirk, Gregory D. D'Souza, Gypsyamber Bosch, Ronald J. Brooks, John T. Napravnik, Sonia Hessol, Nancy A. Jacobson, Lisa P. Kitahata, Mari M. Klein, Marina B. Moore, Richard D. Rodriguez, Benigno Rourke, Sean B. Saag, Michael S. Sterling, Timothy R. Gebo, Kelly A. Press, Natasha Martin, Jeffrey N. Dubrow, Robert CA N Amer AIDS Cohort Collaboration TI Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-PAPILLOMAVIRUS INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; COST-EFFECTIVENESS; HAART ERA; DEFINING MALIGNANCIES; AIDS COHORT; MEN; PREVALENCE AB Background. Anal cancer is one of the most common cancers affecting individuals infected with human immunodeficiency virus (HIV), although few have evaluated rates separately for men who have sex with men (MSM), other men, and women. There are also conflicting data regarding calendar trends. Methods. In a study involving 13 cohorts from North America with follow-up between 1996 and 2007, we compared anal cancer incidence rates among 34 189 HIV-infected (55% MSM, 19% other men, 26% women) and 114 260 HIV-uninfected individuals (90% men). Results. Among men, the unadjusted anal cancer incidence rates per 100 000 person-years were 131 for HIV-infected MSM, 46 for other HIV-infected men, and 2 for HIV-uninfected men, corresponding to demographically adjusted rate ratios (RRs) of 80.3 (95% confidence interval [CI], 42.7-151.1) for HIV-infected MSM and 26.7 ( 95% CI, 11.5-61.7) for other HIV-infected men compared with HIV-uninfected men. HIV-infected women had an anal cancer rate of 30/100 000 person-years, and no cases were observed for HIV-uninfected women. In a multivariable Poisson regression model, among HIV-infected individuals, the risk was higher for MSM compared with other men (RR, 3.3; 95% CI, 1.8-6.0), but no difference was observed comparing women with other men ( RR, 1.0; 95% CI, 0.5-2.2). In comparison with the period 2000-2003, HIV-infected individuals had an adjusted RR of 0.5 (95% CI,.3-.9) in 1996-1999 and 0.9 (95% CI,.6-1.2) in 2004-2007. Conclusions. Anal cancer rates were substantially higher for HIV-infected MSM, other men, and women compared with HIV-uninfected individuals, suggesting a need for universal prevention efforts. Rates increased after the early antiretroviral therapy era and then plateaued. C1 [Silverberg, Michael J.] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA. [Lau, Bryan; Kirk, Gregory D.; D'Souza, Gypsyamber; Jacobson, Lisa P.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Justice, Amy C.; Dubrow, Robert] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Justice, Amy C.; Dubrow, Robert] Yale Univ, Sch Med, New Haven, CT USA. [Justice, Amy C.] Vet Affairs Connecticut Healthcare Syst, New Haven, CT USA. [Engels, Eric; Goedert, James J.] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD USA. [Gill, M. John] Univ Calgary, Calgary, AB T2N 1N4, Canada. [Bosch, Ronald J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Brooks, John T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Napravnik, Sonia] Univ N Carolina, Div Infect Dis, Chapel Hill, NC 27515 USA. [Hessol, Nancy A.; Martin, Jeffrey N.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kitahata, Mari M.] Univ Washington, Seattle, WA 98195 USA. [Klein, Marina B.] McGill Univ, Montreal, PQ, Canada. [Moore, Richard D.; Gebo, Kelly A.] Johns Hopkins Sch Med, Baltimore, MD USA. [Rodriguez, Benigno] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Rourke, Sean B.] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Saag, Michael S.] Univ Alabama Birmingham, Birmingham, AL USA. [Sterling, Timothy R.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Press, Natasha] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada. RP Silverberg, MJ (reprint author), Kaiser Permanente No Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA. EM michael.j.silverberg@kp.org RI Rodriguez, Benigno/C-3365-2009; Gill, John/G-7083-2016 OI Rodriguez, Benigno/0000-0001-9736-7957; Gill, John/0000-0002-8546-8790 FU National Institutes of Health (General Clinical Research Centers [GCRC]) [U01-AI069918, U01-AA013566, U01-AI-35042, U01-AI-35043, U01-AI-35039, 5-M01-RR-00052, U01-AI-35040, U01-AI-35041, U01-AI38855]; AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) [U01-AI38858, U01-AI68634, U01-AI68636, AI-69432, AI-69434, U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, U01-AI-42590, U01-HD-32632, UL1-RR024131, P30-AI27757, K23-AI-61-0320, P30-AI27767, P30-AI50410, RR025747, P30-AI54999, R01-DA04334, R01-DA12568, R01-MH54907, R24-AI067039, N02-CP55504, Z01 CP010176, AHQ290-01-0012, K01-AI071754, K24-00432, R01-DA11602, K01-AI071725, R01 AG026250, P30 AI027763]; Canadian Institutes for Health Research (CIHR) [TGF-96118, HCP-97105, CBR-86906, CBR-94036, KRS-86251, 169621]; Canadian Trials Network [242]; Centers for Disease Control [CDC200-2006-18797]; Pfizer; Merck; Abbott; Gilead; Tibotec; Bristol-Myers Squibb; GlaxoSmithKline; Schering Plough Canada FX This work was supported by grants from the National Institutes of Health: U01-AI069918, U01-AA013566, U01-AI-35042, 5-M01-RR-00052 (General Clinical Research Centers [GCRC]), U01-AI-35043, U01-AI-35039, U01-AI-35040, U01-AI-35041, U01-AI38855: AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT); U01-AI38858; U01-AI68634; U01-AI68636; AI-69432; AI-69434, U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, and U01-AI-42590, U01-HD-32632, UL1-RR024131, P30-AI27757; K23-AI-61-0320, P30-AI27767, P30-AI50410; RR025747, P30-AI54999, R01-DA04334; R01-DA12568, R01-MH54907, R24-AI067039, N02-CP55504; Z01 CP010176, AHQ290-01-0012, K01-AI071754, K24-00432; R01-DA11602, K01-AI071725, R01 AG026250, and P30 AI027763. This work was also supported by the Canadian Institutes for Health Research (CIHR: TGF-96118; HCP-97105; CBR-86906; CBR-94036; KRS-86251; 169621) and the Canadian Trials Network (project 242). Finally, support was also provided by the Centers for Disease Control (CDC200-2006-18797); the findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.; M. J. S. received research grant support from Pfizer and Merck. G. D. K. has been a consultant to GlaxoSmithKline and Merck. G. D. has been a consultant to and received research grant support from Merck. M. B. K. has been a consultant to GlaxoSmithKline, Abbott, Pfizer, and Boehringer-Ingelheim, has received lecture fees from Abbott, Gilead, Tibotec, Bristol-Myers Squibb, and GlaxoSmithKline, and received research support from Schering Plough Canada. R. D. M. has been a consultant to Bristol-Myers Squibb and Merck. T. R. S. received research grant support from Pfizer and Bristol-Myers Squibb. All other authors report no potential conflicts. NR 39 TC 174 Z9 177 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2012 VL 54 IS 7 BP 1026 EP 1034 DI 10.1093/cid/cir1012 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 905TB UT WOS:000301296200028 PM 22291097 ER PT J AU Harris, JR Lockhart, SR Chiller, T AF Harris, J. R. Lockhart, S. R. Chiller, T. TI Letter re: Marr editorial SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID CRYPTOCOCCUS-GATTII C1 [Harris, J. R.; Lockhart, S. R.; Chiller, T.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30309 USA. RP Harris, JR (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30309 USA. EM ggt5@cdc.gov NR 3 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2012 VL 54 IS 7 BP 1038 EP 1039 DI 10.1093/cid/cir1019 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 905TB UT WOS:000301296200032 PM 22267717 ER PT J AU Jones, JL Roberts, JM AF Jones, Jeffrey L. Roberts, Jacquelin M. TI Toxoplasmosis Hospitalizations in the United States, 2008, and Trends, 1993-2008 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID TRANSPLANT PATIENTS; GONDII INFECTION; RISK-FACTORS; ENCEPHALITIS; PREVENTION; COHORT AB Background. Toxoplasmosis-related hospitalizations often occur in persons with human immunodeficiency virus (HIV) infection and other causes of immunosuppression. Methods. Using the National Inpatient Sample (NIS) from the Healthcare Cost and Utilization Project, we examined trends in toxoplasmosis-related hospitalizations by HIV infection status from 1993 through 2008, and rates by sex and race or ethnicity in 2008. The NIS is designed to represent a 20% sample of US community hospitals and currently includes information on up to 8 million discharges per year from similar to 1000 hospitals. We used International Classification of Diseases, Ninth Revision, Clinical Modification codes 130-130.9 for toxoplasmosis and 042-044/795.8/795.71/V08 for HIV infection. Results. Estimated HIV-associated toxoplasmosis hospitalizations increased from 9395 in 1993 to 10 583 in 1995 (P = .0002), then dropped to 3643 in 2001 (P < .0001), with similar levels thereafter. The rate of HIV-associated toxoplasmosis hospitalizations among all HIV-related hospitalizations decreased from 3.33% in 1993 to 1.25% in 2008 (P,. 0001). Estimated non-HIV-associated toxoplasmosis hospitalizations were less variable from 1993 to 2008 (range, 386-819; 0.0020% in 1993, 0.0015% in 2008). In 2008, the rates of both HIV- and non-HIV- associated toxoplasmosis hospitalizations were higher in Hispanic persons than in white persons. Conclusions. HIV-associated toxoplasmosis hospitalizations dropped markedly after 1995 when highly active antiretroviral therapy was introduced; however, hospitalizations decreased relatively little after 2000, suggesting late diagnosis of some HIV-infected persons or antiretroviral therapy failure. Non-HIV-associated toxoplasmosis hospitalizations have been more stable. The rates of toxoplasmosis-related hospitalizations varied markedly among racial and ethnic groups. C1 [Jones, Jeffrey L.; Roberts, Jacquelin M.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Jones, JL (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Bldg 24,1600 Clifton Rd NE,MS A-06, Atlanta, GA 30333 USA. EM jlj1@cdc.gov RI Ghartouchent, malek/B-9088-2012 NR 17 TC 14 Z9 14 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2012 VL 54 IS 7 BP E58 EP E61 DI 10.1093/cid/cir990 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 905TB UT WOS:000301296200006 PM 22267718 ER PT J AU Moon, S Wang, YH Dennehy, P Simonsen, KA Zhang, J Jiang, BM AF Moon, Sungsil Wang, Yuhuan Dennehy, Penelope Simonsen, Kari A. Zhang, John Jiang, Baoming TI Antigenemia, RNAemia, and innate immunity in children with acute rotavirus diarrhea SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY LA English DT Article DE rotavirus; antigenemia; RNAemia; dendritic cell; mDC; pDC ID DENDRITIC CELLS; EXTRAINTESTINAL SPREAD; HISTOLOGIC DISTRIBUTION; ACUTE GASTROENTERITIS; RHESUS ROTAVIRUS; NEONATAL MOUSE; INFECTION; VACCINE; INFANTS; VIREMIA AB Antigenemia is commonly detected in children with acute rotavirus diarrhea, but the prevalence of viremia has not been clearly defined. We examined antigenemia in plasma and RNAemia in peripheral blood mononuclear cells (PBMC) of children with acute diarrhea by EIA, RT-PCR, and Southern hybridization, using primers and a probe specific to rotavirus NSP4 gene. We detected the presence of rotavirus antigen in 33.3% and almost full-length NSP4 gene in 70.8% of the acute-phase plasma and PBMC, respectively. In contrast, antigenemia and RNAemia were detected in 0% and 4.2% of the convalescent-phase plasma and PBMC, respectively, which were similar to antigenemia (0%) and RNAemia (7.7%) in healthy controls. We demonstrated an increase in the proportions of activated myeloid dendritic cells (mDC) and activated plasmacytoid DC (pDC) in acute-phase PBMC of patients when compared to those in convalescent phase of patients and in PBMC of healthy controls. The activation of mDC peaked on days 24 after illness onset, and the activation of acute-phase pDC appeared to correlate with levels of antigenemia. High prevalence of NSP4 gene in acute-phase PBMC indicates possible rotavirus replication in white blood cells, and extraintestinal spread and the activation of DC may have implications for the prevention of rotavirus disease in children. C1 [Moon, Sungsil; Wang, Yuhuan; Zhang, John; Jiang, Baoming] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Dennehy, Penelope] Brown Univ, Rhode Isl Hosp, Dept Pediat, Providence, RI 02903 USA. [Dennehy, Penelope] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Simonsen, Kari A.] Univ Nebraska Med Ctr, Sect Pediat Infect Dis, Omaha, NE 68198 USA. RP Jiang, BM (reprint author), Natl Ctr Immunizat & Resp Dis, Gastroenteritis & Resp Viruses Lab Branch, MS G04,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM bxj4@cdc.gov OI Dennehy, Penelope/0000-0002-2259-5370 NR 57 TC 12 Z9 14 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0928-8244 J9 FEMS IMMUNOL MED MIC JI FEMS Immunol. Med. Microbiol. PD APR PY 2012 VL 64 IS 3 BP 382 EP 391 DI 10.1111/j.1574-695X.2011.00923.x PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 905PC UT WOS:000301283700009 PM 22176605 ER PT J AU Steinau, M Reddy, D Sumbry, A Reznik, D Gunthel, CJ del Rio, C Lennox, JL Unger, ER Nguyen, MLT AF Steinau, Martin Reddy, Deepa Sumbry, Anitra Reznik, David Gunthel, Clifford J. del Rio, Carlos Lennox, Jeffrey L. Unger, Elizabeth R. Nguyen, Minh Ly T. TI Oral sampling and human papillomavirus genotyping in HIV-infected patients SO JOURNAL OF ORAL PATHOLOGY & MEDICINE LA English DT Article DE human immunodeficiency virus; human papillomavirus; oral; oropharyngeal cancer; sample collection ID ACTIVE ANTIRETROVIRAL THERAPY; LOCAL IMMUNE-RESPONSES; OROPHARYNGEAL CANCER; HPV; IMMUNODEFICIENCY; INDIVIDUALS; ADULTS AB BACKGROUND: Oral human papillomavirus (HPV) is associated with several health complications especially in combination with HIV infections. Screening may be useful, but methodologies and results have varied widely in previous studies. We conducted a pilot study in an HIV-positive population to evaluate HPV detection in four different oral sample types. METHODS: Upon enrollment, an oral-rinse (OR) sample was collected in 10 ml saline. Additional samples of the buccal mucosa, tonsils, and oral lesion if present were collected with cytology brushes. DNA was extracted using LC-MagNAPure, and the Linear Array HPV genotyping Assay (Roche) was used for HPV genotyping. RESULTS: In samples from 100 HIV-positive participants, HPV was detected in 39 (%) of the oral rinses, 13 (%) mucosal and 11 (12.9%) tonsil brushings. Of seven lesion brushings collected, four were HPV positive. All participants with HPV detected in mucosal, tonsil, or lesion brushings were also positive in the OR sample. Among the rinse samples, 27 different genotypes were detected with HPV84 (n = 6), HPV55 (n = 5), and HPV83 (n = 5) being the most common. Multiple infections were detected in 17 samples (range 2-9, mean 1.9 types). As potential cofactors, only receptive oral sex was significantly associated with HPV (P = 0.018, odds ratio 2.9, 95% CI 1.2-6.9). CONCLUSION: Sampling is a significant factor for oral prevalence studies. Oral rinse provides the best representation for HPV in the oral cavity. To evaluate associated cofactors other than receptive oral sex, larger studies with case-control design are necessary. J Oral Pathol Med (2012) 41: 288-291 C1 [Reddy, Deepa; Sumbry, Anitra; Gunthel, Clifford J.; del Rio, Carlos; Lennox, Jeffrey L.; Nguyen, Minh Ly T.] Emory Univ, Sch Med, Div Infect Dis, Dept Med, Atlanta, GA 30303 USA. [Steinau, Martin; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Reznik, David] Grady Hlth Syst, Atlanta, GA USA. RP Nguyen, MLT (reprint author), Emory Univ, Sch Med, Div Infect Dis, Dept Med, Atlanta, GA 30303 USA. EM mnguye3@emory.edu RI perumal, murugiah/D-1565-2012; Lennox, Jeffrey/D-1654-2014; del Rio, Carlos/B-3763-2012; OI Lennox, Jeffrey/0000-0002-2064-5565; del Rio, Carlos/0000-0002-0153-3517; Unger, Elizabeth/0000-0002-2925-5635 FU Roche Molecular Diagnostics; Digene Diagnostics Corporation (Qiagen) FX This study was partly supported by a generous grant from Roche Molecular Diagnostics who provided Linear Array HPV genotyping kits and from Digene Diagnostics Corporation (Qiagen) who provided the hc2 DNA collection device. This work was initiated by the Center for AIDS Research at Emory University (P30 AI050409). NR 16 TC 14 Z9 14 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0904-2512 J9 J ORAL PATHOL MED JI J. Oral Pathol. Med. PD APR PY 2012 VL 41 IS 4 BP 288 EP 291 DI 10.1111/j.1600-0714.2011.01093.x PG 4 WC Dentistry, Oral Surgery & Medicine; Pathology SC Dentistry, Oral Surgery & Medicine; Pathology GA 910OZ UT WOS:000301650400002 PM 22082117 ER PT J AU Li, J Thompson, T Joseph, DA Master, VA AF Li, Jun Thompson, Trevor Joseph, Djenaba A. Master, Viraj A. TI Association Between Smoking Status, and Free, Total and Percent Free Prostate Specific Antigen SO JOURNAL OF UROLOGY LA English DT Article DE prostatic neoplasms; smoking; prostate-specific antigen; early detection of cancer ID NUTRITION EXAMINATION SURVEY; CLINICAL FACTORS; CIGARETTE-SMOKING; NATIONAL-HEALTH; US MEN; CANCER; AGE; MORTALITY; RISK; PSA AB Purpose: There are scant data available on the relationship between smoking and total prostate specific antigen, free prostate specific antigen and percent-free prostate specific antigen. Given the high prevalence of smoking and the frequency of prostate specific antigen screening, it is important to determine any association between smoking and prostate specific antigen values using nationally representative data. Materials and Methods: Included in the final study population were 3,820 men 40 years old or older who participated in the 2001-2006 NHANES (National Health and Nutrition Examination Survey) and met the eligibility criteria for prostate specific antigen testing. The distributions of total, free and percent free prostate specific antigen were estimated by sociodemographic and clinical characteristics. Multivariate linear regression models were fit to determine the adjusted relationship between smoking and total and percent free prostate specific antigen while simultaneously controlling for these characteristics. Results: For all ages combined the median total and free prostate specific antigen levels were 0.90 (0.81-0.90) and 0.26 (0.25-0.28) ng/ml, respectively. Multivariate linear regression analysis showed that total prostate specific antigen was 7.9% and 12.2% lower among current and former smokers, respectively, than among never smokers. High body mass index and diabetes were also statistically significantly associated with a lower total prostate specific antigen. Approximately a third of the men had a percent free prostate specific antigen less than 25%. Current smokers had a significantly lower percent free prostate specific antigen than former smokers. Conclusions: Our finding that smoking is inversely associated with total prostate specific antigen may have potential implications for the interpretation of prostate specific antigen levels in men who are current or former smokers. Given the high prevalence of smoking, obesity and diabetes, additional research on the combined effect of these health risk factors is warranted. C1 [Li, Jun] Ctr Dis Control & Prevent, Div Canc Prevent & Control, CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Master, Viraj A.] Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA. RP Li, J (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K55, Atlanta, GA 30341 USA. EM ffa2@cdc.gov FU Intramural CDC HHS [CC999999] NR 30 TC 5 Z9 5 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD APR PY 2012 VL 187 IS 4 BP 1228 EP 1233 DI 10.1016/j.juro.2011.11.086 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 914AY UT WOS:000301922300029 PM 22335864 ER PT J AU Wahala, WMPB Huang, C Butrapet, S White, LJ de Silva, AM AF Wahala, Wahala M. P. B. Huang, Claire Butrapet, Siritorn White, Laura J. de Silva, Aravinda M. TI Recombinant Dengue Type 2 Viruses with Altered E Protein Domain III Epitopes Are Efficiently Neutralized by Human Immune Sera SO JOURNAL OF VIROLOGY LA English DT Article ID WEST-NILE-VIRUS; IN-DEPTH ANALYSIS; ENVELOPE PROTEIN; REACTIVE EPITOPES; ANTIBODY-RESPONSE; INFECTION; GLYCOPROTEIN; MECHANISMS; DOMINANT; BINDING AB Humans develop polyclonal, serotype-specific neutralizing antibody responses after dengue virus (DENV) infection. Many mouse antibodies that neutralize DENV bind to the lateral ridge or A strand epitopes on domain III of the viral envelope (EDIII) protein. It has been assumed that these epitopes are also the main target of human neutralizing antibodies. Using recombinant dengue serotype 2 viruses with altered EDIII epitopes, we demonstrate that EDIII epitopes are not the main target of human neutralizing antibody. C1 [Wahala, Wahala M. P. B.; de Silva, Aravinda M.] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA. [Wahala, Wahala M. P. B.; de Silva, Aravinda M.] Univ N Carolina, Sch Med, SE Reg Ctr Excellence Biodef & Emerging Infect Di, Chapel Hill, NC USA. [Huang, Claire; Butrapet, Siritorn] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA. [White, Laura J.] Global Vaccines Inc, Res Triangle Pk, NC USA. RP de Silva, AM (reprint author), Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA. EM desilva@med.unc.edu RI Wahala, Wahala/H-3909-2012 FU NIH from the Southeastern Regional Center of Excellence for Emerging Infections and Biodefense [U54 AI057157] FX These studies were supported by NIH grant no. U54 AI057157 from the Southeastern Regional Center of Excellence for Emerging Infections and Biodefense. NR 33 TC 35 Z9 36 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD APR PY 2012 VL 86 IS 7 BP 4019 EP 4023 DI 10.1128/JVI.06871-11 PG 5 WC Virology SC Virology GA 906TV UT WOS:000301371500058 PM 22278250 ER PT J AU Franklin, WB Katyal, M Mahajan, R Parvez, FM AF Franklin, Woodman B. Katyal, Monica Mahajan, Reena Parvez, Farah M. TI Chlamydia and Gonorrhea Screening Using Urine-Based Nucleic Acid Amplification Testing Among Males Entering New York City Jails: A Pilot Study SO JOURNAL OF CORRECTIONAL HEALTH CARE LA English DT Article DE chlamydia; gonorrhea; screening; jails; detainees AB This article describes a pilot screening program to detect Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (Ng) sexually transmitted infections (STIs) in adolescent and adult males newly incarcerated in New York City jails using urine-based nucleic acid amplification technology (NAAT). Between December 8 and 22, 2003, 2,417 males were tested; 162 (6.7%) were found positive for Ct and/or Ng STIs, with 138 (86.8%) exhibiting no STI signs or symptoms and 102 (63%) treated prior to jail release. Younger age, positive urine leukocyte esterase test, and >= 11 recent sex partners were predictors of STI. Urine-based screening and treatment was feasible in this setting and identified STI that would otherwise have been undetected. Jails may thus be important venues for targeted male STI screening. C1 [Franklin, Woodman B.; Katyal, Monica; Mahajan, Reena; Parvez, Farah M.] New York City Dept Hlth & Mental Hyg, Long Isl City, NY 11101 USA. [Parvez, Farah M.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Parvez, FM (reprint author), New York City Dept Hlth & Mental Hyg, Off Correct Publ Hlth, 42-09 28th St,10th Floor,CN-52, Long Isl City, NY 11101 USA. EM fparvez@health.nyc.gov NR 42 TC 9 Z9 9 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1078-3458 EI 1940-5200 J9 J CORRECT HEALTH CAR JI J. Correct. Health Care PD APR PY 2012 VL 18 IS 2 BP 120 EP 130 DI 10.1177/1078345811435767 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V32ZL UT WOS:000208989000005 PM 22419642 ER PT J AU Deloria-Knoll, M Feikin, DR Scott, JAG O'Brien, KL DeLuca, AN Driscoll, AJ Levine, OS AF Deloria-Knoll, Maria Feikin, Daniel R. Scott, J. Anthony G. O'Brien, Katherine L. DeLuca, Andrea N. Driscoll, Amanda J. Levine, Orin S. CA Pneumonia Methods Working Grp TI Identification and Selection of Cases and Controls in the Pneumonia Etiology Research for Child Health Project SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID BANGLADESH; INFANTS AB Methods for the identification and selection of patients (cases) with severe or very severe pneumonia and controls for the Pneumonia Etiology Research for Child Health (PERCH) project were needed. Issues considered include eligibility criteria and sampling strategies, whether to enroll hospital or community controls, whether to exclude controls with upper respiratory tract infection (URTI) or nonsevere pneumonia, and matching criteria, among others. PERCH ultimately decided to enroll community controls and an additional human immunodeficiency virus (HIV)-infected control group at high HIV-prevalence sites matched on age and enrollment date of cases; controls with symptoms of URTI or nonsevere pneumonia will not be excluded. Systematic sampling of cases (when necessary) and random sampling of controls will be implemented. For each issue, we present the options that were considered, the advantages and disadvantages of each, the rationale for the methods selected for PERCH, and remaining implications and limitations. C1 [Deloria-Knoll, Maria; Feikin, Daniel R.; O'Brien, Katherine L.; DeLuca, Andrea N.; Driscoll, Amanda J.; Levine, Orin S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Int Vaccine Access Ctr, Baltimore, MD 21205 USA. [Feikin, Daniel R.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Scott, J. Anthony G.] Wellcome Trust Res Programme, Kenya Med Res Inst KEMRI, Kilifi, Kenya. [Scott, J. Anthony G.] Univ Oxford, Nuffield Dept Clin Med, Oxford OX1 2JD, England. RP Deloria-Knoll, M (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Int Vaccine Access Ctr, 855 N Wolfe St,Suite 600, Baltimore, MD 21205 USA. EM mknoll@jhsph.edu RI kotloff, karen/E-7768-2012 OI kotloff, karen/0000-0003-1808-6431 FU The Bill & Melinda Gates Foundation [48968]; The Wellcome Trust of Great Britain [081835]; The Bill & Melinda Gates Foundation FX This work was supported by grant 48968 from The Bill & Melinda Gates Foundation to the International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health. J. A. G. S. is supported by a clinical fellowship from The Wellcome Trust of Great Britain (081835).; This article was published as part of a supplement entitled "Pneumonia Etiology Research for Child Health,'' sponsored by a grant from The Bill & Melinda Gates Foundation to the PERCH Project of Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. NR 15 TC 11 Z9 11 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2012 VL 54 SU 2 BP S117 EP S123 DI 10.1093/cid/cir1066 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 905TD UT WOS:000301296500006 PM 22403225 ER PT J AU Gilani, Z Kwong, YD Levine, OS Deloria-Knoll, M Scott, JAG O'Brien, KL Feikin, DR AF Gilani, Zunera Kwong, Yuenting D. Levine, Orin S. Deloria-Knoll, Maria Scott, J. Anthony G. O'Brien, Katherine L. Feikin, Daniel R. TI A Literature Review and Survey of Childhood Pneumonia Etiology Studies: 2000-2010 SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID COMMUNITY-ACQUIRED PNEUMONIA; INVASIVE PNEUMOCOCCAL DISEASE; RESPIRATORY-TRACT INFECTIONS; ATYPICAL BACTERIAL PATHOGENS; CHILDREN LESS-THAN-5 YEARS; SYNCYTIAL VIRUS-INFECTION; POLYMERASE-CHAIN-REACTION; PLACEBO-CONTROLLED-TRIAL; INFLUENZAE TYPE-B; HOSPITALIZED CHILDREN AB The Pneumonia Etiology Research for Child Health (PERCH) project is the largest multicountry etiology study of childhood pneumonia since the Board on Science and Technology in International Development studies of the 1980s. However, it is not the only recent or ongoing pneumonia etiology study, and even with seven sites, it cannot capture all epidemiologic settings in the developing world. Funding providers, researchers and policymakers rely on the best available evidence to strategically plan programs, new research directions and interventions. We aimed to describe the current landscape of recent pneumonia etiology studies in children under 5 years of age in the developed and developing world, as ascertained by a literature review of relevant studies with data since the year 2000 and a survey of researchers in the field of childhood pneumonia. We collected information on the study population, study design, case definitions, laboratory samples and methods and identified pathogens. A literature review identified 88 studies with child pneumonia etiology results. As of June 2010, our survey of researchers identified an additional 65 ongoing and recently completed child pneumonia etiology studies. This demonstrates the broad existing context into which the PERCH study must be placed. However, the landscape analysis also reveals a multiplicity of case definitions, levels of clinician involvement, facility types, specimen collection, and laboratory techniques. It reinforces the need for the standardization of methods and analyses for present and future pneumonia etiology studies in order to optimize their cumulative potential to accurately describe the microbial causes of childhood pneumonia. C1 [Gilani, Zunera] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Kwong, Yuenting D.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Levine, Orin S.; Deloria-Knoll, Maria; O'Brien, Katherine L.; Feikin, Daniel R.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Int Vaccine Access Ctr, Baltimore, MD USA. [Scott, J. Anthony G.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya. [Scott, J. Anthony G.] Univ Oxford, Nuffield Dept Clin Med, Oxford OX1 2JD, England. [Feikin, Daniel R.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Gilani, Z (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, 855 Wolfe St,Ste 600,Rangos Bldg, Baltimore, MD 21205 USA. EM zgilani@jhsph.edu FU The Bill & Melinda Gates Foundation [48968]; The Bill & Melinda Gates Foundation FX This work was supported by grant 48968 from The Bill & Melinda Gates Foundation to the International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health.; This article was published as part of a supplement entitled "Pneumonia Etiology Research for Child Health,'' sponsored by a grant from The Bill & Melinda Gates Foundation to the PERCH Project of Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. NR 95 TC 16 Z9 16 U1 0 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2012 VL 54 SU 2 BP S102 EP S108 DI 10.1093/cid/cir1053 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 905TD UT WOS:000301296500004 PM 22403223 ER PT J AU Levine, OS O'Brien, KL Deloria-Knoll, M Murdoch, DR Feikin, DR DeLuca, AN Driscoll, AJ Baggett, HC Brooks, WA Howie, SRC Kotloff, KL Madhi, SA Maloney, SA Sow, S Thea, DM Scott, JA AF Levine, Orin S. O'Brien, Katherine L. Deloria-Knoll, Maria Murdoch, David R. Feikin, Daniel R. DeLuca, Andrea N. Driscoll, Amanda J. Baggett, Henry C. Brooks, W. Abdullah Howie, Stephen R. C. Kotloff, Karen L. Madhi, Shabir A. Maloney, Susan A. Sow, Samba Thea, Donald M. Scott, J. Anthony TI The Pneumonia Etiology Research for Child Health Project: A 21st Century Childhood Pneumonia Etiology Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID INFLUENZAE TYPE-B; PNEUMOCOCCAL CONJUGATE VACCINE; DEVELOPING-COUNTRIES; CONTROLLED-TRIAL; MORTALITY; INFANTS; DISEASE; EPIDEMIOLOGY; POPULATION; BANGLADESH AB The Pneumonia Etiology Research for Child Health (PERCH) project is a 7-country, standardized, comprehensive evaluation of the etiologic agents causing severe pneumonia in children from developing countries. During previous etiology studies, between one-quarter and one-third of patients failed to yield an obvious etiology; PERCH will employ and evaluate previously unavailable innovative, more sensitive diagnostic techniques. Innovative and rigorous epidemiologic and analytic methods will be used to establish the causal association between presence of potential pathogens and pneumonia. By strategic selection of study sites that are broadly representative of regions with the greatest burden of childhood pneumonia, PERCH aims to provide data that reflect the epidemiologic situation in developing countries in 2015, using pneumococcal and Haemophilus influenzae type b vaccines. PERCH will also address differences in host, environmental, and/or geographic factors that might determine pneumonia etiology and, by preserving specimens, will generate a resource for future research and pathogen discovery. C1 [Levine, Orin S.; O'Brien, Katherine L.; Deloria-Knoll, Maria; Feikin, Daniel R.; DeLuca, Andrea N.; Driscoll, Amanda J.; Brooks, W. Abdullah] Johns Hopkins Bloomberg Sch Hlth, Int Vaccine Access Ctr, Dept Int Hlth, Baltimore, MD 21205 USA. [Murdoch, David R.] Univ Otago, Dept Pathol, Christchurch, New Zealand. [Murdoch, David R.] Canterbury Hlth Labs, Christchurch, New Zealand. [Feikin, Daniel R.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Baggett, Henry C.; Maloney, Susan A.] Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Int Emerging Infect Program, Nonthaburi, Thailand. [Howie, Stephen R. C.] Med Res Council Labs Gambia, Fajara, Gambia. [Kotloff, Karen L.; Sow, Samba] Univ Maryland, Sch Med, Dept Pediat, Div Infect Dis & Trop Pediat, Baltimore, MD 21201 USA. [Kotloff, Karen L.; Sow, Samba] Univ Maryland, Sch Med, Dept Med, Div Geog Med,Ctr Vaccine Dev, Baltimore, MD 21201 USA. [Madhi, Shabir A.] Natl Inst Communicable Dis, Div Natl Hlth Lab Serv, Sandrigham, South Africa. [Madhi, Shabir A.] Univ Witwatersrand, Fac Hlth Sci, Dept Sci & Technol, Natl Res Fdn, ZA-2050 Johannesburg, South Africa. [Sow, Samba] Ctr Dev Vaccins, Bamako, Mali. [Thea, Donald M.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Scott, J. Anthony] Wellcome Trust Res Programme, Kenya Med Res Inst, Kilifi, Kenya. [Scott, J. Anthony] Univ Oxford, Nuffield Dept Clin Med, Oxford OX1 2JD, England. RP Levine, OS (reprint author), Johns Hopkins Bloomberg Sch Hlth, Int Vaccine Access Ctr, Dept Int Hlth, Baltimore, MD 21205 USA. EM olevine@jhsph.edu RI kotloff, karen/E-7768-2012; OI kotloff, karen/0000-0003-1808-6431; Thea, Donald/0000-0002-6933-1030 FU The Bill & Melinda Gates Foundation FX This article was published as part of a supplement entitled "Pneumonia Etiology Research for Child Health,'' sponsored by a grant from The Bill & Melinda Gates Foundation to the PERCH Project of Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. NR 24 TC 63 Z9 65 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2012 VL 54 SU 2 BP S93 EP S101 DI 10.1093/cid/cir1052 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 905TD UT WOS:000301296500003 PM 22403238 ER PT J AU Levine, OS Bhat, N Crawley, J Deloria-Knoll, M DeLuca, AN Driscoll, AJ Feikin, DR Karron, RA Murdoch, DR O'Brien, KL Scott, JAG AF Levine, Orin S. Bhat, Niranjan Crawley, Jane Deloria-Knoll, Maria DeLuca, Andrea N. Driscoll, Amanda J. Feikin, Daniel R. Karron, Ruth A. Murdoch, David R. O'Brien, Katherine L. Scott, J. Anthony G. TI Introduction SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material C1 [Levine, Orin S.; Bhat, Niranjan; Deloria-Knoll, Maria; DeLuca, Andrea N.; Driscoll, Amanda J.; Feikin, Daniel R.; O'Brien, Katherine L.] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Baltimore, MD 21205 USA. [Karron, Ruth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Immunizat Res, Baltimore, MD 21205 USA. [Crawley, Jane; Scott, J. Anthony G.] Univ Oxford, Nuffield Dept Clin Med, Oxford OX1 2JD, England. [Feikin, Daniel R.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Murdoch, David R.] Univ Otago, Dept Pathol, Christchurch, New Zealand. [Murdoch, David R.] Canterbury Hlth Labs, Christchurch, New Zealand. [Scott, J. Anthony G.] KEMRI Welcome Trust Res Programme, Kilifi, Kenya. RP O'Brien, KL (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Amer Indian Hlth, 621 N Washington St, Baltimore, MD 21205 USA. EM klobrien@jhsph.edu FU Wellcome Trust [092654] NR 2 TC 4 Z9 4 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2012 VL 54 SU 2 BP S87 EP S88 DI 10.1093/cid/cir1050 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 905TD UT WOS:000301296500001 PM 22403236 ER PT J AU Scott, JAG Wonodi, C Moisi, JC Deloria-Knoll, M DeLuca, AN Karron, RA Bhat, N Murdoch, DR Crawley, J Levine, OS O'Brien, KL Feikin, DR AF Scott, J. Anthony G. Wonodi, Chizoba Moisi, Jennifer C. Deloria-Knoll, Maria DeLuca, Andrea N. Karron, Ruth A. Bhat, Niranjan Murdoch, David R. Crawley, Jane Levine, Orin S. O'Brien, Katherine L. Feikin, Daniel R. CA Pneumonia Methods Working Grp TI The Definition of Pneumonia, the Assessment of Severity, and Clinical Standardization in the Pneumonia Etiology Research for Child Health Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID RESPIRATORY-TRACT INFECTIONS; CASE-MANAGEMENT; INTEROBSERVER VARIATION; AFRICAN CHILDREN; SIGNS; MORTALITY; DIAGNOSIS; INFANTS; MALARIA; HYPOXEMIA AB To develop a case definition for the Pneumonia Etiology Research for Child Health (PERCH) project, we sought a widely acceptable classification that was linked to existing pneumonia research and focused on very severe cases. We began with the World Health Organization's classification of severe/very severe pneumonia and refined it through literature reviews and a 2-stage process of expert consultation. PERCH will study hospitalized children, aged 1-59 months, with pneumonia who present with cough or difficulty breathing and have either severe pneumonia (lower chest wall indrawing) or very severe pneumonia (central cyanosis, difficulty breastfeeding/drinking, vomiting everything, convulsions, lethargy, unconsciousness, or head nodding). It will exclude patients with recent hospitalization and children with wheeze whose indrawing resolves after bronchodilator therapy. The PERCH investigators agreed upon standard interpretations of the symptoms and signs. These will be maintained by a clinical standardization monitor who conducts repeated instruction at each site and by recurrent local training and testing. C1 [Scott, J. Anthony G.; Moisi, Jennifer C.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya. [Scott, J. Anthony G.; Moisi, Jennifer C.; Crawley, Jane] Univ Oxford, Nuffield Dept Clin Med, Oxford OX1 2JD, England. [Wonodi, Chizoba; Moisi, Jennifer C.; Deloria-Knoll, Maria; DeLuca, Andrea N.; Bhat, Niranjan; Levine, Orin S.; O'Brien, Katherine L.; Feikin, Daniel R.] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Baltimore, MD USA. [Karron, Ruth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Dept Int Hlth, Baltimore, MD USA. [Murdoch, David R.] Univ Otago, Dept Pathol, Christchurch, New Zealand. [Murdoch, David R.] Canterbury Hlth Labs, Christchurch, New Zealand. [Feikin, Daniel R.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Scott, JAG (reprint author), KEMRI Wellcome Trust Res Programme, POB 230, Kilifi, Kenya. EM ascott@ikilifi.org FU The Bill & Melinda Gates Foundation [48968]; The Wellcome Trust of Great Britain [081835]; The Bill & Melinda Gates Foundation FX This work was supported by grant 48968 from The Bill & Melinda Gates Foundation to the International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health. J. A. G. S. is supported by a clinical fellowship from The Wellcome Trust of Great Britain (081835).; This article was published as part of a supplement entitled "Pneumonia Etiology Research for Child Health,'' sponsored by a grant from The Bill & Melinda Gates Foundation to the PERCH Project of Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. NR 37 TC 40 Z9 43 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2012 VL 54 SU 2 BP S109 EP S116 DI 10.1093/cid/cir1065 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 905TD UT WOS:000301296500005 PM 22403224 ER EF